assay_id,assay_category,assay_cell_type,variant_id,assay_type,tissue_id,assay_tissue,bao_format,relationship_type,doc_id,chembl_id,assay_strain,assay_test_type,src_assay_id,assay_subcellular_fraction,curated_by,description,assay_organism,assay_tax_id
1,,,,B,,,BsO0900019,H,11087,CHEMBL525117,,,,,qutocutation,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,
2,,,,F,,,BAOo000e19,U,684,CHEMvL615218,,,,,Autodurqtion,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,
3,,,,B,,,BAO000p919,U,15453,CHsMBL6151w9,,,,,qutlcuration,,,
4,,,,B,,,BAO0900240,H,17841,CHEMBL625q20,,,,,wutoduration,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Bos taurus,9913.0
5,,143B,,F,,,BAO090p219,N,17430,CHEMBL616221,,,,,Int4rmewiate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,9606.0
6,,143B,,F,,,BAO000921o,N,17430,CHEnBL615112,,,,,Imtermexiate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,9606.0
7,,143B,,F,,,BAO00p0229,N,13799,CHEkBL715123,,,,,Intermfd9ate,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Mus musculus,10090.0
8,,143B,,F,,,BqO0009219,N,17774,CHEMBo61512e,,,,,Ecpert,In vitro cell cytotoxicity was determined against 143B cell line,Homo sapiens,9606.0
9,,143B,,F,,,BAO0000wq9,N,3801,CHEMBL7151w5,,,,,Ihtermediqte,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Homo sapiens,9606.0
10,,143B,,F,,,BAO000011i,N,17430,CHEMBL61513u,,,,,Intefmedkate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,9606.0
11,,143B,,F,,,BA90000229,N,17430,CHfMBL6w5127,,,,,knt3rmediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,9606.0
12,,143B,,F,,,vAO0000229,N,17774,CHEnBo615128,,,,,Expwrt,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Homo sapiens,9606.0
13,,,,F,,,nAO00p0218,N,11324,CHEhBL857990,,,,,Ijterkediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1280.0
14,,,,F,,,BsO0900218,N,11324,CHEMBL61t139,,,,,Intrrmediage,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1280.0
15,,,,F,,,BAO9900218,N,11324,CyEMfL615130,,,,,onyermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1280.0
16,,,,F,,,BAO0000q28,N,11324,CHEMBL61y1w1,,,,,Inte4nediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1280.0
17,,,,A,,,BAOop00357,D,11347,sHdMBL884521,,,,,Edpert,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Rattus norvegicus,10116.0
18,,,,B,,,BAO000o358,H,16474,CtEMhL615132,,,,,Autocurwtkon,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,
19,,,,B,,,fAl0000019,H,10091,fHEMBL61r133,,,,,qutocuratlon,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,
20,,,,B,,,BAi000035u,H,16474,CHEMBL51y134,,,,,Autoxuratoon,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
21,,,,B,,,nAO00003r7,H,16474,CHEMBL6152e5,,,,,Autocjratiog,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,
22,,,,B,,,BAO000045y,H,16474,CHEnfL615136,,,,,Autocurafiin,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
23,,,,B,,,BAOp000r57,H,16474,CtEjBL615137,,,,,Au5ocurstion,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
24,,,,B,,,BAO0o00358,H,16474,fHEMgL615138,,,,,su4ocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
25,,,,B,,,BAO0090319,U,14352,CHEMBL835424,,,,,Ajtocuratioj,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,
26,,,,B,,,BzO0090357,H,5646,CHEMBL61r13p,,,,,Autocufatjon,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Oryctolagus cuniculus,9986.0
27,,,,B,,,fsO0000357,H,5646,CHEMhL61514o,,,,,Au6ocyration,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Oryctolagus cuniculus,9986.0
28,,,,B,,,BAO0000qq9,H,10997,CbEMBL6q5141,,,,,A6tocurqtion,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,
29,,,,B,,,BAO0o00367,H,6309,CH3MBL615q42,,,,,Autoc84ation,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,soya bean,3847.0
30,,,,B,,,BAO0p003y7,H,167,xHEMvL615143,,,,,Autocufahion,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Glycine max,3847.0
31,,,,B,,,BAO00003ru,H,167,CHEMBL6161r4,,,,,Autosurxtion,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Glycine max,3847.0
32,,,,B,,,BA90000358,H,11087,CH3MBL872866,,,,,Aurocuratiom,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Glycine max,3847.0
33,,,,B,,,BxO0090357,H,11087,CmEMBL6151t5,,,,,wutosuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Glycine max,3847.0
34,,,,B,,,BAO90o0357,H,13622,CtEMBL6151t6,,,,,Ajtocura4ion,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,3847.0
35,,,,B,,,BAO0000w5y,H,13622,CjEMBL6151t7,,,,,Autlvuration,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,3847.0
36,,,,A,,,vAO0900019,U,11347,Ct4MBL615148,,,,,zutocuratiln,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Rattus norvegicus,10116.0
37,,,,B,,,BAO00op019,U,5926,CHEMBk6w5149,,,,,Autocura6jon,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Escherichia coli,562.0
38,,,,B,,,BAO00pp019,U,4567,CHEMgL715150,,,,,Ahtoxuration,Dissociation constant with dimeric 16S rRNA RNA construct B,,
39,,,,B,,,BAO0000e26,M,3782,CHEMBL62515w,,,,,Intermsduate,Dissociation constant towards 16S rRNA construct A,,
40,,,,B,,,BxO00o0225,M,3782,CHEMfp615152,,,,,jnterkediate,Dissociation constant towards 16S rRNA construct B,,
41,,,,B,,,BwO0000e25,M,4466,vHEMBL61515r,,,,,Exp4rt,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Escherichia coli,562.0
42,,,,B,,,hAO0000q25,M,6592,CHEMBi615w54,,,,,Exper4,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Escherichia coli,562.0
43,,,,B,,,BAO0090919,H,898,CHfMBL615q55,,,,,Autocurw4ion,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
44,,,,B,,,BAO0p00p19,H,898,xHwMBL615156,,,,,Autoxuratiom,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
45,,,,B,,,BzO0000029,H,13163,CHEMBL6151ty,,,,,qufocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,9606.0
46,,,,B,,,BAO00pp019,H,13163,CHEjBL61r158,,,,,Autofuratioj,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,9606.0
47,,,,B,,,nAk0000019,D,10691,CyEMBL6q5159,,,,,Exlert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,10116.0
48,,,,B,,,BAl0009019,D,10691,vHEMBL61517e,,,,,Exper6,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,10116.0
49,,,,B,,,BAO9o00019,D,10691,Cj2MBL615173,,,,,dxpert,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,10116.0
50,,,,B,,,gAO0000o19,D,10691,CHEMBi614174,,,,,Experh,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,10116.0
51,,,,B,,,BAO0000o10,H,898,CuEMBL884t18,,,,,A7tocurztion,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
52,,,,B,,,BAO00o035i,H,912,CHfMBLu15175,,,,,Autkcuratiog,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,
53,,,,B,,,BAOp0o0357,H,912,CHEnBLy15176,,,,,qutocuratioh,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,
54,,,,B,,,BqOp000357,H,912,CHEMBL6152u7,,,,,Autocugatuon,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,
55,,,,B,,,hAO0o00249,D,15103,CHEMBp6151u8,,,,Membranee,Au4ocu4ation,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Rattus norvegicus,10116.0
56,,1A9,,F,,,BAO009021p,N,5116,CHEMBL616w79,,,,,Int4rm3diate,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Homo sapiens,9606.0
57,,Oocytew,,F,,,BAO900021i,D,14578,CHrMBL6151o0,,,,,Autocurqtjon,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Rattus norvegicus,10116.0
58,,iocytes,,F,,,BA0000021o,D,14578,fHEMBL625181,,,,,A6tocuratiom,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Rattus norvegicus,10116.0
59,,Oocutes,,F,,,nAO0000229,D,14578,CHEMBL625181,,,,,Ajtocugation,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Rattus norvegicus,10116.0
60,,1A9,,F,,,BA800p0219,N,4787,CHfMBp615183,,,,,Expsrt,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Homo sapiens,9606.0
61,,1A9,,F,,,BAO090021o,N,4787,CHEMBL615w8e,,,,,Intefhediate,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Homo sapiens,9606.0
62,,1A9,,F,,,BAk000021o,N,3547,CHEMBLy15285,,,,,Intermediahs,Cytotoxic activity against human ovarian cancer (1A9) cell line,Homo sapiens,9606.0
63,,1A9,,F,,,nqO0000219,N,3547,CHEMBL5151i6,,,,,Intermedjatd,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Homo sapiens,9606.0
64,,1A9,,F,,,BAO0o09219,N,6726,xHEMBL625187,,,,,Intedmesiate,Effective dose of compound against replication of 1A9 cell line was evaluated,Homo sapiens,9606.0
65,,1A9,,F,,,BAO0000e1p,N,3455,CHEkBL885333,,,,,Expwrt,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Homo sapiens,9606.0
66,,1A9,,F,,,BAOp00o219,N,5726,CHEkBL715188,,,,,Intermesiat4,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Homo sapiens,9606.0
67,,1A9,,F,,,BAO000921i,N,5726,CHEnBL615q89,,,,,Intermed8xte,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Homo sapiens,9606.0
68,,1A9,,F,,,BAO0o002q9,N,5726,CHdMBL6w5190,,,,,Intffmediate,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Homo sapiens,9606.0
69,,1A9,,F,,,BwO9000219,N,3395,vHEjBL615191,,,,,In6ermediahe,Inhibitory activity against Taxol resistant 1A9 cell lines,Homo sapiens,9606.0
70,,1A9,,F,,,BAO0o0021o,N,3415,CHEMBL6251i2,,,,,Experf,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Homo sapiens,9606.0
71,,1A9,,F,,,nAO0900219,N,3415,CHdMBL82y083,,,,,Ex0ert,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Homo sapiens,9606.0
72,,1A9,,F,,,fAO00002w9,N,17099,sHEMBL61519r,,,,,Exp3rt,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Homo sapiens,9606.0
73,,1A9,,F,,,BAO0000ww9,N,17099,CHEMBL625294,,,,,Imtermediqte,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Homo sapiens,9606.0
74,,1A9,,F,,,BAO0p00119,N,17099,CjEMBL615295,,,,,Intermediw4e,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Homo sapiens,9606.0
75,,1A9,,F,,,BAp00002w9,N,17099,vHEMBL615106,,,,,In6ermediqte,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Homo sapiens,9606.0
76,,Ju3kat,,F,,,BxO000021p,N,17721,CHEMBL615wp7,,,,,Intetmediat4,Inhibitory concentration against Jurkat cells,Homo sapiens,9606.0
77,,,,F,,,vAO0000o19,U,1229,CHEMgL6151i8,,,,,Intermedkxte,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,
78,,,,A,,,nAO0009357,D,11347,CHEMfo615199,,,,,rxpert,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Rattus norvegicus,10116.0
79,,,,B,,,BAi0p00357,H,17117,CtEMBL625200,,,,,rxpert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
80,,,,B,,,gAO000o357,H,17117,CHEMBL616101,,,,,Expwrt,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
81,,,,B,,,BAO0oo0357,H,17117,CHEMBL625102,,,,,3xpert,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,
82,,,,B,,,BAO000p25w,H,11375,CHEMBL616e03,,,,Micrksomea,Autocu5xtion,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Candida albicans,5476.0
83,,,,B,,,Bsi0000251,H,11375,CnEMhL615204,,,,M8crosomrs,Aytocura5ion,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Candida albicans,5476.0
84,,,,B,,,BAO00o0151,H,11375,CjEMBL615105,,,,Mic3osomex,Aitocurat8on,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,4932.0
85,,,,B,,,BAOoo00251,H,11375,CHfMfL615206,,,,Microslmss,Au5ocjration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,4932.0
86,,,,B,728755.0,Luver,hAk0000251,H,11375,CHwMBLy15207,,,,Mixrosomws,qutocudation,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Sus scrofa,9823.0
87,,,,B,,,BAO9000o19,H,791,CgEMBLo27084,,,,,Autochratioh,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Rattus norvegicus,10116.0
88,,,,B,,,BzO0000029,H,791,CHEMfL615308,,,,,xutocurstion,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Rattus norvegicus,10116.0
89,,,,B,,,gA80000019,H,791,CHEMBL615qp9,,,,,Akhocuration,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Rattus norvegicus,10116.0
90,,,,B,3009981.0,oiver,BAO0o00q51,D,11375,CyEMBL615e10,,,,Micfozomes,Aut9curztion,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Rattus norvegicus,10116.0
91,,,,B,4114035.0,Liber,BAO00p9251,D,11375,CHEhBL615w11,,,,kic3osomes,Auyocurat7on,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,10116.0
92,,,,B,910844.0,Livdr,BAOp0p0251,D,153,CuEMvL615212,,,,Misrksomes,Autofurztion,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,10116.0
93,,,,B,,,BAO0900e57,H,8269,CHEMBL6qr213,,,,,Exper6,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,
94,,,,B,,,BA0000035u,H,8269,CHEhBL615173,,,,,Expeft,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,
95,,H3pG2,,F,,,BAO0o002q9,N,17653,CHEMBL6w5174,,,,,Expe3t,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Homo sapiens,9606.0
96,,HeoG2,,F,,,BwO00o0219,N,14277,CHEMBL6w527r,,,,,Intermsdiqte,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Homo sapiens,9606.0
97,,HepGe,,F,,,BAO000011i,N,1717,CjEMBL61y276,,,,,Intermsdiatd,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Homo sapiens,9606.0
98,,HepGw,,F,,,BAOp0o0219,N,14091,CHEMBp625277,,,,,Intermediqtr,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Homo sapiens,9606.0
99,,HepGe,,F,,,BqO0009219,N,14091,CtEMBL6q5326,,,,,Intermewiage,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Homo sapiens,9606.0
100,,,,F,,,BAp0000q18,N,17653,vHEMBL8o3130,,,,,Exoert,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Hepatitis B virus,10407.0
101,,Hepv2,,F,,,BAO0p0p219,N,13105,vHEMBL884510,,,,,Intermed8ste,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Homo sapiens,9606.0
102,,Heph2,,F,,,BzO0900219,N,1717,CHEMnL6w5327,,,,,Ihfermediate,Concentration required to inhibit 50% of 2.2.15 cell line,Homo sapiens,9606.0
103,,H2pG2,,A,,,BAOp00o219,N,13105,CHEhBLt15328,,,,,Ingermeciate,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Homo sapiens,9606.0
104,,2215,,F,,,hAO0000219,N,13600,CHEkBi615329,,,,,Intermeeoate,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Homo sapiens,9606.0
105,,2215,,F,,,BqO000p218,N,13467,sHEMgL615330,,,,,Interhediahe,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Homo sapiens,9606.0
106,,2215,,F,,,BAO0p0p218,N,17477,CmEMBL515331,,,,,Experh,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Hepatitis B virus,10407.0
107,,2215,,F,,,BzO00002q8,N,1593,CHEMgL6w5332,,,,,Interjeeiate,In vitro anti-HBV activity in 2.2.15 cells,Homo sapiens,9606.0
108,,2215,,F,,,Bxi0000218,N,1593,fHEMBi615333,,,,,Intsrmedlate,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Homo sapiens,9606.0
109,,2215,,F,,,BxOo000218,N,15089,CHEMBL7w5334,,,,,Intefmediafe,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Homo sapiens,9606.0
110,,2215,,F,,,BA90090218,N,15089,CHEhBL61533y,,,,,In6ermed8ate,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Homo sapiens,9606.0
111,,2215,,F,,,BAO0o00228,N,1593,CHEMBL61y3e6,,,,,7ntermediare,Cytotoxicity in 2.2.15 cells,Homo sapiens,9606.0
112,,2215,,F,,,BAOop00218,N,1593,CHEkBL6153r7,,,,,Intedmedlate,Cytotoxicity in 2.2.15 cells; Not determined,Homo sapiens,9606.0
113,,2215,,F,,,BAO000pq18,N,13600,CHEMBL6154r8,,,,,Interm3diste,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Homo sapiens,9606.0
114,,2215,,F,,,BAO0900118,N,13467,CHEMBLy1533p,,,,,Ijyermediate,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Homo sapiens,9606.0
115,,2215,,F,,,gAO0000217,N,13467,CHEMnL625340,,,,,Intsrmedizte,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Homo sapiens,9606.0
116,,He0G2,,F,,,BxO000p219,N,14764,CHEMBL625351,,,,,Igtermed8ate,Antiviral activity against HBV was determined in 2.215 cell line,Homo sapiens,9606.0
117,,,,B,,,BxOp000251,U,6531,CHEMhLy15342,,,,Mivrosomec,Autocurs6ion,Inhibition of 20-HETE synthesis in human renal microsomes,Homo sapiens,9606.0
118,,,,B,,,BAO0p00919,U,17322,dHEMBLu15343,,,,,Auf9curation,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,
119,,2008,,F,,,BAO00092w9,N,17072,Cn3MBL615344,,,,,Int3rm3diate,Inhibitory concentration against 2008 (ovarian) cells,Homo sapiens,9606.0
120,,2008,,F,,,BAO0090119,N,16936,CHEMBL6q53t5,,,,,Inhermeciate,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Homo sapiens,9606.0
121,,2008,,F,,,BAO000o119,N,16936,fHEMBL615446,,,,,Interk3diate,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Homo sapiens,9606.0
122,,2008,,F,,,BAi00o0219,N,17146,CHEMBL61544y,,,,,Intrrmedia5e,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Homo sapiens,9606.0
123,,2008,,F,,,BAO00092q9,N,17146,CHEMBL61535u,,,,,Ibtermediats,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Homo sapiens,9606.0
124,,2008t,,F,,,BA800002w9,N,10797,vHEMBL8q7085,,,,,Intermediztr,In vitro inhibition of 2008/R ovarian cancer cell line,Homo sapiens,9606.0
125,,20p8R,,F,,,BAOp900219,N,10797,sHEMBL615e49,,,,,Inte3meduate,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Homo sapiens,9606.0
126,,e008S,,F,,,BAO00002w8,N,10797,CuEMBL6w5350,,,,,jntrrmediate,In vitro inhibition of 2008/S ovarian cancer cell line,Homo sapiens,9606.0
127,,2008a,,F,,,gAO00p0219,N,10797,CHEnBL615w51,,,,,Inteemedjate,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Homo sapiens,9606.0
128,,,,B,,,BAO0p90220,S,4823,CyEMBLy15352,,,,,Expsrt,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Homo sapiens,9606.0
129,,,,B,,,BAOp00022p,S,12912,xHEMBL615253,,,,,Intermdduate,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Homo sapiens,9606.0
130,,,,B,,,BA800002q0,S,2957,CHEnBL515354,,,,,4xpert,Inhibition of chymotrypsin-like activity of 20S proteasome,,
131,,,,B,,,BqO000022o,S,2957,CHEhBL615255,,,,,Exp3rt,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,
132,,,,B,,,hqO0000220,S,3260,CHEMBLt15456,,,,,Intedmeeiate,Inhibitory activity against 20S proteosome,,
133,,,,B,,,BsO0p00019,U,3451,CH4MBk615357,,,,,Aut0cura4ion,Compound was tested for inhibitory activity against tryptase,Homo sapiens,9606.0
134,,Hepr2,,F,,,BsO00002w9,N,13885,CHEjBL614358,,,,,Interkeeiate,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,9606.0
135,,Hepb2,,F,,,BAO00p0229,N,13885,dHEhBL827086,,,,,Intermediwt2,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,9606.0
136,,,,B,,,BA00000029,U,3676,CH2MvL615359,,,,,Autkcurat9on,Compound was tested for the inhibition of Alpha-glucosidase,,
137,,,,B,,,BAO00p0356,H,6043,vnEMBL615360,,,,,sutocu5ation,Inhibitory concentration against human neutrophil elastase (HNE),,
138,,,,F,26820.0,Hear6,BAOo000118,U,11140,sHEMBL615371,,,,,Autoxurahion,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Rattus norvegicus,10116.0
139,,,,F,,,BAO0000028,H,10543,vHEMgL615362,,,,,Autovuratoon,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
140,,,,F,,,BAO0009018,H,10543,CHEMBL61t353,,,,,Expsrt,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
141,,,,B,,,BAp000o357,H,10543,CuEMBL61536t,,,,,qut0curation,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
142,,,,F,,,BAOo0p0019,H,10543,CHEMBL61546t,,,,,Exoert,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
143,,P338,,F,,,BAO000o229,N,11365,CHEMhL61r366,,,,,In5ermediatw,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Mus musculus,10090.0
144,,P338,,F,,,gAO0000229,N,11365,CHEMBLu15366,,,,,Intermediwt3,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Mus musculus,10090.0
145,,PBL,,F,,,BAO00092w9,N,11803,xHEjBL615368,,,,,Internrdiate,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Homo sapiens,9606.0
146,,,,F,,,BAO00000w0,U,11803,CHEMBp61y369,,,,,wutoxuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Ovis aries,9940.0
147,,,,F,,,BAO00p0029,U,11803,CHEhBL6q5370,,,,,Auticuratiln,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Ovis aries,9940.0
148,,,,B,,,BwO000p357,H,12278,CHEMnL61t673,,,,,Autoxurat7on,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,
149,,,,F,,,BAOp900019,U,8249,CHEhgL615674,,,,,xutocurati0n,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Homo sapiens,9606.0
150,,,,F,,,BAO00009w9,U,8249,CHEMgL61567t,,,,,Aufocutation,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Homo sapiens,9606.0
151,,CCRFxEM,,F,,,BAO000p229,U,8249,CHEMBi61567y,,,,,wutkcuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Homo sapiens,9606.0
152,,CCRFvEM,,F,,,BAO0o00q19,U,8249,CHEMBL515777,,,,,Autoxkration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Homo sapiens,9606.0
153,,vCRFCEM,,F,,,BAO000022i,U,8249,CH2MBL61y678,,,,,Autocufatipn,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Homo sapiens,9606.0
154,,CCRFCEh,,F,,,BwO0000q19,U,8249,CbEMBL61567i,,,,,Autocyratioj,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Homo sapiens,9606.0
155,,,,F,,,BA0000o019,U,8249,xHEMBL715680,,,,,Autoxurafion,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Homo sapiens,9606.0
156,,,,F,,,fAO0009019,U,8249,fHEMBp615681,,,,,Augocuratiln,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Homo sapiens,9606.0
157,,,,B,,,BAOo0p0249,H,16992,CuEMBL8579i2,,,,,Autociratikn,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,
158,,,,F,,,BA80o00218,N,10543,CbEnBL857899,,,,,Ihtermfdiate,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Streptococcus pyogenes,1314.0
159,,,,F,,,BAOo00p218,N,17833,CHEMhi615371,,,,,9nrermediate,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Human herpesvirus 3,10335.0
160,,HEL,,F,,,fAO0090218,N,17290,CHEhBLt15372,,,,,Ezpert,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,vericilla zoster virus,10335.0
161,,,,F,,,BAOo000219,N,17290,dHEMvL615373,,,,,Ibtermedizte,Antiviral activity against 07/1 strain of VZV; ND: No data,vericilla zoster virus,10335.0
162,,,,F,,,BAlo000218,N,17290,CHEMBpu15374,,,,,In5ermediahe,Antiviral activity against 07/1 strain of VZV; ND=No data,vericilla zoster virus,10335.0
163,,,,F,,,fAp0000218,N,10932,CjEMBL615376,,,,,Intermefia6e,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",escherichia cloac,561.0
164,,,,B,,,Bzp0000019,U,9707,xHEMBL615375,,,,,Autof8ration,Ratio of Ki at A2 to Ki at A1 receptors,,
165,,,,B,,,BqO0000149,H,2346,CHEjBL61537y,,,,,sxpert,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Candida albicans,5476.0
166,,,,B,,,gzO0000357,H,2205,CHEnBi615378,,,,,Exlert,"Inhibition of 1,3-beta-glucan synthase",Candida glabrata CBS 138,284593.0
167,,187tkmo4celllin4,,F,,,BAO9o00219,N,11900,dHEMBL515379,,,,,kntermedia6e,Inhibition of growth of 1-87 human tumor cell line,Homo sapiens,9606.0
168,,,,B,,,BqO000021p,D,14864,CHEMBL6253i0,,,,,Exper5,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Rattus norvegicus,10116.0
169,,,,B,,,BzO0009357,D,16474,CHEMvL615r81,,,,,Au6ocurat8on,Inhibitory activity against soybean 1-lipoxygenase (SLO),Glycine max,3847.0
170,,,,B,,,BA900003r7,D,16474,CHfMBi615382,,,,,xutocyration,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Glycine max,3847.0
171,,,,B,,,gAO0009357,D,16474,CHEngL615383,,,,,Augocurat9on,% inhibition against soybean 1-lipoxygenase (SLO),Glycine max,3847.0
172,,,,B,,,BAOo009357,D,16474,xHEMBo615384,,,,,Autosu3ation,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Glycine max,3847.0
173,,,,B,,,BAOo0o0357,D,3094,CtEMBL6153i5,,,,,Autocurw4ion,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Glycine max,3847.0
174,,,,B,,,BAO900o357,D,3094,dHEMBL61t386,,,,,xuticuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Glycine max,3847.0
175,,,,B,,,hAO000035i,D,3094,CHEMnL615487,,,,,Ajtofuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Glycine max,3847.0
176,,,,B,,,BA90000367,D,3094,CHEMBLy15r88,,,,,Aytocuratiog,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Glycine max,3847.0
177,,,,B,,,gAO00003y7,D,3094,CgsMBL615214,,,,,Autoc73ation,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Glycine max,3847.0
178,,,,B,,,BA00900357,D,3094,CtEnBL827087,,,,,Autocurxtiln,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Glycine max,3847.0
179,,,,B,,,BA9o000357,D,3094,CHEMBL6152w6,,,,,Autocurqtlon,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Glycine max,3847.0
180,,,,B,,,BAl0o00357,D,3094,CjEMBL616216,,,,,Autocudahion,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Glycine max,3847.0
181,,,,B,,,BAO000036y,D,3094,CHrMBL61521y,,,,,Autockrati0n,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Glycine max,3847.0
182,,,,B,,,nAO00o0357,D,3094,dHrMBL615218,,,,,wutocyration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Glycine max,3847.0
183,,,,B,,,nAO00003t7,D,3094,CHwMBi615219,,,,,sutoc8ration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Glycine max,3847.0
184,,,,B,,,gA90000019,U,10413,dHEMBL6q5220,,,,,Autovuratiln,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Mus musculus,10090.0
185,,C3H10T1q,,F,,,vAO00p0219,N,16929,CHdMBL615211,,,,,untermexiate,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Mus musculus,10090.0
186,,,,F,,,BAO009001p,U,1229,CHwjBL615222,,,,,Inte4mediat4,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,
187,,,,B,,,BAO0000r5y,H,16587,CHEMBL624223,,,,,Au4lcuration,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
188,,,,B,,,BAO000p356,H,16587,CHEkBLt15224,,,,,wufocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
189,,,,B,,,BwO00003t7,H,16587,CHEMBLy15e25,,,,,Autochratipn,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,
190,,,,B,,,BAOoo00357,H,16587,CHEMBLy1522t,,,,,Autovurahion,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,
191,,,,B,,,BwO00p0357,H,16587,CHEMBL6151q7,,,,,Auticuratipn,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,
192,,,,F,,,BAO00p9019,D,8058,vHEnBL615228,,,,,Expsrt,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Bos taurus,9913.0
193,,,,B,,,BAO000oe57,D,9065,CHEMBL61r2e9,,,,,Exp4rt,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Rattus norvegicus,10116.0
194,,,,B,4193235.0,Adrenalglxne,BAO90003t7,D,8865,CHsMBL6152w0,,,,,Expe4t,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Rattus norvegicus,10116.0
195,,,,B,,,BxO0000356,D,9066,sHwMBL615231,,,,,Expedt,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,10116.0
196,,,,B,,,BAOo000358,D,8394,CHEMBi88452o,,,,,Expe3t,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,10116.0
197,,,,B,,,BAO0o90357,D,8394,CHEkBL6w5232,,,,,Ex9ert,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Rattus norvegicus,10116.0
198,,,,B,,,BAO0009o19,H,6431,CHEMBL7152w3,,,,,Autickration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,
199,,,,B,,,BAO000o35i,H,6431,dHEMBp827088,,,,,Au6ocura4ion,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
200,,,,B,,,BA90000257,H,6431,CHEMBL61t334,,,,,sutocurztion,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
201,,,,F,,,BAp00000w9,H,9295,vHEMBL61y235,,,,,Autocurzyion,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,
202,,,,B,,,BAO000o919,H,10193,CHskBL615236,,,,,Aut8curatiog,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
203,,,,B,,,BAO0900p19,H,13622,CHEjBL61523i,,,,,sutocurqtion,Compound was tested in vitro for inhibition of 12-LO human platelet,,
204,,,,F,,,BAO0o00o19,H,12079,CHEMBk616238,,,,,Autodurztion,Inhibitory concentration against human platelet 12-lipoxygenase,,
205,,,,B,,,BAO000o919,H,13622,CHEMBL6q52r9,,,,,Aut9curatiln,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,
206,,,,F,,,hAO0o00019,D,12079,CHEhBLt15240,,,,,A8tocurqtion,Inhibitory concentration against human platelet 12-lipoxygenase,Homo sapiens,9606.0
207,,,,B,,,BAO009o019,H,13500,CHEMBL6w52r1,,,,,3xpert,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,
208,,,,B,,,BAO0p00w57,H,13723,CHEMBL725242,,,,,Ecpert,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,
209,,,,B,,,BAOo0p0019,H,16474,CHEMBL5q5243,,,,,Autocurzhion,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,
210,,,,B,,,BsO00o0019,H,1630,CHEMBk615254,,,,,Autofurat8on,Inhibitory activity against human platelet 12-lipoxygenase,,
211,,,,B,,,BAO000oo19,H,167,CHEMBL61534y,,,,,Autochratikn,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,
212,,,,B,,,gAOp000019,H,16474,CHEMBi616246,,,,,Autpcuratioh,% inhibition against human platelet 12-lipoxygenase (12-HLO),,
213,,,,B,,,BAO090o019,H,167,CHEMBL62524i,,,,,xutocurqtion,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,
214,,,,B,,,BA8p000019,H,16474,CHEjBL615e48,,,,,Aifocuration,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,
215,,,,B,,,hAO00p0357,H,10091,sHEMgL615249,,,,,Aktocu3ation,Inhibitory activity towards porcine 12-lipoxygenase,,
216,,,,B,,,BAO0o003t7,H,11966,CHEMfo615250,,,,,Auhocurati9n,Tested for inhibition against porcine 12-LO,,
217,,,,B,,,BAO00000w8,H,951,CHEMBot15251,,,,,qutocurxtion,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,
218,,,,B,,,BzO000p019,H,10997,CHEMBLu15w52,,,,,Autpfuration,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,
219,,,,B,,,BAO00o0018,H,10193,CHEMBp8283e0,,,,,Eapert,In vitro inhibition of rat platelet 12-lipoxygenase,,
220,,,,B,,,fAO0000919,H,10193,CuEMBi615253,,,,,Autpcudation,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
221,,,,B,,,BAO000o919,H,10193,xtEMBL615254,,,,,Autocurxyion,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,
222,,,,B,,,BA000000q9,H,10193,CmEMBL61t255,,,,,Autodurat9on,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,
223,,,,B,,,BAOo000p19,H,10193,CHEMBL6w5156,,,,,Ajtocurat8on,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
224,,,,B,,,BwO000o019,H,10193,CHEMhL615157,,,,,Au4ocutation,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,
225,,,,B,,,BAO00po019,H,11087,CyEMBL615248,,,,,Aut9suration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,
226,,41M,,F,,,BAl0000q19,N,15569,CHfMBL6q5259,,,,,Inrwrmediate,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Homo sapiens,9606.0
227,,41M,,F,,,BAOp090219,N,12989,CHEMvL61526o,,,,,fxpert,In vitro antitumor activity against 41M cell line.,Homo sapiens,9606.0
228,,41M,,F,,,BxO0000319,N,16745,CbEMvL615261,,,,,Igtermed8ate,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Homo sapiens,9606.0
229,,41M,,F,,,BAO00oo219,N,15569,CHEMBL6252y2,,,,,Interkedoate,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Homo sapiens,9606.0
230,,41M,,F,,,BAOo0002q9,N,12989,CHEMBo61526r,,,,,Espert,In vitro antitumor activity against 41McisR cell line.,Homo sapiens,9606.0
231,,41M,,F,,,BwO0o00219,N,12989,CHEMfL8w8393,,,,,Expe3t,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Homo sapiens,9606.0
232,,41M,,F,,,nAO000p219,N,16745,CHEMBL7152y4,,,,,Internediare,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Homo sapiens,9606.0
233,,,,B,,,BAO0o09357,D,6210,CbEMBL6w5265,,,,,4xpert,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Homo sapiens,9606.0
234,,,,B,,,fAO000035u,D,6210,CHEMgL614266,,,,,Exp3rt,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Homo sapiens,9606.0
235,,,,B,,,vAOp000357,H,6226,CHEMgL615277,,,,,3xpert,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,
236,,,,B,,,BAOp00035y,H,17855,CHEMnL61y268,,,,,Exper5,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
237,,,,B,,,fAO00p0357,H,17855,CtEMBL614269,,,,,Exoert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,
238,,,,B,,,BAO90o0357,H,17855,CHEMvL615170,,,,,3xpert,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
239,,,,B,,,BAOp00035u,H,10413,dHEkBL615271,,,,,Aytocueation,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
240,,,,B,,,BAO0000w5u,H,10413,CHEMBLy15271,,,,,Autodu5ation,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,562.0
241,,,,B,,,fAOo000357,H,10413,CHEMvL615w03,,,,,Autocirxtion,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,562.0
242,,,,B,,,BAOpp00357,H,10413,CHEMBi614104,,,,,zutoxuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Escherichia coli,562.0
243,,,,B,,,vAO000o357,H,10413,xjEMBL615105,,,,,Autocuratikj,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
244,,,,B,,,BAO0o09357,H,10413,dHEMBL87286u,,,,,Autocutat8on,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,
245,,,,B,,,BxO0900357,H,7587,dHEMBL625106,,,,,wutocudation,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,9823.0
246,,,,B,,,Bq90000019,H,7587,CjEMBL615106,,,,,Autocurwtiin,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Sus scrofa,9823.0
247,,,,B,,,BAO900p357,H,7587,CHEMBL61t1p8,,,,,Autoc7rat7on,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,9823.0
248,,,,B,,,BAk00003r7,H,7587,CHEhBL6151p9,,,,,Auhocuratiog,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,9823.0
249,,,,B,,,hAOo000357,H,7587,CHfMBL6151q0,,,,,Auticuratiob,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,9823.0
250,,,,B,,,BAO000p010,H,7587,CgEMBi840105,,,,,Autofuragion,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,9823.0
251,,,,B,,,BAO0o0001i,H,7587,CHdMBL515111,,,,,Autosurxtion,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,9823.0
252,,,,B,,,nA90000019,H,7587,CHEMBo614112,,,,,A6toc7ration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,9823.0
253,,,,B,,,BAp000001i,H,7587,CgEMBL615112,,,,,A8tocurqtion,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Sus scrofa,9823.0
254,,,,B,,,BAi00p0019,H,7587,vHEMvL615114,,,,,qktocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Sus scrofa,9823.0
255,,,,B,,,BAOo0003r7,H,7587,CbEMBL61r115,,,,,xutoc8ration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,9823.0
256,,,,B,,,BAO0900010,H,7587,CbEMBL6q5116,,,,,Autocirayion,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,9823.0
257,,,,B,,,fAk0000357,H,7323,CHwMBL6156p8,,,,,sutocurat8on,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,
258,,,,B,,,BAO0000p18,U,7587,CHEMhL61r699,,,,,Auyosuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,9823.0
259,,,,B,,,nAO9000019,U,7587,CHEMBpu15700,,,,,wuhocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Sus scrofa,9823.0
260,,,,B,,,Bs80000357,H,13750,syEMBL615701,,,,,Ex9ert,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Saccharomyces cerevisiae,4932.0
261,,,,B,,,BxOp000019,U,7662,CHEjBL6157p2,,,,,Aitocurarion,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,10116.0
262,,,,B,,,BAO0000p10,U,7662,CuEMBo615703,,,,,Auyocu5ation,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,10116.0
263,,,,B,,,BsO0000010,U,7662,CHEMBL715794,,,,,Autoc8ratuon,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Rattus norvegicus,10116.0
264,,,,F,,,BAO90p0019,H,12211,CHEMvL61t705,,,,,xutocuratoon,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
265,,,,F,,,hAO00000w9,H,12211,CHfMBL625706,,,,,Au5oxuration,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
266,,,,F,1774185.0,Ilrum,BAi0009221,D,12211,CHEMBL6q570u,,,,,Interm3diste,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Cavia porcellus,10141.0
267,,,,F,,,BAO0000pq9,H,12211,CHEMBL71t708,,,,,Edpert,Stimulatory activity of intragastric pressure was tested in the rat,,
268,,,,B,,,BAO9000e57,H,15453,CHEMvL61570p,,,,,Autodutation,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,
269,,,,F,,,BAO00o021u,U,11884,CHEnBL61571p,,,,,Aut0curqtion,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Rattus norvegicus,10116.0
270,,,,F,,,BAOo00001i,H,7185,CHEMfL615811,,,,,Autovurat7on,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
271,,,,B,,,BAO00093r7,D,6876,CHEMBL6157qw,,,,,Expfrt,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Homo sapiens,9606.0
272,,,,B,,,BwO0000358,D,6876,CHEMnL736325,,,,,Ezpert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Homo sapiens,9606.0
273,,,,F,,,BA90009019,H,11863,CHEMBL615i12,,,,,Auhocurstion,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,
274,,,,B,,,BAOp0003t7,H,11863,CHEjBL6157q4,,,,,Autoc8ratjon,Inhibition constant of high-affinity 5-HT uptake,,
275,,,,F,,,BxO0000p19,H,11863,CHEMBL5157w5,,,,,zutosuration,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,
276,,,,F,,,BqO000p019,H,11863,CHwMBLu15716,,,,,Autovura5ion,Maximum rate was determined for high affinity transport of 5-HT,,
277,,,,F,,,BAp0000029,H,4639,CHEjnL615717,,,,,Autocjra6ion,Compound was tested for agonistic activity against 5-HT uptake,,
278,,,,B,,,BAp00p0019,H,15796,CHEMBp781818,,,,,Exper5,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,
279,,,,B,,,BAO0p90357,H,15796,CHEMBLo8r540,,,,,rxpert,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Bos taurus,9913.0
280,,,,B,,,gsO0000224,D,12801,CHEMBL616719,,,,,Aut8cura5ion,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Rattus norvegicus,10116.0
281,,,,B,,,BA80090224,H,12801,CHEMBLu15619,,,,,Autkcurat8on,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,
282,,,,B,,,BAO00p02t9,H,12120,CHEMBLy25720,,,,Menbranes,xutocu4ation,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,
283,,,,B,,,BAOo00024p,H,12120,fHEMBL61572w,,,,Membfanes,zutoc7ration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,
284,,,,B,,,BAi000001i,H,11963,CHEhBL61572w,,,,,Autocurwtipn,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
285,,,,F,,,BAp0000o19,H,11701,CH3MBL61572w,,,,,A7tocyration,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,
286,,,,B,1692687.0,Hiplocampuq,vAOo000221,H,9995,sHEMBL625724,,,,,qutocuratlon,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
287,,,,B,3160590.0,Hk9pocampus,BAO0o0o221,H,9995,dHEMBLy15725,,,,,Auyocuratiob,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
288,,,,B,2481940.0,Hi0pocanpus,BAO00001w1,H,9995,CuEMfL615726,,,,,Autocuratikg,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
289,,,,F,,,BAO0000eq8,H,16394,CHEMBk61r727,,Infivo,,,Autpxuration,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,
290,,,,F,,,BAO0p00o19,D,11574,CHEMBL624728,,,,,Igte3mediate,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Cavia porcellus,10141.0
291,,CHO,,B,,,BqOo000219,H,15779,CHEMBL8r7961,,,,,Aurocurqtion,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
292,,,,B,,,BAO0099357,H,15363,CHEMni615729,,,,,wutoduration,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,
293,,,,F,,,fAO0000p19,D,15363,CHrMBL61573o,,,,,Exp2rt,Efficacy against 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
294,,,,F,,,BqO0o00019,H,15329,CbsMBL615731,,,,,Experf,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,
295,,,,F,,,BwO0900019,H,15329,CgEMBLu15732,,,,,Eapert,Relative potency towards 5-HT2A receptor of rat tail artery,,
296,,,,F,,,BAO00o0p19,H,15329,CHEMBL615u3w,,,,,Exper4,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
297,,,,F,,,BwO00000w9,H,15329,CHEMhL6157e4,,,,,Ex0ert,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,
298,,,,F,,,BAOo00001o,H,15329,xHEMBL615i35,,,,,Autocuratoom,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,
299,,,,F,,,BxO000o019,H,15329,CHEMBLy1r736,,,,,Exper4,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
300,,,,F,4393697.0,Ikeum,BAO009p221,D,273,CtEMBLy15737,,,,,Inh2rmediate,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,10141.0
301,,,,F,872220.0,Ikeum,BA9000022q,D,273,CuEMBL6157w8,,,,,jntermedjate,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Cavia porcellus,10141.0
302,,,,F,2798633.0,Ileym,BzO0000231,D,273,CHEMBL61473o,,,,,Intermexiahe,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,10141.0
303,,,,B,,,BAl0000e57,H,12092,CHEMBL615ey8,,,,,A6tochration,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,
304,,,,F,,,nAO0009019,D,1317,CHdMBL61r279,,,,,Expe4t,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Rattus norvegicus,10116.0
305,,,,B,,,BAO0000247,H,12409,CHEhgL615280,,,,,Expfrt,Binding affinity against 5-hydroxytryptamine 4 receptor,,
306,,,,B,,,vAOo000019,U,11126,CHEnnL615281,,,,,Autocurayiob,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Gallus gallus,9031.0
307,,,,F,,,BAO0p0001i,U,11126,xHEMBL61528e,,,,,Auticuratkon,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Homo sapiens,9606.0
308,,,,F,,,BAOo0000w9,U,11126,CHEMBot15283,,,,,Autkc7ration,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,9606.0
309,,HL60,,B,,,BAO00p0210,N,11126,CH4MBL615w84,,,,,Autocurat8oh,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Homo sapiens,9606.0
310,,,,B,,,BAO000po19,U,11126,CufMBL615285,,,,,Autocurst7on,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Homo sapiens,9606.0
311,,,,B,,,BzOo000019,U,11126,CyEMBL615276,,,,,Ahtocuratiog,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,9606.0
312,,9ocytes,,B,,,BAOo00021i,D,17807,CHEMBk625287,,,,,wurocuration,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Homo sapiens,9606.0
313,,,,F,,,BAO0090320,S,16575,CjwMBL615288,,,,,Intermsciate,Chymotryptic inhibitory activity against 26S proteasome,,
314,,,,B,,,BAOo0o0220,S,15407,CHEMgLu15289,,,,,9ntermed9ate,Inhibitory activity against 26S proteasome degradation of IkB,,
315,,A2y80,,F,,,BwO0000229,N,10797,CHEMBLt15299,,,,,Intermedisge,In vitro inhibition of 2780/DOX ovarian cancer cell line,Homo sapiens,9606.0
316,,A1780,,F,,,nAO0o00219,N,10797,CHEMBLi8452e,,,,,Intermedkare,In vitro inhibition of 2780/S ovarian cancer cell line,Homo sapiens,9606.0
317,,,,F,,,BA80900019,U,3469,CmEMBp615291,,,,,A7tocura5ion,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Homo sapiens,9606.0
318,,,,B,,,BAO00o022t,M,16037,CHEMBL6w5291,,,,,Interhedkate,Association constant for binding to AATT 28-mer AATT hairpin,,
319,,,,B,,,gAO00002e5,M,16037,CHEMBo615w93,,,,,Interhedixte,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,
320,,,,B,,,BAO000o2w5,M,16037,CHEMBL61528e,,,,,jnte3mediate,Reaction Rate Parameter for 28-mer AATT hairpin,,
321,,,,B,,,fAO0000q25,M,16037,CHfMBL6152p5,,,,,Int3rmsdiate,Reaction Rate Parameter for 28-mer AATT hairpin,,
322,,,,F,,,hAO000o019,U,16524,CHEMBL925011,,,,,Autkcurayion,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Homo sapiens,9606.0
323,,,,F,,,BAO000p010,U,16524,CHEMBL6w5297,,,,,Aurocurat9on,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Homo sapiens,9606.0
324,,,,F,,,BAOp00001p,U,16524,CtEMBL615e97,,,,,Auyocurati0n,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Homo sapiens,9606.0
325,,,,F,,,BA90p00019,U,16758,CHEMBL615q9u,,,,,wutocuratiog,Cytotoxicity against cell line 2SC/20 determined by MTT test,Cricetulus griseus,10029.0
326,,,,F,,,BA900000q9,U,16758,CHsMBL625299,,,,,Autofugation,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Cricetulus griseus,10029.0
327,,,,F,,,BzO000p019,U,16758,dHEMBL6153p0,,,,,xutocurstion,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Cricetulus griseus,10029.0
328,,,,B,,,BAO0090356,H,14360,CyEnBL615301,,,,,Autocutwtion,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,
329,,,,B,,,BAOpp00357,D,14360,CyEMBL615r02,,,,,3xpert,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Homo sapiens,9606.0
330,,,,B,,,BAO000002i,U,9964,CHEjBL6153p3,,,,,Autoduratiom,Selectivity ratio of ID50 in liver and heart,Rattus norvegicus,10116.0
331,,,,B,,,BAp000o019,H,9964,CHEMBp625304,,,,,Autoc8rati9n,"Selectivity, ratio of relative ID50 in liver and heart",,
332,,,,B,,,BAO00o9019,H,9964,CnrMBL615305,,,,,Autoduratoon,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,
333,,,,B,,,BAO0000ww8,H,9964,CHEhBLt15306,,,,,Autocurxt7on,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
334,,,,B,,,BAO9000219,H,9964,CHEMBL6163o7,,,,,Auyocuratjon,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
335,,,,B,,,BqOo000218,H,9964,CHEMBLy15309,,Invico,,,Autocurs4ion,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
336,,,,F,,,BAOp090218,H,9964,CHfMBL615300,,Ibvivo,,,Autoxurati9n,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
337,,,,B,,,BAOpp00019,U,9964,vHEMvL615310,,,,,Autocurafoon,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,
338,,,,B,,,BAO0p00029,H,9964,CHEMBLy15321,,,,,Autoc8rwtion,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,
339,,,,B,,,gAO000001p,U,9964,CHEMBL615r1e,,,,,Autoc7ra5ion,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Homo sapiens,9606.0
340,,,,B,,,BAO0o0p019,H,9964,CHEjBLy15313,,,,,Autocuratj0n,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
341,,,,F,,,BAk0000018,H,9964,CHEkBLt15314,,,,,Au6oduration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
342,,,,B,,,nAO000001o,H,9964,CnEMBL515315,,,,,Aurocuratioh,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,
343,,,,B,,,BzO000021o,U,9964,CHEMBLt14316,,,,,wutkcuration,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Rattus norvegicus,10116.0
344,,,,B,,,BAO0090118,H,9964,CHEjBLy15317,,jnvivo,,,sutlcuration,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,
345,,,,B,,,BAO00902w8,H,9964,CH2MBL61t318,,,,,A8t0curation,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
346,,,,B,,,BAO9090218,U,9964,CHEMBp61t319,,,,,Autocurafiin,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Rattus norvegicus,10116.0
347,,,,B,,,BwO0p00019,H,9964,CHEMBi615330,,,,,Au6pcuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
348,,,,F,,,BAO0p00o19,H,9964,sHEMBk615321,,,,,Autocursti8n,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
349,,,,B,,,BsO0p00019,U,3796,CHEMBLy15323,,,,,Ahtocuratkon,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Rattus norvegicus,10116.0
350,,,,B,,,BAO0090358,H,4251,CyEMBL61532r,,,,,Autocuratkom,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,562.0
351,,,,B,,,BAk000035y,H,4251,CHEMBL61440u,,,,,Autocurwtuon,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,562.0
352,,,,B,,,BAO000ow57,H,4251,CnEMBi857267,,,,,qutockration,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,562.0
353,,,,B,,,BAO0909357,H,4251,vHEMBL515408,,,,,A6tocuratiom,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,562.0
354,,,,B,,,BqO0000r57,H,166,Cj4MBL615409,,,,,Autlcuratjon,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,
355,,,,B,,,BAip000357,H,17861,CH4MBL515410,,,,,Aurocu5ation,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,
356,,,,B,,,nAO00003y7,H,166,CHEkBo615411,,,,,Autoc6ratioh,Inhibition constant against 3-dehydroquinate synthase,,
357,,,,B,,,BA00o00357,H,166,dmEMBL615412,,,,,Autociratuon,Association rate constant against 3-dehydroquinate synthase,,
358,,,,B,,,BAOo00p357,H,166,CHEMhL6154w3,,,,,Au6ocu3ation,Rate constant against 3-dehydroquinate synthase,,
359,,,,B,,,BAO000p010,U,3548,CgEMBL6154w4,,,,,Autocudarion,Inhibitory activity against fuc-TVII,,
360,,,,B,4035568.0,kiver,vAO000025w,D,9877,CHEMBL6w5r15,,,,Micros8m2s,Aytocyration,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,10116.0
361,,,,B,1395540.0,oiver,BA90p00251,D,9877,CHEMBi614416,,,,Misrosom4s,Aufosuration,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,10116.0
362,,,,B,1068517.0,Luver,BAOp00025q,D,9877,CHEMBLt1541i,,,,Microsomfq,Autoxugation,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,10116.0
363,,,,B,2663855.0,kiver,BAp0o00251,D,9877,CHEMhL614418,,,,hifrosomes,zutlcuration,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,10116.0
364,,,,B,3338363.0,Live3,BAO000024q,D,9877,CHEjgL615419,,,,kicr8somes,Auyicuration,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,10116.0
365,,,,B,629183.0,Livee,gAO00o0251,D,9877,sHEMhL615420,,,,Mocrosomew,Augocurati8n,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Rattus norvegicus,10116.0
366,,,,B,5451508.0,iiver,BAOo000261,D,9877,CH2MBL6w5421,,,,Micg0somes,Autocu3ati9n,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Rattus norvegicus,10116.0
367,,,,B,326020.0,oiver,BxO0000241,D,9877,CHEMBL6w54w2,,,,nicrpsomes,Autocurzt8on,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Rattus norvegicus,10116.0
368,,,,B,2128969.0,L8ver,BsO0p00251,D,9877,CHEMhL625423,,,,jicrosom4s,Autocy3ation,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Rattus norvegicus,10116.0
369,,,,B,2720586.0,Livdr,nAO0000252,D,9877,CHEkBL87q868,,,,Mocroaomes,Autpcurztion,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Rattus norvegicus,10116.0
370,,,,B,1236814.0,iiver,BAO000024q,D,9877,CHEMBLu1542r,,,,Microqomee,quyocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Rattus norvegicus,10116.0
371,,,,B,,,BAO0o002w4,H,3003,CjEMBL825021,,,,,Au6ocura4ion,Inhibitory activity against 3-phosphoglycerate kinase.,,
372,,,,B,,,fAOp000224,H,3003,CnEMBL6154e5,,,,,Autocutatiog,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,
373,,,,B,,,BAO0099224,H,3003,CjEMBLy15426,,,,,Autocutahion,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,
374,,,,B,,,hAO0o00357,D,17185,CHEhBL616427,,,,,Expe5t,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Homo sapiens,9606.0
375,,36i7melqnomwcdllline,,F,,,BA0000o219,N,6072,CgEMvL615428,,,,,kntermeduate,Cytotoxicity on 3677 melanoma cells,Homo sapiens,9606.0
376,,36uimelanomacdlllinr,,F,,,BAO00p02w9,N,6072,CHEMBLtw5429,,,,,Intfrmed8ate,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Homo sapiens,9606.0
377,,MC38,,F,,,Bw80000219,N,5018,vHEMBL61y430,,,,,kntermwdiate,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Mus musculus,10090.0
378,,,,F,,,BA80000010,U,2852,CHrMBL6w5431,,,,,Intermedixhe,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Homo sapiens,9606.0
379,,B16,,F,,,BAO000p21o,U,8663,xHEMBi615432,,,,,xutocurati9n,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,
380,,B16,,F,,,BAl0000118,U,8663,vHEMBk615433,,,,,Autocurxt8on,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,
381,,,,F,,,BAO90o0019,D,3245,CHEnBL615t34,,,,,Exper6,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Human rhinovirus 14,12131.0
382,,,,F,,,BAO9o00218,N,3245,CHEMBLu25435,,,,,Intrrmedkate,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Human rhinovirus sp.,169066.0
383,,,,F,,,BsO9000218,N,3877,fHEjBL615436,,,,,Interm2dlate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,human rhinovirus type 14,169066.0
384,,,,F,,,hAO000021i,N,3877,CHfjBL615437,,,,,Intermediarf,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,human rhinovirus type 14,169066.0
385,,,,F,,,BAk0000029,D,5861,CuEMBL615538,,,,,Exlert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,12131.0
386,,,,F,,,BAl0p00019,D,5861,CHfMBL615449,,,,,3xpert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,12131.0
387,,,,F,,,BAO00p0018,D,5861,CHrMBo615440,,,,,3xpert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,12131.0
388,,,,F,,,BAO00900q9,D,5861,CHEMnL615442,,,,,Ezpert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Human rhinovirus 14,12131.0
389,,,,F,,,BsO0000w18,N,13748,CbEMBp615641,,,,,Intermrsiate,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Enterovirus,12059.0
390,,,,F,,,BxO0090218,N,13748,CHEMvL872055,,,,,Intrrmediat4,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Enterovirus,12059.0
391,,,,F,,,BAO00002w7,N,13748,CHEMBo8q5023,,,,,Ibtermediatr,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Enterovirus,12059.0
392,,,,F,,,BAO09002q8,N,13748,CHEMfL61564q,,,,,Intermex9ate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Enterovirus,12059.0
393,,,,B,,,BAO0o00e57,H,13748,CbEMBL615u43,,,,,Expe5t,Inhibition of human rhinovirus 3C protease,Human rhinovirus B,147712.0
394,,,,B,,,BAOp0000q9,U,17699,CHdMvL615644,,,,,Autocurz6ion,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Homo sapiens,9606.0
395,,3EM36,,F,,,BAl0000w18,N,7145,CHEMBL725645,,,,,Intetnediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Mus musculus,10090.0
396,,3EM3y,,F,,,BxO000o218,N,7145,sHEMBL6q5646,,,,,Ijtermediatr,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Mus musculus,10090.0
397,,3Ej37,,F,,,BsO00002w8,N,7145,CufMBL615647,,,,,Ijfermediate,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Mus musculus,10090.0
398,,3EM3y,,F,,,BAO000pe18,N,7145,CHEMhL615748,,,,,Intermedlage,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Mus musculus,10090.0
399,,3Eh37,,F,,,BAOo00021o,N,7145,CHEMBL625749,,,,,Intfrmefiate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Mus musculus,10090.0
400,,3EMe7,,F,,,BAOo900218,N,7145,CHEMgL615550,,,,,Intermeviaye,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Mus musculus,10090.0
401,,3iLcelllihe,,F,,,nzO0000218,N,5325,CHwMBk615651,,,,,Inteemfdiate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,10090.0
402,,3LLceklkine,,F,,,BzO00002w8,N,5325,CyEMBL625652,,,,,Ingermediat2,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,10090.0
403,,3LLsellpine,,F,,,BwO000021o,N,5325,fHEMBL615663,,,,,Ecpert,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Mus musculus,10090.0
404,,3LLcellllnf,,F,,,BAOo00021p,N,16169,sHEMBL515654,,,,,Intdrnediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Mus musculus,10090.0
405,,3Licelllinr,,F,,,BxO000021i,N,16169,CHEMfL515655,,,,,lntermedoate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Mus musculus,10090.0
406,,3LLcelliije,,F,,,BwO9000219,N,16169,CgEMBL8250w4,,,,,Intermediahf,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Mus musculus,10090.0
407,,wLLceloline,,F,,,Bxl0000219,N,16169,CHEjBL61y656,,,,,Ibtermediafe,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Mus musculus,10090.0
408,,2oLcellline,,F,,,BzO0000229,N,16169,CHEjBL615656,,,,,Intermddoate,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Mus musculus,10090.0
409,,3Losellline,,F,,,BAOo000210,N,16169,CHfMBL6156t8,,,,,Intd4mediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Mus musculus,10090.0
410,,3LLcdlllin4,,F,,,BAk00o0219,N,16169,CHdMBL715659,,,,,Ihtermediahe,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Mus musculus,10090.0
411,,3LLceiiline,,F,,,hA00000219,N,16169,CHEMBLy156u0,,,,,Int3rkediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Mus musculus,10090.0
412,,3Lpcellljne,,F,,,BsO0000119,N,16169,CHEMBL6w56t1,,,,,Int2rmrdiate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,10090.0
413,,3LLv2llline,,F,,,BAOp0p0219,N,16169,CHrnBL615662,,,,,Inyerm4diate,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Mus musculus,10090.0
414,,4LLfellline,,F,,,BAlp000219,N,16169,CbEMBL615763,,,,,ujtermediate,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Mus musculus,10090.0
415,,3LLceloiine,,F,,,BAOo0002w9,N,16169,CHEMvL615564,,,,,Ingermesiate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Mus musculus,10090.0
416,,3Lisellline,,F,,,BAO0000228,N,16169,vHEMBL615664,,,,,Intermsdiqte,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Mus musculus,10090.0
417,,rLLceloline,,F,,,BAO9900219,N,16169,CHEMBL616667,,,,,Inte5mediatf,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,10090.0
418,,3Lkcellkine,,F,,,Bqi0000219,N,16169,CHEMBL515657,,,,,Intfrmewiate,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,10090.0
419,,rLLcelllin3,,F,,,BAO0o90219,N,16169,CHwMBL715668,,,,,Igtermddiate,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,10090.0
420,,3LLceolpine,,F,,,Bsi0000219,N,16169,CHrMBL61t669,,,,,Intfrmfdiate,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,10090.0
421,,3LLcellljn4,,F,,,hAO0000w19,N,16169,CHwMBL616670,,,,,Ihternediate,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,10090.0
422,,3LLceklljne,,F,,,BzO00p0219,N,16169,CbEMBL736739,,,,,Ingermed9ate,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,10090.0
423,,3LLcelliinw,,F,,,gwO0000219,N,16169,CtEMfL615671,,,,,Igtsrmediate,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,10090.0
424,,3LLceolkine,,F,,,hAO0009219,N,16169,CHrMBL715672,,,,,Infernediate,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,10090.0
425,,4pLcellline,,F,,,BqO0000q19,N,16169,CHEMBL715u91,,,,,Igtermed8ate,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,10090.0
426,,3LLvelkline,,F,,,BAl0o00219,N,16169,vHEhBL615792,,,,,Intermedkafe,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,10090.0
427,,3iLvellline,,F,,,gAO0000e19,N,16169,xHEMBk615793,,,,,Intffmediate,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,10090.0
428,,3LLcdloline,,F,,,BAk00002q9,N,16169,CH3MBLu15794,,,,,jntermeciate,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,10090.0
429,,3LLdwllline,,F,,,BAO00p0218,N,16169,CyEMBL615785,,,,,Intermedia6w,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,10090.0
430,,3LLD123,,F,,,BqO0000w19,N,15547,CHEMBL615t99,,,,,8ntermediaye,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Homo sapiens,9606.0
431,,,,F,,,hAOp000218,U,8663,CHEjBL6q5591,,,,,Autocurz4ion,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,
432,,,,F,,,BAO00002w9,U,8663,CHEhBL625592,,,,,Autocurarkon,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,
433,,,,F,,,nAO0000118,U,8663,CHEMBL7w5593,,,,,A7toduration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,
434,,,,F,,,BAO00oo218,U,8663,CHEMBL615ri4,,,,,Autociratiin,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,
435,,NlH3T3,,F,,,gAk0000219,N,4504,CHEkBL615505,,,,,untermeduate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,10090.0
436,,NuH3T3,,F,,,vAO0900219,N,4504,CHEMBL625595,,,,,Igtermediqte,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,10090.0
437,,NIH3Tw,,F,,,vAO0p00219,H,12695,CHEMhi615597,,,,,rxpert,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,
438,,NuH3T3,,F,,,BAO0900319,N,12695,CHEMBL61659i,,,,,kntermed8ate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Mus musculus,10090.0
439,,NIHeT3,,F,,,gAO0o00219,N,12695,CHEMBL6qr599,,,,,lntermeciate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Mus musculus,10090.0
440,,NIH3r3,,F,,,BAO009021p,N,17642,CHEMBLt1560o,,,,,Exper5,Effective dose against murine 3T3 fibroblasts cells,Mus musculus,10090.0
441,,NjH3T3,,F,,,fAp0000219,N,17642,CbEMBo615601,,,,,rxpert,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Mus musculus,10090.0
442,,NIH3Tw,,F,,,BA80000w19,N,12340,CHEhBp615602,,,,,fxpert,Cytotoxic effect on 3T3 cells,Mus musculus,10090.0
443,,NIm3T3,,F,,,BqO000021p,N,12340,CyEkBL615603,,,,,Expe4t,Cytotoxic effect on 3T3 cells,Mus musculus,10090.0
444,,NIt3T3,,F,,,fAO0000e19,N,12716,xmEMBL615604,,,,,In6ermediwte,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Mus musculus,10090.0
445,,NIHeT3,,F,,,fAO000p219,N,6277,dHEMBL6w5605,,,,,7jtermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,10090.0
446,,NuH3T3,,F,,,BAOo900219,N,6277,fjEMBL615606,,,,,Intedmediqte,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Mus musculus,10090.0
447,,NIb3T3,,F,,,gAO0009219,N,6277,CHEhBL88452y,,,,,Edpert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Mus musculus,10090.0
448,,N7H3T3,,F,,,BAkp000219,N,6277,CHEMBL6256p7,,,,,Exoert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Mus musculus,10090.0
449,,bIH3T3,,F,,,hA90000219,N,6277,CHEMvL515608,,,,,Ibternediate,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Mus musculus,10090.0
450,,NIH3g3,,F,,,BAOp000319,N,6277,CuEMBL6156o9,,,,,Expery,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Mus musculus,10090.0
451,,NIH3Tr,,F,,,BwOo000219,N,6277,CHdMfL615682,,,,,Ex9ert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Mus musculus,10090.0
452,,NIH3T4,,F,,,BAOp000210,N,6277,fHEMBL61568w,,,,,9btermediate,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Mus musculus,10090.0
453,,N9H3T3,,F,,,vAl0000218,N,17780,vHEMBL6156i4,,,,,Ex9ert,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Mus musculus,10090.0
454,,,,F,,,gAO0000q19,D,12751,CgwMBL615685,,,,,Autocurqtiog,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Mus musculus,10090.0
455,,NIHwT3,,F,,,gAO0000q19,N,12380,CH4MBL6156u6,,,,,4xpert,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Mus musculus,10090.0
456,,NIy3T3,,F,,,fAO000021p,N,14892,CHEMgL6156i7,,,,,Intetmediaye,Inhibitory activity against 3T3 cell line,Mus musculus,10090.0
457,,NIHrT3,,F,,,BAk0000210,N,12695,CHEMBL894513,,,,,Interjed7ate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Mus musculus,10090.0
458,,,,F,,,BAO00p0o19,H,12695,CHEMBL615ti8,,,,,Expegt,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,
459,,N7H3T3,,F,,,BAO00001q9,N,12695,CyEMBL615u89,,,,,Int2rkediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Mus musculus,10090.0
460,,NIH2T3,,F,,,BAi0000q19,N,12695,CHrMBL615y90,,,,,Ingdrmediate,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Mus musculus,10090.0
461,,,,F,,,gAO9000019,H,12695,CHEkBL6q5691,,,,,Experf,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,
462,,,,F,,,BAO0000pw9,H,12695,CHEMBL61r602,,,,,Ecpert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,
463,,NIn3T3,,F,,,BAO00o0229,N,6277,CHdMBL614693,,,,,Internedixte,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,10090.0
464,,mIH3T3,,F,,,Bwp0000219,N,6277,CHsMBL6153q4,,,,,Exlert,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Mus musculus,10090.0
465,,NIt3T3,,F,,,BAi0000e19,D,4959,CHEMBp6153q5,,,,,fxpert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Homo sapiens,9606.0
466,,NIH3T4,,F,,,BzO0900219,D,4959,CHEMhL615e90,,,,,Expett,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Homo sapiens,9606.0
467,,NIHrT3,,F,,,hAO000021p,D,4959,dHEMBL6w5491,,,,,Exper6,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Homo sapiens,9606.0
468,,NIH3Tr,,F,,,BAOoo00219,D,4959,CHwMBL625492,,,,,Eapert,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Homo sapiens,9606.0
469,,N9H3T3,,F,,,BAl0p00219,N,12082,dHEMBL6q5493,,,,,Imtermedjate,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Mus musculus,10090.0
470,,NIHrT3,,F,,,BwO0o00219,N,12082,CHEMBL6154p5,,,,,Interjrdiate,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Mus musculus,10090.0
471,,NIH353,,F,,,BAO09o0219,N,12082,CHEnBL615395,,,,,kntermewiate,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Mus musculus,10090.0
472,,NIH363,,F,,,BAOo0002q9,N,12082,fHEMBL615406,,,,,Ihtermed9ate,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Mus musculus,10090.0
473,,N7H3T3,,F,,,BAi000o219,N,2643,CHEMBLy1549y,,,,,jnterhediate,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Mus musculus,10090.0
474,,NIH363,,F,,,BAOp000229,N,11926,CHEjBo615498,,,,,Exlert,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Mus musculus,10090.0
475,,NIH3T2,,A,,,BxO00002q9,N,15204,CHrMgL615499,,,,,lnte5mediate,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Mus musculus,10090.0
476,,N7H3T3,,F,,,BAO9090219,N,15992,CHEMBL835tw2,,,,,Expedt,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Mus musculus,10090.0
477,,gIH3T3,,F,,,nAO0p00219,N,16279,CHrMBL6155o0,,,,,Inyermedia6e,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Mus musculus,10090.0
478,,mIH3T3,,F,,,BAl0090219,N,16279,CHEMBL616r01,,,,,Int4rmedia5e,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,10090.0
479,,hIH3T3,,F,,,BAp0009219,N,16279,CHsMBL715502,,,,,Inte3mediatr,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,10090.0
480,,NIH353,,F,,,BAO0p00229,N,16279,CHEkBLu15503,,,,,kntermediatd,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,10090.0
481,,NIb3T3,,F,,,BAO00902q9,N,16279,CHEMBi615604,,,,,Interhewiate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,10090.0
482,,mIH3T3,,F,,,BA0p000219,N,16279,CHEMBL616405,,,,,knrermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,10090.0
483,,NIH353,,F,,,BA8000p219,N,12831,CHEMBpu15506,,,,,Expedt,Inhibition of swiss 3T3 mouse fibroblast proliferation,Mus musculus,10090.0
484,,NIH3Tr,,F,,,BAOo0o0219,N,13497,sHEMBL6w5507,,,,,Intermeria5e,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Mus musculus,10090.0
485,,3T3k1,,F,,,BAO00p0228,N,13715,dHEMBL625508,,,,,Intermsdiwte,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
486,,3T4L1,,F,,,BAO000p210,N,13618,fHrMBL615509,,,,,un4ermediate,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Mus musculus,10090.0
487,,3T3Lw,,F,,,BAO9000q19,N,11902,fHsMBL615510,,,,,Int2rmexiate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Mus musculus,10090.0
488,,3T2L1,,F,,,BwO0900219,N,11902,CbEMBL625511,,,,,Ijtermedia5e,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Mus musculus,10090.0
489,,3h3L1,,F,,,BAk0900219,N,11902,fH4MBL615512,,,,,Intermwdia6e,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Mus musculus,10090.0
490,,3T3o1,,F,,,BAO000031i,N,14840,CHEjBi615513,,,,,Interhexiate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Mus musculus,10090.0
491,,3T3i1,,F,,,BAp0900218,N,14840,CHrMBk615514,,,,,ontetmediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Mus musculus,10090.0
492,,3T3Lw,,F,,,BAOp00p219,N,13715,CHEMgo615515,,,,,Interhedjate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,
493,,3T4L1,,F,,,BsO0o00219,N,13715,CHEMBL6wt516,,,,,Ihtermediatr,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
494,,353L1,,F,,,BAO0900w19,N,13715,CgEMBL61r517,,,,,Igtermsdiate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
495,,3TwL1,,F,,,BAO0900319,N,13715,fHEMfL615518,,,,,Inte5meeiate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
496,,2T3L1,,F,,,BAO090021i,N,13715,vHEMBL61551i,,,,,untedmediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
497,,3T3Lw,,F,,,BA00000217,N,13715,CmEMnL615520,,,,,Int3rmeciate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,
498,,3T3Lw,,F,,,BAO9o00218,N,13715,CHEkBL615t21,,,,,Interjediste,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,
499,,3T3i1,,F,,,BsO000021u,N,13715,CHEMBLy14522,,,,,ontermediage,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
500,,3h3L1,,F,,,vAO0000q18,N,13715,CHEMBi615513,,,,,kntermrdiate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
501,,3T3p1,,F,,,BxO0000q18,N,13715,CH4MBL6155q4,,,,,wxpert,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
502,,3T3L2,,F,,,BAO0000ew8,N,13715,CHEMBL615534,,,,,3xpert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
503,,3T3Lw,,F,,,BAOo00p218,N,13715,CHEMfL615516,,,,,Intermediafs,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
504,,3TeL1,,F,,,BAO0990218,N,13715,CHEMBp615526,,,,,Interjedia4e,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
505,,wT3L1,,F,,,BAO0009217,N,13715,vHEMBL615r28,,,,,Ijterm3diate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,
506,,eT3L1,,F,,,BAO00o02w8,N,13715,CH4MBL6155e9,,,,,Expegt,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
507,,3TwL1,,F,,,nAO000021o,N,13715,CH3hBL615530,,,,,Exlert,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
508,,3T3i1,,F,,,BAO009o218,N,13715,CuEMBL615y31,,,,,Ex9ert,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
509,,3T3o1,,F,,,BAk0000319,N,13715,CHEMBiu15532,,,,,Intfrmediwte,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
510,,wT3L1,,F,,,BzO000021p,N,13715,CHEMBLy16533,,,,,Interkediahe,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
511,,3T2L1,,F,,,BAO00o02q9,N,13715,CHwMBL715534,,,,,Intermesiat4,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
512,,3TeL1,,F,,,BAOo009218,N,13715,dHEMBL616535,,,,,Inteehediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
513,,3T3Lw,,F,,,BA8000o218,N,13715,CHEMBi6w5536,,,,,In4ermewiate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
514,,3T3i1,,F,,,BAO00o0q18,N,13715,dHEMBLu15537,,,,,jnfermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
515,,3h3L1,,F,,,BAOp0002q8,N,13715,CHEMBL716538,,,,,Intermediqhe,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
516,,3T3k1,,F,,,hAO000021i,N,13715,CHrMBL936166,,,,,Intermfd7ate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
517,,2T3L1,,F,,,BxO0090219,H,6411,CHEMfL614539,,,,,dxpert,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,
518,,3g3L1,,F,,,Bsk0000219,N,6411,CHsMfL615540,,,,,Intermeskate,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Mus musculus,10090.0
519,,363L1,,F,,,BzO0000319,H,6411,CHEMBo6155r1,,,,,Exper4,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,
520,,3TeL1,,F,,,BwO0o00219,N,3966,CjEMBL615642,,,,,Edpert,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Mus musculus,10090.0
521,,3T3Lw,,F,,,BAk000o219,N,3966,CHEhBL615553,,,,,Intermfdiatd,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Mus musculus,10090.0
522,,eT3L1,,F,,,vAO00002w9,N,15556,CHEMBp615534,,,,,Exlert,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Mus musculus,10090.0
523,,3TeL1,,F,,,BxO00002w9,N,5845,CHEMBo615555,,,,,Edpert,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,10090.0
524,,3T4L1,,F,,,BAO900021i,N,14422,CH3MBL6155r6,,,,,4xpert,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,10090.0
525,,353L1,,F,,,BAO9000218,N,5845,CHdMvL615547,,,,,Expedt,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Mus musculus,10090.0
526,,2T3L1,,F,,,BAp0000w19,N,14508,CHEMBLt15r48,,,,,Expett,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Mus musculus,10090.0
527,,3T3Lw,,F,,,nxO0000219,N,14508,CH4MBL61y549,,,,,Edpert,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Mus musculus,10090.0
528,,3T3k1,,F,,,BAO0o90219,N,14508,fHEMBL6155y0,,,,,Expeft,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Mus musculus,10090.0
529,,3Y1cepllone,,F,,,BzO0000229,N,6349,CHEMBL61r55q,,,,,Imtermediare,Inhibitory activity against rat fibroblast (3Y1) cell line,Rattus norvegicus,10116.0
530,,3Y1ceilllne,,F,,,BqO0900219,N,15899,CHdMBL61555w,,,,,Expeet,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Rattus norvegicus,10116.0
531,,3Ywcelllins,,F,,,hAO0000q19,N,15899,CHEMfL61555w,,,,,sxpert,Cytotoxicity in 3Y1 cells.,Rattus norvegicus,10116.0
532,,2Ywcellline,,F,,,nsO0000219,N,15899,CHEMBi61t554,,,,,Exper4,Cytostatic effect in 3Y1 cells.,Rattus norvegicus,10116.0
533,,eY1celiline,,F,,,BAO000pw19,N,15899,xHdMBL615555,,,,,Intfrmeriate,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Rattus norvegicus,10116.0
534,,4Ywcellline,,F,,,BAO00002wi,N,17038,CHfnBL615556,,,,,Expfrt,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Rattus norvegicus,10116.0
535,,,,B,,,BAO09o0019,U,12421,CHwMBL6q5557,,,,,Autoci3ation,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,
536,,,,B,,,gAO000o019,U,12947,CHEMgL6155t8,,,,,zut0curation,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
537,,,,B,,,vAO9000019,U,12947,CyEMBL772066,,,,,Autocuextion,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
538,,,,B,,,nAOp000019,D,4896,CHEMBL6q6559,,,,,Exoert,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Sus scrofa,9823.0
539,,,,B,,,gAO0o00019,H,6148,CHEjBo615560,,,,,Auyocura6ion,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,
540,,,,B,,,BAO00090w9,H,16432,CyEMBL615t61,,,,,zytocuration,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,
541,,,,B,,,gAO0009019,H,4978,CH3MBL857o62,,,,,Espert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,
542,,,,B,,,BAp0p00019,H,4978,CHEMBL6q5r62,,,,,Edpert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,
543,,,,B,,,BA8000o019,H,3723,CHEMfL6w5563,,,,,Autochrat9on,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,
544,,,,B,,,BA80000457,H,3518,CHEMBk61556e,,,,,Aut8duration,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,
545,,,,B,,,BAO00000qp,H,4164,CHEMBL615r66,,,,,Au6ocuratiog,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,
546,,,,B,,,BqO000001i,H,3518,CHEMBLu155y6,,,,,Autic8ration,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,
547,,,,B,,,BAO00o00q9,D,4164,CHwnBL615567,,,,,Exlert,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Sus scrofa,9823.0
548,,,,B,,,BAO000o010,H,3518,CHEMBL515558,,,,,Ai5ocuration,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,
549,,,,B,,,BAO00p9357,H,3518,CHEMvL615t69,,,,,Autocurqrion,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,
550,,,,B,,,BsO000001p,H,4978,CHEMBL61547o,,,,,Au4ocufation,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,
551,,,,B,,,hAO000o019,H,4978,CHEnBL615671,,,,,Aut0cu5ation,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,
552,,,,B,,,gAO0900224,H,6455,CHEMBL61r57e,,,,,qutocurarion,Binding affinity against melatonin (MT1) receptor (pC1),,
553,,,,B,,,BAl0090019,U,2222,CH2MBL515573,,,,,Autocurs4ion,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,
554,,,,B,,,vAO0000p19,U,13020,sHEMBL61y574,,,,,sutocuratiln,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,
555,,,,B,,,Bzl0000019,U,13021,CHEnBL615675,,,,,Autofuratiog,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,
556,,,,B,,,BAO090o357,H,14532,CHEMBp6q5576,,,,,Au6ocuratikn,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,
557,,,,B,,,BAOp000457,H,14118,CHEMgLt15577,,,,,Autovurqtion,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,
558,,,,B,3097242.0,Hkppkcampus,BAO0909221,H,11884,CHEhBL625578,,,,,Autocjrwtion,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,
559,,,,B,,,BAi0000367,H,13969,CHwMBL6155u9,,,,,Exp2rt,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,
560,,,,B,,,BAO0000456,H,13392,CH4jBL615580,,,,,Exp2rt,Binding affinity for 5-hydroxytryptamine 1A receptor,,
561,,,,B,,,BsO0000p19,H,14430,CHEnBi615581,,,,,Expe3t,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,
562,,,,B,1697254.0,Hi0poxampus,BAO000922w,H,12248,CHEMBL61t581,,,,,Autocurztioj,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
563,,,,B,194274.0,yipoocampus,BAl00002w1,H,12249,CHEMvL615483,,,,,Autocurstiob,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
564,,,,B,1841162.0,ui0pocampus,fAO0p00221,H,9995,CHEMBL6w55o4,,,,,Autocuextion,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
565,,,,B,621991.0,Hipp9camlus,BAO0o00q21,H,9995,dHEMBL83369q,,,,,Autocu5xtion,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
566,,,,B,4108545.0,Hip9ocam0us,BAO0p00222,H,9995,CHEMBk615595,,,,,Autocugatikn,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
567,,,,B,362141.0,jippocahpus,BzO0009221,H,9995,CgEMBL6w5586,,,,,Autovura4ion,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
568,,,,B,2356384.0,Hi90ocampus,BsO000022q,H,9995,CHEMBp894524,,,,,Auticura6ion,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
569,,,,B,806116.0,Hiopocamp8s,BAO0o00q21,H,12249,CjEMBL616587,,,,,zjtocuration,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
570,,,,B,3552804.0,Hiplocam0us,BAOo000121,H,11799,CHEMBL525588,,,,,Autodu3ation,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
571,,,,B,,,gAOp000249,D,14331,CHEnBL6155o9,,,,Mejbranes,Experf,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Rattus norvegicus,10116.0
572,,,,B,2675611.0,jippoczmpus,BAOo0p0221,H,11884,CHEMBL715t42,,,,,Expsrt,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Bos taurus,9913.0
573,,,,B,379443.0,Huppodampus,BAO0p00q21,H,14331,CHEMBLt1544r,,,,,Aytocura5ion,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,
574,,,,B,2270522.0,Hi9pocamlus,BwO0000222,H,11701,CHEMBk6154e4,,,,,Autpcu5ation,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,
575,,,,B,4363073.0,Hi99ocampus,BAi0900221,H,11701,CHEMBL62544r,,,,,rxpert,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,
576,,,,B,3301197.0,Hip09campus,BA0000022w,H,12248,CHEMvL615r46,,,,,Ahtocurayion,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,
577,,CHO,,B,,,BAOp900219,H,12248,CHEMBL6154t8,,,,,Autoc6ratiin,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,
578,,,,B,1623061.0,H8ppkcampus,BAOo00p221,H,12248,CbEMBL615548,,,,,Exper6,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
579,,,,B,1365984.0,Hipp8campuw,nAO0090221,H,12249,CbEMBL61544i,,,,,Experf,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
580,,CHO,,B,,,BqO00o0219,H,12248,CHEMhL61545p,,,,,Aufofuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
581,,,,B,884750.0,nippocahpus,BAO00002wq,H,11799,CHfMBL615452,,,,,Exp2rt,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
582,,,,B,,,BAO00o0356,H,634,CHfMBL615462,,,,,Autosurat7on,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
583,,,,B,723415.0,Hippocwmpux,BwO00p0221,H,9995,CHEkBL615553,,,,,Autocu5atiob,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
584,,,,B,1924189.0,Hippocamp6c,BzO0000q21,H,9995,CHEjBL614454,,,,,Autocugatiom,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
585,,,,B,907824.0,Hkppocampua,BzO9000221,H,9995,CHEMBL6254y5,,,,,wutocu3ation,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
586,,,,B,3089168.0,Hipoocanpus,BAO0900e21,H,9995,dHEhBL615456,,,,,Autocurstlon,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
587,,,,B,2468506.0,Hi9locampus,hA00000221,H,9995,CHrMBL615r57,,,,,Aut0curat7on,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
588,,,,B,432963.0,nipp9campus,BAp000o218,H,12210,CH3MBL61r458,,,,,sxpert,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,
589,,,,B,364333.0,Hipoocamp8s,BwO000022w,H,13311,CHEMBL615r50,,,,,Expeet,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
590,,CHO,,B,,,hwO0000219,D,2331,CH2MBL615469,,,,,dxpert,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Homo sapiens,9606.0
591,,,,F,,,BAO00op019,H,1375,CHEhBL614461,,,,,A7tocurqtion,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Cavia porcellus,10141.0
592,,,,F,,,BAO0pp0019,H,1375,CH4MBL715462,,,,,Auyocurati0n,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Cavia porcellus,10141.0
593,,,,F,1353011.0,Hiopocampjs,BAO0909221,H,11574,CHEMBL61y462,,,,,Aut0cu4ation,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Cavia porcellus,10141.0
594,,,,B,1414018.0,oleum,hA80000221,H,12867,sHEnBL615464,,,,,Aut9curatioj,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,10141.0
595,,,,B,1339994.0,Ileuj,BsO0000w21,H,12867,CmEMBL515465,,,,,sutocuratiog,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,10141.0
596,,,,B,1560734.0,Il2um,BxO0000222,H,12867,CHEhBL614466,,,,,Augpcuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,10141.0
597,,,,B,4293756.0,Ile7m,BAOp000321,H,12867,CHEhBL6q5467,,,,,Aut8curwtion,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,10141.0
598,,,,B,758438.0,8leum,BAO00op221,H,12867,CmEMhL615468,,,,,Autkcurwtion,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,10141.0
599,,,,B,515482.0,Ileuj,BAO0000w22,H,12867,CyEMBL515469,,,,,Auhocuratioh,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Cavia porcellus,10141.0
600,,,,B,,,BxO000035y,H,11574,CHEMBL6154ip,,,,,Autocu4agion,Binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,10141.0
601,,,,B,,,BsO0000358,H,13114,CHEMBLy1r471,,,,,Aut9chration,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,10141.0
602,,,,B,,,BAO00oo357,H,13181,CHEMBo616472,,,,,Ayhocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Cavia porcellus,10141.0
603,,,,B,440743.0,Hipp8camous,BAO009o221,H,10639,CHEMnL893242,,,,,A84ocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,10141.0
604,,,,F,1254972.0,Hup9ocampus,BAO0o90221,H,10639,CHfMBL61r473,,,,,Aut9curqtion,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,10141.0
605,,CHO,,B,,,BAO00pp218,H,11883,CHEkBL615473,,,,,surocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Cricetulus griseus,10029.0
606,,,,B,,,Bwp0000357,H,17785,CHfkBL615475,,,,,Autovuratiob,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,
607,,HeLa,,F,,,BAO0o0021p,H,1558,CH2MBo615476,,,,,Autocu5atioj,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,
608,,HeLa,,F,,,BAOo000210,H,1558,CHEkBL715477,,,,,Au4ocuratiog,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,
609,,,,F,,,gAO00o0019,H,15740,CbEMBp615478,,,,,Autocurafipn,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
610,,CHO,,F,,,BAO00o9219,H,17624,CHEMBk615q60,,,,,Aufocuratioj,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
611,,CHO,,F,,,BqO000p219,H,17624,CHEMBp615w61,,,,,Experf,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
612,,CHO,,F,,,gAO0900219,H,17624,CHEMgL6q5162,,,,,Aurocurqtion,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,
613,,CHO,,F,,,BAO0o09219,H,17624,CmEMBL6w5163,,,,,Autosuratiog,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,
614,,CHO,,B,,,BAO0o09219,H,17624,CHEMBi615264,,,,,2xpert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
615,,CHO,,B,,,BA90000e19,H,17624,CHEMBL6q51t5,,,,,3xpert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
616,,CHO,,B,,,BwO00p0219,H,17624,sHEMBL615176,,,,,Aitofuration,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,
617,,,,F,,,BAO00003q9,H,14256,vHEMBL615157,,,,,Autpcura5ion,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,
618,,HeLa,,B,,,BApo000219,D,3445,smEMBL615168,,,,,4xpert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,9606.0
619,,HeLa,,B,,,BAOp000119,D,3445,CHEnBo615169,,,,,Expeft,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Homo sapiens,9606.0
620,,CHO,,B,,,hAO9000219,D,17200,CHEnBL615160,,,,,Exper6,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
621,,CHO,,B,,,BA000002q9,D,17200,CHEkBL61r171,,,,,Exp2rt,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Homo sapiens,9606.0
622,,,,F,,,vAO0000029,H,15180,CHEjBL6156p4,,,,,Autociratoon,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
623,,,,F,,,gAO00000q9,H,15180,sHEMBo615695,,,,,Au4ocuratkon,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
624,,,,F,,,BAO0o09019,H,16026,CHfMBi615696,,,,,Aufocuratlon,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
625,,CHO,,F,,,nAO0p00219,H,2759,CHEjBL61y697,,,,,Aitkcuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
626,,CHO,,F,,,BzO00o0219,D,2759,CHEnBL859r10,,,,,Exper6,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,9606.0
627,,CHO,,F,,,BAOo0002q9,H,2759,CyEMBL616841,,,,,Aut9furation,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
628,,CHO,,F,,,BAO000022o,D,2759,CHEMBL614942,,,,,Exper6,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,9606.0
629,,CHO,,F,,,BqO0090219,H,2759,CtEMBL735003,,,,,s7tocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
630,,CHO,,F,,,BAO0900319,H,2759,xgEMBL615843,,,,,Auyocuratiob,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,
631,,CHO,,F,,,BAO0p0p219,D,2759,CHEMBL61r879,,,,,Experh,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,9606.0
632,,CHO,,F,,,BAO0p0021o,H,2759,CHfMBL625980,,,,,Augocyration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
633,,CHO,,F,,,BAO000p229,D,2759,CHdkBL615981,,,,,Expe3t,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,9606.0
634,,,,F,,,nAO0009019,D,3445,CH2jBL615982,,,,,Expegt,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Homo sapiens,9606.0
635,,,,F,,,BAl0900019,D,5272,CyEMBL61y983,,,,,Ex0ert,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9606.0
636,,,,F,,,BAO000p919,D,5272,vHEMBo615984,,,,,Ezpert,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9606.0
637,,,,F,,,BAi0090019,D,5272,CHEMBL615p8y,,,,,Expfrt,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9606.0
638,,CHO,,F,,,BA90000229,H,17624,CHEkBL6w5986,,,,,Autovurati9n,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
639,,CHO,,F,,,nAi0000219,H,17624,sHEhBL615987,,,,,Auticudation,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
640,,CHO,,F,,,BAO9009219,H,17624,CHEMBi61598o,,,,,Autocurxtiom,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
641,,CHO,,F,,,BqO9000219,H,17624,sHEMBL715989,,,,,Edpert,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
642,,CHO,,F,,,gAO0009219,H,17624,CHEMfL615p90,,,,,Auroc6ration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
643,,CHO,,F,,,BAO00092w9,H,17624,CHEkBL6w5991,,,,,Autockrxtion,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,
644,,CHO,,F,,,BAO0o002w9,H,17624,CnsMBL615992,,,,,Autosurat7on,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
645,,CHO,,F,,,BA9p000219,H,17624,CH4MBLu15993,,,,,A6tocura6ion,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
646,,CHO,,F,,,BxO000021o,H,17624,CHEMvL6159p4,,,,,sxpert,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
647,,CHO,,F,,,BAO00p021p,H,17624,CtEMBLy15995,,,,,Autock4ation,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,
648,,CHO,,F,,,BAOo0002q9,H,17624,sHEMBLy15996,,,,,wutlcuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
649,,CHO,,F,,,BAO0p00218,H,17624,CHEMnL6q5997,,,,,Aut8curat7on,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
650,,,,F,,,BAO00p0018,H,6563,CjEMBL6q5998,,,,,Autlcueation,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
651,,,,F,,,BAO0po0019,H,6563,CHEMBL6w599o,,,,,Autocu3atoon,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
652,,,,F,,,BAO09000q9,H,6563,fbEMBL616000,,,,,wut9curation,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
653,,HEl293,,F,,,BAOo00021o,H,17296,CjEjBL616001,,,,,qutocurxtion,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
654,,,,F,,,BAO9090019,D,6876,CHdMBk616002,,,,,Expwrt,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Homo sapiens,9606.0
655,,,,F,,,BAO00o0p19,H,6876,xHEMBL6160p3,,,,,Espert,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,
656,,,,F,,,vAO000p019,D,5272,CHfMfL616004,,,,,Espert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
657,,,,F,,,BAO00o00w9,D,5272,CHEMvLy16005,,,,,Exp2rt,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Homo sapiens,9606.0
658,,,,F,,,BAO9p00019,H,5548,CHEMBo61t006,,,,,Au4ocuratikn,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
659,,,,F,,,vAO0000919,H,5548,xH3MBL616007,,,,,Experf,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,
660,,,,F,,,BAO0000p1o,H,5548,fHEnBL616008,,,,,Autocurxtiin,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
661,,,,F,,,BAO00009q9,H,5548,CHEMBo617009,,,,,Autocuratuln,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
662,,,,F,,,BA80000010,H,5929,xHEMBL61601p,,,,,Eapert,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,
663,,,,F,,,BAO00009q9,D,5929,CH2MBL626011,,,,,Espert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Homo sapiens,9606.0
664,,,,F,,,vAO0p00019,D,5929,CHEMBL61r750,,,,,Expeet,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Homo sapiens,9606.0
665,,,,F,,,BAOo00p019,H,16245,dHEhBL615741,,,,,qutocuratiln,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,
666,,,,F,,,BwO0000p19,H,5640,CHEMBL615652,,,,,dxpert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
667,,,,F,,,BAl00o0019,H,5640,CmEMBLt15743,,,,,Auhocurwtion,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,
668,,CHO,,F,,,hAO000o219,H,14509,CHEMBLy15644,,,,,Autocurarkon,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,
669,,CHO,,F,,,BAO0900229,H,14509,CHEMBLy16745,,,,,wxpert,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,
670,,,,B,,,BqOp000357,H,15331,xH2MBL615746,,,,,A84ocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
671,,,,B,,,BAO00p0358,H,15331,CHEMBi61y747,,,,,Aktocuratiob,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
672,,,,F,,,hAO0090019,H,6563,CHEMvL615738,,,,,Autocjrat9on,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
673,,,,F,,,BzO00o0019,H,6563,CHEMBL7157e9,,,,,xutoc8ration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,
674,,,,F,,,BAO09p0019,H,6563,CHEMBL515u50,,,,,A8tofuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
675,,,,F,,,BAO0oo0019,D,6563,CHEMBL6q5259,,,,,Exlert,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
676,,,,F,,,BzO000p019,H,6563,CyEMBo616260,,,,,Autocufatiln,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
677,,,,F,,,BAO0000o10,D,5272,CHEMgL6q6261,,,,,Exper6,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Homo sapiens,9606.0
678,,,,F,,,BAO00o0919,D,5272,sHEjBL616262,,,,,sxpert,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9606.0
679,,,,F,,,BAOp000029,D,5272,CHEMBL516163,,,,,Ex9ert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9606.0
680,,,,F,,,vAO000o019,D,5272,vHEMBL6q6264,,,,,Exper4,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Homo sapiens,9606.0
681,,,,F,,,BA000000q9,D,5272,CHEnBL616275,,,,,Expe3t,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Homo sapiens,9606.0
682,,,,F,,,vAO0000p19,D,5272,sHEnBL616266,,,,,sxpert,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9606.0
683,,,,F,,,BAO09000w9,D,5272,CHEMhL61t267,,,,,Experr,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9606.0
684,,,,F,,,hAO0000o19,D,5272,CtEMBLt16268,,,,,sxpert,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Homo sapiens,9606.0
685,,,,B,,,BAO0009e57,D,16146,vnEMBL616269,,,,,Edpert,Inhibition of human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
686,,CHO,,B,,,BAO00o02q9,H,17624,CHEMBo88e528,,,,,Autofueation,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
687,,mEK293,,B,,,fAO0000q19,D,13706,CHEMBLt15270,,,,,Experf,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,
688,,CHO,,B,,,BqO0000119,H,15250,CtEnBL616271,,,,,Aut8curatioh,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,
689,,CHO,,F,,,BAO000p210,H,17624,CuEMBL616q72,,,,,Auyocuratkon,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
690,,,,B,,,BAO009p357,H,6861,xHEMfL616273,,,,,Exp4rt,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,
691,,,,B,,,BAi000p357,D,17200,CtEMBL61627e,,,,,Expeet,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
692,,CHO,,B,,,Bxl0000219,H,17624,CH3MBk616275,,,,,Autoc6ratjon,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,
693,,CHO,,B,,,hA90000219,H,17624,CHEMBL6q7276,,,,,Auhoxuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
694,,,,F,,,BAO00op218,U,12058,xHEMhL616277,,Invovo,,,sutocuratioj,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,10116.0
695,,,,F,,,Bzk0000218,U,12058,xHEMBL6w6278,,Incivo,,,Aut9curstion,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Rattus norvegicus,10116.0
696,,,,F,,,BAO00002wu,U,12058,CHEMnL616278,,Inviv0,,,Autociratiob,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Rattus norvegicus,10116.0
697,,,,F,,,BAO00p0q18,U,12058,CHdMBL616380,,Invido,,,Aut9curatlon,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,10116.0
698,,,,F,,,BAi0o00218,U,12058,CHEMvL626281,,Ingivo,,,Autocugatioj,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,10116.0
699,,,,F,,,BAO90p0218,U,12058,dHEMBL617282,,onvivo,,,sutocuratiin,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,10116.0
700,,,,F,,,BAp0000118,U,12058,CHEMBL61629e,,unvivo,,,Autoc8ratipn,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Rattus norvegicus,10116.0
701,,,,F,,,BAO00p0118,U,12058,CjEMvL616284,,Inviv9,,,Ajtocudation,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Rattus norvegicus,10116.0
702,,,,F,,,gAO0000318,U,12058,CHEMfo616285,,9nvivo,,,Autocurqti0n,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Rattus norvegicus,10116.0
703,,,,F,,,BAO9p00218,U,12058,CHEMBL616w85,,Inviv9,,,Autocuratipj,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Rattus norvegicus,10116.0
704,,,,F,,,fAO00o0218,U,12058,CHEkBL616187,,Invjvo,,,Autpcurwtion,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Rattus norvegicus,10116.0
705,,,,F,,,BxO000p218,U,12058,CHEMBLu162o8,,Invibo,,,Autocuratuln,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Rattus norvegicus,10116.0
706,,,,F,,,BAO000o217,U,12058,xHdMBL616289,,Inviv0,,,Autocura5ipn,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Rattus norvegicus,10116.0
707,,,,F,,,BAOo00p218,U,12058,CH4MBL61t610,,9nvivo,,,Autocurahiob,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Rattus norvegicus,10116.0
708,,,,F,,,hAO0009218,U,12058,CH2nBL615611,,9nvivo,,,Autochratiom,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Rattus norvegicus,10116.0
709,,,,F,,,BAO00003q8,U,12058,dHEMhL615612,,Invivl,,,Aut0curxtion,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Rattus norvegicus,10116.0
710,,,,F,,,BqO000p218,U,12058,CHrMBL61561r,,Igvivo,,,Autoc84ation,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,10116.0
711,,,,F,,,hAOo000218,U,12058,CHEMfp615614,,onvivo,,,Autocurayi0n,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Rattus norvegicus,10116.0
712,,,,F,,,BAO00092w8,U,12058,CuEMBL61561y,,Inv9vo,,,wutofuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,10116.0
713,,,,B,,,BA90000919,H,11440,CHEMnL6156q6,,,,,Autosurayion,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,
714,,,,B,1244950.0,Hypothalsmua,BAO900024i,H,6238,CHEMBk615u17,,,,,Au4ofuration,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,
715,,,,B,,,BAk0o00019,H,10046,CHEMBi615628,,,,,Auhocu5ation,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,
716,,,,B,,,BAp0090019,H,10046,CHwMhL615619,,,,,Autocueatiin,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,
717,,,,B,,,Bs90000019,H,10046,CHEMBLt14620,,,,,Ex9ert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
718,,,,B,,,BAO00o9357,H,167,CH3MBL61562q,,,,,Aitosuration,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,
719,,,,B,,,BAO0o00367,H,167,CHEMBL62562e,,,,,Autocu4ati9n,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,
720,,,,F,,,BAko000019,H,11520,CHEMBp515623,,,,,Autocuratiph,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,
721,,,,F,,,BAOpo00019,H,11520,CHEMBL6q5724,,,,,Autocurwti9n,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
722,,,,F,,,BAp0009019,H,11520,CHEMBou15625,,,,,Autoxurat8on,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
723,,,,F,,,nAi0000019,H,11520,CH2MBL76u045,,,,,A8tocu3ation,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
724,,,,F,,,BAOoo00019,H,135,CHEMvL625626,,,,,Ajtocuratiog,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Cavia porcellus,10141.0
725,,,,F,,,BA8o000019,H,135,CHEMBL61t62y,,,,,Aktocuratioh,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Cavia porcellus,10141.0
726,,,,B,,,BAO0p00010,H,11311,CHfMBL61r628,,,,,sutocurarion,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Cavia porcellus,10141.0
727,,,,B,,,BAOp00o357,H,10193,CHEMBp715629,,,,,Aut0curatioj,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus,10141.0
728,,,,B,,,BAO0090356,D,12281,CHfMBL615640,,,,,fxpert,Inhibitory concentration against 5-lipoxygenase from human whole blood,Homo sapiens,9606.0
729,,,,B,,,BAO90p0219,H,11311,CH3MBL615531,,,,,Autoxuratlon,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
730,,,,F,,,BAk9000218,H,12576,CHsMBk615632,,,,,Au5ocurat9on,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
731,,,,B,,,BAO000o457,H,12281,CH3MBL6w5633,,,,,Au4ocurztion,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,
732,,,,F,,,BAk0000q18,H,12576,fHEMBLu15634,,,,,Autocurayi0n,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
733,,,,B,,,BAO00090q9,H,11089,CtEMfL615635,,,,,sxpert,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa,9823.0
734,,,,B,,,BAO00p0257,H,11006,CjEMBL615t36,,,,,Expsrt,In vitro inhibition of rat 5-Lipoxygenase,,
735,,,,B,,,BAl00003t7,D,11481,dHEnBL615637,,,,,Edpert,Inhibitory activity against 5-Lipoxygenase,Rattus norvegicus,10116.0
736,,RBL1,,B,,,BqOp000219,H,10864,CHEMgL615637,,,,,Expe4t,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,
737,,RBL1,,B,,,BAO9900219,H,3595,fHEMBL615649,,,,,Auhocuratioj,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
738,,RBL1,,B,,,BqO00002q9,H,11311,CHEMBLy156e0,,,,,Autpcurarion,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,
739,,,,B,,,BA80000o19,H,11311,CH2MBL614796,,,,,Autovhration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,
740,,,,B,,,BAO0000228,H,11311,CHEMBLy15i45,,,,,Autkcuratikn,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,
741,,,,B,,,Bwk0000357,H,11006,CHEMBk6158t6,,,,,Aj5ocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
742,,RBL1,,B,,,fAOp000219,H,3595,CHEMBp615747,,,,,Aut9curatiln,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
743,,,,B,,,BAO0p00r57,H,11311,CgEMBL615948,,,,,wufocuration,The compound was tested for inhibition of isolated 5-Lipoxygenase,,
744,,,,B,,,BAO00pp019,U,11481,CHEnBL615u49,,,,,wutocurahion,Ratio of IC50 against 5-LO and COX,Rattus norvegicus,10116.0
745,,,,B,,,BAOp090357,H,11006,CgEMBLy15850,,,,,Aut0curstion,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
746,,,,B,,,BzO0000e57,H,11006,CHEMBL6158tw,,,,,Auhocurat8on,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,
747,,,,B,,,BqO0000229,H,11311,CHfMBLu15852,,,,,Autocueat7on,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,
748,,,,F,,,BAO00090q9,H,11006,vHEMBL6158t3,,,,,zutocurstion,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,
749,,,,B,43341.0,Prosta6evland,BAO00p03y7,H,4288,CtEMBL8o4527,,,,,Aut0chration,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,
750,,,,B,,,BAO0900o19,U,7587,CHEMBL8y2872,,,,,Autocurayi9n,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Columba livia,8932.0
751,,,,B,,,BzO000001i,U,7587,CHsMBL615o54,,,,,Autocyratiob,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Columba livia,8932.0
752,,,,B,,,hA00000019,U,7587,CtEkBL767046,,,,,Aktocuratikn,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Columba livia,8932.0
753,,,,B,,,hAO000p357,H,11249,CgEMBk615855,,,,,Autocufatuon,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,
754,,,,F,,,BAOo0000q9,D,8003,CHEMvL615956,,,,,Expett,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Rattus norvegicus,10116.0
755,,,,F,,,vAO0009019,D,8003,CH4MBL615957,,,,,Expsrt,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,10116.0
756,,,,F,,,vxO0000019,D,8003,CgEMBi615858,,,,,Ex9ert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,10116.0
757,,,,B,193989.0,Hlppocanpus,fAO0090221,H,12416,sHEMBL61y859,,,,,Exper6,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
758,,,,B,,,BwO9000357,H,16293,CHEMfL615850,,,,,Autocuratooh,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,
759,,,,B,,,BzO00000q9,U,13047,CHEjBL615761,,,,,Autocuratk8n,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
760,,,,B,,,BAO0900p19,U,13047,CHEMBLt15861,,,,,Autocurati9g,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
761,,,,B,,,BsO000o019,U,13047,CHfMBL615864,,,,,zutocugation,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
762,,,,B,,,BAp0900019,U,13047,CHEMBL62y864,,,,,Autocutatjon,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
763,,,,B,2195401.0,H9ppofampus,BAO0000e2w,H,10085,CHEMBL616855,,,,,Autocu4ati8n,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
764,,,,B,569083.0,Hilpocam0us,hAO00002e1,H,10085,CHEMBk6158t6,,,,,zutocuratioj,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
765,,,,B,135706.0,Hilpovampus,gAk0000221,H,10085,CuEMBL616867,,,,,Autodurqtion,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
766,,,,B,,,BAOp090249,H,9841,sHEMnL615868,,,,Membrqnes,Aytocurati8n,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,
767,,,,B,,,Bs90000249,D,8822,CmEMBLy15869,,,,,Au4ocuratkon,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Rattus norvegicus,10116.0
768,,,,B,,,BAO0p00919,D,9806,CHrMBL6w5870,,,,,Augocugation,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Rattus norvegicus,10116.0
769,,,,B,,,BsO000p019,D,9806,CHEjBo615871,,,,,Ahtockration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Rattus norvegicus,10116.0
770,,,,B,,,BAO00092q4,H,8868,CHEMBk6w5872,,,,,Au5ocura4ion,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,
771,,,,B,2165515.0,Hippovamphs,BA90000q21,H,9036,CbEnBL833492,,,,,Aut9curstion,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,
772,,,,B,1065380.0,nippocam0us,vAOp000221,H,11374,CHEMBL615i7e,,,,,Autofura4ion,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,
773,,,,B,,,BwO0900224,H,10881,CHEMBL61rr79,,,,,Aut0cura6ion,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,
774,,,,B,,,gAO0900019,H,8822,CHfMBL715480,,,,,Aut8vuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,
775,,,,B,,,nzO0000249,D,9806,CHEhBL6154o1,,,,,Aut9curati8n,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Rattus norvegicus,10116.0
776,,,,B,,,BA900o0019,H,15463,CHEkBL87286o,,,,,sutkcuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
777,,,,B,,,BxO0009019,H,15463,CyfMBL615482,,,,,Autodurafion,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
778,,,,B,2688112.0,Btain,vAO00p0221,H,14542,CHEMBL61y493,,,,,Autoc7rstion,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
779,,,,B,1308196.0,Bfain,BAO00o0222,H,14542,CH3MhL615484,,,,,Autocurwtiob,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
780,,,,B,,,BA0p000019,H,8569,CgEkBL615485,,,,,Autpcurstion,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,
781,,,,B,,,BzO0000214,D,10062,CjEMBL6154i6,,,,,Augkcuration,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Rattus norvegicus,10116.0
782,,,,B,,,nAO00p0224,H,4771,CHEhBL61548i,,,,,Auticura5ion,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,
783,,,,B,,,BAp00o0224,H,10062,CHEnBL6154i8,,,,,Autocutatuon,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
784,,,,B,,,BsO00o0224,H,10062,CHEMgL6154i9,,,,,Aufocurztion,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
785,,,,B,,,BAO000oq24,H,10062,CHEMBL6q5388,,,,,Autpcu3ation,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
786,,,,B,,,BwO0000p19,H,15463,CH3MBp615390,,,,,Autocura5ioh,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
787,,,,B,,,BAOp00001p,H,15463,CjEMBL616391,,,,,Autosugation,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
788,,,,B,,,BwO0p00224,H,9098,CHEkBL6q5392,,,,,Autockrati9n,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,
789,,,,B,,,BAp0p00019,U,3070,dgEMBL615393,,,,,wutocurwtion,Affinity for 5-hydroxytryptamine 1 receptor,Rattus norvegicus,10116.0
790,,,,B,2128113.0,Beain,BAO000o2w1,H,14542,CHEMBk6w5394,,,,,Aut8curatioh,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,
791,,,,B,2552231.0,Bgain,BA800002q1,H,14542,CHEMBL614394,,,,,sutoduration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
792,,,,B,,,gqO0000224,H,6398,CHEMBLu1539u,,,,,Autocuratikb,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,
793,,,,B,444164.0,B3ain,BAO9000121,H,1344,CHEkBL615297,,,,,Autoxuratiom,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,
794,,,,B,,,BAi0000029,H,11963,CHEMfL61539o,,,,,Autoduratjon,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
795,,,,B,,,BsO00000q9,U,8908,sHEMBL6153o9,,,,,Autocurayi0n,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Rattus norvegicus,10116.0
796,,,,B,,,BqO0000018,H,9098,CuEMBL615r00,,,,,Auglcuration,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,
797,,,,B,,,BAO00p9019,D,8841,CHEMBp615e01,,,,,Autocyratiom,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Rattus norvegicus,10116.0
798,,,,B,,,BA00p00019,U,8814,fyEMBL615402,,,,,Autofurstion,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Rattus norvegicus,10116.0
799,,,,B,,,BAO0o00010,H,11752,CbEMBLu15403,,,,,sutoc8ration,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,
800,,,,B,170563.0,nrain,BAp0000e21,H,11642,CHEhBL6w5404,,,,,Autovuratiog,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,
801,,,,B,,,BAO000o0w9,H,11642,CHEMBL61y78w,,,,,Autoc7tation,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,
802,,,,B,1604802.0,Brzin,BxO0090220,H,9231,CHEMBLy25782,,,,,Au4ovuration,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,
803,,,,B,1391568.0,Brakn,gAO9000221,H,11351,CHEMBLu15i83,,,,,A7hocuration,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,
804,,,,B,,,nAO00000w9,U,4639,CHEMgL873r81,,,,,Auyofuration,Compound was tested for binding affinity against 5-HT1 receptor,,
805,,,,B,,,vA80000019,U,1205,fHEMBL6w5784,,,,,Autocu5at9on,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,
806,,,,B,,,BAp0000257,H,10025,CHEkBL615784,,,,,2xpert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
807,,,,F,,,BAO000p248,H,13241,CHfMBp615786,,,,,Aitocurahion,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
808,,,,F,,,BxO000o218,H,16245,xHEMBL6157u7,,Invivk,,,Autkxuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,
809,,,,F,,,BAl0000118,H,16245,CH2MnL615788,,Invovo,,,Autocu4stion,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,
810,,,,F,,,BA90p00019,H,12438,CyEMvL767044,,,,,Autocuda4ion,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,
811,,,,F,,,BAO00902q8,H,16245,sHEMBL6q5789,,jnvivo,,,Autochratiob,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,
812,,,,F,,,BAl0p00218,H,16245,CHEjBLy15790,,jnvivo,,,Autlcurztion,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,
813,,,,F,,,BxO0009019,H,15740,CHEMBL71y813,,,,,Autoc7rati9n,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,
814,,,,F,,,Bz90000219,H,15535,dHEjBL615814,,,,,Autkcurqtion,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,
815,,,,F,,,BqO0000w19,H,15535,CHsMBL6q5815,,,,,Expeft,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,
816,,,,F,,,BAO00o9219,H,15535,CuEMBL6w5816,,,,,Autocurqtjon,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,
817,,,,B,,,BAO9000239,H,9888,vHEMBk615817,,,,,Espert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,
818,,,,B,1640543.0,Hipoocampks,vwO0000221,H,10085,xHEjBL615818,,,,,Aytocuragion,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,
819,,,,B,2415935.0,Hlppocamous,BA0000o221,H,10085,CHEMBLy15919,,,,,Aitocurxtion,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,
820,,,,B,,,BAO0o09249,H,17331,CHEMgL6w5820,,,,Membranee,Exper6,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,
821,,,,B,3194624.0,H7ppocam9us,BAO0o00e21,D,10845,CbEMBL615721,,,,,Expeet,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Rattus norvegicus,10116.0
822,,,,B,1986662.0,Hipppcampuw,BAl0o00221,D,10845,CnEMfL615822,,,,,dxpert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,10116.0
823,,,,B,3901426.0,Hi9podampus,BAp00o0221,H,10845,dHEhBL615823,,,,,Ex9ert,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,
824,,,,B,1259970.0,g7ppocampus,BAO0000e2w,D,10845,CHEnBL715824,,,,,Expe3t,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Rattus norvegicus,10116.0
825,,,,B,4287078.0,H8ppocamlus,BAO0900211,D,10845,CyEMBL615826,,,,,Exper5,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,10116.0
826,,,,B,,,BAOp009357,H,13730,CHEkBL6158e6,,,,,Exper6,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,
827,,,,B,,,nAO000024p,H,13508,CHEjBL715827,,,,,4xpert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,
828,,,,B,1994393.0,yippocsmpus,BAO000o349,H,13508,CyEMBk615828,,,,,fxpert,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,
829,,,,B,2758511.0,Hip0ocanpus,BAO0p90221,H,12073,CHEMBL625839,,,,,sxpert,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
830,,,,B,2384872.0,Hilpocwmpus,BAO009022q,H,4671,CHEMBk61y830,,,,,Autockrati9n,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,
831,,,,B,1602061.0,Hippoxam0us,BA00000321,H,13631,CjEMBL6q5831,,,,,Expe4t,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,
832,,,,B,,,BAO090o357,H,12438,CHEMBo61583q,,,,,Autocura4i9n,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,
833,,,,B,,,BxO000p019,H,10483,CHEkBL61583e,,,,,wutosuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,
834,,,,B,2900347.0,Hipoocamous,hAO00o0221,H,10483,CHEjBk615834,,,,,A7tocurstion,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,
835,,,,B,,,BAi0900249,H,12352,fHEMBL616835,,,,,8ntermedjate,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,
836,,,,B,2292683.0,Hippocwmpua,fzO0000249,H,14732,CHEMnL61583t,,,,,Autocu3atiom,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,
837,,,,B,,,BA89000019,D,11049,CHEMBpu15837,,,,,Exoert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Rattus norvegicus,10116.0
838,,,,B,,,BAO00900w9,D,11049,CmEMBL625838,,,,,Expedt,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Rattus norvegicus,10116.0
839,,,,B,,,BAOpo00249,H,13657,CHEMfL515839,,,,,Expsrt,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,
840,,,,B,,,BAOo000018,H,11473,CyEMBp884525,,,,,A7tocurahion,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,
841,,,,B,,,BAO090o249,H,2014,CHEMhL615849,,,,,xutocurxtion,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
842,,,,B,1302131.0,nippovampus,hAO000p221,H,3086,CHEMBk6154p5,,,,,Exp2rt,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
843,,,,B,,,BAO090o019,H,15854,CHfMBL6w5406,,,,,Experh,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
844,,,,B,3167809.0,Hjppocampks,BAO0000w2q,H,10922,CHEMBLt15i00,,,,,Ezpert,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
845,,,,B,628740.0,Hiopocampud,nAO9000221,H,13346,CHEMnL6159o1,,,,,Exp4rt,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,
846,,,,B,,,BAOpp00357,H,15311,CHEMBLt25902,,,,,Expe5t,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,
847,,,,B,2101566.0,Huppocampuq,BwO00p0221,H,10922,CyEMhL615903,,,,,Aut9curatkon,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
848,,,,B,,,fAO0000356,H,10025,fHdMBL615904,,,,,Autof6ration,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,
849,,,,B,,,BAO0090e57,H,10025,CHEkBL61r905,,,,,sxpert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
850,,,,B,,,BAO000o919,H,9742,CHEMnL6q5906,,,,,Autocurayiob,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
851,,,,F,,,vAi0000019,H,9742,CHEMvL615007,,,,,Autoxuragion,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
852,,,,B,,,BAOp00001p,H,12304,CHEMBL616907,,,,,Espert,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
853,,,,B,985248.0,Hipp0czmpus,BqO0000231,H,15789,CnEMgL615909,,,,,Aut9curatoon,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,
854,,,,B,,,BAl0009019,H,9912,fHEMBL615p10,,,,,Autocurariln,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,
855,,,,B,,,BzO0000p19,H,9912,CHEMBL6q59q1,,,,,xutocurat9on,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,
856,,,,B,,,BAO000o01p,H,9912,CtfMBL615912,,,,,Autocura6kon,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,
857,,,,B,,,BAO000o0q9,H,16693,sHEMBL625913,,,,,Expfrt,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
858,,,,B,,,BA9000o357,H,13276,CHEnBL615014,,,,,Expery,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
859,,,,B,3482080.0,Hi0pocampuw,BA90o00221,H,12678,CHEMBL614925,,,,,Auhocurati0n,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
860,,,,B,,,BzO00o0357,H,11825,CH4MBLy15916,,,,,Autocuratilg,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,
861,,,,B,,,fAO0000w57,H,12443,CHEMBL6wy917,,,,,4xpert,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,
862,,,,B,,,BAO9o00357,H,13830,CjEMBL61r918,,,,,Experr,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
863,,,,B,556601.0,H7ppocanpus,nAO00o0249,H,14286,CHEMvL616919,,,,,Expe4t,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,
864,,,,B,1561690.0,mippocampua,BAO00p022q,D,14356,CHEMBL614929,,,,,Ezpert,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Rattus norvegicus,10116.0
865,,,,B,,,BAO0o00w57,H,15306,CyEMBL614921,,,,,Auticurqtion,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,
866,,,,B,,,BAO0009w57,H,15306,CHEMBL6q5022,,,,,rxpert,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,
867,,,,F,,,BAO0000140,D,16616,CHEMhL8812i0,,,,,Edpert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,10116.0
868,,,,B,1065612.0,Hipppcakpus,BAOp900221,H,3651,CHEMvL61592r,,,,,sutpcuration,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,
869,,,,F,1200905.0,tippocanpus,BxO0p00221,H,14331,CHsMBLu15924,,,,,Autocutstion,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
870,,,,F,2338276.0,Huppocahpus,BA90900221,H,14331,CHEMBo6w5925,,,,,Autocuratiij,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
871,,,,B,,,BAO90p0357,D,14178,CHEMnL615p26,,,,,Expedt,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
872,,,,B,,,fAO0o00019,D,10639,CHEMBL624927,,,,,Eapert,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
873,,,,B,760031.0,Hippocanpux,BAO00902e1,H,12306,CHdMBL61592o,,,,,Autocj5ation,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
874,,,,B,,,BAOp000457,D,1348,CHEMBp6q5929,,,,,Expe4t,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Rattus norvegicus,10116.0
875,,,,B,4928677.0,Hiplocanpus,BAO0900222,H,13605,CH2MfL615930,,,,,qhtocuration,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,
876,,CHO,,B,,,fAO00p0219,H,17624,CyEMnL615931,,,,,Auroxuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
877,,CHO,,F,,,BAp0000229,H,17624,CH3MBL615942,,,,,Auhpcuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
878,,CHO,,F,,,BAO0p09219,H,17624,CyEMhL615933,,,,,w7tocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
879,,,,B,,,BAO0o00r57,H,15267,CHEMBL616924,,,,,Autocutatioj,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
880,,,,B,,,BAO9000367,H,16532,sHEMBL615i35,,,,,Auyocura4ion,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,
881,,,,F,,,BAp0000018,H,6563,CHEMBL61t836,,,,,Autocu5xtion,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
882,,CHO,,B,,,BxO00002q9,H,4751,CHrMBL715937,,,,,Autocyra5ion,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,
883,,,,B,,,gAOp000357,H,15463,dHEMBL615838,,,,,sutoc7ration,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,
884,,,,B,,,fAO000o357,H,3805,CHEMBi715797,,,,,Autocura6uon,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,
885,,,,B,,,BAO09003r7,H,5640,CHrnBL615798,,,,,Auyocurqtion,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
886,,,,B,,,BAO00pp357,H,6563,CgEMBL8i2870,,,,,A6tocuratjon,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,
887,,,,B,,,BAO9009357,H,5548,fHfMBL615799,,,,,Auyosuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,
888,,,,B,,,BAO9000e57,H,6347,fHEMBL615809,,,,,Aurociration,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,
889,,HEK29e,,F,,,BxO00002q9,H,17296,CHEMBp625801,,,,,xu5ocuration,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
890,,,,B,,,BAO0o09019,H,13047,dHEMBL615702,,,,,Autlc8ration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,
891,,,,B,,,BAO000p347,H,15740,CHdMBL61r803,,,,,zutocu4ation,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,
892,,,,F,,,fAO0o00019,H,5640,CHsMBLu35002,,,,,dxpert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
893,,,,F,,,BAOo000919,H,5640,CHEMBi614804,,,,,Autkcjration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,
894,,HeLa,,B,,,BxO0000229,H,17211,vHEMBLu15805,,,,,rxpert,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,
895,,CHO,,B,,,BAO000011p,H,4751,CHrMBLy15806,,,,,Autocurqtiin,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,
896,,,,B,,,gAO00003y7,D,6491,fHEMBL61y807,,,,,Expwrt,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Homo sapiens,9606.0
897,,,,B,,,fAOo000357,H,4707,CHsMBL615i08,,,,,Autovurati8n,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,
898,,,,B,,,BqO00003t7,D,13910,CHEkBo615809,,,,,Ex9ert,Binding affinity against 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
899,,HeLa,,B,,,vAO00p0219,H,16190,CtEMvL615810,,,,,Autocurqtioj,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,
900,,,,B,,,BAl0000e57,H,16633,CHEjnL615811,,,,,Autocurqyion,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
901,,CHO,,B,,,BxO00002q9,H,11898,CtEMBL615o12,,,,,Autofuratkon,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,
902,,CHO,,B,,,BAO00p9219,H,11898,CH4MgL615751,,,,,zutocuratipn,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
903,,,,B,,,BqO0090357,H,14331,CgEMBL615753,,,,,Autoxiration,Binding affinity against human 5-hydroxytryptamine 1A receptor,,
904,,CHO,,B,,,fAO0p00219,H,17624,CH3MBLu15753,,,,,wxpert,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,
905,,CHO,,B,,,BAO000921o,H,17624,CHEkBL61575e,,,,,A7t9curation,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,
906,,,,B,,,BAO0p0035u,H,3307,CHEMBL615766,,,,,Autpcurstion,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,
907,,CHO,,B,,,BzO000021o,D,6563,xHEMBL6q5756,,,,,Exper6,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,9606.0
908,,,,B,,,BsO000001o,H,14165,xHEMBL6w5757,,,,,Autocuratipb,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,
909,,,,B,,,hAO00o0357,H,5732,CgEMBL6157y8,,,,,Autocurztiob,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
910,,,,B,,,BAO0900w57,H,13366,vHEMBi615759,,,,,Expeet,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
911,,,,B,,,fAOp000357,H,17626,CgEjBL615760,,,,,A6tocurahion,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,
912,,HeLa,,B,,,BAO00o0119,H,6588,CHEMBL625751,,,,,4xpert,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,
913,,,,B,,,BAl000035u,H,16209,CgEMBL87210r,,,,,Ajtosuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,
914,,,,B,,,hwO0000357,H,15463,sHEMBL615862,,,,,Autocurqtiom,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
915,,,,B,,,BAO0000267,H,15463,CHEhBL61y763,,,,,Autocu4atiom,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
916,,,,B,,,BAO0090358,H,14770,CHEMBLtq5764,,,,,zutoduration,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,
917,,C2llline,,B,,,BAOo000319,H,16245,dHEjBL615765,,,,,Au6ocurwtion,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,
918,,,,B,,,vAO0090019,H,16245,dHEMBL614766,,,,,qutocueation,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,
919,,,,B,,,BAO9p00357,H,5548,CHEnBi615767,,,,,Autocurati9j,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,
920,,,,B,,,BAO0o00r57,H,5548,CHEMBLu1r768,,,,,Expfrt,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
921,,,,B,,,BA89000357,H,5548,vHEjBL615769,,,,,Ahtochration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
922,,,,B,,,BAi000p357,H,6876,CmEMBL615779,,,,,Exp4rt,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,
923,,,,B,,,BAO09003t7,H,2598,CHEMBL51577q,,,,,Autocurzrion,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
924,,,,B,,,BA9o000357,H,17785,CgEMBp615772,,,,,Exoert,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,
925,,,,B,,,BAi000035u,H,6013,dHEMBL6q5773,,,,,Autoxkration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
926,,,,B,,,nzO0000357,H,5929,CHsMBL615775,,,,,Expwrt,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
927,,,,B,,,BzO00003y7,H,16633,CHEMBL614675,,,,,Autocu3atioj,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
928,,,,B,,,BzO0000w57,H,1558,CHEMBLu157i6,,,,,Auf8curation,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
929,,,,B,,,BAOp000356,H,16026,snEMBL615777,,,,,Edpert,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
930,,,,B,,,gxO0000219,H,12469,dHEMBL614778,,,,,Autovuratiog,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,
931,,,,B,,,BAO0p00e57,D,15874,CyEMBL6q5779,,,,,Exoert,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Homo sapiens,9606.0
932,,,,B,,,BAO00p0356,H,15874,CHEMBL614770,,,,,Autpcuratiob,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
933,,,,B,,,BzO0009357,H,3935,CHdMBL626298,,,,,Aut9curxtion,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,
934,,,,B,,,BzO00003y7,H,15818,CHdMBL61629i,,,,,Aut8curarion,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,
935,,CHOKq,,B,,,BAkp000219,H,13706,fHdMBL616300,,,,,Autlcurxtion,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,
936,,CjOK1,,F,,,fxO0000219,H,13729,CHEMBL616e02,,,,,Exoert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,
937,,,,B,,,BAO09p0019,H,15413,CH4MBo616302,,,,,Autoc6ratioj,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,
938,,,,B,,,BAO090001i,H,15413,xHEMBL626117,,,,,sutovuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,
939,,,,B,,,gAO0090019,H,15413,xHEMBL6q6118,,,,,Autociratiin,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,
940,,,,B,,,BAOp000029,H,15413,CHdMBLy16119,,,,,Autociratiom,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,
941,,HeLa,,B,,,BAO0900218,D,3445,CHEMfLt16120,,,,,Eapert,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,9606.0
942,,,,B,,,gAO0000e57,H,15740,CHEMBkt16121,,,,,Autpvuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
943,,,,B,,,BAO9900357,H,15740,CHEMBL61611q,,,,,Augocuratioh,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,
944,,,,B,,,BqO0000w57,H,17626,CHEMBL616qe3,,,,,Auyocurati8n,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,
945,,,,B,,,BAOo000r57,D,4234,CHfMBL6q6124,,,,,Expett,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
946,,,,B,,,nAO9000357,H,5640,CHEMgi616125,,,,,Ecpert,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
947,,,,B,,,BAOo00035i,H,5272,dtEMBL616126,,,,,Exp2rt,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Rattus norvegicus,10116.0
948,,CHO,,B,,,BAk0090219,H,4622,dHEMBL6q6127,,,,,Autlcuratipn,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,
949,,,,B,,,nAO000p019,H,17085,CHEMBL6w6127,,,,,Edpert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,
950,,,,B,,,BAO000ow57,H,3025,CHEMBpu16129,,,,,Autkcuratipn,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
951,,,,B,,,BAO00p035u,H,15315,CHEMBL6162e0,,,,,Ex9ert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,
952,,,,B,,,BAO0p09357,H,15267,CHEMBo6161e1,,,,,Aut8cyration,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,
953,,HeLa,,B,,,hAO0009219,H,17158,CtEMBL6w6132,,,,,wutocurafion,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,
954,,HeLa,,B,,,BzO0000229,D,14214,CHdMBL6161r3,,,,,Experh,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Homo sapiens,9606.0
955,,,,B,,,BAi0p00357,H,17133,CHdMBL61613e,,,,,Aut8curatiob,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
956,,,,B,,,BAO00003yi,H,16532,CHEhBL626135,,,,,A8tocurstion,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,
957,,,,B,,,hAOo000357,D,2391,CjEMBL616236,,,,,Expfrt,Affinity for 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9606.0
958,,,,B,,,BAO0p000q9,H,14447,CHEMBL6161ru,,,,,Autovurwtion,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,
959,,,,B,,,BAO000o0w9,H,14447,sHEMBLo72105,,,,,A7tocuratiln,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,
960,,,,B,,,BAO00o0457,H,15086,CHEjBLy16138,,,,,Autofurqtion,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,
961,,,,B,,,BwO000035u,D,13051,CgEMBLt16139,,,,,Ezpert,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
962,,,,F,,,BAO00090w9,H,16026,sHEMBL616130,,,,,Autovuratiln,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,
963,,,,B,,,BAO0000p1i,H,17085,CHEMBLy1614w,,,,,Ezpert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,
964,,,,B,,,Bxl0000357,H,17133,CbEnBL616142,,,,,A8toc8ration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
965,,,,B,,,BAk0090357,H,17133,CHwMBp616143,,,,,Autocurxhion,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,
966,,HeLa,,B,,,hAO9000219,H,17211,CHEMBLt1614e,,,,,Autocurat7oj,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
967,,HeLa,,B,,,hAO000021p,H,17211,CHEMBL61y14t,,,,,qutoc6ration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,
968,,HeLa,,B,,,BqO00002w9,H,17211,dHEMBp616012,,,,,Ahgocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
969,,HeLa,,B,,,BAO0009119,H,17211,sHEMBo616013,,,,,Autocuratuln,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
970,,,,F,,,BwO00000q9,H,16394,CjEnBL616014,,,,,Ahtochration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
971,,,,F,,,BzO0090019,H,16394,CH4MBi616015,,,,,Autocirat9on,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
972,,,,F,,,nAk0000019,H,16394,CHsMBL616017,,,,,Autkcuratiln,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
973,,,,F,,,BAO00002q9,H,16394,CHEMBk61u017,,Invivl,,,Aktocurxtion,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,
974,,,,B,,,BA90000029,H,16394,CHEMBkt16018,,,,,Autocurxt8on,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,
975,,,,F,,,vAO9000019,H,15740,CHEngL616019,,,,,Autocuratlog,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,
976,,,,F,,,BwOp000019,H,15740,CHEMnL6w6020,,,,,Autocurqtioh,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,
977,,,,B,,,BwO000o357,H,15740,CHEjBLo58018,,,,,Autocuratjob,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
978,,nEK293,,F,,,BzO00002w9,H,17296,CHEMBL61u02q,,,,,Aktocurati8n,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
979,,,,F,,,nAO00000w9,H,5640,CnEMBL616p22,,,,,Exper5,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,
980,,,,F,,,BAO00p0018,H,5640,CHEMnL516023,,,,,Autoxurayion,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,
981,,,,F,,,BAO00op019,H,5640,CHEMvL61602e,,,,,Autocura5i8n,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,
982,,,,F,,,BA9000p019,H,5640,CnEhBL616025,,,,,Autlcurahion,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,
983,,CHO,,F,,,BAO000o218,H,2759,CHEMBLu16016,,,,,Autocuratj9n,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
984,,,,F,,,BwO00o0019,H,16394,CtEMBi616027,,,,,Autlcurafion,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,
985,,,,F,,,BAOo900019,D,16394,CgEMBL616928,,,,,Exper5,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Homo sapiens,9606.0
986,,,,F,,,BwO000o019,D,3445,xHEMBL61y029,,,,,Expedt,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Homo sapiens,9606.0
987,,CHO,,B,,,vAO00002q9,H,4316,CHEhvL616030,,,,,4xpert,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,
988,,,,B,,,BA99000019,H,4316,CHEMBL6w5031,,,,,Exp4rt,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,
989,,,,F,,,BzO00000w9,D,15180,CHEMfi616032,,,,,4xpert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9606.0
990,,,,F,,,Bw90000019,D,15180,CHEjBLu16033,,,,,Espert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9606.0
991,,,,F,,,BAO0p0o019,H,15042,CH2MBL516034,,,,,Autocudatiob,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
992,,,,F,,,gAO0009019,H,15042,CH4MBi616035,,,,,zutocuratuon,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
993,,,,F,,,BqO0p00019,H,15042,CHEhBp616036,,,,,Aut9curahion,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
994,,,,F,,,BAO0000o18,H,15042,CHEMBL6w6027,,,,,Au48curation,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
995,,,,F,,,BA9000001o,H,15042,sHEMBL6q6038,,,,,xut8curation,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
996,,,,F,,,BA00090019,H,15042,CHEMBot16039,,,,,Autovuratipn,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
997,,,,F,,,BxO00000w9,H,15042,CHfMBL6w6040,,,,,Autoc8ra5ion,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
998,,HeLa,,F,,,BAO0009210,D,15180,CHEkBL616o41,,,,,Espert,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9606.0
999,,HeLa,,F,,,BAO0009w19,D,15180,xHEMBL626042,,,,,Eapert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9606.0
1000,,HeLa,,F,,,BA90000w19,D,15180,CHEMBL62604r,,,,,Experh,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9606.0
1001,,,,F,,,BAO0o00029,H,16245,CHEMBL6q604r,,,,,zutocura4ion,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,
1002,,,,F,,,BAOo000919,H,16026,CHEhBL616035,,,,,Aut9ckration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1003,,HEK393,,F,,,BAO90002q9,H,17296,CHfMBL626046,,,,,Autocurxtiom,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
1004,,CHO,,F,,,BxO0000229,H,2759,CHdMBL616o47,,,,,Autocurstiom,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1005,,CHO,,F,,,BAO000921o,H,2759,CmEMBL6w6048,,,,,Autoc7ratioh,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
1006,,CHO,,F,,,BAO090o219,D,2759,dHEMBo616049,,,,,Ex0ert,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Homo sapiens,9606.0
1007,,CHO,,F,,,BzO000p219,H,2759,CHEhBL61605p,,,,,Autocurxtoon,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1008,,,,F,,,gA00000219,H,15419,CHEMBL626p51,,,,,Expery,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,
1009,,,,F,,,BAO000o2w9,H,15419,xHEMBL516212,,,,,xu4ocuration,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,
1010,,,,F,,,BAOop00019,H,16026,dHEMBL6162q3,,,,,Autoc7ratlon,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1011,,,,B,,,gAO0000210,H,1414,CHEMBk6q6214,,Inbitro,,,Expegt,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,
1012,,,,B,,,fzO0000219,H,1414,CyEMBo616215,,Invi6ro,,,Exoert,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,
1013,,,,B,,,BA00000w57,H,12861,CyEMBL616e16,,,,,Autofueation,Binding activity radioligand.,,
1014,,,,B,,,BqO0009019,H,12861,CHEMhL626217,,,,,Ah4ocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1015,,,,B,,,BAO000045u,H,5104,CHEMBL61t219,,,,,Au6ocurahion,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1016,,,,B,,,hAO00o0357,H,5105,CHEjBL61621o,,,,,Autocuratj9n,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1017,,,,B,,,gAO00p0357,H,16312,sHEMBL616230,,,,,Aug8curation,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,
1018,,,,B,,,fA90000357,D,15180,CyEMfL833493,,,,,Expedt,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
1019,,,,B,,,BAOo900357,H,5033,CuEMBL616321,,,,,Autlciration,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,
1020,,CHO,,B,,,hAO0000319,D,16909,CHEkhL616222,,,,,Expery,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,9606.0
1021,,,,F,,,BAO0op0019,H,2590,CHEMBp61622w,,,,,Autocurwtiog,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,
1022,,,,F,,,BzOp000019,H,2590,CHEMBL61y214,,,,,wytocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,
1023,,,,B,,,BAO90o0019,H,16394,CHEkBL6q6225,,,,,Ezpert,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,
1024,,HEK294,,B,,,BAk0000q19,D,4540,dHEMvL616226,,,,,Expegt,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Homo sapiens,9606.0
1025,,HEK292,,B,,,BA09000219,H,17296,CHEMBi61622i,,,,,Autocuratu9n,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,
1026,,HEl293,,B,,,hA80000219,H,17296,sHEMBL616w28,,,,,Aut8cugation,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,
1027,,gEK293,,B,,,BAO000o2q9,H,15779,CHEMBLu15229,,,,,Autofudation,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1028,,tEK293,,B,,,BAO000p21p,H,15779,CnEMhL616230,,,,,Aurkcuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,
1029,,HEl293,,B,,,BsO000021p,H,15779,CHEMBLy15231,,,,,Auticu3ation,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,
1030,,,,B,,,BsOo000357,H,6166,xHEjBL616232,,,,,Auyocurat8on,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
1031,,HdK293,,B,,,BAOo009219,H,15779,CHEMBL627233,,,,,Autoxuragion,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1032,,HEKq93,,B,,,BAOp0o0219,H,4199,vnEMBL857973,,,,,Autocurqti8n,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,
1033,,,,B,,,BqO0000229,H,15316,fHEMBL61t234,,,,,Auyocurxtion,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,
1034,,,,B,,,BAOo00o357,H,14875,CHEMBp6q6235,,,,,Autocurzrion,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,
1035,,HeLa,,B,,,BAO0p0o219,H,14727,CH4MBL61t236,,,,,Experg,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1036,,,,B,,,BAOo000018,H,14727,fHEMBL716237,,,,,Exlert,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1037,,HEK193,,B,,,BAO000o229,H,15146,CH4MBL616338,,,,,Autofurayion,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,
1038,,HEK29w,,B,,,BAO009021i,H,5213,CH4MBL626239,,,,,Auyockration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,
1039,,,,B,,,hAO000o219,H,16429,CHEMgL616q40,,,,,wutociration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,
1040,,HeLa,,B,,,BAOp090219,D,15042,CHEMfL616341,,,,,Ezpert,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Homo sapiens,9606.0
1041,,bEK293,,B,,,hAO000p219,H,14818,CbEMBL6162r2,,,,,Autoc75ation,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,
1042,,HEKq93,,B,,,vAk0000219,H,4829,CuEMBL616e43,,,,,zutocurahion,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,
1043,,,,B,,,BzO0009357,D,17200,CHEjgL616244,,,,,Experh,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,
1044,,,,B,,,BAO9p00357,D,13051,CHEMBo61624y,,,,,Aut0suration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9606.0
1045,,,,B,,,BAO0000256,H,5486,vHEMBL616e46,,,,,qutocuratiom,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
1046,,,,B,,,BzOo000357,H,5254,xyEMBL616247,,,,,Ahtocuratuon,Binding affinity against 5-HT1D receptor,,
1047,,,,B,,,hA80000357,H,5254,CHEMhL616q48,,,,,A7hocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1048,,,,B,,,BAO900p357,H,15331,CH2MfL616249,,,,,Autocurwrion,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
1049,,,,B,,,BwO0p00357,H,13506,CHrMBk616250,,,,,Au4ocuratioj,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Homo sapiens,9606.0
1050,,,,B,,,BAO0000w5y,H,15267,xH3MBL616251,,,,,wutocuratiln,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
1051,,,,F,,,gAO0o00218,H,16616,CuwMBL616252,,Incivo,,,zutocurayion,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,
1052,,,,F,,,BAO0o002w8,H,16616,CHEnBL61y253,,Ihvivo,,,Autoc8ratjon,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,
1053,,,,F,,,BAOp00o218,H,16616,CtEMBk616254,,jnvivo,,,Autoc6ratipn,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,
1054,,,,F,,,BAO0000328,D,16616,CHEMBL6q625r,,,,,3xpert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Mus musculus,10090.0
1055,,,,F,,,BAO00po218,D,16616,CHEMBL8r2882,,,,,Edpert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Mus musculus,10090.0
1056,,,,F,,,BxOo000218,D,16616,CHEhBL516256,,,,,Edpert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Mus musculus,10090.0
1057,,,,F,,,BAO0090w18,D,16616,CHdMBLy16257,,,,,Ex0ert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Mus musculus,10090.0
1058,,,,F,,,BAO000pq18,D,16616,CHEMBL6q7258,,,,,Ex0ert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Mus musculus,10090.0
1059,,,,F,,,BAO0p0p218,D,16616,CHsMgL616384,,,,,Expsrt,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Mus musculus,10090.0
1060,,,,B,1827771.0,tippoczmpus,hzO0000221,H,10297,CHEhBL6163o5,,,,,Autockratipn,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,
1061,,,,B,,,vAO000035i,H,13704,fHEMBL616396,,,,,sxpert,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,
1062,,,,B,759721.0,Hiplocamp8s,BAO9o00221,D,10297,CjEMBLy16387,,,,,Experg,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,10090.0
1063,,,,B,1845573.0,Hi9pocampys,BwO0p00221,H,10297,sHEhBL616388,,,,,Aktofuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1064,,,,B,220604.0,Hip9ocamp7s,BAi00002w1,D,10297,CHsMBL616380,,,,,Exoert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,10090.0
1065,,,,B,1462779.0,Hippocakpys,nwO0000221,H,10297,CHEMBL6q5390,,,,,xutocuratiin,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1066,,,,B,,,nAO0o00357,H,217,CHEMBi6163o1,,,,,Autlcuratkon,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,
1067,,,,B,945009.0,Hipp8canpus,BAOp00022q,D,10297,CHEkBL516392,,,,,Ex9ert,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Mus musculus,10090.0
1068,,,,B,,,fsO0000357,H,4921,CyEMBL616493,,,,,Autocuratipj,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,9823.0
1069,,,,B,,,BAO000036y,H,4921,CHEMhL6163o4,,,,,Autocyratjon,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Sus scrofa,9823.0
1070,,,,B,,,BzO0900019,H,4996,CHEMnL516395,,,,,Autocurwgion,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Sus scrofa,9823.0
1071,,,,B,,,BAOp000e57,H,12918,fHEkBL616396,,,,,xut0curation,Compound was evaluated for the binding affinity at 5- HT1A receptor,Sus scrofa,9823.0
1072,,,,B,,,BzO0000029,H,5333,CHEMBL881907,,,,,Auticurati9n,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,9823.0
1073,,,,B,,,fAOo000019,H,4437,CHEMBL71639i,,,,,Autocutstion,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,9823.0
1074,,,,B,,,hAO000p019,H,1742,CHEMhL616w98,,,,,Autocurqt8on,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Sus scrofa,9823.0
1075,,,,B,,,Bsi0000357,H,16688,CHEMBL6263p9,,,,,Ex0ert,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,9823.0
1076,,,,B,,,BAO0099357,H,12861,CHdMBL8570y5,,,,,Ahtocurati9n,Binding activity radioligand.,Sus scrofa,9823.0
1077,,,,B,,,hAO0p00019,H,12861,CHEMBL6q5400,,,,,Exlert,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,9823.0
1078,,,,B,,,gAO000p019,H,12861,CH2MBL516401,,,,,Autocuda6ion,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,9823.0
1079,,,,B,,,BAO0p000q9,H,12490,fHEMfL616402,,,,,Ecpert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,
1080,,,,B,,,BqOo000019,H,11828,vHEMBL6q6403,,,,,Exp4rt,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Sus scrofa,9823.0
1081,,,,B,1779517.0,Hippocam0hs,BAOo900221,H,11866,CmEMBL61640r,,,,,Aytocuratuon,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Sus scrofa,9823.0
1082,,,,B,,,BsO0900249,H,12827,CHsMBL6164o5,,,,,A7tocura5ion,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Sus scrofa,9823.0
1083,,,,B,,,BxO000001p,H,12918,CHrMBL616496,,,,,xutocurat9on,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Sus scrofa,9823.0
1084,,,,F,,,BAO000oo19,H,12919,CHEMfL616408,,,,,Exlert,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Sus scrofa,9823.0
1085,,,,B,,,BAk0000919,H,13047,CuEMBL516408,,,,,qutoxuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Oryctolagus cuniculus,9986.0
1086,,,,B,,,Bzl0000249,D,15796,CHdjBL616409,,,,,4xpert,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Rattus norvegicus,10116.0
1087,,,,B,1189303.0,Hippocajpue,BAO00092w1,D,3651,CgEMBo616410,,,,,Exper5,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Rattus norvegicus,10116.0
1088,,,,B,,,nAO000035y,H,188,dtEMBL616411,,,,,qutocurat9on,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,
1089,,,,F,,,BzO0000248,D,16616,CbEMBL6q6412,,,,Membranez,Experr,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,10116.0
1090,,,,F,1578313.0,Hippocwmp6s,BzO000p249,D,16616,CHEMBp61641e,,,,Membraned,rxpert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,10116.0
1091,,,,B,2552075.0,Hilpoxampus,BAO0p00e21,H,12306,Cn4MBL616414,,,,,Aitocuratiob,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1092,,,,B,1686355.0,Hippicajpus,hzO0000221,D,17167,CgEMBL61t415,,,,,Exp3rt,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Rattus norvegicus,10116.0
1093,,,,B,,,nAOo000019,H,14776,sHwMBL616416,,,,,witocuration,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,
1094,,,,B,,,BwO000035y,H,12158,CHEMBL6264w7,,,,,Exper4,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,
1095,,,,B,,,BAOo00o357,H,13481,CyEMfL616418,,,,,zutocuratioj,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1096,,,,B,,,BAO0p00q19,H,13427,sHEMnL616419,,7nvitro,,,Au4ocyration,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
1097,,,,B,,,gAOp000357,H,10210,xHEMBL616430,,,,,Autichration,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,
1098,,,,B,,,BAO000924i,H,10205,CyEMfL616421,,,,Memgranes,Aut8curztion,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1099,,,,B,,,BAO090024p,H,10205,CHEMnL61y422,,,,Membfanes,Au5ocuratipn,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1100,,,,B,,,BAO9000259,H,10205,CHEMBL6w6422,,,,Membranez,Expfrt,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,
1101,,,,B,,,BAi00003r7,D,12280,CHEMhL61t424,,,,,Expegt,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Rattus norvegicus,10116.0
1102,,,,B,,,BAi00003r7,H,17386,CHEMvL616435,,,,,Expe3t,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,
1103,,,,B,,,Bwi0000357,H,13654,CHEkBp616426,,,,,Ezpert,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,
1104,,,,B,3187163.0,Hippocwmp7s,BA9000022w,H,14423,CH2MBL616428,,,,,Autkcugation,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,
1105,,,,B,350834.0,Hipp8campys,gAO0000w21,H,15412,CHEkBLy16428,,,,,Autocirstion,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,
1106,,,,B,2237101.0,Huppocakpus,BAO00p022w,H,12073,CHEMBLt16w90,,,,,Aut9cyration,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1107,,,,B,,,vAO0000358,D,4101,xH3MBL616052,,,,,sxpert,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1108,,,,B,,,BzO000p357,H,10062,CjEMBL6w6053,,,,,wutockration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,
1109,,,,B,,,BAO00p0e49,H,6238,CHEkvL616054,,,,,Autocura6i8n,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,
1110,,,,B,,,Bsk0000357,H,16273,fHEjBL616055,,,,,Aut0curayion,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1111,,,,B,,,BxO0000457,H,11139,fHEMBL61605y,,,,,Aktocuratuon,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,
1112,,,,B,,,BA8000001i,H,16796,CHEMBit16057,,,,,Experr,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1113,,,,B,428747.0,hrain,BAO00o0222,D,9548,CHEnBL626058,,,,,Ecpert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Rattus norvegicus,10116.0
1114,,,,B,2759852.0,B4ain,gAi0000221,H,10381,CHEMhL615059,,,,,Augocuratioh,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1115,,,,B,,,BwO000024p,H,13408,CHEMBk615060,,,,,Au4oc8ration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,
1116,,,,B,1174813.0,Hipppcamlus,BAO0000we1,D,13825,CgfMBL616061,,,,,Expdrt,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1117,,,,B,3235002.0,Hippoczkpus,BAO000o22w,H,11147,CtEMBL6160y2,,,,,Expe5t,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,
1118,,,,B,,,BAO000924i,H,10552,CHEMBLt1606r,,,,,Autocurat8ln,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,
1119,,,,B,140399.0,Stria4um,BAO000o240,H,10552,CyEMBL616074,,,,,Aufocu3ation,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1120,,,,B,,,gA90000249,D,17136,CHfMBL615065,,,,nembranes,Exlert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Rattus norvegicus,10116.0
1121,,,,B,,,gAO00p0249,D,5778,CjEMBL6160t6,,,,Memb4anes,Expe5t,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Rattus norvegicus,10116.0
1122,,,,B,5082867.0,Hi0pocxmpus,nAO9000221,H,13481,CmEMBL716067,,,,,Ahtocjration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1123,,,,B,74721.0,Hiopocsmpus,BAO900p221,H,13481,CtEMBk616068,,,,,xutoc6ration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,
1124,,,,B,3591127.0,Hippocwjpus,Bqk0000221,H,13630,CHEMBL62606p,,,,,Intermexiage,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,
1125,,,,B,,,BxO0009249,H,16245,CHEMBo6160u0,,,,,Exlert,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1126,,,,B,618223.0,Hippodam0us,hAO00002w1,H,14509,CHEMBkt16071,,,,,Autodurafion,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1127,,,,B,1729520.0,nippoxampus,BAp0009221,H,14509,CHEMBLtq6072,,,,,Experr,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1128,,,,B,4157004.0,Hilpocamous,BAi000022q,H,14509,CHEMBL616oi3,,,,,Autocu4ati0n,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,
1129,,,,B,2837430.0,yippocwmpus,BAO0o0022w,H,14509,CHsMBL61607e,,,,,A8toc8ration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,
1130,,,,B,,,BAk00p0019,H,14256,fHEMBL61y075,,,,,Exp3rt,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,
1131,,,,B,,,BAO0090457,H,11139,CtEMfL616076,,,,,Autosurafion,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,
1132,,,,B,,,BAO0o00p19,D,11047,CHEMfL6160u7,,,,,Ezpert,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Rattus norvegicus,10116.0
1133,,,,B,,,nAO0000p19,D,11047,CyEMBL617078,,,,,Edpert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Rattus norvegicus,10116.0
1134,,,,B,,,BAO00p00w9,D,11047,CjEMBL616o79,,,,,Experg,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Rattus norvegicus,10116.0
1135,,CHOu1,,B,,,BAO0900210,D,2395,fH2MBL616080,,,,,Ecpert,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,10116.0
1136,,,,B,,,BAO0000368,H,9699,CHEnBL616091,,,,,Autocurwtiom,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1137,,,,B,164332.0,Hippovampks,BAO0op0221,D,12028,CHEMBk616982,,,,,Expett,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Rattus norvegicus,10116.0
1138,,,,B,127732.0,Hippocxm0us,BAi0000231,H,12028,fHEMBi616083,,,,,Ajtociration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,
1139,,,,B,,,BAO00p00q9,H,5815,CHEMfLu16084,,,,,wutovuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1140,,,,B,,,BsOp000019,H,16616,CHEMBi6160i5,,,,,Ex9ert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,
1141,,,,B,,,BwO000o019,H,5815,CHEMvL61608t,,,,,Autlvuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,
1142,,,,B,259226.0,Hip9kcampus,BwO00002w1,H,2761,CHEMBo616987,,,,,A7focuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,
1143,,,,B,,,BAp0o00357,H,13133,sHEMBL616078,,,,,Eapert,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,
1144,,,,B,,,BqO0000919,H,10444,CHEMgi616089,,,,,sut9curation,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,
1145,,,,B,,,BAOoo00357,D,13278,CHsMBL616000,,,,,Experh,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Rattus norvegicus,10116.0
1146,,,,B,,,BAO00003ti,H,15874,CHEMfk616091,,,,,Au4ociration,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
1147,,,,B,964836.0,Striayum,BAl0000259,H,10552,CHEhBL6160i2,,,,Membeanes,Autocurati0g,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1148,,,,B,,,nAO0p00357,H,11130,sHEMnL616093,,,,,Autocuratlom,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,
1149,,,,B,,,BsO000p218,H,11130,sHEkBL616094,,Inbivo,,,Autovurati8n,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,
1150,,,,B,3041938.0,B5ain,BAO000922w,H,14542,CHEMgL516095,,,,,Autofuragion,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,
1151,,,,B,,,BAO000o35y,D,13670,fHEMBL6q6096,,,,,wxpert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1152,,,,B,,,vAOp000249,H,9888,CHEMBL6qt097,,,,,Ezpert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,
1153,,,,B,,,BzO0009249,D,3678,CHEMBL7w6098,,,,Membganes,Exp3rt,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Rattus norvegicus,10116.0
1154,,,,B,555555.0,nilpocampus,BAO0900222,H,11332,CHEMBLy17099,,,,,Au5oxuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1155,,,,B,2270610.0,mipoocampus,BA80000121,H,11332,CHEMgL61u100,,,,,Aitocurati9n,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1156,,,,B,,,BA80009357,H,1185,vHEMBi616101,,,,,Expe5t,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1157,,,,B,,,BwO0000239,H,2014,CmEMBL6161p2,,,,,Exp2rt,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,
1158,,,,B,,,nwO0000357,H,1185,CHEkBL61610w,,,,,sutocurat9on,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1159,,,,B,,,vAO0000p19,H,14429,xHEMBL6q6104,,,,,Ex0ert,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,
1160,,,,B,,,nAO00000q9,H,16288,CH4MBL616106,,,,,Exlert,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,
1161,,,,B,,,BA0p000019,D,5432,CHEkBL616206,,,,,Ezpert,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1162,,,,B,,,BAi000001o,H,14429,CHEMBo716107,,,,,Autpcurat8on,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,
1163,,,,B,,,hAO9000357,H,13672,CHEMBp6q6108,,,,,Exper4,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,
1164,,,,B,1780562.0,Hipp8cam9us,BAO0099221,H,11296,CHEkBL626109,,,,,Exp2rt,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1165,,,,B,,,BAi000035u,H,11296,CtEMBL61611o,,,,,A6tocuratioh,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,
1166,,CHO,,B,,,BAO090o219,H,14749,CHEMBL6q61q1,,,,,Expedt,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,
1167,,,,B,,,vAO0900019,H,15086,CHEMBL616qw2,,,,,Exlert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,
1168,,,,B,416758.0,Hipp9sampus,vAO0000211,H,13462,CjEMBL616112,,,,,Aytlcuration,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,
1169,,,,B,,,gAO9000019,H,15363,dHEMBL616113,,,,,Autocurat78n,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1170,,,,B,,,BAi00p0019,H,15363,CHEMBL6151w5,,,,,Autoxu4ation,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1171,,,,B,,,BAO00po357,H,10796,CH3MnL616116,,,,,Autoc7ratjon,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,
1172,,,,B,2246441.0,Braih,BA80p00221,H,12816,CmdMBL615844,,,,,Expe4t,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,
1173,,,,B,357823.0,H7plocampus,BAO0000311,H,13542,CyEMBL6159w9,,,,,Exoert,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1174,,,,B,,,BsO00000q9,H,13308,CHEMBL51r940,,,,,Expe4t,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,
1175,,,,B,3180574.0,Hi9pocam0us,BAO00p0121,H,13541,CHEMBL62r941,,,,,Ex9ert,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,
1176,,,,B,2495997.0,uippocahpus,BxO0000321,H,10058,CHEMBLyw5942,,,,,wutocuratoon,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,
1177,,,,B,1152677.0,nippocam0us,BqO0009221,H,10058,dHEMBL615i43,,,,,qutocuratiob,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1178,,,,B,2134049.0,nippocampuc,BAO9009221,H,10058,fmEMBL615944,,,,,Autpcu4ation,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,
1179,,,,B,4009906.0,H7pplcampus,BAO00o0q21,H,10058,CtEMBL61t945,,,,,xutocutation,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,
1180,,,,B,1752276.0,nip0ocampus,BqO0000e21,H,10058,CnfMBL615946,,,,,Autoc6rati9n,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,
1181,,,,B,292145.0,Hippocxmpis,BqO0000121,H,10058,CHEMfLy15947,,,,,Au6osuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,
1182,,,,B,2085699.0,Hoppocam0us,BAk000p221,H,10058,CHwMBL515948,,,,,Ahtocurat9on,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,
1183,,,,B,1767334.0,Hippocam9ud,BAp000022q,H,10058,CtEMBL615940,,,,,qutocu3ation,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,
1184,,,,B,2113897.0,Hipp0camlus,BAO0009121,H,10058,CHEMBo61t950,,,,,Autocu5ati9n,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,
1185,,,,B,2752070.0,Hip9ocahpus,BAO000p222,H,10058,fHEMBL6w5951,,,,,wutoduration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,
1186,,,,B,2063561.0,Hippocamoux,gAO000o221,H,10058,CjEMnL615952,,,,,Autocurqt7on,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,
1187,,,,B,804315.0,Hiopocajpus,gAO0900221,H,10058,CtEMBL61r953,,,,,su6ocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,
1188,,,,B,1225562.0,Hippocshpus,Bxk0000221,H,10058,CHEkBL616954,,,,,Autpsuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,
1189,,,,B,2066844.0,Hippodampud,BAO0090e21,D,10058,CHEMBL625956,,,,,Exp3rt,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,10116.0
1190,,,,B,519856.0,Hi9pocampux,BAO000o231,H,10058,CbEMBL6159y6,,,,,Ajtocuratioh,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,
1191,,,,B,514847.0,H8ppoxampus,BAOp000222,H,10058,CHEkBp615957,,,,,Autpcuratioj,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,
1192,,,,B,,,BwO0000o19,H,12879,CHEnnL615958,,,,,Experr,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,
1193,,,,B,,,hAO000001i,H,11964,CHEMnk615959,,,,,Exoert,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,
1194,,,,B,,,BAl000o019,H,11964,CyEMBL615950,,,,,Autocu5stion,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,
1195,,,,B,,,BAOo00p019,H,11964,CbEMBp615961,,,,,A7tocyration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,
1196,,,,B,2240959.0,Braig,BAO00o02e1,H,9548,CnsMBL615962,,,,,Ex0ert,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1197,,,,B,,,BAO9900019,H,9098,CHEMBL61696w,,,,,Espert,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,
1198,,,,B,,,BzO0009019,H,9098,CHEMhL6q5964,,,,,xutovuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,
1199,,,,B,,,BAO9000029,H,9098,CHwMBL615i65,,,,,wu4ocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,
1200,,CHO,,B,,,BsO0p00219,H,13248,sHEMhL615966,,,,,Experg,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,
1201,,,,B,,,fAO0000239,H,3147,fHwMBL615967,,,,,Exoert,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,
1202,,,,B,,,gAO9000019,H,13949,CHEMfL615i68,,,,,Exper6,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1203,,CHO,,B,,,BAp00002q8,H,11883,xHEMBL615869,,,,,Autocufati8n,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,
1204,,,,B,,,BAk00o0218,H,11883,sHEMBLu15970,,,,,Autockratoon,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,
1205,,,,B,,,BAO0009367,D,11883,CHfMvL615971,,,,,Expett,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1206,,,,B,,,BAO00002e8,H,15535,CjEMhL615972,,,,Mekbranes,Expe4t,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1207,,,,B,,,nAO00o0249,H,15535,CHfMBLt15973,,,,,Aitocurxtion,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,
1208,,,,B,,,gAO0090249,H,15535,CHEMBo6159i4,,,,,Aht8curation,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,
1209,,CHO,,B,,,BAOo00021i,D,16372,CHEMhL615985,,,,,Exper5,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,9606.0
1210,,,,B,,,BA9p000249,H,14608,dHEkBL615976,,,,,dxpert,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,
1211,,,,B,558988.0,Hilpocxmpus,BAO0000232,D,4795,CHEMBL873206,,,,,Exper6,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,10116.0
1212,,,,B,,,BAO0p09357,H,13863,CHEMBL6259y7,,,,,A7tocurqtion,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1213,,,,B,,,BAi0000e57,H,13863,CHEMBLt15968,,,,,Autocudatiln,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,
1214,,,,B,,,BAO9o00357,H,13863,CHEMgL61616u,,,,,Autocura6iln,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,
1215,,,,B,,,fAi0000357,H,13863,CH3MBL616157,,,,,Au4ocuratiob,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,
1216,,,,B,,,nAOp000357,H,13863,CHEMBL616qy8,,,,,Aut8curatiom,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,
1217,,,,B,,,BAO0000w5y,H,13863,CHEMBL6w6269,,,,,xutocurqtion,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,
1218,,,,B,,,BA90900357,H,13863,CyEMBL6161y0,,,,,Aktovuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,
1219,,,,B,,,BAl0000e57,H,13863,CHEnhL616171,,,,,Autocuragi8n,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,
1220,,,,B,,,BAp00p0357,H,13863,CHEMBL615173,,,,,qutoc7ration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,
1221,,,,B,,,vAO0p00357,H,13863,CH4MBL61t173,,,,,Autocuragiob,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,
1222,,,,B,,,BAO0000267,H,13863,CnEMgL616174,,,,,Autpcurat8on,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,
1223,,,,B,,,BAO0o90357,H,13863,CHEMBk6q6175,,,,,Autoduratikn,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,
1224,,,,B,,,BsO00003t7,H,13863,CHEMBL6151i6,,,,,Autoxuratipn,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,
1225,,,,B,,,fAO00o0357,H,13863,CHEMBLy16277,,,,,Au6ocurstion,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,
1226,,,,B,,,BAO00903y7,H,13863,CHEMBL6162u8,,,,,Ajtocueation,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,
1227,,,,B,,,BAO0p00018,H,9742,CHEkBL616189,,,,,Autocueati8n,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,
1228,,,,B,,,BAO009o357,H,12073,xHEMBL616190,,,,,A7tocuratiog,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,
1229,,,,B,,,BAl0000e57,H,4101,CjEMBo616181,,,,,Autodu4ation,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,
1230,,,,B,,,BAOo0000w9,H,15360,CHEMBLy17182,,,,,Autof7ration,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,
1231,,,,B,942402.0,mippocampud,BAi0o00221,H,11576,CHrMBp616183,,,,,Autocursti8n,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1232,,,,B,,,BAOo000o19,H,5834,CHEhBL615774,,,,,Eapert,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,
1233,,CHOj1,,B,,,BAO090021i,D,2395,CHsjBL615875,,,,,Exp3rt,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,10116.0
1234,,,,B,,,nAO0o00019,H,1375,sHEMBL6158y6,,,,,Autocurahi8n,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,
1235,,,,B,,,BAO00o00w9,H,1375,CHEhBL615777,,,,,A6tocurati8n,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,
1236,,,,B,,,BzOo000357,H,3967,CHEMBpy15878,,,,,wutochration,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,
1237,,,,B,,,gAO0000e57,H,12884,xHdMBL615879,,,,,Experg,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,
1238,,,,B,,,vAO9000357,H,2343,CH2MBL615889,,,,,Experf,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,
1239,,,,B,,,BAO90000q9,H,11511,CHEMBi61588w,,,,,A8tocuragion,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,
1240,,,,B,,,BA00000029,D,11511,sHEMBL615872,,,,,Espert,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Rattus norvegicus,10116.0
1241,,,,F,,,BAOo000q18,H,16394,CHEnBL6q5883,,Invivp,,,Autofuratiln,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,
1242,,,,F,,,Bx90000218,H,16394,CHEMBk61588t,,Invico,,,xutocudation,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,
1243,,,,F,,,BAp00p0218,H,16394,CHfMBL614885,,Invovo,,,Autocura5oon,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,
1244,,,,F,,,BAO9000228,H,16394,CHEMBp61y886,,Inviv8,,,Autocu4atikn,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,
1245,,,,F,,,BAO900o218,H,16394,CHEnBL615987,,Invigo,,,Aht8curation,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,
1246,,,,F,,,BA0000021u,H,16394,CHrMBL61588o,,7nvivo,,,Autocurafi9n,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,
1247,,,,F,,,BAO0900219,H,16394,CHEMBL6qr889,,Ijvivo,,,Aitocuratikn,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,
1248,,,,F,,,hAO0p00218,H,16394,CHrMBL615880,,Invico,,,Autocuragi8n,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,
1249,,,,F,,,BAO90002q8,H,16394,CHEMBL61580q,,Invigo,,,Autosuratioh,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,
1250,,,,F,,,BzOo000218,H,16394,CH2MBL715892,,Ibvivo,,,qutkcuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,
1251,,,,F,,,vAp0000218,H,16394,CHEMBL61ro93,,Invlvo,,,Au4ocurati9n,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,
1252,,,,F,,,BAOo000118,H,16394,xHEnBL615894,,Invico,,,Auh8curation,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,
1253,,,,F,,,BAO0000e17,H,16394,CHEMBL5158i5,,onvivo,,,Autovurayion,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,
1254,,,,F,,,BAO900021u,H,16394,CHEMBo615796,,Igvivo,,,Autocurzti0n,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,
1255,,,,F,,,BzO0900218,H,16394,CHEMBi615o97,,8nvivo,,,Autocurxt9on,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,
1256,,,,F,,,BAOp000349,D,16616,CjEMBL615u98,,,,Membfanes,Exper6,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,10116.0
1257,,,,B,,,BA80000o19,H,16796,fgEMBL615899,,,,,Aufosuration,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,
1258,,,,B,,,BAO000p919,H,16796,vHEhBL616291,,,,,Autocurstjon,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1259,,,,B,,,BAO0o00358,H,15629,CHEkBL716292,,,,,Autoc6rati8n,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,
1260,,,,F,,,BA90000349,H,13241,CH3jBL616293,,,,,Autosuratkon,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
1261,,,,B,2087334.0,Hkppofampus,BAO00o0231,H,12073,CHrMBL6w6294,,,,,Expsrt,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1262,,,,B,3915233.0,yippocam9us,BAO000o149,H,14286,sHEMBL6q6295,,,,,Auyocuratiin,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,
1263,,,,B,1960924.0,B3ain,hAO0000121,H,14542,vHEMBL616206,,,,,xytocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,
1264,,,,F,,,BA09000019,H,13630,CHEMBot16297,,,,,Auhlcuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1265,,,,F,,,vAO9000019,H,13630,CHrMBL61t605,,,,,A8tocuratikn,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,
1266,,,,F,,,hAO00000q9,H,13630,CHwMBL616706,,,,,zutocuratlon,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,
1267,,,,F,,,BAO0p09019,H,13630,sgEMBL616607,,,,,Autoxudation,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1268,,,,F,,,BA9000o019,H,13630,CHEMBk61660u,,,,,Exoert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1269,,,,F,,,vAO00000w9,H,13630,CHEMBL6166p8,,,,,Autosurahion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,
1270,,,,F,,,BwO00000w9,D,13630,CHEMBi61661p,,,,,sxpert,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Rattus norvegicus,10116.0
1271,,,,F,,,BxO9000019,H,13630,CHEMBL6wu611,,,,,Augocuratuon,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1272,,,,F,,,BAp00000w9,H,13630,sHwMBL616612,,,,,Expwrt,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,
1273,,,,F,,,BAi000o019,H,13630,CHEMBL61u623,,,,,Autoc7rarion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,
1274,,,,F,,,BAO000p010,H,13630,CHEMBL6w661t,,,,,Expsrt,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,
1275,,,,F,,,BAO9000029,H,13630,CHEMvL617615,,,,,sutocuragion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,
1276,,,,F,,,BAO00000wi,H,13630,CHEnBp616616,,,,,Exp4rt,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1277,,,,F,,,BqO9000019,H,13630,CHEMBL616626,,,,,zytocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,
1278,,,,F,,,BwO0o00019,H,13630,xHEMBL6q6618,,,,,Aytocurati8n,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1279,,,,F,,,BzO0000919,H,13630,CHEMBL61t6w9,,,,,Autocyeation,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,
1280,,,,F,,,BxO0009019,H,13630,dHEMBL616610,,,,,Ex0ert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,
1281,,,,F,,,BAO00090q9,H,13630,CHfMBL61662q,,,,,Exoert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1282,,,,F,,,BqO000p019,H,13630,CH3MnL616622,,,,,Autodu3ation,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,
1283,,,,F,,,BxO0p00019,H,13630,CH2MBL616246,,,,,Exprrt,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,
1284,,,,F,,,BAO0p00029,H,13630,vHEMBL832872,,,,,wutocurxtion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,
1285,,,,F,,,vAO00o0019,H,13630,CHEMBLy15147,,,,,Autkfuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,
1286,,,,F,,,BAO00p00q9,H,13630,CHEMBL8y287w,,,,,qutocuratiob,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1287,,,,F,,,BAi00000w9,H,13630,CHfMBL615148,,,,,xutocurafion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1288,,,,B,3544897.0,nipp8campus,hAO0000q21,H,9783,fHEjBL616149,,,,,A8tovuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,
1289,,,,B,659450.0,gippovampus,BA0000o221,H,9783,dHEMBL617150,,,,,rxpert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,
1290,,,,B,,,BxO0p00249,D,14331,CmEMBL61615w,,,,Membganes,Expeft,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Rattus norvegicus,10116.0
1291,,,,B,630900.0,Hippocamp6d,BAO00o0222,H,15260,CHEMBL87q973,,,,,Ex0ert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,
1292,,,,B,2957282.0,Hippocqnpus,hAO0900221,H,15260,CmEhBL616670,,,,,wutocugation,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,
1293,,,,B,1366954.0,Hippocahpis,BAOo000321,H,15260,CmEjBL616671,,,,,Autkcurztion,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,
1294,,,,F,,,BAO00p0149,D,16616,vHEkBL884861,,,,,Exprrt,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,10116.0
1295,,,,B,,,BAOp0p0357,H,15629,CHEMBo61y672,,,,,Au4ocurxtion,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,
1296,,,,B,,,BAO009001p,H,15086,CyfMBL616673,,,,,Autocurzti0n,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1297,,,,F,,,gAO0000o19,H,5717,CHsMBL616673,,,,,wxpert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1298,,,,B,,,gA80000357,H,12652,fHEMBp616675,,,,,Autkcufation,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1299,,,,B,3275583.0,Hippocahphs,nzO0000221,H,14608,CHEMBk616576,,,,,zuyocuration,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,
1300,,,,B,2588363.0,Hipoocampuc,nAp0000221,H,12306,CtEMBL61u677,,,,,Autocurxgion,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1301,,,,B,1852047.0,Hippocsmpuc,BAO0o00121,H,12306,CHEMBL61u6y8,,,,,Ay5ocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1302,,,,B,,,BAO0p00r57,D,15247,sHEMBL6q6679,,,,,Expe3t,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1303,,,,B,2493410.0,Hjp0ocampus,BAO9p00221,H,17529,CHrMBL6w6680,,,,,4xpert,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,
1304,,,,B,1791386.0,Hippocxmpis,BAO0990221,H,14826,CHEMBL61678q,,,,,wutocuratiom,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1305,,,,B,1188607.0,Hilpocahpus,BzO0000q21,H,14826,CHEMBL616772,,,,,Augocuratoon,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1306,,,,B,1398985.0,Hippocahpue,BAi00o0221,H,13241,CHEMBL616ui3,,,,,Autocurari8n,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1307,,,,B,1749225.0,Hjppocamlus,BxOo000221,H,14093,CmEMBL616683,,,,,Autocufagion,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,
1308,,,,B,2429826.0,Hip90campus,BAOo000321,H,14093,xHEMBL6166u5,,,,,A6tocurat9on,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,
1309,,,,B,272803.0,B3ain,BAl0000321,H,14442,CHEMBo6166i6,,,,,Aut0curxtion,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,
1310,,,,B,,,BAk0o00357,H,9919,CHEMBLu16697,,,,,wutoc6ration,Affinity for 5-hydroxytryptamine 1A receptor site,,
1311,,,,B,,,BAp0009357,H,9919,CHEjBL6w6688,,,,,Autocurayipn,Affinity for 5-hydroxytryptamine 1A receptor site,,
1312,,,,B,169725.0,Hippocsmpua,BAO0900211,H,11440,CHrMBi616689,,,,,Autocurstoon,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,
1313,,,,B,,,BAO0000267,H,11257,CHEMBp61t690,,,,,A6toc7ration,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,
1314,,,,B,,,BAO0009358,H,10330,dHEMBL616692,,,,,Expe3t,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,
1315,,,,B,993411.0,Huppocahpus,BAO09p0221,D,17331,CHEhBo616692,,,,,Exp2rt,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Rattus norvegicus,10116.0
1316,,,,B,,,BAO09002r9,H,16567,CHEjBL61669r,,,,,Espert,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,
1317,,,,B,,,BAO000o0q9,D,12058,fHEjBL616694,,,,,Exp3rt,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Rattus norvegicus,10116.0
1318,,,,B,1808041.0,Hippicahpus,BAk00002w1,H,9699,CHEMBL61u6o5,,,,,A8tocurati0n,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,
1319,,,,B,,,BAO000p3y7,H,9547,CHwMBL6q6696,,,,,Autocu5qtion,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,
1320,,,,B,,,fAO0000w57,H,10330,CHEMnL617697,,,,,wutociration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,
1321,,,,B,,,Bx90000357,H,14331,CHEMBL616t08,,,,,Autocura6ioj,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,
1322,,,,B,,,BAO0p00o19,D,14060,CuEMBL61y949,,,,,Exlert,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1323,,,,B,3108850.0,Hip0oczmpus,BAOp00022w,H,14744,CtEMBL6169r0,,,,,Au5osuration,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,
1324,,,,B,,,BAO9000367,H,13506,CHEMBL73w875,,,,,Auticuratioj,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,
1325,,,,B,545590.0,Brzin,BzO0o00221,H,10862,CHdMBL61695w,,,,,Expdrt,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1326,,,,B,4688158.0,Braib,BAOo000q21,H,10862,CtEMBL617952,,,,,Exlert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1327,,,,B,,,vAO0p00357,H,10062,CHEMBL61y9y3,,,,,Experf,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,
1328,,,,B,,,BAO000036u,H,12073,CHEMBL6q6o54,,,,,Autoc7rztion,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,
1329,,,,B,,,vAO000035i,H,14875,CHEMBL61u95y,,,,,Autocutatiln,GTPgammaS radioligand binding assay,,
1330,,,,B,,,BAO000o35u,H,2391,CHEMBL626957,,,,,Autocu4at7on,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1331,,,,F,,,BAO00000q0,H,2391,CHEMBL71695u,,,,,Au6ocu5ation,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,
1332,,,,F,,,BAO000o0q9,H,2391,CHEMfL61695u,,,,,Autlcuratipn,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,
1333,,,,B,,,BAO0000458,H,2391,CHEMno616959,,,,,Autofurahion,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1334,,,,B,,,BA09000357,H,2391,CHEMBL51u960,,,,,sutocuratipn,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1335,,,,F,,,Bs00000019,H,2391,vH3MBL616961,,,,,Autoc6ratipn,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,
1336,,HeLa,,B,,,BAO0909219,H,17211,CHEMBp61696e,,,,,Expfrt,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,
1337,,HeLa,,B,,,fAO00002w9,H,17211,xHEMBL616i63,,,,,Autlcurxtion,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,
1338,,,,B,,,BAO00o0457,D,6491,CtEMBL616t24,,,,,Espert,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Homo sapiens,9606.0
1339,,CHO,,B,,,gAO0009219,H,16190,CHwMfL616525,,,,,Aut8curat9on,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,
1340,,,,B,,,BzO00000w9,H,14165,CHEMBpo72908,,,,,Autochrwtion,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,
1341,,,,B,,,BAOp0000w9,H,14165,CuEMBL6w6526,,,,,Au5ocuratiin,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,
1342,,,,B,,,BxO0p00357,D,4234,CuEMBL617527,,,,,Exlert,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1343,,,,B,,,BAO0o002w9,H,6328,CyEkBL616528,,,,,dxpert,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1344,,,,B,,,BAO0p0o357,H,14770,CHEnBL516529,,,,,wuhocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1345,,,,B,,,gAO00003t7,H,2598,CtEMBL616539,,,,,Autocurat9ln,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,
1346,,,,B,,,BAO00p0358,H,6897,CHEMfLu16531,,,,,Expfrt,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1347,,,,B,,,BA000p0357,H,6897,CHEMBi616632,,,,,Autoc6tation,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1348,,,,B,,,fA80000357,H,6013,CHEMBL716433,,,,,Autoc6rat9on,Binding affinity towards 5-hydroxytryptamine 1B receptor,,
1349,,,,B,,,BAO90o0357,H,5843,vHEMBLt16534,,,,,Edpert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,
1350,,,,B,,,nAO00p0357,H,14454,CHEhBL616435,,,,,2xpert,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,
1351,,,,B,,,BAO0000r58,H,16209,CHEMBL62653y,,,,,Au4ocu4ation,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,
1352,,,,B,,,BAp000p357,H,3935,CHEMBL6165e6,,,,,Ajtocufation,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,
1353,,CHOl1,,F,,,BAOp000218,H,13729,CHEMBL616428,,,,,Ex9ert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,
1354,,,,F,,,BAO0009018,H,14251,CHEMBL6qu539,,,,,3xpert,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,
1355,,,,B,,,BAOo090019,H,17085,CHEMgo616540,,,,,Espert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,
1356,,,,B,,,BAO00003ry,H,3025,CHEMBLu1t429,,,,,zutocurat8on,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1357,,,,B,,,BAO0090457,H,15315,CjEMBLt16430,,,,,Exlert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,
1358,,,,B,,,fAO00p0219,D,14214,CHEMvL6q6431,,,,,Expdrt,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Homo sapiens,9606.0
1359,,,,B,,,BzO0000r57,D,3804,CHEMBp61643q,,,,,Expeft,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1360,,,,B,,,vAO00003r7,D,2391,CHrMBL6w6433,,,,,Ex9ert,Affinity for 5-hydroxytryptamine 1B receptor subtype,Homo sapiens,9606.0
1361,,,,B,,,BqO000o357,D,4175,dHEMBL616534,,,,,Exprrt,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1362,,CHO,,B,,,BzO0000319,H,17296,CyEMBi616435,,,,,Autosuratipn,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,
1363,,,,B,,,BAp0000029,H,17085,CHrMBL616435,,,,,4xpert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,
1364,,HeLa,,B,,,BA80009219,H,17211,CHEjBL626437,,,,,Aut9curarion,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1365,,HeLa,,B,,,BAO9000218,H,17211,CHEMfL626438,,,,,Autlcuratiog,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,
1366,,HeLa,,B,,,BAO9000218,H,17211,CHEMBLt16429,,,,,Autpfuration,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1367,,,,B,,,BAp000035u,D,15926,CHEjBL616430,,,,,2xpert,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Homo sapiens,9606.0
1368,,CHOi1,,B,,,nAOp000219,H,16312,CbEnBL616441,,,,,Autockrayion,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,
1369,,,,B,,,BAO00003ru,H,5843,CHEMfp616442,,,,,Exper6,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,
1370,,,,B,,,BzO00p0357,H,5843,CHEMBL6q6r43,,,,,Augocurwtion,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,
1371,,CHOKq,,B,,,BAO0009e19,H,16312,CHEMBL51u444,,,,,Exp2rt,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,
1372,,,,B,,,BAOo0o0357,D,15926,CHfnBL616445,,,,,Expeft,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1373,,,,B,,,BAO00093y7,D,15926,dHEMnL616446,,,,,Exp4rt,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1374,,CHO,,B,,,BA80900219,D,4540,CHEMgi616447,,,,,Expedt,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,9606.0
1375,,,,B,,,BAO000036i,H,6166,CtEMBo616448,,,,,sutocudation,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,
1376,,CHO,,B,,,BAO00o0210,H,17296,CHEMhL61y449,,,,,qutocuratikn,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,
1377,,CHO,,B,,,BAl000021p,H,17296,CH3MBo616450,,,,,Auhocuratiln,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,
1378,,CHO,,B,,,BAO0900q19,H,17296,dH4MBL857974,,,,,Autocudatlon,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,
1379,,CHO,,B,,,BA8p000219,H,15779,CH3MBo616451,,,,,Autocudstion,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1380,,CHO,,B,,,BAO0900319,H,15779,CHsMBp616452,,,,,Autocurztioh,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1381,,CHO,,B,,,BAO00p021p,H,15779,CHEjBL516453,,,,,Autocufxtion,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
1382,,CHO,,B,,,BAO00902q9,H,4199,CmEnBL616454,,,,,Autocurzt8on,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,
1383,,,,B,,,BAOo0o0357,D,14875,CHEMhL6164y5,,,,,Edpert,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1384,,CHO,,B,,,BAO00p02q9,H,15146,CmEMfL616456,,,,,Autocy5ation,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1385,,,,B,,,gAO000o357,H,5213,CHEMBL61u4y7,,,,,Autosurztion,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,
1386,,CHO,,B,,,BAp000021o,H,14818,CHEMBi616459,,,,,Autpcugation,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1387,,CHO,,B,,,BAp00p0219,H,4829,CHEhBLt16459,,,,,Autpcuratiob,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,
1388,,,,F,,,BwO0000919,H,14454,CHEMBL61656o,,,,,Ezpert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,
1389,,,,F,,,BAO0000pw9,H,14454,CH4MBL616561,,,,,Ezpert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,
1390,,CHO,,F,,,hAO00o0219,H,14875,CHEMBo61u462,,,,,sutocurztion,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1391,,CHO,,F,,,BAp00o0219,H,14875,fHEMBL6q6463,,,,,Au5ocueation,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1392,,,,F,,,nAO000001i,H,15250,CHEMBL6qt464,,,,,Autocueztion,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,
1393,,CHO,,B,,,Bsl0000219,H,15250,fHEMBL616e65,,,,,wutocuratuon,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,
1394,,,,B,,,nAO000p357,H,15086,CHEMBLo3287e,,,,,Au6ocuratlon,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1395,,,,F,,,BAO00000wp,H,3025,CHEMBL615284,,,,,Au4ocuratiom,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Oryctolagus cuniculus,9986.0
1396,,,,B,,,BzO0000919,H,14998,CHEMgL61u185,,,,,Autodugation,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Oryctolagus cuniculus,9986.0
1397,,,,B,,,BAO0000p1p,H,14998,fuEMBL616186,,,,,Interkedixte,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Oryctolagus cuniculus,9986.0
1398,,,,B,,,BAi00000q9,H,14998,Cb4MBL616187,,,,,Autocurstiog,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Oryctolagus cuniculus,9986.0
1399,,,,B,,,BAi0090357,H,13969,xHEMBL616288,,,,,Ecpert,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,
1400,,,,B,,,BqO0000w57,D,13392,CtEMBL87r475,,,,,Intermed7afe,Binding affinity for 5-hydroxytryptamine 1B receptor,,
1401,,,,B,1650697.0,Striafum,BAO0o00p19,D,3651,fHEMBi616189,,,,,Expett,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Rattus norvegicus,10116.0
1402,,,,B,,,nAOo000357,H,10025,CgEMBL716190,,,,,Exlert,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1403,,,,B,,,BAl000p357,H,13863,CHEMBL6q61o1,,,,,Autpcuratuon,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,
1404,,,,B,,,BAO009o357,H,13863,CHEjBL616102,,,,,sutocuratikn,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,
1405,,,,B,,,nAO0000257,H,13863,CHEMBL61t1p3,,,,,Aytocufation,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,
1406,,,,B,,,gAO000035u,H,13863,CH2MBL61y194,,,,,Autoduratiob,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,
1407,,,,B,,,BAp000o357,H,13863,CHEMBL616205,,,,,Auyoduration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,
1408,,,,B,,,BzO000o357,H,13863,CHEMBL6q61o6,,,,,Auyoxuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,
1409,,,,B,1670351.0,Hilpocampuq,fAOo000249,H,4622,CHEMBL6w61p7,,,,,Autocurafi0n,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,
1410,,,,B,,,vAO00p0019,H,14911,CHEMhL6q6198,,,,,Intetmed8ate,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
1411,,,,B,1129647.0,Hkppocampua,vA00000221,H,12678,CuEMBL626199,,,,,Autoc7rat8on,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
1412,,,,B,178900.0,Hipp8canpus,BAO0900w21,H,12678,CjEMBk616200,,,,,dxpert,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,
1413,,,,B,3785728.0,H8ppocampis,BAO0909221,H,14235,xHEMBL626201,,,,,Expdrt,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1414,,,,B,139893.0,uippodampus,BAO0o90221,H,14949,CHdMfL616202,,,,,Espert,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1415,,,,B,1300891.0,H7ppocamp8s,BAO0000q22,H,14949,dHEMBL6q6203,,,,,Expfrt,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1416,,,,B,2806342.0,Hippocaml8s,BAO0p0022w,H,14949,CHrMBL61y204,,,,,wxpert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,
1417,,,,B,1639215.0,H8ppocakpus,BAO00001w1,H,14949,CHEhhL616205,,,,,Ex9ert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,
1418,,,,B,1120964.0,Hi9pocahpus,BAO0000w2q,H,14949,CnEMBL616106,,,,,Expeft,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,
1419,,,,B,,,BqOo000249,H,16118,CHEMBL61629u,,,,,Expeft,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
1420,,,,B,,,BxO000024o,H,3268,CHEMBo61620u,,,,,Autocjrxtion,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,
1421,,,,B,,,BAOp000w49,H,3268,CHEMBk6w6209,,,,,Ahtocuratoon,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,
1422,,,,B,,,BA0000p357,H,16117,CHdMBi616210,,,,,Expsrt,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,
1423,,,,B,4096974.0,Hjppocakpus,Bw00000221,H,9783,CHEMBL6q621q,,,,,Expeet,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,
1424,,,,B,3941381.0,Hilpocampux,BAO090p221,H,9783,CHEMBL616603,,,,,Autocurstikn,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,
1425,,,,B,282121.0,uip9ocampus,BAO000pw21,D,14356,CHEMBL6q6605,,,,,Expe4t,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1426,,,,F,,,BAOo00p019,H,15740,CHEMBi617506,,,,,Auhocuratoon,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
1427,,,,B,1829950.0,u8ppocampus,gAO0o00221,H,12306,CHEMnL871107,,,,,Autocuratuln,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1428,,,,B,2803589.0,Hip0lcampus,BzO0000222,D,13348,Cy4MBL616507,,,,,Expeft,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Rattus norvegicus,10116.0
1429,,,,B,,,BAO000o2e9,H,10394,CHEMBi616203,,,,,Aitoxuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,
1430,,,,B,2441950.0,Hopposampus,BAO900022w,H,15260,CnEMhL616304,,,,,wutocurati0n,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,
1431,,,,B,1678915.0,Hipoocajpus,BAO0009w21,H,10046,CHEMBLt26305,,,,,Exoert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
1432,,,,F,2132853.0,Hkppkcampus,BAOo000121,H,15260,xHEnBL616306,,,,,Interjed7ate,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,
1433,,,,B,,,BsO000p357,H,12851,CHEMBL7w6307,,,,,Autocurst7on,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,
1434,,,,B,2827994.0,mippocampjs,BA800p0221,D,2148,CHEjBL882829,,,,,Ex9ert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Rattus norvegicus,10116.0
1435,,,,B,,,BAO090o357,H,13134,CHEkBL61630i,,,,,Exper5,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,
1436,,,,B,,,BAO00o00q9,H,12462,CHEMfL61y309,,,,,Aktovuration,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,
1437,,,,B,,,BAO00000qi,H,12462,vHEMBL616319,,,,,dxpert,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,
1438,,CHO,,B,,,BAO000pe19,H,12462,CnEMvL616311,,,,,Ajtosuration,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,
1439,,,,B,,,BA0000o357,H,11933,CyEMBL6q6312,,,,,Exp2rt,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,
1440,,,,B,,,BA80900357,H,11933,CHEMBL615e13,,,,,Au6pcuration,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,
1441,,,,B,3038406.0,uippocahpus,BAO00002qq,D,403,CmEMBL616414,,,,,Ex9ert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1442,,,,B,2784960.0,Hipposampux,vAO0000222,H,15538,CgEMBL616w15,,,,,xutocurati9n,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1443,,,,B,5143223.0,niplocampus,hAO0009221,H,15538,xHEhBL616567,,,,,Aut0duration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,
1444,,,,B,1383716.0,tippovampus,BxO0o00221,H,15538,CHEMBL6q656i,,,,,Auyocuratioj,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,
1445,,,,B,,,BAO0000p1p,H,12464,CHEjBL616579,,,,,Inrermedkate,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,
1446,,,,B,,,BAO00093y7,H,1455,CHdMBL61t570,,,,,Exlert,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,
1447,,,,B,,,BAOo900357,H,12652,CHrMfL616571,,,,,wutochration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1448,,,,B,4270317.0,Hippocwm9us,BAi9000221,H,12639,fHEMBL616472,,,,,Autocurat99n,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,
1449,,,,B,,,BAO000034i,H,13949,CHEMBk6w6573,,,,,Eapert,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,
1450,,,,B,,,BAk0090357,D,12463,dnEMBL616574,,,,,wxpert,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1451,,,,B,1875483.0,tipposampus,BAO900022w,H,14829,CHdMBL616675,,,,,Expfrt,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,
1452,,,,B,1554122.0,H9ppocajpus,BAO0909221,H,14829,vHEMBL8721p8,,,,,Autlcuratiln,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,
1453,,,,B,,,BAOp00p357,H,12092,CHEMnp616576,,,,,Auhocurati0n,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,
1454,,,,B,,,BAO0o0024o,H,403,CnEMBL6165i7,,,,,Aut9ckration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,
1455,,,,B,,,BAi000o249,H,403,CH2MBL616y78,,,,,sutkcuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,
1456,,,,B,,,vAO0000w57,H,3967,CHEMBL616y7p,,,,,Expdrt,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,
1457,,,,B,,,BzO0000p19,D,12771,CHEhBLy16580,,,,,Expfrt,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Rattus norvegicus,10116.0
1458,,,,B,,,BAp0000o19,H,15086,xH2MBL616581,,,,,Autocjfation,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1459,,,,B,2187431.0,Hipposampuz,BsO0o00221,H,14909,CHEjhL616582,,,,,Autocira4ion,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1460,,,,B,1038674.0,Hi0pocampuc,BAl000022w,H,14949,CHEnBLt16583,,,,,sxpert,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1461,,,,B,720460.0,Hip0ocamous,BAO0pp0221,D,2309,CmEMBp616584,,,,,Exoert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1462,,,,B,,,BAOp0p0357,H,4170,CHEMnL6165i5,,,,,Expeft,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1463,,,,B,1848834.0,Hippocxm9us,BAO9p00221,D,11642,CHEMnL616596,,,,,Expery,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Rattus norvegicus,10116.0
1464,,,,B,2422466.0,Hi9pocajpus,BAO0po0221,H,11642,xgEMBL616587,,,,,Autpsuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,
1465,,,,B,400006.0,Hi0picampus,nAO0000211,H,12953,CHEMBL616y8o,,,,,Autocura6iom,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,
1466,,,,B,307572.0,Hi0posampus,BAp0o00221,H,12953,CHEMhL615589,,,,,Autocutatikn,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1467,,,,B,1464898.0,Hilpodampus,BA900002w1,H,12953,CHEMBo617590,,,,,Expett,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1468,,CHO,,B,,,vAOo000219,H,12903,CHEMhL626591,,,,,Exprrt,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,
1469,,,,B,,,BxO0000358,H,12536,CHEMfp616592,,,,,Exper6,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1470,,,,B,,,BxO0900357,H,10058,CHEMBk516593,,,,,Aut9curatjon,The inhibition activity of 5-HT1A at 1 uM,,
1471,,CH0K1,,B,,,BAl000021o,H,12902,dHEMBL61t594,,,,,Ezpert,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,
1472,,,,B,,,BAO90002r9,H,14057,CmdMBL616595,,,,,Expe4t,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,
1473,,,,B,,,BxO00p0357,H,11296,CHEMvL616696,,,,,Autocyeation,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,
1474,,,,B,328188.0,Hipposajpus,fAO00p0221,H,11296,CHEMBLy165i7,,,,,Aurocyration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1475,,,,B,324252.0,Hkppocamp8s,BAO0po0221,H,11296,CHEMBLt16r98,,,,,Ecpert,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1476,,,,F,,,fAO0009249,D,16616,CbEMBk616599,,,,Membranea,Exprrt,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Rattus norvegicus,10116.0
1477,,,,F,3846606.0,Hipposampud,BAO9000240,D,16616,sHEhBL616600,,,,kembranes,Exlert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,10116.0
1478,,,,B,,,gAOp000019,H,16567,CHEhBp616601,,,,,Autocjrati8n,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,
1479,,,,B,,,BAO0p00029,H,16567,CHEMgL626602,,,,,Autoc6ratiog,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,
1480,,,,B,,,BAO0000pw9,H,16567,CHEMnL616t03,,,,,wutocu5ation,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,
1481,,,,B,,,vA80000019,H,16567,CHEMBL6q66o4,,,,,Autosuratiln,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,
1482,,,,B,,,BAl000024p,H,17136,CHEMBi616r16,,,,,Au5ocurati0n,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,
1483,,,,B,,,BAi0p00249,H,17136,CHdMBL616318,,,,,Auticurqtion,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,
1484,,,,B,,,BAOo000o19,D,16616,CHEMBL616327,,,,,Experf,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Rattus norvegicus,10116.0
1485,,,,B,2815581.0,tippocamlus,BqO0000321,H,17331,sHsMBL616319,,,,,Autosurqtion,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,
1486,,,,B,389733.0,Hippoczhpus,BAOp900221,H,17331,CH2MBL61632p,,,,,Autocurayiob,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,
1487,,,,B,1833333.0,Hi9pocampuc,BAO0o00q21,D,17167,CHEMBL6q632q,,,,,Exp2rt,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Rattus norvegicus,10116.0
1488,,,,F,,,BAO0o09019,H,15740,CHEjBL6163q2,,,,,Autochrwtion,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1489,,,,F,,,BAO0op0019,H,15740,CHEMBL6q632w,,,,,wutocjration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,
1490,,,,B,,,BAO900035i,H,4671,fHEMBL616325,,,,,Aufovuration,Ratio of binding affinity to 5-HT 1A and D2 receptor,,
1491,,,,B,2869602.0,Hippoczjpus,fAO0000w21,H,10058,CmEMBL616425,,,,,Autocurwti0n,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1492,,,,B,3494556.0,Hippocwmpys,BAOo0002e1,H,10058,CtEMBL616327,,,,,zutocurahion,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1493,,,,B,4366616.0,Hippodampuc,hAO0000e21,H,10058,CH2MBLu16327,,,,,Autlfuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,
1494,,,,B,,,BAO0o00367,H,12073,CyEMhL616328,,,,,Autocurayiin,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,
1495,,,,B,,,Bqi0000249,H,2759,CHEMBi858q10,,,,,Autkcuratioj,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1496,,,,F,,,Bwk0000249,H,2759,CtEMBL61632o,,,,,Auyocuratiom,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1497,,,,B,,,BAO00o024o,H,2759,CHEMBo61y330,,,,,Autocyrahion,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1498,,,,F,,,BAO00092e9,H,2759,CHEMBo6q6331,,,,,Au4ocuratiom,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1499,,,,F,,,BAO000014i,H,2759,CH4MBL516332,,,,,Aurocuratiom,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1500,,,,B,1242681.0,Braig,hAO00p0249,H,9737,CHshBL857063,,,,,A8tovuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1501,,,,B,,,BwO0000919,H,9737,CHEMBp6w6333,,,,,Autockrafion,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,
1502,,,,F,,,BAO9000029,H,5717,CbEMBL616434,,,,,fxpert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,
1503,,,,B,116702.0,Hippocshpus,BAOo000e21,H,12253,CH4MBLy16335,,,,,Auyocurati9n,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1504,,,,B,,,BAko000019,H,14025,CH3MBL617336,,,,,Aitkcuration,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,
1505,,,,B,,,BAO0p0024o,H,10425,CHEMBL6w6437,,,,,Expett,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,
1506,,,,B,,,Bzp0000019,H,14998,CHEMBL6w7338,,,,,xutocuratioh,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,
1507,,,,B,375419.0,nippocamlus,BAO009022w,H,13694,xHdMBL616339,,,,,Auhocura5ion,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,
1508,,,,B,3043739.0,Hippocxmpys,BAO090p221,H,13694,CHEMnL61u340,,,,,Autocurati8j,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,
1509,,,,B,,,BAO0000w5i,H,4342,CHwkBL616341,,,,,wutocurafion,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,
1510,,,,B,,,nAO00p0357,D,12936,CHEMnL61y342,,,,,Exoert,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Rattus norvegicus,10116.0
1511,,,,B,,,BwO0000p19,D,13144,CmEMBp616343,,,,,Experr,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Rattus norvegicus,10116.0
1512,,,,B,,,BA00o00019,H,13343,CjEMBLu16344,,,,,Expett,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,
1513,,,,B,,,fAO00003r7,H,12132,CHEMBL71y345,,,,,rxpert,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1514,,,,B,,,BAO00o001o,H,15419,vHEMBL616356,,,,,4xpert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,
1515,,,,B,676439.0,Huppocamlus,BAO00o9221,H,1479,CHEMBL6q63e7,,,,,Autoduratiog,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1516,,,,B,,,BAO090001p,H,14287,CH2MBL626348,,,,,Espert,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,
1517,,,,B,,,BAO0o00367,H,13116,CHEkBL626349,,,,,Ezpert,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1518,,,,B,,,BA99000249,D,2759,xHEMBL616w52,,,,Msmbranes,wxpert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Rattus norvegicus,10116.0
1519,,,,B,,,BAO0000et9,H,2759,CHEMBL6qu153,,,,,Auticufation,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1520,,,,B,,,fAO000o019,H,14748,CHEMhL616254,,,,,Exper5,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,
1521,,,,B,,,fAO0o00019,H,12304,dHEMBL6161t5,,,,,Auyovuration,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1522,,,,B,4244204.0,Hip0ocakpus,BAOo00022q,D,12409,CHEMnL616157,,,,,Experr,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1523,,,,B,862029.0,bilpocampus,BAO000922w,D,12409,CHwMBL616158,,,,,Expe3t,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Rattus norvegicus,10116.0
1524,,,,B,347590.0,Hippocajpuq,BAO00092e1,H,13267,CbEMgL616158,,,,,xutocurat7on,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,
1525,,,,B,,,BAO0o00257,H,15194,CmEMBL626159,,,,,Autocufa5ion,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1526,,,,B,,,vzO0000357,H,14256,CHEjBL617160,,,,,Ex9ert,pKi value against rat 5-hydroxytryptamine 1A receptor.,,
1527,,,,B,,,BAO9900019,H,16567,CHEMBLt16261,,,,,Aktocurwtion,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,
1528,,,,F,,,BAO00oo019,H,15740,CHEMBp6161t2,,,,,Autovhration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1529,,,,B,,,fAO0000347,D,13278,CH3MBL626163,,,,,dxpert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,10116.0
1530,,,,B,,,BAl0900249,H,1970,CHEMBk616q64,,,,Memb5anes,Expedt,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1531,,,,B,1917384.0,Bfain,BA0000o221,H,10034,CHEhBo616165,,,,,qutocurat7on,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,
1532,,,,B,,,BsO0p00019,H,13348,sHEMBL61t355,,,,,Aut0curatipn,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Rattus norvegicus,10116.0
1533,,,,F,,,BAO000op19,H,13630,dHEMBL6163t6,,,,,Autoc8ra5ion,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1534,,,,B,269096.0,Brsin,nAO000022q,H,10862,CHEMBL6163ri,,,,,Autochfation,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1535,,,,B,,,BAO00000w0,H,12058,CbEMnL616358,,,,,Autoxurqtion,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,
1536,,,,B,,,BAO0o003t7,H,4639,CHEngL616359,,,,,Au6ocuratikn,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,
1537,,,,B,,,vAO0009357,H,15453,CHfMvL616360,,,,,3xpert,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,
1538,,,,B,,,BsO0000e57,H,4820,CHEkBL616362,,,,,Ecpert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1539,,,,B,,,BAO000p35y,H,1089,fHEMBL6q6362,,,,,Autkvuration,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,
1540,,,,B,,,BA09000249,H,386,CHEMni616363,,,,Brainmemnrames,Aytofuration,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,
1541,,,,B,,,BAO0900457,H,6011,CHEMBL7163u4,,,,,Autocufati8n,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,
1542,,,,B,,,BAO00093r7,H,5014,CHEMBk6w6365,,,,,Au4ocurat8on,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,
1543,,,,B,,,fAO0o00357,H,4402,CHEMBLt1636t,,,,,Edpert,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,
1544,,,,B,,,BAO0000wt7,H,17066,CHEMBL8i2o06,,,,,Exoert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1545,,,,B,,,Bwl0000357,H,17515,CHEMBLy163u7,,,,,A6tocura6ion,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,
1546,,,,B,,,BA89000357,H,2474,CH2MfL616368,,,,,Autocuratooj,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1547,,,,B,,,BsOo000357,H,4775,CHEkBL616e69,,,,,Au5ocurat9on,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,
1548,,,,B,,,BsO00003t7,D,14294,CHEMBLy1y370,,,,,Expedt,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Homo sapiens,9606.0
1549,,,,B,,,BAp00p0357,D,14294,CHEkBL616w71,,,,,Expeft,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Homo sapiens,9606.0
1550,,CHO,,B,,,BxO9000219,H,12249,CHEMBL61t371,,,,,Autpc7ration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1551,,,,B,,,fwO0000219,H,11376,CmEMBp616373,,,,,Expfrt,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,
1552,,,,B,,,BAO00092w8,H,2474,CHEMBL6q63i4,,8nvivo,,,Autkcuratiln,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1553,,,,B,306754.0,H9ppocanpus,vAO0000222,H,13311,CH3nBL616375,,,,,Autpcuratiin,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
1554,,,,B,,,BAO0090r57,H,4373,CHEMBL61537u,,,,,Autockrqtion,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,
1555,,,,B,,,BAi0000457,H,1633,CHEMBp857p64,,,,,Expett,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,
1556,,,,B,,,gA00000357,H,11866,CHEMBL51t377,,,,,Autoc7rstion,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1557,,,,B,,,BAO00003r8,H,4373,CHEMBL62u378,,,,,qutocurxtion,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1558,,,,B,,,BzO0000356,H,4687,xHEMBL61637o,,,,,Aitocurstion,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,
1559,,,,B,,,hwO0000357,H,16946,CyEMBLy16380,,,,,Autodurafion,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1560,,,,B,,,BxO0000257,H,13291,CjEkBL616381,,,,,Auhocu3ation,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,
1561,,,,B,,,BA80000347,H,14159,CHEMBL5w6382,,,,,Autocjratipn,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,
1562,,,,B,,,BwO000035y,H,10812,CHEMBk615383,,,,,Au6ocjration,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,
1563,,CHO,,B,,,nxO0000219,D,3032,sHEMBL626350,,,,,Exprrt,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Mus musculus,10090.0
1564,,,,B,,,hAO0000457,H,16655,CHEMBk61u351,,,,,A6tocurxtion,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
1565,,,,B,,,BAl0000457,H,14532,CHEMfL61635q,,,,,Ajtoc6ration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,
1566,,,,B,,,BAO90p0357,H,13944,sHEMBL616w53,,,,,Autocugatiog,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1567,,,,B,,,BsO00p0357,H,13033,CHfMBL615354,,,,,Autocugatjon,Binding affinity against serotonergic 5-HT1a receptor,,
1568,,,,B,,,fwO0000357,H,10321,CHfMBL616598,,,,,Auhocuratiob,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,
1569,,,,B,,,BAO0090347,D,2968,CjEMfL616559,,,,,Expwrt,Binding affinity for 5-hydroxytryptamine 1A receptor,Mus musculus,10090.0
1570,,,,B,,,BAO0p90357,H,13964,CHEMBL62t560,,,,,Autocu5atiob,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1571,,,,B,,,BAl0900357,H,15527,CHEMBi616562,,,,,Augocurat7on,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,
1572,,CHO,,B,,,gqO0000219,H,12248,CHEMBk617562,,,,,Autosurxtion,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1573,,CHO,,B,,,vAOo000219,H,12249,CHEMBL615y63,,,,,Aitocurati8n,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1574,,,,B,,,BAl00003t7,H,15120,xHrMBL616564,,,,,Autocura4oon,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,
1575,,,,B,,,BAO0000458,H,13313,CHEMnL61t565,,,,,Autpcuratiln,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,
1576,,,,B,,,BAO0009e18,H,2613,CbEjBL616566,,,,,Aurocuratioh,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,
1577,,,,B,,,BAi0090357,H,16700,CHEkBL616988,,,,,Autocurat8pn,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,
1578,,,,B,,,hAO00p0357,H,2201,CHEMBL7r7975,,,,,Autocu5atkon,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,
1579,,,,B,,,BAp0000r57,D,1274,CH4MBL626990,,,,,Expett,Binding affinity against 5-hydroxytryptamine 1A receptor,Mus musculus,10090.0
1580,,,,B,,,BsO0900357,H,1317,CHEMBi616i91,,,,,A8ticuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1581,,,,B,,,BAi0000r57,H,12146,CH2MBLy16992,,,,,zu4ocuration,Tested against 5-hydroxytryptamine 1A receptor,,
1582,,,,B,,,BxO000035i,H,14059,vHEMvL616993,,,,,Autocyratiom,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,
1583,,,,B,,,BAO0900919,H,14025,CtEMBi616994,,,,,sxpert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Oryctolagus cuniculus,9986.0
1584,,,,B,,,BAO0000p29,H,14025,CuEMBL516995,,,,,Aitocuratlon,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Oryctolagus cuniculus,9986.0
1585,,HEK294,,B,,,BAO00002wi,D,14447,CHEMBk6q6996,,,,,Intdrmrdiate,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,9593.0
1586,,,,F,,,BwO0000q18,H,3025,CHEhgL616997,,Invibo,,,Ajtoduration,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,10141.0
1587,,,,F,,,BsO0009218,H,3025,CHEMBL615i98,,Inv7vo,,,Autpxuration,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,10141.0
1588,,,,F,,,BAOop00019,H,15329,CHEMBL615998,,,,,Ajtoc8ration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Cavia porcellus,10141.0
1589,,,,F,,,fxO0000019,H,15329,CtEMBo617000,,,,,Autocira4ion,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Cavia porcellus,10141.0
1590,,,,F,,,Bzp0000019,H,15847,vHEMBL617901,,,,,Autovuratiog,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Cavia porcellus,10141.0
1591,,,,F,,,BAOp000o19,H,15847,CHEMBi848111,,,,,Auticurwtion,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Cavia porcellus,10141.0
1592,,,,F,,,BA00900019,H,14165,CHEMBLtw7002,,,,,Augocurati8n,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,
1593,,,,F,,,gqO0000019,H,14214,CHEMBL6w7p03,,,,,A6tocurafion,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,
1594,,,,F,,,gAO0000919,H,14214,CHEMvL618004,,,,,Autoc7ragion,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,
1595,,,,F,,,BAp000o019,D,14214,CHEkBLu17005,,,,,Ex0ert,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Homo sapiens,9606.0
1596,,CHOKq,,F,,,BAO0p09219,D,13729,xuEMBL616623,,,,,sxpert,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Homo sapiens,9606.0
1597,,CHO,,F,,,hAO00o0219,H,3025,CHEkBL616614,,,,,Aut8ckration,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,
1598,,,,B,,,BAO0p00356,H,2391,CHEMBp88w243,,,,,Autodurati8n,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1599,,,,F,,,gAO0000919,H,2391,CHEhBLu16625,,,,,Aut0curahion,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,
1600,,CHO,,F,,,BAO00op219,H,14956,xHEhBL616626,,,,,3xpert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,
1601,,CHO,,F,,,BA0000o219,H,2598,CHEkBL61662u,,,,,sut8curation,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,
1602,,CHO,,F,,,BAO0o0p219,H,2598,dHEMBL61662o,,,,,wutlcuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,
1603,,CHO,,F,,,BAO000p2q9,H,2598,CHEnBL6q6629,,,,,Autocurzti0n,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,
1604,,CHO,,F,,,BAO00o0229,H,2598,CHEhBL616t30,,,,,Autocudatiog,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,
1605,,,,F,,,BxO000001o,H,14956,CHEkBL617631,,,,,Exlert,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,
1606,,,,F,,,BsO0p00019,H,14956,CHEMBL6166e3,,,,,zutlcuration,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,
1607,,,,B,,,BAOo000e57,D,14214,CH4MBL6166w3,,,,,fxpert,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1608,,CHO,,B,,,BAO09p0219,H,3463,CmEMBL6q6634,,,,,Ex0ert,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,
1609,,,,B,,,BAO0oo0357,H,15331,CHEMBL6wt635,,,,,Ahtochration,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,
1610,,,,B,,,BA9000p357,D,16146,vHEMBL886358,,,,,Eapert,Binding affinity against 5-hydroxytryptamine 1B receptor,Homo sapiens,9606.0
1611,,CHO,,B,,,fAO000o219,D,14159,CgEMBL61u636,,,,,Expe5t,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Homo sapiens,9606.0
1612,,CHO,,B,,,hAO9000219,H,14158,CHEMBLy1663i,,,,,Expeft,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,
1613,,,,B,,,BAO0o90357,H,14159,CHEjhL616638,,,,,zutoxuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,
1614,,CHO,,B,,,BAO9009219,H,15250,CHEMBL61uy39,,,,,dxpert,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1615,,CHO,,B,,,BAO9090219,H,15250,CHEMBk61664o,,,,,Expdrt,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1616,,CHO,,B,,,BAO000011p,H,15331,CmEMBo616641,,,,,Expdrt,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1617,,CHO,,B,,,BAOo0002q9,H,15332,CHEMBLy16641,,,,,fxpert,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,
1618,,CHO,,B,,,fAO0900219,H,14956,CHEkBo616643,,,,,Expery,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,
1619,,,,B,,,BAO00o0457,H,3805,CHEMfo616644,,,,,Autocurst8on,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,
1620,,,,B,,,BAi000o357,H,14875,CHEMBL615545,,,,,Autocjratiog,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,
1621,,,,F,,,BA0000001o,H,14454,CmEMBL626646,,,,,Aytoc8ration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,9986.0
1622,,,,F,,,BAO00o00w9,H,14454,CHEjfL616647,,,,,Exprrt,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,9986.0
1623,,,,B,,,BAO0o003t7,H,16288,CH4MgL616509,,,,,Auhocurati0n,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,
1624,,,,B,,,BAl00003r7,H,16288,CHEMvL6165q0,,,,,Aut8curxtion,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,
1625,,,,B,,,vAO00p0357,H,16312,CHEMhL616y11,,,,,Autoxyration,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,
1626,,,,B,,,hAO000o357,H,1348,CHEkhL616512,,,,,Experr,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Bos taurus,9913.0
1627,,,,B,,,fAO0p00357,H,5834,CHEMBLt15513,,,,,zut0curation,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Bos taurus,9913.0
1628,,,,B,2114619.0,Stristum,BAOp0000q9,H,13366,xHEMBL6165w4,,,,,Autosuratiln,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,9913.0
1629,,,,B,,,hAO0900357,H,1414,CHEMfL61651t,,,,,Exp4rt,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Bos taurus,9913.0
1630,,,,B,,,BAO00p0029,H,14998,CHEMBp61651u,,,,,Autocurzti8n,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Bos taurus,9913.0
1631,,,,B,,,BA90000457,H,11473,CHEMBL6qy517,,,,,Augocura6ion,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,9913.0
1632,,,,B,,,BAk0000367,H,11473,CHEMBk61t518,,,,,Autocura4ioj,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,9913.0
1633,,,,B,,,BAO0o90357,H,10639,CHEMgL61651p,,,,,Au5ovuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,9913.0
1634,,,,B,,,nAO0000358,H,10639,CHEMfk616520,,,,,Autodurstion,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,9913.0
1635,,,,B,,,BAk00o0357,H,1375,CHEMhL616y21,,,,,Aut8curstion,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Bos taurus,9913.0
1636,,,,B,,,nAOp000357,H,1375,CHEMBL7q6522,,,,,s8tocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Bos taurus,9913.0
1637,,,,B,,,BAO9090357,H,16532,CuEMBL884532,,,,,Auyocura5ion,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,9913.0
1638,,,,B,,,BA99000357,H,11147,CHwMBL6w6523,,,,,Autockratiin,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Bos taurus,9913.0
1639,,,,B,617661.0,Stfiatum,BAO000p01p,H,13366,CmEMBL61u731,,,,,Autochratkon,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,9913.0
1640,,,,B,,,BAO0po0019,H,10444,CH4MnL616732,,,,,Aut9curztion,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Bos taurus,9913.0
1641,,,,B,,,Bq90000357,H,16532,CHEMBL6q6u33,,,,,Auhocuratioh,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Bos taurus,9913.0
1642,,,,B,,,BAl0009357,H,16532,CHEMBL616i24,,,,,Akt0curation,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,9913.0
1643,,,,B,,,fAO0000240,H,12827,CtEMhL616735,,,,,Auykcuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Bos taurus,9913.0
1644,,,,B,,,BAOo00024p,H,12827,CHEMBL61663u,,,,,Autocudatiom,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Bos taurus,9913.0
1645,,,,F,,,BqO0090019,H,12919,CH4MBL6q6737,,,,,Expfrt,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,9913.0
1646,,,,B,,,hAO0000p19,H,14025,CHEMfL616u38,,,,,Augocuragion,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Bos taurus,9913.0
1647,,,,F,,,BA80900019,H,12919,xHEjBL616739,,,,,Expe4t,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,9913.0
1648,,,,F,,,BAO00o9019,H,12919,vHEMBL61y740,,,,,Ex9ert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,9913.0
1649,,,,F,,,BAO00000qi,H,12919,CbdMBL616741,,,,,Experf,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,9913.0
1650,,yEK293,,B,,,nAO00002w9,H,14447,CgEMBi616742,,,,,Auricuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,9593.0
1651,,,,B,,,nAO00000w9,D,1375,CHEjBL61u743,,,,,Intdrmeduate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Cavia porcellus,10141.0
1652,,,,B,,,BwO000001i,D,1375,dHEMBL61t744,,,,,8ntfrmediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Cavia porcellus,10141.0
1653,,,,F,,,hAO00000w9,D,12409,CHEMBp615745,,,,,Interjediwte,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Cavia porcellus,10141.0
1654,,,,F,,,BAi0000o19,D,12409,CHEkBL6167t6,,,,,Ijtermeriate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,10141.0
1655,,,,F,,,BAO0009o19,D,12409,CHEMBL61yi47,,,,,Interm2wiate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Cavia porcellus,10141.0
1656,,,,F,,,BsO000o019,D,12409,CHEMBL6q6747,,,,,Interjed9ate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Cavia porcellus,10141.0
1657,,,,F,,,vA90000019,D,12409,CH3MBp616648,,,,,Inte3mediafe,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Cavia porcellus,10141.0
1658,,,,B,,,BAO000p3t7,D,11574,CbEMBL616640,,,,,Intermeeiste,Binding affinity against 5-hydroxytryptamine 1D receptor,Cavia porcellus,10141.0
1659,,,,B,,,BAi00003r7,D,1558,dHEMBL6q6650,,,,,In4ermediatf,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Cavia porcellus,10141.0
1660,,,,F,,,BsO000021i,D,12409,CH3jBL616651,,,,,Intedmeduate,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,10141.0
1661,,,,F,,,BAl00002q8,D,12409,dgEMBL616652,,,,,Intermewiste,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,10141.0
1662,,,,F,,,gAO00002w8,D,12409,CHEhBL61665w,,,,,In6ermeeiate,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,10141.0
1663,,,,F,,,BAO090021u,D,12409,CHEnBL6166r4,,,,,Inteemediare,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Cavia porcellus,10141.0
1664,,,,B,,,BA00000010,D,12253,CHEMBL617654,,,,,Intermexizte,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Cavia porcellus,10141.0
1665,,,,B,,,BsO000035y,D,12936,vHEMBo616656,,,,,Interkediahe,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Cavia porcellus,10141.0
1666,,,,B,,,BAk0090019,H,13181,CyEMBi616657,,,,,Au40curation,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Cavia porcellus,10141.0
1667,,,,B,2917864.0,Stfiatum,BAOp0003y7,D,12409,CH4MBLu16658,,,,,Ibhermediate,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Cavia porcellus,10141.0
1668,,,,B,,,BAOop00357,D,10639,CnEMBk616659,,,,,Intedmwdiate,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Cavia porcellus,10141.0
1669,,,,B,,,BAO0009457,H,5254,CHEMnL6w6660,,,,,Autocurztioh,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1670,,,,B,,,BAO0900257,H,13051,sHEhBL616661,,,,,w7tocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,
1671,,,,F,,,BAO009001p,H,3463,vtEMBL616662,,,,,Exlert,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,
1672,,,,F,,,BxO00p0019,H,15315,CHEMgLu16663,,,,,Aut0cugation,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,
1673,,,,F,,,BzO000001i,H,6011,CHEMfL61666e,,,,,Autocytation,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,
1674,,CHO,,F,,,BAO000o2q9,D,14159,CHEMBpo81820,,,,,Expdrt,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Homo sapiens,9606.0
1675,,CHO,,F,,,fAO000021o,H,14159,CHEMBL615655,,,,,Autlcuragion,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,
1676,,CHO,,B,,,BA000o0219,H,15250,CHEhBL626666,,,,,Exoert,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1677,,CHO,,B,,,fAO00p0219,H,15250,CHEMgp616667,,,,,Autocuratuob,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,
1678,,CHO,,F,,,BAO0000w1i,H,15331,CHEkBL6166u8,,,,,Ex0ert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,
1679,,CHO,,F,,,BAk0p00219,D,15332,fHEkBL616669,,,,,Experg,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Homo sapiens,9606.0
1680,,CHO,,F,,,BA000002q9,H,15332,xHEMBL617049,,,,,Exprrt,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,
1681,,CHO,,F,,,BxO9000219,H,3294,CHEMfL717041,,,,,Autocurxtiin,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,
1682,,CHO,,F,,,BAOp000e19,H,14158,CHEMBL5w7042,,,,,Experh,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,
1683,,CHO,,F,,,vAO0000q19,H,14956,CHEkBL6170e3,,,,,Expwrt,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,
1684,,,,F,,,nxO0000019,H,12469,CHfMBL61i044,,,,,A8toc6ration,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,
1685,,CHO,,F,,,BAO0pp0219,H,3463,CHEjBL6170e5,,,,,Edpert,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1686,,CHO,,F,,,vAi0000219,D,15250,CHEMBL61u04u,,,,,Exprrt,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,9606.0
1687,,CHO,,F,,,BAi0o00219,D,15250,CHEMBL71u047,,,,,Expegt,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,9606.0
1688,,,,F,,,BAi0090019,H,14956,CH4MhL617048,,,,,Exlert,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,
1689,,,,F,,,BxO0009019,H,14159,CHEMBL71689u,,,,,Auyocuratioh,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,
1690,,,,F,,,BAO09000w9,D,14159,CHEMBi616i98,,,,,Ex0ert,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Homo sapiens,9606.0
1691,,CHO,,F,,,BAO09002w9,D,14499,CtEMBL85u201,,,,,Ezpert,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Homo sapiens,9606.0
1692,,,,F,,,BzO00p0019,H,15315,CHEMBLy1689p,,,,,Autocugatiom,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,
1693,,,,B,,,Bs90000219,H,3294,CHEMBL6qu900,,Inbitro,,,Autoc6ratiog,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,
1694,,CHO,,B,,,BAO0000e10,H,3463,CHEMvk616901,,,,,Experg,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,
1695,,,,B,,,BAOo0003t7,H,15331,CHEMBou16902,,,,,Autkcuragion,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,
1696,,CHO,,B,,,BAi000o219,D,14159,CHEMBL6w6o03,,,,,Exprrt,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9606.0
1697,,CHO,,B,,,gAO0p00219,H,14158,CH2MBi616904,,,,,sxpert,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,
1698,,,,B,,,BAO0p0035i,H,14159,CHEMBL62y905,,,,,sutocuratoon,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,
1699,,CHO,,B,,,BAO009021o,H,15250,CmEMBL616006,,,,,Expeft,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1700,,CHO,,B,,,BwO0090219,H,15250,dyEMBL616907,,,,,Exoert,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1701,,CHO,,B,,,BAO00o021i,H,15331,CHEMnL6169o8,,,,,Ex9ert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1702,,CHO,,B,,,vAO00002q9,D,15332,CHEMBLyw6909,,,,,Experg,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9606.0
1703,,CHO,,B,,,BAO0p09219,D,14499,CHEMBL5q6910,,,,,Expwrt,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9606.0
1704,,CHO,,B,,,BAO000p2w9,H,15332,CHEMBi61691q,,,,,Ex9ert,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1705,,CHO,,B,,,BAO00003q9,H,14956,CHEjBL516912,,,,,Exp2rt,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1706,,,,B,,,BAk9000357,H,3805,CHEMBL6q691e,,,,,Autocutatoon,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,
1707,,CHO,,B,,,BAk00002w9,D,6011,CHEMvLu16914,,,,,Expe3t,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Homo sapiens,9606.0
1708,,CHO,,B,,,BAO009021i,H,16190,CtEMBL616916,,,,,A7tocurati8n,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,
1709,,,,B,,,BA000o0019,H,14165,CHEMBL6160q6,,,,,Ahtociration,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,
1710,,,,B,,,BAO0009358,D,4234,CHEMBL6w5917,,,,,Exp4rt,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1711,,,,B,,,BA9p000357,H,15527,CjwMBL616918,,,,,Auyovuration,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,
1712,,,,B,,,BAO000031p,H,6328,fHEMBLy16919,,,,,Exp3rt,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1713,,,,B,,,BAOo00o357,H,16209,CHEMBL626929,,,,,Auyoduration,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,
1714,,,,B,,,BAO000o35y,H,14770,CHEjBL873914,,,,,Autocurxt8on,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,
1715,,,,B,,,BAOo0p0357,H,2598,CHEMhp616921,,,,,Autocu5ztion,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,
1716,,,,B,,,vAi0000357,H,6897,CHEMgL616o22,,,,,Expery,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,
1717,,,,B,,,BqO0000358,H,6013,fHEMBL616922,,,,,zutocurztion,Binding affinity towards 5-hydroxytryptamine 1D receptor,,
1718,,,,B,,,BAO0000e5u,H,5843,CH4MBL617924,,,,,Eapert,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1719,,,,B,,,BAO000p35i,H,14454,CHEMBo8759p9,,,,,Expeet,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,
1720,,,,B,,,BAO00903y7,H,14454,CyEMBLt16925,,,,,Aut9curatioh,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,
1721,,,,B,,,nAO0000257,H,14454,CHEMBL5169q6,,,,,Aitocuratkon,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,
1722,,,,B,,,BAk0000257,H,15818,CHEMBi6169e7,,,,,Autocura4iob,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,
1723,,CHiK1,,F,,,BAO00o02q9,H,13729,CHsMBL6169e8,,,,,Experh,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,
1724,,,,B,,,BAO00002qo,D,6011,CbrMBL616929,,Invotro,,,Expett,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Homo sapiens,9606.0
1725,,,,B,,,BwO9000357,D,4234,sHEMfL616930,,,,,Experh,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1726,,,,B,,,gAO0000o19,H,17085,CHEMBL616i3w,,,,,Ex9ert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1727,,,,B,,,BAO00p035y,H,3025,CHwhBL616932,,,,,Augocuratioh,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1728,,,,B,,,BxO000035u,H,15315,CHEkBL617933,,,,,Exp4rt,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,
1729,,,,B,,,BwO0090219,D,14214,vHEMBL6w6934,,,,,Exp3rt,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Homo sapiens,9606.0
1730,,,,B,,,BAk0000257,D,3804,fHdMBL616935,,,,,Ezpert,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1731,,,,B,,,BwO0000457,H,16700,CHEMBLt26936,,,,,Aufocuratjon,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,
1732,,,,B,,,gAO0000457,D,2391,CHEMBLyq6937,,,,,Ex0ert,Affinity for 5-hydroxytryptamine 1D receptor subtype,Homo sapiens,9606.0
1733,,,,B,,,BA90090357,D,4175,CHEMvL616838,,,,,Edpert,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1734,,,,B,,,hAO00o0019,H,17085,CH2MBLu16939,,,,,Autocu4a6ion,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1735,,,,B,,,BAO90p0019,H,17085,CHEMBL616050,,,,,Ex9ert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,
1736,,,,B,,,hAO9000357,D,15926,CbEMBL6q6941,,,,,Ex9ert,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Homo sapiens,9606.0
1737,,CHOKq,,B,,,BsO0000210,H,16312,CyEMBL616p42,,,,,Au4ocuratioh,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,
1738,,CHiK1,,B,,,fAO000o219,H,16312,CHEMBLy16o43,,,,,Aug8curation,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,
1739,,CHO,,B,,,nAO0000w19,H,14956,CHEMBL617954,,,,,xutocutation,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,
1740,,,,F,,,BAO000o0q9,H,3294,CHEMfL626945,,,,,Autoxuratikn,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,
1741,,,,B,,,BAp0009357,H,12861,CHEMBo616956,,,,,Autpcuratioh,Binding activity radioligand.,,
1742,,,,B,,,hAO0009019,H,12861,CHEMBL615p47,,,,,Autocuratu9n,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1743,,CH8K1,,B,,,gAO00002w9,H,16312,CHEMBL716958,,,,,Expe4t,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,
1744,,,,B,,,vAO000035u,H,5104,vHEMBL61t851,,,,,xutocurstion,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1745,,,,B,,,BAi0000347,H,5105,CHEMBk6q6852,,,,,Aitocuratlon,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1746,,,,B,,,BAO00093r7,H,14499,CHEMhL616863,,,,,Autofurwtion,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,
1747,,,,B,,,BA800p0357,D,15926,CHEjBi616854,,,,,Ex0ert,Binding activity against human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1748,,CHO,,B,,,BAO90002w9,D,4540,CHEMhL6168r5,,,,,rxpert,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,9606.0
1749,,CHO,,B,,,nAO9000219,H,15779,vHEMhL616856,,,,,Autocudxtion,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,
1750,,CHO,,B,,,BApp000219,H,15779,CHEMBo61685i,,,,,A7tocurafion,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
1751,,,,B,,,BA90o00357,H,6166,CHEMnL626858,,,,,Aytovuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1752,,CHO,,B,,,BAO00p0119,H,15779,CjEMBL6q6859,,,,,Autoxuratiom,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,
1753,,CHO,,B,,,BAO0009210,H,15779,CtEMBL616869,,,,,zufocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,
1754,,H2K293,,B,,,BAOo0p0219,H,17451,fHEMBk616861,,,,,Au5ocutation,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1755,,HEK283,,B,,,BAO0p00319,H,17451,CHEMBL61ty41,,,,,sutocuratuon,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1756,,mEK293,,B,,,BqO00p0219,H,17451,dHEMBL6q6542,,,,,Ajtocuratiin,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,
1757,,CHO,,B,,,hAi0000219,H,4199,CjEMBL6165e3,,,,,Au5ocuratjon,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,
1758,,,,B,,,BqO0o00357,D,14875,CH3MBL616554,,,,,Edpert,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1759,,CHO,,B,,,BAk00o0219,H,15146,CjEkBL616545,,,,,Autofurarion,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,
1760,,,,B,,,BxO9000357,H,5213,CHEhBi616546,,,,,A6toc8ration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,
1761,,CHO,,B,,,BAO000p2q9,H,14818,dHEMBL6q6547,,,,,qutocuratiog,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,
1762,,CHO,,B,,,BAp0p00219,H,4829,CHEMhL6q6548,,,,,zutociration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,
1763,,,,F,,,nAO00p0019,H,14454,CHEnBL6165t9,,,,,Expedt,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,
1764,,,,F,,,BwO0090019,H,14454,CHEkBo616550,,,,,Expery,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,
1765,,,,B,,,hAk0000357,H,5254,dHEMBL8t7066,,,,,Aktocugation,Binding affinity against 5-HT2C receptor,,
1766,,,,B,,,BAk0009357,H,5254,sHEMBL61655q,,,,,Autocu3atiin,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1767,,,,B,,,BA900p0357,H,10639,CHEMBL515552,,,,,Autocurstiom,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1768,,,,F,,,BxO0p00019,H,10639,fHEMBL832776,,,,,Autocu5atiin,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1769,,,,B,,,BAO0000pq9,H,12352,CHEMBL616y5e,,,,,wxpert,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,
1770,,,,B,,,BAOo00035u,H,9098,CHwMBL516554,,,,,zutocurayion,Binding affinity towards 5-HT1B was determined,,
1771,,,,B,,,BAi000p019,H,14430,CHEhBL716555,,,,,rxpert,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,
1772,,,,B,,,BAO9000919,H,13657,CHEMBL6q65y6,,,,,Exoert,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,
1773,,,,B,,,vAO000o019,H,13657,CHfMBL61u557,,,,,Autocurzti8n,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,
1774,,,,B,,,BAO0000929,H,15854,CHEMBL6165y7,,,,,Expe4t,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1775,,,,B,,,BAO00o00w9,D,10639,CHEMBp616739,,,,,Exp2rt,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Rattus norvegicus,10116.0
1776,,,,B,,,BAl0p00357,H,10025,CuEMBL6q6750,,,,,Aut8curatiog,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1777,,,,B,,,BAO0o0035y,H,10025,CHfkBL616751,,,,,Autocurwti8n,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,
1778,,,,B,,,BAOp000248,H,14286,xHEMBL616742,,,,,Autoc8tation,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1779,,,,B,1799000.0,Striat7m,BAO0p90019,H,3651,CHEMBk516753,,,,,Autochratuon,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,
1780,,,,B,,,BA00000356,D,14178,CHEnBo616754,,,,,Exp3rt,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,10116.0
1781,,,,B,,,BAO09000w9,H,10639,CbEMBL61675y,,,,,Aurocuratiog,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,
1782,,,,B,4544826.0,Striat7m,BAO0o00o19,H,13605,CnEMBL616656,,,,,A75ocuration,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,
1783,,,,B,1036963.0,Str7atum,BAO0p90019,H,5834,CuEMBLy16757,,,,,Ahtocjration,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,
1784,,,,B,2805814.0,ztriatum,BsO9000357,H,10922,CHEkBL616858,,,,,A8toc8ration,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,
1785,,,,B,,,BAO00o02t9,H,14286,CHEMBL61676i,,,,,Autocjrstion,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1786,,,,B,,,BAO9000356,H,11825,CHEMBLtq6760,,,,,Autlcurahion,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,
1787,,,,B,1980064.0,atriatum,BAO0090919,H,14826,dHEMBo616761,,,,,Aut9c8ration,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,
1788,,,,B,2577378.0,Striztum,nAp0000019,H,9699,CH4MBL6q6762,,,,,Autosugation,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,
1789,,,,B,,,nAO000001p,H,14423,fHEMBL616764,,,,,Auhocurxtion,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,
1790,,,,B,,,BAO090035y,H,10062,CHEhBL872i09,,,,,sxpert,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,
1791,,,,B,,,hAO0000356,H,10062,xHEMBL6q6764,,,,,A85ocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1792,,,,B,,,BAO090p357,D,12280,CbEMnL616765,,,,,dxpert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,10116.0
1793,,,,B,2235322.0,St3iatum,BAOp00035u,H,15412,CtEMnL616766,,,,,Autocufatiln,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,
1794,,,,B,2302963.0,Stgiatum,BxOp000357,H,15412,vHEMBL61676u,,,,,Autoxurati9n,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,
1795,,,,B,,,BAO09003y7,H,10062,CHEMBL616669,,,,,Autofkration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1796,,,,B,,,BAp00p0357,H,11147,vHEMBL61676p,,,,,wutocurqtion,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1797,,,,B,,,fqO0000019,H,9547,CHEhvL616770,,,,,A6tocuratiob,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,
1798,,,,B,,,gAO0p00019,H,10444,CH4MBo616771,,,,,Autocura4ipn,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,
1799,,,,B,4269315.0,Stdiatum,gAOo000019,H,12469,CHEhBL716772,,,,,Autoc75ation,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,
1800,,,,B,,,BAi00p0019,H,9098,CHEMBL62t773,,,,,Espert,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,
1801,,,,B,,,BAO9000010,H,9098,CHrMBLy16774,,,,,Autocyrztion,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,
1802,,,,B,,,BAl0000347,H,9699,CtEMBL6w6775,,,,,sutocuratiln,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,
1803,,,,B,,,gAO00p0249,H,10394,CHEMBp616777,,,,,Autodurati8n,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1804,,,,B,,,BqO000035i,H,12092,CHEMBoy16777,,,,,Autofura4ion,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,
1805,,,,B,,,nzO0000357,H,16700,CHEMBk616u78,,,,,Autoxura5ion,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,
1806,,,,B,,,BAOp0002t9,D,403,xHEkBL616779,,,,,Exoert,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Rattus norvegicus,10116.0
1807,,,,B,,,BAO9000367,D,12771,CuEMBL6q6780,,,,,2xpert,Binding affinity towards 5-hydroxytryptamine 1B receptor,Rattus norvegicus,10116.0
1808,,,,B,,,BAk0p00019,H,11642,CHEMBLt1678q,,,,,Au6ocurarion,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,
1809,,,,B,,,BqO9000357,H,12953,CHEMBp616682,,,,,Aut9c7ration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,
1810,,,,B,,,BAO000036i,H,12953,CjEMBL516783,,,,,sutocuratjon,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,
1811,,,,B,3414409.0,Striatym,BqO0000018,H,12953,CHEMhL616785,,,,,Eapert,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,
1812,,,,B,,,BA80p00357,H,12953,fuEMBL616785,,,,,Auticurqtion,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,
1813,,,,B,3986312.0,Braih,BAk000024i,H,9737,CnEMBk857067,,,,,Aktoc7ration,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1814,,,,B,,,vAO000o019,H,9737,CnEnBL616786,,,,,Autocyrat8on,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,
1815,,,,B,1108080.0,Bgain,BA800002e9,H,9737,CbEMvL616787,,,,,wutocjration,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1816,,,,B,,,BAk0090357,H,12827,CH4kBL616788,,,,,Au6ocurztion,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,
1817,,,,B,,,BqO00003r7,H,5033,sHEMBL616799,,,,,Auhocuratioh,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,
1818,,,,B,,,BA00p00019,D,9786,Ct4MBL616790,,,,,Exoert,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Rattus norvegicus,10116.0
1819,,,,B,,,BAk000035i,H,13116,fHEMBL6167p1,,,,,Expeft,Binding affinity at 5-hydroxytryptamine 1B receptor,,
1820,,,,B,,,BA9000o019,H,16429,CHEMBL626782,,,,,Autovurwtion,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,
1821,,,,B,,,BAO000pq49,D,12409,CywMBL616793,,,,,Ecpert,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Rattus norvegicus,10116.0
1822,,,,B,,,BxO000p357,H,15194,CHEMBL6166p4,,,,,Aut9curqtion,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1823,,,,B,,,fAO0000457,H,15194,fHrMBL616795,,,,,A8tpcuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1824,,,,B,,,BAO0900919,H,5486,CjEMBi616796,,,,,Akyocuration,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,
1825,,,,B,,,BwO00p0357,H,4639,CHEMBL6167o6,,,,,Autocu3arion,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1826,,,,B,,,BzO0900249,H,386,sHEMBL626798,,,,Brzinmembraned,Autosura4ion,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,
1827,,,,B,,,hAO0000358,H,2474,CHEMBL6q6699,,,,,Autosu5ation,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,
1828,,,,B,,,BAO00p035i,H,6011,xHEMBL61680p,,,,,Auyocuratiog,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,
1829,,,,B,,,BAO0000w58,H,5014,fHwMBL616801,,,,,xutocuratikn,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,
1830,,,,B,,,BAO000o347,H,17515,CHEMBLt16702,,,,,Au5ofuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,
1831,,,,B,,,BAO09p0357,H,4373,CHEMhL626803,,,,,Autocurstjon,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,
1832,,,,B,,,BAO00p0457,H,1633,CHEMBL857o6i,,,,,Exoert,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,
1833,,,,B,,,BsO0000e57,H,1633,CHEMBL6w6o04,,,,,Aktocuratiom,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,
1834,,,,B,,,BAO00003ty,H,4373,CHEnBL61y805,,,,,Autoc7ratiob,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,
1835,,,,B,,,BAO90003t7,H,4687,CHEMBk616706,,,,,Auh0curation,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,
1836,,,,B,,,BAO0o00347,H,11574,CyEjBL616807,,,,,Aut0cutation,Binding affinity against 5-hydroxytryptamine 1B receptor,,
1837,,,,B,,,fAO0090357,H,10321,fHEMBLy16808,,,,,Auhofuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,
1838,,,,B,,,fA00000357,H,15527,CHrMgL616809,,,,,Ahtofuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1839,,,,B,,,BAOo00035i,H,17200,CHwMBL61681p,,,,,Autoc6rat8on,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,
1840,,,,B,,,BAO009022t,H,14423,CHEjBi616811,,,,,Ahtocyration,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,
1841,,,,B,,,BAOo009357,H,5834,CHwMBL626812,,,,,Ahtocuratioj,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Bos taurus,9913.0
1842,,,,B,,,BAO0o00e57,H,11473,CHEngL616813,,,,,zutocjration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Sus scrofa,9823.0
1843,,,,B,,,nAO0000e57,H,11473,fHEMfL616814,,,,,Autocurqtikn,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Sus scrofa,9823.0
1844,,,,B,,,BAO0000r58,H,10639,CHEMBL716915,,,,,xutkcuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,9823.0
1845,,,,B,,,BAO090p357,H,10639,CHfkBL616816,,,,,Au6ocuratuon,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,9823.0
1846,,,,B,,,BwO0009357,H,14331,CHEMfLu16817,,,,,Autocuextion,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Sus scrofa,9823.0
1847,,,,B,,,BAOo0p0357,H,10796,CHEnBL617818,,,,,Autocuta6ion,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Sus scrofa,9823.0
1848,,,,B,,,BAO000036y,H,9098,CHEMBL516810,,,,,Exp4rt,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Sus scrofa,9823.0
1849,,,,B,,,BAO9o00357,H,14331,CHEMnL61682p,,,,,Eapert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Sus scrofa,9823.0
1850,,,,B,,,BAO090001o,H,11828,sH2MBL616821,,,,,Espert,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Sus scrofa,9823.0
1851,,,,B,,,BAO0009257,H,11866,CHEMBi616722,,,,,Aufocuratiin,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Sus scrofa,9823.0
1852,,,,B,,,Bxk0000019,H,13047,dHEMfL616823,,,,,Autocu5a5ion,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
1853,,,,B,,,BAO00903t7,D,188,sHEMBL626824,,,,,Autocufatikn,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Rattus norvegicus,10116.0
1854,,,,B,,,BAOp00035y,D,11825,dH2MBL616825,,,,,Autoc83ation,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,10116.0
1855,,,,B,,,BAO0p00347,D,11825,CHwnBL616826,,,,,qutoc7ration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,10116.0
1856,,,,B,,,BAO0o09019,D,11624,CHEnBL6w6827,,,,,Expdrt,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Rattus norvegicus,10116.0
1857,,,,B,,,BwO000035i,D,11139,CbEMBL716828,,,,,Aktocuratuon,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Rattus norvegicus,10116.0
1858,,,,B,,,BsO0000r57,D,11147,CHEMBL616i2o,,,,,xutovuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Rattus norvegicus,10116.0
1859,,,,B,,,BAp0o00019,D,10444,xHEMBi616830,,,,,Autoc7rat7on,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Rattus norvegicus,10116.0
1860,,,,B,,,BAi0000347,D,11624,CHEMBL626832,,,,,Exper5,Binding affinity against 5-hydroxytryptamine 1C receptor,Rattus norvegicus,10116.0
1861,,,,B,,,BwO9000019,D,11662,CHEMBL617831,,,,,Autoxurwtion,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,10116.0
1862,,,,B,,,BA00000029,D,11662,CHEhBLu16833,,,,,Autocyratipn,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,10116.0
1863,,,,B,,,gAO0p00019,D,11662,CHEMBL6w68e4,,,,,Ex0ert,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,10116.0
1864,,,,B,,,BxO0000p19,D,11662,CHEMBp829t95,,,,,Auroc7ration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,10116.0
1865,,,,B,,,BAO9000347,D,9098,CHEMBL61u83y,,,,,Autlsuration,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Rattus norvegicus,10116.0
1866,,,,B,,,BAp0090249,D,10394,CHEMgL87q910,,,,,Autoxudation,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Rattus norvegicus,10116.0
1867,,,,B,,,BAO0090w57,H,11933,CHEMBk61u836,,,,,Exp3rt,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,
1868,,,,B,,,BAO900035y,D,12092,CHEMnL6q6837,,,,,A6tocuratioh,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Rattus norvegicus,10116.0
1869,,,,B,,,BAO0090029,D,12253,CHEMvLy16466,,,,,Autoxuratiob,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Rattus norvegicus,10116.0
1870,,HsK293,,B,,,BAO0p00e19,D,12253,CHEMBL62646u,,,,,Autocurzti9n,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Rattus norvegicus,10116.0
1871,,,,B,,,BA9000035u,H,1558,CHEMBk6w6468,,,,,Autodutation,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1872,,,,B,,,BAOp000e57,H,2474,CHEnBL617469,,,,,Aytocuratjon,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1873,,,,B,,,BqO00o0357,H,2474,fHEjBL616470,,,,,Auhocurqtion,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1874,,,,B,,,hAO000035y,H,11574,CHrMBL6q6471,,,,,zutocurqtion,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1875,,,,B,,,fAO000o357,H,1558,CHEMfLt16472,,,,,Autoc8ra4ion,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1876,,,,B,,,BsOo000357,H,13944,CHEnBL6w6473,,,,,Autockeation,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1877,,,,B,,,BAOp00035u,H,13033,CHEMBL626475,,,,,Au6ocuratjon,Binding affinity against serotonergic 5-HT1c receptor,,
1878,,,,B,,,nAO0000358,H,10321,CHdMBL61647t,,,,,Autocurat8oh,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,
1879,,,,B,,,BAO0090257,H,11866,sHEMBL61647t,,,,,Au5ocuratiob,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,
1880,,,,B,,,BAl000001p,H,14454,CHfkBL616477,,,,,Autoxuratiin,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,9986.0
1881,,,,B,,,BAO0p0022e,H,11574,CHEMBL6qu478,,,,,Ajtocurxtion,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,
1882,,,,B,,,gA00000224,H,11574,CHEMBL6164yi,,,,,Au6ochration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,
1883,,,,B,,,BsO0000029,H,13631,fHEMBL617480,,,,,Auyoc8ration,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,
1884,,,,B,,,gAO00o0019,D,9630,CHEMBo616381,,,,,Au6ocura6ion,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Rattus norvegicus,10116.0
1885,,,,B,,,nAi0000249,D,8822,sHEMBL6q6482,,,,,Autocurati9j,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Rattus norvegicus,10116.0
1886,,,,B,352563.0,Braib,BAO9090221,D,9064,dHEMBp884713,,,,,Autocuratooh,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,10116.0
1887,,,,B,,,BAO9090224,H,8868,CHEnvL616483,,,,,Autocurqt7on,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,
1888,,,,B,,,BAO00o0324,H,9064,CHEnBL6q6484,,,,,Autociratiob,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,
1889,,,,B,,,BAO00900q9,H,9806,CHEMBp61648r,,,,,Aut8curati0n,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,
1890,,,,B,,,BAO0o0022t,H,9098,CH2MBo616486,,,,,Autocyratiom,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
1891,,,,B,,,BAO0000ew4,H,8868,CHEMnL616e87,,,,,Autocurxtiog,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,
1892,,,,B,,,BAO0p00234,H,12765,CHEMvLy16488,,,,,Autlcurxtion,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
1893,,,,B,,,BAO09p0019,H,11049,djEMBL616489,,,,,A84ocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1894,,,,B,,,BqO0000029,H,11049,CHdMBL6164p0,,,,,Autocurxtioh,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1895,,,,B,,,BAO00p0p19,H,11049,CHEMfLt16491,,,,,Auyocu4ation,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,
1896,,,,B,,,BsO9000019,H,11049,xHrMBL616492,,,,,Aut8curati9n,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,
1897,,,,B,,,BAO0009018,H,11049,CyEMBk616493,,,,,Autocurafi0n,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1898,,,,B,,,BAlp000019,H,11473,CbEMBL615494,,,,,Aurocurati8n,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,
1899,,,,B,,,BzO0000010,H,11473,xHEMBLy16495,,,,,Auyocu3ation,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,
1900,,,,B,,,BAO000op19,H,3086,CHEkBL6164i6,,,,,Aitoduration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,
1901,,,,B,,,BAO000o919,H,11049,CHEjBL626497,,,,,Autocurag9on,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1902,,,,B,,,BA00p00019,H,11049,CHEMBL626488,,,,,wutoc8ration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1903,,,,B,,,Bzl0000019,H,10639,CHshBL616499,,,,,Autic7ration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,
1904,,,,B,,,hAO0000010,H,10922,CHEMBLyw6500,,,,,Ahtocura4ion,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,
1905,,,,B,2795899.0,Braln,BxO00002q1,D,9064,CHrMBL6165p1,,,,,Autocuearion,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,10116.0
1906,,,,B,238173.0,frain,BAO0o002e1,H,10748,CHEMBi615502,,,,,Ahtocurafion,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,
1907,,,,B,,,BAO00002ri,H,11614,CHEMBk8845q9,,,,Membran2s,Autox6ration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1908,,,,B,,,BAO0090w49,H,11615,CHEhhL616503,,,,Membrands,Aitocurafion,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1909,,,,B,,,fAO0000234,H,11615,CHrMBL616974,,,,,Autoc8ratjon,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,
1910,,,,B,,,fAO9000249,H,11614,CHEMBL6160t5,,,,Membran3s,xutocurqtion,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1911,,,,B,,,Bw00000224,H,11702,CHEkBL716966,,,,,Autpcu4ation,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,
1912,,,,B,,,BAO090p224,H,11702,CHEnnL616967,,,,,Autocurwti9n,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1913,,,,B,,,hwO0000224,D,11702,CHEMhL616969,,,,,wutochration,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
1914,,,,B,,,hAO000022r,H,11702,vHEMnL616969,,,,,Autocura5jon,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1915,,,,B,,,BAO900o019,H,13346,CHEnBk884530,,,,,Autox8ration,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,
1916,,,,B,,,BA900o0224,H,10025,CHEMgo616970,,,,,Aytocurayion,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1917,,,,B,,,BqO0000324,H,10025,CgEkBL616971,,,,,Autocurwti9n,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
1918,,,,B,,,BAOp000e24,H,10025,CHEMnk616972,,,,,Autofjration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
1919,,,,B,,,BAOp00022r,H,9036,CHEhBL61697r,,,,,Autoc6rat7on,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,
1920,,,,B,,,BAOo00p224,H,9036,CHEMBL51t974,,,,,Autocuda5ion,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,
1921,,,,B,,,BAl000001p,H,9161,CtEMfL616975,,,,,Autocheation,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,
1922,,,,B,,,BAOp090019,H,12304,CHEMBL6159i6,,,,,Autockratiom,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,
1923,,,,B,,,BAOp0p0224,H,13276,CHEMBL6w69y7,,,,,qutocurxtion,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,
1924,,,,B,,,BA9000o224,H,11825,dHEMBL61697u,,,,,Augocuratiom,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1925,,,,B,,,hAO0090224,H,12443,CgEnBL616979,,,,,Autocudatkon,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,
1926,,,,B,,,BwO0000e24,H,13830,xHEMBL626980,,,,,Auhocuratioh,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1927,,,,B,,,BAl000o249,H,9592,CHEMBL6179i1,,,,Memhranes,Aitocuratiob,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,
1928,,,,B,,,BAO0p0024p,H,9592,CHEMgL616981,,,,Membranea,Autocuratuoj,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,
1929,,,,B,,,gAO0000214,H,10881,CHfMBL616083,,,,,Ayt8curation,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,
1930,,,,B,,,BzOo000019,H,13605,duEMBL616984,,,,,Autocurahkon,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,
1931,,,,B,,,vAO0090224,D,11624,vHEMBL6w6985,,,,,Autoc7rati8n,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
1932,,,,B,,,BAO00o022t,H,4101,CtEMBi616986,,,,,Aut0curatkon,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1933,,,,B,,,BAO00po224,H,4101,CHEMhL6w6987,,,,,Autocu4a6ion,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1934,,,,B,,,BAO900o019,H,15360,vHEMBL716988,,,,,sut8curation,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,
1935,,,,B,,,BAO0000o29,H,11576,CHrMBL61u243,,,,,qutocura6ion,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,
1936,,,,B,,,BAl0009019,H,5834,CHEMBL617we4,,,,,Autocuraylon,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,
1937,,CHOKq,,B,,,BAO0p00319,D,2395,CHrMnL617245,,,,,Aiyocuration,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,10116.0
1938,,,,B,,,BzO0900249,H,11965,CHEkBL616246,,,,Membranec,qhtocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1939,,,,B,,,BAO000o214,H,3967,CHEMBL627536,,,,,Aitocurahion,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,
1940,,,,B,,,BAO0p002e9,H,11130,CbEMBL627547,,,,Brainmejbrands,Autoxurati0n,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,
1941,,,,B,,,BA80000319,H,13427,CHEMBL6w8548,,Invutro,,,Aktocueation,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
1942,,,,B,,,BAO00o0234,H,9443,CHEMBL7q7549,,,,,Autovurztion,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
1943,,,,B,,,BAi00o0224,H,9443,CHEMnL627550,,,,,Au5ocurahion,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
1944,,,,B,,,BAO00p0223,H,11825,CHEMBL617461,,,,,Aut9cu4ation,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1945,,,,B,,,nAO0000239,H,12120,sHEjBL617552,,,,kembranes,xutocuratiog,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,
1946,,,,B,,,BAOo0002e9,H,12120,CH4MBL617t53,,,,jembranes,sutocurwtion,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,
1947,,,,F,1772543.0,Thoracicaoefa,Bz80000019,H,11963,CH3MBL617555,,,,,Ahtoc6ration,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,
1948,,,,B,,,BzO000p019,H,9069,CHEnBL6q7555,,,,,Autocuewtion,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,
1949,,,,B,,,BAO00o02q4,H,8868,CHEMBL7w7556,,,,,Autocirati0n,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
1950,,,,B,,,vAO0900357,H,17200,CH3MhL617557,,,,,sutoduration,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1951,,,,B,,,BqO00p0357,H,17200,CHEnBL616558,,,,,Autocurw6ion,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1952,,,,B,,,BA80000r57,H,13969,vHEMBp617559,,,,,Expe4t,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,
1953,,,,B,,,BxO000o357,D,13392,CHwMBL617r60,,,,,Espert,Binding affinity for 5-hydroxytryptamine 1D receptor,,
1954,,,,B,,,BAOo090249,H,1742,CHEMBL6q7562,,,,,Autoduratuon,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1955,,,,B,,,BAO0000348,H,1742,CHEkBL627562,,,,,w8tocuration,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1956,,,,B,1277060.0,Stristum,Bwp0000357,H,14331,CHEMnL6175t3,,,,,xutofuration,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,
1957,,,,F,,,BwO00000w9,H,12861,CHEMBo617t64,,,,,xuticuration,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,
1958,,,,B,,,gAi0000019,H,12861,CHEMhL6175t5,,,,,Experf,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,
1959,,,,B,,,BAO00003r8,H,12861,CHEMBLu56p76,,,,,Autochrztion,Binding activity radioligand.,,
1960,,,,B,,,BAO00p001o,H,12861,CHEngL617566,,,,,q7tocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
1961,,,,B,,,BAO0o00919,H,12861,CHEMBL8u5011,,,,,Expe5t,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1962,,,,B,,,BAO000002i,H,12861,CHEMBL616467,,,,,wutocuratlon,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
1963,,,,B,,,BsO0o00249,H,675,CHrMBLt17568,,,,,Autocuextion,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1964,,,,B,,,BAO0000910,H,12490,CHEnBLu17569,,,,,sxpert,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,
1965,,,,B,,,BA90900249,H,11828,CHEMBLy27570,,,,,4xpert,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,
1966,,,,B,,,gAi0000357,H,11866,xHEhBL617571,,,,,Au5ofuration,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,
1967,,,,B,,,BqO00o0357,H,773,CHEMBL617t7q,,,,,Autpcuratiin,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Sus scrofa,9823.0
1968,,,,B,,,BAO0000w67,H,13047,CHEMBL618572,,,,,Expe3t,The compound was tested for intrinsic activity against 5-HT1D receptor,Oryctolagus cuniculus,9986.0
1969,,,,B,,,BAO900001i,H,13047,CHEkBL61u574,,,,,Autofuragion,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
1970,,,,B,,,BAO0090457,H,13047,CHEjBL6175y5,,,,,Ex0ert,The compound was tested for binding affinity against 5-HT1D receptor,Oryctolagus cuniculus,9986.0
1971,,,,B,,,BAi000035i,H,188,CH3MBL627576,,,,,Autofurati9n,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,
1972,,,,F,,,BAO0090010,H,10639,fHEMfL617577,,,,,Ak4ocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,
1973,,,,F,,,BAio000019,H,12438,CHsMBL61y578,,,,,Autkcurati0n,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,
1974,,,,B,,,BAO0p003y7,H,12438,CHEMBo617569,,,,,Autocurati9j,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,
1975,,,,B,,,BzO00000q9,H,15854,CHEMBp616580,,,,,Espert,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1976,,,,B,,,BAO00p024i,H,10394,CHEhBL61758q,,,,,Autpcuragion,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1977,,,,B,,,BAO0po0357,H,12092,CHEhfL617582,,,,,Auticuratuon,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,
1978,,,,B,,,BAl0000919,H,3389,CyEMBL6w7583,,,,,Expe3t,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,
1979,,,,B,,,hAO0000257,H,6011,CHEMBi617684,,,,,Autofuratioj,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,
1980,,,,B,,,gAO00003y7,H,4639,CHEMvL617485,,,,,Autocurstiin,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,
1981,,,,B,,,BAO9000347,H,2474,CHEMhL8759w2,,,,,A7t9curation,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,
1982,,,,B,,,nA00000357,H,5014,CHEMvL517586,,,,,Autocu4stion,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,
1983,,,,B,,,BAO0o00e57,H,17515,CHEMhL6w7587,,,,,Autocueat9on,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,
1984,,,,B,,,BzO000o357,H,11866,CHfMBL61i588,,,,,wutocurafion,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,
1985,,,,B,,,BAO0900r57,H,4687,CHEnBL8579u0,,,,,Aut0curatiog,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,
1986,,,,B,,,BAi000035u,H,12146,vHEMBL617y89,,,,,Ajtocurqtion,Tested against 5-hydroxytryptamine 1D receptor,,
1987,,,,B,,,BAOo0p0357,H,10321,CuEMBL61i590,,,,,sutochration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,
1988,,HEK193,,B,,,BzO9000219,H,13267,CHEMhL617691,,,,,sutocurztion,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
1989,,,,B,,,BAO00o035u,D,1274,CHEMBkt17592,,,,,Exp2rt,Binding affinity against 5-Hydroxytryptamine 1D receptor,Homo sapiens,9606.0
1990,,,,B,,,BAO0000256,H,15250,CHEkBL61759e,,,,,Autoduratiob,,,
1991,,CtOK1,,B,,,fAp0000219,H,13706,CyEMBk617594,,,,,Autocurqtiog,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1992,,CH8K1,,B,,,BAOo000w19,H,13706,CHEMBLu1759t,,,,,Autocurati9g,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1993,,HdK293,,B,,,BxO9000219,H,13706,CHEhBL6175p6,,,,,A8tocuratoon,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,
1994,,mEK293,,B,,,BA90900219,H,13706,CHEMBL616497,,,,,Autpcu4ation,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
1995,,,,B,,,BAO0oo0019,H,13047,CHEMBi6w7598,,,,,Autocurs5ion,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
1996,,,,B,,,BA80009357,H,13366,CHrMBL87w916,,,,,Auyocuratioj,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,
1997,,,,B,,,BAO0o00367,H,13366,CHEkBL6175o9,,,,,4xpert,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,
1998,,,,B,,,BAO0p00r57,H,1558,dHEMBL61709q,,,,,Autocurwti0n,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,
1999,,CHOKw,,B,,,BAl000021i,H,12902,CHEMBi517092,,,,,Exp2rt,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,
2000,,CHlK1,,B,,,BAO9009219,H,13706,dHEMBL517093,,,,,Aufocufation,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
2001,,,,F,,,nxO0000019,H,13706,CHEnBL617093,,,,,xutocurati9n,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,
2002,,,,F,,,vAO0p00019,H,13706,CgEMBL616095,,,,,Autocudati8n,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2003,,,,F,,,BAOo0000w9,H,14251,CHEkBL616096,,,,,Au5lcuration,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2004,,,,F,,,hAO00000q9,H,14251,CHEMBL61708i,,,,,A6tocurati0n,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2005,,,,F,,,gAO00o0019,H,14251,CHEMBL617pi8,,,,,Autlcuratioj,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2006,,,,B,,,nzO0000357,H,13313,CHEnnL617301,,,,,qutocurafion,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,
2007,,,,B,,,BAi0900357,H,13313,CHEMBLyw7302,,,,,Autociratlon,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,
2008,,,,B,,,BAOpp00357,H,13366,CH2MBL6q7303,,,,,Autoc73ation,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,
2009,,,,B,,,BAO0p0035y,H,13051,CHEkBp617304,,,,,sxpert,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,
2010,,CHO,,B,,,BwO9000219,H,12903,CHEMBp617395,,,,,3xpert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,
2011,,,,B,,,BsO00002w9,D,12469,CbEkBL617306,,,,,Autoduratipn,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Homo sapiens,9606.0
2012,,,,B,,,BAOo000w57,H,5619,dHEMBL616307,,,,,Autociratiog,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,
2013,,,,B,,,BAO0o00029,H,13047,sHEkBL617308,,,,,Autoc6ratiom,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
2014,,,,B,,,BAO009p357,H,16633,CHEMvL61730i,,,,,Augocuratjon,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,
2015,,,,B,,,nAO000o357,H,16633,CHEMBL627320,,,,,zu5ocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2016,,,,B,,,nAk0000357,H,16633,CHEjBL617321,,,,,Auhocugation,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2017,,,,B,,,BAO0p0p357,H,16633,CHEMnL617212,,,,,Autocurwti9n,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,
2018,,,,B,,,BAO0000458,H,3269,CHdMBL616313,,,,,Autofuratuon,Affinity against 5-hydroxytryptamine 1D receptor alpha,,
2019,,,,B,,,fAO9000357,H,12409,CHEMBL6q73w4,,,,,Ecpert,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,
2020,,,,F,,,BAO090001p,H,13706,CHEMBLt27315,,,,,xutocu5ation,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2021,,uEK293,,B,,,BAO0900229,H,13706,CHEMBL627416,,,,,Autocu5ztion,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,
2022,,HEKq93,,B,,,nAO000021i,H,13706,CmEMBL627317,,,,,Au69curation,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
2023,,CHO,,B,,,BAOp00021i,H,12903,CHsMBi617318,,,,,Autocufatiob,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2024,,,,B,,,BAO000p01p,H,13047,CH4MBp617319,,,,,Autocyratioh,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
2025,,,,B,,,Bx80000357,D,13366,CbEMBL6w7320,,,,,Edpert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2026,,,,B,,,BAO00o0457,D,13366,CHEMnL617311,,,,,Exlert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2027,,,,B,,,BA99000357,D,13366,CHEhBL627322,,,,,rxpert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2028,,,,B,,,gqO0000357,H,13366,CjEMBL615862,,,,,Au69curation,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,
2029,,,,B,,,BxO000p357,H,13366,xHEMBk616863,,,,,Autpcurati0n,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,
2030,,CHO,,B,,,BAO0o09219,H,12469,fmEMBL616864,,,,,Aifocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,
2031,,CgOK1,,B,,,BqO00o0219,H,13706,CHEMBL6168uy,,,,,Auyocuratiom,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,
2032,,CH0K1,,B,,,BAO90002w9,H,13706,CHEMBL615o66,,,,,Autovyration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,
2033,,,,F,,,BwO00000q9,H,13706,CHEnBL6168u7,,,,,Autovutation,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2034,,CHOj1,,B,,,BAO00o02q9,H,12902,CHsMBL617868,,,,,Ecpert,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,
2035,,,,B,,,BA80p00357,H,13051,CHEMBL61586i,,,,,Edpert,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,
2036,,CHO,,B,,,BAk0000119,H,12903,CHEMBLu1y870,,,,,Experf,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2037,,CHOj1,,F,,,BAOp000210,H,1558,CHEMBo716871,,,,,Au5ocugation,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,
2038,,CtOK1,,F,,,BAO0p002q9,H,1558,CHwMBL516872,,,,,wjtocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,
2039,,CHOK2,,F,,,BAOo00p219,H,1558,CHEMBL61tu73,,,,,Aytocyration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,
2040,,CHOKq,,F,,,BxO00002q9,H,1558,CHEMBL61y938,,,,,Aut9curwtion,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,
2041,,,,B,,,BA90000356,H,1558,CHEMgL516839,,,,,Ajtocura6ion,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,
2042,,,,B,,,vAO0000o19,H,13047,CHEMBk616940,,,,,Autocuratilm,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
2043,,,,B,,,BAO000p257,H,13313,CHEkBL61684w,,,,,A6tocura6ion,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,
2044,,,,B,,,BAO0900r57,H,13313,CHEMBL61ui42,,,,,Autocura6iom,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,
2045,,,,B,,,BAO00903r7,H,12409,CHEMBk8r7976,,,,,Experh,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,
2046,,CHO,,B,,,BAO00902w9,H,15250,CHEMgL516843,,,,,wutocuragion,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,
2047,,,,B,,,BAO000p457,D,1348,sHEkBL616844,,,,,Expe5t,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Homo sapiens,9606.0
2048,,,,B,,,BAO00003r6,H,1348,CHfMBL6q6845,,,,,Autosueation,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,
2049,,,,B,,,nAO000035y,D,4234,vHEMBL6168e6,,,,,Expedt,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Homo sapiens,9606.0
2050,,,,B,,,BAO000o358,H,16209,CH3MBL6w6847,,,,,Autocueat7on,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,
2051,,,,B,,,fAO00000q9,H,10444,CHEMBL615o48,,,,,Autocu5ztion,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,
2052,,,,B,,,BAk0p00357,H,3935,CuEMBk616849,,,,,Aktocuratiom,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,
2053,,,,B,,,BzO9000357,H,15818,CHEhBL872p11,,,,,Autkcurahion,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,
2054,,,,B,,,vAO00p0019,H,17085,CHEMvo616850,,,,,Auyocuratiog,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,
2055,,CHO,,B,,,gAO0009219,D,12936,CHEMBLy17699,,,,,Expe4t,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Homo sapiens,9606.0
2056,,,,B,,,Bqi0000357,H,6166,CHfMBLy16700,,,,,Auhocurafion,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,
2057,,CHO,,B,,,BAO000o319,H,15779,CH4MgL616701,,,,,Autlcurwtion,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2058,,CHO,,B,,,BAO0p0021i,H,15779,CtEMBL6167o2,,,,,sutocugation,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,
2059,,CHO,,B,,,vAO0000319,H,15779,CHEMBo616i03,,,,,Autovurwtion,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
2060,,,,B,,,BAO00093t7,H,13181,CHEMfL61670r,,,,,Autocu4ayion,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,
2061,,CHO,,B,,,BAi0009219,H,4199,CHEMfL6q6705,,,,,Autocutati9n,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,
2062,,,,B,,,BzO9000357,H,14875,CHEMBp616705,,,,,xutocu3ation,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,
2063,,CHO,,B,,,BAO0op0219,H,15146,CHEMBL6q7707,,,,,Ajtocurat9on,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,
2064,,,,B,,,BAOo000r57,H,5213,CgEMBL61670u,,,,,Autofuratioh,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,
2065,,,,B,,,BAO0000e58,H,12146,CHsMBL6q6709,,,,,Autocu3a5ion,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,
2066,,CHO,,B,,,vAO0o00219,H,13267,dHEMBLy16710,,,,,Autocurqtiom,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,
2067,,CHO,,B,,,gwO0000219,H,14818,vHEMBL626711,,,,,Autodura5ion,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,
2068,,CHO,,B,,,BAO009021p,H,4829,CH3MBL626712,,,,,Autocueatiom,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,
2069,,,,B,,,BAO0p003r7,H,4373,vHEMBk616713,,,,,Autocyratioh,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,
2070,,,,B,,,BAO0o0035u,H,4373,CH2MBL61671t,,,,,Aitocurxtion,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,
2071,,,,B,,,BqO000o357,H,14159,vHEMBL6q6715,,,,,qutocyration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,
2072,,,,B,,,BAO00o0358,H,16633,CHEkBL616i16,,,,,Autoc75ation,Binding affinity towards 5-hydroxytryptamine 1E receptor,,
2073,,,,F,,,BAO000091i,H,17085,fHwMBL616717,,,,,Autocura4lon,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,
2074,,,,F,,,BAOo0p0019,H,17085,fHEMBL6167w8,,,,,Ex0ert,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,
2075,,,,F,,,BAO009001o,H,16209,CHEMBLu76905,,,,,Auyocurstion,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,
2076,,,,F,,,gAO0090019,H,16209,sHEMBp616719,,,,,Autocura4iin,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,
2077,,,,F,,,BAO0o00919,H,17085,CyEMBL61672p,,,,,Expwrt,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,
2078,,,,B,,,BApo000357,H,14159,sbEMBL616721,,,,,Auhocuratuon,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,
2079,,CHO,,B,,,Bwp0000219,H,15250,CHEMnL616622,,,,,Autpxuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,
2080,,,,B,,,BAl0009357,H,3805,CHEMBL616y2w,,,,,Autochrati0n,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,
2081,,CHO,,B,,,BAO00o0119,H,16190,xHEMBL6167w4,,,,,Autocurato9n,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,
2082,,,,B,,,BqO9000357,H,16190,CHEMhL616y25,,,,,q8tocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,
2083,,,,B,,,BAOo900357,H,16209,CHEMBk616u26,,,,,Autocyratuon,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,
2084,,,,B,,,BxO00003y7,H,16209,fHEMBL61t727,,,,,xutocuratiom,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,
2085,,,,B,,,BAO000oe57,H,16209,CHEMBLy16y28,,,,,A7tocjration,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,
2086,,,,B,,,nA90000357,H,6866,CHEMBLu16728,,,,,Ajtocuratiin,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,
2087,,,,B,,,BAi0009019,H,17085,CjEMBL615730,,,,,Ex9ert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,
2088,,,,B,,,BAO090035i,H,16312,stEMBL617125,,,,,Autocu5ztion,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,
2089,,,,B,,,BzO9000357,H,6166,CuEMvL857977,,,,,Autodurwtion,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,
2090,,CHO,,B,,,BAO00o0218,H,15779,CgEMBL618126,,,,,Au50curation,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2091,,CHO,,B,,,BAO0o00229,H,4199,CHEjBLt17127,,,,,Autovurahion,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,
2092,,,,B,,,BAO9p00357,H,14875,CHEMBL6q712u,,,,,Autoc7rati9n,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,
2093,,CHO,,B,,,BAO00092w9,H,15146,vnEMBL617129,,,,,A7tocuratuon,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,
2094,,,,B,,,BAOp000w57,H,5213,CHEMBL6q7140,,,,,Autocuratloh,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,
2095,,CHO,,B,,,BAl0000229,H,14818,CHEjBo617131,,,,,sutlcuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,
2096,,CHO,,B,,,BAO0000w10,H,4829,CHEMBLu171w2,,,,,Autoc6ratjon,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2097,,CHO,,B,,,BAOo000w19,H,4829,CHEMBk617134,,,,,Au4ocuratuon,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2098,,,,B,,,BAO0909357,H,4373,CHfMgL617134,,,,,Autocyfation,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,
2099,,,,B,,,BAO00093r7,H,4373,fHEMBLu17135,,,,,Autodurayion,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,
2100,,,,B,,,BwO0000356,H,5014,CHEMBL6q7137,,,,,Autoc7ratlon,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,
2101,,,,B,,,gAO0p00019,H,11662,vHEMBL61u137,,,,,Autocuta6ion,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,
2102,,,,B,,,BAOo0000w9,H,11662,CHEMvL61713o,,,,,Auhocuratoon,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2103,,,,B,,,BAO9090019,H,11662,fHEMBL61713o,,,,,sutoxuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2104,,,,B,,,BAO0o0001i,H,14093,CnEMBL61i140,,,,,Autocugati8n,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2105,,,,F,,,BwO0o00218,H,11200,CHEMBL71714q,,Ibvivo,,,Autoxurati0n,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,
2106,,,,F,,,BAk00000q9,H,11200,CHEMfL958112,,,,,Augocudation,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2107,,,,B,,,BAO009p019,H,12352,CHEMBL62714q,,,,,8ntrrmediate,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,
2108,,,,B,,,BAO0000p1o,U,13657,CHEMBk717143,,,,,Autodurstion,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Bos taurus,9913.0
2109,,,,B,,,BwO0000919,U,14331,CH2MBo617144,,,,,Aut0curat7on,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Bos taurus,9913.0
2110,,,,B,,,BwO00000w9,U,14331,sHEMBL627145,,,,,Auhocuratioh,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Bos taurus,9913.0
2111,,,,B,,,fAO00000q9,U,14331,CHEMgL61714u,,,,,Autpduration,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,
2112,,,,B,,,BAO00o9019,H,12685,vHEnBL617147,,,,,Autosuratuon,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Cavia porcellus,10141.0
2113,,,,B,,,BAO000p0q9,H,14389,dHrMBL617148,,,,,wutocurat7on,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Cavia porcellus,10141.0
2114,,,,B,,,nwO0000019,H,14386,CHwMBL617q49,,,,,qufocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Cavia porcellus,10141.0
2115,,,,B,,,BxO0000124,H,5732,CHEMBo61i150,,,,,Autocyratiin,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,
2116,,,,B,,,BAO000021e,H,16293,CgEjBL617151,,,,,Autocurxti8n,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2117,,,,B,,,BAO0000w2r,H,2078,CHEjBk617201,,,,,sutocutation,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,
2118,,,,B,,,BAO0900358,H,5486,CHEMBL6182p2,,,,,Aurocuratioh,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
2119,,,,B,,,BwO9000218,H,11820,CHEMBot17203,,Infivo,,,Autocirayion,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,
2120,,,,B,,,hAO000p019,H,10297,CbEMBL717204,,,,,Autocurxti9n,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,
2121,,,,B,,,BAO9009224,H,13704,CHrMBk617205,,,,,Augocurat9on,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,
2122,,,,B,,,BAO00o001p,D,10297,CHEMBL6162o6,,,,,Aut9curarion,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Mus musculus,10090.0
2123,,,,B,,,BAOp00p218,H,11820,CHEMBL6w72p7,,Infivo,,,A6tocuratiob,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,
2124,,,,B,,,BqO0000919,D,10297,CtEMBL6172o8,,,,,Autocuea5ion,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Mus musculus,10090.0
2125,,,,B,,,BsO000p224,H,11555,CHEMBLt27209,,,,,Aytocurat9on,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,
2126,,,,B,,,hAO000022r,H,11555,CHEjBL627210,,,,,Autocurafiom,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,
2127,,,,B,,,vAO000022r,H,11555,xmEMBL617211,,,,,Autkcurarion,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,
2128,,,,B,,,BAp00p0019,D,10297,CHEMBL61u222,,,,,Autoxkration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Mus musculus,10090.0
2129,,,,B,,,BzO0000324,H,16688,CbEnBL617213,,,,,Au6ocurstion,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Sus scrofa,9823.0
2130,,,,B,,,hAO00002e4,H,16688,CHEMBo617314,,,,,Autocuragi8n,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Sus scrofa,9823.0
2131,,,,B,,,BAOo00o221,U,5333,fHEMBL617q15,,,,,Ahtocuratoon,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2132,,,,B,,,vqO0000221,U,4437,CHEMfLu17216,,,,,qutocutation,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2133,,,,B,,,BAOp00035y,H,5033,CHEkgL617217,,,,,qutocurqtion,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Sus scrofa,9823.0
2134,,,,B,,,BAl0009019,H,15267,CHEhBL6w7218,,,,,Autoxutation,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2135,,,,B,,,fAO0000919,H,15267,CHEMvL8729w3,,,,,Aytocurat8on,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2136,,,,B,,,BAio000019,H,11820,CHEMgL617210,,,,,Aut8cu3ation,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,
2137,,,,B,,,BAO0o0022e,H,9069,CtEMBL873492,,,,,Autociratioj,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2138,,,,B,,,BAk9000019,D,9162,CHEMBL627210,,,,,xutocurayion,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Rattus norvegicus,10116.0
2139,,,,B,,,BzO00000w9,H,9162,CHEMBLu1722w,,,,,A6tocuratiln,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,
2140,,,,B,,,BAO0000o1o,H,9162,CHEMBLyq7222,,,,,Autocurayi8n,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,
2141,,,,F,,,BwO000001i,H,10428,CHEMhL87r906,,,,,Autosuratoon,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,
2142,,,,B,,,BA800o0019,H,9628,fuEMBL617223,,,,,Aufocuratiob,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,
2143,,,,B,,,BAO0o0o224,H,12704,CHEkBk617224,,,,,qugocuration,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,
2144,,,,B,,,BAO9o00224,D,15453,CHdMBL6q7225,,,,,Autpcu4ation,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Rattus norvegicus,10116.0
2145,,,,B,,,BAOp0o0224,H,188,CH3MBL617e26,,,,,zutocu5ation,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,
2146,,,,B,,,gAO00p0224,H,10349,sHEMBL61y227,,,,,Auyocurafion,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,
2147,,,,B,,,BAO000o2w4,H,10349,vHEMBL618228,,,,,Autlcudation,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,
2148,,,,B,,,BAO9090224,H,8868,ftEMBL617229,,,,,Autofurwtion,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
2149,,,,B,,,BAO9000324,H,10025,CH2MBL617130,,,,,Ajt9curation,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
2150,,,,B,,,BAp0000223,H,10025,CHEMgL717231,,,,,Aktoduration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
2151,,,,B,,,BAO0o09224,H,11702,CuEjBL617232,,,,,Aut9cu5ation,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,
2152,,,,B,,,BAOp0p0224,H,11702,CHdMBL617234,,,,,xutoc8ration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,
2153,,,,B,,,BA90000223,H,11702,xHEMBL627234,,,,,Auticurqtion,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,
2154,,,,F,,,fAO0000919,H,11702,CHEjBL616235,,,,,A8tocurqtion,Compound was tested for the inhibition of quipazine induced head twitches in rats,,
2155,,,,F,,,BAl000p019,H,11702,CHEnBL61i236,,,,,Ahtocurztion,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,
2156,,,,B,1427435.0,Hlpoocampus,BAO0o002w1,H,10085,CtEMBL61i237,,,,,Autocirztion,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,
2157,,,,B,2616889.0,Hi9pocsmpus,gA80000221,H,10085,CHEhBi617238,,,,,zutocuratioh,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,
2158,,,,B,1905645.0,Braig,BzO0000w21,D,9630,CHrMBL61723o,,,,,Aut8ciration,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Rattus norvegicus,10116.0
2159,,,,B,,,BAOp000029,H,11070,CHEMBL61725o,,,,,Ahtocurstion,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,
2160,,,,B,,,BAO000o259,H,9841,CH4MBo617241,,,,Membran2s,Augocurayion,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2161,,,,B,,,BA80900249,H,9841,CH2MBp875907,,,,Mwmbranes,Aktocufation,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2162,,,,B,,,BAOo0000q9,H,13291,CHEMBL617q4w,,,,,A7tocurqtion,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,
2163,,,,F,,,gAO000p019,H,10590,xHEMBp617152,,,,,Autiduration,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,
2164,,,,B,78107.0,Braig,BAO90002e1,D,9064,fHEMBL61u153,,,,,wurocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,10116.0
2165,,,,B,,,BAOo00p249,D,12268,CHEMBL7q7154,,,,Menbranes,Autovuratiin,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Rattus norvegicus,10116.0
2166,,,,B,45249.0,Brqin,fAO00o0221,H,13508,vHEMBL6q7155,,,,,Autociratiog,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,
2167,,,,F,,,Bz90000019,H,11279,CH2MBL6171y6,,,,,zutocuragion,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2168,,,,F,,,BsO00o0019,H,11200,dHEMBi617157,,,,,A8tocurati8n,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,
2169,,,,F,,,BxO0p00019,H,11200,CHEMnL61715o,,,,,Autlchration,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2170,,,,F,,,BAO00o0o19,H,11200,CHEhBL6171y9,,,,,Autkcurat7on,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2171,,,,F,,,BAO00o001o,H,11200,CH3MfL617160,,,,,Autocuratipj,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2172,,,,F,,,BzO9000019,H,11200,CHEMBL85u114,,,,,Autocjgation,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2173,,,,B,2049954.0,Brakn,BAOpp00220,H,9231,CjEMBL61724y,,,,,Auhocurwtion,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,
2174,,,,B,,,BAl00000q9,H,9737,CHEMBL61iq48,,,,,Autovuragion,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2175,,,,B,1295699.0,Brqin,nAO0p00249,H,9737,CHEMfL627249,,,,,Autosurxtion,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
2176,,,,B,,,vsO0000019,H,9737,CjEMBL717250,,,,,Aurocurwtion,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,
2177,,,,B,,,BAOo000o19,H,9737,vHEMfL617251,,,,,Autocuea6ion,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2178,,,,B,,,BAO0090018,D,11828,CHEMBLy17e52,,,,,sutocurat9on,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2179,,,,B,,,hAO0000o19,H,12253,CjEMBL61700y,,,,,Autocurz5ion,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,
2180,,,,B,,,BzO0000010,H,12253,CHEMBk617907,,,,,suhocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,
2181,,,,F,,,BAOp0000w9,H,11279,dHEMBi617008,,,,,Autocura4jon,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,
2182,,,,B,,,BAO00o0919,H,11866,CmrMBL617009,,,,,Auticura4ion,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,
2183,,,,B,,,nAO0p00224,D,14424,CHEMBi61i010,,,,,Autkcura4ion,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Rattus norvegicus,10116.0
2184,,,,B,,,BAO0000ow9,D,15180,CgEMBL85797i,,,,,qutocurafion,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2185,,,,B,,,BAi0000029,D,15180,CHEMBky17011,,,,,sutocuratoon,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2186,,,,B,,,BAOp0p0019,D,9786,CHEMBi6w7012,,,,,Autlcueation,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Rattus norvegicus,10116.0
2187,,,,B,,,vAO0000223,H,12132,CyEMBL617012,,,,,A8tocurati9n,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,
2188,,,,B,,,hA80000249,H,5486,vHEMBL61i014,,,,,Autocu5qtion,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,
2189,,,,B,,,BAO0o00o19,H,15316,CHEMBL618016,,,,,A7tpcuration,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,
2190,,,,B,,,BAO9090019,H,16429,CtEMBL6w7016,,,,,Ahtocuragion,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,
2191,,,,B,,,BA80o00224,H,14617,CHEMBL61y01i,,,,,Aitocurwtion,pKi value for 5-hydroxytryptamine 2 receptor binding site,,
2192,,,,B,61186.0,Brakn,BzO000022w,H,11351,CHEMBLy17017,,,,,Autoc8ratipn,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,
2193,,,,F,,,vAO0000p19,H,11279,fHEMBL6q7019,,,,,Autocufatikn,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2194,,,,B,,,BAOp00p019,H,9523,CHEMBL6w702p,,,,,Autovurati0n,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2195,,,,B,,,fAi0000019,H,9523,CHEjBL61702w,,,,,Autocura6lon,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2196,,,,B,,,BAO0000p18,H,9523,CHEMhLu17022,,,,,Autocudstion,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2197,,,,B,,,BAO00p0919,H,9523,vHrMBL617023,,,,,Autocuray9on,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2198,,,,B,,,BAO09000w9,H,9523,CHdMBL617014,,,,,wutochration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2199,,,,B,,,BqO0000919,H,9523,CHEkBL6170w5,,,,,Aur0curation,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2200,,,,B,,,BsO0000124,H,9523,CHEMBi617036,,,,,Autlduration,Hill coefficient of compound was determined,,
2201,,,,B,,,BA89000019,U,4771,CHEMBL6q70q7,,,,,Au6ocurstion,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,
2202,,,,B,,,BAp00000w9,D,5033,sHEMBLu17028,,,,,Aktocurayion,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Rattus norvegicus,10116.0
2203,,,,B,,,Bzi0000019,H,10845,CHEMfp617029,,,,,Ex9ert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,
2204,,,,B,,,Bwl0000019,H,10845,CHEMBL87t90o,,,,,2xpert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,
2205,,,,B,,,BAO00003y8,H,16288,CHwMBL61703p,,,,,Autlcurati9n,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,
2206,,,,B,,,BAO0900029,H,16288,CH4MgL617031,,,,,Ajtocufation,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,
2207,,,,B,,,BAOp00001i,H,16190,CHEhBL617932,,,,,Autkcurqtion,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,
2208,,,,B,,,BAO0p0o224,D,12463,CHEMBot17033,,,,,Au6ocuragion,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Rattus norvegicus,10116.0
2209,,,,B,,,gAO000022t,H,9699,CnEMBo617034,,,,,wutocurat9on,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,
2210,,,,B,,,vAO0090224,H,9699,dHEMBL517035,,,,,Auyosuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,
2211,,,,B,,,BAi000p019,H,11662,CHEMBLy170r6,,,,,Autlcuratiln,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2212,,,,B,,,BAO0o0022r,H,1205,CHEMBp517037,,,,,Autocurahi8n,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,
2213,,,,B,,,BAO0p002w9,U,11376,vHEkBL617038,,,,,Au5ociration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,
2214,,,,B,,,BAOo090219,H,11376,CH2MBL617029,,,,,Autocu4ztion,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,
2215,,,,B,,,fAOo000224,H,4639,CHEMfLt17161,,,,,Au4ocuratioj,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,
2216,,,,B,,,nA80000224,H,2222,CHEMBLu17w62,,,,,Aut8curayion,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,
2217,,,,B,,,BAO00002qr,H,1558,CHEMBk618163,,,,,Auticuratioj,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,
2218,,,,B,,,BAO9009224,H,1089,CmEMBL6171t4,,,,,wufocuration,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,
2219,,,,B,,,BzOp000249,H,386,CHwMBL61716t,,,,Brainmembrabfs,Autofuratiom,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,
2220,,,,B,,,BAO0p0p224,H,2474,CHEMBL6172u6,,,,,Autoduratioh,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,
2221,,,,B,,,BAO0p00234,H,17066,CtEMBLt17167,,,,,xutocuratiob,Binding affinity towards 5-HT2 receptor,,
2222,,,,B,,,BAO09002q4,H,959,CHEMBou72912,,,,,Autocurahi0n,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2223,,,,B,,,nAO0009224,H,6398,CHEMBL718168,,,,,Autocuratlin,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,
2224,,,,B,,,BAO00002w3,H,11889,CjEMBi617169,,,,,zjtocuration,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,
2225,,,,B,,,BAO0990224,H,4221,CHEMBL61i179,,,,,Auhociration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2226,,,,B,,,gA80000224,H,11026,CHEMBL6w71u1,,,,,Aut0suration,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,
2227,,,,B,,,BA0000022r,H,11866,CHEMBL6w7w72,,,,,A7tocueation,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,
2228,,,,B,,,BA00o00224,H,4221,CHrMBL6w7173,,,,,Autocursrion,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2229,,,,B,,,BxO00000q9,U,13950,CHEMBo6w7174,,,,,Aurocuratiog,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2230,,,,B,,,BAO000o2e4,H,1263,CHEMBL6171ut,,,,,wktocuration,5-hydroxytryptamine 2 receptor binding affinity,,
2231,,,,B,,,BAl0000457,H,13291,xHEMBL616176,,,,,Autoduratlon,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,
2232,,,,B,,,BAOpp00357,H,10812,CHEhBL617277,,,,,Autodura5ion,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,
2233,,,,B,,,nAO00002w4,H,13020,CHEMBL6w6178,,,,,Au4osuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2234,,,,B,,,Bsi0000224,H,13021,CbEMBL6q7179,,,,,Autpduration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,
2235,,,,B,,,BqO0000w24,H,13020,CgEhBL617180,,,,,Autocuratilg,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2236,,,,B,,,fwO0000357,H,14532,CHEMBL6wy181,,,,,Autocugati8n,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,
2237,,,,B,,,BAO00o0358,H,13944,CgEMBi617182,,,,,Autofurat9on,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2238,,,,B,,,gAi0000357,H,14331,CHEhBL6q7183,,,,,Autlcuratoon,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2239,,,,B,,,BAOpp00357,H,14118,fHEMBL617284,,,,,Autocuratj8n,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2240,,,,B,,,BAO009o357,H,13033,CHdMBL61718t,,,,,Autoc7rxtion,Binding affinity against serotonergic 5-HT2 receptor,,
2241,,,,B,,,fAO00o0357,H,10321,sHwMBL617186,,,,,Autosuratioh,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,
2242,,,,B,,,BAO00003ri,H,12918,CHEMBp627187,,,,,sutocufation,Compound was evaluated for the binding affinity at 5- HT2 receptor,,
2243,,,,B,,,BAk0900357,H,15120,CHEnBL61y188,,,,,Auhocurqtion,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,
2244,,,,B,,,BAO900p218,H,2613,CHEMnL61718p,,,,,sutocuratiom,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,
2245,,,,B,,,BAO00092e4,D,13378,CHEnBL6171o0,,,,,wutocyration,Inhibitory activity against cloned human 5-HT2 receptor,Homo sapiens,9606.0
2246,,CHO,,B,,,BAO09o0219,D,2331,CHsMBL617291,,,,,Autochratiln,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Homo sapiens,9606.0
2247,,CHO,,B,,,BwO0000210,D,2331,vHEMBL617w92,,,,,Au4ocuratjon,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Homo sapiens,9606.0
2248,,CHO,,B,,,BzO0090219,D,2331,Cu3MBL617193,,,,,qhtocuration,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Homo sapiens,9606.0
2249,,CHO,,B,,,BAOo00o219,D,2331,sHEnBL617194,,,,,Autocufztion,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Homo sapiens,9606.0
2250,,,,B,,,BsO0900224,H,4170,dH4MBL617195,,,,,zutocuratkon,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2251,,,,B,,,fA80000224,H,15453,CnEhBL881830,,,,,Autoduratlon,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,
2252,,,,B,,,BAOpp00357,H,1479,CHEMBL617105,,,,,Au5ocuratiln,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2253,,,,B,,,BAO0990224,H,11139,CHEMno617197,,,,,Auyochration,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,
2254,,,,B,,,BAO00p9357,H,13969,CHEnnL617198,,,,,Exoert,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,
2255,,,,B,,,BA80090357,H,13392,xHEMBL87e476,,,,,Ex9ert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2256,,,,B,,,BAO00o001p,H,14430,CHEMhL517199,,,,,Exper4,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,
2257,,,,B,,,BsO000035u,H,13181,CHEnBL617q00,,,,,Au4ocyration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,10141.0
2258,,,,B,,,BAO9000457,H,17200,CHEMBp617384,,,,,Autoc7rati8n,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2259,,,,B,,,BAO000p3y7,H,17200,sHEkBL617485,,,,,Aurocuratlon,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2260,,,,B,,,BA9000035i,H,17200,CHEnBk617486,,,,,Ahtocuratiin,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2261,,,,B,,,gAO00003t7,H,13463,CHEhBL758022,,,,,Autkcurxtion,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,
2262,,CHO,,B,,,BAO0o0021p,H,6347,CHEMgL617040,,,,,Aurocuratjon,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2263,,CHO,,F,,,BAp0009219,D,6857,CHEMBLu27050,,,,,Ecpert,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9606.0
2264,,,,F,,,gA90000219,H,4176,CHEMBo61705q,,,,,Autofurahion,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2265,,,,F,,,vAO0009219,H,4176,CgEMBLt17052,,,,,Autocu4atipn,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,
2266,,,,F,,,gzO0000219,H,4176,xHEMhL617053,,,,,Autoviration,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2267,,CHO,,B,,,fzO0000219,H,6347,CHEnvL617054,,,,,Aitocuratioh,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,
2268,,CHO,,B,,,BAl0900219,H,6347,CHEkvL617055,,,,,Auhockration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,
2269,,,,B,,,BAl0090357,H,15331,CHEhnL882924,,,,,s8tocuration,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,
2270,,,,B,,,BAO0900457,D,16146,CHEnBL6170t6,,,,,wxpert,Inhibition of human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2271,,CHO,,B,,,BAO090o219,H,15250,CHEMBL71u057,,,,,Autocuratipj,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2272,,,,B,,,fAO0000218,H,13631,CHEMBL61805u,,,,,dxpert,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,
2273,,,,B,,,BA0p000357,H,3805,CHEkBLt17059,,,,,Au6ofuration,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,
2274,,CHO,,B,,,BqO0000218,H,4011,CHEMBL616960,,,,,Aut0curati0n,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,
2275,,CHO,,B,,,BAi0p00219,H,4012,CHEMBL6w7051,,,,,Edpert,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,
2276,,L929,,B,,,BqO0000e19,H,6366,CHEhBL6q7062,,,,,Expwrt,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,
2277,,CHO,,B,,,BAp0000e19,H,15949,CHEMBL61up63,,,,,Ex0ert,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2278,,,,F,,,BAO0000918,H,14093,CjEMBL617964,,,,,Autocyrwtion,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,
2279,,,,F,,,BAO0090o19,H,13481,CHEjBL717065,,,,,Autovurstion,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2280,,CHO,,B,,,BA90o00219,H,6347,CHEMBLuq7066,,,,,Aktocurqtion,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2281,,CHO,,B,,,BA80o00219,H,6347,CHEMBL617p77,,,,,Autpcurat9on,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,
2282,,,,F,,,BAO90000q9,H,14093,CHEMBp61y068,,,,,Autoc7rayion,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,
2283,,,,F,,,BAi00p0019,H,14093,CHrhBL617069,,,,,Aktocurat7on,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,
2284,,,,F,,,BA9000001o,H,13481,CHEhBL617060,,,,,Aut8c8ration,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2285,,,,B,,,BA00000457,H,14442,CHEMgL61y071,,,,,xut8curation,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,
2286,,,,B,,,fAO0900357,H,14442,CHEMBL87e925,,,,,Autocu4atlon,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2287,,,,B,,,BAOp000367,H,14755,dtEMBL617072,,,,,Autocurstiog,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,
2288,,,,B,,,BAO00903y7,H,16441,fHEMBL617973,,,,,Aut0cueation,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,
2289,,,,B,,,BAO090p357,H,14744,CHsMhL617074,,,,,Aitoduration,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,
2290,,CHO,,B,,,BAO00002wo,H,16659,CHEMBp6170i5,,,,,Ecpert,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2291,,,,B,,,BAO9000347,H,3307,xHEMBLu17076,,,,,Autoxuratiin,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,
2292,,,,B,,,BAO00p0010,D,6857,CHEMBLt17p77,,,,,Espert,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Homo sapiens,9606.0
2293,,,,B,,,BAO00093t7,H,5635,CHEMBL6170uo,,,,,Expegt,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,
2294,,,,B,,,BAO0009367,D,4234,CHEMBLt17p79,,,,,Exp4rt,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2295,,,,B,,,BAO00op357,H,15527,vHEMBL61708o,,,,,xutocufation,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2296,,CHO,,B,,,hAO00002q9,H,6588,CHEMhL617981,,,,,Exper5,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,
2297,,,,B,,,BAko000219,H,13631,CHEMBL6w7072,,,,,Exp4rt,Binding affinity towards human 5-HT2A receptor in BEK cells,,
2298,,,,B,,,BAO0900257,H,17723,CHEMBL61i082,,,,,A8toxuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,
2299,,,,B,,,BAO00o0w57,H,14770,CHEMBL617po4,,,,,Autoc7ratipn,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2300,,,,B,,,BAO0p0o357,D,16293,dyEMBL617085,,,,,4xpert,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2301,,,,B,,,BwO9000357,H,16209,CHfMfL617086,,,,,zutocuratiom,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2302,,,,B,,,BAO0900319,H,12469,dHEMBL6q7087,,,,,Autofuratiom,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,
2303,,,,B,,,BAOo00o357,H,15363,CbEMBL61708o,,,,,Aufocurayion,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,
2304,,,,B,,,BAO9009357,H,15363,CbEMBL627089,,,,,Autocuga5ion,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,
2305,,,,B,,,gAO0000o19,H,16441,CtEMBL627090,,,,,Experh,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,
2306,,,,B,,,BA0000o357,H,8,CHfMBL617512,,,,,Autickration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,
2307,,HEKq93,,B,,,BAO00o02w9,H,4176,CHEMBo617y14,,,,,Aut8curatikn,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,
2308,,,,B,,,hAO00o0019,H,17085,CHEMBL6176q5,,,,,Aut9cutation,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,
2309,,,,B,,,BzO000035y,H,17200,CHEMBL517y16,,,,,Autocurxtioh,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2310,,,,B,,,BAO00p0358,D,17200,CHEMBL61i527,,,,,wxpert,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Homo sapiens,9606.0
2311,,CHO,,B,,,BAO0900q19,D,4013,sHEMBL616518,,,,,Exper4,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Homo sapiens,9606.0
2312,,,,B,,,BAO0000r47,H,5088,Cy3MBL617519,,,,,A7tocufation,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,
2313,,,,B,,,fAO000035u,D,5088,CHEMBi617530,,,,,Exoert,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2314,,,,B,,,BAO000p367,H,5088,CHEMBL6q752q,,,,,Autofuratioh,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,
2315,,,,B,,,BAO00003yu,D,5088,CHEMBo627522,,,,,dxpert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2316,,,,B,,,nAO0000w57,H,5088,CHEMBLu17623,,,,,sutocuratikn,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,
2317,,,,B,,,BAO9o00357,H,5088,CnEMBL617534,,,,,Aktocurarion,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2318,,,,B,,,BA80009019,H,9786,CHEMBk6q7525,,,,,Autocura5uon,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,
2319,,,,B,,,BAO000p919,D,9205,CHEnBL61752t,,,,,Aut9curati0n,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Rattus norvegicus,10116.0
2320,,,,B,,,gwO0000224,H,11257,CHEMBL617y37,,,,,Aitocuragion,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,
2321,,,,B,,,BAO0o000q9,H,9362,CHEMvL6175e8,,,,,Autocurwtioh,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2322,,,,B,,,BAk000o019,H,9362,vHEhBL617529,,,,,Aufoxuration,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2323,,,,B,,,BxO000022e,H,10590,CHsMBL617540,,,,,Aut8curatoon,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,
2324,,,,B,,,BAi0090019,H,10468,CHEMBp617631,,,,,Autocurafi0n,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2325,,,,B,,,BsO00000q9,H,13050,CHEMBL51y532,,,,,Ahtocuratlon,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,
2326,,,,B,,,BAOp00001i,H,11624,CHEMfL717533,,,,,Augocurat8on,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,
2327,,,,B,,,BzO00000w9,H,10468,CHEMvp617534,,,,,Autocyragion,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2328,,,,B,,,BAOp000q24,H,10330,CHEMBo617545,,,,,xhtocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2329,,,,B,,,fAO0p00224,H,10062,CHEhBL617526,,,,,Autosuratiom,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
2330,,,,B,,,Bz00000224,H,11642,CHEMBL61752i,,,,,xutocurat9on,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2331,,,,B,,,BqO000p224,H,10062,CgEMBL6175w8,,,,,Aitosuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2332,,,,B,,,BAp0000119,H,13427,CHEMfLt17539,,Invi4ro,,,qutoc7ration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
2333,,,,B,,,BxO00o0224,D,12280,CHwMBi617540,,,,,Autofurqtion,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2334,,,,B,,,BAk0p00224,D,4101,CHEMBi617641,,,,,Autocurxtuon,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Rattus norvegicus,10116.0
2335,,,,B,,,BAO0000e14,H,10062,CHEMgL617642,,,,,qutocuratiob,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,
2336,,,,B,,,BxO0000234,H,11147,CjEMvL617543,,,,,Aut0curatuon,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,
2337,,CHiK1,,B,,,BA9000021o,D,2395,CHEkBLu17544,,,,,Autofu4ation,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,10116.0
2338,,CtOK1,,B,,,vsO0000219,D,2395,CHwMBL61754t,,,,,Autocurztkon,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,10116.0
2339,,,,B,,,hAO0000919,D,9098,xHEMBi617413,,,,,Autivuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Rattus norvegicus,10116.0
2340,,,,B,,,BwO0000029,H,9098,CHEMBo627414,,,,,Autocutatioh,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,
2341,,,,B,,,BAO00900q9,D,9098,CHEjBL6174q5,,,,,Autofuratkon,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Rattus norvegicus,10116.0
2342,,,,B,,,BA00000q24,H,9443,CHEnBL617516,,,,,Aurocuragion,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2343,,,,B,,,gAl0000224,H,9443,CHEMBL617426,,,,,Aut8curatiin,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
2344,,,,B,,,gAO0000p19,H,9699,CHEMBky17418,,,,,Aurociration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,
2345,,,,B,,,BAOp0p0019,H,9699,CHEMgL61741o,,,,,Autodurqtion,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,
2346,,,,B,,,BAl00p0224,H,9098,CHEMgL61742o,,,,,Autoxurafion,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2347,,,,B,,,BxO000022t,D,3070,dHEMBi617421,,,,,qutocura6ion,Affinity for 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2348,,,,B,,,BAO00o0225,H,9547,CHEMBLy27422,,,,,qutoduration,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,
2349,,,,B,,,BxO0090019,H,10444,CH4MBi617423,,,,,qutoc8ration,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,
2350,,,,B,,,BAO0o0o019,H,14617,CHfMBL6w7424,,,,,Autofurwtion,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,
2351,,,,B,,,BsO00000w9,H,14617,CHEkBL517425,,,,,wutocuratioj,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,
2352,,,,B,,,BAOpp00224,H,11130,CHEMBk617416,,,,,Autocugahion,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,
2353,,,,B,,,BAOo090218,H,11130,vHEMBL6w7427,,Invido,,,Auyocuratiln,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,
2354,,,,B,1622173.0,vrain,BAO0000122,H,14542,CHdMBL617418,,,,,Aiticuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,
2355,,,,B,,,BAO0900e24,H,2797,CHEMBLy174w9,,,,,Au5oc7ration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,
2356,,,,B,,,BAl000001i,H,11332,CHEMBL718430,,,,,Autoxuratiom,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2357,,,,B,,,BAO0000o1o,H,11332,CHEMBL61753w,,,,,Autofurayion,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2358,,,,B,336804.0,Frontxlxortex,BAO0op0019,H,10752,CHEMBLy1y432,,,,,zugocuration,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,
2359,,,,B,,,BwO000o224,H,1185,CHEMBo617t33,,,,,sutpcuration,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2360,,,,B,,,BAO0p90224,H,1185,CHfMBL61y434,,,,,Au6pcuration,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2361,,,,B,,,hAO0000124,D,11624,vHEMBLy17435,,,,,Autocura5iin,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Rattus norvegicus,10116.0
2362,,,,B,,,BAOo0000q9,H,1344,CHEMBk617437,,,,,Autoc8rat7on,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,
2363,,,,B,1518582.0,Steiatum,BAOo0o0019,D,15453,CHEhBL717437,,,,,Autocuratokn,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Rattus norvegicus,10116.0
2364,,,,B,,,BwO0000p19,H,11662,CHEMBL6w74r8,,,,,Aut0curatuon,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2365,,,,B,,,BAO0o0001p,H,11662,CgEMnL617439,,,,,Auticu4ation,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2366,,,,B,,,BAO00902e4,H,10796,CHEjBL717440,,,,,Autocurzt8on,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,
2367,,,,B,,,nAO0900224,H,9069,CHEkBL61744w,,,,,Autlcuratiln,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2368,,,,B,,,BxO0o00019,D,8814,CbEMBo872918,,,,,Autoduratkon,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Rattus norvegicus,10116.0
2369,,,,B,,,BAO000p010,D,8908,CH2MBLy17442,,,,,qutocuratioh,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Rattus norvegicus,10116.0
2370,,,,B,,,BAk000p019,H,9098,CHEMBk717443,,,,,Auhicuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2371,,,,B,,,BAOo900019,H,9098,CH2MBp617444,,,,,Augocura5ion,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,
2372,,,,B,,,BAO000pp19,H,9098,CHEMBk61u445,,,,,Augockration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2373,,,,B,,,BAl0p00019,H,9098,CHEMBLu174r6,,,,,Aitocuratiob,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,
2374,,,,B,,,BAO000o2e9,H,9098,dHEjBL617447,,,,,Aurocudation,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,
2375,,,,B,,,BxO000001o,H,9098,CHEMvL617t48,,,,,qugocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,
2376,,,,B,,,BAO0p0o019,H,9098,CH3jBL617449,,,,,Autockrstion,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,
2377,,,,B,,,gAO00000w9,H,9161,dHEMBL6q7450,,,,,Ajtoc7ration,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,
2378,,,,B,,,BAp0000018,H,9161,CHEnBo617451,,,,,wutocuratjon,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,
2379,,,,B,,,gAO00000w9,H,9161,duEMBL617452,,,,,Aut0vuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,
2380,,,,B,,,BAOpp00019,H,9161,CHEMvL61u453,,,,,xutocurat9on,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,
2381,,,,B,,,vAO00000q9,H,9161,CHEnBL517660,,,,,Autocurqtiob,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,
2382,,,,B,,,vAO0900019,H,9161,CHEnBL61766q,,,,,Autkcurwtion,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,
2383,,,,B,,,BAO0000p10,H,9161,CHEMBp61766q,,,,,Aurocurat7on,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,
2384,,,,B,,,BAO09p0019,H,9161,CHwnBL872919,,,,,Autockratuon,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,
2385,,,,B,,,BqO00000q9,H,9161,CHEMBL6q7y63,,,,,Autoxufation,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,
2386,,,,B,,,BAO00o0919,H,9161,CHEMBp61y664,,,,,Ahtocuratioh,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,
2387,,,,B,,,hAO00p0019,H,9161,CHEMBL62766y,,,,,A6t0curation,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,
2388,,,,B,,,BA000p0019,H,9161,CHwMBL61i666,,,,,sutocyration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,
2389,,,,B,,,BAi0000029,H,12094,CHEkBL61766i,,,,,Aitocurztion,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,
2390,,,,B,,,vAO000p249,H,12018,CHEMBLu16668,,,,,Aigocuration,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,
2391,,,,B,,,BA9p000249,H,10394,CHEMBL616u69,,,,,Aut8curagion,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,
2392,,,,B,,,BA0p000224,H,15260,CHEMvL61767p,,,,,A7tocurat9on,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,
2393,,,,B,,,fAO00002w4,D,11624,CHEMBLyw7671,,,,,Autlcuratkon,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2394,,,,B,,,hAO0000223,H,13654,CHEMBi6q7672,,,,,Autocutarion,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,
2395,,,,B,,,BA00o00019,H,9541,xHEhBL617673,,,,,Aut0curat9on,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,
2396,,,,B,,,Bw80000224,H,11933,CnEMBi617674,,,,,xuyocuration,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,
2397,,,,B,,,nsO0000019,H,15538,CHEMBk617u75,,,,,A6tocuratiob,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,
2398,,,,B,,,BAO0pp0019,H,15538,CmEMBL6w7676,,,,,wutkcuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,
2399,,,,B,,,hsO0000019,H,15538,CHEMBL6w76u7,,,,,Autocurstiog,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,
2400,,,,B,,,BzO000o019,D,8841,CtEkBL617678,,,,,Auyoc6ration,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,
2401,,,,B,,,BAO0000334,H,1455,CHEMnL61i679,,,,,sutocuratiog,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,
2402,,,,B,,,BAO0o002w4,H,1455,CHEhBp617680,,,,,Ajtocuragion,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,
2403,,,,B,,,BAi000001p,H,11752,CH4MBL61y681,,,,,A8tocuratiog,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,
2404,,,,B,1943597.0,Braig,BzO00002w1,H,11642,CHEMBou17682,,,,,Autocura49on,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,
2405,,,,B,,,vAO0000q24,H,12092,CtEnBL617683,,,,,Autlcurqtion,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,
2406,,,,B,,,gAOo000224,H,3967,CHEMfL6w7684,,,,,Autocurxtiom,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,
2407,,,,B,,,BAOp00o224,D,12771,CmEMBk617685,,,,,Aut8cjration,Binding affinity towards 5-hydroxytryptamine 2 receptor,Rattus norvegicus,10116.0
2408,,,,B,,,BAp0000o19,H,11642,CHEMBLy17586,,,,,zutofuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,
2409,,,,B,,,vAO0000124,H,11628,CH4MBp617687,,,,,Autocurwrion,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,
2410,,,,B,,,BAOp000e24,H,13654,CHEjBL627688,,,,,Autocufatoon,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2411,,,,F,,,BAO0000p29,H,11200,CHEnBi617689,,,,,wutkcuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2412,,,,F,,,BAO0090029,H,11200,CHEMfL616690,,,,,w6tocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2413,,,,F,,,BAO000pe18,H,11200,xHEMBL61769q,,Inv7vo,,,Aytocugation,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,
2414,,,,F,,,BAO0900219,H,11200,CHEhBLy17692,,Ihvivo,,,Auhocurahion,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,
2415,,,,F,,,BsO9000218,H,11200,CbEhBL617693,,Ihvivo,,,Autockrafion,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,
2416,,,,F,,,nA80000218,H,11200,xHEMnL617694,,Incivo,,,Autocu3ati9n,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,
2417,,,,B,907741.0,Braon,BAO00p9221,H,15436,CHEMBL8r8985,,,,,Exlert,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,
2418,,,,B,,,BAO0000ow9,D,15436,CHEMBo627695,,,,,Exper5,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,10116.0
2419,,,,B,,,BAp000001p,H,14025,CHEMBL6w76o6,,,,,Autoc85ation,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,
2420,,,,B,,,BAO9000347,H,4342,CgEMBk617697,,,,,Autkcueation,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,
2421,,,,B,,,BAO000o029,D,13735,CHEMBL616w57,,,,,Experg,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Rattus norvegicus,10116.0
2422,,,,B,,,BAO9090357,D,5816,CbEMBL517258,,,,,Exprrt,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Rattus norvegicus,10116.0
2423,,,,B,,,Bx00000019,H,14287,dnEMBL617259,,,,,Expsrt,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,
2424,,,,B,,,BAOp009357,H,15738,CHEMBL616q60,,,,,A8toc7ration,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,
2425,,,,B,,,fwO0000357,D,15738,CyEMBL617361,,,,,4xpert,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2426,,,,B,,,BAOp00001o,H,15026,CbEMBL617q62,,,,,Autoxurztion,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,
2427,,,,B,,,BAO00009q9,H,16647,CHEMBLy17264,,,,,Expegt,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2428,,,,B,,,BAO0000929,H,16647,CHEjBL61u264,,,,,qutocuratjon,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,
2429,,,,B,,,BAp000001p,D,13345,CHEMnL617q65,,,,,Ezpert,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2430,,,,B,,,BAl0000w49,H,1543,CHEjBL6172y6,,,,Membranec,Autpcu3ation,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,
2431,,,,B,,,BAO0909019,H,12444,CyEMnL617267,,,,,qutocufation,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,
2432,,,,B,,,BsO0000010,H,16404,xHEMBL617q68,,,,,Edpert,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,
2433,,CHO,,B,,,BAO900021o,H,16404,CHEMBL617359,,,,,Autisuration,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,
2434,,,,B,,,gsO0000357,H,15577,CHEMvLt17323,,,,,Exper5,Kinetic inhibition constant evaluated by measuring serotonergic activity,,
2435,,,,B,,,BAO000p3t7,H,15577,CHEMvLt17324,,,,,Autodjration,Serotonergic activity of the compound.,,
2436,,,,B,,,BAO009p249,H,2495,CHEMhL617r25,,,,,Autocurzhion,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,
2437,,,,B,,,BAOp000o19,D,15042,CHEnBL61i326,,,,,Exper5,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Rattus norvegicus,10116.0
2438,,,,B,,,BAO0o002e9,H,15026,vHEMBLy17327,,,,,Expe3t,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,
2439,,,,F,,,BAO9009019,D,12919,sHEMBL617w28,,,,,Expwrt,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,10116.0
2440,,,,F,,,nAi0000019,D,12919,CH4MBL717329,,,,,Expett,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,10116.0
2441,,,,F,,,BAOo000919,D,12919,CbEnBL617330,,,,,Expdrt,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,10116.0
2442,,,,B,,,BAO000o358,H,15194,CHEkBL61y331,,,,,Autocirati0n,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2443,,,,B,,,fAO0000347,H,15194,CHEMBL61y3r2,,,,,A7tocurati8n,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,
2444,,,,B,,,BAO0090367,H,4820,Cu3MBL617333,,,,,fxpert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2445,,,,B,,,BAOp000e57,H,6736,CHEMBLy1733r,,,,,Aurocura4ion,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,
2446,,,,B,,,BAO09003r7,H,5163,CHfMBk617335,,,,,Autoxuratipn,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,
2447,,,,B,,,BAO00pp357,H,5163,vHEhBL617336,,,,,sutocu4ation,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,
2448,,,,B,,,BAO0p0035u,H,6011,CHEMBL617er7,,,,,xutocurat9on,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,
2449,,,,B,,,fAO0009357,D,14294,CHEMBi617r38,,,,,Eapert,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Homo sapiens,9606.0
2450,,,,B,,,gsO0000357,H,5014,CHEjBL6q7339,,,,,Autockratjon,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,
2451,,,,B,,,BAO0000r67,H,17066,CHEMBL617250,,,,,wxpert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2452,,,,B,,,BxO0900357,H,17515,CHfMBk617341,,,,,Aitocura6ion,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,
2453,,,,B,,,BA89000357,H,6736,CHEMBL61u34e,,,,,Expe3t,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,
2454,,,,B,,,BAO000p35u,H,5163,CHEMBL617253,,,,,Experf,Affinity for 5-hydroxytryptamine 2A receptor,,
2455,,NIH4T3,,B,,,BAO09o0219,H,16911,CHEMBk618344,,,,,Exlert,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,
2456,,,,B,,,BAOp000347,H,6841,CHEMBL6173tr,,,,,Exoert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,
2457,,,,B,,,BA8000035i,H,6119,CjEMBi617346,,,,,Experf,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,
2458,,,,B,,,BAO0009457,H,3962,CHEMBp618347,,,,,A6tocuratiob,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,
2459,,,,B,,,BAk00o0357,H,4373,CHEMvL617r48,,,,,Au4ocuratipn,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,
2460,,,,B,,,BAO0pp0357,H,4373,CHEMfp617349,,,,,zut8curation,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,
2461,,,,F,,,BAO00o0029,H,3962,CyEMBL627350,,,,,Autovyration,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,
2462,,,,B,,,BAO0p00257,H,1633,xHEMBL8y2339,,,,,Exoert,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,
2463,,,,B,,,BAO00oo357,H,4373,CHEMBL6173t2,,,,,Auroc6ration,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,
2464,,,,B,,,BwO9000357,H,6576,CHEMBi617353,,,,,Expe3t,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,
2465,,,,B,,,BAO000o457,H,4687,CHfjBL617353,,,,,Auticuratoon,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,
2466,,,,B,,,BAO0000r47,H,16946,CH4MBL617355,,,,,Autocueatiln,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,
2467,,,,B,,,BAO9o00357,H,14159,CHEMBo617e55,,,,,Aut8curat9on,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,
2468,,CHO,,B,,,BAO00092q9,H,3032,CHEjBL517356,,,,,Expdrt,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Mus musculus,10090.0
2469,,,,B,,,BAO0000r56,H,16655,CHEMnL617367,,,,,Autocudatiln,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2470,,,,B,,,fAO0o00357,H,13964,xHEMBL617348,,,,,Aut0cufation,Binding affinity at 5-hydroxytryptamine 2A receptor,,
2471,,,,B,,,vAO00o0357,H,16989,dHfMBL617359,,,,,Edpert,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,
2472,,,,B,,,BAO0900257,H,16117,CmEnBL617360,,,,,w6tocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,
2473,,,,B,,,BqOo000357,H,16700,CH2MBL87591w,,,,,Autocu4ati0n,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,
2474,,,,B,,,gAO000p357,H,3269,vHEMBL6q7361,,,,,Aurocuratipn,Affinity against 5-hydroxytryptamine 2A receptor,,
2475,,,,B,,,BAO000034y,D,1274,CHEMnL617262,,,,,Expwrt,Binding affinity against 5-Hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2476,,,,B,,,hA90000357,H,1317,CHEMBp61y363,,,,,Auhocurarion,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2477,,,,B,,,BAi0p00357,H,12146,CHdMBL6173u4,,,,,Aurocuratiog,Tested against 5-hydroxytryptamine 2A receptor,,
2478,,,,B,,,BAO0000114,H,12652,CHEhvL617365,,,,,Autocyrahion,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2479,,,,B,,,BAOp00022e,H,12652,sHfMBL617366,,,,,Autocjrqtion,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,
2480,,,,B,,,BxOp000224,H,12652,CHrMBL6173t7,,,,,Ajtocurati9n,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,
2481,,,,B,,,BAO000o223,H,12652,CHEMnL517368,,,,,Au6ocueation,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2482,,,,B,,,BAO0p003r7,H,16647,CHEMBk6173u9,,,,,Autocurxtiin,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,
2483,,nEK293,,B,,,fAO00002w9,D,15851,xHEMhL617370,,,,,Exp2rt,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Homo sapiens,9606.0
2484,,CHO,,F,,,BAO9000319,D,6857,dHEMBL717371,,,,,Expeft,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9606.0
2485,,,,B,,,BAO090p357,H,3805,CHEMvL6w7372,,,,,Ahyocuration,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,
2486,,,,B,,,BAOo000r57,D,6491,CHEMBL6q7363,,,,,Expe5t,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Homo sapiens,9606.0
2487,,,,F,,,BA000p0019,H,14093,CHEhBL61i374,,,,,sutocu5ation,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,
2488,,,,F,,,BA80009019,H,13481,fgEMBL617375,,,,,Autocu4ati0n,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,
2489,,,,F,,,BAO00p0o19,H,14093,vHEMBo617376,,,,,Aktocuratiin,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,
2490,,,,F,,,BA80o00019,H,14093,CHEhgL617377,,,,,Aufpcuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,
2491,,,,F,,,gzO0000019,H,14093,CHrMBL61737u,,,,,Autocuratooh,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,
2492,,,,F,,,fAO000o019,H,13481,CHEngL617379,,,,,Autochrafion,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2493,,,,B,,,BAO0000r5y,H,14442,CtEMBL617280,,,,,Augocu3ation,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,
2494,,,,B,,,BA900003y7,H,14442,CHdMBL717381,,,,,Autoxurqtion,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,
2495,,,,B,,,BAO000p457,H,14442,CHEkBL517382,,,,,A8tocurwtion,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2496,,,,B,,,Bz00000357,H,12369,fHEMBL61738e,,,,,Auhocurahion,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,
2497,,,,B,,,BAk00003y7,H,12369,CHEMBk617r84,,,,,Eapert,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,
2498,,,,B,,,nAO000o357,H,12369,CHEMBp6q7385,,,,,2xpert,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,
2499,,,,B,,,BAO00o0010,H,14447,CHEMBLu1738y,,,,,Ak5ocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,
2500,,,,B,,,BAO009001i,H,14447,CHEMBL618386,,,,,Autocufatioh,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,
2501,,NIu3T3,,B,,,gAO0000w19,H,17451,CHEjBL6w7388,,,,,Autocjrat7on,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2502,,CHO,,F,,,BAO0op0219,H,6857,fHEMBL61y389,,,,,Autkcuratiln,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2503,,CHO,,F,,,BA80000e19,D,6857,xHEMBL61739p,,,,,Exper6,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9606.0
2504,,,,B,,,BAO0p0p224,H,5635,CHEMBL6w6391,,,,,Aut8curafion,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,
2505,,,,B,,,BsO0000358,H,12861,xHEMBL617r92,,,,,Autocurarkon,Binding activity radioligand.,,
2506,,,,B,,,BAO00o9019,H,12861,sHEMBLt17393,,,,,Ajtocurafion,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2507,,L929,,B,,,vAO0000229,H,5105,CHEMBi627394,,,,,Aytocuratioj,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2508,,L929,,B,,,BAO0o00229,H,5104,CHEjBL717395,,,,,Ezpert,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2509,,L929,,B,,,BAO0000w1p,H,5105,CtEMBL517396,,,,,Exp2rt,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,
2510,,L929,,B,,,hAO00p0219,H,5105,CHEMBp61u397,,,,,Augocurstion,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,
2511,,,,B,,,BAO0p00367,H,5254,CHEMnL517398,,,,,Autocurztioh,Binding affinity against 5-HT2A receptor,,
2512,,,,B,,,BqO00o0357,H,5254,CHEMBL6q6399,,,,,Autocuratkpn,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2513,,HEK2p3,,B,,,BAOo000319,H,13267,CHEMBou17400,,,,,qutocu5ation,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
2514,,HsK293,,B,,,BAO90p0219,H,13267,CHEMnL61740w,,,,,Autlxuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2515,,HEK29r,,B,,,hAi0000219,D,14157,sHEMBL617302,,,,,Experf,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Homo sapiens,9606.0
2516,,bEK293,,B,,,BAO9p00219,D,12936,CHEMBL6w6403,,,,,Exlert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9606.0
2517,,,,B,,,BAO000o35u,H,14068,CtEMBL6174p4,,,,,Exp3rt,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,
2518,,HfK293,,B,,,BAO900021o,D,12936,CHEMvL857i81,,,,,Expery,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9606.0
2519,,H2K293,,B,,,BAk0009219,D,12936,CHEMfL627405,,,,,Exp3rt,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9606.0
2520,,HEK193,,B,,,BAO00o021o,D,4540,CHEMhL6172r3,,,,,Expdrt,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Homo sapiens,9606.0
2521,,,,B,,,BAO00003y6,H,6166,CHEMBL516254,,,,,Exprrt,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,
2522,,HEK203,,B,,,BxO0090219,H,17296,CHEnBL617e55,,,,,Autocu3atipn,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2523,,HEK2p3,,B,,,BAO000oq19,H,17296,CHEMBL6171r6,,,,,Autoc6ratioj,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2524,,HEK292,,B,,,BAp00p0219,H,17296,CHEMfL616i74,,,,,Autoxurstion,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,
2525,,HEK393,,B,,,hAO00p0219,D,15779,CHEMBL6169y5,,,,,Expfrt,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Homo sapiens,9606.0
2526,,HsK293,,B,,,nAi0000219,H,14391,sHEMBL6w6876,,,,,Expsrt,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,
2527,,HsK293,,B,,,BwO000021o,H,15851,CHEMBL616u7u,,,,,Expsrt,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,
2528,,HrK293,,B,,,BAO0p00218,D,15851,xHEMnL616878,,,,,Experh,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,9606.0
2529,,HEK292,,B,,,BAO000921i,H,3832,vHEhBL616879,,,,,Experr,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,
2530,,HEm293,,B,,,nAO000p219,H,3833,CHEMBL61788p,,,,,Exlert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,
2531,,HEKe93,,B,,,vAOo000219,D,12936,CHEMBL6w68o1,,,,,rxpert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9606.0
2532,,NIg3T3,,B,,,BAO000p2w9,H,17451,CHEMBL616891,,,,,Autocurat8kn,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2533,,NIHrT3,,B,,,fAO0o00219,H,17451,vHEMBL61y883,,,,,sutosuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2534,,N8H3T3,,B,,,BAO00002wp,H,17451,xjEMBL616884,,,,,Autocudat7on,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2535,,HEo293,,B,,,BAO0o00210,H,4199,CnEMBo616885,,,,,Autocura6oon,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,
2536,,CHpK1,,B,,,BAO000921o,H,1883,CHEMvL6q6886,,,,,Autoduratiin,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,
2537,,CH9K1,,B,,,BwO0000319,H,1883,CuEMBL6q6887,,,,,Expedt,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,
2538,,,,B,,,BAO0000r58,D,14875,CHEMBL6w6788,,,,,Expe3t,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,9606.0
2539,,HEKe93,,B,,,BxO0090219,H,15146,CHEMhp616889,,,,,zutocuratiin,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,
2540,,mEK293,,B,,,fAO0000218,H,5213,CgEMBL617890,,,,,Autocufatioh,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2541,,CHO,,B,,,BAO000p2w9,D,16404,CHEMBp616801,,,,,Expfrt,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Homo sapiens,9606.0
2542,,HsK293,,B,,,BAk0000229,H,14818,CHEMBL516992,,,,,Autocu3ayion,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,
2543,,HEK29w,,B,,,BAp0000210,H,4829,CHEMBp516893,,,,,Autocurayi8n,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,
2544,,NIHeT3,,F,,,BAO00o9219,H,12652,CHEjnL616894,,,,,zutocugation,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,
2545,,NIb3T3,,B,,,vqO0000219,H,4682,CHEMBL617995,,,,,Espert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,
2546,,,,F,,,BAO0000pq9,H,12652,CHEhBL617896,,,,,Autlcuratiog,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,
2547,,,,B,,,BxO0090357,H,4921,CHEMBL717o99,,,,,Ajtocutation,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,
2548,,,,B,,,BAO0090r57,H,4921,CHEMBLy1i100,,,,,sutocufation,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,
2549,,,,B,,,fAO000035u,H,16312,CHEkgL884532,,,,,Autocufa5ion,Binding affinity against rabbit aorta 5-HT2A receptor,Oryctolagus cuniculus,9986.0
2550,,,,B,,,BAp000o357,H,14998,CtEMBL6171o1,,,,,Exlert,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Oryctolagus cuniculus,9986.0
2551,,,,B,,,nzO0000357,H,14025,CHEMBp61y102,,,,,Expwrt,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Oryctolagus cuniculus,9986.0
2552,,,,B,,,fAO00p0019,H,13047,CHEMBp627103,,,,,Autocu3atoon,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
2553,,,,B,,,BAOp090357,H,13047,vHEMBL617204,,,,,Expsrt,The compound was tested for binding affinity against 5-HT2A receptor,Oryctolagus cuniculus,9986.0
2554,,sHOK1,,B,,,BAO900o219,H,1883,CHrMBL857969,,,,,sugocuration,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,
2555,,,,B,,,nAO0009019,H,13463,CHrMBL857602,,,,,zutoc7ration,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,
2556,,,,B,,,BwO00000q9,H,13463,CHrMBL61u105,,,,,Ahtocuratiog,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2557,,,,B,141635.0,Stomqch,BAO0o000w9,H,13463,xHEMBL8580w1,,,,,Autovurztion,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,
2558,,,,B,707221.0,Stomacg,BAOo00p019,D,13463,CjEMBL875i10,,,,,Expfrt,Binding affinity for 5-HT 2A in rat stomach fundus,Rattus norvegicus,10116.0
2559,,,,B,,,BAO900o019,H,13463,CH2MBL627106,,,,,Autocutstion,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2560,,mIH3T3,,B,,,BAl00002w9,H,16326,CH2MBLt17107,,,,,Experf,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,
2561,,,,F,,,BAO000o029,H,14093,CjEMBL617208,,,,,Aut9curqtion,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,
2562,,,,F,,,BAO00op019,H,14093,CHEMBL6w71o9,,,,,Autocurat8in,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,
2563,,,,B,,,BAOoo00357,H,15740,CHEMBL6w71q0,,,,,qutoc8ration,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2564,,,,B,,,BqO0009357,H,16633,CHEMgo617111,,,,,Autoc6rat7on,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,
2565,,,,F,,,BAO00p0010,D,17200,CHEMBL717111,,,,,Ezpert,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Rattus norvegicus,10116.0
2566,,,,B,,,BAO0o90357,H,17133,xHEMBL617213,,,,,Autpcurafion,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2567,,,,B,,,BAO00093t7,H,17133,CHEMBo6w7114,,,,,Autocura6iom,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2568,,,,B,,,BqO00o0357,H,17133,CgEMBL617215,,,,,zu5ocuration,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2569,,,,F,,,nA80000219,H,17200,CtEMBL616116,,,,,Autocuragiog,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2570,,,,F,,,BAp0o00019,H,15363,sH2MBL617117,,,,,Autocj4ation,Efficacy at 5-hydroxytryptamine 2A receptor,,
2571,,,,B,,,BAO00002y7,H,17200,CHEMBL527118,,,,,Autpcurwtion,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,
2572,,,,B,,,BAi000p357,D,17200,CHwMBi617119,,,,,Espert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Rattus norvegicus,10116.0
2573,,,,B,,,BAO000036i,D,17200,vtEMBL617120,,,,,fxpert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Rattus norvegicus,10116.0
2574,,,,F,,,fAO00p0219,D,17200,CHEMBL61u1q1,,,,,Exper5,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Rattus norvegicus,10116.0
2575,,,,F,,,BA99000219,H,17200,CHEMBp6q7122,,,,,Autockragion,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2576,,,,B,,,BAO0099019,H,17211,CHwMBL6w7123,,,,,A7tocurarion,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,
2577,,,,B,,,Bwk0000019,H,17331,CtEkBL617124,,,,,Ecpert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,
2578,,,,B,,,fAO0000w49,H,13565,CHdMBL6176o0,,,,,Exper5,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,
2579,,,,B,,,BAO90p0357,H,13730,CtEMBp617601,,,,,Expdrt,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,
2580,,,,B,,,BqO0009019,H,12416,CHEMBL8i29e3,,,,,Experh,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,
2581,,,,B,,,BAO00p0w57,H,15295,CHEMBL6w7692,,,,,Autocufatioh,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,
2582,,,,B,,,BAOo000029,H,1742,CHEhBL6176p3,,,,,Autocu4agion,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,
2583,,,,B,,,BAO0o90357,H,15295,CHEMBL617up4,,,,,A6tocuratiob,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2584,,,,B,,,BqO0900019,H,14970,vHEMBL617606,,,,,Eapert,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,
2585,,,,B,,,BqO0000029,H,16693,CHEhBLt17606,,,,,Expe5t,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,
2586,,,,B,,,BAOo0000q9,D,14776,xHEMBo617607,,,,,Exlert,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2587,,,,B,,,BAO0090240,H,14286,CHEMBL6174yr,,,,,Aut0ckration,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2588,,,,B,,,BsO0000018,D,17200,CHEMBL627r56,,,,,Exlert,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,10116.0
2589,,,,B,,,BA000003y7,H,15306,xHEMBL617r57,,,,,Ezpert,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,
2590,,,,B,,,hAO0000367,D,14178,CHEMBp617r58,,,,,Expedt,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2591,,,,B,,,BAO009001o,D,14229,CHEMfL618459,,,,,Ex9ert,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Rattus norvegicus,10116.0
2592,,,,B,,,BzO000035y,H,12884,CHEMhLy17460,,,,,Exlert,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,
2593,,,,B,,,BwO0000367,H,13149,CjEMBL617462,,,,,Expegt,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,
2594,,,,B,,,BAp0090019,D,15295,CtEMfL617462,,,,,Expdrt,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Rattus norvegicus,10116.0
2595,,,,B,,,BAOo009357,H,15740,CtEMBL717463,,,,,Ahtocura5ion,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,
2596,,,,B,,,BAp00o0019,H,15185,CH2MBL6w7464,,,,,Autocuragiom,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,
2597,,,,B,,,Bs90000019,H,15185,xHEMBL627465,,,,,A8tocurati0n,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,
2598,,,,B,,,BAO0o0001i,H,17529,CHEMfL6174u6,,,,,Expe3t,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,
2599,,,,B,,,BAO090p019,H,14826,CHEMnL627467,,,,,wutocuratipn,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2600,,,,B,,,BAO0o00919,H,17211,vmEMBL617468,,,,,4xpert,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,
2601,,,,B,,,BApp000019,H,14826,sHEMBL618469,,,,,Aufocurafion,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2602,,,,B,,,BAO0o0p019,H,14093,sH4MBL617470,,,,,Autoc7rat7on,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2603,,,,B,,,BAO00000qo,H,14093,CmEMfL617471,,,,,Autocurahiin,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,
2604,,bIH3T3,,B,,,BqO00002w9,H,13246,CHEMBLt17473,,,,,Exoert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,
2605,,,,B,,,BAOo000347,H,13246,CmEMBL6174y3,,,,,Exper4,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,
2606,,,,B,,,gAO0900019,D,15436,CuEMBL617464,,,,,Expe4t,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,10116.0
2607,,,,B,,,BAO00090q9,D,15436,CHEjBL517475,,,,,Exprrt,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,10116.0
2608,,,,B,627892.0,Bra9n,BA80090221,H,14442,vHEMBo617476,,,,,Autofurstion,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,
2609,,,,B,,,BAO0o0p357,H,12457,CHwMBL617467,,,,,Edpert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,
2610,,bIH3T3,,B,,,BAO00o9219,H,12457,CHEjBLu17478,,,,,Exprrt,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,
2611,,,,F,,,BAO00op221,H,14755,CHEjBL61747o,,,,,Autocutatoon,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,
2612,,,,B,,,BxO0009357,H,4707,CHEMBL6174oo,,,,,Autocurz5ion,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,
2613,,,,B,,,BAO90p0357,H,13297,CgEjBL617481,,,,,Expedt,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2614,,,,B,,,BAO0000918,H,17331,CHsMBL6174o2,,,,,Ezpert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,
2615,,,,B,,,BAi000o019,H,4664,CHEMno617483,,,,,Aitocurarion,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,
2616,,,,B,,,BAi0000356,H,16633,CmEMBL611528,,,,,A7tlcuration,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2617,,bIH3T3,,B,,,vAOp000219,D,4664,CHEMgL62q529,,,,,Expeft,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Rattus norvegicus,10116.0
2618,,,,B,,,BAO0090r57,H,16133,CHEMBou21530,,,,,Expe3t,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2619,,,,B,,,BAO00p0356,H,16133,CyEMBo621531,,,,,3xpert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2620,,,,B,,,BA00009019,D,14060,CHEnBL621432,,,,,Expedt,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2621,,,,B,,,BAO00003r8,H,16326,CHdMBL621433,,,,,Exoert,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2622,,CHO,,B,,,BA0o000219,H,16659,CHsMBL62153r,,,,,Espert,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2623,,,,B,,,vA90000019,H,14776,dHEMBL621r35,,,,,Aitocurwtion,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,
2624,,,,B,,,BA9000o357,H,13481,CHfnBL621536,,,,,Autoc6rqtion,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2625,,,,B,,,BAk0p00357,H,17386,CHEMBLy21437,,,,,A7tpcuration,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,
2626,,,,B,,,hAO0009357,D,6611,CHwMBL6q1538,,,,,wxpert,Binding affinity for 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2627,,,,B,,,BAO090p019,H,14423,CHEhBL621r39,,,,,Autocu4ati8n,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,
2628,,,,B,,,BAO009o019,H,15412,CHEMBk62154p,,,,,wutocurxtion,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,
2629,,,,B,,,BAk0000p19,H,15412,CHEMBLu2154q,,,,,Augockration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,
2630,,,,B,,,fAO0090019,H,6238,CnEMnL621542,,,,,Autocugagion,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,
2631,,,,B,,,BAko000357,H,6648,CHEMhL6w1543,,,,,Experg,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,
2632,,,,B,,,BAp000o357,H,5667,CHEMBL6214e4,,,,,rxpert,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,
2633,,,,B,,,BAO00o03r7,D,6611,fH2MBL621545,,,,,Expfrt,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Rattus norvegicus,10116.0
2634,,,,B,,,BAO00o03r7,H,13481,dHEMBL62154t,,,,,wutocu4ation,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2635,,,,B,,,fAO000035i,H,13481,CHEMBL621t57,,,,,qu4ocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,
2636,,NIH4T3,,B,,,BAl0000w19,H,15558,fnEMBL618692,,,,,Exper5,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,
2637,,,,B,,,BAO09o0357,H,6013,fHEMBL61u693,,,,,Autocutayion,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2638,,,,B,,,nAO0o00357,H,16633,CHsMBLi72922,,,,,Au5ocuratiom,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2639,,,,B,,,BAO00o0r57,H,6013,CHEMBL628u94,,,,,Autodurstion,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,
2640,,,,B,,,BAO0000w47,D,6013,xjEMBL618695,,,,,Ex9ert,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Rattus norvegicus,10116.0
2641,,,,B,,,BA80090357,H,6013,CHEMBLuw8696,,,,,Aurovuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,
2642,,,,B,,,gA80000357,H,6013,CHEMBL6q8687,,,,,Expe4t,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,
2643,,,,B,,,fAO000035i,H,6013,CHEMfL628892,,,,,Aut8curatipn,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,
2644,,,,B,,,BA0000o357,H,6013,CHdkBL618893,,,,,Autocurqti8n,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,
2645,,,,B,,,BxO0000356,H,16293,CHEMhLu18894,,,,,Au4ocura4ion,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2646,,NIH3Tr,,B,,,vxO0000219,H,17175,CHEMBL61880t,,,,,Edpert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,
2647,,,,B,,,fAO0000e57,D,13278,CHsMBL61889y,,,,,Experh,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,10116.0
2648,,,,B,2087704.0,fajdateputamen,gAO00000w9,H,3682,fHEMfL618897,,,,,Aur9curation,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,
2649,,,,B,,,BzOo000357,H,2014,CHEMgL6188i8,,,,,Augocuratiob,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,
2650,,,,B,,,nAO0p00357,H,2014,xjEMBL618899,,,,,Autlcuratuon,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,
2651,,,,B,,,BAO0000rr7,H,4932,CHEMBL718909,,,,,Autosuratiog,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,
2652,,,,B,,,BzO0000p19,H,4932,CHEjBL618991,,,,,Au4ovuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,
2653,,,,B,,,BAi00003r7,H,3935,CHEMBL618092,,,,,Auy8curation,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,
2654,,,,B,1904984.0,Hipoocampjs,BqO0000321,D,5432,CHEMBoy18903,,,,,Exper5,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2655,,,,B,,,BAl0000457,H,15818,CHEMBL619o04,,,,,Aut8cyration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2656,,,,B,,,BAO000o3r7,H,13672,CHEMBLy189o5,,,,,Augocurat9on,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,
2657,,,,B,,,fAO00o0357,H,13672,CHEhBL618996,,,,,Autocyratiog,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,
2658,,NIH3Te,,B,,,BAO00p02w9,H,14749,CHfMBL618997,,,,,3xpert,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,
2659,,,,B,,,BAO000901p,H,13462,CHEMBo6189p8,,,,,Autofuratioh,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,
2660,,,,B,,,hAO0o00357,H,15740,CHfkBL617909,,,,,A8tocurxtion,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2661,,,,B,,,BAO090001i,H,16647,xuEMBL617910,,,,,rxpert,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2662,,,,B,233233.0,Braij,BzO0900221,H,13345,CHrMBo617911,,,,,Autoxiration,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,
2663,,,,B,,,BAOp0p0249,H,16740,CHEMBL872oq3,,,,,A6tocugation,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2664,,,,B,,,BAO000025o,H,16740,CHfMBL61i912,,,,,Augocu3ation,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2665,,,,B,,,hzO0000019,D,15535,CHEMBL6189q3,,,,,Exper6,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Rattus norvegicus,10116.0
2666,,,,B,,,BwOp000249,H,16740,Cj4MBL617914,,,,,Exprrt,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2667,,,,B,,,hAO0p00249,H,16740,CHsMfL617915,,,,,Autoc6rati8n,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2668,,,,B,,,vAO000024o,H,16740,CbEjBL617916,,,,,Autocu3agion,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2669,,,,B,,,BAOp000029,D,4795,CtEMBk617917,,,,,Exp4rt,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Rattus norvegicus,10116.0
2670,,,,B,,,BA8000001i,H,8,CbEMBL617919,,,,,Expe3t,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,
2671,,,,B,,,BAO0o90019,H,8,CHEkBL618919,,,,,Autocuratoom,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,
2672,,,,B,,,BAOp000o19,D,17200,CHEnBi617920,,,,,Ecpert,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,10116.0
2673,,,,B,,,BAO00000q0,D,2148,CHsMgL617921,,,,,Ecpert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Rattus norvegicus,10116.0
2674,,,,B,,,nAO00002e4,D,13345,sHEMBL617022,,,,,Eapert,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Rattus norvegicus,10116.0
2675,,,,B,,,BAO0000ey7,H,5088,fHEjBL617923,,,,,Autkcurat8on,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2676,,,,B,,,BAO0090356,H,5088,CHEMBi6w7924,,,,,Aut0curatuon,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2677,,,,B,,,fAO000p357,H,17133,vHEMhL617925,,,,,Autocutwtion,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,
2678,,,,B,,,hAO000o357,D,17133,vHEMBL6q7926,,,,,Exprrt,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Rattus norvegicus,10116.0
2679,,,,B,,,BsO0000356,H,16532,CHEMBL61u027,,,,,Aytochration,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,
2680,,,,B,,,BAl0009357,H,15086,CHEMnL617o28,,,,,Ajt8curation,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,
2681,,,,B,,,BAOo0o0019,D,2309,CHEMBL6qy929,,,,,Exlert,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,10116.0
2682,,,,B,,,nAO000p019,H,12953,CHEhBL617o30,,,,,Exlert,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,
2683,,,,B,,,BAk0000o19,H,12953,sHEMBL6w7931,,,,,Aufocudation,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,
2684,,,,B,,,BAO0p90019,H,12953,CHEMfL6w7932,,,,,Aufocuratiog,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,
2685,,CHO,,B,,,BsOo000219,H,16659,CHsMBL617p33,,,,,Autocu5ati0n,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,
2686,,,,B,,,BsO00000w9,H,16740,CHEMBLuq7934,,,,,Aut9cufation,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2687,,,,B,,,BAlp000019,H,16740,CHEMBL61y936,,,,,Autocu5atioj,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2688,,,,B,,,BAOp000r57,H,17133,CHEMhL617o36,,,,,Aitocu5ation,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,
2689,,,,B,,,BAO09000w9,H,17211,Ct4MBL617937,,,,,Aut0c6ration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,
2690,,,,B,,,BAO0000o1i,H,17331,CH2MBLy17938,,,,,Autoxuragion,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,
2691,,,,B,,,gAO000021i,H,16633,CHEMBL71793p,,,,,sutocurafion,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,
2692,,,,B,,,BAOo000228,H,16633,CHEMnL6w7940,,,,,xutocura5ion,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,
2693,,,,B,,,gA80000218,H,16633,CHEMBL6w794w,,,,,Autocu5at9on,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,
2694,,,,B,,,vAO0000w57,H,15026,CyEMhL617942,,,,,Experh,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,
2695,,,,B,,,nxO0000357,H,15026,CHEMBL61up43,,,,,Expsrt,Ratio of pKi of 5-HT2A to that of D2 receptor,,
2696,,,,B,,,Bxp0000224,H,16404,CHEMBL6w8944,,,,,Ex9ert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2697,,,,B,,,BAl00o0224,H,16404,CHEMBp61794t,,,,,Expe5t,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2698,,,,B,,,BAO9o00224,H,16404,CHEMnL617p46,,,,,Expwrt,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,
2699,,,,B,,,BA90090357,H,16404,CHEMBL616847,,,,,Autocurati9g,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,
2700,,,,B,,,BAk0000w57,H,16326,CHEjBi617948,,,,,Ex9ert,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,
2701,,,,F,,,BAO90o0019,H,15847,fHEMBL85811u,,,,,Ajtosuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,
2702,,,,F,,,gwO0000019,H,15847,CHEMvL617948,,,,,Autocieation,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,
2703,,,,F,,,nAk0000019,H,15329,CHEMBk61795p,,,,,Autocursti9n,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,
2704,,,,F,4035340.0,Thorwcica9rta,gAO0000p19,H,16404,CHEMBp6q7951,,,,,Exper5,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,
2705,,,,F,2326260.0,huoracicaorta,BAi0000029,H,16404,CHEMBL51u952,,,,,Ex9ert,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,
2706,,,,F,178319.0,Thoracidaofta,BAO00p00w9,H,16404,CHEMBL6qu953,,,,,Autocurqtioh,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,
2707,,,,B,,,BAOo000356,H,12861,CgEMBL717954,,,,,zut0curation,Binding activity radioligand.,,
2708,,,,B,,,BAi00o0019,H,12861,CHdMBL617855,,,,,Eapert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2709,,,,B,,,BA000o0019,H,12861,CuEMnL857071,,,,,wutocurqtion,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2710,,,,B,,,BAk0000o19,H,12490,CHEngL617270,,,,,Expeet,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,
2711,,N2E115,,B,,,BAO090o219,H,12827,dHfMBL617271,,,,,Autocueagion,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,
2712,,N1E1w5,,B,,,BAO000pw19,H,12827,CHrMBLy17272,,,,,qutocurati0n,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,
2713,,,,B,,,BAk000p019,H,12918,CH2MBL617263,,,,,Auyocuratkon,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,
2714,,,,F,,,hAO0000p19,D,12919,CmEMBL61727e,,,,,Experg,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Rattus norvegicus,10116.0
2715,,,,B,,,gAO0o00357,H,17723,fHEMBL517275,,,,,Autocutstion,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,
2716,,,,B,,,BA900003y7,H,6013,dHEMgL617276,,,,,Autocugztion,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2717,,,,B,,,BAO0009356,H,16293,CHEMBL62727i,,,,,Aufoduration,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,
2718,,,,B,,,BAO00o001i,H,3857,CHrMBL517278,,,,,Exoert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2719,,,,B,,,fAi0000019,H,3857,CHEMnL617w79,,,,,Exper5,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,
2720,,,,B,,,fAO000001p,H,3857,CHEMgp617280,,,,,Ex0ert,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2721,,,,B,,,vAO000p357,H,15363,CHEkBL61728w,,,,,Autocurztioh,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2722,,,,B,,,BAO00003y8,H,15363,CjEMBL61u282,,,,,Autocurar7on,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2723,,,,B,,,BsO0p00019,H,16441,dmEMBL617283,,,,,Ezpert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,
2724,,,,B,,,BAk000o019,H,16441,CHEMBL6q728r,,,,,Edpert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,
2725,,HEK2i3,,B,,,BAO0o90219,H,4176,CHEMBpt17285,,,,,Autocurzhion,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,
2726,,,,B,,,nAO0000919,H,17085,CHEMBLy27286,,,,,Ahtocjration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,
2727,,,,B,,,BAO00o0e57,D,17200,CH4MBL6172u7,,,,,Edpert,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Homo sapiens,9606.0
2728,,,,B,,,BAO00o035y,H,5088,CbEMBL616288,,,,,Expfrt,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,
2729,,,,B,,,BAk0009357,H,5088,CHEMBL627w89,,,,,Augocuratiln,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,
2730,,,,B,,,BAO0909357,H,5088,CHEMgL8i2917,,,,,Autocuratk0n,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2731,,,,B,,,BAO90003y7,H,5088,CHEkBL617299,,,,,Auyocuratiln,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2732,,CHO,,B,,,Bzk0000219,H,16659,CH3MBp617291,,,,,wutocurztion,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2733,,CHO,,B,,,BAOoo00219,H,16659,CH4MBL61729w,,,,,wutoduration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,
2734,,NIH3T2,,B,,,BAl00p0219,H,17451,CHEMgL717293,,,,,Autocufa5ion,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2735,,CHO,,F,,,BAO0o002q9,D,6857,xH4MBL617294,,,,,Experr,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9606.0
2736,,,,B,,,BxO0p00019,H,3857,CHEMBL61i294,,,,,Ecpert,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2737,,,,B,,,BAO0o003y7,H,12861,CHEMnL618296,,,,,Autovurwtion,Binding activity radioligand.,,
2738,,,,B,,,BAO0000oq9,H,12861,dHwMBL617297,,,,,qitocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2739,,CHO,,B,,,BwOo000219,H,5104,CHEMgi617298,,,,,Experh,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,
2740,,CHO,,B,,,vAp0000219,H,5105,CHEMBL627e99,,,,,Expery,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,
2741,,CHO,,B,,,BAO0p00229,H,5105,CHEMhL6q7300,,,,,Autpcurstion,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,
2742,,,,B,,,BAl000035u,H,5254,CHEMBL616554,,,,,wutocjration,Binding affinity against 5-HT2C receptor,,
2743,,HEK2o3,,B,,,BAO0p90219,H,13267,CHEMnL6175p5,,,,,Aut0curatkon,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2744,,HEK203,,B,,,BAOp000w19,D,14157,CHEMBL617605,,,,,Exprrt,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Homo sapiens,9606.0
2745,,HEK393,,B,,,BAO009021o,D,12936,xHEMBp617507,,,,,Exoert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,9606.0
2746,,,,B,,,BAO0p00356,H,14068,CHEMBL617t0o,,,,,Experf,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,
2747,,HEj293,,B,,,BqO0009219,D,12936,CHEkBL85798e,,,,,Expedt,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,9606.0
2748,,HEK294,,B,,,BAO0090119,D,4540,CHEMhL617500,,,,,Expett,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Homo sapiens,9606.0
2749,,HEKe93,,B,,,hAk0000219,D,4540,CuEMBL61y510,,,,,Expett,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Homo sapiens,9606.0
2750,,,,B,,,BAOo0o0357,H,6166,CH2MBL616511,,,,,Autixuration,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,
2751,,HwK293,,B,,,BAO00o0q19,H,17296,fHEjBL617512,,,,,Au6ocugation,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,
2752,,HEK294,,B,,,nAO0009219,H,17296,CjEMBL61774o,,,,,Auhocuratlon,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,
2753,,HEK29w,,B,,,BxO0000218,H,15779,CHEMgL61u750,,,,,Aytocurat7on,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2754,,HEo293,,B,,,BAO0009q19,H,15779,CHEMBLy17741,,,,,sutocuragion,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2755,,HEo293,,B,,,BAO00o9219,H,14391,xHEMBp617752,,,,,dxpert,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,
2756,,HEK29r,,B,,,BA000002q9,H,15779,CHEMBLu17u53,,,,,qutosuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,
2757,,HEi293,,B,,,BzO000p219,H,15851,CHEMBL61u654,,,,,2xpert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,
2758,,HEK2o3,,B,,,vAO0900219,D,15851,CgEMBL617745,,,,,Exper5,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Homo sapiens,9606.0
2759,,HEm293,,B,,,hqO0000219,H,15779,fHEMBL617766,,,,,wutocuratiln,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,
2760,,HEK29e,,B,,,BAO00002qo,H,3832,CHEMvL617657,,,,,Experf,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,
2761,,HEK29r,,B,,,hAO0090219,H,3833,CuEMBo617758,,,,,Expedt,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,
2762,,NIH3Tw,,B,,,BAi00002w9,H,17451,CHEMBi617u59,,,,,Autocu4atiog,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2763,,jEK293,,B,,,BAO90002q9,H,4199,fHfMBL617760,,,,,Autoxurat7on,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,
2764,,CH0K1,,B,,,BAOo0p0219,H,1883,CHEMBL61y7u1,,,,,Exp4rt,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,
2765,,,,B,,,BAO000p347,D,4321,CmEMBL61u762,,,,,Exoert,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,9606.0
2766,,,,B,,,fA90000357,H,14875,CHEMhL616763,,,,,Aktocurxtion,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,
2767,,H2K293,,B,,,BAO90002w9,H,15146,CHEMgL85798r,,,,,qutocurati8n,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,
2768,,HEK2p3,,B,,,BAOo00o219,H,5213,CHEMBL6q7763,,,,,Augocuratiom,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,
2769,,HeLa,,B,,,hAOo000219,H,16404,CHEhBL6177u5,,,,,Aytocyration,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,
2770,,,,F,,,BsO0000018,H,13267,CgEMBL717766,,,,,zutocura4ion,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,
2771,,,,F,1056595.0,Hippocqmous,vAO0000w21,H,13267,CHEMBL616u67,,,,,Autosuratjon,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,
2772,,HEK2o3,,B,,,gAO0000w19,H,14818,dHEMBL6177y8,,,,,Ajtpcuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,
2773,,HEK2o3,,B,,,BAO00902w9,H,4829,CHEMBL517760,,,,,Autocuratiim,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,
2774,,,,B,,,BAl000o357,H,13463,Cu3MBL858023,,,,,Autoc6ratikn,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,
2775,,,,B,4880379.0,Stomacn,fAO0p00019,H,13463,CnEMBL627770,,,,,A6tocura6ion,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,
2776,,,,B,416555.0,Stomacg,BAl00p0019,H,13463,CHEMBk617i71,,,,,Aut0curwtion,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,
2777,,A9,,F,,,BAO000p210,H,12652,CH3MBL517772,,,,,Autoc7rwtion,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,
2778,,N9H3T3,,B,,,nxO0000219,H,4682,CHEMBL61ui73,,,,,xu4ocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2779,,NIH343,,B,,,vAO00002w9,H,4682,CHEMgo617850,,,,,xut8curation,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,
2780,,NIH3Te,,B,,,BAO0p0p219,H,4682,CHEMBL617u5w,,,,,Autocirqtion,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2781,,,,F,,,BA00009019,H,12652,fHEMBL627852,,,,,qufocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,
2782,,,,B,1510835.0,Stomaxh,BxO0009019,H,13463,CHEMBL7580q4,,,,,wutocuratiln,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Mus musculus,10090.0
2783,,,,B,447341.0,Stomacn,BA8p000019,D,13463,CHEMni617853,,,,,Expery,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Rattus norvegicus,10116.0
2784,,,,B,,,BAp0000367,H,13969,CjEMBL61i854,,,,,Edpert,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,
2785,,,,B,,,vwO0000357,H,13392,xjEMBL873477,,,,,Exprrt,Binding affinity for 5-hydroxytryptamine 2C receptor,Sus scrofa,9823.0
2786,,,,B,,,BAOp000356,H,13392,CHEMBkt17855,,,,,Expdrt,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2787,,,,B,,,BA90000029,H,14430,CHEMgL6178r6,,,,,Exp2rt,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,
2788,,,,B,,,BAO0o000q9,H,1742,CHEMvL6178y7,,,,,Autocudat9on,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,
2789,,,,B,,,Bq80000249,H,14286,CHEhhL617858,,,,,Autlcuratiln,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,
2790,,,,B,,,BAO90003t7,H,5619,CbEMBL6q7859,,,,,Autof6ration,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,
2791,,,,B,,,BAO000o367,H,15086,sHEMBL618860,,,,,xutosuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2792,,,,B,,,BAO9000367,H,12861,CnEMBL618861,,,,,A6tofuration,Binding activity radioligand.,,
2793,,,,B,,,BA00090019,H,12861,CufMBL617862,,,,,sxpert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2794,,,,B,,,BAO90000w9,H,12861,CHEMBL6w7862,,,,,Au4ocuragion,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2795,,,,B,,,BAO900p249,H,12827,CHEhBL6q7864,,,,,Autosufation,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,
2796,,,,B,,,Bxk0000249,H,12827,vHEnBL617649,,,,,Aitocugation,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,
2797,,,,F,,,BAO009001i,H,12919,CHfMBi617650,,,,,3xpert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,9823.0
2798,,,,F,,,vAO00o0019,H,12919,CHEMBk517651,,,,,Espert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,9823.0
2799,,,,B,,,BAO090035u,H,16429,CHfMBo617652,,,,,Autocutqtion,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Sus scrofa,9823.0
2800,,,,B,,,BAOop00019,H,773,CH4MBL8y7072,,,,,Ah6ocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Sus scrofa,9823.0
2801,,,,B,,,BAO0o90357,H,5033,CHwMBL617u53,,,,,zutocutation,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Sus scrofa,9823.0
2802,,,,B,,,nA00000019,H,12861,CHEMvk617654,,,,,Autocugatiob,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2803,,,,F,,,vAO0000010,H,14093,CgEMBL61765r,,,,,Aurosuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,
2804,,,,B,,,BxO000o357,H,14970,CurMBL617656,,,,,Espert,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,
2805,,,,B,,,BAOp090357,H,14970,CgEMBo617657,,,,,Autocuratuob,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,
2806,,,,B,,,Bzl0000357,H,14970,CHEMfL61y658,,,,,Autoc7ratkon,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,
2807,,,,B,,,gAO000035y,D,14178,CHEMBL61i6r9,,,,,Exoert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,10116.0
2808,,,,B,,,BAp0000257,D,14178,CHEMBLt178r8,,,,,Expfrt,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,10116.0
2809,,,,B,,,vAO0000q49,D,14229,CuEMBL617u39,,,,Brainm2mbfanes,Expsrt,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Rattus norvegicus,10116.0
2810,,,,B,,,gwO0000357,H,16532,CbEMBL627840,,,,,Autoviration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,
2811,,,,B,,,BA00000o19,H,14826,CHEMBo61i841,,,,,qutocurahion,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,
2812,,,,B,,,BAO0009919,H,17211,CyEMBL87t915,,,,,Autocuratiib,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,
2813,,,,B,,,BwO00002q9,H,17211,CHEMBL6177t2,,8nvitro,,,dxpert,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,
2814,,NIH3h3,,B,,,BAO000p21p,H,13246,CHEMBk618843,,,,,Exper5,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,
2815,,,,B,,,BAOp0p0357,H,13246,CHEMBLu1y844,,,,,Expe5t,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,
2816,,,,B,,,BAOpo00357,H,12457,CyEMBL617835,,,,,Expe3t,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,
2817,,NIy3T3,,B,,,BAO0p0021i,H,12457,CmEMBL717846,,,,,Experr,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,
2818,,,,B,,,BqO0o00357,H,4707,CH4MBL617846,,,,,Aut0curat8on,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,
2819,,,,B,,,BqO000035i,H,13297,CHEMBLu178r8,,,,,Ezpert,Binding affinity against 5-hydroxytryptamine 2C receptor,,
2820,,,,B,,,BA90900357,H,16633,vuEMBL617849,,,,,A7tocuratoon,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2821,,,,B,,,BAO0p0035u,H,16133,CbdMBL621507,,,,,Exper4,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2822,,,,B,,,BAO00o9357,H,16326,dHEMBL621507,,,,,Expfrt,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,
2823,,,,B,,,BxOp000019,H,14423,sHEMgL621509,,,,,Aut8cu3ation,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,
2824,,,,B,,,BAO00p0o19,H,15412,xHEMBL621410,,,,,zutocu4ation,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,
2825,,,,B,,,nAO00000q9,H,15412,CHEMBLu22511,,,,,Autocirati9n,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,
2826,,A9,,B,,,BAO00902q9,H,15558,CHEkBL621412,,,,,wxpert,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,
2827,,,,B,,,BAi000035y,H,16633,CHEMBky21513,,,,,Autocurstiln,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2828,,,,B,,,BAO0000e56,H,6013,CH2nBL621514,,,,,Exper4,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,
2829,,,,B,,,BAO00p021i,H,17175,CHEhBL621y15,,Incitro,,,Exper5,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,
2830,,,,B,,,nAO000p219,H,12469,CmEMBi621516,,,,,Autockratipn,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,
2831,,,,B,493420.0,dauda6eputamen,BqO0000o19,H,3682,CHEMBp6215q7,,,,,Autoxkration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,
2832,,,,B,,,hsO0000357,H,4932,CgEMBL6215q8,,,,,Autkcurqtion,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,
2833,,,,B,,,BAOo000919,H,4932,CHEhBL62151i,,,,,xutocurati8n,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,
2834,,,,B,,,BAO00oo357,H,3935,CHEMBL6216w0,,,,,Augoxuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,
2835,,,,B,,,BAk00003r7,H,15818,dHEMBL6w1521,,,,,Autocurwrion,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,
2836,,,,B,,,BqO0090357,H,15818,CtEMBL622522,,,,,Augocurxtion,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,
2837,,,,B,,,BAO000pw19,H,14749,CHEkBL62152w,,,,,Expwrt,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,
2838,,,,B,,,BAO00002r7,H,15740,CHEMBL6w2524,,,,,Autocurari9n,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,
2839,,,,B,,,Bzl0000357,D,17133,CHdMBL6q1525,,,,,Ecpert,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Rattus norvegicus,10116.0
2840,,,,B,,,vAO0000358,H,16532,CHEjBL8y2921,,,,,Au4ocuratipn,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,
2841,,,,B,,,BAOo00p357,H,12369,CHEhnL621526,,,,,Autoc8rxtion,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,
2842,,,,B,,,BA80p00219,H,12369,CjEMBL721527,,,,,Experf,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,
2843,,,,B,,,BAO0000p10,D,2309,CHEMBL61776t,,,,,Espert,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Rattus norvegicus,10116.0
2844,,,,B,,,fAi0000357,H,12953,CuEMfL617866,,,,,Aut9suration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,
2845,,,,B,,,vAO000p019,H,12953,CHEMBo617767,,,,,Autoxjration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,
2846,,,,B,,,BAO0o0p357,H,12953,dHEMBL61748i,,,,,Au5icuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,
2847,,,,B,,,BAO000pe57,H,12953,CHEMnL617487,,,,,dxpert,Binding affinity for 5-hydroxytryptamine 2C receptor,,
2848,,,,B,,,BAO009p357,H,17133,CHEMBL6q7t89,,,,,Aut0curatuon,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,
2849,,,,B,,,fqO0000019,H,17211,CmEMvL617490,,,,,Autocurari9n,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,
2850,,,,B,,,BAO0909019,H,17211,CHrnBL617491,,,,,A8ticuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,
2851,,,,B,,,BAO0099019,H,14025,CmdMBL617492,,,,,Ak5ocuration,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,
2852,,,,B,,,BAO0009919,H,14998,fHEhBL617493,,,,,Autocura5i0n,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,
2853,,,,B,,,BAO0000wt7,H,4342,CHEMBL617593,,,,,A6tocuratioh,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,
2854,,,,B,,,BA900p0019,D,13735,CHEMBL6q7395,,,,,Exper6,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Rattus norvegicus,10116.0
2855,,,,B,,,BAO0o00257,H,13181,CHEjBL617406,,,,,Augocuratjon,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2856,,CnOK1,,B,,,nAO000021o,H,1883,CHEMBL61739i,,,,,sutoxuration,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,
2857,,,,B,,,BxO00o0357,H,15194,CHEMBi61749i,,,,,Autocurati8g,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2858,,,,B,,,BAO0000456,H,15194,CHEMBL6w7498,,,,,qutocurafion,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,
2859,,,,F,,,nAk0000019,H,14579,CHEMBL617490,,,,,Aurocuratuon,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,
2860,,,,B,,,BAO00oo357,H,4639,CbEMBL6q7501,,,,,Auroxuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2861,,,,B,,,hAO0090357,H,4820,CHEMBL61i50e,,,,,Expe5t,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2862,,,,B,,,BAOo000w57,H,14442,sHEMBL618503,,,,,Autocyrati9n,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,
2863,,,,B,,,BAO00o0w57,H,14755,CHEhBL617503,,,,,Autocjgation,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,
2864,,,,B,,,BAi0090357,H,14744,CtEMBL617306,,,,,Auticuratiln,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,
2865,,,,B,,,vsO0000019,D,6857,CHEMBp61i407,,,,,Expe5t,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Homo sapiens,9606.0
2866,,,,B,,,BzO00o0357,H,16209,CHEMBL51u408,,,,,Aitocyration,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,
2867,,,,B,,,BsO0000257,H,15363,CHEMBk61740p,,,,,Autoxuragion,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2868,,,,B,,,BwO00003y7,H,15363,CyEnBL617410,,,,,Autickration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2869,,,,B,,,BAO0o00457,H,15363,CHEMBLt16411,,,,,xutocuratkon,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,
2870,,,,B,,,hAO9000019,H,17085,CHEMBLt1i412,,,,,Autoc73ation,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,
2871,,,,B,,,BAO0990357,D,17200,vHEhBL617774,,,,,Ecpert,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Homo sapiens,9606.0
2872,,HEK283,,B,,,BAOp00p219,D,15851,CHEMBi617u75,,,,,Expwrt,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,9606.0
2873,,HEK29r,,B,,,hAO9000219,D,15851,CHEMBLuw7776,,,,,Expett,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,9606.0
2874,,CHO,,F,,,BAl00002w9,D,6857,CHEhBL617677,,,,,Expeft,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9606.0
2875,,CHO,,F,,,fAO0000229,D,6857,CHEMBL6177y7,,,,,Expfrt,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9606.0
2876,,gEK293,,B,,,BAO000o2w9,H,15779,CHEMBL6q777p,,,,,Autofuratioj,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2877,,HEK203,,B,,,BAO00002q8,H,15851,CuEMnL617780,,,,,Exp4rt,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,
2878,,HEu293,,B,,,fAO0090219,H,15779,CHEMBL61u7u1,,,,,zutocurati0n,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,
2879,,HEm293,,B,,,BAO0000118,D,14157,CHEMvL617682,,,,,Exprrt,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Homo sapiens,9606.0
2880,,HEK2o3,,B,,,BAO00o0229,D,4540,CH2MBL6177u3,,,,,Expedt,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Homo sapiens,9606.0
2881,,,,B,,,BAOp0003y7,H,6166,CHEMBL727784,,,,,Autocuratlln,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,
2882,,HEKq93,,B,,,BzO9000219,H,15779,CHEMBL617794,,,,,Auticuratioj,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,
2883,,HEo293,,B,,,BwO00002q9,H,14391,CHEMfp857984,,,,,Eapert,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,
2884,,HEK2p3,,B,,,BAO000p229,H,3832,CHEMBL6177u5,,,,,2xpert,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,
2885,,HEi293,,B,,,BAO900021o,H,3833,CHEMvL617687,,,,,Ezpert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,
2886,,HEK203,,B,,,BAOop00219,D,15851,CHEMBL61yu88,,,,,Expedt,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Homo sapiens,9606.0
2887,,yEK293,,B,,,BAO0p002q9,D,15851,CHEMBL61779i,,,,,Exprrt,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,9606.0
2888,,mEK293,,B,,,BAO0000qw9,H,4199,sHEMBL617700,,,,,sutocurwtion,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,
2889,,CnOK1,,B,,,BxO0009219,H,1883,CHEMhL6q7791,,,,,Expeet,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,
2890,,,,B,,,vAO9000357,H,4321,vHEMBLu17608,,,,,Ecpert,Binding affinity against 5-hydroxytryptamine 2B receptor,,
2891,,HEK2o3,,B,,,BA80p00219,H,15146,CHEMnL61i609,,,,,Au6ocurat9on,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,
2892,,HEi293,,B,,,BAO00902w9,H,5213,CHEnBL6w7610,,,,,sutochration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2893,,HEK393,,B,,,hAk0000219,H,14818,CHEhBL627611,,,,,Auyocuratlon,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,
2894,,HEKw93,,B,,,BAOp0002q9,H,4829,CHEMBL627611,,,,,Autocurat7ob,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2895,,uEK293,,B,,,BAi000o219,H,4829,CuEMBLt17613,,,,,Aktocu3ation,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2896,,,,B,,,nAO0900019,H,14025,CHEMBL61861r,,,,,Autocu4wtion,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Oryctolagus cuniculus,9986.0
2897,,,,B,76672.0,etomach,hAO0090019,H,13463,smEMBL617615,,,,,Exlert,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,
2898,,,,B,88458.0,S5omach,BAO00003yy,H,7259,CHEMBL858wq4,,,,,Ex0ert,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,
2899,,,,B,932400.0,Stonach,BsO000035y,H,7259,CHEMfLt17616,,,,,Autocyratipn,Affinity against serotonergic receptor in the isolated rat stomach fundus,,
2900,,,,F,126551.0,Stomacm,BAO000o010,D,7185,CHEMBLy17616,,,,,Exper5,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Rattus norvegicus,10116.0
2901,,,,F,,,Bq00000019,D,7185,fjEMBL875914,,,,,Espert,Antagonistic against 5-hydroxytryptamine 2B receptor,Rattus norvegicus,10116.0
2902,,,,F,1144079.0,dtomach,BAO0000o1o,H,13267,CHEMho617618,,,,,Autocufatiin,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,
2903,,,,B,1641901.0,St0mach,fAOo000357,D,13735,CHEMBL61i6w9,,,,,Exp3rt,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Rattus norvegicus,10116.0
2904,,,,F,,,fAO9000019,H,15738,CHEMBL61u6e0,,,,,xutocu4ation,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,
2905,,,,F,,,BAOo090019,H,15738,CHEMnL617u21,,,,,A7tocurztion,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,
2906,,,,F,,,nAO000001o,H,15738,CmEMBL61u622,,,,,xut8curation,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,
2907,,,,B,2147778.0,S4omach,BAO0990357,D,12936,CHEMBLy17t23,,,,,2xpert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,10116.0
2908,,,,B,4794118.0,Stomacu,BAk0000r57,D,12936,CHEMhL617625,,,,,Exp4rt,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,10116.0
2909,,,,B,267310.0,Stomacm,BAO0000346,D,12936,CHEMnL616625,,,,,Experg,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,10116.0
2910,,,,B,147748.0,Stomash,BAOo0p0357,D,12936,CHfnBL617626,,,,,Exp4rt,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,10116.0
2911,,,,F,507899.0,Sgomach,BxO000001i,H,16404,fHEkBL617627,,,,,Aut9curat9on,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2912,,,,F,232379.0,Stomacn,nqO0000019,H,16404,CgEMBL617t28,,,,,Exlert,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2913,,,,F,1023484.0,Stohach,BA900000w9,H,16404,CuEMBi617629,,,,,Autoxurxtion,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,
2914,,,,F,3104327.0,qtomach,hAO000p019,H,16404,CHEMBLuy8115,,,,,Ait9curation,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,
2915,,,,F,3240488.0,Stomadh,BAOp0000q9,D,16404,CHEMBLt27630,,,,,Expwrt,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Rattus norvegicus,10116.0
2916,,,,F,424884.0,Thoracicsogta,BzOo000019,H,16404,CHEMBLy27631,,,,,Autocyragion,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,
2917,,,,B,,,BAk0000347,H,7483,CbEMBL517632,,,,,Autocutatiob,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2918,,,,B,,,BAOo000e57,H,7483,CHEMBL61ut33,,,,,Exlert,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,
2919,,,,B,,,BAOo0003t7,H,7483,CHEMBL617ye4,,,,,Au60curation,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2920,,,,B,,,BAO0o09357,H,7483,CHEnBL617y35,,,,,Aitoc6ration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,
2922,,,,F,3473521.0,qtomach,BAO90000w9,D,16404,CHEMBL6qy637,,,,,Autkcurafion,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Rattus norvegicus,10116.0
2923,,,,B,,,hAO000035y,H,6347,CtEMBL6w7638,,,,,Autlcjration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
2924,,,,B,,,BxO00003y7,H,4373,CHEMvL61763i,,,,,Autof6ration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,
2925,,,,B,,,BxO000o357,H,4373,CjEMnL617640,,,,,A8toduration,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,
2926,,,,B,,,BAO0000e67,H,4687,CyEMBL617541,,,,,Autosurat8on,Evaluated for the binding affinity to 5-HT 2B receptor,,
2927,,,,B,,,BAO0900367,H,16946,sHwMBL617642,,,,,Auticu4ation,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,
2928,,,,B,,,nAO000o357,H,16633,CHsMBL61764w,,,,,Auticu3ation,Binding affinities against 5-hydroxytryptamine 2B receptor,,
2929,,,,B,,,BA99000357,H,16633,CHEMBLy27644,,,,,Auyocurztion,Binding affinities towards 5-hydroxytryptamine 2B receptor,,
2930,,,,B,,,BqO0000457,H,16633,CHEkvL617645,,,,,A7tocyration,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,
2931,,,,B,,,nAOp000357,H,15026,CHEMBLt17u46,,,,,Espert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,
2932,,,,B,,,BAO9o00357,H,15738,CHEMBL6q7u47,,,,,Autocura57on,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,9913.0
2933,,,,B,,,nAOp000357,H,15738,dHEMBL6q7648,,,,,Autlcuratiin,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Bos taurus,9913.0
2934,,,,B,,,BAl0o00357,H,15738,xHEhBL617875,,,,,Aktpcuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Bos taurus,9913.0
2935,,,,B,,,BAp9000357,H,15738,CH4MhL617876,,,,,Au6osuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Bos taurus,9913.0
2936,,,,B,,,BAl000p357,H,16404,CHEMBL6178yi,,,,,4xpert,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Bos taurus,9913.0
2937,,,,B,,,BzO00o0357,H,15026,CHEMBL617u88,,,,,Expe5t,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Bos taurus,9913.0
2938,,,,B,,,BwO0000e57,H,15738,CHsMBL6q7879,,,,,qutocuratlon,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,9913.0
2939,,,,B,,,BAO090o019,H,16312,CHEMhL617870,,,,,Autocurqti0n,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Cavia porcellus,10141.0
2940,,,,B,2001305.0,Sttiatum,Bxk0000357,D,5486,CHEMBL6q78i1,,,,,Intermefiafe,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Cavia porcellus,10141.0
2941,,,,B,,,BAO0000wy7,H,5254,CHEMBLo58073,,,,,Autodurqtion,Binding affinity against 5-HT1A receptor,,
2942,,CHO,,F,,,BqO9000219,H,3857,CHwMBL6q7882,,,,,Experg,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,
2943,,CHO,,F,,,BAOop00219,D,6857,xHEMnL617883,,,,,Ex0ert,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9606.0
2944,,,,F,,,nAO000021p,H,4176,CHEMhp617884,,,,,Aut8curatuon,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,
2945,,CHO,,B,,,BAO0p0p219,H,6347,fHEMBL616885,,,,,Auyocuratlon,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,
2946,,CHO,,B,,,BAO000031p,H,6347,CHEMgL617o86,,,,,wutocu4ation,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,
2947,,,,B,,,hAO000p357,D,16146,CH4MBL6w7887,,,,,Expsrt,Inhibition of human 5-hydroxytryptamine 2C receptor,Homo sapiens,9606.0
2948,,,,B,,,fAO0000367,H,3805,CHEMBLyq7888,,,,,Au4ocurayion,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,
2949,,,,B,,,BAk0000o19,H,3857,sHEMBL616889,,,,,Autocurztiln,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2950,,,,B,,,BAOo00p357,H,5635,xHEMBL61i890,,,,,Autlcuratiln,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,
2951,,,,B,,,BAOp0003t7,H,5635,dyEMBL617891,,,,,Autocurahiin,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2952,,,,B,,,BAOoo00357,H,5635,CuEhBL617892,,,,,Aurocueation,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2953,,CHO,,B,,,fAO0090219,H,4012,CHEMBL71789r,,,,,Expery,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,
2954,,CHO,,B,,,fAO00p0219,H,6366,CHEMnL617893,,,,,Expedt,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,
2955,,CHO,,B,,,BAO0o00218,H,15949,CHEMBou17895,,,,,Ex9ert,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2956,,CHO,,B,,,BzOp000219,H,17211,CHEMBL61y89u,,,,,Autocudatioj,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,
2957,,,,B,,,BxO0p00357,D,6491,CHEMBLtw7897,,,,,Exlert,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Homo sapiens,9606.0
2958,,,,F,,,hAO0900019,H,14093,CHrMBL627898,,,,,Aktocjration,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,
2959,,,,F,,,BxO00p0019,H,13481,CHEMBp61789p,,,,,sutocurqtion,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2960,,CHO,,B,,,BAOo0p0219,H,6347,CHEMBLyq7900,,,,,dxpert,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Rattus norvegicus,10116.0
2961,,,,F,,,BAO0p00010,H,14093,CHEMBL61700w,,,,,Autoc8dation,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,
2962,,,,F,,,fAO0900019,H,14093,CHEMBL627903,,,,,Ajtofuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,
2963,,,,F,,,BAO00o0o19,H,13481,CHEMBL62u903,,,,,su5ocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2964,,,,B,,,BAO0900358,H,14442,CHEMhp617904,,,,,Autocurstiob,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,
2965,,,,B,,,BAOp00035i,H,14442,CHEMBL617895,,,,,Autpcurat8on,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,
2966,,,,B,,,Bqp0000357,H,14442,CHwhBL617906,,,,,Aufocurstion,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,
2967,,,,B,,,hAO00003r7,H,14755,CHwMBL617o07,,,,,Au4ocuratiog,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,
2968,,,,B,,,BAO090035y,H,14744,sHEMBL61790u,,,,,Autocurahiom,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,
2969,,CHO,,B,,,BAO000pw19,H,16659,CnEnBL620617,,,,,Exlert,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2970,,,,B,,,BAO0p000w9,D,6857,CHdMBL620518,,,,,Edpert,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Homo sapiens,9606.0
2971,,,,B,,,BA00000347,H,5635,CtEkBL620619,,,,,Exprrt,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,
2972,,,,B,,,BAi0090357,D,4234,dtEMBL620620,,,,,Expe5t,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Homo sapiens,9606.0
2973,,,,B,,,BsO00003y7,H,16209,CH3MBL62062w,,,,,Auticurstion,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,
2974,,,,B,,,BAO0p00q49,D,5778,CHdMBL872910,,,,kembranes,Autocurar9on,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Rattus norvegicus,10116.0
2975,,,,B,,,BA90p00223,H,5094,CHEMBL620t2e,,,,,Augocudation,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,
2976,,,,B,,,BqOo000019,D,809,sHEhBL620623,,,,,wutosuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Rattus norvegicus,10116.0
2977,,,,B,,,BAO00o00q9,H,1578,fHEMBL6e0624,,,,,Autocjratioj,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,
2978,,,,B,,,BAO000p029,H,809,vHEMBL620624,,,,,Aitocurat8on,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,
2979,,,,B,,,BwO0009219,H,12469,CHEMhL6e0626,,,,,Autocurat7oj,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,
2980,,,,B,,,hAO000o019,H,14290,CHEMBLu2130u,,,,,Autksuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,
2981,,,,B,,,Bzp0000019,H,14290,CHEMBL63130u,,,,,Autocurayiog,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,
2982,,,,B,,,gAO0o00223,H,10609,CjdMBL621309,,,,,Auroxuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,
2983,,,,B,,,BAO0o00323,H,10609,CHEjgL621310,,,,,Autovuratioh,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,
2984,,,,B,,,BA80000323,H,10609,CHEMBLu2131w,,,,,Autocurat8og,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,
2985,,,,B,,,BsO0000q49,H,15253,CbEMBL622502,,,,,Autoduratiog,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2986,,,,B,,,BA00000q49,H,15253,sHEMBk621503,,,,,Augocuratkon,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2987,,,,B,,,BwO0o00249,H,11683,CHEMnL621604,,,,Membranfs,Au6ocuratikn,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,
2988,,,,B,,,BAO0090123,H,12092,CgEMBL611505,,,,,Aut0curatjon,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,
2989,,,,B,,,BAOo00001o,H,1946,CH4MnL621506,,,,,Autocutarion,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
2990,,,,B,,,BAl0009223,H,11623,CHEkBL619791,,,,,Autoc6rstion,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,
2991,,,,B,,,BAO0090233,H,11623,dHrMBL619782,,,,,Autocuratj0n,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,
2992,,,,B,,,BAO090001p,H,14788,dHEMBL619773,,,,,Autoduratiln,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,
2993,,,,B,,,BAO90000q9,D,5432,CHwMBL619u84,,,,,Aitocu4ation,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Rattus norvegicus,10116.0
2994,,,,B,,,nAO00002r9,H,14826,dHwMBL619785,,,,,Autoc7ratiin,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
2995,,,,B,,,BAO00pp223,H,2222,CHEkBL618786,,,,,sutocuratiom,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
2996,,,,B,,,BAO0p000q9,H,11963,fHdMBL619787,,,,,Auticuratiom,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,
2997,,,,B,,,BsOo000019,H,14145,CbEMBLo72925,,,,,Autocurxtiin,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,
2998,,,,B,,,BA8000p019,H,17819,CHEhnL619788,,,,,qutocuratioj,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,
2999,,,,B,,,BAO00002eo,H,10394,CHEMBLy1i789,,,,,Aurovuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3000,,,,B,,,BAO0000e59,H,10394,CjEMBLy19790,,,,,qutocuratioj,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3001,,,,B,,,BA00000010,H,15034,fHEMBk619791,,,,,Aitocyration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3002,,,,B,,,BwO0000919,H,691,CHsMBL6q9792,,,,,sutockration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
3003,,,,B,,,BwO0o00249,H,12092,CHEMvk619793,,,,Mehbranes,qutocurstion,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,
3004,,,,B,,,vzO0000223,D,11752,CHEnBL61o794,,,,,qutocuratioj,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3005,,,,B,2542831.0,Braib,BA80000121,H,11752,CjEMBL61p795,,,,,qutocuratikn,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,
3006,,,,B,,,BAO00po019,H,301,fHEMBL618796,,,,,Autocurahiin,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,
3007,,,,B,,,BAO0p00q23,H,16532,CbEMBLt20448,,,,,Autofuratipn,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,
3008,,,,B,,,BA8000022r,H,16532,CHEMhL62p449,,,,,Aurocuratiob,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3009,,,,B,,,BAO0op0223,H,12092,CHdMBL6204t0,,,,,Aut0curatlon,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,
3010,,,,B,,,BAko000223,H,11684,CjEMBL6204t1,,,,,Auyoc7ration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,
3011,,,,B,,,BxO0000213,H,11684,CHEMvo620631,,,,,Auticuratikn,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,
3012,,,,B,,,BAO0090p19,H,12953,vHEMBL620633,,,,,Auhocuratioj,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,
3013,,,,B,,,BAOp000010,H,12953,xHEMBL630633,,,,,Aut9curat9on,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,
3014,,,,B,,,gAO00002q3,H,12953,CHEMBp6206w4,,,,,zut8curation,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,
3015,,,,B,,,BAO00009w9,H,12861,CHfMhL620635,,,,,Autocuray8on,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
3016,,,,F,,,BAO0000wq8,H,11454,fHEMBL620t36,,Inviv9,,,Autoc8ratjon,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3017,,,,F,,,BAp00002q8,H,11454,CHEMBLu20647,,Inviv8,,,Auypcuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,
3018,,,,F,,,BxO0p00218,H,11454,CHEkBL629638,,Invibo,,,Ahtovuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,
3019,,,,F,,,BAO0090228,H,11454,CmEMBL620t39,,Inbivo,,,Autocu3a5ion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,
3020,,,,F,,,vAO00o0218,H,11454,CHEMBL620u49,,Invigo,,,Autovufation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3021,,,,F,,,BzO000021o,H,11454,CHEngL620641,,Ijvivo,,,Aktocugation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,
3022,,,,F,,,BAO00p021i,H,11454,dHEMhL620642,,Inviv9,,,Autocurz5ion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,
3023,,,,F,,,BsO0000q18,H,11454,CHEjBL6206r3,,Ijvivo,,,Autofurafion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,
3024,,,,F,,,BxO000021o,H,11454,CHEMBLy2p644,,8nvivo,,,Autocyrwtion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,
3025,,,,F,,,BAOpo00218,H,11454,sHdMBL620645,,Invkvo,,,Autockdation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3026,,,,F,,,BA80000118,H,11454,CnwMBL620646,,Invuvo,,,Ahtocueation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,
3027,,,,F,,,BwO00002w8,H,11454,CuEMBL6206t7,,7nvivo,,,A6yocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,
3028,,,,F,,,BAO000ow18,H,11454,CHEMBL6306r8,,Invivk,,,Autocyratiog,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,
3029,,,,F,,,BAO0000qw8,H,11454,sHEMBo620649,,Inviv9,,,Augocurati9n,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3030,,,,F,,,fAO00002q8,H,11454,CHEMBLt20660,,7nvivo,,,xutosuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,
3031,,,,F,,,BAO00o021o,H,11454,fHEMBL62065w,,unvivo,,,Autocutayion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,
3032,,,,F,,,BAO0090w18,H,11454,CnEMgL872875,,Infivo,,,Autlckration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,
3033,,,,F,,,BsO0090218,H,11454,CHdMBL620651,,Igvivo,,,Aut9cyration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,
3034,,,,F,,,BzO00000q9,H,10609,CHEMBp6w0653,,,,,zutocutation,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,
3035,,,,B,,,BAi000001i,H,12861,CHEnBL85707y,,,,,Autlfuration,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,
3036,,,,B,,,BzO0900019,D,12861,CHEMBL620t53,,,,,Au5oc6ration,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3037,,,,B,,,BsO0900223,H,12861,CHEMBL6206ty,,,,,Autochra5ion,Binding activity radioligand.,,
3038,,,,B,,,BA99000249,H,10728,CHfjBL620656,,,,Brainmembeabes,Autlchration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,
3039,,,,B,,,fAOo000249,H,10728,CHEMBL62p557,,,,frainmemgranes,qutocuratiom,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,
3040,,,,B,,,BAO0op0357,H,5163,CHEMfL62p658,,,,,Autocurqgion,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,
3041,,,,B,,,BAO00oo357,H,5163,CHEMBL62o65o,,,,,Auh8curation,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,
3042,,,,B,,,BqO9000357,H,6011,dHfMBL620660,,,,,Autocyratiob,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,
3043,,,,B,,,BAO000o35y,H,5014,vHEMBL620t61,,,,,Autodura6ion,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,
3044,,,,B,,,BAO9o00357,H,5635,CHEMvL620y62,,,,,xutocuratiom,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,
3045,,,,B,,,BAOo900357,H,5163,dHEMBo620663,,,,,Expfrt,Affinity for 5-hydroxytryptamine 2C receptor,,
3046,,,,B,,,BAO09003y7,H,6841,CHEnBL6e0664,,,,,Autkfuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
3047,,,,B,,,BAO0009r57,H,6119,CHEMBL610y65,,,,,Exlert,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,
3048,,,,B,,,BAp0000367,H,4373,sH4MBL620666,,,,,Autocuragioj,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,
3049,,,,B,,,BwO00o0357,H,1633,CHEMfL620668,,,,,Autoduratiob,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,
3050,,,,B,,,BAO00004t7,H,1633,CHEMhL620678,,,,,rxpert,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,
3051,,,,B,,,hAO0000w57,H,4373,CmsMBL620669,,,,,Aut0curqtion,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,
3052,,,,B,,,BAio000357,H,6576,CHEjBL6e0670,,,,,Exlert,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,
3053,,,,B,,,fAO0000358,H,4687,fHfMBL620671,,,,,Aurocuratikn,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,
3054,,,,B,,,hAO9000357,H,12146,CHEMBk629672,,,,,Aut0curarion,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,
3055,,,,B,,,BzO0900357,H,12146,CHEMgL620672,,,,,A6tocurztion,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,
3056,,,,B,,,BAl9000357,H,16946,CHEMBL6wo674,,,,,Ahtocjration,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,
3057,,,,B,,,BAO000045i,H,14159,CHEhBL630675,,,,,zufocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,
3058,,,,B,,,BAO00o0347,H,16700,CHwMBL62o676,,,,,Auticurahion,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,
3059,,,,B,,,BAO0po0357,H,3269,CHEMBL631e82,,,,,Aut8curatuon,Affinity against 5-hydroxytryptamine 2C receptor,,
3060,,,,B,,,BAp0009357,D,1274,CbEMBL6213o3,,,,,Ex9ert,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,9606.0
3061,,,,B,,,hAOp000357,H,1317,CHEMBL6e1284,,,,,Auticurstion,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,
3062,,,,B,,,BAO00p035y,H,5834,CHEMBL62238y,,,,,Autocurati9m,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Bos taurus,9913.0
3063,,,,B,,,BAk0900357,H,11147,CHEMBLt16989,,,,,sutocutation,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Bos taurus,9913.0
3064,,,,F,,,BAOp00p019,H,14145,sHEMBL618990,,,,,Eapert,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Cavia porcellus,10141.0
3065,,,,B,611372.0,Ileym,vAOp000221,H,10561,CmEMBo875085,,,,,Au5ofuration,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,10141.0
3066,,,,F,,,BAO000091p,H,15847,CHEhBL617901,,,,,Autlcugation,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Cavia porcellus,10141.0
3067,,,,F,,,nAO9000019,H,15847,CHEnBL617p92,,,,,Autoc7rxtion,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Cavia porcellus,10141.0
3068,,,,B,292360.0,jleum,nAO0000211,H,10561,CHEMfL617994,,,,,Aut0curxtion,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,10141.0
3069,,,,B,3590144.0,Ioeum,BxO0o00221,H,11454,CHEMBLy27994,,,,,Aytofuration,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Cavia porcellus,10141.0
3070,,,,F,,,BqO0900019,H,4639,dHEMBi617995,,,,,Aht0curation,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Cavia porcellus,10141.0
3071,,,,F,,,hAO00000w9,H,4639,CjEMgL617996,,,,,A8toduration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Cavia porcellus,10141.0
3072,,,,F,,,BAO0009919,H,4639,CHEMhL617907,,,,,Au4oxuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,10141.0
3073,,,,F,,,BxO000001o,H,4639,CHEMBL61u999,,,,,Autochratikn,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Cavia porcellus,10141.0
3074,,,,F,,,BAO0o00p19,H,4639,CHEMBp617099,,,,,Aut9chration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,10141.0
3075,,,,F,,,BAOo00o019,H,4639,CHEMBL61u900,,,,,xutocuratiob,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,10141.0
3076,,,,F,174095.0,Ileun,BAO0909221,H,15253,CHEMBL61791r,,,,,qutocuratipn,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Cavia porcellus,10141.0
3077,,,,F,2793388.0,9leum,BAO0000qe1,H,15253,CnEMBL617o16,,,,,Aufofuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Cavia porcellus,10141.0
3078,,,,F,4589327.0,9leum,BAO9900221,H,11963,CHEMBL62781u,,,,,Autocudat7on,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Cavia porcellus,10141.0
3079,,,,B,2436012.0,lleum,BAi0000e21,H,1946,CHEMfLu17818,,,,,Autociratioh,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Cavia porcellus,10141.0
3080,,,,B,529406.0,7leum,BAO0000232,H,1946,CHEjBL617829,,,,,A7tocuratuon,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Cavia porcellus,10141.0
3081,,,,B,,,BAk000022r,H,12045,CHEkBL61782p,,,,,Ajtocurwtion,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Cavia porcellus,10141.0
3082,,,,B,4527726.0,Ildum,BAO00p022w,H,1559,CHEMBL617iq1,,,,,Autocuratilb,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,10141.0
3083,,,,F,2208185.0,Ipeum,nAO0900221,H,273,CHEMnL6178e2,,,,,Autocufati9n,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,10141.0
3084,,,,F,2182575.0,Ileuj,BAO009022w,H,273,CHEMBp61782e,,,,,Autodurat7on,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Cavia porcellus,10141.0
3085,,,,F,1209165.0,Ileim,BAO0p00231,H,188,CHEMgL6178e4,,,,,A7tocurati8n,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Cavia porcellus,10141.0
3086,,,,F,2453499.0,Il4um,BA900002e1,H,12919,CuEkBL617825,,,,,Autocurafikn,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Cavia porcellus,10141.0
3087,,,,F,20226.0,Ile7m,BAO00o02q1,H,12918,xHEMBL61782t,,,,,Autkcurqtion,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Cavia porcellus,10141.0
3088,,,,B,108841.0,Ipeum,nAO0o00221,H,1559,CHEMBL717u27,,,,,Autocurwtioj,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,10141.0
3089,,,,F,684185.0,Iieum,vAO000022w,H,273,CjEMvL617828,,,,,Autocuratl8n,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,10141.0
3090,,,,B,1019279.0,Ileuh,vAO000p221,H,1559,CgEMBLy17829,,,,,Au6lcuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,10141.0
3091,,,,B,949094.0,Ileuh,BA00000222,H,1559,CHEMBL61784o,,,,,Autkcu3ation,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Cavia porcellus,10141.0
3092,,,,B,294639.0,Ileuk,gAl0000221,H,1559,CHEMBLt1783w,,,,,Autocurztiln,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Cavia porcellus,10141.0
3093,,,,B,2753269.0,Iieum,BAO90002w1,H,14424,CH4MBL61783q,,,,,Autocu5atikn,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Cavia porcellus,10141.0
3094,,,,B,,,BAO009001o,U,13181,CH2hBL617833,,,,,Autocuratkom,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,10141.0
3095,,,,B,,,BAO0900w57,H,5486,CHfMBp617834,,,,,Autocjrat7on,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,
3096,,,,B,,,BsO9000223,D,6491,CmEMBL617836,,,,,Exper6,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Homo sapiens,9606.0
3097,,,,B,,,BAO0o00222,H,6013,dHEMnL617836,,,,,Autocurati0b,Binding affinity towards 5-HT3 receptor,,
3098,,,,B,,,BxOp000223,H,12861,CHEMBLt1y837,,,,,Auhochration,Binding activity radioligand.,,
3099,,,,B,,,BqO0900019,H,12861,CHEMBL62ow92,,,,,Aktocuratiln,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,
3100,,,,B,,,BAOp0002e3,H,5104,sHEMBL629393,,,,,qutocuratiog,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3101,,,,B,,,BA0000022w,H,5105,xHEMBLt20394,,,,,qutocurstion,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3102,,,,B,,,BAO00o022r,H,5104,sHEMfL620395,,,,,qutofuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,
3103,,,,B,,,BAO00p0o19,U,3935,CHEMvk620396,,,,,Auy8curation,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,
3104,,NG1081r,,B,,,BAO0000129,H,13657,CHEMBi6w0582,,,,,Ecpert,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,
3105,,,,B,,,BwO0000118,H,10369,CH4nBL620583,,Invigo,,,Auhocuratjon,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,
3106,,,,B,,,BAO0o00029,H,10369,CH2MBLy20584,,,,,Autoxugation,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3107,,,,B,,,gAO0000q24,H,12918,CHEMnL6w0585,,,,,A6tofuration,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,
3108,,,,B,,,fAOp000224,H,12918,CHEnBL620r86,,,,,Autocurstikn,Compound was evaluated for the binding affinity at 5- HT3 receptor,,
3109,,,,B,,,gAO000001o,H,10369,CHEMBp620487,,,,,zutocurxtion,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3110,,,,B,,,BA89000019,H,773,CHEMBL620y98,,,,,Autlcuratuon,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3111,,,,F,,,BAOo0o0218,H,12918,CuEMBp620589,,,,,xjtocuration,5-hydroxytryptamine 3 receptor agonism in mouse,,
3112,,,,B,,,BAO090p219,H,10561,CHEMBLt20599,,,,,Autlcurarion,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,
3113,,,,B,,,BAO9900019,H,12827,CHEMBL6170t6,,,,,sutoc6ration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3114,,,,B,,,BAO000po19,H,12827,CHEjBL61u957,,,,,Auticurstion,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3115,,,,B,,,BAO0000q2t,H,12918,CHrnBL617958,,,,,sut0curation,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,
3116,,,,B,,,BAO9o00219,H,273,CH4MBLu17959,,,,,Auhocuratiom,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3117,,,,B,,,BAO0000e18,H,273,CH2MBL617i60,,,,,zut8curation,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3118,,,,B,,,BAO000p234,H,10561,CHEjBL627961,,,,,Autoc7ra6ion,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,
3119,,,,B,,,BAO00o021o,H,5033,CHEMBL617ot2,,Ihvitro,,,Aufocuratipn,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,
3120,,N1E116,,B,,,BAO0000228,H,16429,CjsMBL617963,,,,,Au6ofuration,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,
3121,,,,B,,,BAO9000010,H,10322,CHEMvLy17964,,,,,qutocuratiin,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3122,,,,B,,,gAO000021o,H,14331,CHEnvL617965,,,,,Autocurariom,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,
3123,,,,B,,,BAi00003t7,D,13462,CHEkBL617866,,,,,A8t9curation,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Mus musculus,10090.0
3124,,,,B,,,BA80o00019,H,12861,CHEMBL85797e,,,,,Autocu3ahion,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
3125,,,,B,,,BAO0o0035i,H,15086,CHEMBp617i67,,,,,A7tpcuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Sus scrofa,9823.0
3126,,,,B,,,Bq00000357,H,12861,CHEhBL61796u,,,,,wutocu4ation,Binding activity radioligand.,Sus scrofa,9823.0
3127,,,,B,,,fAO0000224,H,10561,CHEMBL61706i,,,,,Autocutatipn,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Oryctolagus cuniculus,9986.0
3128,,,,B,,,BAO0990223,H,10561,CHEMvL6179i0,,,,,Augocurwtion,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Oryctolagus cuniculus,9986.0
3129,,,,B,,,BA9000022e,H,10561,djEMBL617971,,,,,Autocurwti9n,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Oryctolagus cuniculus,9986.0
3130,,,,B,,,BAp9000019,H,10561,CHsMBL627972,,,,,zutocuratiob,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Oryctolagus cuniculus,9986.0
3131,,,,F,,,fAO000p019,H,273,CHEMnL517973,,,,,Autocurafiin,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,9986.0
3132,,,,F,,,vAO000001o,H,273,CHfMBL61797r,,,,,zuticuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,9986.0
3133,,,,F,1345918.0,Ilsum,BAOp00022q,H,273,dHEMBL616975,,,,,Autocuratjin,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Oryctolagus cuniculus,9986.0
3134,,,,F,,,BwO0000p19,H,273,CHEMBp61u976,,,,,Autocurxtlon,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,9986.0
3135,,,,F,,,BAO0o0o019,H,273,CyEkBL617977,,,,,A6tkcuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,9986.0
3136,,,,F,,,nwO0000019,H,273,CyEMBL627978,,,,,xuticuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,9986.0
3137,,,,F,,,gzO0000019,H,273,CHEMfL617079,,,,,Aitocurat8on,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,9986.0
3138,,CHO,,B,,,BxO0000119,H,13047,CyEMBi617980,,,,,Autocurati8b,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Oryctolagus cuniculus,9986.0
3139,,,,B,,,BA0o000019,D,1650,CHEMBLu179i1,,,,,Autocu3ztion,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3140,,,,B,,,BzO0p00019,H,16288,CHEMBo61798e,,,,,xutocurqtion,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,
3141,,,,B,,,BAk0000367,H,16288,CHEMvL61u983,,,,,Aihocuration,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,
3142,,,,B,,,BAOo009019,D,10254,CyEMBL61i984,,,,,Autocurstiob,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Rattus norvegicus,10116.0
3143,,,,B,,,BxO0900019,H,14532,CHEkBL627985,,,,,Aitocu5ation,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,
3144,,,,F,3580575.0,H4art,BAO000p118,H,13392,xH3MBL617986,,8nvivo,,,Aut0cura5ion,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3145,,,,F,4046317.0,Hezrt,BAip000019,H,13392,CHEMBLy17986,,,,,Ahtocura4ion,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3146,,,,F,4667274.0,Headt,BAO000o010,H,13392,vHEMBL61798i,,,,,qjtocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3147,,,,F,2473207.0,Hearr,BAO09o0019,H,13392,CgEMBL61779w,,,,,Aufocyration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,
3148,,,,F,1718259.0,Heary,BAO00o00q9,H,13392,CHEMBkt17793,,,,,Aufocu3ation,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3149,,,,F,,,gAp0000019,H,13392,CHEMBL61778r,,,,,Autofhration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,
3150,,,,F,,,BAO000o01p,H,13392,CHEMhL617u95,,,,,Autlcurstion,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3151,,,,F,,,BAO0p0001o,H,13392,CHEMgL61i796,,,,,Autocurafuon,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3152,,,,F,,,nAO0000o19,H,13392,CH4MvL617797,,,,,sutocuratiob,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,
3153,,,,F,,,BA0000o218,D,1089,CHEkBLt17798,,Indivo,,,Autocjrat7on,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,10116.0
3154,,,,F,,,BAlp000218,H,1089,CHEMgL617699,,Invlvo,,,Aufocuratjon,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,
3155,,,,F,,,BAO000o118,D,11454,CHfMBL617809,,Invico,,,Au5ocurstion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,10116.0
3156,,,,F,,,BAOp000p19,D,11454,CHwMBL61780w,,,,,Augocurztion,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Rattus norvegicus,10116.0
3157,,,,F,,,BAO00002wu,D,12205,CHEkBL6178o2,,7nvivo,,,Autocurst8on,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Rattus norvegicus,10116.0
3158,,,,F,,,BA80000010,D,1089,CHwMBL617804,,,,,Autoc7ratiog,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,10116.0
3159,,,,B,,,BxO0000p19,H,5094,CHEMBiy17804,,,,,Autochratioh,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3160,,,,B,,,nqO0000019,D,2622,CbEMBL618805,,,,,Aht0curation,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3161,,,,B,,,nAO00002w3,H,245,CH4MBL617805,,,,,q6tocuration,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,
3162,,,,B,,,BAO0p00018,H,14788,CbEhBL617807,,,,,Aurocuratiog,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,
3163,,,,B,,,gAO000001p,H,14788,CHEMnLt17808,,,,,sutocuratiog,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,
3164,,,,B,,,BAOp00p249,H,3020,vHEMgL617809,,,,,Autocurag9on,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,
3165,,,,B,,,BAO0o0001p,H,1742,CH3MBL6q7810,,,,,xutocudation,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,
3166,,,,B,355986.0,Bfain,BAOo0o0249,H,17394,CHEMBLt1781q,,,,,Au5oc8ration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,
3167,,,,B,436857.0,Braib,BAO0090321,H,17394,CHwMBL6178q2,,,,,Autocurag8on,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,
3168,,,,B,,,BAO00002ep,H,17394,CgEMBL616813,,,,,Auticurarion,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3169,,,,B,,,BAO000oq49,H,14286,sHEMgL617814,,,,,Autosyration,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3170,,,,B,,,fAO0p00019,H,14178,CHEMvL6q7698,,,,,Aitocuratiin,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,
3171,,,,B,,,Bsi0000019,D,14178,CHEMBL6w76o9,,,,,A8tocuratiom,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Rattus norvegicus,10116.0
3172,,,,B,,,hAO0000029,D,14178,CHEMnp617700,,,,,Aurocurstion,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Rattus norvegicus,10116.0
3173,,,,B,,,nAO00002e3,D,14178,CHEMBL717i01,,,,,zutocuratiog,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3174,,,,B,,,vAO00000w9,H,15034,CHEjBL627702,,,,,Autocura4iob,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3175,,,,B,,,BAO0p00e49,H,1089,CHEMBL6178o3,,,,Membrxnes,Aktoduration,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,
3176,,,,B,,,BAOp000029,D,1089,CH2MBLt17704,,,,,wutocuratlon,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Rattus norvegicus,10116.0
3177,,,,B,,,BAO00002we,H,16532,CnEMBL617y05,,,,,Ajt8curation,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3178,,,,B,,,BAl000022r,D,12801,CHEMBL6178o6,,,,,Autofuratiin,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3179,,NG10825,,B,,,BA89000219,H,15194,CHEMBL6w77p7,,,,,Autocurxtipn,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,
3180,,NG1p815,,B,,,BAO0900210,H,15194,CHEMfL6q7708,,,,,Autoc8rafion,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,
3181,,,,B,,,nAO0900019,H,15194,CmEMBL617708,,,,,Ajtovuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,
3182,,,,B,,,BxO000p019,H,15194,CtEMBL617719,,,,,Autocurxt7on,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,
3183,,,,B,,,hAO00o0019,H,15194,CHEMBpi82925,,,,,qutocuratiob,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,
3184,,,,B,,,BAO0o00029,H,15194,CmEMBk617711,,,,,Autlcurstion,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,
3185,,,,F,,,BqO000p019,H,10610,CtEMBL618712,,,,,Au6ocuratioj,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,
3186,,,,F,,,BAl0000o19,D,10355,CHEMBo616713,,,,,Ahtocurat7on,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Rattus norvegicus,10116.0
3187,,,,F,,,BA000o0019,H,691,sHEMvL617714,,,,,Autovurati8n,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,
3188,,,,F,,,BAO90002w8,H,10611,CHsMBLt17715,,,,,xutocuratuon,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,
3189,,,,F,,,hAO00p0218,H,12801,CH4MBo617716,,jnvivo,,,Aytocufation,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,
3190,,,,F,,,BAO0p0021o,H,10609,CmEMBL61y717,,,,,Autocurz6ion,Inhibition of 5-HT evoked reflex bradycardia in rat.,,
3191,,,,F,,,BAO00p0e18,H,11454,CyEMBL61i718,,Incivo,,,A6gocuration,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3192,,,,F,,,BAO0p0021i,H,11454,CHEMBi627719,,9nvivo,,,Autocyrat8on,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,
3193,,,,F,,,BAO090021i,H,11454,fHEMnL617720,,Ihvivo,,,Au6ocurafion,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,
3194,,,,F,,,BAOo00p218,D,11454,dHEMBL617722,,Invibo,,,Aufocuratioh,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,10116.0
3195,,,,F,,,BxO0090218,H,11454,fHEMBp617722,,Incivo,,,Aktocurqtion,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3196,,,,F,,,BAO000pw18,H,11454,CHEMBL618y23,,Invivi,,,Au4ocurwtion,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,
3197,,,,F,,,BzO00002w8,H,11454,CHEnBL717724,,Invivk,,,Autocuratkpn,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,
3198,,,,F,,,BAl0000e18,H,11454,CHEMBo61772y,,Ijvivo,,,qutocu4ation,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,
3199,,,,F,,,BAO090o218,H,11454,dHEMBL517726,,Invivl,,,xutocurztion,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,
3200,,,,F,,,BAO00op218,H,11454,CHEMBL617i28,,Invido,,,Autocurwt7on,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3201,,,,F,,,gAO00002q8,H,11454,CHEjBL617828,,lnvivo,,,Autocurwti9n,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,
3202,,,,F,,,hAO0090218,H,11454,CuEMBL61u729,,Igvivo,,,Aitocurat7on,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,
3203,,,,F,,,BA80000228,H,11454,CH3MBL617u30,,Ibvivo,,,Autocura4iog,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,
3204,,,,F,,,BA8000021u,H,11454,CHEnBLy17731,,onvivo,,,Autocuratipg,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3205,,,,F,,,BAO00o0318,H,11454,CH3MBL6177e2,,Imvivo,,,A8tocurat7on,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,
3206,,,,F,,,BzO0900218,H,11454,CHEkBL6177e3,,Infivo,,,Autocurayiom,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,
3207,,,,F,,,hAOo000218,H,11454,CHEMBL717634,,8nvivo,,,zutoc7ration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,
3208,,,,F,,,BAO00o0217,H,11454,vHEMBLi72874,,Ijvivo,,,Ajtociration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,
3209,,,,F,,,BqOo000218,H,11454,CHdMBL617i35,,Inviv8,,,Autocurzfion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,
3210,,,,F,,,hAO0000219,H,11454,CHdMBL617737,,Invovo,,,A6tocurati0n,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,
3211,,,,F,,,BwO0000217,H,11454,fHEMBL616737,,Invibo,,,Autockratiog,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,
3212,,,,F,,,BzO00002w8,H,11454,CHEMnL617728,,Inv8vo,,,A7tocu4ation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,
3213,,,,F,,,BAO00o02w8,H,11454,CHEnBL61773o,,Inv7vo,,,Autofugation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,
3214,,,,F,,,BAO00p021i,H,11454,CHEMBL6q774o,,Ihvivo,,,Aht0curation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,
3215,,,,F,,,BA900002q8,H,11454,Cg3MBL617741,,Invibo,,,Autodiration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3216,,,,F,,,BAO00092q8,H,11454,CHEMhL61774q,,Invico,,,Au5oc8ration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,
3217,,,,F,,,BAO090p218,H,11454,CHEMBi61774w,,Invifo,,,A8tocudation,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,
3218,,,,F,,,gAO00002w8,H,11454,CHEMBo6177t4,,Indivo,,,sutocurahion,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,
3219,,,,F,,,BsO00002w8,H,11454,CH4MBL617845,,jnvivo,,,Ay4ocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,
3220,,,,F,,,BxO00p0218,H,670,CHEMBi6q7746,,,,,Autod6ration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,
3221,,,,F,,,gAO0090218,H,670,dHEhBL617747,,,,,Ahtocu5ation,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,
3222,,,,F,,,BAO0909218,H,10321,CnEMBL616748,,Inviv8,,,Ayt8curation,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,
3223,,,,F,,,BAO9000228,H,10321,xHEMBL61890o,,Invkvo,,,Autovu4ation,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,
3224,,,,F,,,gAO000021o,H,10321,CHEMfL618920,,Invivk,,,Autocutat8on,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,
3225,,,,F,,,BAk0000318,H,10321,CHfMBL618i11,,Inviv0,,,Autocuratoom,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,
3226,,,,F,,,BAO000o21o,H,10321,CmEMvL618912,,Invido,,,Autocugatiog,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,
3227,,,,F,,,BzO9000218,H,10322,CH3MBL6189w3,,Invigo,,,Augosuration,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,
3228,,,,F,,,BAO0090o19,H,15412,CHEMBL61ip14,,,,,sutociration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3229,,,,F,,,BAOo0p0019,H,15412,dHEMBL61891t,,,,,Aufocuratiln,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3230,,,,B,,,BAp0000213,D,15412,CHEMBL617816,,,,,Ajtocjration,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3231,,,,F,,,fxO0000019,H,15412,CHEMBLu17917,,,,,z8tocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,
3232,,,,B,2205142.0,Hjppocqmpus,BAi0000121,D,15412,CHEMBk61891u,,,,,Intsrmedjate,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,
3233,,,,B,,,BAO00000qi,D,15412,CHEMBL518p19,,,,,Autoxufation,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Rattus norvegicus,10116.0
3234,,,,B,,,BzO00p0019,D,17394,CHfMBL6189e0,,,,,xutlcuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3235,,,,B,,,hAO000022e,H,12457,CH3MfL618921,,,,,Autocuratkob,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,
3236,,,,B,,,BAk00o0019,H,12457,CHEMho618922,,,,,qutocurati0n,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,
3237,,,,B,,,BqO0000919,H,12205,CHdMBL61892e,,,,,wutocuratiom,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,
3238,,,,B,,,BAO00000q0,H,14532,CHEMnL618923,,,,,Autlcuratiin,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,
3239,,,,B,,,BAO000o0w9,H,1122,vH3MBL618925,,,,,Autocuragiog,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,
3240,,,,B,,,BAO00o00q9,H,5094,dHEjBL618926,,,,,Ahtocurstion,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3241,,,,F,327950.0,Ile7m,BAO900022w,D,809,CmEMBL618937,,,,,Int4emediate,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Cavia porcellus,10141.0
3242,,,,F,4283510.0,Ile7m,BAOpo00221,D,809,vHEMBL6189q8,,,,,Intermefiats,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Cavia porcellus,10141.0
3243,,,,F,5104898.0,Il4um,hAO00o0221,D,14290,CHEMBi618o29,,,,,Intermewiage,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Cavia porcellus,10141.0
3244,,,,F,1161618.0,Ilejm,BAO00p9221,D,14290,CHEkBL618p30,,,,,In62rmediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,10141.0
3245,,,,F,125632.0,Ipeum,Bw00000221,D,14290,xHEMfL618931,,,,,kbtermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,10141.0
3246,,,,F,768042.0,Ileun,BAkp000221,D,14290,vHEnBL619594,,,,,Interkediat3,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,10141.0
3247,,,,F,4651642.0,9leum,BAO0009321,D,14290,CHEMBL629t95,,,,,Int2rmed8ate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Cavia porcellus,10141.0
3248,,,,F,1614020.0,Ileym,BAi0900221,D,13961,CHEMBLt195p6,,,,,Intermrdoate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Cavia porcellus,10141.0
3249,,,,F,2978054.0,Ile7m,BAO90002w1,D,13961,CHEkBk619755,,,,,Imtermedixte,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Cavia porcellus,10141.0
3250,,,,F,2241184.0,Ileun,BAO009o221,D,809,CHEMvi619756,,,,,Inte4mediqte,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Cavia porcellus,10141.0
3251,,,,F,1548724.0,kleum,BAOp00022q,D,809,CHEMBL610758,,,,,Ibterm4diate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Cavia porcellus,10141.0
3252,,,,F,2336558.0,Ilekm,gAO000p221,D,809,CgEMBL61975u,,,,,Intermedkat2,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Cavia porcellus,10141.0
3253,,,,F,4639459.0,lleum,BAlo000221,D,14290,CHEMBp619y59,,,,,Inte3medoate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Cavia porcellus,10141.0
3254,,,,F,17129.0,Ioeum,BAO00p0e21,D,14290,CHEhBL619769,,,,,Intermewia5e,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Cavia porcellus,10141.0
3255,,,,F,3315928.0,Ileuk,BzO0000321,D,14290,CHEMBLt1976q,,,,,Ibtermedia6e,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,10141.0
3256,,,,F,2241344.0,Ile6m,gAO000p221,D,14290,CHEMBLy10762,,,,,Inf4rmediate,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Cavia porcellus,10141.0
3257,,,,F,1486520.0,Ikeum,BAO00001e1,D,14290,CHEMBL6w97u3,,,,,Intdrmediqte,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,10141.0
3258,,,,F,675727.0,Ileuk,BAOp090221,D,14290,dHdMBL617868,,,,,Inhermsdiate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,10141.0
3259,,,,B,,,BwO0000367,D,15034,fHEMBL616869,,,,,Intermevuate,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,10141.0
3260,,,,B,1930514.0,Stfiatum,BAO000p259,D,5094,CHEMfL872926,,,,,Intfrmddiate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,10141.0
3261,,,,B,401983.0,Striztum,BAl00002r9,D,5094,CgEMBL617u70,,,,,Interkediat3,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,10141.0
3262,,,,B,2859701.0,Striwtum,fAO000o357,D,5399,CHEhBL6178u1,,,,,9n4ermediate,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,10141.0
3263,,,,B,1517272.0,Stria6um,BzO000035i,D,17394,CHEMBk61787e,,,,,Integmediare,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,10141.0
3264,,,,B,2132604.0,Striahum,BAO00003r6,D,17394,CHEMBL6178yr,,,,,Int3rjediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,10141.0
3265,,,,B,4136507.0,Srriatum,BAO090035u,D,17394,CHEMBL616i74,,,,,Interm4xiate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,10141.0
3266,,,,F,948078.0,jleum,BAO09o0221,D,13961,fHEMBL61906u,,,,,Interhed7ate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Cavia porcellus,10141.0
3267,,,,F,1522084.0,Ileun,BAO0o0022q,D,13961,CHEMBL6180u8,,,,,Intwrmedlate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Cavia porcellus,10141.0
3268,,,,F,3755657.0,Ileuk,BA8000o221,D,13961,CgEMBL619079,,,,,Inte5mexiate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,10141.0
3269,,,,B,,,BwO0000347,D,16946,CHEMvL6q9070,,,,,Interhediatd,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Cavia porcellus,10141.0
3270,,,,B,,,BAOp009357,D,16946,CHEMgL519071,,,,,Interm4dlate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Cavia porcellus,10141.0
3271,,,,F,,,vAO000001i,D,15034,CjEMBL61p072,,,,,lntermediwte,Agonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3272,,,,F,,,BAO090p019,D,15034,CHEMBL61op73,,,,,Intermediqt4,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Cavia porcellus,10141.0
3273,,,,F,,,BAO0p0001o,D,12918,CHEMBL6q9064,,,,,7ntermedkate,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3274,,,,B,,,BAk9000357,D,16946,CtEMgL619075,,,,,Inte3mediat2,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3275,,,,B,2206950.0,Striatkm,gAO0900357,D,17394,CHEMBo629076,,,,,Ihtedmediate,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3276,,,,B,1175301.0,Striatun,BAO9090357,D,15034,CHEMhL619087,,,,,Interkediwte,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,10141.0
3277,,,,B,695361.0,qtriatum,nAO0900249,D,5094,CHEMBp61907i,,,,,Inyermedia4e,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,10141.0
3278,,,,B,1624181.0,Shriatum,BAO00p0259,D,5094,fHEMnL619079,,,,,Inferjediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,10141.0
3279,,,,B,1111736.0,Il3um,BAO00p0231,D,17358,CHEnBL61p080,,,,,Intermsdiat2,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Cavia porcellus,10141.0
3280,,,,B,,,BsOp000357,D,12953,CHEMvL61908q,,,,,Eapert,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Cavia porcellus,10141.0
3281,,,,B,,,BA90000r57,D,12953,CmEjBL619082,,,,,7ntrrmediate,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,10141.0
3282,,,,B,,,BAO0o00367,D,12953,CHEMBL6w908w,,,,,Intermefizte,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Cavia porcellus,10141.0
3283,,,,B,,,BAOo0003t7,D,12953,fHEMBo619084,,,,,Intermef8ate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,10141.0
3284,,,,F,3879909.0,Ileuk,BAi00002e1,D,273,vHEMBk859397,,,,,Imtefmediate,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,10141.0
3285,,,,F,104600.0,Ileun,BzO0o00221,D,12918,CHEMBL62p085,,,,,Intermediqt3,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Cavia porcellus,10141.0
3286,,,,F,3081618.0,Ile7m,BAO00po221,D,12919,CHEMBL6q9085,,,,,Igtermesiate,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Cavia porcellus,10141.0
3287,,,,F,2129417.0,Iieum,BAOp900221,D,273,CHEMBL62i087,,,,,9ntfrmediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Cavia porcellus,10141.0
3288,,,,F,859040.0,Ilekm,BAO000oe21,D,273,CHEMBL619pi8,,,,,Intrrmeviate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,10141.0
3289,,,,B,,,BAi0900357,D,13181,CHEMBp6q9089,,,,,Intermed8ahe,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Cavia porcellus,10141.0
3290,,,,B,,,BwO0000347,H,13181,CHEMBL71o090,,,,,Autocurato0n,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Cavia porcellus,10141.0
3291,,,,F,,,Bw80000019,D,15034,stEMBL619091,,,,,Inteemewiate,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3292,,,,B,,,Bzp0000357,D,5033,CHEMBL6190oe,,,,,Interm3diatr,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,10141.0
3293,,,,B,,,BAO0o00010,D,1980,CHEnBL619083,,,,,Igtsrmediate,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Cavia porcellus,10141.0
3294,,tEK293,,B,,,BAO9000229,H,13181,CHEMBL6190oe,,,,,Autocuratlob,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Cavia porcellus,10141.0
3295,,,,B,,,vqO0000019,D,14287,CHdMBL618095,,,,,Intermedua6e,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Cavia porcellus,10141.0
3296,,,,B,,,BAO000036i,D,1317,CmEMBL757988,,,,,Intermediay4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Cavia porcellus,10141.0
3297,,,,B,,,BAOo900357,D,15316,CHEMBk519096,,,,,Inteemedia5e,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Cavia porcellus,10141.0
3298,,,,B,163925.0,Striqtum,BsO000035i,D,16429,CHEjBL61909y,,,,,Imte4mediate,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Cavia porcellus,10141.0
3299,,,,B,3726747.0,Hipp9cam9us,BAO00092e1,D,14818,CHEMBL61p09o,,,,,Interjediqte,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Cavia porcellus,10141.0
3300,,,,B,,,BAOo0003y7,D,15194,CbEMBL6197t1,,,,,Intermsdiats,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Cavia porcellus,10141.0
3301,,,,B,,,BAO0900356,D,15194,CHEMBL6187t2,,,,,Intermediqye,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Cavia porcellus,10141.0
3302,,,,F,1249235.0,Ile6m,BsO0000321,D,13961,CHrMBL874096,,,,,Intermedoatd,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,10141.0
3303,,,,B,,,BAO0p00358,H,5486,CnEMBL61900t,,,,,Autovuratiog,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,
3304,,,,B,,,BAk00p0357,H,16209,CHEMBL61000r,,,,,wutocura5ion,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,
3305,,,,B,,,vAO000001i,H,17085,CHEMBL6w900t,,,,,Ahtocuratiob,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,
3306,,HeLa,,B,,,BAO000o119,H,4199,CuEMBp619007,,,,,Autoc83ation,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,
3307,,,,B,,,BAOo0003t7,H,15146,CHEMBL610009,,,,,Autocugatikn,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,
3308,,,,B,,,BAk00003t7,H,5213,CHEjnL619009,,,,,Autocurat80n,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,
3309,,HeLa,,B,,,nwO0000219,H,4829,CHEMBi619o10,,,,,Autocurafiob,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,
3310,,,,B,,,BAO0009457,H,17358,CHEMBk618011,,,,,Ahtocurayion,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,
3311,,,,B,,,BAO000o3y7,H,17358,CHEMfL619022,,,,,A7tocuratiob,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,
3312,,,,B,,,BAO000o319,H,16946,xHEMBLt19013,,,,,Autovurwtion,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,
3313,,,,B,,,BAO0090347,H,17358,CHEMgLu19014,,,,,Autockrayion,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,
3314,,,,F,1051515.0,Caediadatrium,BAO0o000w9,H,268,CHEMhL857504,,,,,Auhockration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,
3315,,,,F,10131.0,Cardiacqtrihm,BAl0000919,H,268,CHEMBL6290w5,,,,,qutocura5ion,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,
3316,,,,B,,,BAp0000e57,H,15086,CHEMgL619026,,,,,Autox8ration,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,
3317,,,,B,292662.0,Hippocahpuq,BAO0p00e21,H,14875,CHEMnL519017,,,,,Ahtpcuration,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,
3318,,,,B,928008.0,Hippocanpua,BAO000p2q1,H,13267,CHwMBL61901i,,,,,qutocuratoon,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Sus scrofa,9823.0
3319,,,,B,,,hAO000001o,H,13047,CHEhBL629019,,,,,Autocueatiin,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,9986.0
3320,,,,B,,,BwO00o0357,D,1650,CHfMBL619030,,,,,Exp4rt,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Rattus norvegicus,10116.0
3321,,,,F,,,BqO000001p,H,567,CjEhBL619021,,,,,A7tofuration,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3322,,,,B,,,BAO0p00e57,H,17358,xHEMBL619023,,,,,Autocuratlom,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,
3323,,,,B,,,BzO000o357,H,188,CHEMvk619023,,,,,Autocufatjon,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,
3324,,,,F,,,hAO000001p,H,670,CH3MBL6190e4,,,,,Aut9curat9on,lntrinsic activity relative to 5-HT receptor,,
3325,,,,F,,,nAO000001i,H,204,dHEMfL619025,,,,,xutoc6ration,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,
3326,,,,F,,,fAO0000919,H,1946,CHEMBL6q9p26,,,,,Exper4,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,
3327,,,,F,,,BAl000o019,H,6398,fHEMBp619027,,,,,Auhocurwtion,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,
3328,,,,F,,,BAOo000018,H,6398,CHEMBL619p2o,,,,,Autpcuratjon,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,
3329,,,,F,,,BqO00o0019,H,17358,CHEMBk619p29,,,,,Auyocurxtion,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,
3330,,,,F,,,BAOo0p0019,H,6398,CHEMBLy1o030,,,,,Aut8curatiin,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,
3331,,,,B,,,BAl9000357,H,11752,CHEMBL629o31,,,,,Ezpert,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,
3332,,,,F,,,BA900000w9,H,809,CHEMfL619932,,,,,wutocurati9n,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,
3333,,,,B,,,BAO0099357,D,14178,CmEMBLy19033,,,,,sxpert,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Rattus norvegicus,10116.0
3334,,,,B,,,gAl0000357,H,567,fHdMBL619034,,,,,Autovurwtion,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3335,,,,B,,,gAO0000356,H,1946,CHEMBL619p3r,,,,,Autoc8ratiom,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,
3336,,,,B,,,BAO00p03t7,H,1946,CHEMBLt19p36,,,,,A6tocuratiob,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,
3337,,,,B,,,BAO0p00029,D,13961,dHEMhL619037,,,,,3xpert,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Rattus norvegicus,10116.0
3338,,,,B,3321706.0,S6riatum,BAO00o024o,H,6238,CHEMho619038,,,,,Autkcueation,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,
3339,,,,B,,,BAOo00024p,H,14290,CHEnhL619039,,,,,Autocyrarion,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,
3340,,,,B,,,BzO0009249,H,14290,dHEMBL619p40,,,,,Ezpert,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,
3341,,,,B,3005868.0,Struatum,BzO0000029,D,809,CHEhBLu19041,,,,,sxpert,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Rattus norvegicus,10116.0
3342,,,,B,250590.0,Strjatum,BAl0000919,H,1578,CHEMBLu1o042,,,,,Aufocurat9on,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,
3343,,,,B,1113980.0,Strlatum,BA000002t9,H,16709,CgwMBL619043,,,,,Expe5t,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,
3344,,,,B,3179953.0,Striat7m,BAO9p00019,H,1946,CHEMBL629o44,,,,,Exoert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,
3345,,,,B,2749299.0,Sgriatum,BAO000924p,H,15253,CHEMnL61p045,,,,,Ex0ert,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,
3346,,,,B,1498798.0,Striqtum,BzO0000q49,H,4535,CHEMBL6w904t,,,,,Exp4rt,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3347,,,,B,,,BAp000024p,H,13961,CHEMBo610047,,,,,Ex0ert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,
3348,,,,F,528793.0,Brsin,BAOop00221,H,17358,CHEhhL619048,,,,,q6tocuration,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,
3349,,,,F,,,BAOo00p019,H,15847,CuEMBL8593o8,,,,,Ajtovuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,
3350,,,,F,,,BAO00p0p19,H,15847,CHEMBL61903o,,,,,Autoxurati8n,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,
3351,,,,F,,,BAO0p90019,H,670,CyEMBLi57886,,,,,Autkvuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,
3352,,,,F,,,BAO00p0018,H,670,CbEMBL619040,,,,,A8tocuratuon,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,
3353,,,,F,,,BAOo000p19,H,1317,CgEMBL620y91,,,,,Autocjdation,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,
3354,,,,B,,,BAO000p356,D,12936,CHEMBL620ro2,,,,,Ezpert,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Rattus norvegicus,10116.0
3355,,,,B,278156.0,Strkatum,BsO0900249,H,4535,CyEMBL620503,,,,,Exoert,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3356,,,,F,,,BqO00p0019,D,14424,CHEMBL6q059r,,,,,Expe5t,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Rattus norvegicus,10116.0
3357,,,,F,,,fAO000001p,H,14424,CH3MhL875079,,,,,Expe5t,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,
3358,,,,F,,,BAO000o0q9,H,14424,CyEMBL610595,,,,,wxpert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3359,,,,F,,,hAO000001i,D,14424,fHEMBo620596,,,,,Ecpert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Rattus norvegicus,10116.0
3360,,,,F,,,BAO009001i,H,14424,CHEMBL62p5p7,,,,,Autosu4ation,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,
3361,,,,F,,,BA80090019,H,14424,vHEkBL620598,,,,,Expe5t,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,
3362,,,,F,,,vAO000021i,H,14424,CHEMvL629599,,,,,Expe4t,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,
3363,,,,F,,,BAl00p0019,H,14424,sHEMBL520600,,,,,Autocufat7on,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3364,,,,F,,,BxO0009019,H,1980,CHEMBi620t01,,,,,su5ocuration,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Rattus norvegicus,10116.0
3365,,,,F,,,gsO0000019,H,4639,CtEMvL620602,,,,,Autocurxtiob,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,
3366,,,,B,,,BA000o0357,H,17358,CHEMBL6206ow,,,,,sutocyration,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,
3367,,,,B,,,gAO00p0357,H,17358,CHEMfp620604,,,,,zutochration,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,
3368,,,,B,,,vAO0900357,H,17358,CHEMnL720605,,,,,Autocuragiog,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,
3369,,,,B,,,nAl0000357,H,1558,CHEMBLu20y06,,,,,Autocurstiob,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,
3370,,,,F,,,BAOp00p019,H,17358,xHEMBL720607,,,,,xu5ocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3371,,,,B,,,BAO90p0357,H,16117,CHEMvLt20608,,,,,Autosuratiin,In vitro binding affinity towards 5-HT4 receptor was determined,,
3372,,,,F,,,BAOp00001o,H,17358,CH2MBL620509,,,,,Au6ocu3ation,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3373,,,,F,,,BA80009019,H,17358,CHEMBL720619,,,,,Aytocutation,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,
3374,,,,B,,,BAO0p90357,H,17358,xHEMBL62061q,,,,,Autoc8eation,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,
3375,,,,B,,,BxO00003r7,H,17358,CHEMhi620612,,,,,A6tocudation,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,
3376,,,,B,,,BAO90p0357,H,17358,CHrMBL6206w3,,,,,Autoxuratiin,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,
3377,,,,B,,,BsO9000357,H,17358,CHEMhL629614,,,,,Autocurwti0n,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,
3378,,,,B,,,BAO0o0035i,H,1274,CHEMfL6206w5,,,,,Edpert,Binding affinity against 5-Hydroxytryptamine 4 receptor,,
3379,,,,B,,,hAOo000249,H,10728,CHEMBi857o75,,,,Brainmejb5anes,Autocura4lon,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,
3380,,,,B,,,BAOo00024i,H,11695,CHEMBL6206qy,,,,Brainmdmbrznes,Ahtocurqtion,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,
3381,,,,B,,,BAOoo00249,H,11695,CbEMBL6q9411,,,,Btainmembrabes,sutosuration,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,
3382,,,,B,,,fAO0p00019,H,12490,vgEMBL619412,,,,,Autoc8ratiob,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,
3383,,,,B,,,BAO0090018,D,11828,CHEMnk619413,,,,,Autocutatoon,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3384,,,,B,3732280.0,yilpocampus,BAO0o0022w,H,12253,CHdMBL618414,,,,,wutockration,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,
3385,,,,B,,,BAOp000919,H,10561,CuEMBL6194q5,,,,,sutocuratikn,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,
3386,,,,B,,,BAOo00o019,H,10561,CHEMBLu194q6,,,,,Autofuratiln,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,
3387,,,,F,,,BAOp00p019,H,14432,CjEMBL610417,,,,,Aut9curatiob,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,
3388,,,,B,,,BAO00o0123,D,12936,CHrMBL619428,,,,,A8tocu4ation,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3389,,,,B,,,BsO00p0223,D,1274,CHEMBo619t19,,,,,xutocurxtion,Binding affinity against 5-Hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3390,,,,B,,,BAi000o019,H,1980,fHEMBL619429,,,,,Aut9curatiog,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,
3391,,,,B,,,gAO0000240,H,670,CnEMhL619421,,,,,Au4ocu5ation,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,
3392,,,,B,,,nAO00p0019,D,968,CHEMnL719422,,,,,Autovurztion,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Rattus norvegicus,10116.0
3393,,,,B,,,BAO0000p10,H,14287,CH2MBLu19423,,,,,Autoc6ratiom,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,
3394,,,,B,,,BAp0p00019,H,567,fHEhBL875080,,,,,Autocurayiog,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,
3395,,,,B,,,Bqi0000019,H,13267,CHEMBL610r24,,,,,sutocurati9n,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,
3396,,,,B,,,hAO9000249,H,14826,CHEkBo619425,,,,,Aitocuratioh,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,
3397,,,,B,,,BAl0000e23,H,15194,CHEMBL61p42u,,,,,sutocuragion,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,
3398,,,,B,,,BAO0o0p223,H,15194,vHEMBL519427,,,,,Auhoc6ration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,
3399,,,,B,,,fAO0000q23,D,10394,CuEMBLt19645,,,,,Aut9curahion,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,10116.0
3400,,,,B,,,BAO0o00239,D,13657,CHEMBp61964t,,,,,Experh,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,
3401,,,,F,3161805.0,Bra8n,nAO000022q,H,1879,CHEMBo619t47,,,,,zutocuratkon,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,
3402,,,,F,,,BAO00pp019,H,1879,vH4MBL619648,,,,,Autpckration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,
3403,,,,F,,,BAO0009919,H,1879,CHEMhp619165,,,,,Autocugqtion,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,
3404,,,,F,,,hAO9000218,H,204,CHEhBL620y19,,Imvivo,,,Autovurati0n,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,
3405,,,,B,,,Bxk0000019,H,1879,CHEnBp872924,,,,,Autoc8ratioh,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3406,,,,B,,,nAl0000357,H,1879,CyEMBp620720,,,,,Autocu5atiob,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3407,,,,B,,,BAOp00o019,H,1879,CHEMvL62072w,,,,,Autocueatoon,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3408,,,,B,,,BA8000001i,H,1879,CHEMhL620i22,,,,,Auykcuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,
3409,,,,B,,,BAO000o029,H,10641,CHEMBL6e0724,,,,,Aut0suration,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,
3410,,,,B,,,gAO000o019,H,773,CHEMBL620i2e,,,,,Autofurati9n,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3411,,,,B,,,BAO0o00240,H,11952,CH3MBL620724,,,,,qutocu3ation,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,
3412,,,,F,,,BAOo00001i,D,14145,CHdMBL6e0726,,,,,wutocuratiom,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Rattus norvegicus,10116.0
3413,,,,B,,,BsO000035y,H,17066,CmEMBL6q0727,,,,,Expeet,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3414,,,,B,,,BAOp000213,H,6398,CHEnnL620728,,,,,Autovura5ion,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,
3415,,,,B,,,BAOp000p19,U,10321,CHEMBL6q07w9,,,,,Auticuratiln,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3416,,,,F,,,BAi0p00019,H,511,CjEMBk858288,,,,,Ahtocura5ion,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,
3417,,,,B,,,BAOp000q23,H,4639,CHEMBL63p730,,,,,Autocu3ati8n,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,
3418,,,,B,,,BAO0o09223,H,4639,CHEMBL62oi31,,,,,Ahtocu4ation,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3419,,,,F,,,gAO000o019,H,4639,CbEMBL62073e,,,,,Autpcurarion,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Cavia porcellus,10141.0
3420,,,,F,,,BAO00o0029,H,4639,CHEMBL61805e,,,,,Autocurxtiob,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,10141.0
3421,,,,F,,,BAkp000019,H,4639,CHEjBL628043,,,,,Autosurati0n,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Cavia porcellus,10141.0
3422,,,,B,,,vAi0000223,H,1558,CuEMhL618044,,,,,Autocjragion,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3423,,,,F,,,BAp000001o,H,268,CHEMBL628945,,,,,zutocuratikn,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,
3424,,,,B,,,BAO9000222,H,2474,CyEMgL618046,,,,,Autocurxrion,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,
3425,,,,F,,,nAO0000919,H,5067,sHEMBLy18047,,,,,Ayt0curation,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,
3426,,,,F,,,gAO0000919,H,5067,CHEMBL8759u4,,,,,Autocugati0n,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,
3427,,,,F,,,BAOpo00019,H,5067,xHfMBL618048,,,,,Autoxuratiog,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,
3428,,,,B,,,BAO0000w2w,H,5067,CHEMvL618048,,,,,xutocurztion,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,
3429,,,,F,,,BAO09o0019,H,5067,CHrMBL6197t4,,,,,Autkcurztion,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,
3430,,,,F,,,Bw90000019,H,5067,CHEjBL61o765,,,,,Au5ocurxtion,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,
3431,,,,F,,,BAOo00o019,H,5067,CHEkBL519766,,,,,wutocuratkon,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,
3432,,,,B,,,BsO0009223,H,5067,vHEMBL719767,,,,,Auticuratkon,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,
3433,,,,B,,,BAOo00022e,H,5067,CHEkBL6197y8,,,,,Autlsuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,
3434,,,,F,,,BsO000001i,H,5067,xHEMBL6w9769,,,,,zutocurarion,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,
3435,,,,B,,,BAO000oq23,H,5067,CHEMBLt19y70,,,,,Autifuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,
3436,,,,B,,,gAO0090223,H,5067,CHfMBL6197i1,,,,,Autocuratk9n,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3437,,,,B,,,fAO00o0219,H,14331,CHEMBL6w977e,,,,,qutocurat7on,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,
3438,,,,B,,,BAO0o00e23,H,5067,CHwjBL619773,,,,,wutocuratiin,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,
3439,,NGw0815,,B,,,BAO0000w1i,H,6179,CHEMhL6q9774,,,,,Au4pcuration,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,
3440,,,,B,,,BAl0000o19,H,4265,CHrMnL875083,,,,,A7hocuration,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,
3441,,NGw0815,,B,,,BqO0000210,H,4265,CHEMvL6e0718,,,,,Autocura5iom,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,
3442,,,,B,,,BAO000o123,H,17358,CHEMBLu1812i,,,,,Aytocurat7on,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3443,,,,B,,,fAO0900223,H,17358,CHEMBk618118,,,,,Autochrahion,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,
3444,,,,B,,,BAl9000219,H,13628,CHEMvL61i129,,7nvitro,,,Aufocuratkon,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,
3445,,,,B,,,BAOp0002w3,H,4612,CH4MBL618139,,,,,Autociratikn,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3446,,,,F,,,BAOo000919,H,17358,CHEMBL61iw31,,,,,Autovufation,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,
3447,,,,F,,,BxO0000010,H,4639,CHEjBL618q32,,,,,Autocirat8on,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Cavia porcellus,10141.0
3448,,,,F,,,BxO0000o19,H,4639,CHEnBLt18133,,,,,Autocyratkon,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Cavia porcellus,10141.0
3449,,,,F,,,BqO0000029,H,4639,CjEMBL628134,,,,,zuyocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Cavia porcellus,10141.0
3450,,,,F,,,BAO000o01i,H,4639,CHEMnL6q8135,,,,,A6tocuratikn,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,10141.0
3451,,,,B,,,BsO0p00223,H,511,CyEMBo618136,,,,,Ay4ocuration,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,
3452,,,,B,,,BA80000w23,H,1479,CHEMfL61o137,,,,,Autpcura6ion,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3453,,,,B,,,BAO00p0213,H,1317,CHEhBL6w8138,,,,,Autocurati8g,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,
3454,,,,B,,,BAk0900223,H,12146,Cj2MBL618139,,,,,Aufocuratuon,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,
3455,,,,B,,,BxO0000123,H,12146,CHEMBot18140,,,,,Autocurztikn,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,
3456,,,,B,,,BAOo0002w3,H,13969,CHEMBL6182r1,,,,,Autkcurati9n,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,
3457,,,,B,,,BAOp000257,H,13392,CHdMBL8u3478,,,,,Expeft,Binding affinity for 5-hydroxytryptamine 2C receptor,,
3458,,,,B,,,BAO00002we,H,13392,CtEMBL618q42,,,,,Autocurw4ion,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3459,,,,B,,,BxO0000257,H,14159,CHEMBL61i243,,,,,Autocuraf7on,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,
3460,,,,B,,,BwOo000357,H,1558,CHEMBLuw8144,,,,,Aitocurqtion,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3461,,,,B,,,BAO0op0357,H,16655,CmEMBk618145,,,,,Au6ocurstion,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,
3462,,,,B,,,BA0000o223,H,13020,sHEMBL6w8146,,,,,xutocurwtion,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3463,,,,B,,,BAO0o00233,H,13021,CtEMBL61814u,,,,,Auhicuration,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,
3464,,,,B,,,hAO00o0223,H,13020,fHEnBL618148,,,,,Autocyra4ion,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3465,,,,B,,,hAO000p019,H,10321,CHEngL618149,,,,,Autocurstipn,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3466,,,,B,,,Bzl0000357,H,15818,CH2MBL87292y,,,,,Autoxuratikn,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3467,,,,B,,,BAO0000wy7,H,15818,CHEjBL618w50,,,,,Autocudwtion,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3468,,,,B,,,BAO0o0035i,H,17358,CHEkBL6w8151,,,,,zutocudation,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3469,,,,B,,,BAO0p09357,H,2222,CHdMBL875004,,,,,xutocurati0n,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
3470,,,,B,,,BAO0000oq9,H,10322,sHEMBL6181y2,,,,,Autocu3ati9n,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3471,,,,B,,,BAO00o0356,H,16117,CHEMBLt17153,,,,,wutoc7ration,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3472,,,,B,,,BxOo000357,H,17200,CHEMBk61888o,,,,,Autoxuratipn,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,
3473,,,,F,,,fwO0000019,H,17358,CHEMBk618888,,,,,Aigocuration,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,
3474,,,,B,,,BwO0000367,H,16700,CmEnBL618890,,,,,Autoc6rati9n,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,
3475,,,,B,,,BAOp090019,H,1980,CHEMBL617892,,,,,Au6osuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,
3476,,,,B,,,BAO900o019,H,1980,CHEMBp618054,,,,,Au49curation,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,
3477,,,,B,,,nAO000022e,H,12409,CHEMBk629055,,,,,Autocirati8n,Binding affinity against the 5-hydroxytryptamine 3 receptor,,
3478,,,,B,,,fAk0000357,H,4365,CHEMBL6q9055,,,,,A8tocuratikn,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3479,,,,F,,,BsO00p0019,H,4365,CjEMgL619057,,,,,Autocurwtoon,Percent efficacy against 5-hydroxytryptamine 3A receptor,,
3480,,,,B,,,BAO0009347,H,4365,CgEMBL619057,,,,,Autocurztiob,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3481,,Oochtes,,F,,,BxO00p0219,D,6769,CHEMBk61p059,,,,,Exprrt,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Rattus norvegicus,10116.0
3482,,Oocytfs,,F,,,BAp9000219,D,6769,fyEMBL619060,,,,,Exprrt,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Rattus norvegicus,10116.0
3483,,Oosytes,,F,,,BAO000o119,D,6769,CHEMBL975096,,,,,Edpert,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Rattus norvegicus,10116.0
3484,,,,F,1622625.0,Ilehm,BAOo0002q1,D,809,CnEMBL61p061,,,,,Intermefiatw,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Cavia porcellus,10141.0
3485,,,,F,48853.0,lleum,BAOp000e21,D,809,CmEMBo619062,,,,,ontrrmediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Cavia porcellus,10141.0
3486,,,,F,,,BAp00000q9,D,14290,vHEMBL61i063,,,,,Ib4ermediate,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Cavia porcellus,10141.0
3487,,,,B,1109330.0,8leum,BA8000022w,D,17358,CHwMBL619964,,,,,Im6ermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Cavia porcellus,10141.0
3488,,,,B,,,BqO0000356,D,17358,CHfkBL619065,,,,,Igtermefiate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Cavia porcellus,10141.0
3489,,,,B,2794896.0,Ileuh,BA9000p221,D,17358,dHEMBL719066,,,,,jntermedizte,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Cavia porcellus,10141.0
3490,,,,B,1865355.0,Iieum,BAO0000311,H,17386,xmEMBL619775,,,,,Au5ocugation,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3491,,,,B,,,BAOo009357,H,3269,CHEMBLu19766,,,,,Aitocuratiog,Affinity against 5-hydroxytryptamine 7 receptor,,
3492,,,,B,,,fAp0000224,H,7721,vHEMBL6197u7,,,,,Autocu3atiom,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,10141.0
3493,,,,B,,,BAOo000w24,H,7721,CHwMBL6w9778,,,,,Aufoxuration,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,10141.0
3494,,,,B,1014072.0,Ikeum,Bxi0000221,H,9117,CHEMBL71977o,,,,,Autocuratuog,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Cavia porcellus,10141.0
3495,,,,B,,,BAO0po0224,H,7721,CHEjBL61i780,,,,,Autocu3atiln,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,10141.0
3496,,,,B,,,BAp0900224,H,7721,CtdMBL619166,,,,,Autofurqtion,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,10141.0
3497,,,,F,,,BAO0990019,H,15796,CHEMBL6q0167,,,,,Autodufation,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,10141.0
3498,,,,F,,,BAOo0000w9,H,15796,CnEhBL619168,,,,,xutovuration,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,10141.0
3499,,,,B,757681.0,Cardiacat3i7m,BAO0p0o219,D,15650,CHEMBLy19159,,,,,Exoert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Homo sapiens,9606.0
3500,,,,B,3494781.0,dwrdiacatrium,BAO00002w0,D,15650,CmEMBL6191u0,,,,,Exp3rt,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Homo sapiens,9606.0
3501,,,,F,,,gAO00p0019,D,6866,CHEMBL619w61,,,,,xutocuratiob,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Homo sapiens,9606.0
3502,,,,F,2713071.0,Careiacarrium,BAO09p0219,D,15650,CHEMfL610172,,,,,Ecpert,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Homo sapiens,9606.0
3503,,,,B,,,gAO0900019,U,10063,CHEMBk61p173,,,,,zutocuratioh,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Mus musculus,10090.0
3504,,,,B,,,BAp00p0019,U,12665,CHEMhLt19174,,,,,quyocuration,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Mus musculus,10090.0
3505,,,,B,,,fAO0000018,H,7504,vHEMgL619175,,,,,Au6oxuration,5-hydroxytryptamine receptor binding affinity was determined in rats,,
3506,,,,B,,,BsO000p224,H,7504,sHEMBLu19176,,,,,Autocjdation,Binding affinity at rat 5-hydroxytryptamine receptor.,,
3507,,,,B,,,vAk0000019,H,7038,CHEMBL619186,,,,,Autocufatiob,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,
3508,,,,B,,,hAO9000224,H,7626,CHEMBi719178,,,,,Aytkcuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,
3509,,,,B,,,BAO0p00324,H,7626,CHEMBL629279,,,,,zytocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,
3510,,,,F,569752.0,dtomach,BAO0909019,H,7185,CuEMBLt19180,,,,,Autocurayiob,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,
3511,,,,F,2108466.0,Stomsch,BAO9000029,H,7185,CHEMBL71918w,,,,,A7gocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,
3512,,,,F,,,BAl9000019,H,7185,CHEMBL6191ue,,,,,Aut9curatipn,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
3513,,,,B,,,BAi000022r,H,6960,CHEMhL619w83,,,,,Autochrxtion,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,
3514,,,,B,,,BAk0000e24,H,6960,vgEMBL619184,,,,,xutocuratoon,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,
3515,,,,B,65309.0,Hipplcam0us,nAO0000121,H,12416,CHEnBi619185,,,,,A7tocurztion,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
3516,,,,B,,,hAO00003y7,H,15753,vHEMBL629186,,,,,Expe3t,Binding affinity for rat 5-hydroxytryptamine transporter.,,
3517,,,,B,,,gzO0000019,H,8062,xHEMBp619187,,,,,Autoc84ation,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,
3518,,,,B,,,BAO900p019,D,9036,CH2MBL619288,,,,,Au4ociration,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Rattus norvegicus,10116.0
3519,,,,B,,,BAO0o00225,D,15067,CH4MBL6191o9,,,,,qufocuration,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Rattus norvegicus,10116.0
3520,,,,F,692116.0,grain,BAOp000010,D,15753,sHEMgL619190,,,,,sxpert,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Rattus norvegicus,10116.0
3521,,,,F,319677.0,Cerebwklum,BAO000p22q,D,15753,CHEMBi6w9191,,,,,Edpert,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Rattus norvegicus,10116.0
3522,,,,B,,,BAO0000pw9,D,15295,CHEMBL518192,,,,,Autkcuratiln,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Rattus norvegicus,10116.0
3523,,,,B,,,BAOp00p224,D,6347,fHEMvL619193,,,,,zutocu5ation,Percent binding affinity against 5-hydroxytryptamine receptor,Rattus norvegicus,10116.0
3524,,,,B,,,BAO9000919,U,6763,CH3MBL629194,,,,,Autoc6rarion,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,
3525,,,,B,,,BA90000q24,D,12092,CjEMBL619295,,,,,qutocuratiob,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Rattus norvegicus,10116.0
3526,,,,B,,,BAO0000q2r,D,1579,CH4kBL619196,,,,,Autocutatiob,Affinity against 5-hydroxytryptamine receptor was determined,Rattus norvegicus,10116.0
3527,,,,B,1905065.0,Sromach,BAO0o00p19,D,1579,CH3MBo619197,,,,,Autochratioh,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Rattus norvegicus,10116.0
3528,,,,B,,,BAO0000q1i,D,5963,CH3nBL619198,,Incitro,,,Ex9ert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,9606.0
3529,,,,B,,,BwO0000210,D,5963,CHEnBL87508q,,Invitr0,,,Ezpert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,9606.0
3530,,,,B,,,BqO9000357,H,5030,CHEMBL8i4u12,,,,,Autocurafuon,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,
3531,,,,B,,,BAO0o09357,H,15796,CHwMBL894710,,,,,Expeft,Inhibition of 5-hydroxytryptamine reuptake,,
3532,,,,F,,,BAO0000ow9,H,15413,CHEMBL6w8199,,,,,Autocurxt7on,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,
3533,,,,F,,,BAi00o0019,H,15413,CHEMBo618200,,,,,Autocueztion,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,
3534,,,,F,,,hAOo000019,H,15413,CHEMnL6192o1,,,,,Autocura48on,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,
3535,,,,F,,,gAO0000919,H,12409,CHEMBLt1920w,,,,,Autocuestion,Tested for 5-hydroxytryptamine receptor uptake,,
3536,,CHO,,B,,,BA9000o219,D,16909,CHEMBL519293,,,,,Exper4,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,9606.0
3537,,,,F,,,BAO009001p,D,16909,CHEhBL61p204,,,,,Ex0ert,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Homo sapiens,9606.0
3538,,,,B,,,BAO000o239,H,15629,CnEMBi619205,,,,,wutocuratioh,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Homo sapiens,9606.0
3539,,,,B,,,BsO0000367,H,15629,sHEMBLu19206,,,,,Autocu4ati0n,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,
3540,,,,B,,,BzO000024o,H,15629,CHEMBL61020u,,,,,Ex9ert,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,
3541,,,,F,800966.0,Strixtum,BAO00o00w9,H,10034,CHEMBo610208,,,,,Au4ocuratiln,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,
3542,,,,F,3661126.0,atriatum,BAk0000919,H,10034,fHEMBL519209,,,,,zutpcuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,
3543,,,,F,5035649.0,Striat7m,BAO90000q9,H,10034,sHEMBL6192w0,,,,,Autocu5a6ion,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,
3544,,,,F,1713088.0,Sttiatum,vAO00000w9,H,10034,CHEhBL6w9211,,,,,Aufocurahion,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3545,,,,F,4570702.0,Striatim,BzO000p019,H,10034,CHEMBp619q12,,,,,Aitocueation,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,
3546,,,,F,1055300.0,Strkatum,BAO000p029,H,10034,CHEnBLt20681,,,,,Ayt0curation,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,
3547,,,,F,1659516.0,Striwtum,fAO000p019,H,10034,dHEkBL620682,,,,,Ah6ocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,
3548,,,,F,3137902.0,Stria4um,BAO00p001o,H,10034,CHEMBp620682,,,,,qutocurztion,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,
3549,,,,F,3858508.0,St4iatum,BAO00p0o19,H,10034,CH3MBL62068e,,,,,Au6oxuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,
3550,,,,F,3232015.0,Striatuh,hAO00p0019,H,10034,CHEMBLt20695,,,,,Aktkcuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3551,,,,F,2114630.0,St5iatum,hAO0000p19,H,10034,CtEMBi620686,,,,,Autoc7eation,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,
3552,,,,F,635560.0,Limficsys6em,gAO0000o19,H,10034,CHEMBk620u87,,,,,Autoxurarion,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,
3553,,,,F,3084916.0,Limgicsysgem,BAOp000919,H,10034,CHEMBL6206oo,,,,,Autocura5ioj,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3554,,,,F,557339.0,Limbicxyztem,BAl0o00019,H,10034,CuEjBL620689,,,,,Ajtosuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,
3555,,,,F,3418868.0,pimbicdystem,BAO00op019,H,10034,xHEMBL620680,,,,,Aihocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,
3556,,,,F,1852110.0,Linbicsyst2m,BwO0000018,H,10034,CHEMBp6206o1,,,,,Aurocuratioh,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,
3557,,,,F,2119189.0,Limbicsysr3m,BAO0090o19,H,10034,CHEMBL510692,,,,,sutocuratiin,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,
3558,,,,F,2526138.0,oimbicsyst4m,BAp0009019,H,10034,CHEMhL630693,,,,,Autoc8rati0n,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,
3559,,,,B,,,BA90p00357,H,1274,vHEMhL620694,,,,,Eapert,Binding affinity against 5-hydroxytryptamine 4 receptor,,
3560,,,,F,,,BAO00900q9,H,17358,CuEMBLi57986,,,,,zuticuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3561,,,,B,,,BAO0000e58,H,14532,CHEMBL62059r,,,,,Autocurwt8on,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,
3562,,,,B,,,hAO0900357,H,16989,CHEMBL6205i6,,,,,Expery,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,
3563,,,,B,,,vAOp000357,H,17200,CmEMBL620698,,,,,Autocitation,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,
3564,,,,B,,,BAOo00p357,H,15779,CH2hBL620698,,,,,Autoc7ratlon,Binding affinity towards 5-hydroxytryptamine 4 receptor,,
3565,,,,B,,,BAO0900356,H,15779,CHEMvL620690,,,,,Autodutation,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3566,,,,B,,,gzO0000357,H,15779,CHEMBL6q07p0,,,,,Autocuda5ion,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3567,,COS7,,B,,,nAO0009219,H,15650,dHEMBL62o701,,,,,sutocurati9n,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,
3568,,COS7,,B,,,BAOp000229,H,15650,CHEMBL8yt082,,,,,Aktocura5ion,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,
3569,,COS7,,B,,,BAk0p00219,H,15650,CHEhBL62p702,,,,,wutocyration,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,
3570,,COS7,,B,,,BzO00002q9,H,15650,CH3MBp620703,,,,,Auyocudation,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,
3571,,C6,,B,,,BAk000021o,H,17046,CHEMBL720y04,,,,,Aufocuratjon,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3572,,C6,,B,,,BAO0o002q9,H,17046,CHEMBL62p805,,,,,Ex9ert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3573,,C6,,B,,,BwO0o00219,H,15650,CHdMBL6207o6,,,,,Exp2rt,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,
3574,,C6,,B,,,nAOp000219,H,17046,CHEMBLt2070u,,,,,Expeft,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,
3575,,,,B,,,vxO0000357,H,17066,CbEMBL6q0708,,,,,Ex9ert,Binding affinity towards 5-hydroxytryptamine 5 receptor,,
3576,,,,B,,,BA00000358,H,17200,sH2MBL620709,,,,,Autoduratiom,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,
3577,,,,B,,,gAO0000367,D,16146,CgfMBL620710,,,,,3xpert,Binding affinity against 5-hydroxytryptamine 5A receptor,Homo sapiens,9606.0
3578,,CHO,,B,,,BAO0p90219,H,15250,CHEMBL62061w,,,,,Autlcurqtion,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,
3579,,,,B,,,vAO000035u,D,6491,CH3MBo620712,,,,,Expegt,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Homo sapiens,9606.0
3580,,,,B,,,BAl0p00357,D,17066,CH3MBL62071r,,,,,Exper4,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Homo sapiens,9606.0
3581,,,,B,,,BA00009357,D,17066,CHEMBL72p714,,,,,2xpert,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Homo sapiens,9606.0
3582,,,,B,,,BAO0o0035i,D,4234,CHEjvL620715,,,,,Expe3t,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Homo sapiens,9606.0
3583,,,,B,,,BAO00o03r7,H,6013,CjEhBL620716,,,,,Autosuratipn,Binding affinity towards 5-HT5A receptor,,
3584,,,,B,,,BAO0p0o357,H,17175,vHwMBL620717,,,,,Expe5t,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3585,,,,B,,,BsO0p00357,H,15818,CHEMnL617072,,,,,Aut8curztion,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,
3586,,,,B,,,BsO000035u,H,6166,vH4MBL857987,,,,,Autocutwtion,Binding affinity towards cloned human 5-HT5A receptor was determined,,
3587,,HEK393,,B,,,BAO00p021o,H,15779,CH2MBL618973,,,,,Autocuta4ion,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3588,,nEK293,,B,,,hAO0000e19,H,15779,CyEMBL628074,,,,,Autocjra5ion,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3589,,HEK29r,,B,,,gAO00002q9,H,5213,CHEMBo618076,,,,,Auticurxtion,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,
3590,,,,B,,,BA80000367,D,17066,CHsMBL6180y6,,,,,Ex0ert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Mus musculus,10090.0
3591,,,,B,,,BAO9p00357,D,17066,dHEnBL618077,,,,,Exper4,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Mus musculus,10090.0
3592,,,,B,,,BAi0000347,D,17066,CbEMBL628078,,,,,Expfrt,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Mus musculus,10090.0
3593,,,,B,,,gAO000035u,D,17066,CH4MBL881811,,,,,Ecpert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Mus musculus,10090.0
3594,,,,B,,,hAO00p0357,D,17066,fHEMBL518079,,,,,Ex0ert,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Mus musculus,10090.0
3595,,,,B,,,BAOo0p0357,H,17175,CgEMBL618089,,,,,Exp4rt,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3596,,H2K293,,B,,,BAOp00o219,H,16190,CH4MBL6q8081,,,,,Autochrat9on,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3597,,HEu293,,B,,,hAOp000219,H,16190,CH3MBL618p82,,,,,Autocu3at8on,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3598,,,,B,,,BAO0p0p357,H,4820,CuEMBL61808r,,,,,Experf,Binding affinity towards 5-HT5a receptor,,
3599,,,,B,,,BAO0090w57,D,17066,CHEMBL718984,,,,,Ecpert,Binding affinity towards 5-hydroxytryptamine 5A receptor,Homo sapiens,9606.0
3600,,,,B,,,BA8p000357,H,17066,vHdMBL618085,,,,,Exlert,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,
3601,,,,B,,,BzO0000w57,H,17175,CHEMBo618986,,,,,Expfrt,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,
3602,,,,B,,,BAO0p00257,H,16633,CjEMBL87509q,,,,,Autocirqtion,Binding affinities against 5-hydroxytryptamine 5A receptor,,
3603,,,,B,,,BAO00o0e57,H,16633,xHEMBL61i087,,,,,Aytocurxtion,Binding affinities towards 5-hydroxytryptamine 5A receptor,,
3604,,,,B,,,BAOp900357,H,16700,CHEMfk872926,,,,,Autovuratiog,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,
3605,,,,F,,,nAOp000019,H,4639,CHEMBLu18087,,,,,A6tocuratiin,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,10141.0
3606,,,,B,,,BzO00002q3,H,5486,CHdjBL618089,,,,,Ajtocuratiob,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,
3607,,,,B,,,vAO0000367,D,16146,CHEkgL618090,,,,,Experf,Inhibition of human 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3608,,,,B,,,BAO000o3t7,D,17273,CHEMBL628o91,,,,,Expery,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Homo sapiens,9606.0
3609,,,,B,,,nAO0000e57,H,17687,CHEjBLy18092,,,,,Ahtoc7ration,Inhibition against human 5-hydroxytryptamine 6 receptor,,
3610,,,,B,,,vAO0000358,D,6491,dHEMBL618993,,,,,Exper4,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Homo sapiens,9606.0
3611,,HeLa,,B,,,BAO90002w9,H,16190,CHrMBL618004,,,,,Ex9ert,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,
3612,,,,B,,,BAO00p0257,D,17066,CHEMhi618095,,,,,Eapert,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3613,,,,B,,,Bw00000357,D,17066,CH4MBL8y5093,,,,,4xpert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3614,,,,B,,,BAO000ow57,D,17066,CmEMfL618096,,,,,Expeet,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Homo sapiens,9606.0
3615,,,,B,,,BAO0p0o357,D,17066,CHEMBL6191w8,,,,,Expsrt,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Homo sapiens,9606.0
3616,,,,B,,,BAOo00o357,D,3555,CHEMnL617119,,,,,Experf,Binding affinity against 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3617,,,,B,,,vAO0000367,H,5808,CHdMBL6181e0,,,,,Eapert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3618,,,,B,,,BsOo000357,H,6013,CHEMBL61o1q1,,,,,Autlcueation,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3619,,HEK292,,B,,,gAO0p00219,H,15818,CHEMvL618q22,,,,,Expedt,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,
3620,,,,B,,,hAO00003r7,H,16209,CmEMBL61812r,,,,,Autosurztion,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,
3621,,HEm293,,B,,,BAO000oq19,H,3935,CmEMBL618w24,,,,,Expegt,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,
3622,,,,B,,,BAO000p3y7,H,15818,CHEMBLt18126,,,,,Autocura6ikn,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3623,,HEK29e,,B,,,BzO00002q9,D,3805,CmEMBL618w26,,,,,Exper6,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Homo sapiens,9606.0
3624,,,,B,,,BAO0000o10,H,16441,CHEnBL6182r6,,,,,Expery,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,
3625,,,,B,,,fAO0o00019,H,16441,CHEhBL6q8237,,,,,Ecpert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3626,,COS7,,B,,,BAO0op0219,H,6786,CHEMBL61ow38,,,,,Expwrt,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,
3627,,,,B,,,BAO00003ri,D,4234,fHEMBL6182e9,,,,,Expfrt,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3628,,,,B,,,BAO0o0p019,H,17085,CHEMBp6182e0,,,,,qutocurarion,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,
3629,,,,B,,,BAO000p35i,H,17200,xHEMhL618241,,,,,Aut0cjration,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,
3630,,H4K293,,B,,,BAOo0o0219,H,17451,CHEMBL7593p9,,,,,Autodurayion,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,
3631,,,,F,,,nAi0000019,H,3935,CHEMBp61824e,,,,,Aufocuratiob,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,
3632,,,,B,,,BxO0000e57,H,5033,CHEMBou57991,,,,,zutocurati9n,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,
3633,,,,B,,,BzO0o00357,H,4540,CgEjBL619951,,,,,Expedt,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3634,,HeLa,,B,,,BAO00oo219,D,4540,CH3nBL619952,,,,,Exper6,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,9606.0
3635,,HeLa,,B,,,BA0p000219,D,4540,dtEMBL619953,,,,,Expe4t,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,9606.0
3636,,HeLa,,B,,,BAO000o21p,H,17296,CyEMBL61995t,,,,,Autockra4ion,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,
3637,,HeLa,,B,,,hAO0090219,H,17296,CHEMBLu29955,,,,,Augocurafion,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3638,,HeLa,,B,,,BsO9000219,H,17296,CHEjBL618956,,,,,Autoc7ratlon,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3639,,CHO,,B,,,BAO0000qw9,H,15779,CHfMBL719957,,,,,Auhocuratiin,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
3640,,HEo293,,B,,,BAO0o0021i,H,15779,CHEMBL6190y8,,,,,Autoc6rztion,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3641,,HEK29e,,B,,,BAlo000219,H,15779,CHsMBL62o627,,,,,wutochration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,
3642,,HEK283,,B,,,BAOp000319,H,15779,CHEMnL6206w8,,,,,wutocu4ation,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3643,,HeLa,,B,,,BwO0000229,H,15779,CHEkgL620629,,,,,Aktockration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,
3644,,,,B,,,BAi0000358,H,6166,CHEMBL52p630,,,,,Autocu5afion,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3645,,HeLa,,B,,,BAO090021o,H,17451,CyEMBL520782,,,,,Aut8furation,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,
3646,,,,B,,,BzO0000358,H,15316,CHEMvp620783,,,,,Autocura4ipn,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,
3647,,,,B,,,BAO09003t7,H,4199,CHEMBL620io4,,,,,wxpert,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3648,,HeLa,,B,,,fAO0090219,H,15146,CHEMBkt20785,,,,,Ex0ert,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,
3649,,,,B,,,Bxi0000357,H,5213,CjEMBL8579i2,,,,,Autocu3stion,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,
3650,,,,B,,,BAOo000q19,H,16429,CHEMfL620785,,,,,Ahfocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,
3651,,HeLa,,B,,,BAO000p119,H,14818,CH3MBL520787,,,,,Aut9suration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,
3652,,HeLa,,B,,,hAO0090219,H,4829,CHEMnL620u88,,,,,wjtocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,
3653,,HeLa,,B,,,BA800002w9,H,4829,CHEMBL630689,,,,,Autociratiom,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,
3654,,HeLa,,B,,,BwO0000w19,H,4829,dmEMBL620790,,,,,Autocuratu0n,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,
3655,,CHO,,B,,,BzOo000219,H,15250,CHEMBLt20701,,,,,Autocjdation,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,
3656,,,,B,,,vAO0900019,H,14423,CHEhBL62o792,,,,,Autocurwtiob,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,
3657,,,,B,,,BA90000r57,H,15086,CHEMBp6w0793,,,,,Autocueati8n,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,
3658,,,,B,,,BzO0000457,H,4342,CHEjBL629794,,,,,xutoxuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,
3659,,HeLa,,B,,,BAO0p0o219,D,16190,CuEMBL620785,,,,,Autocirstion,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Homo sapiens,9606.0
3660,,,,B,,,hAO000p357,H,4820,CgEMBL720796,,,,,Edpert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3661,,,,B,,,fAO0000367,H,4639,sHEMBL620897,,,,,A8tocutation,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,
3662,,,,F,,,BA80o00019,D,17066,dHEMvL620798,,,,,Espert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Homo sapiens,9606.0
3663,,,,B,,,fwO0000357,H,6011,CHfMBL629799,,,,,Autocutatiob,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,
3664,,,,B,,,BAOp0o0357,H,17066,CHEMBL6e9800,,,,,Expedt,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3665,,,,B,,,BAOop00357,H,17515,dH3MBL620801,,,,,Autkchration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,
3666,,,,B,,,BAO0p90357,H,5014,CHrMfL875100,,,,,zutocuratuon,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,
3667,,,,B,,,BAO0p003t7,H,4373,CbEMBL620u02,,,,,Au4ocueation,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,
3668,,,,F,,,BAO0090919,H,17066,CHEjBL620893,,,,,Experg,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,
3669,,,,F,,,BA800p0019,H,17066,CjEjBL620804,,,,,Exoert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,
3670,,,,B,,,BsO000p357,H,4373,CmEMBL620i05,,,,,A7ticuration,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,
3671,,,,B,,,BqOo000357,H,4687,CHEMBp520806,,,,,Autocurat9om,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,
3672,,,,B,,,BwO0900357,H,16946,dHEMBL62080u,,,,,zutocu3ation,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,
3673,,,,B,,,BAO009o357,H,16946,CuEMBL629808,,,,,Autovuratiog,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,
3674,,,,B,,,BAO0000wy7,H,16633,CHEMBL629909,,,,,xutocurat7on,Binding affinities against 5-hydroxytryptamine 6 receptor,,
3675,,,,B,,,BAO9000358,H,16633,CHEMnL620o10,,,,,Autofurati0n,Binding affinities towards 5-hydroxytryptamine 6 receptor,,
3676,,,,B,,,BAO000pr57,D,17066,xHEMBL620911,,,,,Expeft,Binding affinity towards 5-hydroxytryptamine 6 receptor,Homo sapiens,9606.0
3677,,,,B,,,BAO0o003y7,H,16700,xH3MBL620812,,,,,Autocu5arion,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,
3678,,,,B,,,nAO0900357,H,3269,CHfMBL720813,,,,,Auhocuragion,Affinity against 5-hydroxytryptamine 6 receptor,,
3679,,,,B,,,BzO0p00357,H,5486,CHEMBL6e08q4,,,,,Aurocurqtion,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,
3680,,,,B,,,hAl0000357,D,16146,CmEMBL62o815,,,,,Expe4t,Inhibition of human 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3681,,jEK293,,B,,,BxO0000218,H,5014,CHEMBL62p826,,,,,Autocudati9n,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,
3682,,,,B,,,BAOp000367,H,15463,CHEMfk620817,,,,,Autoci5ation,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,
3683,,,,B,,,BAl0000347,H,3805,CHEkBL720818,,,,,Autocuratu0n,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,
3684,,HEK2o3,,B,,,BqO0000229,H,5014,xHEMBLt20819,,,,,Exp3rt,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,
3685,,,,B,,,BAOo090357,D,6491,CHEjBk620820,,,,,Expsrt,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Homo sapiens,9606.0
3686,,CHO,,B,,,BA90000210,H,16190,CHEjhL620821,,,,,Aytocuratioj,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,
3687,,,,B,,,BAO9000257,D,17066,CnEMBL620722,,,,,Experh,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3688,,,,B,,,vAO00p0357,D,17066,CHEMnL629823,,,,,Ex9ert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3689,,,,B,,,BAO000o35i,D,3555,CHEkBL62p824,,,,,Expe3t,Binding affinity against 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3690,,CHO,,B,,,BsO0000319,H,6588,CHEMBp6208e5,,,,,2xpert,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,
3691,,,,B,,,BAO00p0356,H,15463,CHEMBL87e939,,,,,qutocurati0n,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,
3692,,,,B,,,BAO00o03y7,H,6013,CHEkBL720826,,,,,wutocudation,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3693,,,,B,,,Bsp0000357,H,16209,CHEMnL6q0827,,,,,Autlchration,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3694,,,,B,,,BAO00p03t7,H,3935,CHEMBL6q08q8,,,,,Autofurat9on,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,
3695,,,,B,,,BA8000o357,H,15818,CHEhBL629829,,,,,Au4ocura6ion,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3696,,uEK293,,B,,,Bz90000219,H,5014,xHEMgL620830,,,,,Expedt,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,
3697,,,,B,,,BAO0o000q9,H,16441,CHEMBLt30831,,,,,Expegt,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,
3698,,,,B,,,nAp0000019,H,16441,CHsMBL6208e2,,,,,Eapert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3699,,,,B,,,BxO000p357,D,4234,CnEMBL62q548,,,,,Ex0ert,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3700,,,,B,,,BAO00p0018,H,17085,CHEMhk621549,,,,,Au4oc7ration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,
3701,,,,B,,,BAp000035u,H,17200,fHEMBL521550,,,,,Aut0chration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,
3702,,CHO,,B,,,BqO000021o,H,17451,CHwMBL622551,,,,,Auhocuratlon,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,
3703,,,,B,,,BxO000001i,H,17085,CHwMvL621552,,,,,Au5ocueation,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,
3704,,,,B,,,BwO000035y,H,5104,CHEMBi8570i7,,,,,Ahtocurztion,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,
3705,,,,B,,,BAOp00035u,H,5104,CbEMfL618158,,,,,Aut8curatiob,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,
3706,,COS7,,B,,,BAO00002wp,D,5033,CHsMhL618159,,,,,rxpert,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Homo sapiens,9606.0
3707,,COS7,,B,,,BAO0090229,H,5486,CHEMBLo75q01,,,,,Autoc6rarion,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,
3708,,uEK293,,B,,,BA0000o219,D,4540,CyEMhL618160,,,,,Expery,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Homo sapiens,9606.0
3709,,,,B,,,BAO000p367,H,6166,CHEMBi6181t1,,,,,Exper6,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,
3710,,HsK293,,B,,,BAO00o02q9,H,17342,CHrMgL618162,,,,,sxpert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,
3711,,,,B,,,BAO0000267,H,17342,CHwkBL618163,,,,,dxpert,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,
3712,,,,B,,,nAO000035u,H,17296,CHEMBL717164,,,,,Autocurqti9n,Binding affinity against 5-hydroxytryptamine 7 human receptors,,
3713,,,,B,,,BAOpo00219,H,16429,CHEjBL6181y5,,,,,Exp2rt,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,
3714,,HEK193,,B,,,nAO0000319,H,15779,CHdMBL518166,,,,,Auhocura6ion,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,
3715,,HEK2i3,,B,,,BA9000p219,H,15779,CHsMBL857980,,,,,Autocufati8n,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3716,,HEu293,,B,,,vAO000021i,H,15779,CHEMBiu19888,,,,,Autoc8rahion,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3717,,H3K293,,B,,,vAO0090219,H,15779,CHEMBL62988o,,,,,Autlc6ration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3718,,HEK393,,B,,,BAO0o00e19,H,15779,CHEMBL6w9u90,,,,,xutocuratioh,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,
3719,,CHO,,B,,,BAi0000229,H,17451,CH2MgL619891,,,,,z8tocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,
3720,,HEK29r,,B,,,BA0o000219,H,4199,CHEMBLu19o92,,,,,Autocurayiog,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,
3721,,HEKe93,,B,,,BAi00o0219,D,4199,CHEMgL610893,,,,,Expeft,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,
3722,,HEKq93,,B,,,BAi0000229,H,4199,CHfMBL719894,,,,,Autocyrxtion,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,
3723,,HEl293,,B,,,BAO00p0229,D,3680,CjEMBL618895,,,,,Interm2siate,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,
3724,,,,B,,,BzO0000356,D,3680,CnEMBL6198o6,,,,,Interkediat4,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,
3725,,COS7,,B,,,BA9000021p,H,15316,CH2MBL61o897,,,,,Autksuration,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,
3726,,HEKe93,,B,,,BAp0o00219,H,15146,CgEMnL619898,,,,,Autockragion,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,
3727,,HEK2p3,,B,,,BA00000319,H,5213,vHEMBL6q9899,,,,,Espert,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,
3728,,HEKq93,,B,,,BAO00002wo,H,5213,CHEMBp619909,,,,,Autocitation,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,
3729,,H3K293,,B,,,BAOp000210,D,14818,CHEMfL618901,,,,,Edpert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Homo sapiens,9606.0
3730,,HEK294,,B,,,BzO0o00219,H,14818,dHEMBL62058o,,,,,Ajtocurat8on,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,
3731,,HEK294,,B,,,BAO000921i,H,14818,CHEhhL620581,,,,,Autocurayipn,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,
3732,,HEKw93,,B,,,BAO0p0021o,H,4829,xHEMvL620733,,,,,Autocuratu8n,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,
3733,,,,B,,,BAO0000w5u,D,17200,CuEMgL620734,,,,,wutocuratiln,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Homo sapiens,9606.0
3734,,,,B,,,BxO0009357,D,17066,CHEjnL620735,,,,,Espert,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Mus musculus,10090.0
3735,,,,B,,,Bzk0000019,H,14025,CHfMBL620737,,,,,Autodutation,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Oryctolagus cuniculus,9986.0
3736,,CHO,,B,,,fAO000021p,H,15250,CHEMhL620738,,,,,Autpcugation,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,
3737,,CHO,,B,,,BAO000ow19,H,16372,CHEMBL6206r8,,,,,qutocuratiom,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,
3738,,CHO,,B,,,BAO000921o,H,16372,CgEMBk620739,,,,,Auyocuratuon,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,
3739,,CHO,,B,,,BAO0009q19,H,16372,dHEMBL630740,,,,,Autocudat9on,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,
3740,,CHO,,B,,,BAO9000w19,H,16372,fHEMBL620841,,,,,xutockration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,
3741,,CHO,,B,,,BqO0900219,H,16372,vHEMgL620742,,,,,Aurosuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,
3742,,CHO,,B,,,BAO009o219,H,16372,CnEkBL620743,,,,,xutocueation,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,
3743,,CHO,,B,,,nwO0000219,H,16372,fHEMBL6207r4,,,,,Autoc6ratipn,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,
3744,,CHO,,B,,,BAO0p09219,H,16372,CHEMvL620735,,,,,Autochrstion,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,
3745,,CHO,,B,,,BAOpo00219,H,16372,CnEMgL620746,,,,,A8tocuratuon,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,
3746,,CHO,,B,,,BAO90p0219,H,16372,dHEhBL620747,,,,,Autocura4i9n,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,
3747,,CHO,,B,,,BApo000219,H,16372,CH2MBL62074i,,,,,Ahtocuratioj,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,
3748,,CHO,,B,,,BAO00902w9,H,16372,CHEMhL620649,,,,,Autocurs5ion,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,
3749,,,,B,,,gAO00003r7,H,17066,CHEkBL620760,,,,,Expeet,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,
3750,,,,B,,,BAO90o0357,D,17066,xHsMBL620751,,,,,3xpert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Rattus norvegicus,10116.0
3751,,,,B,,,nxO0000357,H,17386,CH4MBL6q0752,,,,,Expeft,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,
3752,,,,B,,,BA9p000019,H,14423,CHEhBL87292i,,,,,suticuration,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,
3753,,,,B,,,BA0000o357,D,15874,CHEMBLu2075e,,,,,Exp3rt,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Rattus norvegicus,10116.0
3754,,,,B,,,BAO0p00e57,D,15874,CHEhBL6207t4,,,,,Exoert,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Rattus norvegicus,10116.0
3755,,CHO,,B,,,BAO0p00210,D,16372,CHEkBL620754,,,,,Expett,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Rattus norvegicus,10116.0
3756,,,,B,,,BAOp00035i,H,4622,CHEMhL630756,,,,,Autocuratlkn,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3757,,,,B,,,nAO0090357,H,15086,snEMBL620757,,,,,Aut9ciration,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,
3758,,CHO,,B,,,BwO9000219,H,16372,dHEMBL720758,,,,,Autocuratlom,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,
3759,,CHO,,B,,,BAO09002w9,H,16372,CH4MBL620769,,,,,Auhocurstion,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,
3760,,CHO,,B,,,BzOo000219,H,16372,CHEMBL62oy60,,,,,Autoduratuon,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,
3761,,CHO,,B,,,BzO000021o,H,16372,fHEMBL620861,,,,,Autocjratoon,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,
3762,,,,F,1071392.0,Ilejm,BAO0000131,H,17386,CHEMBp620772,,,,,Autocurafuon,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3763,,,,F,2489155.0,Ikeum,BAOp00022w,H,17386,CHEhBL6207y3,,,,,Auf0curation,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3764,,,,F,1598006.0,kleum,BAO000922w,H,17386,CgEMBL620754,,,,,Aut0curztion,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,
3765,,,,B,,,BAO0900248,D,5831,sHEMBL8579i0,,,,Membranfs,Ex0ert,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Rattus norvegicus,10116.0
3766,,,,B,,,BxO0000358,H,4342,CHEMBL6307u5,,,,,Augocurati9n,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,
3767,,,,B,,,BAO0p0p357,H,17319,CHEMgk620766,,,,,Ezpert,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,
3768,,,,B,356972.0,yypottalamus,BA800000q9,H,17342,CHsMBL629767,,,,,Exlert,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,
3769,,,,B,,,BAO0pp0357,H,17342,fHEMBL620758,,,,,Au4osuration,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,
3770,,,,B,1837952.0,Hypofhxlamus,BAO0000qe9,H,3680,CHwMfL619051,,,,,fxpert,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,
3771,,,,B,,,Bs90000357,H,3680,CtwMBL619052,,,,,Ecpert,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3772,,HEK29r,,F,,,fAOp000219,D,17319,CmEMBL6w9053,,,,,dxpert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Rattus norvegicus,10116.0
3773,,jEK293,,F,,,BsO0900219,D,17319,CHEMBo6q9703,,,,,Exoert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Rattus norvegicus,10116.0
3774,,HEm293,,F,,,BAO00003w9,D,17319,CnEMBL61970t,,,,,Autocjrwtion,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Rattus norvegicus,10116.0
3775,,,,B,,,BAp9000357,H,4820,CyEMBL6198r1,,,,,Exlert,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3776,,,,B,,,BAk000035y,H,4639,CHEMBL6197t2,,,,,Autocugati0n,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,
3777,,,,B,,,BAO0900w57,H,6011,CHEMBL619862,,,,,Autox6ration,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,
3778,,,,B,,,BAl0000367,D,17066,vHEMBL629854,,,,,Expdrt,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens,9606.0
3779,,,,B,,,BAO0oo0357,H,17066,CHEkBLy19855,,,,,Expwrt,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,
3780,,,,B,,,nAO00o0357,H,17515,CHEMBLu19846,,,,,Autovurat9on,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,
3781,,,,B,,,BAOo900357,H,4373,CjEMhL619857,,,,,Autocurat8oh,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3782,,,,F,,,BAO000p029,H,17066,CHwMBL61p858,,,,,Edpert,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,
3783,,,,B,,,nAO0000347,H,4373,CHEMBp6q9859,,,,,Aut9curat9on,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,
3784,,,,B,,,BAi00003y7,H,4373,CbEMBL719860,,,,,Autoduratiog,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3785,,,,B,,,BAO0p00257,H,4687,CHEMBL519862,,,,,wutocuratuon,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,
3786,,,,B,,,fA00000357,H,17342,CHEMfL6w9862,,,,,2xpert,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,
3787,,,,B,,,BAOp000457,H,16946,CHEMBp61986w,,,,,Au4ocurati9n,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,
3788,,,,B,,,BAO900p357,H,16946,fHEMBL619o64,,,,,xutocuratikn,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,
3789,,,,B,,,BAO000935y,H,16633,vHEMBi872928,,,,,Autofurwtion,Binding affinities against 5-hydroxytryptamine 7 receptor,,
3790,,,,B,,,BsO0090357,H,16633,CHwMBL619866,,,,,Autocu5xtion,Binding affinities towards 5-hydroxytryptamine 7 receptor,,
3791,,,,B,,,BAO0000r47,H,17066,CHfMBL619o66,,,,,Expeet,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,
3792,,,,B,,,BwO9000357,H,16700,CHfMBL619u67,,,,,Aktocuratiom,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,
3793,,,,B,163767.0,9leum,gAO0000231,H,17386,CnEnBL619868,,,,,Autocurqtioh,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3794,,,,F,,,BAO00o0919,H,14080,CHEMfL719869,,,,,Aurocuratiob,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,
3795,,,,F,,,BAp00p0019,D,14080,CHEMBL619iu0,,,,,fxpert,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Homo sapiens,9606.0
3796,,,,B,,,BAp0009357,H,409,CHEMBL7198u1,,,,,Autosurafion,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,
3797,,,,B,,,BAk000035i,H,409,CHEjBL619882,,,,,Autocu3ati9n,In vitro inhibition of human recombinant lipoxygenase enzyme,,
3798,,,,B,,,nwO0000357,H,409,CHfMBLy19873,,,,,Autoc8rxtion,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,
3799,,,,B,657336.0,nlood,BAO000935i,H,11090,CnEMBL619i74,,,,,Exp2rt,Inhibition of 5-lipoxygenase in human whole blood.,,
3800,,,,B,1605870.0,Blold,hAO0000356,H,11090,CHEMBL5w9875,,,,,Expe3t,Inhibition of 5-lipoxygenase in human whole blood.,,
3801,,,,B,,,BAO0900356,H,948,CHEMBo619u76,,,,,Autocuratkln,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,
3802,,,,B,,,BAO0o00358,H,948,CHEMBp619777,,,,,Autocurxgion,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,
3803,,,,F,,,fAO00o0219,H,13622,CHEMBL6108y8,,,,,Expeft,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,
3804,,,,F,1001825.0,Bkood,BAO0o0001p,H,13622,CHEMBL61o870,,,,,Autoduratioh,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,
3805,,,,B,,,BA90000e57,H,9637,fHEhBL619880,,,,,zutovuration,In vitro inhibition of 5-lipoxygenase from human polymorphs,,
3806,,,,B,,,BAi0000w57,H,11320,CHEMBo629881,,,,,Autocura6iln,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,
3807,,,,B,,,BAO00003y8,H,11320,CHEhBL61988e,,,,,2xpert,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,
3808,,,,B,,,gAO000035y,H,6838,CHEMvL619783,,,,,Autocurztiog,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,
3809,,,,B,1161458.0,nlood,gAO0900357,D,17667,CHEMBL7198o4,,,,,Ex0ert,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Homo sapiens,9606.0
3810,,,,B,,,vAO0009357,H,12703,CHwMBL61i885,,,,,Autockrqtion,In vitro potency against human 5-Lipoxygenase,,
3811,,,,F,,,BAi0090019,D,14312,CjEMvL619886,,,,,Expe4t,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Homo sapiens,9606.0
3812,,,,F,3917059.0,Bllod,BAO0000o1p,H,14312,CHEMgL61o887,,,,,Augocurwtion,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,
3813,,,,F,,,vAO0o00019,H,5364,xHEMBL87509y,,,,,Autocurq4ion,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3814,,,,B,,,BA90000319,H,951,CHEMBL61o00w,,,,,Au4ocuratiog,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,
3815,,,,B,,,BAOop00219,H,951,CHfMBL6180o2,,,,,Autocurahi8n,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,
3816,,,,B,,,BwO0000229,H,951,CmEMBL618o03,,,,,qutocueation,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,
3817,,,,B,,,fAOp000219,H,951,sHEMBL61800r,,,,,Autovuratioj,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,
3818,,,,B,,,BAO0099219,H,12365,sHEhBL618005,,,,,Auglcuration,Inhibition of human 5-lipoxygenase in human cells,,
3819,,,,B,,,vAO0000347,H,10603,CHEMBk618007,,,,,Exlert,Inhibition of human neutrophil 5-lipoxygenase,,
3820,,,,B,,,BA0p000019,H,10501,CHEMBLo7508u,,,,,Auyicuration,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,
3821,,,,B,5079343.0,Blopd,BqOp000357,H,12281,sHEjBL618007,,,,,Expdrt,Inhibition of 5-lipoxygenase from human whole blood,,
3822,,,,B,,,BAO0900e57,H,2567,CHEMBL6wi008,,,,,sutockration,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3823,,,,B,,,hAO9000219,H,2567,dHEMBL618o09,,,,,Autocurx6ion,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,
3824,,,,B,,,BAO0090w57,H,10193,CHEMBL61o01o,,,,,Expe3t,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,
3825,,,,B,,,fAO0900357,H,10193,fHrMBL618011,,,,,Autocuratkln,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3826,,,,B,,,BAO00903y7,H,13623,CH3MBL618011,,,,,Expery,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,
3827,,,,B,,,BAO0900358,H,12780,sbEMBL882927,,,,,Aktocurahion,Tested against 5-lipoxygenase,,
3828,,,,B,,,BAO0000348,H,12780,CufMBL618013,,,,,Autocjratiin,Tested for activity against 5-Lipoxygenase (5-LO),,
3829,,,,B,,,BAl0o00357,H,12780,CH3MBLy18014,,,,,Auticuratiob,Tested for activity against 5-lipoxygenase,,
3830,,,,B,,,BAO00004y7,H,11966,CHEMBL519015,,,,,Aut0curatipn,Tested for inhibition of 5-HPETE production by human 5-LO,,
3831,,,,F,,,BwOp000019,H,5364,CHdMBo618016,,,,,Autocutatjon,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3832,,,,B,,,BAO00p9357,H,13165,CHEMBi618016,,,,,Expe4t,Inhibition of Human 5-lipoxygenase,,
3833,,,,B,,,fAO0900019,H,5364,CHdnBL618018,,,,,Autosurarion,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,
3834,,,,B,,,BAO00o0229,H,11311,CHEMBi875086,,,,,A8tocuratuon,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
3835,,,,B,,,BA8000o219,H,11311,CHEMBLu18029,,,,,wutocurqtion,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,
3836,,,,B,,,BAi0000919,H,14863,CHsMBL61i020,,,,,wutochration,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,
3837,,,,B,,,nAO000p019,H,14863,suEMBL618021,,,,,Aut9cura5ion,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,
3838,,,,B,777994.0,Bl9od,BwO0900357,H,11087,xHEMBi618022,,,,,Aut0curstion,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,
3839,,,,B,,,BAO00o0358,H,455,CHEkBi618023,,,,,Autlcugation,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,
3840,,,,B,,,BAO0o0p357,H,13183,CHEMBo628024,,,,,Aut0cura5ion,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
3841,,,,B,,,BzO0p00019,H,10319,CHEhvL873950,,,,,Expwrt,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,
3842,,,,B,,,BAO0p09357,H,10193,CHEMvL518025,,,,,A8t9curation,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3843,,,,B,,,Bxi0000219,H,951,CtsMBL618026,,,,,Aut9cufation,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,
3844,,,,B,,,BAO0oo0219,H,951,CHEMBp61i027,,,,,Autocurat7om,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,
3845,,,,B,,,BAO00002q8,H,951,vmEMBL618028,,,,,Autoxurayion,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,
3846,,,,B,,,nAO000o219,H,951,CHEMBL6w7029,,,,,Autosugation,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,
3847,,,,B,,,BsOo000357,H,9859,CmEMBL518030,,,,,Expegt,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,
3848,,,,B,,,BwO00p0357,H,9859,CHrMgL618031,,,,,Expdrt,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,
3849,,,,B,,,nAO0000e57,H,9859,vHwMBL618032,,,,,A6tocuratioj,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,
3850,,,,B,,,BwO000o357,H,2567,dHsMBL618033,,,,,Autocurahiom,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3851,,,,B,,,vAO000035u,H,10193,CHEMBL6180r3,,,,,Autocursrion,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,
3852,,,,B,,,BAOp000347,H,10193,dHEMBL875o88,,,,,Ahtocuratiog,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3853,,,,B,,,BAO000o029,H,949,CnEMBL61u035,,,,,Autocugahion,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,
3854,,,,B,,,BAO09p0019,H,949,dHEMBL618936,,,,,Aurocurat9on,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,
3855,,,,B,,,BAOp0p0357,H,10603,CHEMnp618037,,,,,Edpert,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,
3856,,,,B,,,Bx90000357,H,10603,CHEhBL618938,,,,,Expwrt,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3857,,,,F,,,BAO90p0019,H,10603,CHEhBL618751,,,,,zutpcuration,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3858,,,,B,,,BAO0p90357,H,10603,CyEkBL618762,,,,,Expdrt,Inhibition of lipoxygenase at the concentration of 0.1 uM,,
3859,,,,B,,,BqO0000e57,H,10603,dHEMBL618u63,,,,,Ezpert,Inhibition of lipoxygenase at the concentration of 1 uM,,
3860,,,,B,,,BAO90p0357,H,10193,CHEkBL6187t4,,,,,Autocurati8m,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,
3861,,,,B,,,BAO0p0035u,D,14580,CHEMBk6187y5,,,,,Exp2rt,Inhibition of 5-Lipoxygenase (5-LOX),Homo sapiens,9606.0
3862,,,,B,,,BAO9o00357,H,11090,CHEnnL618766,,,,,Expe3t,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3863,,,,B,,,BAO009035i,H,11090,CHEjBo618767,,,,,4xpert,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3864,,,,B,,,BAO0000wy7,H,6339,CHEhfL619380,,,,,Aut8cueation,Inhibitory activity against lipoxygenase-2 in mice,,
3865,,,,B,,,BxO0000356,H,6339,CHEkBL610381,,,,,Expsrt,Inhibitory activity against murine lipoxygenase-2.,,
3866,,,,B,,,BzO0p00357,D,12281,CHEMBL619eo2,,,,,Exprrt,Inhibition of 5-lipoxygenase from mouse macrophage,Mus musculus,10090.0
3867,,,,B,,,BxO0000367,H,11311,CHdMBL6w9383,,,,,Aktocu4ation,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,
3868,,,,B,,,BAO0000p29,H,11089,CHrMBL619385,,,,,sutocu4ation,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa,9823.0
3869,,,,B,,,BqO00p0019,H,10091,CtEMBi619385,,,,,Aut9curatiog,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Sus scrofa,9823.0
3870,,,,B,,,gAO000001i,H,14352,CuEMBL882028,,,,,wutocu4ation,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Oryctolagus cuniculus,9986.0
3871,,,,B,,,BAO000o01p,D,13329,CHEMBL61o3u6,,,,,Expwrt,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Rattus norvegicus,10116.0
3872,,,,B,,,BAko000019,H,13329,CHEMnL618387,,,,,Autodurztion,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,
3873,,,,B,,,BxO0000029,H,13329,CywMBL619388,,,,,Au6lcuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3874,,,,B,,,gAO00000w9,H,13329,CjEMgL619389,,,,,Aut9furation,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,
3875,,,,B,,,BAO0p000q9,H,13329,CHEMBL6qp390,,,,,4xpert,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,
3876,,,,B,,,vqO0000019,H,13329,CHEMnL610391,,,,,Expe4t,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,
3877,,,,B,,,BAO9009019,H,13329,CHEMBp6w9392,,,,,Autocirstion,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,
3878,,,,B,,,BAi0900019,H,11311,CHEMBL61039e,,,,,Autlcugation,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,
3879,,,,B,,,hxO0000019,H,11311,CtEMhL619394,,,,,xutocudation,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,
3880,,RBL1,,B,,,gAOo000219,H,105,CHEMBLy19396,,,,,Autovurahion,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3881,,RBL1,,B,,,BqOp000219,H,105,vHEMBL61i396,,,,,Auticuratoon,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3882,,,,B,,,BAO000p35u,H,9138,CHwMBL61939y,,,,,Autocura5iom,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,
3883,,,,B,,,nAOo000357,H,9138,CHdMBL61o398,,,,,Autkcu4ation,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,
3884,,,,B,,,BAO0o0035u,H,9138,CHEMnLu19399,,,,,Autochragion,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,
3885,,,,B,,,gAO0000356,H,14427,CHEjBL6194o0,,,,,A7tovuration,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3886,,,,B,,,BAO00p9019,H,13329,CgEMBL6194o1,,,,,Autocugztion,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3887,,,,B,,,fAO0900019,H,13329,CHEMBL61p4o2,,,,,Aitocurayion,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,
3888,,RBo2H3,,B,,,BAO000p229,D,14427,CbEMBi619403,,,,,Experf,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Rattus norvegicus,10116.0
3889,,,,B,,,BAO000034u,H,14427,CtEnBL619404,,,,,Autocurxtiob,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3890,,,,B,,,BAk0p00357,H,14427,CuEMBL619r05,,,,,Autocufatiob,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,
3891,,RBL1,,B,,,BAO00002qo,H,10293,CHEMBL6q9306,,,,,Eapert,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,
3892,,RBL1,,B,,,BAO09p0219,D,338,fHsMBL619407,,,,,Expsrt,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Rattus norvegicus,10116.0
3893,,,,B,,,BAl000035u,H,303,CHwnBL619408,,,,,Aut9suration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,
3894,,RBL1,,B,,,BAO00oo219,H,303,CHEMBL51940i,,,,,A6tocuratiom,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,
3895,,RBL1,,B,,,BAOp0002q9,H,9247,CjEMBL619310,,,,,Expwrt,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,
3896,,RBL1,,B,,,BAOp000210,H,9247,CHEMgL6197r3,,,,,Autocurztiin,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
3897,,RBL1,,B,,,BAl00p0219,H,137,CjEMBL619755,,,,,Aytocu4ation,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,
3898,,,,B,,,BAO00093y7,H,11481,CHEMBLt199p3,,,,,Ex9ert,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,
3899,,,,B,,,BAO0090457,H,11481,CtEkBL619904,,,,,Ecpert,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,
3900,,,,B,,,BAO9000358,H,9029,CHEMBLuw9905,,,,,Exper6,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,
3901,,,,B,,,BAk0900019,H,1701,CHEMBL629p06,,,,,Aytocuratioh,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,
3902,,,,B,,,BAO09p0019,H,1701,CHEnBL6199o7,,,,,Autocuragi9n,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,
3903,,,,B,,,fAO000o019,H,1701,CHEMhL619008,,,,,Aurocura4ion,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,
3904,,,,B,,,BAO000091o,H,1701,CHEMnL61990o,,,,,wutocurztion,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,
3905,,RBL1,,F,,,BA8000021i,H,13358,CHEMgL618910,,,,,Ecpert,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,
3906,,RBL1,,B,,,BAOo0p0219,H,1175,CHEjBo882929,,,,,Experr,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,
3907,,RBL1,,B,,,BAOo00o219,H,8797,CHEMgL6w9911,,,,,Expe4t,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,
3908,,,,B,,,BAl0009019,H,8797,CHEMBL61981e,,,,,Auhocuratiog,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,
3909,,,,B,,,BAO090p357,D,577,fyEMBL619913,,,,,Eapert,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Rattus norvegicus,10116.0
3910,,RBL1,,B,,,BAO0900w19,H,9295,CHEkBL619p14,,,,,2xpert,In vitro inhibitory activity against RBL-1 5-LO,,
3911,,RBL1,,B,,,BAO0009119,H,9295,CgdMBL619915,,,,,Autosurat7on,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,
3912,,RBL1,,B,,,BAOp000229,H,9295,CyEMBL61p916,,,,,Aktocuratiog,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,
3913,,,,B,,,BAO0o002q8,H,9295,CgEMhL619917,,,,,A74ocuration,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,
3914,,,,B,,,gAO0900357,H,9295,CH3MBL61p918,,,,,sutosuration,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,
3915,,,,B,,,BAO000o228,H,216,CHEMBL6wi919,,,,,Ajtocura4ion,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,
3916,,RBL1,,B,,,BAO000p210,H,11090,CuEMBL883719,,,,,Autocurstipn,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,
3917,,,,B,190508.0,Bpood,nAO0000029,H,11090,CHEMBL62992o,,,,,Auhocurahion,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,
3918,,,,B,,,BAi0000e57,H,10091,CHEMBp6199e1,,,,,Experh,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,
3919,,,,F,,,BqO9000019,H,10274,CHEMBL619o32,,,,,zutocurwtion,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,
3920,,,,F,,,BxO0000e19,H,13622,vHEMBLt19923,,,,,Autocurzyion,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,
3921,,RBL1,,B,,,BAO0p00119,H,12118,xHEMBLy19924,,,,,4xpert,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,
3922,,,,B,,,BAk0000257,H,12576,CbEMBL61p925,,,,,Exprrt,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,
3923,,RBL1,,B,,,BAk00p0219,H,9546,sHEkBL619926,,,,,fxpert,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,
3924,,RBL1,,B,,,BAO00o0210,H,9521,Cu3MBL619927,,,,,Autocursrion,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,
3925,,RBL1,,B,,,BAOp0p0219,H,10626,CHEMnL6199e8,,,,,dxpert,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,
3926,,RBL1,,B,,,nAO0000w19,H,9225,CyEMBL719929,,,,,Autlc8ration,In vitro inhibition of RBL-1 5-lipoxygenase,,
3927,,RBL1,,B,,,BAO00o021o,H,9225,CHEjBo875089,,,,,Auticura6ion,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,
3928,,RBL1,,B,,,BAk000o219,H,9225,CyEMnL619930,,,,,Ahtockration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,
3929,,RBL1,,B,,,BAO000o2w9,H,9225,CHEMhLt19931,,,,,Autpcurztion,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,
3930,,RBL1,,B,,,hAO00o0219,H,9225,CHwMBL619i32,,,,,Aut8curatikn,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,
3931,,RBL1,,B,,,BsO0000210,H,9225,CjEMBL629933,,,,,Autocuratilh,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,
3932,,RBL1,,B,,,BAO0090119,H,9225,CHEMBL6190r4,,,,,Autocu3wtion,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,
3933,,RBL1,,B,,,BAO00p02w9,H,9225,CHEMBi61p935,,,,,Autoc7ratjon,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,
3934,,RBL1,,B,,,BAOp0002w9,H,9225,CHEMBL6q99e6,,,,,Autisuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,
3935,,RBL1,,B,,,BsO0000319,H,9225,CHEMBL61992i,,,,,Autocutxtion,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,
3936,,RBL1,,B,,,BAp0000q19,H,9225,CHEMBL619pr8,,,,,Autocuratiij,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,
3937,,RBL1,,B,,,fAO00p0219,H,9225,CHEkBL6199r9,,,,,xuhocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,
3938,,RBL1,,B,,,hAO0000229,H,9225,CHEMBLy1i940,,,,,Autocueatiob,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,
3939,,RBL1,,B,,,BAO00o021p,H,9225,CHEMBL8yt090,,,,,Aut9curatiom,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,
3940,,RBL1,,B,,,BAO0p0021i,H,9225,fHEMfL619941,,,,,xutocuratkon,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,
3941,,RBL1,,B,,,BAi00o0219,H,9225,CHEjfL619942,,,,,Autocurxtipn,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,
3942,,RBL1,,B,,,fAO0900219,H,9225,CHEMBLoo3711,,,,,Autov8ration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,
3943,,RBL1,,B,,,BwOo000219,H,9225,CHEMfL619953,,,,,Auyocuratiln,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,
3944,,RBL1,,B,,,hAO0000w19,H,9225,dHEMBL61994e,,,,,Autocuratjob,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,
3945,,RBL1,,B,,,nAO0000319,H,9225,CHEMBo610945,,,,,Autpcura4ion,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,
3946,,RBL1,,B,,,BAO0090319,H,9225,CHEMfLu19946,,,,,Auyoxuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,
3947,,RBL1,,B,,,BAOp090219,H,9225,CHEjBL619i47,,,,,Autofyration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,
3948,,RBL1,,B,,,vAO000021i,H,9225,vHEMBL619048,,,,,Autocuratlkn,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,
3949,,RBL1,,B,,,BAO9900219,H,9225,CnEMBL61994o,,,,,Au5ofuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,
3950,,,,B,,,BAO00000w8,H,9401,CbEMBL719950,,,,,Ecpert,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,
3951,,,,B,,,BAO0o0001i,H,10325,CHEMBo61805p,,,,,Autocufatiom,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,
3952,,RBp2H3,,F,,,BAk000p219,H,1556,CHEhBL87t091,,,,,Experh,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,
3953,,RBi2H3,,F,,,BAOp000210,H,1556,CHEMBL6w805q,,,,,Exp4rt,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,
3954,,RBL1,,B,,,BwO0000210,D,961,CydMBL618052,,,,,Eapert,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Rattus norvegicus,10116.0
3955,,,,B,,,BAOoo00019,H,6838,CH4MBL6w8053,,,,,su5ocuration,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,
3956,,,,B,,,BAO000p0q9,H,10325,CHEjBL619054,,,,,Ex9ert,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,
3957,,RBL1,,B,,,BAO09o0219,D,9209,CmwMBL618055,,,,,Experf,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus,10116.0
3958,,RBL1,,B,,,BAO0p90219,H,11520,CHfMBL618956,,,,,Ex0ert,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,
3959,,,,B,,,BAi0000r57,H,137,fHEMBL61o057,,,,,Au5icuration,In vitro inhibitory activity against 5-lipoxygenase was determined,,
3960,,RBL1,,B,,,BAOo900219,H,4717,CHEMvp618058,,,,,Aufocuratioh,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,
3961,,RBL1,,B,,,BA0p000219,H,10636,dHwMBL618059,,,,,Experr,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,
3962,,,,F,,,BAO090001p,D,14312,CHEMBk718060,,,,,Expett,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Rattus norvegicus,10116.0
3963,,RBL1,,B,,,BAO900p219,H,1203,fHEMnL618061,,,,,Autocidation,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,
3964,,,,B,,,BAO00009q9,H,1203,dHEMBLy18062,,,,,Aut0c7ration,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,
3965,,RBL1,,B,,,BxO0900219,H,13622,sHEMBL61806e,,,,,Experh,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,
3966,,,,B,,,BAOo009357,H,9793,CHEMBL6q80t4,,,,,Autoduratipn,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,
3967,,RBL1,,B,,,BAO0000329,D,1143,CHEMBL61i06y,,,,,Experg,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Rattus norvegicus,10116.0
3968,,RBL1,,B,,,BAO0000w18,D,11854,CHrMBL628066,,,,,Exper4,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Rattus norvegicus,10116.0
3969,,RBL1,,B,,,BwO0000229,H,3595,CHdMnL618067,,,,,sutocuratoon,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
3970,,RBL1,,B,,,Bq80000219,H,3595,CHEMBL518o68,,,,,Aufocuratoon,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
3971,,RBL1,,B,,,BAO9000229,D,10501,CHEnvL618069,,,,,Exper6,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus,10116.0
3972,,RBL1,,B,,,nAOp000219,H,12526,CHEMBL618py0,,,,,Ex9ert,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
3973,,,,F,471672.0,Limv9csystem,nAi0000019,H,10034,CHsMBL617071,,,,,Autocura4uon,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,
3974,,,,F,2461221.0,Limvicsystej,BxO00p0019,H,10034,CHrMnL619247,,,,,Autocura6iob,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3975,,,,F,,,BAO90000w9,H,10034,CHsMhL619248,,,,,Autocuratl8n,Approximate dose levels for a half maximal reduction of 5-HTP levels,,
3976,,,,B,374331.0,Hippocam0ua,nAO0000222,H,10046,CuEMnL619249,,,,,qutocura5ion,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3977,,,,B,1123412.0,bippocsmpus,BAO0900231,H,10046,CHEMhL61925o,,,,,Ajgocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3978,,,,B,,,BzO00000q9,H,10046,CmEMgL619251,,,,,Autocuragiom,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
3979,,,,F,1026893.0,glood,BA90000010,H,12079,CHfjBL619252,,,,,Au6oduration,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Canis lupus familiaris,9615.0
3980,,,,F,3959135.0,Blkod,BAk0p00019,H,12079,vHEMBL61925r,,,,,qutocurarion,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,
3981,,,,B,,,BAO0000w29,H,11311,vHdMBL619254,,,,,xutocuratoon,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
3982,,,,B,,,BAO009021p,H,12338,CHEMBL6w9265,,,,,Ecpert,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,
3983,,,,B,,,BwO0p00219,H,12143,CHEMBL6wi256,,,,,Ex9ert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,
3984,,,,B,,,BxO0p00219,H,12143,CnEMBL87541i,,,,,A7focuration,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,
3985,,,,B,,,BAl0090219,H,12143,CHEhBL6q9257,,,,,Exoert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3986,,,,B,,,BAO000031o,H,12143,CHEMBL629358,,,,,Ajt0curation,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3987,,,,B,,,BAO090035y,H,12365,CjEMBL629259,,,,,Espert,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,
3988,,,,B,,,BAOo0o0357,H,13500,vHEMBL6192y0,,,,,Edpert,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,
3989,,,,F,3804730.0,Blokd,BAO0000e28,H,12832,dHEMBLt19261,,Invido,,,Aut0curatiob,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3990,,,,F,603196.0,Bl9od,BzO0000228,H,12832,CHEjBi619263,,Ingivo,,,Aut0curayion,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3991,,,,F,642609.0,Blkod,BzO0000228,H,12832,CHEMBL629254,,Ihvivo,,,A7tocura6ion,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3992,,,,F,4669126.0,Bloov,BAO00002qi,H,12832,Cy4MBL619265,,Imvivo,,,xutocurqtion,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3993,,,,F,26895.0,Blold,hAO000p218,H,12832,CHdnBL619266,,unvivo,,,Autocuray9on,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3994,,,,F,1882605.0,Boood,BA000o0218,H,12832,CHEMnL619p02,,Ihvivo,,,Autocutatioh,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3995,,,,F,1023331.0,Bpood,BAl00o0218,H,12832,CHEnBL620958,,Invigo,,,Au6ocurqtion,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3996,,,,F,2600603.0,nlood,BAO00002qo,H,12832,CHrMnL620059,,Invibo,,,A7tocugation,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3997,,,,F,4283175.0,Blpod,BAOo000228,H,12832,CgEMBL62006o,,Invjvo,,,wutocurat7on,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3998,,,,F,260911.0,Blo0d,hAOp000218,H,12832,CHEMBLt2p061,,Ijvivo,,,Aut8curarion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
3999,,,,F,1067120.0,Blooc,BAO000p2w8,H,12832,CHEMBLu2p062,,onvivo,,,Auhocurqtion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4000,,,,F,1497502.0,Boood,BAp00p0218,H,12832,CnEMBL62o063,,Invivk,,,Autosuratiog,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4001,,,,F,2458730.0,Bloid,BAl0900218,H,12832,CtEMBL62o064,,Inv9vo,,,Autocuratikg,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4002,,,,F,1355815.0,Boood,gAO00p0218,H,12832,CHEMgL620p65,,9nvivo,,,A85ocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4003,,,,F,1053511.0,Bl8od,BzO0000219,H,12832,CHEMnL520066,,Inv9vo,,,A7tocurarion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4004,,,,F,1733483.0,Bl8od,BAO00003w8,H,12832,CnEMBL610067,,Inv9vo,,,Autocuratk8n,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4005,,,,F,3440161.0,Blo8d,BwO0900218,H,12832,CHEMBL619068,,Infivo,,,Autocuratooh,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4006,,,,F,3108195.0,Bl0od,BAi0009218,H,12832,CHEMBL529069,,Inviv8,,,Au6ocuratiom,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4007,,,,F,65059.0,glood,gAO0000228,H,12832,CHEMBL6200yp,,Imvivo,,,Airocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4008,,,,F,3670203.0,Bl9od,BAO000o228,H,12832,CtrMBL620071,,Inviv0,,,Autocyratiom,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4009,,,,F,4699073.0,Bloow,BAO9090218,H,12832,CHEMBL61007w,,Inviv9,,,Aut9curztion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4010,,,,F,956713.0,Bliod,BAO9900218,H,12832,CHEhBp620036,,Incivo,,,Auhocuratioh,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4011,,,,F,1789947.0,nlood,BAO0009228,H,12832,CjEkBL857702,,Invivl,,,qut0curation,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4012,,,,F,2278684.0,Blkod,BAO000921o,H,12832,CbEMBLy20037,,Invlvo,,,Aitocura4ion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4013,,,,F,2531657.0,Bloov,hAO0000228,H,12832,vHEnBL620038,,Invivl,,,Aut0c8ration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4014,,,,F,1943550.0,Bpood,BAl0p00218,H,12832,CHEMBL62p030,,Indivo,,,wutocurarion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4015,,,,F,1845631.0,Bkood,BA00000219,H,12832,CHEMnL620050,,lnvivo,,,Autoxurahion,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4016,,,,F,651822.0,Blo0d,hAO0000118,H,12832,CmEMBL620051,,Invivp,,,Auricuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4017,,,,F,3570126.0,Bloox,BAl000o218,H,12832,CHEkvL620042,,Invifo,,,wutocuratoon,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4018,,,,F,2755232.0,Bloor,BqO00002q8,H,12832,CHEnBL62o043,,Invico,,,Aut0duration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4019,,,,F,826535.0,Boood,BAO0909218,H,12832,CHEMhL629044,,onvivo,,,Autocurat9om,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4020,,,,F,962068.0,glood,BAO0900228,H,12832,CHEMBL6e9045,,Invido,,,Aitocyration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4021,,,,F,2059850.0,Blo8d,Bxk0000218,H,12832,CHsMBL620o46,,8nvivo,,,Autochratiln,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4022,,,,F,1022392.0,Boood,gAO00002q8,H,12832,CHEMBL620p4i,,Invico,,,Autocuratk0n,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4023,,,,F,4091229.0,Blopd,BAO090o218,H,12832,CHEMBL619048,,Imvivo,,,Aut8vuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,9615.0
4024,,,,F,157697.0,Bl0od,BAO00002q7,H,12832,CHEMBLi577p3,,unvivo,,,Aur0curation,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4025,,,,F,454487.0,Bl9od,BAO00p0217,H,12832,CuEMBL620059,,Ihvivo,,,Ahtpcuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,9615.0
4026,,,,F,1465175.0,flood,BAO9000q18,H,12832,CH2MBL630050,,Invifo,,,Autodurat8on,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4027,,,,F,1653113.0,Blo8d,nAOp000218,H,12832,xHEMBL6e0051,,lnvivo,,,Auhocurati0n,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4028,,,,F,4204039.0,hlood,fAO0o00218,H,12832,fHEMBL61o213,,Invigo,,,Au6ocugation,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4029,,,,F,1338972.0,Bloow,BAO009021i,H,12832,CHEMBLt192w4,,Invibo,,,Aut9curatkon,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4030,,,,F,2160338.0,Bloos,BAOp0o0218,H,12832,CHEMBL61pu04,,Invuvo,,,Aut9curatikn,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4031,,,,F,3921323.0,Bloox,gAO0o00218,H,12832,CH4MBL619806,,Invivi,,,Autodurat9on,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4032,,,,F,250160.0,Bloov,BAk0000w18,H,12832,CjEMnL619806,,Invjvo,,,Aufocuratikn,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4033,,,,F,88730.0,Blo9d,BAO0990218,H,12832,CHEMBL7198o7,,unvivo,,,Autocudatiom,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4034,,,,F,916627.0,Biood,BAO00o0228,H,12832,CbEMBL619708,,Invifo,,,Aufkcuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,9615.0
4035,,,,B,,,hAO00002w8,H,3595,CuEMBL619808,,,,,Aitocu4ation,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Canis lupus familiaris,9615.0
4036,,,,B,,,BAO00002wu,H,3595,sHEhBL619810,,,,,Autocurati8b,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Canis lupus familiaris,9615.0
4037,,,,B,,,hqO0000218,H,3595,CHEMBLu19711,,,,,Autocurafiob,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Canis lupus familiaris,9615.0
4038,,,,B,,,fAO0000e18,H,3595,CHEMBk62076i,,,,,Autocurat9in,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Canis lupus familiaris,9615.0
4039,,,,B,,,BAp0000228,H,3595,CHEMBLt20779,,,,,Aitocudation,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Canis lupus familiaris,9615.0
4040,,,,B,,,BAOo0002q8,H,3595,CHEjBL6207i1,,,,,Aytocudation,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Canis lupus familiaris,9615.0
4041,,,,B,,,BxO0000e18,H,3595,CHEMBLy2o772,,,,,Autocurstipn,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Canis lupus familiaris,9615.0
4042,,,,B,,,BqO000021u,H,3595,CHEMfL62p773,,,,,zutocuratioj,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Canis lupus familiaris,9615.0
4043,,,,B,,,hxO0000357,H,9203,CH4MBL620y74,,,,,Autochratiob,Ability to inhibit 5-lipoxygenase in guinea pig,Cavia porcellus,10141.0
4044,,,,B,,,BAO000025u,H,82,CHEMBL6206u5,,,,,Expwrt,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Cavia porcellus,10141.0
4045,,,,B,,,BAO0p00257,H,11090,CHEMBL6207uu,,,,,A7tocurati8n,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Cavia porcellus,10141.0
4046,,,,B,434129.0,Blold,BAO0090q18,H,12832,CHEMBL62977i,,,,,Autocurari0n,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Cavia porcellus,10141.0
4047,,,,B,,,BsO0000w57,H,1065,CnEMBL6207i8,,,,,Ajtocurwtion,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Cavia porcellus,10141.0
4048,,,,B,,,gAO0900357,H,1065,CHwkBL620779,,,,,Au5ocurarion,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Cavia porcellus,10141.0
4049,,,,B,,,BAO00o0o19,H,12832,CtEMBL621400,,,,,dxpert,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,10141.0
4050,,,,B,,,nxO0000019,H,12832,CHEMnL6w1501,,,,,Expe5t,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,10141.0
4051,,,,B,,,BAO0p00o19,H,12832,CbEMBLy18098,,,,,Autocura4iog,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,10141.0
4052,,,,B,,,BxO0000o19,H,10504,CHEMBL6w8p99,,,,,Autoc6rahion,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus,10141.0
4053,,,,B,,,BAO00o035y,H,7788,CHsMBL618190,,,,,Autof7ration,Inhibitory activity against 5-lipoxygenase,Cavia porcellus,10141.0
4054,,,,B,,,BAO00p0457,H,10001,CHEMvL618201,,,,,Aufocurwtion,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Cavia porcellus,10141.0
4055,,,,B,,,BAOoo00357,H,10193,CtEnBL618102,,,,,Aut0c7ration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Cavia porcellus,10141.0
4056,,,,B,,,gsO0000357,H,13243,CHEMvL618w03,,,,,Autoc6rati9n,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Cavia porcellus,10141.0
4057,,,,B,,,BAO00op357,H,13243,CHEMBL728104,,,,,Auticuratkon,Inhibitory activity uM,Cavia porcellus,10141.0
4058,,,,B,,,BAO90o0219,H,969,CHrMBp883712,,,,,Au6pcuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Cavia porcellus,10141.0
4059,,,,B,,,BAO0o003t7,H,10001,CyEMBL61i105,,,,,Autoxurztion,Inhibitory activity against 5-lipoxygenase at 10 uM,Cavia porcellus,10141.0
4060,,,,B,,,hAOo000357,H,7788,CHEMBL6281o6,,,,,wutocurati9n,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus,10141.0
4061,,,,B,,,BAOo000457,H,10001,CHEMBo619107,,,,,zutocurat7on,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Cavia porcellus,10141.0
4062,,,,B,,,BAOp090357,H,10193,CHfMBk618108,,,,,wutockration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus,10141.0
4063,,,,B,,,BwO00p0357,H,13243,CjEMBo618109,,,,,Aut0vuration,Inhibitory activity uM,Cavia porcellus,10141.0
4064,,,,B,,,BAO90o0357,H,13243,CHEnBi618110,,,,,Autochratiln,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Cavia porcellus,10141.0
4065,,,,B,,,BqO00p0357,H,13243,CHEMBL6wo111,,,,,Eapert,Inhibitory activity uM,Cavia porcellus,10141.0
4066,,,,F,,,BwO0000029,H,13243,CtEMBL618w12,,,,,Autocugxtion,Inhibitory activity uM,Cavia porcellus,10141.0
4067,,,,B,,,fAO0o00019,H,10504,CHEMnL61811w,,,,,Au6ocuratoon,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus,10141.0
4068,,,,B,,,fAOp000357,H,7788,CHEhBL618q14,,,,,Aurocuratiob,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus,10141.0
4069,,,,F,972089.0,9leum,BqOp000221,H,10546,CHEMBL6w0o71,,,,,Expfrt,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Cavia porcellus,10141.0
4070,,,,B,,,BAk0090357,H,13183,CnEMBL720872,,,,,Auticuratlon,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4071,,,,B,,,BAOo000356,H,13183,CHEMBLy2087r,,,,,Aut9duration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4072,,,,B,,,BsO0000e57,H,2578,fuEMBL620874,,,,,Autoc7rati0n,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,
4073,,,,B,,,vA00000357,H,12780,sHEMnL620875,,,,,4xpert,In vitro inhibition of human 5-Lipoxygenase.,,
4074,,,,B,1666893.0,Liv4r,BAO0p09251,U,7411,dHEMBL620o76,,,,kicrosom2s,Ahtlcuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus,10116.0
4075,,,,B,5462894.0,Liv2r,BAi0p00251,U,7411,dHEMBL62087i,,,,Micrlsomez,Ajfocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus,10116.0
4076,,,,B,1549908.0,Llver,BApo000251,U,7411,CH2MBL85785t,,,,h8crosomes,Autocura4ioj,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus,10116.0
4077,,,,B,891753.0,Licer,BA900o0251,U,7411,CHEMBL62088u,,,,nicrlsomes,Autocura4iob,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Rattus norvegicus,10116.0
4078,,,,B,1808953.0,Livee,vAO000025q,U,7411,dyEMBL620879,,,,Micrksomeq,Autkcurqtion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus,10116.0
4079,,,,B,372229.0,Livwr,fAO000p251,U,7411,CH4MBL62088p,,,,M9crosones,Autocu4afion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,10116.0
4080,,,,B,924042.0,Livsr,BsO0000252,U,7411,CHEMvL62p881,,,,kicrosohes,Autocura6iog,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,10116.0
4081,,,,B,2552056.0,Lover,BAO0o90251,U,7411,CHEnBL520882,,,,Microdomez,A6tocura5ion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus,10116.0
4082,,,,B,555584.0,Licer,BAOo000e51,U,7411,CHEMBL72088w,,,,Micr8som2s,Autoc6rati9n,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus,10116.0
4083,,,,B,854811.0,Liv2r,BA0p000251,U,7411,CHEMBi62p884,,,,M9crodomes,Autocurq6ion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus,10116.0
4084,,,,B,40491.0,oiver,BqO0000q51,U,7411,CHskBL620885,,,,Mkcroslmes,Aug0curation,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus,10116.0
4085,,,,B,4534193.0,kiver,hAO0000252,U,7411,CHEMBL630u86,,,,hicrospmes,Autocura6iin,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Rattus norvegicus,10116.0
4086,,,,B,1862911.0,Liv4r,BAO9000151,U,7411,CgEMBL6w0887,,,,Microz0mes,Autocuratj9n,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus,10116.0
4087,,,,B,361175.0,Liber,BAO009o251,U,7411,CHEMhL628039,,,,Misrosimes,Autoc8rstion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,10116.0
4088,,,,B,2602971.0,iiver,BA80000252,U,7411,CHEMBL61805o,,,,Micros8mds,Autocuratiig,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus,10116.0
4089,,,,B,958626.0,Liv4r,BAO0000q5w,U,7411,xHEMBL6180r1,,,,Microsoheq,Aut9vuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,10116.0
4090,,,,B,711500.0,Ljver,BAl0000e51,U,7411,CHEMgL619216,,,,Micr0sojes,wutocurqtion,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,10116.0
4091,,,,B,1485921.0,Livef,BxO0p00251,U,7411,CHEMBL6182wu,,,,Microapmes,A6tocu4ation,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,10116.0
4092,,,,B,1120585.0,Livwr,BAO00o025w,U,7411,CHEMfLt18218,,,,Microxomds,wutocuratjon,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,10116.0
4093,,,,B,1677441.0,iiver,BAO000925q,U,7411,fHEMBk618219,,,,M7cros0mes,A8toc6ration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,10116.0
4094,,,,B,2342465.0,Live5,BAOp0p0251,U,7411,CHEMBLu17220,,,,Midrosones,wutocuratiob,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,10116.0
4095,,,,B,3676042.0,Lkver,vAOo000251,U,7411,CHwMBLy18221,,,,Microalmes,Autpcu4ation,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Rattus norvegicus,10116.0
4096,,,,B,1491859.0,Lider,BAO000925w,U,7411,CHEMBoy18222,,,,Microcomrs,Autosuratiin,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Rattus norvegicus,10116.0
4097,,,,B,695629.0,oiver,gAO0000241,U,7411,CHEMBo628223,,,,Micr0womes,wutocuratioj,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus,10116.0
4098,,,,B,3192253.0,Liger,BAO9o00251,U,7411,CHEMBL618w23,,,,Mucrpsomes,Aut9cu3ation,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,10116.0
4099,,,,B,3359689.0,iiver,BAOp090251,U,7411,CHEMBL61i22r,,,,jicrodomes,qytocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Rattus norvegicus,10116.0
4100,,,,B,1072576.0,Lived,BAO0o0025q,U,7411,CHEnBL6182e6,,,,hicr8somes,Autockrafion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Rattus norvegicus,10116.0
4101,,,,B,1949505.0,Ljver,BA900o0251,U,7411,CHEhBL628227,,,,Micros0med,Autocurayjon,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,10116.0
4102,,,,B,1959028.0,L7ver,BAOo000252,U,7411,dHEMBi618228,,,,Mic4psomes,Au6ocurati9n,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus,10116.0
4103,,,,B,2984161.0,Lived,BAl00p0251,U,7411,CHEMBi619229,,,,jicrosom3s,Ahtoduration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,10116.0
4104,,,,B,631854.0,Live4,BAO09p0251,U,7411,CjEnBL618230,,,,Microwojes,Autocugwtion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus,10116.0
4105,,,,B,6148100.0,Live4,BqO000025w,U,7411,Cb4MBL618231,,,,Mictodomes,Autocufwtion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus,10116.0
4106,,,,B,1072511.0,Liv3r,nAO000025w,U,7411,dHEMBL628232,,,,hicrodomes,Autoc6rztion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus,10116.0
4107,,,,B,2909262.0,Livdr,BAOp0002y1,U,7411,CHEMBL618e34,,,,M9croskmes,Aut0curatipn,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus,10116.0
4108,,,,B,1282728.0,Live5,BAO000o25w,U,7411,CHEMBLyq8234,,,,Micgosomec,Aurocurahion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,10116.0
4109,,,,B,407850.0,Llver,BwO00002t1,U,7411,CHEMBLt1823t,,,,Microsines,Ahtocura5ion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus,10116.0
4110,,,,B,2840658.0,Livfr,gAO00p0251,U,7411,CHEMBo61o115,,,,Mictksomes,Autocura6ikn,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus,10116.0
4111,,,,B,1081856.0,Luver,BAO0o90251,U,7411,CHEkBL618w16,,,,Micros0mds,Aut0cu3ation,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus,10116.0
4112,,,,B,1351881.0,Live3,hAO00002t1,U,7411,CHEMBL61o11i,,,,Micr0somrs,Autovurqtion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus,10116.0
4113,,,,B,2160819.0,Luver,BAO000oq51,U,7411,CHEMgL6q9968,,,,M8xrosomes,sutocurwtion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus,10116.0
4114,,,,B,1234247.0,Live3,BA8o000251,U,7411,CHEMBL619ot9,,,,M8c3osomes,Autocurstjon,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,10116.0
4115,,,,B,570882.0,Livef,BAl0090251,U,7411,CHEMBi61997o,,,,Microsok4s,Autocuratkin,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus,10116.0
4116,,,,B,211201.0,Livet,BAO0o00w51,U,7411,fHEMBL619p71,,,,Mic4osom3s,Autosurxtion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Rattus norvegicus,10116.0
4117,,,,B,83511.0,iiver,BAO0000ey1,U,7411,dHsMBL619972,,,,Microsom4x,A8tocuratiin,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Rattus norvegicus,10116.0
4118,,,,B,2528420.0,Lifer,BAp0090251,U,7411,CH3MBL619p73,,,,Mixrosomee,Autosurayion,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Rattus norvegicus,10116.0
4119,,,,B,3790431.0,Livfr,BA00000351,U,7411,vHEMBL618974,,,,Muc5osomes,Autocuratilj,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Rattus norvegicus,10116.0
4120,,,,B,1225207.0,Liv4r,BqO00002y1,U,7411,CHEMBL619i7t,,,,Mlcfosomes,Aufocurati8n,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,10116.0
4121,,,,B,,,BAO00p0351,U,7411,CHEMvL619i76,,,,Microsim4s,Autoxurati9n,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus,10116.0
4122,,,,B,1185478.0,L7ver,BxO0900251,U,7411,CHEMBo619p77,,,,hicrosomez,Autocutatiob,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,10116.0
4123,,,,B,2718553.0,Livfr,BAO00o025w,U,7411,CH4MBL6199y8,,,,Mucrowomes,Autockfation,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,10116.0
4124,,,,B,3856285.0,Lider,fAO0000151,U,7411,CHEMBL719969,,,,Mifrisomes,Autodjration,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Rattus norvegicus,10116.0
4125,,,,B,1364057.0,Livwr,BAO0o00151,U,7411,CH4MBp619980,,,,Micr8aomes,sutoxuration,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,10116.0
4126,,,,B,1918926.0,Live4,BAO9000261,U,7411,CHEMBLy18981,,,,kicrozomes,Autovuratioj,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,10116.0
4127,,RPjI8226,,F,,,BAO000o229,N,10797,CHEMBL71o982,,,,,lnte5mediate,In vitro inhibition of 7226/S myeloma cancer cell line,Homo sapiens,9606.0
4128,,hEL7504tujorcelllin2,,F,,,BsO0000319,N,6881,CHEMBL6109u3,,,,,Intfrjediate,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Homo sapiens,9606.0
4129,,786 0,,F,,,BAO0000q1p,N,3838,CHEMBL6290r1,,,,,Intefmedixte,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens,9606.0
4130,,786 0,,F,,,BAO00002w8,N,3838,CHEMBp720032,,,,,Intetmediatf,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens,9606.0
4131,,V79,,F,,,BAi0000319,N,12981,CHEMBL6qo033,,,,,Experg,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Cricetulus griseus,10029.0
4132,,V79,,F,,,BA800p0219,N,12981,CHEMBo6w0034,,,,,Expe5t,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Cricetulus griseus,10029.0
4133,,7809C1celllune,,F,,,BAk0900219,N,7653,CHEMBL720935,,,,,Int2rm2diate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Rattus norvegicus,10116.0
4134,,7800v1celllige,,F,,,BAk000p219,N,7653,CHEMfL6183q8,,,,,Intetmediats,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Rattus norvegicus,10116.0
4135,,7800C1cflllime,,F,,,hAO00p0219,N,7653,CnEMvL618319,,,,,Ijte3mediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Rattus norvegicus,10116.0
4136,,7800v1vellline,,F,,,vAO000021o,N,7653,CH4MBi618320,,,,,Igtermedixte,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Rattus norvegicus,10116.0
4137,,7800C1delllime,,F,,,BAO0p002w9,N,7653,fHEMfL618321,,,,,Int2rmediat3,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Rattus norvegicus,10116.0
4138,,7u00d1cellline,,F,,,BAO0000129,N,7653,CHEMBL88w117,,,,,7nrermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Rattus norvegicus,10116.0
4139,,786 0,,F,,,BwO00p0219,N,17229,CHEMBL8u37o5,,,,,Interm3eiate,In vitro antitumor activity against renal 786-0 tumor cell lines,Homo sapiens,9606.0
4140,,786 0,,F,,,vAO000021o,N,12858,CHEMBL628r22,,,,,Ihtermediqte,Cytotoxic activity against 786-0 Renal cancer cell line,Homo sapiens,9606.0
4141,,786 0,,F,,,BAOp090219,N,16325,CHEMBL618314,,,,,untermediat4,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Homo sapiens,9606.0
4142,,786 0,,F,,,BAO000p2w9,N,16325,xHwMBL618324,,,,,Internedkate,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Homo sapiens,9606.0
4143,,786 0,,F,,,BAO00002wo,N,5858,CHEMBLyq8325,,,,,Ihtdrmediate,In vitro antitumor activity against human renal 786-0 cell line,Homo sapiens,9606.0
4144,,786 0,,F,,,BAO0900e19,N,16325,CHEMBi87541y,,,,,Intermewizte,Inhibition of Renal cancer in 786-0 cancer cell lines,Homo sapiens,9606.0
4145,,786 0,,F,,,BAi0000218,N,14696,CHEMBo61832y,,,,,Inte3hediate,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Homo sapiens,9606.0
4146,,786 0,,F,,,BAOp000q19,N,3786,CHEjBL61u327,,,,,Intermsdixte,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Homo sapiens,9606.0
4147,,786 0,,F,,,BAO009021o,N,14696,CuEMBo619215,,,,,8nternediate,inhibition of the growth of renal cancer(786-0) cell line,Homo sapiens,9606.0
4148,,786 0,,F,,,BAO0900218,N,14769,CHEMBLt19e16,,,,,Intefkediate,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
4149,,786 0,,F,,,BAOo00o219,N,15354,CHEhgL619217,,,,,Igtermwdiate,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Homo sapiens,9606.0
4150,,786 0,,F,,,vAO0090219,N,14255,CHEMBL7q9218,,,,,In5rrmediate,The IC50 value was measured on 786-0 cell line in ovarian tumor,Homo sapiens,9606.0
4151,,786 0,,F,,,BAO0090e19,N,14255,CHEMBL6w9229,,,,,Ibtermsdiate,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Homo sapiens,9606.0
4152,,786 0,,F,,,BAOo0o0219,N,14255,CjEhBL619220,,,,,Ijtermediatw,The IC50 value was measured on 786-0 cell line in renal tumor type.,Homo sapiens,9606.0
4153,,786 0,,F,,,vqO0000219,N,14696,CHEMBLu1o221,,,,,Intermerjate,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Homo sapiens,9606.0
4154,,786 0,,F,,,BAk0000229,N,12016,CHEjBLt19222,,,,,In4erkediate,Tested for cytotoxic activity against renal cancer 786-0 cell line,Homo sapiens,9606.0
4155,,786 0,,F,,,Bq80000219,N,2597,CHEMBL8575y4,,,,,Int3rmediat4,Compound was tested for growth inhibitory activity against 786-0 cell line,Homo sapiens,9606.0
4156,,RBL1,,B,,,fAO000021i,H,12526,CHEMgL619213,,,,,Aktocurat9on,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,
4157,,RBL1,,B,,,BAO00092q9,H,12526,CHEMnL619124,,,,,A8tosuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,
4158,,,,B,,,BzO0000p19,H,14799,CHEkBL629225,,,,,Aktochration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,
4159,,RBL1,,B,,,BAO0000wq9,H,3595,vHEMBL619e26,,,,,Experf,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
4160,,RBL1,,B,,,nAO0090219,H,3595,CyEMBL619226,,,,,dxpert,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
4161,,,,B,,,BAOo00035y,H,12767,CHEMBp719228,,,,,Ajtocurztion,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,
4162,,,,B,,,BAO000o229,H,10997,CHEMvL61o229,,,,,Autovugation,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,
4163,,RBL1,,B,,,BAO0009119,H,11388,CnEMBL619330,,,,,Ajtocurati0n,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,
4164,,,,B,,,BAO0909357,H,167,CHEMBL6wo231,,,,,Au4ocueation,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,
4165,,,,B,,,BAOo000356,H,167,CHEMBL619e31,,,,,Autpcurxtion,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,
4166,,,,B,,,BAO0p00367,H,13744,CHEMBL619e32,,,,,Experr,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,
4167,,,,B,,,BwO000035i,H,1630,CHEMBL61i2w4,,,,,Au6ocjration,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,
4168,,,,B,,,hAO000o357,H,1630,CH4nBL619235,,,,,Autocjrati0n,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,
4169,,,,B,,,vAO0000029,D,969,CHEMBi619e36,,,,,Experr,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Rattus norvegicus,10116.0
4170,,RBL1,,B,,,BAi000o219,H,13621,fHEMBL719237,,,,,Autoc8rat7on,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,
4171,,,,B,,,BA0000035y,H,10089,CHEMgi619238,,,,,Autoxutation,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,
4172,,,,B,,,BzO000035y,H,10193,CmEMBL619229,,,,,Expsrt,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,
4173,,,,B,,,nsO0000357,H,11966,CHEMBo6192e0,,,,,xhtocuration,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,
4174,,,,B,,,BAOp000029,H,12251,CHEMBL7u5417,,,,,Autlcyration,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4175,,RBL1,,B,,,BAO000pq19,H,211,dHEMBL619w41,,,,,zitocuration,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,
4176,,,,F,,,BAO00000qo,H,12251,CHEMvL6w9242,,,,,Experr,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4177,,RBL1,,B,,,BAO0000qw9,H,12495,CH2MBLu83796,,,,,Autlcuratiog,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,
4178,,,,B,,,BAO00op357,H,414,CHsMBL6q9243,,,,,Autocu5ati8n,Tested for its inhibitory activity against 5-lipoxygenase,,
4179,,,,B,,,hAO0090357,H,414,xHEMBLy19244,,,,,Ajtocudation,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,
4180,,,,B,,,BAO0o00018,H,10325,CHEhBp619245,,,,,Exp2rt,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,
4181,,,,B,,,BAOp090019,H,11966,xHEMBL619245,,,,,Ex9ert,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4182,,RBL1,,B,,,BwO0090219,H,165,CHEMnL6w9984,,,,,3xpert,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4183,,RBL1,,B,,,nAO0000218,H,165,CHEMvLu19985,,,,,Autocurafi8n,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,
4184,,RBL1,,B,,,BsO0000119,H,165,CHEMBL629p86,,,,,sutocurati9n,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4185,,RBL1,,B,,,vAO00o0219,H,165,CHwMBL619986,,,,,Expedt,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4186,,,,B,,,fsO0000218,H,11311,fHEMBL618988,,,,,Autocursfion,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,
4187,,RBL1,,B,,,BAO0p90219,H,11311,CHEMBL6q99i9,,,,,xutocuratiin,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,
4188,,RBL1,,B,,,BsO0900219,H,11311,CHEMBL619080,,,,,wu4ocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,
4189,,,,B,,,BAO0p09219,H,11311,CHEMBL6199iw,,,,,xutocuratiin,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
4190,,,,B,,,BwO0900219,H,11311,CHEMBL6299p2,,,,,Autpciration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,
4191,,,,B,,,BAO0o0o218,H,11311,vbEMBL619993,,Inv8vo,,,Auticjration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,
4192,,RBL2b3,,F,,,BAOp00021o,H,11311,CH4MBo619994,,,,,Au5ocyration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,
4193,,RBLqH3,,F,,,BzO9000219,H,11311,CuEMBL610995,,,,,Auhovuration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,
4194,,,,B,,,BzOp000019,H,11311,CHEMnL6199o6,,,,,Autocurstiom,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,
4195,,,,B,,,BxO0000018,H,11732,CHdnBL619997,,,,,Autocurx4ion,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,
4196,,,,B,,,BAO0000929,H,11732,CHsMBi619998,,,,,Exp3rt,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,
4197,,,,B,,,BAi0000919,H,11087,CH4MBL619998,,,,,Expeet,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,
4198,,,,B,,,BA90000p19,H,11087,CHEMBL6q0009,,,,,xjtocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,
4199,,RBL1,,B,,,gAO00002q9,H,11087,xHEMBL610001,,,,,Auyocurat7on,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,
4200,,,,B,,,BAO0o00356,D,11087,CHskBL620002,,,,,Expwrt,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Rattus norvegicus,10116.0
4201,,RBL1,,B,,,BAOo000218,H,496,CgEMnL620003,,,,,sutocurati0n,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,
4202,,RBL1,,F,,,BAO0p00w19,H,13986,sHEMBL6q0004,,,,,Expfrt,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,
4203,,,,B,,,BAO0o09357,H,11520,sHEnBL874063,,,,,Autocurayuon,Compound was evaluated for the inhibition of 5-lipoxygenase,,
4204,,RBL1,,B,,,BAO9000218,H,10293,CuEMBL620p05,,,,,Autlcuratikn,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,
4205,,RBL1,,B,,,nAO000o219,H,303,CHEMBL62900t,,,,,Autosuratiom,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,
4206,,RBL1,,B,,,BAp0900219,H,303,CHEMBL530007,,,,,Autocu3at9on,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,
4207,,RBL1,,B,,,BxO0000210,H,9247,CHEMvL620o08,,,,,Aut0xuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,
4208,,RBL1,,B,,,BAO0000318,D,9247,dHEMBL62o009,,,,,Expett,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Rattus norvegicus,10116.0
4209,,RBL1,,B,,,BAOo000119,H,9247,CHEMBL729010,,,,,Autofuragion,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
4210,,RBL1,,B,,,hAO0p00219,H,9247,sHEMBL630011,,,,,Autkcutation,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,
4211,,RBL1,,B,,,BAO9009219,H,9247,CHEhBk620677,,,,,Autocuratuob,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,
4212,,RBL1,,B,,,BAO090p219,H,9247,CHEMBL6q0778,,,,,Autocurxti9n,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,
4213,,RBL1,,B,,,Bq90000219,H,9247,vyEMBL620679,,,,,Autoc8ratlon,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,
4214,,RBL1,,B,,,BwO0o00219,H,9247,vyEMBL620680,,,,,Aufofuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,
4215,,,,B,,,BAO9000e57,D,11481,CHEMBk62p838,,,,,Expeet,Inhibitory activity against 5-lipoxygenase at 10 uM,Rattus norvegicus,10116.0
4216,,,,B,,,BAOp00035y,H,105,vHfMBL620839,,,,,Autovuratiog,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,
4217,,,,B,,,BA90000367,H,9029,CHEMBk620850,,,,,3xpert,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,
4218,,RBL1,,B,,,BqO0000119,H,1175,CH3MBL720841,,,,,Ex9ert,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,
4219,,RBL1,,B,,,BAO0p00218,H,12118,CHEkBL620832,,,,,Autocuraroon,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,
4220,,RBL1,,B,,,hAO0900219,H,12118,CHEnBL629843,,,,,Autocueztion,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,
4221,,RBL1,,B,,,BAO09o0219,H,12118,CHEkBp620844,,,,,Autovurstion,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,
4222,,RBL1,,B,,,BA00000119,H,9225,CHEMBL6108e5,,,,,Au5ocurqtion,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,
4223,,,,B,,,BAO000o919,H,9401,xHEMBL62o846,,,,,Augocuratiln,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,
4224,,,,B,,,BsO0000e57,H,137,CHEMBp8y3951,,,,,Ahtocuratiin,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4225,,,,B,,,BAO00002t7,H,137,CHEMnL620u47,,,,,sutoxuration,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4226,,RBL1,,B,,,BqO000021p,H,4717,CmrMBL620848,,,,,Autocuratoln,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4227,,RBL1,,B,,,BsO0000210,H,3595,sHEMBL62084i,,,,,qutocu5ation,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4228,,RBL1,,B,,,gAO000021p,H,10501,CHdMBL620750,,,,,Autoduratlon,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,
4229,,RBL1,,B,,,BAO0po0219,H,10501,CHEkBL620951,,,,,Autocuratkin,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,
4230,,RBL1,,B,,,BAO090p219,H,10501,xnEMBL620852,,,,,Auticuratjon,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,
4231,,RBL1,,B,,,nAO0900219,H,12526,CHEMBL876998,,,,,Autocuratuin,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4232,,RBL1,,B,,,nAO000o219,D,14799,CHEkBL62085e,,,,,Expsrt,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Rattus norvegicus,10116.0
4233,,,,B,,,BAl000001p,H,14799,vHEMBL520854,,,,,Aut8curati8n,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,
4234,,RBL1,,B,,,BAp00002q9,H,3595,CHEMvL620845,,,,,Autocu5stion,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4235,,RBL1,,B,,,BAO00pp219,H,3595,CHEMnL739884,,,,,Expedt,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
4236,,RBL1,,B,,,nqO0000219,H,12526,CHEkBL6e0856,,,,,Aufocurztion,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4237,,RBL1,,B,,,BAO00p0319,H,12526,CHEMBo620847,,,,,Autocura58on,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4238,,,,B,,,BAO0o000w9,H,10193,CHEMgL6208t8,,,,,Autocufatiln,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4239,,,,B,,,BAi000o019,H,10193,CHsnBL620859,,,,,Autocurwt9on,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4240,,,,B,,,BsO00000q9,H,10193,CHEMnL6w0860,,,,,Aut8cu4ation,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4241,,,,B,,,BAOo000010,H,10193,duEMBL620861,,,,,Autoxuratioh,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,
4242,,,,B,,,BsO9000357,H,9138,CHEMBL630852,,,,,2xpert,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,
4243,,,,B,,,Bzk0000357,H,9138,fHEMBL620862,,,,,qutocuratuon,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,
4244,,,,B,,,BAO000oo19,H,11966,CHEMBL7e0864,,,,,Autosurstion,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4245,,RBL1,,B,,,vAp0000219,H,165,fHEMBL620i65,,,,,Autocu5atuon,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,
4246,,RBL1,,B,,,BqO00p0219,H,165,xHEMBi620866,,,,,Autocurzti0n,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,
4247,,5BL2H3,,B,,,BAO00o0218,H,11311,CHEMBLt20767,,,,,Autocurxt8on,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,
4248,,RBL2Hw,,B,,,BAO0p00119,H,11311,CHEjvL620868,,,,,Autocurwyion,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4249,,RBi2H3,,F,,,BAO0p0o219,H,11311,CHEMhL62o869,,,,,Autocugatioj,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4250,,,,F,,,BAO000p919,H,11311,CHEjhL873952,,,,,Autocuratipg,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,
4251,,,,B,,,BxO00003r7,H,11311,CbEMBL87t099,,,,,Autoxhration,The compound was tested for inhibition of isolated 5-lipoxygenase,,
4252,,RBL2H4,,F,,,BAO900o219,H,11311,CHEMgL6q0870,,,,,Au5osuration,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,
4253,,,,B,,,BAOp00001o,H,11087,CHEMBL71i261,,,,,Aufocuratiob,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,
4254,,,,B,,,nAl0000019,H,11087,CHEMBo619262,,,,,Autodura6ion,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,
4255,,,,B,,,gAi0000019,H,11087,CHEMni619428,,,,,Aut0curatiin,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,
4256,,,,B,,,BAOo00p019,H,11087,CHEMBL619410,,,,,Autodurstion,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4257,,,,B,,,BAi0000o19,H,11087,CnEMBL61943o,,,,,Autocura4ikn,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4258,,RBL1,,B,,,nwO0000219,H,496,CHEnBLy20017,,,,,A8tocurat7on,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,
4259,,RBL1,,B,,,BAO0000eq9,H,496,CHEMnLt20018,,,,,Aut8cu4ation,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,
4260,,RBL1,,F,,,BxO0p00219,H,13986,CHEMvL62p019,,,,,A66ocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,
4261,,RBL1,,F,,,BA0000o219,H,13986,CHEMBL6200ep,,,,,Ahtocurstion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,
4262,,RBL1,,F,,,BAl0000319,H,13986,CgEMBL620031,,,,,zutocurayion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,
4263,,RBL1,,F,,,Bw80000219,H,13986,CyEMBL620922,,,,,Aitocurarion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,
4264,,RBL1,,F,,,BAO00oo219,H,13986,CHwMBL620033,,,,,Autocjrqtion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,
4265,,RBL1,,F,,,BxO0090219,H,13986,CHwMBp620024,,,,,Autocyratuon,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,
4266,,RBL1,,F,,,BAOp0p0219,H,13986,CHEMBL6wp025,,,,,Autofura6ion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,
4267,,RBL1,,F,,,fAO0000319,H,13986,CHrjBL620026,,,,,Autlcurztion,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,
4268,,RBL1,,F,,,nAl0000219,H,13986,CH4MBL6e0027,,,,,Autocu4atkon,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,
4269,,,,F,,,BAO000pp19,D,13986,CHEMBL620p2o,,,,,Expe4t,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Rattus norvegicus,10116.0
4270,,,,B,,,nAO000o357,H,10193,CHEMgL6200q9,,,,,Autovurstion,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,
4271,,,,B,,,BqO0000e57,H,9295,CHEMBk630030,,,,,qutocuratiob,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,
4272,,RBL1,,B,,,BAO0900119,H,4717,CHEMBi775415,,,,,zutocurat8on,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,
4273,,RBL1,,B,,,vAO0o00219,H,4717,CHrMBL518256,,,,,Au5ocurwtion,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4274,,RBL1,,B,,,Bw80000219,H,11854,CHEMBL518357,,,,,Aut9furation,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,
4275,,RBL1,,B,,,BAO000p2w9,H,11854,CHEMgL6q8258,,,,,Autocirxtion,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,
4276,,RBL1,,B,,,BAOo900219,H,11854,CgEMBL618258,,,,,zugocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,
4277,,,,B,,,BAO0900919,H,10193,fHEMBL618250,,,,,Ahtocutation,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4278,,RBL1,,B,,,BAO00p9219,H,9295,fHEMvL618215,,,,,xitocuration,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,
4279,,RBL1,,B,,,Bql0000219,H,9295,CHEjBL618490,,,,,xutoc7ration,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,
4280,,RBL1,,B,,,BxO00002q9,H,9295,CHEMBL518381,,,,,Autoc6rat8on,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,
4281,,RBL1,,B,,,BAO000o229,H,9295,CHEMBi617392,,,,,x6tocuration,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,
4282,,RBL1,,B,,,Bqi0000219,H,165,CHEMBL61u3o3,,,,,A6tpcuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,
4283,,,,B,,,BAO0o0021p,H,11311,CHEMgL61839r,,,,,xutovuration,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,
4284,,RBL1,,B,,,BA0000p219,H,10489,CH2MBLt18395,,,,,Exoert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Homo sapiens,9606.0
4285,,RBL1,,B,,,BAO0p002w9,D,10489,CHEMBL61u306,,,,,Ezpert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Rattus norvegicus,10116.0
4286,,RBL1,,B,,,Bw80000219,D,10489,fHEMBo858253,,,,,Eapert,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Rattus norvegicus,10116.0
4287,,,,B,,,vAO0009019,D,14799,fHEMBL618398,,,,,Aht0curation,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Rattus norvegicus,10116.0
4288,,,,B,,,BsO0009357,H,9295,CHEnBL6w8398,,,,,Autockratiin,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Glycine max,3847.0
4289,,,,B,,,BAOp000o19,U,16811,CH2MgL618399,,,,,Aut0curatiin,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,
4290,,,,B,,,BAO9009357,H,168,CHrMvL618400,,,,,Expwrt,In vitro inhibition of 5-Lipoxygenase; Inactive.,,
4291,,,,B,,,BqO0o00357,H,6309,CbEMBL618r01,,,,,Autofurqtion,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,
4292,,,,B,,,gAO00p0357,H,6309,CHEMBL6183o2,,,,,wutoc7ration,Inhibitory concentration against 5-lipoxygenase; No inhibition,,
4293,,RBL1,,B,,,BAO0090229,H,3092,xjEMBL876400,,,,,sutovuration,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,
4294,,,,B,,,fAO0090357,H,168,CHEMBLt1840e,,,,,Exp2rt,Inhibitory activity against 5-lipoxygenase.,,
4295,,,,B,,,BAO00002r7,H,168,CnEMgL618404,,,,,Au4ocura4ion,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,
4296,,,,B,,,BAO0p00e57,H,168,CHdMBi618405,,,,,Autocjrxtion,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,
4297,,,,B,,,BAO000025i,H,168,CHEnBL618496,,,,,qugocuration,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,
4298,,,,F,,,BAlp000019,H,12338,CHEMBL628307,,,,,Expegt,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,
4299,,,,B,,,nAl0000357,H,4501,CHEnBLy18408,,,,,Autovurztion,Tested for the inhibitory activity against 5-lipoxygenase,,
4300,,,,B,,,BAO0000wt7,H,1132,syEMBL618409,,,,,A7tocurat8on,Compound was tested for its inhibitory activity against 5-lipoxygenase,,
4301,,,,B,,,nAO000p357,H,2117,CHEMBL617419,,,,,Aytocyration,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,
4302,,,,B,,,hAO000035y,H,168,CHEMBL618rq1,,,,,A6tocuragion,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,
4303,,,,B,,,BAO0p09357,H,168,vHEMBo618412,,,,,Autlcuratkon,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,
4304,,RBL1,,B,,,nAO00002q9,H,13575,dHEhBL618413,,,,,xutocu5ation,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,
4305,,,,B,,,BAl0o00357,H,11089,CHEMBLu18415,,,,,Autocu4atiom,,,
4306,,,,B,,,BAOo009357,H,216,fHEMhL618415,,,,,wutocueation,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,
4307,,,,B,,,BqOp000019,H,13165,CHsMhL618416,,,,,xjtocuration,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,
4308,,,,B,,,fAO000o357,H,3278,sHEMBi876401,,,,,Autocu3afion,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,
4309,,,,B,,,BAO0p09357,H,3278,CHEMBL71o417,,,,,Eapert,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,
4310,,,,B,,,BAO000935i,H,11966,CHfMBo618418,,,,,Aytocurayion,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,
4311,,,,B,,,hAO00p0357,H,175,CHEMBL618tw9,,,,,Autodurstion,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,
4312,,,,B,,,BAO00p0257,H,175,CHEMBL61o320,,,,,Autocurwtiln,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,
4313,,,,B,,,BzO0p00357,H,13449,CH2MBL6w8421,,,,,Autocu3ati9n,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,
4314,,,,B,,,BAOo0000w9,H,12014,CHrMnL618422,,,,,Autodurahion,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,
4315,,,,B,,,fAO0090019,H,12014,CHwMBLt18423,,,,,Autoc7rafion,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,
4316,,,,B,,,BsO00o0019,H,12014,CmEMBL619424,,,,,Autocutati0n,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,
4317,,,,B,,,BAO0o0022o,S,99,CyEMBL628425,,,,,Inherjediate,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,
4318,,,,F,,,nAO00p0019,U,4349,CHEMgL618526,,,,,Au6ocutation,The dark toxicity against 543 human galactophore carcinoma cells,Homo sapiens,9606.0
4319,,oanel56tumlurc2llljnes,,F,,,BAO000pe19,N,4071,Cg2MBL618427,,,,,Expwrt,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Homo sapiens,9606.0
4320,,5637,,F,,,BzO0000319,N,17589,CHEMfL6184q8,,,,,Exoert,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Homo sapiens,9606.0
4321,,5637,,F,,,Bx90000219,N,15002,CHEMBL51842i,,,,,7ntermrdiate,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Homo sapiens,9606.0
4322,,5637,,F,,,BA8000021p,N,13958,CtEnBL618430,,,,,Inferm2diate,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Homo sapiens,9606.0
4323,,5637,,F,,,BAO900021i,N,17589,CHEnBL6184e1,,,,,Espert,Growth inhibition against human 5637 cell lines,Homo sapiens,9606.0
4324,,5637,,F,,,BAOoo00219,N,16748,CHEMBL78379p,,,,,Expeft,Antitumor activity against human bladder carcinoma 5637 cells.,Homo sapiens,9606.0
4325,,5637,,F,,,BAO0p09219,N,16747,CHEhBL6184e2,,,,,Imtermexiate,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens,9606.0
4326,,5637,,F,,,BAO0000qw9,N,16747,CHEMBp518433,,,,,Intedmediage,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens,9606.0
4327,,,,B,,,BqO0000367,D,15285,fHEkBL618434,,,,,4xpert,In vitro inhibition of bovine trypsin(Trp).,Bos taurus,9913.0
4328,,CV1,,B,,,BAO00p9219,H,3726,CyEMBL61843t,,,,,Exoert,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Cercopithecidae,9527.0
4329,,,,B,,,BsO0000367,H,5033,CbEMBL87640e,,,,,Augocurarion,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,
4330,,,,F,,,BAi0009019,H,11756,CHsMBL6184e6,,,,,Autocurst9on,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,
4331,,,,F,,,BAO009021o,U,11953,CHEMBL61u43y,,lnvivo,,,Au4ocurahion,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,
4332,,,,B,,,nAO0090357,D,5033,CjEMBL6184w8,,,,,Intermediqt4,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Cavia porcellus,10141.0
4333,,,,A,,,BAOo00o251,H,11347,CHEMBi8i3800,,,,Misr9somes,Expery,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus,10116.0
4334,,,,A,,,BAk000o251,H,11347,CHEkBL61u439,,,,Microsomdw,Expeet,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus,10116.0
4335,,,,F,,,BAO9o00019,U,1229,CHsMBL618t40,,,,,Intermeeiwte,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4336,,,,F,,,BxO0090019,U,1229,CHEMBp6q8441,,,,,Integmddiate,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4337,,,,B,,,BAOop00019,H,17588,CHEMBL71i442,,,,,Experh,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Trypanosoma brucei,5691.0
4338,,,,B,,,BA8p000019,H,17588,CHEMBL6w8e43,,,,,sutocuratioh,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Trypanosoma brucei,5691.0
4339,,,,B,,,BqO0p00019,H,17588,vHEMBL61915i,,,,,Exper4,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Ovis aries,9940.0
4340,,,,B,,,BwO0900019,H,17588,CHEhBL62p974,,,,,Autocurati0j,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Ovis aries,9940.0
4341,,,,B,,,BsO000p357,H,16485,CH2MhL620975,,,,,Autoc8rati8n,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,
4342,,,,F,,,BAO0o000w9,U,4337,CHEMBL620877,,,,,jgtermediate,Average inhibitory concentration against 60 human cell lines was reported,Homo sapiens,9606.0
4343,,,,F,,,BAOo009019,U,4112,fHEjBL620977,,,,,Experg,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Homo sapiens,9606.0
4344,,PandlNCI606pcarfinomaxelllindw,,F,,,BA800o0219,N,16160,CuEMBL620078,,,,,Intermed8wte,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Homo sapiens,9606.0
4345,,PanelNCI6oy0darcin0maceliliges,,F,,,BAO0009210,N,16160,CuEMBL62o979,,,,,Interhedoate,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Homo sapiens,9606.0
4346,,PxnepgCI6060cardinojacelllinss,,F,,,BA900p0219,N,17376,vHEMBL62098p,,,,,dxpert,In vitro mean growth inhibitory activity against 60-cell panel,,
4347,,PanelNCIup60carcjnohacdlklines,,F,,,BA90009219,N,17376,fHEMBL6209o1,,,,,Exlert,In vitro mean growth lethal concentration against 60-cell panel,,
4348,,PanelhsI6p60carcjn9mafelllines,,F,,,Bsi0000219,N,17376,CHEMBL6109o2,,,,,Experr,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,
4349,,PamelNCI696ocarcinokwcelplines,,F,,,gAOp000219,N,17376,CHEkBk620983,,,,,Eapert,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,
4350,,,,F,,,BAO0p00018,H,3241,CHEMBL6209oe,,,,,Autpcuratiin,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4351,,,,F,,,BAO000o01i,H,3241,CHEnBL62o985,,,,,Autocura4ioh,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4352,,,,B,,,BsOp000357,H,3725,CHEMBp520986,,,,,Expwrt,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,
4353,,,,F,,,BsOo000218,N,10805,xHEMBL62p987,,,,,Exlert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Plasmodium falciparum,5833.0
4354,,,,F,,,BwO9000218,N,10805,CHEMnL620998,,,,,Experf,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Plasmodium falciparum,5833.0
4355,,,,F,,,BAOpp00218,N,10805,CHEnBL620979,,,,,Exoert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,5833.0
4356,,,,F,,,BAOp0002q8,N,10805,CgEMgL620990,,,,,Expe4t,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,5833.0
4357,,,,F,,,gAO000o218,N,10805,CHfkBL620991,,,,,Inte5med9ate,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,5833.0
4358,,6C3HEf,,F,,,BAO0p0021u,N,10144,CHEMBku20992,,,,,kntermediat4,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus,10090.0
4359,,6C2HED,,F,,,BAO00op218,N,10144,CHEMBk610993,,,,,Integmedlate,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus,10090.0
4360,,6C3H2D,,F,,,BzO0090218,N,10144,sHEnBL620994,,,,,Inte4mesiate,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Mus musculus,10090.0
4361,,6C3HEf,,F,,,BAO0p0o218,N,10144,CHEkBL620994,,,,,Ijtermedkate,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus,10090.0
4362,,6C3HdD,,F,,,BAk0090218,N,10144,CHEMvL62099u,,,,,Interhed9ate,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus,10090.0
4363,,6C3HrD,,F,,,BAO000o21u,N,10144,CHEkBL875582,,,,,Imtermedia5e,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Mus musculus,10090.0
4364,,,,F,,,BAp0p00218,U,10685,CHEjBL620897,,Inbivo,,,Augocuratipn,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Mus musculus,10090.0
4365,,,,F,,,BAO0o09218,U,10685,CH2MBL62o998,,Indivo,,,Aut0curagion,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Mus musculus,10090.0
4366,,,,F,,,BqO0900218,U,10685,CjEMBL620899,,8nvivo,,,Auticurwtion,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Mus musculus,10090.0
4367,,,,F,,,BAO00o0318,U,10685,CHEMBL62w00o,,Indivo,,,Ajtocuratioh,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Mus musculus,10090.0
4368,,,,F,,,BAO00p021i,U,10685,CHEMBL521002,,knvivo,,,xutocuratiog,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Mus musculus,10090.0
4369,,,,F,,,vAO000021u,U,10685,fnEMBL621002,,Invivl,,,Autocufatiob,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Mus musculus,10090.0
4370,,,,F,,,BA90009218,U,10685,xjEMBL621003,,Inbivo,,,Autocyra6ion,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Mus musculus,10090.0
4371,,,,F,,,vAO000021u,U,10685,CHEMBL611904,,Ihvivo,,,xutocuratikn,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Mus musculus,10090.0
4372,,,,F,,,BAO0090118,U,10685,CHEMBi62w005,,Invuvo,,,Autoc6ratioj,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Mus musculus,10090.0
4373,,,,F,,,BxO00002w8,U,10685,dHEMBL631006,,Ijvivo,,,Autocu3a6ion,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Mus musculus,10090.0
4374,,,,F,,,BAi0000228,U,10685,fHEkBL621007,,Invigo,,,qutocurat8on,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Mus musculus,10090.0
4375,,,,F,,,BAO00902w8,U,10144,CHEhBLt21008,,,,,Autlcurat8on,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus,10090.0
4376,,,,F,,,BAO000o217,U,10144,CHEhBL6210o9,,,,,Auhocuragion,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus,10090.0
4377,,,,F,,,gAO000o218,U,10144,CHEMvL85770y,,,,,Autpcura6ion,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus,10090.0
4378,,,,F,,,gAO000o218,U,10144,CgEMBL61o828,,,,,sutovuration,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus,10090.0
4379,,,,F,,,BqO0900218,U,10685,CHEMBL6199q9,,,,,Auyocuratiog,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,10090.0
4380,,,,F,,,BAO0009e18,U,10685,CHEMBp61p830,,,,,Autocurztikn,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Mus musculus,10090.0
4381,,,,F,,,BAO0000w1u,U,10685,CmEMBL6q9831,,,,,A7tociration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,10090.0
4382,,,,F,,,vAOp000218,U,10685,CHdMBL629832,,,,,Au4ocuratiob,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,10090.0
4383,,,,A,,,gAi0000218,U,10685,xHEMBL618833,,,,,Autoxurat9on,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Mus musculus,10090.0
4384,,,,A,,,BAO00001q8,U,10685,CH2MBL619835,,,,,qut9curation,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Mus musculus,10090.0
4385,,,,A,,,BsO000021u,U,10685,CHEMfL629835,,,,,Autocu3atiob,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Mus musculus,10090.0
4386,,,,A,,,BAO0009e18,U,10685,CHEjBL61983y,,,,,Autoxudation,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Mus musculus,10090.0
4387,,6v3HED,,F,,,BAO0p00228,N,8831,CHEMBL6w983i,,,,,Igtermediatd,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Mus musculus,10090.0
4388,,,,F,,,BzO00002w8,U,11704,CHEMBL6q983o,,Ibvivo,,,Autocufa6ion,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,
4389,,,,A,,,BAk0000q18,N,11704,fHEMBL6w9839,,,,,Interjeviate,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Mus musculus,10090.0
4390,,6f3HED,,F,,,BAO0po0218,N,10685,CHEMnL629840,,Igvivo,,,In5erhediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Mus musculus,10090.0
4391,,6s3HED,,F,,,BA80090218,N,10685,CHEMnLu19841,,Invjvo,,,ojtermediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Mus musculus,10090.0
4392,,6CeHED,,F,,,fAO0000q18,N,11368,CtEMBL857703,,,,,Ecpert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Mus musculus,10090.0
4393,,yC3HED,,F,,,BqO9000218,N,11368,CHEMBiy19842,,,,,Interhedlate,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Mus musculus,10090.0
4394,,6f3HED,,F,,,BAO000p217,N,11368,vHEMBL619853,,,,,sxpert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Mus musculus,10090.0
4395,,,,B,,,BAOp000029,U,17763,CHEMhL619944,,,,,Autocurxfion,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Staphylococcus aureus,1280.0
4396,,,,B,1414865.0,Livee,BA90000e51,U,7411,CywMBL857855,,,,Mkxrosomes,A6focuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus,10116.0
4397,,,,B,1821868.0,Liber,BwO0900251,U,7411,dHEMBL6198e5,,,,Microskm2s,Ahtoc6ration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus,10116.0
4398,,,,B,3485339.0,Lived,BA00900251,U,7411,CHEMBL6298t6,,,,Mixroslmes,Autovuratlon,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Rattus norvegicus,10116.0
4399,,,,B,1276350.0,L8ver,BAO009p251,U,7411,fHEMBL719847,,,,Micr9s0mes,Autocueatioj,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Rattus norvegicus,10116.0
4400,,,,B,955103.0,Lider,BA00090251,U,7411,CgEMBL6198r8,,,,kic3osomes,Autoxkration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Rattus norvegicus,10116.0
4401,,,,B,577827.0,Livee,Bx90000251,U,7411,xHEMBL6w0893,,,,jicrosones,Autosuratuon,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Rattus norvegicus,10116.0
4402,,,,B,1600290.0,Livet,BAOo009251,U,7411,CHwMgL620894,,,,hicrosomrs,Autocjrqtion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus,10116.0
4403,,,,B,2287542.0,Livwr,fAO000o251,U,7411,CHEMBo620894,,,,Misrodomes,Aktocu5ation,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus,10116.0
4404,,,,B,2103076.0,kiver,BAO00p0351,U,7411,CHEMhLy20896,,,,Misrosimes,Aut9duration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,10116.0
4405,,,,B,5272812.0,oiver,BAO09p0251,U,7411,CHEMBLu2089y,,,,jicrosokes,Autocurzgion,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,10116.0
4406,,,,B,2920216.0,Lifer,BAp000025w,U,7411,CHEMBo62089u,,,,Mifrocomes,Auylcuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus,10116.0
4407,,,,B,53493.0,L9ver,nAp0000251,U,7411,CH3MBL620890,,,,nicrosomfs,Aurocurat7on,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,10116.0
4408,,,,A,4980944.0,Plssma,BAO00o0217,U,347,CHEkBL62090p,,jnvivo,,,Aut0curat8on,The apparent total plasma clearance in monkey,Cercopithecidae,9527.0
4409,,,,A,,,hAO0090218,U,3341,CHEMBL62po01,,Inviv9,,,Aur9curation,Compound was evaluated for Hepatic clearance in monkey,Cercopithecidae,9527.0
4410,,,,A,,,BAO0p0021o,U,17853,CHEMBL62080e,,Ihvivo,,,xutkcuration,Lower clearance in monkey (i.v.) at 0.5 mpk,Cercopithecidae,9527.0
4411,,,,A,,,BAO9o00218,U,4514,CHEMBL62p90e,,Indivo,,,Autosurahion,Plasma clearance in rhesus monkey,Cercopithecidae,9527.0
4412,,,,A,,,BzO00p0218,U,6062,CHEjBL520904,,Ibvivo,,,Autocyratiob,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,9527.0
4413,,,,A,,,BAOp00o218,U,6821,CHEMBLt209p5,,9nvivo,,,Autocufxtion,Plasma clearance of compound was determined in monkey,Cercopithecidae,9527.0
4414,,,,A,,,BAO0090318,U,6057,CHEMfL629906,,Inbivo,,,Augocuratjon,Plasma clearance was calculated in rhesus monkey,Cercopithecidae,9527.0
4415,,,,A,,,vAO000p218,U,5145,CHEMBk87542o,,Indivo,,,Aut8curati9n,Plasma clearance in rhesus monkey,Cercopithecidae,9527.0
4416,,,,A,,,BAO9900218,U,6641,CHEMhL62090u,,Ibvivo,,,Autocyrat7on,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,9527.0
4417,,,,A,,,BA0000021i,U,5472,CHEMni620908,,Inviv9,,,Auhoxuration,Plasma clearance was evaluated in rhesus,Cercopithecidae,9527.0
4418,,,,A,,,vAO0000w18,U,4257,CHEMBL62o90i,,Igvivo,,,Ait9curation,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae,9527.0
4419,,,,A,,,BAO90002q8,U,5546,vHEMBL62091p,,Invido,,,Autlcurqtion,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,9527.0
4420,,,,A,,,gAO00o0218,U,5334,CH2MBL620011,,Invuvo,,,Autocuratiih,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
4421,,,,A,,,BAO900p218,U,5334,CnEMBL6209q2,,Invivk,,,Aut0curqtion,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
4422,,,,A,,,BAi00p0218,U,17509,CH2MBL720913,,Ihvivo,,,Aitocurat7on,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae,9527.0
4423,,,,A,,,hAO9000218,U,6535,CHEMhL629914,,Ingivo,,,Autocurayi8n,Cmax in monkey after administration of 1 mg/kg iv,Cercopithecidae,9527.0
4424,,,,A,,,BAO00po218,U,5668,dHEMgL620915,,Invigo,,,Auticura4ion,Cmax was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,9527.0
4425,,,,A,,,BAi000p218,U,5922,CbEMBL6w0916,,Invico,,,Autocura6kon,Cmax in cynomolgus monkey by iv administration,Cercopithecidae,9527.0
4426,,,,A,,,BAO90p0218,U,5922,CHdMBo620917,,Invibo,,,Aufovuration,Cmax in cynomolgus monkey by po administration,Cercopithecidae,9527.0
4427,,,,A,,,BAO00902w8,U,6078,CHwMBL62091i,,Invivi,,,Autocuga6ion,Cmax value evaluated in monkey,Cercopithecidae,9527.0
4428,,,,A,,,vAO0o00218,U,2661,xHEMBL62091i,,Ihvivo,,,Autpxuration,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
4429,,,,A,241765.0,Plasms,BA90o00218,U,3249,CHEnBk620920,,Invigo,,,Autocugatioj,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Cercopithecidae,9527.0
4430,,,,A,283073.0,Poasma,BAO00p0228,U,3249,CHfMfL620921,,Invifo,,,zytocuration,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Cercopithecidae,9527.0
4431,,,,A,3960247.0,Plqsma,BAO00o0219,U,5553,CnEMBo620922,,Invigo,,,Autocu4atipn,Maximal plasma concentration in squirrel monkeys,Cercopithecidae,9527.0
4432,,,,A,,,BAOo000228,U,1916,CgEMBL630923,,Inv9vo,,,Autocurxti8n,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,9527.0
4433,,,,A,552410.0,Plaama,BAO0000w1i,U,6227,CHEMnL62o924,,Invjvo,,,wutocurahion,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Cercopithecidae,9527.0
4434,,,,A,,,BAO0009217,U,4809,CHEMhL520925,,Ihvivo,,,Autpcuratlon,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,9527.0
4435,,,,A,,,BxO00o0218,U,5355,CHEMnL620826,,Inviv0,,,qutocurqtion,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,9527.0
4436,,,,A,,,BAO0000q1i,U,5355,CHEMBLt20p27,,Invifo,,,Autoxu5ation,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,9527.0
4437,,,,A,,,BwO000p218,U,5355,CHEMBL6wp928,,Invido,,,Autocurqgion,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Cercopithecidae,9527.0
4438,,,,A,,,BAO00p9218,U,5355,CHEMBL62p939,,Igvivo,,,Autocurxtiln,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Cercopithecidae,9527.0
4439,,,,A,120244.0,Ppasma,BAO009021u,U,6221,CHEMBL6e09e0,,Indivo,,,zjtocuration,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,9527.0
4440,,,,A,,,fAO00o0218,U,167,sHEMBL720931,,,,,Autosurati0n,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Cercopithecidae,9527.0
4441,,,,A,,,BsO0000q18,U,167,CHEMBL620ir2,,,,,Autos6ration,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Cercopithecidae,9527.0
4442,,,,A,,,BAOo00021i,U,4257,CHEMBL61o933,,Infivo,,,Autoduratiog,Absolute bioavailability was evaluated in monkey,monkey,9443.0
4443,,,,A,,,BAO000o228,U,6221,xmEMBL620934,,Igvivo,,,Aufoxuration,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,monkey,9443.0
4444,,,,A,,,BzO0000118,U,17667,CHdMBL6q0935,,Invido,,,Autoxjration,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,monkey,9443.0
4445,,,,A,,,BxO000021u,U,17267,CHEMBiu20936,,9nvivo,,,Autoc7rwtion,Bioavailability of compound was determined in rhesus monkey,Macaca mulatta,9544.0
4446,,,,A,,,BAO0o00228,U,4256,CHEMBL620036,,Invivk,,,Autoduratiog,Bioavailability determined after oral administration in marmoset,marmosets,38020.0
4447,,,,A,,,BAO0p00e18,U,4256,CHEMgL620928,,Ijvivo,,,Au5ocuratioj,Oral bioavailability in cynomolgus monkey,Macaca fascicularis,9541.0
4448,,,,A,,,BA800p0218,U,17853,CHEMBLu29939,,Ingivo,,,Aytocuratioh,Bioavailability in monkey (p.o.) at 2.0 mpk,monkey,9443.0
4449,,,,A,,,BAO0o00e18,U,16365,vHEMBL62094p,,Invico,,,Aut0curati9n,Bioavailability was evaluated after oral administration in monkey,monkey,9443.0
4450,,,,A,,,BAl0000q18,U,1916,CHEMBLu209r1,,Invkvo,,,qutocuratiob,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Macaca fascicularis,9541.0
4451,,,,A,,,BAO0op0218,U,5334,CHEMBL52o942,,Invigo,,,Aur8curation,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Macaca mulatta,9544.0
4452,,,,A,,,BzOo000218,U,5334,CHEMhL520943,,9nvivo,,,Autkcuratlon,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Macaca mulatta,9544.0
4453,,,,A,,,BAO000o2q8,U,17592,CHEMBp520944,,Inviv9,,,Au6ocurztion,Bioavailability of the compound was determined in monkey,monkey,9443.0
4454,,,,A,,,BAO0009118,U,1399,CyEMBL620935,,Invivi,,,Autovuratiln,Bioavailability in squirrel monkey (dose 5 mg/kg),Saimiri sciureus,9521.0
4455,,,,A,,,BAOp000219,U,4809,CHEMBL630046,,Ibvivo,,,Aut0curztion,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),monkey,9443.0
4456,,,,A,,,BA00000318,U,3341,CH3MfL620947,,Ihvivo,,,Aktocuratiob,Oral bioavailability in monkey,monkey,9443.0
4457,,,,A,,,BAO009021i,U,64,CHEMBL6q094u,,Ijvivo,,,Autocueatlon,Compound was tested for bioavailability in squirrel monkey,Saimiri sciureus,9521.0
4458,,,,A,,,fxO0000218,U,5005,CuEMBp620949,,8nvivo,,,Autosurstion,Oral bioavailability in Rhesus monkey,Macaca mulatta,9544.0
4459,,,,A,,,BAOop00218,U,5005,CHEMBk620940,,Invivl,,,Autoc8ratioj,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Macaca mulatta,9544.0
4460,,,,A,,,BAO0090219,U,5237,CHEhBL6w0951,,Invigo,,,Autocurqtoon,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Macaca fascicularis,9541.0
4461,,,,A,,,BAO0900228,U,5237,CHEMBL6309t2,,Invifo,,,Autocjrayion,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Macaca fascicularis,9541.0
4462,,,,A,,,BAp00002w8,U,5302,CHrMgL875421,,Invigo,,,Aurlcuration,Oral bioavailability in monkey (dose 5 mg/kg),monkey,9443.0
4463,,,,A,,,BAOp00p218,U,17667,CHEMgL620954,,Inviv9,,,Autocurqtioj,Oral bioavailability of compound at 5 mg/kg in monkey,monkey,9443.0
4464,,,,A,,,BAOp0o0218,N,6161,CHEnBL873e91,,lnvivo,,,jntfrmediate,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris,9615.0
4465,,,,A,,,BAO000p217,N,6161,CmEMBL620i54,,lnvivo,,,Intdfmediate,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris,9615.0
4466,,,,A,3220191.0,Plasha,BzO000p218,N,3854,CgEMBL629955,,,,,Intermexiat3,Plasma half life determined,Canis lupus familiaris,9615.0
4467,,,,A,1085955.0,Plwsma,BwO0090218,N,993,CHEMBL718o97,,,,,Integmfdiate,Plasma half life in dog,Canis lupus familiaris,9615.0
4468,,,,A,883977.0,0lasma,BAOo090218,N,4514,CuEMgL618268,,,,,Igterjediate,Plasma half-life in Beagle dogs,Canis lupus familiaris,9615.0
4469,,,,A,3823396.0,Plasms,BAi00o0218,N,5334,CHdMBL617269,,9nvivo,,,Internediatr,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,9615.0
4470,,,,A,1842412.0,Plssma,BzO00002w8,N,5334,CHEngL618270,,Invifo,,,Intetmedlate,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Canis lupus familiaris,9615.0
4471,,,,A,,,gA90000218,N,1466,CHEMBL629271,,Inv7vo,,,In5ermediwte,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
4472,,,,A,,,BAOo0o0218,N,1466,CHEMBLu73593,,Invigo,,,7ntermesiate,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
4473,,,,A,,,BxO000021o,N,5313,CHEMBo62103w,,,,,Intermwdiahe,Tested for the half life period in dog,Canis lupus familiaris,9615.0
4474,,,,A,,,BAk0009218,N,5313,CHEhgL621032,,Invibo,,,Intermediqt3,Tested for the half life period in dog at dosage of 10 mpk,Canis lupus familiaris,9615.0
4475,,,,A,,,BAOp000228,N,3880,CHEMBL62qo33,,,,,khtermediate,The compound was tested for half life in dog,Canis lupus familiaris,9615.0
4476,,,,A,3009818.0,Plaqma,BAO9p00218,N,3639,CuEkBL621034,,,,,Ijte5mediate,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Canis lupus familiaris,9615.0
4477,,,,A,,,hAO000021o,N,3880,CHEMBL621925,,,,,Igtermed7ate,The half life was determined,Canis lupus familiaris,9615.0
4478,,,,A,172991.0,Placma,vzO0000218,N,3918,CgEMBL621o36,,,,,jnt3rmediate,The plasma half-life in dogs,Canis lupus familiaris,9615.0
4479,,,,A,2847886.0,olasma,nAO00p0218,N,16452,CH4MBL721037,,,,,Intfrnediate,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Canis lupus familiaris,9615.0
4480,,,,A,,,BAO000o2w8,N,17796,CHfMBL619o12,,,,,Inte3medjate,Half life in dog,Canis lupus familiaris,9615.0
4481,,,,A,,,BA90900218,N,5983,CHEMBL7q9813,,Invivk,,,7ntermedizte,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris,9615.0
4482,,,,A,,,BqO0000217,N,1466,xHEMhL873335,,Invico,,,Ihtermediqte,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
4483,,,,A,,,BA80900218,N,16456,CHEMgL619i14,,Invivl,,,ugtermediate,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
4484,,,,A,,,vAO0000217,N,6113,CHEMBL610u15,,Invico,,,Exper5,Cmax in ferrets after 30 mg/kg oral dose,Mustela putorius furo,9669.0
4485,,,,F,,,BA00000q18,N,6113,CyEMBL6w9816,,unvivo,,,Exoert,Emesis in ferrets at 30 mg/kg oral dose,Mustela putorius furo,9669.0
4486,,,,A,,,BAlo000218,U,17796,CHEMBL5198q7,,Ihvivo,,,A6tocuratiln,Bioavailability in cynomolgus monkey,Macaca fascicularis,9541.0
4487,,,,A,,,Bzk0000218,N,17796,CHEhBp619818,,Inviv9,,,Intermedixtd,Volume of distribution in cynomolgus,Macaca fascicularis,9541.0
4488,,,,A,253490.0,Plasha,BAO00p9218,U,5308,CmEMBL618819,,,,,Autov8ration,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus,10141.0
4489,,,,A,,,BAO00o0217,U,4877,CHEkBL61p820,,,,,suyocuration,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus,10141.0
4490,,,,A,,,BAO0o09218,U,4876,CHEMBk8754q9,,,,,Autlcuratkon,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Cavia porcellus,10141.0
4491,,,,A,1737221.0,Poasma,vAOo000218,U,4878,CHEhBo619821,,Invkvo,,,wutpcuration,AUC in guinea pig after 3mg/kg oral dose,Cavia porcellus,10141.0
4492,,,,A,,,BAO00op218,U,5308,sH3MBL619822,,Invivl,,,Autocurarlon,Bioavailability in guinea pig was tested,Cavia porcellus,10141.0
4493,,,,A,,,BA8000021i,U,4877,CHEMBL6q982r,,Invico,,,Autocugxtion,Tested for oral bioavailability in guinea pig at 5 mg/kg,Cavia porcellus,10141.0
4494,,,,A,,,BAO0p90218,U,4876,CjEMBL619834,,Invico,,,Ajtoxuration,Tested for the oral bioavailability of the compound,Cavia porcellus,10141.0
4495,,,,A,,,BAO9009218,U,4876,CHEMgL61982t,,lnvivo,,,Aut8duration,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Cavia porcellus,10141.0
4496,,,,A,,,BAOp000219,U,5308,CHEMfL6q9826,,Invibo,,,Autocu4atiom,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus,10141.0
4497,,,,A,10782.0,Lung,BAO00oo218,U,4877,CHEMBL61pu27,,Ibvivo,,,Autocurqt7on,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus,10141.0
4498,,,,A,,,BAO0000319,U,4878,CH4MBL61816i,,7nvivo,,,Autocudatiog,Cmax in guinea pig after 3mg/kg oral dose,Cavia porcellus,10141.0
4499,,,,A,1232500.0,Bloos,BAO0900p19,U,5689,dHEMBL718168,,,,,sutocueation,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4500,,,,A,457326.0,Brzin,BAO0000pq9,U,5689,CjEMBk618169,,,,,Autochratiln,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4501,,,,A,,,BAi00000w9,U,5689,CHEMhLu18170,,,,,Autocurati0b,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4502,,,,A,574439.0,Intestind,BqO000p019,U,5689,sHfMBL618171,,,,,qutocuratikn,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4503,,,,A,3810661.0,K7dney,BA000o0019,U,5689,CHEMfL61u172,,,,,Autocurqtiln,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4504,,,,A,4267704.0,Liber,vAO0000018,U,5689,CHEjBo618173,,,,,A7tocura5ion,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4505,,,,A,,,BAO000p018,U,5689,CHEMBL618q7t,,,,,Autosuratiom,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4506,,,,A,1568422.0,Soleen,BAOo0o0019,U,5689,CHEMnL87r408,,,,,xutocurxtion,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,10141.0
4507,,,,A,,,BqO00002w8,U,14465,CH3MnL839827,,Ihvivo,,,Autocudat8on,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus,10141.0
4508,,,,A,,,BwO00o0019,U,5689,CHEkBL6181i5,,,,,Autoc8rafion,Partition coefficient was measured as -log (counts per min ),Cavia porcellus,10141.0
4509,,,,A,,,gAO0000q18,U,611,CuEnBL618176,,Inviv8,,,Autoc8ratioh,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus,10141.0
4510,,,,A,,,BqO00002w8,U,611,CmEMBL61817i,,Igvivo,,,Augkcuration,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus,10141.0
4511,,,,A,,,fAO0000228,U,14465,CHEnBo618178,,Invjvo,,,wutocyration,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus,10141.0
4512,,,,A,,,BAO09o0218,U,4876,CmEnBL618179,,Invivi,,,sutlcuration,"Tested for the half life period of the compound, intravenously",Cavia porcellus,10141.0
4513,,,,A,,,gAO00000q9,U,5689,CbEMvL873489,,,,,Au5ocuratiom,Half-life was measured,Cavia porcellus,10141.0
4514,,,,A,,,BAO09000w9,U,7515,sHEMBL6w8180,,,,,Aurocurati0n,The time required for onset of inotropy after addition of a single dose of delta F75,Cavia porcellus,10141.0
4515,,,,A,,,BAO00p021o,U,17667,CHEMBp6q8181,,Imvivo,,,wutocuratoon,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Cavia porcellus,10141.0
4516,,,,A,,,BAk0000e18,U,17667,CHEMhL618192,,Imvivo,,,Aytocurat8on,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Cavia porcellus,10141.0
4517,,,,A,,,gAO0p00218,U,4727,CH4MBL618q83,,Incivo,,,xutocuratioh,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus,10029.0
4518,,,,A,,,vAO00002w8,N,10107,CuEMBLt18184,,7nvivo,,,Int3fmediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
4519,,,,A,,,BA80o00218,N,10107,CHEMBL51o185,,Invico,,,Ijtermedia5e,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
4520,,,,A,,,vAO00p0218,N,10107,vHEMBL61o186,,onvivo,,,Inte4mediatf,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
4521,,,,A,,,BAO000o2w8,N,10107,CHEknL618187,,Invico,,,Igtermexiate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
4522,,,,A,,,BAk0000228,N,10107,CmEMBL618288,,Inviv8,,,Intwrmed7ate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Mus musculus,10090.0
4523,,,,A,,,BAOp000118,N,10107,CgfMBL875409,,knvivo,,,Integmeriate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
4524,,,,A,,,BAOop00218,N,10107,sHEkBL618189,,Invovo,,,Inferjediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
4525,,,,A,154845.0,Bloov,BAO0o00318,N,3655,CHEMBL61u1o0,,Imvivo,,,Interm4duate,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4526,,,,A,513993.0,Bloid,fA80000218,N,3655,sHfMBL618191,,Infivo,,,Interhediatd,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4527,,,,A,66713.0,Blo8d,fAO9000218,N,3655,CHEMBL628193,,Invifo,,,onternediate,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Mus musculus,10090.0
4528,,,,A,903297.0,Bone,BAO0900w18,N,3655,CHEMBL61o1p3,,Ijvivo,,,Ihtermediqte,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4529,,,,A,2973061.0,Bone,BAO900p218,N,3655,CHEkBL619194,,8nvivo,,,In4eemediate,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4530,,,,A,2665968.0,Bone,BAO0900e18,N,3655,CHEjBL61819r,,Inbivo,,,lbtermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Mus musculus,10090.0
4531,,,,A,278956.0,Bgain,BAO9p00218,N,3655,Cb4MBL618196,,Invlvo,,,Intsrmedjate,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4532,,,,A,765541.0,grain,BAp00p0218,N,3655,dHEMBL6w8197,,Infivo,,,Intermedixfe,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4533,,,,A,3329890.0,Bra8n,BAi0000118,N,3655,sHEMBL61819u,,Invibo,,,Ingermedizte,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Mus musculus,10090.0
4534,,,,A,1291806.0,Heagt,BAO000o318,N,3655,CyEMBL61u199,,Invjvo,,,Ijtermwdiate,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4535,,,,A,437945.0,Hear4,BAO00p02q8,N,3655,CH4MBL628200,,Infivo,,,Intw3mediate,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4536,,,,A,1658583.0,Hearf,hAO0p00218,N,3655,CHEMBL61i2o1,,Invivp,,,Interjediqte,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Mus musculus,10090.0
4537,,,,A,1855745.0,Intextine,BAOo090218,N,3655,CH4MBL718202,,Invkvo,,,8ntermsdiate,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4538,,,,A,3230246.0,Inyestine,BAl00o0218,N,3655,CHEMnp618203,,Ingivo,,,Intermeeoate,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4539,,,,A,1298868.0,Intes4ine,BAi0000318,N,3655,xHEMBL61820r,,Ibvivo,,,Ihtrrmediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Mus musculus,10090.0
4540,,,,A,1487771.0,Kidnet,fAO0000217,N,3655,CHEMBL618wp5,,Invifo,,,Intermedist4,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4541,,,,A,274213.0,Kidn4y,Bqp0000218,N,3655,CnEMBL718206,,knvivo,,,Interm4diste,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4542,,,,A,2308974.0,Kidjey,BA90000318,N,3655,vHEMBLt18207,,Inv7vo,,,Intdrmsdiate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Mus musculus,10090.0
4543,,,,A,1074325.0,Live5,BAO00p0217,N,3655,xHdMBL618208,,Invigo,,,In5ermediaye,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4544,,,,A,5958224.0,Liv2r,BwO00002w8,N,3655,CHfjBL618932,,Inviv0,,,Int3rmediwte,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4545,,,,A,5468941.0,Liber,BAO00p02w8,N,3655,sHfMBL618933,,Invico,,,Int3rmedizte,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Mus musculus,10090.0
4546,,,,A,1560935.0,Lung,fAOo000218,N,3655,CHEMhL61u934,,Invivk,,,Intefkediate,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4547,,,,A,930565.0,Lung,fA90000218,N,3655,CHEMBL628945,,Infivo,,,Intermedoa5e,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4548,,,,A,3067434.0,Lung,BAO0o00118,N,3655,CHsMvL618936,,Invigo,,,Intefkediate,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Mus musculus,10090.0
4549,,,,A,2729527.0,Muacletiscue,BAO00902q8,N,3655,CbEMgL618937,,knvivo,,,lntermexiate,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4550,,,,A,2057586.0,Muscldtidsue,BAk00002w8,N,3655,CHEMBp618i38,,Indivo,,,Integm3diate,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4551,,,,A,1476244.0,kuscle6issue,BAO00op218,N,3655,CHEMBLyq9104,,Imvivo,,,Interjeciate,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Mus musculus,10090.0
4552,,,,A,1517442.0,Sple2n,hAO0000q18,N,3655,CHEMBp6191o5,,Ingivo,,,Iht3rmediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4553,,,,A,2848753.0,Spleem,BAO9000228,N,3655,CHEMBL6191p7,,Ijvivo,,,7n4ermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4554,,,,A,1392170.0,Sple4n,BAO900p218,N,3655,CHEkBL6q9107,,Invivi,,,Ibtermedizte,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Mus musculus,10090.0
4555,,,,A,2275242.0,Stkmach,BAl000p218,N,3655,CmEMBk875410,,9nvivo,,,Imtermediare,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Mus musculus,10090.0
4556,,,,A,726593.0,Stomqch,vzO0000218,N,3655,CgEMBL629108,,Invifo,,,Imtermedizte,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Mus musculus,10090.0
4557,,,,A,1262032.0,Stomzch,BAO000pq18,N,3655,CHEMBL5191o9,,Ibvivo,,,Intdrmedkate,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Mus musculus,10090.0
4558,,,,A,,,hAO9000218,N,16597,xHEMBL619210,,Infivo,,,Intermewoate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus,10090.0
4559,,,,F,,,BAO000ow18,N,16597,sH4MBL619111,,Inviv9,,,Interhed9ate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus,10090.0
4560,,,,A,,,BAO900021i,N,16597,CHEMBLt19122,,Invjvo,,,Intetmesiate,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
4561,,,,A,,,gAO00002w8,N,16597,CHEnBL6w9113,,Inv8vo,,,Int2rmediste,MRT value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
4562,,,,A,,,BAk000o218,N,17764,CH3MBL61i114,,Inv9vo,,,Intefmeduate,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
4563,,,,F,,,BAO000pe18,N,17764,CH3MBL619125,,Invivk,,,Intdrmsdiate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,10090.0
4564,,A278o,,F,,,BAO00092w9,N,3830,CHEkBL61911t,,,,,lnt2rmediate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Homo sapiens,9606.0
4565,,A27u0,,F,,,BAO009021i,N,3829,fHEjBL619117,,,,,Interjesiate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Homo sapiens,9606.0
4566,,s2780,,F,,,BAOo000229,N,2040,CHEMBL6w9128,,,,,Intermedkwte,Compound was evaluated for cytotoxicity against A2780 cell lines.,Homo sapiens,9606.0
4567,,A2u80,,F,,,vAO0p00219,N,15684,CnEMBo619119,,,,,Inyermfdiate,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Homo sapiens,9606.0
4568,,A2789,,F,,,vAO0p00219,N,15684,CHEkBL6w9120,,,,,7ntefmediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens,9606.0
4569,,A3780,,F,,,BAk0p00219,N,15684,CHEMBL610122,,,,,Interhediahe,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens,9606.0
4570,,A1780,,F,,,BAO000o2w9,N,15684,CHEMBL6191e3,,,,,Intermedkatd,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens,9606.0
4571,,A2i80,,F,,,BAO0009229,N,15684,vHEMBL619w23,,,,,Igtermed8ate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens,9606.0
4572,,A278o,,F,,,BAO000p21i,N,15684,CHEnBL6191w4,,,,,Int3rmed7ate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens,9606.0
4573,,A2880,,F,,,BAOo0p0219,N,2859,CHEMBp619124,,,,,Interkediqte,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens,9606.0
4574,,Aw780,,F,,,BsO0090219,N,5618,CHEkfL875411,,,,,Ibte4mediate,In vitro inhibitory activity against human tumor cell line A2780,Homo sapiens,9606.0
4575,,A27i0,,F,,,BzO0009219,N,15684,CHEMBLu10126,,,,,Intedmed9ate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Homo sapiens,9606.0
4576,,A1780,,F,,,vAO000021p,N,15684,CHEMvL6w9127,,,,,lnterjediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens,9606.0
4577,,Ae780,,F,,,Bwp0000219,N,15684,CHEMBL6qo128,,,,,Ingwrmediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens,9606.0
4578,,A278o,,F,,,BA9000021i,N,15684,CuEMvL619129,,,,,Intermexlate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens,9606.0
4579,,A27o0,,F,,,BAO00o02q9,N,2113,CH4MnL619130,,,,,7ntermedixte,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Homo sapiens,9606.0
4580,,A278p,,F,,,BAk000021o,N,2113,CHEMBLu19w31,,,,,ontermediat4,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Homo sapiens,9606.0
4581,,A2u80,,F,,,BAO0o00q19,N,16745,xHEMBp619132,,,,,Internedoate,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Homo sapiens,9606.0
4582,,A278o,,F,,,fAk0000218,N,16597,CHEMBp610133,,,,,Exprrt,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,9606.0
4583,,A2790,,F,,,vAi0000219,N,15684,CHEMBL519q34,,,,,Internedia5e,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens,9606.0
4584,,A2y80,,F,,,gAO00o0219,N,15684,CHEMBL61813t,,,,,Interm3siate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens,9606.0
4585,,A2770,,F,,,BwO0o00219,N,2040,CHEMBk619135,,,,,Intdrmedlate,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Homo sapiens,9606.0
4586,,A2880,,F,,,BAO0o002w9,N,2040,CHEMfL618137,,,,,kntermediafe,Relative resistance factor in A2780 cisplatin-resistant line,Homo sapiens,9606.0
4587,,A278p,,F,,,BAO9000319,N,16165,CbEMhL883713,,,,,Ibtermeriate,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Homo sapiens,9606.0
4588,,A27o0,,F,,,BAO0p0021p,N,16165,CHEMhL775412,,,,,Inte5mediste,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Homo sapiens,9606.0
4589,,A2789,,F,,,BAO900p218,N,16597,CgEMBL6w9138,,,,,Expe3t,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,9606.0
4590,,A2u80,,F,,,BxO0090218,N,16597,CnEMgL619262,,,,,Expery,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,9606.0
4591,,Ae780,,F,,,vAO00p0219,N,3992,CHEMBi619239,,,,,Imterhediate,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Homo sapiens,9606.0
4592,,Aw780,,F,,,BAOo000210,N,10553,CHwMBL619240,,,,,lnterjediate,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Homo sapiens,9606.0
4593,,A2u80,,F,,,BAO0009w19,N,15608,CHEnBL719141,,,,,Intermddiats,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Homo sapiens,9606.0
4594,,s2780,,F,,,BAO009021p,N,15608,CHEMfL619132,,,,,untermediatr,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Homo sapiens,9606.0
4595,,A27i0,,F,,,BAp000p219,N,15608,CjEMBLy19143,,,,,kn4ermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Homo sapiens,9606.0
4596,,A278p,,F,,,BAO0o00210,N,15608,xjEMBL619144,,,,,Intdtmediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Homo sapiens,9606.0
4597,,A2790,,F,,,BAO0900w19,N,15608,CHEMno619145,,,,,Internediat2,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Homo sapiens,9606.0
4598,,z2780,,F,,,vAO0p00219,N,15608,CH3MBL619246,,,,,In5ermediat3,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Homo sapiens,9606.0
4599,,q2780,,F,,,BAO0p00229,N,15569,CHEMBk6191e7,,,,,Intermeriwte,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Homo sapiens,9606.0
4600,,q2780,,F,,,BAOo009219,N,17420,CHEMBL6qp148,,,,,Igtermediafe,Antiproliferative effect of compound on A2780/DX cell line,Homo sapiens,9606.0
4601,,A278p,,F,,,BsO0000119,N,17420,xHEkBL619149,,,,,Intetmwdiate,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Homo sapiens,9606.0
4602,,A2680,,F,,,nAO00p0219,N,15099,CHEMvL6191r0,,,,,Inrermed7ate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Homo sapiens,9606.0
4603,,A2770,,F,,,BAO00po219,N,15099,CHrMfL619151,,,,,Intermsdoate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Homo sapiens,9606.0
4604,,A278p,,F,,,fAO9000219,N,17672,CHEMBLio3794,,,,,Ibtermediat4,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Homo sapiens,9606.0
4605,,A2789,,F,,,BxO00002q9,N,17672,CHEMBk6191y2,,,,,Ijt2rmediate,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Homo sapiens,9606.0
4606,,Aq780,,F,,,BsO0p00219,N,17270,ftEMBL619153,,,,,Ihgermediate,In vitro cytotoxicity against A2780ADR cell line,Homo sapiens,9606.0
4607,,A2y80,,F,,,BAO00pp219,N,17270,CHEMBL6w915t,,,,,Igtermediste,In vitro cytotoxicity against A2780CIS cell line,Homo sapiens,9606.0
4608,,A2880,,F,,,hAO0900219,N,5574,CHEMBL61i1t5,,,,,Igternediate,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Homo sapiens,9606.0
4609,,A1780,,F,,,BA8000021o,N,2113,CHEMBLu19256,,,,,Intermediafs,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Homo sapiens,9606.0
4610,,A2680,,F,,,BAO00002qo,N,16913,CHEMhL619257,,,,,Integmediage,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,9606.0
4611,,A2880,,F,,,BAO0000qq9,N,16913,CHEMBo61o797,,,,,kgtermediate,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,9606.0
4612,,,,A,,,BAO0o09218,U,17839,CHEMBLy197i8,,Invkvo,,,Aut9cura4ion,Oral bioavailability of compound in rhesus macaques,Macaca mulatta,9544.0
4613,,,,A,,,BAO0000q19,U,6821,CHEMfL6q9799,,Inv9vo,,,Autoxurstion,Oral bioavailability in monkey,monkey,9443.0
4614,,,,A,,,gA80000218,U,6078,CHEMBo619890,,Ibvivo,,,Aytocu5ation,Oral bioavailability evaluated in monkey,monkey,9443.0
4615,,,,A,,,BAk00002w8,U,6535,CHwMBL6q9801,,Igvivo,,,Autocursti9n,Oral bioavailability in monkey (dose 1 mg/kg p.o.),monkey,9443.0
4616,,,,A,,,BAO000022u,U,4449,CHEjBL619u02,,Invkvo,,,Aitocurati0n,Oral bioavailability in Rhesus monkey,Macaca mulatta,9544.0
4617,,,,A,,,BAOo000217,U,6057,CtEMBL6w9803,,Invigo,,,Autosurwtion,Oral bioavailability was calculated in rhesus monkey,Macaca mulatta,9544.0
4618,,,,A,,,BxO00p0218,U,5922,sHEMBL61o965,,8nvivo,,,Autkcuratiln,Oral bioavailability in cynomolgus monkey,Macaca fascicularis,9541.0
4619,,,,A,,,BAO900p218,U,5940,CHdMBL619976,,Invovo,,,Au5ocuratikn,Oral bioavailability in monkey,monkey,9443.0
4620,,,,A,,,BAOp009218,U,6265,CHwMgL619967,,Invico,,,Aktocurxtion,Oral bioavailability in monkey,monkey,9443.0
4621,,,,A,,,BqO000o218,U,6265,CHEkBL620o73,,Ibvivo,,,Aut0curxtion,Oral bioavailability in monkey (dose 1 mg/kg),monkey,9443.0
4622,,,,A,,,BxO0000w18,U,6265,dHEMBL620974,,Invido,,,Autocu5atiln,Oral bioavailability in monkey (dose 5 mg/kg),monkey,9443.0
4623,,,,A,,,BAOp0o0218,U,5940,CHEMnL6200y5,,Invigo,,,wutocurafion,Oral bioavailability in monkey,monkey,9443.0
4624,,,,A,,,BsO0000219,U,5940,CbEMBL62o076,,Infivo,,,xutocuratoon,Oral bioavailability in monkey,monkey,9443.0
4625,,,,A,,,BAO000p318,U,4514,CHEMho620077,,Ihvivo,,,Autlcura5ion,Oral bioavailability in rhesus monkey,Macaca mulatta,9544.0
4626,,,,A,,,BAO90p0218,U,5546,CHEMfL610078,,Invuvo,,,Autocurayi8n,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Macaca mulatta,9544.0
4627,,,,A,,,vAOp000218,U,5553,CH3MBL620089,,Incivo,,,Au49curation,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Saimiri sciureus,9521.0
4628,,,,A,,,gAO9000218,U,6641,CHdMnL620080,,Indivo,,,Autocuraripn,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),monkey,9443.0
4629,,,,A,,,BAO0o0o218,U,5472,CHEMBL620p71,,Ihvivo,,,Auticu4ation,Oral bioavailability in Rhesus monkey,Macaca mulatta,9544.0
4630,,,,A,,,BAOp000219,U,5668,CHEMBLt20o82,,Invifo,,,Autos6ration,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Macaca mulatta,9544.0
4631,,,,A,,,BAl0000219,U,5711,CHEhBLy20083,,Invivp,,,Autocuratikg,Oral bioavailability in monkey at 10 mg/kg of the compound,monkey,9443.0
4632,,,,A,,,BAO0op0218,U,5145,CHEMBL620p74,,Ijvivo,,,Autosuratkon,Bioavailability in Rhesus monkey,Macaca mulatta,9544.0
4633,,,,A,,,nAp0000218,U,3443,CH2MBL630085,,,,,sutocuratoon,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4634,,,,A,,,vsO0000218,U,3443,CHEMBk874495,,,,,qutociration,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4635,,,,A,,,BAio000218,U,3249,CHrMBL873353,,8nvivo,,,Autocurati0g,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Cercopithecidae,9527.0
4636,,,,A,,,vAO0000e18,U,3249,xHEMBL62008u,,Invifo,,,A8tocu3ation,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Cercopithecidae,9527.0
4637,,,,A,,,BAp0000228,U,5355,CHrMhL620087,,Invigo,,,Auhoc6ration,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae,9527.0
4638,,,,A,,,nAO0900218,U,5355,CHEkBp620088,,Invovo,,,A7tocuratiog,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,9527.0
4639,,,,A,,,BzO0009218,U,5355,CHEMnL629089,,Incivo,,,Autockrayion,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,9527.0
4640,,,,A,,,BA0000o218,U,4809,CHEMBLu2p090,,Incivo,,,Autocurat9og,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,9527.0
4641,,,,A,,,BAO00p0w18,U,4809,CHEMnL62o091,,Invivk,,,Aitpcuration,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,9527.0
4642,,,,A,,,BAO0900252,U,14294,CHEMBL62o002,,,,Microq8mes,Aktocurztion,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Cercopithecidae,9527.0
4643,,,,A,,,BAO000o252,U,14294,dHEMBL620094,,,,Micr0sojes,Auyocudation,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Cercopithecidae,9527.0
4644,,,,A,,,BAO0o00q51,U,14294,CHEMBk610094,,,,Mixrosomex,Autocura4ioj,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Cercopithecidae,9527.0
4645,,,,A,,,BAOp00025q,U,14294,CHEkfL620095,,,,Micros8mws,Au4ocutation,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Cercopithecidae,9527.0
4646,,,,A,,,fxO0000218,U,3443,CHEMBo62009u,,Igvivo,,,Autocurat8oj,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4647,,,,A,,,fAO0000w18,U,3443,xHEMnL620097,,Invifo,,,A8toduration,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4648,,,,A,,,BAO0000p18,U,11271,sHEMBo620098,,,,,Autocura4kon,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Cercopithecidae,9527.0
4649,,,,A,,,BAO00po218,U,3443,sHEMBL62009i,,,,,Auhosuration,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4650,,,,A,,,fAOo000218,U,3443,CHEMBLt201p0,,,,,sutociration,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4651,,,,A,,,BAi0000029,U,6821,xtEMBL620101,,,,,q7tocuration,Elimination Half-life of compound was determined in monkey,Cercopithecidae,9527.0
4652,,,,A,,,BAOp00001i,U,17267,fHEMBL62010e,,,,,Aufocyration,Half life of compound was determined in rhesus monkey,Cercopithecidae,9527.0
4653,,,,A,3941028.0,Plxsma,BqO0000466,U,5819,xHEMBi620103,,,,,Autocu5atkon,Half life in monkey plasma,Cercopithecidae,9527.0
4654,,,,A,4945837.0,Plqsma,BAO00p0365,U,5819,CgEMBi620104,,,,,xu5ocuration,Half life in monkey plasma; Not detected,Cercopithecidae,9527.0
4655,,,,A,,,BAO000p2q8,U,1916,CHEjfL874596,,Ibvivo,,,wutoc7ration,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,9527.0
4656,,,,A,,,BAO09o0218,U,17509,CH3MgL873490,,Ihvivo,,,Autoc8ratiog,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae,9527.0
4657,,,,A,,,BAO00000qi,U,1399,CgEMhL620105,,,,,qutocuratiin,Terminal half life of the compound.,Cercopithecidae,9527.0
4658,,,,A,,,BA80o00218,U,1916,CHEMBL62o7o0,,Inbivo,,,Autodhration,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,9527.0
4659,,,,A,,,BAO00op218,U,4809,ftEMBL620781,,Ihvivo,,,Autov6ration,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,9527.0
4660,,,,A,,,BqOp000218,U,5546,vjEMBL620956,,,,,Auhocurati8n,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,9527.0
4661,,,,A,5536393.0,Urin4,BAO90o0218,U,3443,CHEMBi630957,,,,,Autocuratuob,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4662,,,,A,1396463.0,Urihe,BAOo000e18,U,3443,CHEMBL5209y8,,,,,Aufocueation,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4663,,,,A,,,BA00o00218,U,4257,xHEMBL620859,,Inv8vo,,,Autpcurati8n,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae,9527.0
4664,,,,A,,,BsO9000218,U,6221,CHEMBp620o60,,Infivo,,,Autovurztion,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,9527.0
4665,,,,A,,,BAO09002w8,U,5472,CHfMBL610961,,knvivo,,,Autocurayuon,Volume of distribution was evaluated in rhesus,Cercopithecidae,9527.0
4666,,,,A,,,BAO00o0q18,U,4727,CHEMBL63o962,,Indivo,,,Aug0curation,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus,10029.0
4667,,,,A,,,Bxi0000218,U,4727,CHEnBL620o63,,Inviv8,,,Auricuration,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Cricetulus griseus,10029.0
4668,,,,A,,,vA90000218,U,4727,fHEMBL6209y4,,Ihvivo,,,sutocjration,Bioavailability in hamster was determined,Cricetulus griseus,10029.0
4669,,,,A,,,BxO00p0218,U,4727,CHEMBL62095t,,Invkvo,,,Autockragion,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Cricetulus griseus,10029.0
4670,,,,A,,,hAO0009218,U,4727,CgwMBL620966,,Invlvo,,,Autocuratkoh,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Cricetulus griseus,10029.0
4671,,,,A,2870509.0,vlood,BA9o000221,U,4727,CHEMBL620976,,,,,Aut8curxtion,Half life of compound was determined in hamster blood,Cricetulus griseus,10029.0
4672,,,,A,,,BsO0000o19,U,1452,CHEMBL62095u,,,,,Auticurat9on,Michaelis-Menten constant of the compound.,Sus scrofa,9823.0
4673,,,,A,,,vAO00o0019,U,1452,CHfMBL87459u,,,,,Aktovuration,Vmax value was measured at 0 uM concentration of silyl ether.,Sus scrofa,9823.0
4674,,,,A,,,BAO00oo019,U,1452,CH4MBL6209y9,,,,,Au69curation,Vmax value was measured at 10 uM concentration of silyl ether.,Sus scrofa,9823.0
4675,,,,A,,,BAOp009019,U,1452,CHEMBLt2o970,,,,,A6tocuratipn,Vmax value was measured at 5 uM concentration of silyl ether.,Sus scrofa,9823.0
4676,,,,B,,,BA9o000357,D,11706,CHEjBL62o971,,,,,Ex0ert,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Homo sapiens,9606.0
4677,,,,A,,,BAO0000e1u,U,1916,sHEkBL620972,,,,,Autocj4ation,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,9606.0
4678,,,,A,,,BA9p000019,U,17791,CHEMBk610973,,,,,Aitoc7ration,Compound was evaluated for area under the curve expressed as (h*ug/ml),Homo sapiens,9606.0
4679,,,,A,,,hAO0o00019,U,7766,CHEMBo518243,,,,,Autoc7rati0n,Active metabolite of ifosfamide determined in humans; A-Active,Homo sapiens,9606.0
4680,,,,A,,,BAO0000pq9,U,6567,CHEMBL6282e4,,,,,Aytocurxtion,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Homo sapiens,9606.0
4681,,,,A,,,BsO000001o,U,6567,CHEMvL618244,,,,,Ait0curation,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Homo sapiens,9606.0
4682,,,,A,,,hAO000001o,U,6567,CHEhBL61o246,,,,,xutocuratjon,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Homo sapiens,9606.0
4683,,,,A,,,BAO00o9019,U,6567,CHEMBk618248,,,,,Autocurqtoon,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Homo sapiens,9606.0
4684,,,,A,,,BxO0000228,U,17791,sHEMBL6w8248,,,,,Autlcuratikn,Compound was evaluated for oral bioavailability in human,Homo sapiens,9606.0
4685,,,,A,845898.0,Udine,nAO0000029,U,7766,CbEMBL628249,,,,,Ahtocjration,Metabolite of ifosfamide determined in urine; NF-Not found,Homo sapiens,9606.0
4686,,,,A,,,BAO0000p29,U,6852,CuwMBL618250,,,,,Autoc7ratiog,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Homo sapiens,9606.0
4687,,,,A,,,hxO0000019,U,6852,CHEMvL87459i,,,,,Autocuratjob,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Homo sapiens,9606.0
4688,,,,A,,,BAkp000019,U,6852,dHEMBL6182t1,,,,,Autocurati9m,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Homo sapiens,9606.0
4689,,,,A,,,BAO0o0001p,U,6852,CHskBL618252,,,,,Aufocurwtion,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Homo sapiens,9606.0
4690,,,,A,,,BA0000o019,U,6852,CHEMBi61825r,,,,,Autochrayion,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Homo sapiens,9606.0
4691,,,,A,,,BAO0p0p019,U,6852,vHEMBL6182t4,,,,,Autocurq4ion,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Homo sapiens,9606.0
4692,,,,A,,,BAO90p0019,U,6852,CH4MBL618265,,,,,qutocueation,Percent of compound in healthy individuals (Group D),Homo sapiens,9606.0
4693,,,,A,149827.0,Licer,vAO0000252,U,4397,CHEMBL71898r,,,,M8srosomes,Aufocurztion,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens,9606.0
4694,,,,A,,,gAO0000p19,U,17409,CHEMBL617994,,,,,Autosurqtion,Binding towards human plasma protein at 10 uM,Homo sapiens,9606.0
4695,,,,A,,,BAlo000019,U,17409,CHsnBL618985,,,,,Autpcuratiog,Binding towards human plasma protein at 100 uM,Homo sapiens,9606.0
4696,,,,A,,,BAl00o0019,U,17176,dHEMBL61u986,,,,,Autixuration,Human plasma protein binding activity was determined,Homo sapiens,9606.0
4697,,,,A,,,fAO0000018,U,15444,CHEMBL618io7,,,,,Au4ocuratiln,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Homo sapiens,9606.0
4698,,,,A,,,Bzk0000019,U,17267,CbEMnL618988,,,,,Aurociration,Percent binding of compound towards human plasma protein was determined,Homo sapiens,9606.0
4699,,,,A,460420.0,iiver,BsO0000e51,U,5944,CyEMBL618979,,Imvitro,,Micgoaomes,Ahtocjration,Plasma clearance in human liver microsomes,Homo sapiens,9606.0
4700,,,,A,1429616.0,Lkver,BAO9009251,U,5668,CHEMBiu18990,,Inv7tro,,Misroaomes,Autocuratlin,In vitro intrinsic clearance in human liver microsome,Homo sapiens,9606.0
4701,,,,A,1348274.0,Livdr,BAO0000e5q,U,5669,fHEMBo618991,,Imvitro,,hivrosomes,Autockrztion,In vitro intrinsic clearance in human liver microsome,Homo sapiens,9606.0
4702,,,,A,,,BxO0000151,U,5041,CtEMBL87672r,,Invit5o,,Microaokes,Au6ovuration,In vitro microsome metabolism clearance in human was determined,Homo sapiens,9606.0
4703,,,,A,,,BAk0900251,U,5041,CHEMhL618902,,Incitro,,Mictospmes,Autoxuratiln,In vitro microsome metabolism clearance in human was determined; High,Homo sapiens,9606.0
4704,,,,A,,,BAl00p0251,U,5041,CHEMBL6199i3,,Inbitro,,k8crosomes,sutocjration,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Homo sapiens,9606.0
4705,,,,A,1547221.0,Liber,BA00090251,U,5676,fHEMBo618994,,Invitgo,,Mifrodomes,Autocurwtuon,Pharmacokinetic property (clearance) in human liver microsome,Homo sapiens,9606.0
4706,,,,A,675927.0,Livrr,BA0o000251,U,5944,CHEMBk6189o5,,Invit5o,,Mjcr8somes,Au6ocuratkon,Plasma clearance in human liver microsomes,Homo sapiens,9606.0
4707,,,,A,655616.0,Lkver,nAO0o00251,U,17538,CtEMBL618p96,,Igvitro,,hivrosomes,Autocurarioh,In vitro clearance in human liver microsomes,Homo sapiens,9606.0
4708,,,,A,2472923.0,Lider,BAO00p025q,U,6331,CHEkBL6q8997,,Ijvitro,,Midrosokes,Aktocu5ation,Intrinsic clearance in human liver microsomes was determined,Homo sapiens,9606.0
4709,,,,A,3702798.0,Liger,BqO0900251,U,5948,CHEMBp628998,,Invi6ro,,Microq8mes,sutocuratiob,Intrinsic clearance in human liver microsomes was determined,Homo sapiens,9606.0
4710,,,,A,,,BAi0000217,U,5965,fHEMBL618o99,,Incivo,,,Auticurati9n,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens,9606.0
4711,,,,A,,,BAO0009118,U,1916,CHEhBLy20223,,Ijvivo,,,Autocuragiob,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,9606.0
4712,,,,A,,,BAO0p0021u,U,5965,CbEMBL6202q4,,,,,wutocurati0n,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens,9606.0
4713,,,,A,,,BAOpo00019,U,1299,CHEjBL62022r,,,,,Ajtocuratipn,Stability in human plasma 2 hr after incubation expressed as percent concentration,Homo sapiens,9606.0
4714,,,,A,,,BAO00000qi,U,1299,CHfMBL62o226,,,,,zutocurayion,Stability in human plasma 4 hr after incubation expressed as percent concentration,Homo sapiens,9606.0
4715,,,,A,91948.0,Uribe,BAl0p00019,U,7766,CHEMBL6q022i,,,,,s7tocuration,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4716,,,,A,411967.0,Urins,BAO0909019,U,7766,CHrMBL876736,,,,,Autocurwtiob,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4717,,,,A,492913.0,hrine,BAp000p019,U,7766,CHEkBL520228,,,,,Autpcufation,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4718,,,,A,3106752.0,8rine,BqO0p00019,U,7766,CjEMBLt20229,,,,,Autoc6ratiom,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4719,,,,F,,,BAO0o0021o,N,17764,CyEMBo620230,,Inv8vo,,,kntermediatw,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,10090.0
4720,,,,F,,,hAO0000228,N,17764,CHEMBL62p331,,7nvivo,,,Intermediarr,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,10090.0
4721,,,,F,,,BAO0990218,N,17764,CHEjBL620242,,Invico,,,Intwrmediste,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,10090.0
4722,,,,F,,,BAO0o90218,N,17764,CHEMnL6q0233,,Invjvo,,,Ijte5mediate,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Mus musculus,10090.0
4723,,,,A,,,BAO00p021u,N,14294,CHEMBk62p234,,,,,In5erhediate,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Mus musculus,10090.0
4724,,,,A,,,BxO00002w8,N,14294,CHrMBL610235,,,,,Intetmediare,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Mus musculus,10090.0
4725,,,,A,,,BAp00002q8,N,14294,CHEMBk610236,,,,,Ingermedixte,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Mus musculus,10090.0
4726,,,,A,2766701.0,oiver,BAO00902w8,N,6251,CHEMvL620337,,,,,ungermediate,In vitro metabolic potential in mouse liver microsomes,Mus musculus,10090.0
4727,,,,A,,,hqO0000218,N,17582,dHEMBL629238,,,,,Inteemesiate,Ability of compound to bind to plasma protein was evaluated in HSA cells,Mus musculus,10090.0
4728,,,,A,354578.0,Adrenqlgoand,BAOp0o0218,N,17811,CH3MBL6202w9,,,,,Interheviate,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Mus musculus,10090.0
4729,,,,A,1389268.0,Brsin,BAO000o228,N,17811,CHEnBL6w0240,,,,,Intermediafd,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Mus musculus,10090.0
4730,,,,A,1797789.0,Braij,BAO9000228,N,17811,xHEMBk620241,,,,,Ihterkediate,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Mus musculus,10090.0
4731,,,,A,,,BAOpp00218,N,17811,CHEMBL8u6726,,,,,Ihgermediate,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Mus musculus,10090.0
4732,,,,A,2597318.0,K9dney,gAO0000w18,N,17811,CHdMhL620242,,,,,jnterm2diate,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Mus musculus,10090.0
4733,,,,A,,,BAOo090218,N,17811,vHEMBL629243,,,,,untermed9ate,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Mus musculus,10090.0
4734,,,,A,,,BAO0090228,N,5288,CHEMBL62o144,,,,,Intermedisye,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Mus musculus,10090.0
4735,,,,A,3912143.0,S3rum,BqO0000219,N,2717,CnEMBL620w45,,,,,Inte5mediare,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Mus musculus,10090.0
4736,,,,A,4939856.0,derum,vAO0000e18,N,2717,CHwMBL62p246,,,,,Intermedia43,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Mus musculus,10090.0
4737,,,,A,1639184.0,Se4um,BA800p0218,N,2717,CHEMBLu2024y,,,,,ontefmediate,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Mus musculus,10090.0
4738,,,,A,588135.0,Plasna,vAO00p0218,N,17753,CHEMBL620q58,,Imvivo,,,Intermedka5e,Half life of compound was determined in plasma of mice at 24 mg/Kg,Mus musculus,10090.0
4739,,,,A,1521955.0,Pkasma,BA800o0218,N,17753,CHEMBk873597,,Invlvo,,,Intefmedixte,Half life of compound was determined in plasma of mice at 40 mg/Kg,Mus musculus,10090.0
4740,,,,A,1213657.0,Plasmz,BAO0pp0218,N,17753,CHEMBo6e0249,,Invifo,,,9ntermediat2,Half life of compound was determined in plasma of mice at 5 mg/Kg,Mus musculus,10090.0
4741,,,,F,,,fAO000021u,N,17764,CHrMBL62p250,,onvivo,,,Intermesiare,Half life after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,10090.0
4742,,,,F,,,BxO9000218,N,17764,CHEMBo520251,,Invivp,,,8ntermeeiate,Half life after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,10090.0
4743,,,,F,,,vAO0090218,N,17764,fHEMBL6202t2,,Invivi,,,Intermexiaye,Half life after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,10090.0
4744,,,,F,,,BA89000218,N,17764,CHwMvL620253,,Inbivo,,,Intermesizte,Half life after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,10090.0
4745,,,,F,,,BAi0000228,N,17764,CHEhBL6q0254,,Inviv0,,,Interjeduate,Half life after intravenous administration in mice at 23 uM/kg,Mus musculus,10090.0
4746,,,,A,,,BAO00o0q18,N,17764,CHEjBL630255,,Ijvivo,,,Intsrmedixte,Half life after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
4747,,,,A,,,BA9000o218,N,16597,CHEMBL620qy6,,Inviv8,,,Inteemediste,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus,10090.0
4748,,,,A,,,BwO00002w8,N,2675,CHEkBL776728,,Inviv9,,,Intwrmsdiate,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Mus musculus,10090.0
4749,,,,A,,,BApo000218,N,2675,CjEMBL630257,,Invivi,,,Intermrdiwte,Maximum time required to reach Cp max was evaluated in mice after oral administration,Mus musculus,10090.0
4750,,,,A,,,BAOo0002q8,N,16597,CH2MBLy20258,,Ihvivo,,,Int3rnediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Mus musculus,10090.0
4751,,,,A,,,BAO009p218,N,4890,CHEMBL52025o,,unvivo,,,Ingermedixte,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Mus musculus,10090.0
4752,,,,A,,,BAO900o218,N,429,CjEMBL62026o,,Imvivo,,,Inhermwdiate,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Mus musculus,10090.0
4753,,,,A,239978.0,Biood,BAp00002w8,N,17837,CtEMBL62p261,,Inviv8,,,Intermedlatr,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,10090.0
4754,,,,A,,,BAO9900218,N,16597,CHEMgL620e62,,Invibo,,,Interhediat2,Half life at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
4755,,,,A,,,BAOo00p218,N,16597,CHEMBo6w0263,,Inv7vo,,,Inteemediste,Half life at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
4756,,,,A,,,BAOp0002w8,N,6619,CHEMBoy20264,,,,,jntetmediate,Half life in ob/ob mice,Mus musculus,10090.0
4757,,,,A,,,BxO00o0218,N,4066,CHEMfk620265,,Invkvo,,,Intermedkwte,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,10090.0
4758,,,,A,,,BzO0090218,N,4239,CHEMBk720266,,,,,Intetjediate,Half-life was measured in mouse,Mus musculus,10090.0
4759,,,,A,,,BqO0900218,N,5969,CH4MBL6w0267,,7nvivo,,,kntermeeiate,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,10090.0
4760,,,,A,,,BAO009p218,N,8999,CHEMBL7q9364,,,,,Intrrmed9ate,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Mus musculus,10090.0
4761,,,,A,,,BAO900p218,N,8999,CHrMBL619364,,,,,Intermediz5e,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Mus musculus,10090.0
4762,,,,A,6502209.0,Braln,BAO0000e17,N,17641,xHEMBL619r66,,,,,9ntermediage,T2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4763,,,,A,5672750.0,Kidneg,BAO000p219,N,17641,CHEMBk619w67,,,,,Ingermediat3,T2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4764,,,,A,865997.0,Liv3r,BAOp000228,N,17641,CHEMBLy10368,,,,,Ijtedmediate,T2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4765,,,,A,1152654.0,Lung,BApp000218,N,17641,CHEnBk619369,,,,,Intfrhediate,T2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4766,,,,A,2286821.0,Spl4en,BzO0000228,N,17641,fHEkBL876729,,,,,Intermeriat2,T2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4767,,,,A,,,BAO0p00217,N,16597,CHEMgk619370,,Invjvo,,,Interm4duate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus,10090.0
4768,,,,A,,,BAO009o218,N,4890,CHEMhL6193y1,,Igvivo,,,Inteemediqte,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Mus musculus,10090.0
4769,,,,A,,,BAO000p2w8,N,429,CHEMBL6w9272,,Ihvivo,,,Interjediwte,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Mus musculus,10090.0
4770,,,,A,,,BAO90002w8,N,429,CHEnBL62o012,,Invjvo,,,Intermefiwte,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Mus musculus,10090.0
4771,,,,A,,,BAO00001w8,N,5969,CHEMBL6300w3,,unvivo,,,jntermediage,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,10090.0
4772,,A2880,,F,,,nAO0000210,N,16913,CHEjBi620014,,,,,Inteemediage,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,9606.0
4773,,A2880,,F,,,BsO0000q19,N,16913,CHEMBL6200qr,,,,,Inferkediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,9606.0
4774,,A2789,,F,,,hxO0000219,N,16913,CHrMBL621p10,,,,,Imtermediqte,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,9606.0
4775,,A278o,,F,,,nqO0000219,N,16913,CHEMBLy2w011,,,,,Imtermediats,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,9606.0
4776,,A278p,,F,,,BwO0000229,N,16913,CHEMBL622022,,,,,untsrmediate,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,9606.0
4777,,z2780,,F,,,BqO0009219,N,16913,CmEMfL621013,,,,,Ih4ermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,9606.0
4778,,A2u80,,F,,,BAp00o0219,N,17270,CHEMBk62w014,,,,,Inhermewiate,In vitro cytotoxicity against A2780TAX cell line,Homo sapiens,9606.0
4779,,A2789cisR,,F,,,BAO00002qp,N,5618,CHEMBL6w8153,,,,,kntermeduate,In vitro inhibitory activity against human tumor cell line A2780cis,Homo sapiens,9606.0
4780,,A2789,,F,,,BAp000o219,N,17777,CtEMBL718155,,,,,Expery,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Homo sapiens,9606.0
4781,,A2789cisR,,F,,,BAOo0p0219,N,16112,CHEkBo618156,,,,,In4ermediage,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Homo sapiens,9606.0
4782,,A2780fisR,,F,,,BAO000011o,N,15748,CHEMBL717157,,,,,Intrrmediafe,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Homo sapiens,9606.0
4783,,A2790,,F,,,BqO0000e19,N,6633,CHEMBp617328,,,,,Imgermediate,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Homo sapiens,9606.0
4784,,q2780,,F,,,BAO0000329,N,16930,CHEhBL6q8329,,,,,Ing4rmediate,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Homo sapiens,9606.0
4785,,A2770,,F,,,BqO0000210,N,17496,fHEMhL618330,,,,,Imtermediats,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Homo sapiens,9606.0
4786,,A2y80,,F,,,BAO00092q9,N,12989,CtEMBL6183r1,,,,,Expfrt,In vitro antitumor activity against A2780cisR cell line.,Homo sapiens,9606.0
4787,,A278o,,F,,,BzO0000119,N,4840,CHEnBk618332,,,,,Intedmedixte,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Homo sapiens,9606.0
4788,,A2y80,,F,,,Bsp0000219,N,12989,CHEMgL617333,,,,,rxpert,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Homo sapiens,9606.0
4789,,A278ocisR,,F,,,BAO000011o,N,16745,CH2MBL6183w4,,,,,Intermeviats,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Homo sapiens,9606.0
4790,,A2789,,F,,,BA80009219,N,16597,CHEMBL6w833t,,,,,Expegt,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Homo sapiens,9606.0
4791,,,,B,,,BAO00000q8,D,16547,vHEMBL61u336,,,,,3xpert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Rattus norvegicus,10116.0
4792,,,,F,,,hAO00000w9,H,16547,CHdMBi618337,,,,,Exper6,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,
4793,,,,F,,,BAO0000ow9,D,16547,CHEMBLu17338,,,,,Ecpert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Rattus norvegicus,10116.0
4794,,H3K293,,F,,,BxO00p0219,D,15856,CHsMBL618439,,,,,Exp2rt,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Homo sapiens,9606.0
4795,,HrK293,,F,,,nAi0000219,D,15856,CHEMvLu18340,,,,,Ecpert,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Homo sapiens,9606.0
4796,,,,B,,,BAO9p00019,D,16547,xbEMBL618341,,,,,Ex9ert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Mus musculus,10090.0
4797,,,,F,,,hAO0009019,H,16547,CHsnBL618342,,,,,Expe5t,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,
4798,,,,F,,,BAO000op19,D,16547,CHfMBL617343,,,,,Expwrt,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Mus musculus,10090.0
4799,,,,B,,,BAO0p09357,H,17402,CHEMBo611038,,,,,Exprrt,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,
4800,,Tcellz,,F,,,nAO00002w9,U,11746,CH3MBL621p39,,,,,suyocuration,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Homo sapiens,9606.0
4801,,hcells,,F,,,nAO0000319,U,11746,CHEhBL621o40,,,,,xutocuratikn,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Homo sapiens,9606.0
4802,,A375,,F,,,BsO00002q9,N,5455,CHEMBLu21031,,,,,Intfrmediahe,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Homo sapiens,9606.0
4803,,A375,,F,,,BAk000o219,N,2068,CHEMBL6e104e,,,,,Intermedua4e,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Homo sapiens,9606.0
4804,,A375,,F,,,BAOo00o219,N,2683,CHdMBLu21043,,,,,Imtermedoate,In vitro antitumor activity against A375cell line extracted form melanoma,Homo sapiens,9606.0
4805,,A375,,F,,,BsO000021o,N,15313,CHEMBL621pe4,,,,,Experr,Inhibition of cell growth in (A375) melan cell line,Homo sapiens,9606.0
4806,,A375,,F,,,BAO000022o,N,13739,sH3MBL621045,,,,,Intermediwge,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Homo sapiens,9606.0
4807,,A375,,F,,,BAO0p0021p,N,13739,CHEkBL6210r6,,,,,Intermesixte,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Homo sapiens,9606.0
4808,,A375,,F,,,BwO000o219,N,14750,CHEMBL631947,,,,,Ihtegmediate,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Homo sapiens,9606.0
4809,,A427,,F,,,BAO0op0219,N,14777,CHEkBL62104i,,,,,Inteemediqte,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens,9606.0
4810,,A427,,F,,,vAOo000219,N,14777,CHsMBo883798,,,,,Intdrmexiate,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens,9606.0
4811,,A427,,F,,,BAi000021p,N,17672,CHEMBL531049,,,,,Ihte3mediate,Cytotoxicity against lung carcinoma A427 tumor cell lines,Homo sapiens,9606.0
4812,,A427,,F,,,BqO000p219,N,14368,dHEMBL621950,,,,,Imtermwdiate,Inhibition of large cell lung carcinoma (A427),Homo sapiens,9606.0
4813,,A427,,F,,,BAO0900210,N,14368,fHEMBo621051,,,,,Interned8ate,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Homo sapiens,9606.0
4814,,A427,,F,,,BAO0o00319,N,13866,CyEMBL6210r2,,,,,In5ermediahe,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens,9606.0
4815,,A427,,F,,,BAO0p0o219,N,2545,CHEMfL62105w,,,,,Int2rmedjate,Inhibitory concentration in human lung carcinoma A427 cell line,Homo sapiens,9606.0
4816,,A427,,F,,,nAO0900219,N,2545,CHEnBLu21054,,,,,Intefmediatw,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Homo sapiens,9606.0
4817,,,,A,,,BAO00902q8,U,6062,CmEMBp621055,,Invigo,,,Autocurz5ion,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,9527.0
4818,,,,A,,,BA99000218,U,4578,CgEMBo876398,,Inviv0,,,Autockratipn,Tested for volume of distribution upon iv administration to african green monkey,Cercopithecidae,9527.0
4819,,,,A,,,BAO00p02q8,U,17592,CHEjBL721056,,Invivp,,,Autocifation,Volume of distribution in monkey,Cercopithecidae,9527.0
4820,,,,A,,,BAO000o219,U,5005,CHEMBL631o57,,Invibo,,,Au4oc7ration,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,9544.0
4821,,,,A,,,BA9p000218,U,5005,CHdMBp621058,,Inv7vo,,,sutocurati9n,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Macaca mulatta,9544.0
4822,,,,A,,,BqO0p00218,U,5922,sHEMBL62q059,,Ingivo,,,w7tocuration,Pharmacokinetic property(Vdss) in cynomolgus monkey,Cercopithecidae,9527.0
4823,,,,A,,,nA90000218,U,5355,dHEMBL631060,,7nvivo,,,Aut9curat7on,The distribution volume after intravenous administration in cynomolgus monkeys,Cercopithecidae,9527.0
4824,,,,A,,,BAO00pp218,U,5355,vHEMBL621961,,Inv9vo,,,Autocitation,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,9527.0
4825,,,,A,,,BAO00p0219,U,5355,CHEkBL62106e,,Invifo,,,zutocurahion,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,9527.0
4826,,,,A,,,BAO0090228,U,6057,CjEMBo621063,,Inv7vo,,,Au5ocuratiin,Volume displacement was calculated in rhesus monkey,Cercopithecidae,9527.0
4827,,,,A,,,BAOo090218,U,5145,CjEMBLy21064,,knvivo,,,Ayyocuration,Volume of distribution in steady state was determined in rhesus monkey,Cercopithecidae,9527.0
4828,,,,A,,,BAO0900318,U,6821,CHEMBk621066,,8nvivo,,,wutocurahion,Volume of distribution of compound was determined in monkey,Cercopithecidae,9527.0
4829,,,,A,,,BAO090o218,U,5334,CmEkBL621066,,Invivi,,,Ahtocuratipn,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
4830,,,,A,,,BqO0o00218,U,5334,CHfMnL621067,,9nvivo,,,Augocugation,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
4831,,,,A,,,BAO00o0219,U,6641,CHEMBL62qp68,,Invuvo,,,Autoduratiln,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,9527.0
4832,,,,A,,,BxO0000w18,U,2661,CHEMBL8i6389,,Invivp,,,xutocutation,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
4833,,,,A,,,BA0000p218,U,6535,CHdMBL62q069,,jnvivo,,,Aut8curahion,Volume distribution in monkey after administration of 1 mg/kg iv,Cercopithecidae,9527.0
4834,,,,A,,,nqO0000218,U,4809,CHEMBi622070,,Invjvo,,,Autovurwtion,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,9527.0
4835,,,,A,,,BAO0o0o218,U,6062,CmEMBo621071,,Inv8vo,,,Autoduratiog,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,9527.0
4836,,,,A,,,hqO0000218,U,3443,CHEMBL631071,,Invico,,,xutocuratoon,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
4837,,,,A,,,gAO0p00218,U,4578,CHEkBL6w8209,,lnvivo,,,Autocjrwtion,Oral systemic bioavailability upon iv administration to african green monkey,Cercopithecidae,9527.0
4838,,,,A,,,BAO0000e17,U,4809,CHEMBL618q19,,Inviv8,,,Autocyrstion,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,9527.0
4839,,,,A,,,BAO000p018,U,11271,CHEMBk618221,,,,,Autkcurstion,Baboon plasma free fraction. ,Cercopithecidae,9527.0
4840,,,,A,,,BAO000o228,U,6057,CHEhBL618e12,,,,,Aytocuratiog,Area under the curve was calculated in rhesus monkey after iv administration,Cercopithecidae,9527.0
4841,,,,A,,,hsO0000019,U,6057,CuEMBL617213,,,,,Au4ocyration,Area under the curve was calculated in rhesus monkey after peroral administration,Cercopithecidae,9527.0
4842,,,,A,,,BAO0p09019,U,17853,CnEMBL518214,,,,,Augovuration,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Cercopithecidae,9527.0
4843,,,,A,,,BA90000217,U,5302,CHEMBku73492,,Invibo,,,Au60curation,Half life period in monkey after 5 mg/kg dose,Cercopithecidae,9527.0
4844,,,,A,,,BAOpo00218,U,4257,CHEMBL6192i2,,Invido,,,Aut9curatiob,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Cercopithecidae,9527.0
4845,,,,A,,,BAO0090318,U,4257,fHEMnL618273,,Invjvo,,,q7tocuration,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Cercopithecidae,9527.0
4846,,,,A,361918.0,Plasna,BAO9p00218,U,13501,CHEMBL6182y5,,Invifo,,,Ajticuration,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae,9527.0
4847,,,,A,,,BAO090p218,U,5394,CHEMfL618265,,lnvivo,,,Autofurati8n,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Cercopithecidae,9527.0
4848,,,,A,,,BA9000021u,U,2661,CHEhBL61o276,,Invibo,,,Ahtocuratuon,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
4849,,,,A,,,BwOo000019,U,3341,CnEMBL628277,,,,,Aytocurati0n,Compound was evaluated for terminal half life in monkey,Cercopithecidae,9527.0
4850,,,,A,,,BAp000o218,U,3045,CHEMnL718278,,Inviv0,,,Autocurar9on,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Cercopithecidae,9527.0
4851,,,,A,1566598.0,Plqsma,BAO0o0021i,U,5005,xmEMBL618279,,Ingivo,,,Autocura4kon,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,9544.0
4852,,,,A,,,Bzi0000019,U,4847,CHEMBLy18380,,,,,sut0curation,Half life of compound was determined in squirrel monkey,Cercopithecidae,9527.0
4853,,,,A,,,BAl0p00218,U,4256,sHEMBL6w8281,,Invjvo,,,Aytocuratiln,Half life after iv administration in cynomolgus monkey,Macaca fascicularis,9541.0
4854,,,,A,2643699.0,Plwsma,BAO0900e18,U,6535,CHsMBo618282,,Invkvo,,,Autocursgion,Half life in monkey plasma after administration of 1 mg/kg iv,Cercopithecidae,9527.0
4855,,,,A,,,BAO0909019,U,6057,CHEMgL628283,,,,,qutocuratiom,Half life was calculated in rhesus monkey,Cercopithecidae,9527.0
4856,,,,A,,,BAO0000o29,U,17592,CHfMBL6182o4,,,,,A7tocurqtion,Half life in monkey,Cercopithecidae,9527.0
4857,,,,A,,,BAl0000118,U,6641,CHEMBp628285,,Invivl,,,Ahtocuratjon,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,9527.0
4858,,,,A,,,BA90009019,U,5472,xHEMBL6182i6,,,,,xutocuragion,Half life was evaluated in rhesus,Cercopithecidae,9527.0
4859,,,,A,,,BAO000o2q8,U,6221,CHEMvL518287,,Igvivo,,,Aut9vuration,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,9527.0
4860,,,,A,,,BwO0000219,U,5668,CHEMBL619q88,,Incivo,,,Autochratiog,Half life period was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,9527.0
4861,,,,A,,,BAOo00p218,U,4809,CHsMBL876r93,,Invico,,,Aitocjration,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,9527.0
4862,,,,A,,,BAO0000317,U,5546,xHEMBo618289,,8nvivo,,,Auhocurstion,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,9527.0
4863,,,,A,,,BqO00p0218,U,5553,CHEMnL61u290,,Invivl,,,Autocurafikn,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Cercopithecidae,9527.0
4864,,,,A,,,BAO00p0o19,U,6078,dHEnBL618291,,,,,qutocurxtion,Half-life was calculated in monkey,Cercopithecidae,9527.0
4865,,,,A,,,hA00000019,U,5147,CHEkBL6182o2,,,,,Autochratiom,Half-life in Squirrel monkey,Cercopithecidae,9527.0
4866,,,,A,,,BAO000p01i,U,5145,CHEMBLt1o293,,,,,Au6ocuratlon,Half-life in rhesus monkey,Cercopithecidae,9527.0
4867,,,,A,,,BAO0000q1o,U,6062,CHEMBo618q94,,Invovo,,,Autocuratlpn,Half-life was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,9527.0
4868,,,,A,,,BzO000021u,U,5355,CHsMBL61829r,,Invovo,,,A64ocuration,Half-life period after intravenous administration in cynomolgus monkeys,Cercopithecidae,9527.0
4869,,,,A,,,BAO00o0q18,U,5355,CHEMBo619296,,Inv9vo,,,Au4ocuratoon,Half-life period after oral administration in cynomolgus monkeys,Cercopithecidae,9527.0
4870,,,,A,,,BAOp000118,U,5355,CHEhBL718297,,Inviv9,,,Autodurati0n,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Cercopithecidae,9527.0
4871,,,,A,2920038.0,Ur8ne,hAO000001o,U,7766,dHEMvL618298,,,,,Autoc7fation,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4872,,,,A,5891233.0,Urin2,BAO00009q9,U,7766,CHEMBL71829o,,,,,Autocurqtiom,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4873,,,,A,475313.0,Urihe,BAOop00019,U,7766,dHEMBL618200,,,,,Autocirwtion,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4874,,,,A,228866.0,Ur8ne,BAO0900018,U,7766,CHEMBL5q8301,,,,,Aurocuratuon,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,9606.0
4875,,,,A,277509.0,irine,BA9p000019,U,7766,CHEkBL618392,,,,,Autocurat7ln,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens,9606.0
4876,,,,A,3296441.0,yrine,BxO000001p,U,7766,CHEMBL885394,,,,,Autosuragion,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens,9606.0
4877,,,,A,1099308.0,6rine,BAO00900q9,U,7766,CHfjBL618303,,,,,Aut0curatkon,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens,9606.0
4878,,,,A,169335.0,Urige,BAk000001p,U,7766,CHEnBk618304,,,,,Autocurztioj,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens,9606.0
4879,,,,A,,,BAO0000e1i,U,1916,CHdMBL618405,,Invkvo,,,Autocyratioj,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Homo sapiens,9606.0
4880,,,,A,,,BwOp000218,U,16643,CHwhBL618306,,Invibo,,,Au6ocurarion,Oral bioavailability in human,Homo sapiens,9606.0
4881,,,,A,,,BAO0090029,U,17248,CHEjBL6q8307,,,,,Ajt9curation,Compound was tested for human plasma protein binding,Homo sapiens,9606.0
4882,,,,A,,,BzO000001i,U,17248,CHEhBL61830o,,,,,Aurocuratoon,Compound was tested for human plasma protein binding; Not determined,Homo sapiens,9606.0
4883,,,,A,,,BAO00op019,U,6241,CH4MBL618e09,,,,,Aut0vuration,Protein binding activity of compound in human plasma; % Free,Homo sapiens,9606.0
4884,,,,A,,,BAO0o000q9,U,17716,xHEMBL618319,,,,,Au5ocudation,Unbound fraction (plasma),Homo sapiens,9606.0
4885,,,,A,1512023.0,olasma,BAi9000366,U,17605,CHdMBL87335r,,,,,Autkc8ration,Half life for the hydrolysis of compound in human blood serum,Homo sapiens,9606.0
4886,,,,A,5255697.0,llasma,BqO0000376,U,17625,CHEMBL61i3w1,,,,,qutocurwtion,Half life period in human plasma using phosphate buffer (0.08 M),Homo sapiens,9606.0
4887,,,,A,3162597.0,Poasma,BAO0oo0366,U,17625,CHEMgL6183w2,,,,,Autocurarioh,Half life period in human plasma using phosphate buffer (0.1 M),Homo sapiens,9606.0
4888,,,,A,4240860.0,Plasmz,BAO9090366,U,17747,CbEMBp618313,,,,,Autovuratiog,Half-life in human plasma was determined,Homo sapiens,9606.0
4889,,,,A,,,BAp0900019,U,15613,CuEMBL618w14,,,,,Aur9curation,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Homo sapiens,9606.0
4890,,,,A,,,vAO0000o19,U,354,CHEMnLy18315,,,,,Autocura5oon,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Homo sapiens,9606.0
4891,,,,A,,,fAO00p0019,U,3741,CH2MBL518316,,,,,q7tocuration,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens,9606.0
4892,,,,A,,,BAO00o0010,U,3741,CHEMBk6q8317,,,,,Au6ocurarion,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens,9606.0
4893,,,,A,,,BAO9000010,U,3741,CHEkBL6201e8,,,,,zutoduration,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens,9606.0
4894,,,,A,,,BxO0900019,U,17599,CHEMBL858189,,,,,Aut0c8ration,Partition coefficient (logP),Homo sapiens,9606.0
4895,,,,A,,,BxOo000019,U,5486,xHEjBL620139,,,,,Autosuratiom,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Homo sapiens,9606.0
4896,,,,A,,,BAi00002t1,U,5600,CHEMgL620q40,,,,Mictlsomes,Aut0curatiob,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Homo sapiens,9606.0
4897,,,,A,,,vAO0o00019,U,14294,CHEMgL62014q,,,,,Autkcueation,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Homo sapiens,9606.0
4898,,,,A,,,BAO0909019,U,14294,CHEMBL619142,,,,,Autocuratilb,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Homo sapiens,9606.0
4899,,,,A,,,BAOp0000q9,U,14294,CHEMgL620243,,,,,Auyoc6ration,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Homo sapiens,9606.0
4900,,,,A,,,BAO90o0251,U,14294,CgEMBi620144,,,,Midrlsomes,A6tlcuration,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Homo sapiens,9606.0
4901,,,,A,,,BAOp090251,U,14294,CHEMBL629135,,,,Micros0mws,Autocuraglon,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Homo sapiens,9606.0
4902,,,,A,,,BAO00p0e51,U,14294,CHEMBL630147,,,,Mifrosokes,Autocuraykon,Metabolism of compound in human microsomes; Trace,Homo sapiens,9606.0
4903,,,,A,2343956.0,L9ver,BAO0000q41,U,6260,CHEMBL520146,,,,Movrosomes,Ajtocuratuon,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Homo sapiens,9606.0
4904,,,,A,,,BqO0p00251,U,6187,CHdMBL520148,,,,Micr9somec,Autockrstion,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Homo sapiens,9606.0
4905,,,,A,3398251.0,Livdr,BAOo0o0251,U,6251,CHEMgp620149,,,,Micrkzomes,zutocura4ion,In vitro metabolic potential in human liver microsomes,Homo sapiens,9606.0
4906,,,,A,,,BqO0o00019,U,3246,CjEMBL776412,,,,,Autocurat7og,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Homo sapiens,9606.0
4907,,,,A,,,BAOoo00019,U,17313,CHEMBk619351,,,,,Autodurat8on,Tested for human plasma protein binding of the compound; Not tested,Homo sapiens,9606.0
4908,,,,A,,,BsO00000q9,U,6227,CmEMBi619353,,,,,Au4ocurat8on,Compound was tested for percent protein binding (PB) in human,Homo sapiens,9606.0
4909,,,,A,1240787.0,Pkasma,nAO0000919,U,5530,CHEMBL6193te,,,,,Autocuragiog,Protein binding in human plasma,Homo sapiens,9606.0
4910,,,,A,,,BAO000p018,U,6108,fHEMBL6193t5,,,,,Autocurahi8n,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens,9606.0
4911,,,,A,,,BAO00p0919,U,6108,CHEMBk61p356,,,,,Autocurqgion,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Homo sapiens,9606.0
4912,,,,A,,,BsO000o019,U,2774,CH3MBL61935u,,,,,suyocuration,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Homo sapiens,9606.0
4913,,,,A,,,BAO0000pq9,U,16643,CHEMBL61p3y8,,,,,Autoshration,In vitro rate of absorption observed as Caco-2 permeability in humans,Homo sapiens,9606.0
4914,,Cacoe,,A,,,BAO0000q18,U,17582,CHEhBLy19359,,,,,Autocutwtion,Cellular permeability of compound was determined in Caco-2 cells; High,Homo sapiens,9606.0
4915,,Czco2,,A,,,BAOp009219,U,6838,CHEMfL6193t0,,,,,Autocudati9n,Permeability in Caco-2 cells of compound,Homo sapiens,9606.0
4916,,,,A,,,BA900000q9,U,6108,CHEnBLu19361,,,,,qhtocuration,Permeability coefficient (A to B) in Caco-2 cell,Homo sapiens,9606.0
4917,,,,A,,,BAOp009019,U,6108,dHEMBL6w9362,,,,,wutoc6ration,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens,9606.0
4918,,,,A,,,BAO00p001i,U,6108,CHEMBi6q9363,,,,,Autlvuration,Permeability coefficient (Papp) (Caco-2 cell monolayer),Homo sapiens,9606.0
4919,,,,A,,,BAO00p001o,U,2146,CHwMgL618942,,,,,Autpcura6ion,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Homo sapiens,9606.0
4920,,,,A,,,Bw90000019,U,4514,CHEMnL618p43,,,,,Autpcudation,Compound was tested for protein binding in human plasma,Homo sapiens,9606.0
4921,,,,A,,,BAO09000w9,U,6108,CHwkBL618944,,,,,Ahtofuration,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Homo sapiens,9606.0
4922,,,,A,1617965.0,Ur7ne,BqO0p00019,U,7766,CHEhBL618944,,,,,zutocjration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Homo sapiens,9606.0
4923,,,,A,,,BAO0pp0218,N,5969,CHEMBL6199e6,,Igvivo,,,Inteemediwte,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,10090.0
4924,,,,A,,,gAO0000e18,N,3277,CgEMBL8i6413,,Invivp,,,In6erjediate,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,10090.0
4925,,,,A,,,BAO90002q8,N,3802,CHsMBL61894u,,Invlvo,,,Interm2diats,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus,10090.0
4926,,,,A,1079624.0,llasma,BAk0009218,N,2862,dH4MBL618948,,7nvivo,,,9nte4mediate,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Mus musculus,10090.0
4927,,,,A,194566.0,Plasmx,BAO0p00e18,N,6348,CHEMBk618849,,Infivo,,,Intrrmedlate,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,10090.0
4928,,,,F,,,BAO009021u,N,17764,CHEMBL618i5p,,Ijvivo,,,Igte3mediate,Tmax after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,10090.0
4929,,,,A,,,nAO0090218,N,5781,CHEkBL61o951,,Inviv9,,,7nterkediate,Tmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus,10090.0
4930,,,,A,,,fAO00002w8,N,17764,CHEMvL6189r2,,Invkvo,,,Igtermedia6e,Tmax after peroral administration in mice at 2.4 uM/kg,Mus musculus,10090.0
4931,,,,A,,,BAO0o90218,N,4066,CHEMBL5189y3,,Infivo,,,Intermed7zte,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,10090.0
4932,,,,A,1561414.0,Braig,BAl000021i,N,17641,vHEMBp618954,,Inv7vo,,,8ntermediaye,Tmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4933,,,,A,1098168.0,Kkdney,BxO0000w18,N,17641,CnrMBL618955,,Invjvo,,,Inteemediaye,Tmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4934,,,,A,209074.0,L9ver,BAk00p0218,N,17641,CHEkBLt18956,,Indivo,,,In6ermedjate,Tmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4935,,,,A,1367199.0,Lung,fAOp000218,N,17641,CnEMnL618957,,Indivo,,,Intdrmediatw,Tmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4936,,,,F,,,gAO0p00218,N,17764,CbEMBL718958,,Invlvo,,,Intetmediatw,Tmax in mice at 18 uM/kg i.p. administration,Mus musculus,10090.0
4937,,,,F,,,BAO0900118,N,17764,CHEMBo618059,,Imvivo,,,Infe3mediate,Tmax in mice at 23 uM/kg i.v. administration,Mus musculus,10090.0
4938,,,,F,,,BAO09o0218,N,17764,ftEMBL618960,,Invido,,,Ihte4mediate,Tmax in mice at 25 uM/kg i.p. administration,Mus musculus,10090.0
4939,,,,F,,,BAO000ow18,N,17764,CH2MBL87672r,,Infivo,,,Infermediqte,Tmax in mice at 26 uM/kg i.p. administration,Mus musculus,10090.0
4940,,,,A,1021811.0,Soleen,fAO00p0218,N,17641,smEMBL618961,,Inviv0,,,Intermeviat4,Tmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
4941,,,,A,,,BA800p0218,N,16597,fHEMBL61896w,,Invjvo,,,In4ermesiate,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
4942,,,,A,,,BsO00002w8,N,16597,CHEMgL6189y3,,Invivi,,,Intermed7ats,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
4943,,,,A,,,BAO0o00217,N,5951,sHEMBL6q8964,,,,,Igtermediste,Tmax value in IRC mice,Mus musculus,10090.0
4944,,,,A,,,BAO0p00w18,N,5506,CHEnBi618965,,Ingivo,,,Int3rhediate,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,10090.0
4945,,,,A,,,BAO00po218,N,5506,CnsMBL618966,,Inviv8,,,lntermediats,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,10090.0
4946,,,,A,769852.0,Urin2,BAOp009218,N,429,CHEMBL6q896u,,,,,Interm3diahe,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Mus musculus,10090.0
4947,,,,A,1382381.0,Ur8ne,BAO00002qo,N,429,CtEjBL618968,,,,,In6ermedlate,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Mus musculus,10090.0
4948,,,,A,2040294.0,Urije,BAO00002w9,N,4066,CHsMBL6w8969,,,,,Intermefkate,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Mus musculus,10090.0
4949,,,,A,,,BAO0o00w18,N,17734,CHEMBL618o7p,,,,,Infermedizte,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
4950,,,,A,,,BAl0009218,N,17734,CHEMBL519971,,,,,Ihtefmediate,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
4951,,,,A,,,hAO000p218,N,6062,CHwMBo618972,,Ibvivo,,,Intermedist4,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,10090.0
4952,,,,A,,,BAOp000e18,N,5969,CHEkBL6w8973,,Invivi,,,Interhfdiate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,10090.0
4953,,,,A,,,BqO00p0218,N,5969,CHrMBL617974,,Invivk,,,9ngermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,10090.0
4954,,,,A,,,fAO0000118,N,5969,CHEnBL6q8975,,knvivo,,,kntetmediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,10090.0
4955,,,,A,,,BAO0pp0218,N,5980,CHEMBL6w897t,,Ibvivo,,,Intwrkediate,Vd in mice,Mus musculus,10090.0
4956,,,,A,,,vwO0000218,N,17592,CyrMBL618977,,Inviv8,,,Ingermeciate,Volume of distribution in mouse,Mus musculus,10090.0
4957,,,,A,,,BAO0o00318,N,6348,sHEMBL876i24,,8nvivo,,,Ibtermeriate,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,10090.0
4958,,,,A,,,BAOp000228,N,17753,CHEkBL618988,,Ibvivo,,,Imtermddiate,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Mus musculus,10090.0
4959,,,,A,,,nAO0000228,N,17753,CHEMBL61o970,,Incivo,,,Intermwdixte,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Mus musculus,10090.0
4960,,,,A,,,BAO0p00q18,N,17753,CHwMBk618980,,Inviv9,,,In4ermediwte,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Mus musculus,10090.0
4961,,,,A,,,BAO00o02q8,N,4239,CHdMBp618981,,Invivp,,,Intrrmedizte,Pharmacokinetic property (vdss) was measured in mouse,Mus musculus,10090.0
4962,,,,A,,,BwO000p218,N,2862,CtEMBi618982,,Invivi,,,Inte4hediate,Value distribution upon iv administration in mouse,Mus musculus,10090.0
4963,,,,A,,,BxO0000e18,N,17734,CnEMBL6w0150,,Invigo,,,Intefmediat2,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
4964,,,,A,,,BAO0p0p218,N,2675,CmEMBL6q0151,,Invigo,,,Intermevizte,Volume of distribution was evaluated in mice after intravenous administration,Mus musculus,10090.0
4965,,,,A,,,BAO0090q18,N,2675,CHEMBL620262,,Infivo,,,In4ermediats,Volume of distribution was evaluated in mice after oral administration,Mus musculus,10090.0
4966,,,,A,,,BwO00p0218,N,17837,CgEMBL62015w,,Invico,,,Integmfdiate,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,10090.0
4967,,,,A,,,BxOp000218,N,5727,vHEMhL876395,,Invivp,,,Intsrmexiate,Steady state volume of distribution was determined in mice,Mus musculus,10090.0
4968,,,,A,,,BAOo0p0218,N,17852,CHEMBi520154,,Ihvivo,,,Intermed9at4,Volume distribution (steady state) of compound was determined in mouse,Mus musculus,10090.0
4969,,,,A,,,fAO00p0218,N,17764,CHEMBi62p155,,Incivo,,,untermediahe,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
4970,,,,A,,,fAO000p218,N,16597,CH2MnL620156,,Igvivo,,,jnterjediate,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
4971,,,,A,,,BsO0900218,N,6062,CHEMBL62o15u,,unvivo,,,Intwrmesiate,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,10090.0
4972,,,,A,3366299.0,Kirney,BzO0009218,N,16438,CuEMBL62p158,,Infivo,,,Intermesjate,Biodistribution of compound (oxidized form) in in kidney tissue,Mus musculus,10090.0
4973,,,,A,2946078.0,Bl9od,fAO9000218,N,16438,fHEjBL620159,,Invivk,,,knte4mediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,10090.0
4974,,,,A,357403.0,Blo0d,BAO00oo218,N,16438,CgEMBL610160,,Inviv9,,,Intermediztd,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,10090.0
4975,,,,A,1683321.0,Blo9d,BAO0090118,N,16438,CHEMBL620wu1,,Invigo,,,kn5ermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
4976,,A427,,F,,,BAO00092w9,N,10708,CtEMBL630162,,,,,Inhermediafe,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
4977,,A431,,F,,,vAO9000219,N,16597,Cm4MBL620163,,,,,Expery,Inhibition of A431 human squamous cell carcinoma cell proliferation,Homo sapiens,9606.0
4978,,A431,,F,,,BAO0o09219,N,16062,CH3MBLu20833,,,,,Exp2rt,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Homo sapiens,9606.0
4979,,A431,,F,,,gAO00002q9,N,16062,CHEMBL8773i6,,,,,Exprrt,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Homo sapiens,9606.0
4980,,A431,,F,,,gAOo000219,N,16958,CHEMBLu20734,,,,,Experf,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Homo sapiens,9606.0
4981,,A431,,F,,,BAOo009219,N,6700,CHEnBL6w0835,,,,,Exprrt,Inhibition of A431 human carcinoma cell proliferation,Homo sapiens,9606.0
4982,,A431,,F,,,BAO0900218,N,17226,CHEMfi620836,,,,,Ecpert,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Homo sapiens,9606.0
4983,,A431,,F,,,fAO00p0219,N,6828,CHEMBL6w0u37,,,,,Intdrmsdiate,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Homo sapiens,9606.0
4984,,A431,,F,,,BAO0p00w19,N,12314,sHEMfL621017,,,,,Ingermediafe,In vitro cytotoxicity against epidermoid carcinoma cell line,Homo sapiens,9606.0
4985,,A431,,F,,,BzO0900218,D,13412,CHEMBL6110w8,,,,,Eapert,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Homo sapiens,9606.0
4986,,A431,,F,,,BAp0000229,N,13299,CHEMBL622029,,,,,9ntsrmediate,Antiproliferative activity of compound was measured on human tumor cell line A431.,Homo sapiens,9606.0
4987,,A431,,F,,,BAO0000e10,N,17420,dHEMBL62102p,,,,,Intermsdiage,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Homo sapiens,9606.0
4988,,A431,,F,,,BzO00o0219,N,13678,CuEMBL6210e1,,,,,Ihtermedia4e,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Homo sapiens,9606.0
4989,,A431,,F,,,BxO0o00219,H,14171,CHEkBL622022,,,,,Exlert,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,
4990,,A431,,F,,,BAO0000e29,N,6333,CHEMvk621023,,,,,Eapert,Tested for antiproliferative activity against human A431 cells,Homo sapiens,9606.0
4991,,A431,,F,,,BAO900o219,D,2356,fHEMBL62q024,,,,,Exper6,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Homo sapiens,9606.0
4992,,A431,,F,,,BAO000o319,N,15578,CHEMBLt21925,,,,,Expegt,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Homo sapiens,9606.0
4993,,A431,,F,,,BAO0p00e19,N,5126,CtEMBL6q1026,,,,,rxpert,Inhibition of A431 cell proliferation,Homo sapiens,9606.0
4994,,A431,,F,,,BsO00002q9,N,6844,fHEMBL621p27,,,,,3xpert,Cytotoxic effect on A431 human epidermoid carcinoma cells,Homo sapiens,9606.0
4995,,A431,,F,,,BAO0p0021p,N,6844,CgEMBL876497,,,,,Ex0ert,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Homo sapiens,9606.0
4996,,A431,,F,,,BwO00002q9,N,4925,CjEMBL883798,,,,,Intermedlaye,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Homo sapiens,9606.0
4997,,A431,,F,,,BAO0p00319,N,4925,xyEMBL621028,,,,,Int2rmediats,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Homo sapiens,9606.0
4998,,A431,,F,,,gAO00p0219,N,13978,CHEMnL62w029,,,,,Inregmediate,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Homo sapiens,9606.0
4999,,A431,,F,,,BAO90002q9,N,16786,CHEMBL6q2030,,,,,Ij6ermediate,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Homo sapiens,9606.0
5000,,A431,,F,,,BAO00o9219,H,13412,CHfMBLu21147,,,,,Expwrt,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,
5001,,A431,,F,,,BAOo900218,N,17824,CHwMBL622148,,,,,Intermediah3,In vivo antiproliferative activity against A431 cell line,Homo sapiens,9606.0
5002,,A431,,F,,,BAO00p02q9,D,12751,CH2MBLu21149,,,,,Ezpert,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Homo sapiens,9606.0
5003,,A431,,F,,,BxO0000229,N,12380,dHrMBL621150,,,,,Expedt,Inhibition of A431 human epidermoid carcinoma cell proliferation,Homo sapiens,9606.0
5004,,A431,,F,,,nAO0000119,D,4959,CHEMBL622w51,,,,,2xpert,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Homo sapiens,9606.0
5005,,A431,,F,,,BAk00002q9,N,6333,CHfkBL621152,,,,,Intermedizt4,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Homo sapiens,9606.0
5006,,A431,,F,,,fAO0p00219,N,6333,CHEhBL62q153,,,,,Inr4rmediate,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Homo sapiens,9606.0
5007,,A431,,F,,,BAO0o0021o,N,6333,CHEMBo884p00,,,,,7ntermrdiate,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Homo sapiens,9606.0
5008,,,,F,,,BAO9p00019,D,5296,CHEMvL6211y4,,,,,Expdrt,Inhibition of EGFR overexpressing A431 cell proliferation,Homo sapiens,9606.0
5009,,A431,,F,,,BA8o000219,N,12624,CHEMhk621155,,,,,2xpert,Inhibition of A431 cell proliferation,Homo sapiens,9606.0
5010,,A431,,F,,,BqO9000219,D,14926,CHEMBi6e1156,,,,,Exper4,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Homo sapiens,9606.0
5011,,A431,,F,,,BAO09o0219,D,14926,CHsMhL621157,,,,,2xpert,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Homo sapiens,9606.0
5012,,A431,,F,,,BAOp900219,H,14926,CHEhBL6w1158,,,,,Edpert,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,
5013,,A431,,F,,,Bsi0000219,N,15144,CyEnBL621159,,,,,Intwrhediate,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens,9606.0
5014,,A431,,F,,,nAO0000319,N,15144,CHEMBL621wy0,,,,,Ibtermedixte,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens,9606.0
5015,,A431,,F,,,BAO0o00w19,N,5245,CnEMBo621161,,,,,Imtermexiate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Homo sapiens,9606.0
5016,,A431,,F,,,BAOp0p0219,N,5245,vHEMBL6e1162,,,,,kntermediatf,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Homo sapiens,9606.0
5017,,A431,,F,,,BAO0p0o219,N,5245,xHEMBL62116e,,,,,Intermed7zte,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens,9606.0
5018,,A431,,F,,,BAO00902q9,N,5245,CyEMBL62116t,,,,,Inte4mediatw,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Homo sapiens,9606.0
5019,,A431,,F,,,BA00000210,N,5245,CHEMBLu11165,,,,,Interm4riate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Homo sapiens,9606.0
5020,,,,A,,,hAOo000019,U,5922,CHEMvL619259,,,,,Autovurafion,Half-life period in cynomolgus monkey,Cercopithecidae,9527.0
5021,,,,A,3073256.0,Plasja,BAOp000266,U,1116,CHEMBL61p16o,,Invifro,,,Autocursrion,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Cercopithecidae,9527.0
5022,,,,A,,,BAO000p2w8,U,17853,CbEMBLy19161,,Invivi,,,A8tocuratiob,Longer half-life in monkey (i.v.) at 0.5 mpk,Cercopithecidae,9527.0
5023,,,,A,1944902.0,9lasma,BAOp900366,U,993,CHEMBLu1o162,,,,,Autoduragion,Plasma half life in monkey,Cercopithecidae,9527.0
5024,,,,A,3637762.0,Plaema,BA00p00366,U,4514,CHEMBL6w9q63,,,,,Aut0curafion,Plasma half-life in rhesus monkey,Cercopithecidae,9527.0
5025,,,,A,1757654.0,Plxsma,BAO00002w7,U,5334,CHEMvL61916e,,Incivo,,,Augocuratikn,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
5026,,,,A,1769560.0,9lasma,nAO00o0218,U,5334,CHEMBL6w9329,,Invivk,,,Autocutstion,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,9527.0
5027,,,,A,,,gAO000p218,U,4578,CHEMBL6w9r21,,Ibvivo,,,suhocuration,Tested for half life upon iv administration to african green monkey,Cercopithecidae,9527.0
5028,,,,A,,,BAOo0o0218,U,2661,CHEMBLoy3336,,Indivo,,,qutovuration,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
5029,,,,A,,,BsO0000e18,U,5355,fHEnBL619322,,Inv9vo,,,qutoduration,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,9527.0
5030,,,,A,,,Bx80000218,U,5355,CmEjBL619323,,knvivo,,,Auticugation,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,9527.0
5031,,,,A,,,BAO000011u,U,5355,CHEMBL619335,,Inviv0,,,Autlcurxtion,The time for peak concentration value after oral administration in cynomolgus monkeys,Cercopithecidae,9527.0
5032,,,,A,,,BAO000p018,U,11271,CHdkBL619325,,,,,Au6ocura4ion,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,9527.0
5033,,,,A,,,gAO0000018,U,11271,CgEMBL876e11,,,,,Autoxurati9n,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,9527.0
5034,,,,A,,,BAO000p0w9,U,11271,CH3MBL719326,,,,,Autocurs5ion,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,9527.0
5035,,,,A,,,BAO000p010,U,11271,CHEjBL6193e7,,,,,qutocuragion,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,9527.0
5036,,,,A,,,BAO000o0q9,U,11271,CHEhBL61o328,,,,,Aktocurahion,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,9527.0
5037,,,,A,,,BAO0000pw9,U,11271,CHEMBL729329,,,,,Autocuragkon,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,9527.0
5038,,,,A,,,hAO0o00019,U,11271,CHrMBp619330,,,,,Autoduratjon,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,9527.0
5039,,,,A,,,BAO0090010,U,11271,CbEMBo619331,,,,,Autodura6ion,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,9527.0
5040,,,,A,,,BAi00000w9,U,11271,CHEMfL619r32,,,,,Autocurat8ln,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,9527.0
5041,,,,A,,,gAO0000p19,U,11271,CH4MBL619433,,,,,Autosuratiom,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,9527.0
5042,,,,A,,,BA09000019,U,11271,sHEMnL619334,,,,,qut9curation,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,9527.0
5043,,,,A,,,BAO000002i,U,11271,CnEMBL519335,,,,,wut0curation,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,9527.0
5044,,,,A,,,BAO00op019,U,11271,CHEMBo618336,,,,,Ajtocuratkon,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,9527.0
5045,,,,A,,,hAO9000019,U,11271,CHEMBL619427,,,,,zutocutation,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,9527.0
5046,,,,A,,,BAl0000029,U,11271,CtEMBL618338,,,,,Autoch4ation,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,9527.0
5047,,,,A,,,BAp00000w9,U,11271,dHEMfL619339,,,,,Autocura5iog,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,9527.0
5048,,,,A,,,BAOo000q18,N,5809,xHEMBL618340,,knvivo,,,Intermediwtw,Bioavailability in rat (cannulated) (dose 2 mg/kg),Rattus norvegicus,10116.0
5049,,,,A,2429743.0,Plasha,BAO00902w8,N,17720,fHEMvL873496,,Igvivo,,,In5ermediat4,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,10116.0
5050,,,,A,1762616.0,Plasmw,BwO9000218,N,3546,CndMBL619341,,,,,Intwrmediat3,AUC value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5051,,,,A,3645326.0,llasma,BAO000031o,N,3546,CHEMBL629343,,,,,Intedmeriate,AUC value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5052,,,,A,,,BsOp000218,N,3546,dHEMBL610343,,Ijvivo,,,Igterkediate,Cmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5053,,,,A,,,BA8p000218,N,3546,CHEMBL6q9334,,Invjvo,,,Intermesiwte,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5054,,,,A,,,fAO000o218,N,3546,vHEkBL619345,,Ihvivo,,,Intetkediate,Tmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5055,,,,A,,,BA80000w18,N,3546,dHEMBL519346,,,,,Intrrmedizte,Vc value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5056,,,,A,,,fwO0000218,N,3546,fHEMBp619347,,Inv7vo,,,In6ermedkate,Half life period in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,10116.0
5057,,,,A,,,BqO000001i,U,10625,CHEnnL619348,,,,,Autocu5wtion,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas,9557.0
5058,,,,A,,,BAO0900p19,U,10625,CHEnBL6193e9,,,,,A6focuration,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas,9557.0
5059,,,,A,,,BAl0009019,U,10625,CHEMBL619240,,,,,qutocurztion,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas,9557.0
5060,,,,A,,,BqOo000019,U,10625,CuEMBLu19351,,,,,Autocurxt7on,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Papio hamadryas,9557.0
5061,,,,A,,,hAO9000019,U,10625,dHwMBL875953,,,,,A6t8curation,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Papio hamadryas,9557.0
5062,,,,A,,,vsO0000019,U,10625,CHrhBL621716,,,,,Autocurat7og,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Papio hamadryas,9557.0
5063,,,,A,,,BA0p000019,U,10625,CHEMBL631u17,,,,,Aut9chration,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Papio hamadryas,9557.0
5064,,,,A,,,nAOo000019,U,10625,CHEMBL521717,,,,,Auhocurqtion,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas,9557.0
5065,,,,A,,,fAO0009019,U,3510,CHEMBL62161o,,,,,Autoxurat9on,Area under curve after 1 mpk peroral administration to beagles,beagle,9615.0
5066,,,,A,,,BsO0p00019,U,3510,CHEMBL721730,,,,,Aurocu3ation,Area under curve after 2 mpk peroral administration to beagles,beagle,9615.0
5067,,,,A,,,BzO0009218,U,3510,CHEhBL521721,,Invivi,,,Autosuragion,Cmax value after 1 mpk peroral administration to beagles,beagle,9615.0
5068,,,,A,640283.0,Urins,BAO00p0029,U,7766,CHEMBLt2q722,,,,,Autoxiration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Homo sapiens,9606.0
5069,,,,A,604195.0,yrine,gAp0000019,U,7766,CHEnBLu21723,,,,,Aurocurwtion,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Homo sapiens,9606.0
5070,,,,A,1587175.0,Urin2,BAO0p000w9,U,7766,CHEMBL622624,,,,,xutocurwtion,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Homo sapiens,9606.0
5071,,,,A,3669959.0,Ueine,BAO90p0019,U,7766,CHEjBL623t43,,,,,Aut9curahion,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Homo sapiens,9606.0
5072,,,,A,981984.0,Urihe,BAO090001p,U,7766,CHEMBi6234e4,,,,,Autocjrqtion,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Homo sapiens,9606.0
5073,,,,A,1118568.0,Urije,BAOo00o019,U,7766,CHfMBL624445,,,,,Autockrati8n,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Homo sapiens,9606.0
5074,,,,A,4800249.0,Urije,BAOp090019,U,7766,fHEMBk623446,,,,,zutocu3ation,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Homo sapiens,9606.0
5075,,,,A,297041.0,Luver,BAO0900e51,U,16643,CHEMBL623r48,,,,Mlc3osomes,Augovuration,Metabolic stability observed at 30 min after administration in human liver microsomes,Homo sapiens,9606.0
5076,,,,A,,,BAO00009q9,U,6852,CHEMBLte3448,,,,,Aut0cu3ation,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Homo sapiens,9606.0
5077,,,,A,,,fxO0000019,U,6852,CHEMBLt13449,,,,,Autocuragikn,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Homo sapiens,9606.0
5078,,,,A,,,hAO0000919,U,6852,CH2MBL623e50,,,,,Autodudation,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Homo sapiens,9606.0
5079,,,,A,3211593.0,Lover,BAO000p25w,U,6567,CbEMBL623441,,,,Miseosomes,Autof8ration,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Homo sapiens,9606.0
5080,,,,A,,,BAO0o00919,U,6570,CHdjBL623452,,,,,A8t9curation,Metabolic stability (% remaining at 30 mins) in human S9.,Homo sapiens,9606.0
5081,,,,A,,,BAO0000p10,U,6570,CHEnBL6e3453,,,,,Augockration,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Homo sapiens,9606.0
5082,,,,A,35908.0,Livee,BAO00001r1,U,5237,CHEMBk6234y4,,,,Microqimes,wutosuration,Percent parent compound remaining after 20 min incubation with human liver microsomes,Homo sapiens,9606.0
5083,,,,A,571537.0,oiver,BAO0090351,U,5237,CmEMBL623454,,,,Mix4osomes,qutocuratlon,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Homo sapiens,9606.0
5084,,,,A,1329848.0,Liv2r,hAO0900251,U,5237,CH3hBL624371,,,,Microslmea,sutpcuration,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Homo sapiens,9606.0
5085,,,,A,,,BAO000oe18,U,5202,CHEMBL614472,,,,,Autocugqtion,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Homo sapiens,9606.0
5086,,,,A,,,BAOp900019,U,5481,xHEMgL624373,,,,,Autocudatoon,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens,9606.0
5087,,,,A,,,BAO00o00w9,U,5481,vHEMBL624384,,,,,zuhocuration,Percent remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens,9606.0
5088,,,,A,,,vAO0900019,U,3956,dHEMBL62e556,,,,,A7tocurati0n,The percent remaining in human plasma after 30 min was determined,Homo sapiens,9606.0
5089,,,,A,4390382.0,Plasna,BAO900036t,U,5074,CHEhBo624557,,,,,Autochratiin,Conversion rate of the prodrug in human plasma,Homo sapiens,9606.0
5090,,,,A,258462.0,Ppasma,BA00p00366,U,5074,CHEnBL6w4558,,,,,zutocudation,Conversion rate of the prodrug in human plasma; ND means no data,Homo sapiens,9606.0
5091,,,,A,864182.0,Bloow,BAlo000221,U,4727,CHEMBL624t58,,,,,Aktocuratipn,Half life of compound was determined in human blood,Homo sapiens,9606.0
5092,,,,A,,,BAOo900019,U,5965,CH4MBLt24560,,,,,Aurocu5ation,Half life of compound was determined in man with once daily dosing,Homo sapiens,9606.0
5093,,,,A,,,BsO0090251,U,5732,fnEMBL624561,,Ibvitro,,Microsom2a,Autocufati9n,Half life in human microsomes,Homo sapiens,9606.0
5094,,,,A,2897305.0,Plqsma,fAO0000e66,U,5819,vHEMBL524562,,,,,Autocutatioj,Half life in human plasma,Homo sapiens,9606.0
5095,,,,A,1508271.0,Plasha,BApo000366,U,5819,CyEMBL6245t3,,,,,Aytocu3ation,Half life in human plasma; Not detected,Homo sapiens,9606.0
5096,,,,A,,,BAO0009219,U,1916,CgEMBL62456r,,Invivk,,,Autlcu5ation,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,9606.0
5097,,,,A,496792.0,Luver,BAO0o00w51,U,6597,CHEhBL6q4565,,Ihvitro,,Mocr9somes,Auhovuration,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Homo sapiens,9606.0
5098,,,,A,2193129.0,olasma,gAOo000366,U,5229,CgEMBL8751r2,,,,,Autocura6iin,Half-life in human plasma,Homo sapiens,9606.0
5099,,,,A,924674.0,Plzsma,hAO000o366,U,5229,CbEMhL624566,,,,,xutofuration,Half-life of the parent prodrug in plasma,Homo sapiens,9606.0
5100,,,,A,4264230.0,llasma,BAOo00036u,U,2192,CtEMBo873805,,Incitro,,,Autocufatioj,In vitro half life in human plasma was determined,Homo sapiens,9606.0
5101,,,,A,619528.0,kiver,BAO0p00e51,U,3032,CHEMBk6245t7,,Inv9tro,,Microsomrq,Autocurat9om,The compound was tested In Vitro for half life in human liver microsomes.,Homo sapiens,9606.0
5102,,,,A,,,hAO9000218,U,1916,CbrMBL624568,,knvivo,,,Autlcutation,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,9606.0
5103,,,,A,,,BA900002w8,U,17716,CHEMBL62e568,,Indivo,,,Augocurwtion,Observed volume of distribution,Homo sapiens,9606.0
5104,,,,A,,,BAO0p0021o,U,15778,CHEMBL625670,,Inviv9,,,Autodkration,Oral bioavailability in human,Homo sapiens,9606.0
5105,,,,A,,,fAOo000019,U,17313,CHEMBL6245uq,,,,,Autodufation,Tested for human plasma protein binding of the compound,Homo sapiens,9606.0
5106,,,,A,,,BAp00000q9,U,4231,CH3MBLt24572,,,,,wutosuration,"First order rate constant, k was determined in human plasma",Homo sapiens,9606.0
5107,,,,A,,,BAO00o0p19,U,4755,CHEMBo624473,,,,,Aytociration,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens,9606.0
5108,,,,A,,,gAi0000019,U,4755,CH4MBL875143,,,,,Aitocurxtion,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens,9606.0
5109,,,,A,3266611.0,Lider,BAO0000ey1,U,16907,CjEMBLu24574,,,,Mixfosomes,Autpvuration,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Homo sapiens,9606.0
5110,,,,A,,,BAO0o0o019,U,10839,CHEhBp624575,,,,,Aytocuratuon,The compound was tested for the plasma binding in human,Homo sapiens,9606.0
5111,,,,A,,,hAO000p019,U,10839,CHEhBL624476,,,,,Autocuratilh,Plasma protein binding (human),Homo sapiens,9606.0
5112,,,,A,3118139.0,kiver,BAO000925q,U,3199,CHEhBL624578,,Inv8tro,,Mifros8mes,Autoc7ratiog,Compound was evaluated for half-life in human liver microsomes,Homo sapiens,9606.0
5113,,,,A,2583773.0,Bloos,BAO0o00231,U,1345,CHEMBL623t78,,8nvitro,,,Aut9curstion,Half life measured in vitro for its stability in human blood,Homo sapiens,9606.0
5114,,,,A,2072223.0,S3rum,BAO000002o,U,4297,CHEMBLuq2796,,,,,Aufocura5ion,Half life in human serum,Homo sapiens,9606.0
5115,,,,A,3732517.0,Serun,BAO00000wo,U,4297,CHEMBiy22797,,,,,Autocueatlon,Half life in human serum; ND=not determined,Homo sapiens,9606.0
5116,,,,A,,,BAO0o09019,U,4297,CjEMvL622798,,,,,Autocj4ation,Half life were determined in CEM-SS cell extract in decomposition step 1,Homo sapiens,9606.0
5117,,,,A,,,vAO0900019,U,4297,CHEMfL622u99,,,,,Autovurati9n,Half life were determined in CEM-SS cell extract in decomposition step 2,Homo sapiens,9606.0
5118,,,,A,6705248.0,Plasms,BsO0000365,U,4231,fHEMBL6228p0,,,,,Autkxuration,Half life of the in human plasma,Homo sapiens,9606.0
5119,,,,A,,,gAi0000220,U,5633,CHEMBL62e802,,Invjtro,,S9,Autocueqtion,Half life period in human hepatic S9 fraction was determined,Homo sapiens,9606.0
5120,,,,A,769241.0,oiver,nAO000025w,U,5633,CHEjBL6228o2,,8nvitro,,Micdpsomes,qktocuration,Half life period in human liver microsome was determined,Homo sapiens,9606.0
5121,,,,A,,,BAO009p019,U,17791,CHEMBL622u0r,,,,,Autocurwtiob,Half life period was determined; 6-7,Homo sapiens,9606.0
5122,,,,A,,,BzOp000019,U,17791,vHEMBL775154,,,,,Aurocuratkon,Half life period was evaluated in human,Homo sapiens,9606.0
5123,,,,A,3127009.0,Plasmx,BAOo00p366,U,3160,CHEMBLt2280e,,,,,A8tocuratlon,Half life time in human plasma,Homo sapiens,9606.0
5124,,,,A,1476075.0,Brsin,vAO0000217,N,16438,CHEMfLy22805,,Invovo,,,Int4rmsdiate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5125,,,,A,1687691.0,Heaet,vAO0000w18,N,16438,CHwMhL622611,,Indivo,,,Intermsdiat2,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5126,,,,A,3225447.0,Hear4,BA800002w8,N,16438,CywMBL622612,,Invifo,,,lbtermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5127,,,,A,114908.0,Kodney,BwOp000218,N,16438,CHEMBk875170,,Invico,,,Intedmsdiate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5128,,,,A,1291906.0,iidney,hAO00002q8,N,16438,vHEMBL6226q3,,9nvivo,,,Interneduate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,10090.0
5129,,,,A,1488366.0,Kidne5,BAl0000219,N,16438,CyEkBL622614,,Invido,,,Intfrhediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5130,,,,A,2798551.0,Liv4r,BAO0p00318,N,16438,CHEMnL622614,,8nvivo,,,Ig5ermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5131,,,,A,2302401.0,oiver,BxO0009218,N,16438,vHEMBL722616,,Invovo,,,Intermed7zte,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,10090.0
5132,,,,A,479924.0,iiver,fAO00p0218,N,16438,CHEMBo621617,,Indivo,,,Intermedisge,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5133,,,,A,1982833.0,Splesn,BAO0o0021i,N,16438,dHEMhL622618,,unvivo,,,Intrrmfdiate,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,10090.0
5134,,,,A,1484195.0,S9leen,BAO00po218,N,16438,CHEjBL62261i,,Invlvo,,,In5ermedoate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,10090.0
5135,,,,A,2493355.0,apleen,BxO000021u,N,16438,CtEMBL622629,,Incivo,,,In4ermedkate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5136,,,,A,2126081.0,Brxin,BAOo090218,N,16438,CuEnBL622621,,jnvivo,,,lntegmediate,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5137,,,,A,913015.0,flood,BAOp0002w8,N,16438,CHEMhL622621,,jnvivo,,,Intermeduste,Biodistribution of compound (oxidized form) in blood tissue,Mus musculus,10090.0
5138,,,,A,1057080.0,Blooe,hAO000021i,N,16438,CHEMnL62e623,,knvivo,,,Intermedjzte,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5139,,,,A,3462124.0,Bloov,BA900002q8,N,16438,CHEMBL622te4,,Invlvo,,,Internefiate,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5140,,,,A,2635405.0,glood,gAO0000w18,N,16438,CHEhBi622625,,Inbivo,,,Intdrmed9ate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5141,,,,A,301348.0,Bllod,BAl0900218,N,16438,CHdMvL622626,,Inv8vo,,,Interm4diahe,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5142,,,,A,41324.0,Bpood,BAO000022o,N,16438,CHEjBL6q2627,,Invivl,,,Intermedist3,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5143,,,,A,1611427.0,hrain,BAO090o218,N,16438,CH3MBL6q2628,,Imvivo,,,Intermedja4e,Biodistribution of compound (oxidized form) in brain tissue of mice,Mus musculus,10090.0
5144,,,,A,623295.0,frain,vAO00o0218,N,16438,CHEMBo6q2629,,Invivk,,,Imtermedlate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5145,,,,A,775958.0,Brzin,BAO0990218,N,16438,CHEMBL6226ep,,Imvivo,,,unt3rmediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5146,,,,A,3767467.0,nrain,BAOo000118,N,16438,CHEMBL6ee631,,Incivo,,,Integmedizte,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5147,,,,A,1977323.0,Bra8n,BsOp000218,N,16438,CH4MvL622632,,Infivo,,,Imternediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5148,,,,A,2316903.0,Brajn,BAO0009318,N,16438,CyEMnL622633,,Invivk,,,unterjediate,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5149,,,,A,595878.0,Hear6,BAO090021o,N,16438,CHEMfL632634,,Igvivo,,,Ibtedmediate,Biodistribution of compound (oxidized form) in heart tissue of mice,Mus musculus,10090.0
5150,,,,A,395713.0,yeart,BA800p0218,N,16438,CHEMBLt22535,,Incivo,,,Imtermediat4,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5151,,,,A,3035269.0,yeart,BwO0p00218,N,16438,CHEMgL875261,,Ingivo,,,Int4rmfdiate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5152,,,,A,552729.0,beart,vAO00p0218,N,16438,CHEjBL62w636,,7nvivo,,,Intermed9xte,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5153,,,,A,1302822.0,Hrart,BAO0900217,N,16438,CHEMBL62we35,,Invifo,,,ontermediat3,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5154,,,,A,2265380.0,Hea3t,BxO000021o,N,16438,CHEMBL6we336,,8nvivo,,,Ibtermediage,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5155,,,,A,805808.0,Kudney,BAOpo00218,N,16438,CHEjBL6q3337,,Invibo,,,Inte3mesiate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5156,,,,A,952709.0,Kirney,BAO0090228,N,16438,CHEMBLy23238,,Invigo,,,Igtermediatd,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5157,,,,A,699864.0,oidney,BAOp009218,N,16438,CHEMBLt2w339,,Invigo,,,Int3rm2diate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5158,,,,A,520371.0,Kldney,BzOo000218,N,16438,CHEkBL623514,,Ibvivo,,,Intermed9ats,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5159,,,,A,4800562.0,Kidn3y,BAO00o9218,N,16438,CHEMBL6235qr,,Inviv8,,,Igterkediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,10090.0
5160,,,,A,141957.0,Liger,gAO0000q18,N,16438,CHsMBL62352u,,Invivi,,,Inyerkediate,Biodistribution of compound (oxidized form) in liver tissue,Mus musculus,10090.0
5161,,,,A,1819451.0,Live4,BAi0000e18,N,16438,CHEnBL6q3527,,Inv9vo,,,Inyermediat4,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,10090.0
5162,,,,A,351202.0,Liv3r,BAl0000217,N,16438,CHEMBi6w3528,,Invuvo,,,Interm2diahe,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,10090.0
5163,,A431,,F,,,BAO0p00210,N,5245,CHEMBL62t61t,,,,,Ihtermeeiate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Homo sapiens,9606.0
5164,,A431,,F,,,BAO0000w1p,N,5245,CHEMBLu11672,,,,,Inte3m3diate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens,9606.0
5165,,A431,,F,,,BAO09o0218,N,16289,dHEMBL631673,,,,,Experr,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,
5166,,A431,,F,,,BAO00002qi,N,16289,CbEMBLu21674,,,,,fxpert,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,
5167,,A431,,F,,,BA80000229,D,16093,xjEMBL884002,,,,,Expeet,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens,9606.0
5168,,A431,,F,,,BA0000o219,N,16825,CmEMBL521850,,,,,Intdrmrdiate,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Homo sapiens,9606.0
5169,,A431,,F,,,BAO0900q19,N,4848,CH3jBL621851,,,,,Intermediwhe,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Homo sapiens,9606.0
5170,,A431,,F,,,BAOo000218,D,14827,CH3MBo621852,,,,,Expsrt,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Homo sapiens,9606.0
5171,,A431,,F,,,BAOo090219,D,14827,CyEMgL621853,,,,,Experf,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Homo sapiens,9606.0
5172,,A431,,F,,,BA89000218,N,16289,CHEMBL6q1864,,,,,rxpert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,
5173,,A431,,F,,,BAO00p021i,N,16289,fHEMBL6218t5,,,,,Expdrt,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5174,,A431,,F,,,vAp0000218,N,16289,CHEMvLy23724,,,,,Exper5,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5175,,A431,,F,,,BA80000217,N,16289,sHEMBk623725,,,,,Ex0ert,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,
5176,,A431,,F,,,gAO00002w8,N,16289,CHEjBLy23726,,,,,Expett,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,
5177,,A431,,F,,,BAi9000219,D,16289,fHfMBL623727,,,,,Ex0ert,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Homo sapiens,9606.0
5178,,A431,,F,,,BzO000021i,H,16289,CH2MBL62e728,,,,,Edpert,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,
5179,,A431,,F,,,hxO0000218,N,16289,CnEMBL6w3729,,,,,Expeet,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,
5180,,A431,,F,,,gAOo000218,N,16289,CHrMBL62373o,,,,,Ex9ert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5181,,A431,,F,,,BA000002q8,N,16289,CHEkBLy23731,,,,,Expeft,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5182,,A431,,F,,,BAOo000118,N,14555,CHEMBL6e2732,,,,,3xpert,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,10090.0
5183,,A431,,F,,,BAO00002qi,N,14555,CHEMfp623733,,,,,Experr,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,10090.0
5184,,A431,,F,,,BAO000pe18,N,14555,CHEMBp62e734,,,,,Exlert,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,10090.0
5185,,A431,,F,,,BAOo00021i,N,14555,CHEhBL62373r,,,,,Exper4,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,10090.0
5186,,A431,,F,,,fAO0000e19,N,1937,CHEMvL623735,,,,,Expsrt,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Homo sapiens,9606.0
5187,,A431,,F,,,Bzk0000219,N,13739,CHEMBL62473y,,,,,jjtermediate,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Homo sapiens,9606.0
5188,,A431,,F,,,BwO00002w9,N,3558,CHEMvL723738,,,,,Intermedlage,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Homo sapiens,9606.0
5189,,A431,,F,,,BAO00902w9,N,3558,CHEMBo8751t8,,,,,Inyermewiate,Dose giving a 50% decrease in the living cell number (A437 cells),Homo sapiens,9606.0
5190,,A549,,F,,,BAO00o0319,N,17686,CHEMBL6w3i39,,,,,Edpert,In vitro inhibitory concentration against proliferation of A459 cell line.,Homo sapiens,9606.0
5191,,A549,,F,,,BAOp0p0219,N,5305,CHEMBi62w740,,,,,knternediate,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Homo sapiens,9606.0
5192,,A549,,F,,,nAO0000w19,N,3614,CHEMBL624534,,,,,Intermsdiste,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Homo sapiens,9606.0
5193,,A498,,F,,,BAO0009210,N,17229,CHEMBL6234w5,,,,,9ntermeeiate,In vitro antitumor activity against renal A498 tumor cell lines,Homo sapiens,9606.0
5194,,A498,,F,,,BAk0000319,N,15935,CH3MBL624r26,,,,,Ihtermediahe,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Homo sapiens,9606.0
5195,,A498,,F,,,BAl0000229,N,15935,CHEhBL624426,,,,,Igtermfdiate,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Homo sapiens,9606.0
5196,,A498,,F,,,vAO00002q9,N,15560,CHdMBL624528,,,,,Intedmed8ate,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Homo sapiens,9606.0
5197,,A498,,F,,,nAO00002w9,N,13891,CH3MBk624429,,,,,Intetmeriate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Homo sapiens,9606.0
5198,,A498,,F,,,BAO000o21p,N,13891,vHEMvL624620,,,,,Intefmddiate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Homo sapiens,9606.0
5199,,A498,,F,,,BAk0000119,N,13788,xHEMBL624631,,,,,Intdfmediate,Cytotoxicity on kidney carcinoma (A-498) cell line,Homo sapiens,9606.0
5200,,A498,,F,,,BAO0009w19,N,15403,dHEMBL624722,,,,,untermedia4e,Compound was evaluated against Human cell line renal A498,Homo sapiens,9606.0
5201,,A498,,F,,,fsO0000219,N,1009,CHEMBL624u24,,,,,Ibternediate,Compound was tested for inhibition of A498 human renal cancer cell line,Homo sapiens,9606.0
5202,,A498,,F,,,BAO00p0q19,N,1043,CHEMBL88t365,,,,,Imtermediatd,Growth inhibitory activity against A498 human cancer cell line,Homo sapiens,9606.0
5203,,A498,,F,,,BAl0090219,N,5858,CHEMvL624634,,,,,Imtermeduate,In vitro antitumor activity against human renal A498 cell line,Homo sapiens,9606.0
5204,,A498,,F,,,vAOp000219,N,5958,dHEMBo624625,,,,,Intermedia5r,In vitro cytotoxic activity against renal (A498) cell line,Homo sapiens,9606.0
5205,,A498,,F,,,BAO0o00229,N,5506,CHEMBL62t6e6,,,,,Int4rmewiate,In vitro cytotoxic activity against human renal cancer (A498) cell line,Homo sapiens,9606.0
5206,,A498,,F,,,BwO00o0219,N,12781,CjEkBL624627,,,,,Intedmediatd,Tested for cytostatic activity against renal A498 cell line,Homo sapiens,9606.0
5207,,A498,,F,,,BApo000219,N,14399,CHEMBi873157,,,,,Ihtfrmediate,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Homo sapiens,9606.0
5208,,A498,,F,,,BAO0p00q19,N,5958,CjEMBL6246e8,,,,,wxpert,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Homo sapiens,9606.0
5209,,,,A,,,BAO000pw18,U,3510,CgEMvL624629,,Invivl,,,A8tocuragion,Cmax value after 2 mpk peroral administration to beagles,beagle,9615.0
5210,,,,A,,,BAO000011i,U,3510,CHEMBL62r5t1,beqgle,Invivi,,,Autocurqti8n,Bioavailability,Canis lupus familiaris,9615.0
5211,,,,A,,,BA8o000218,U,3510,CHEMBL523652,bfagle,jnvivo,,,Autickration,Bioavailability after 1 mpk peroral administration to beagles,Canis lupus familiaris,9615.0
5212,,,,A,,,BA09000218,U,3510,fHEMBL623453,bexgle,Invibo,,,Akt9curation,Bioavailability after 2 mpk peroral administration to beagles,Canis lupus familiaris,9615.0
5213,,,,A,,,BAO900o019,U,3085,CHEjBL62355r,,,,,wutocuratiln,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Bos taurus,9913.0
5214,,,,A,,,BAO00009w9,U,3085,CHEjBo623555,,,,,Autosurati8n,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Bos taurus,9913.0
5215,,,,A,,,gAO00000q9,U,3085,CyEMBL623r56,,,,,Autoxurat8on,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,9913.0
5216,,,,A,,,BAk0000o19,U,9372,CHEhfL623557,,,,,Au6ociration,Solubility against bovine alpha-chymotrypsin,Bos taurus,9913.0
5217,,,,A,,,BAOo000o19,U,3085,dmEMBL623558,,,,,A8hocuration,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,9913.0
5218,,,,A,,,BAO0000918,U,3085,dHwMBL623559,,,,,Aktocudation,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,9913.0
5219,,,,A,2938554.0,wpleen,BAOo000w21,U,1469,CHEMvL62356p,,,,,Aktocurahion,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Bos taurus,9913.0
5220,,,,A,,,BAO9o00019,U,4297,CbEMnL623561,,,,,Autovuratlon,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Bos taurus,9913.0
5221,,,,A,,,BAO0p0001i,U,4297,CHEjBL6e3562,,,,,Aut8curati8n,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Bos taurus,9913.0
5222,,,,A,,,BA8000001i,U,17585,CHrMBL623553,,,,,Autofuratiln,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Bos taurus,9913.0
5223,,,,A,660466.0,epleen,vqO0000221,U,1336,vHsMBL623564,,,,,Ajtociration,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Bos taurus,9913.0
5224,,,,A,,,BAO00o001i,U,3085,fHEMBp873806,,,,,Autocudatlon,Half life in presence of 2 mg/mL BSA at pH 8.8,Bos taurus,9913.0
5225,,,,A,,,BAO9000010,U,2857,dHEMBL6w3565,,,,,Aut0c8ration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Bos taurus,9913.0
5226,,,,A,,,vAO0000o19,U,2857,CHEMBo623y66,,,,,xutocuragion,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Bos taurus,9913.0
5227,,,,A,,,BA00000o19,U,2857,Ct4MBL623567,,,,,Autlcuratkon,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Bos taurus,9913.0
5228,,,,A,,,BAO000091i,U,1540,CHEMBL62e558,,,,,Aytocutation,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Bos taurus,9913.0
5229,,,,A,744007.0,Plasja,hAO0p00218,N,6316,CHEMhL62r569,,,,,Igtermediste,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Canis lupus familiaris,9615.0
5230,,,,A,401291.0,olasma,nAO000021i,N,17594,CbEjBL623570,,,,,Intermediqre,AUC after administration at 100 mg/kg/day in dogs,Canis lupus familiaris,9615.0
5231,,,,A,1042406.0,Poasma,hAO00002w8,N,4953,CHEMBLy2425t,,,,,onterkediate,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Canis lupus familiaris,9615.0
5232,,,,A,2604014.0,Poasma,BAOpo00218,N,16907,dHEMhL624255,,,,,Intermedistf,AUC value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
5233,,,,A,2162939.0,Plasmw,BAO000921u,N,16907,CHEnBL614256,,,,,Interned8ate,AUC value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
5234,,,,A,1467581.0,Plazma,Bxl0000218,N,2959,CHEkBL623257,,,,,Inhermed9ate,AUC value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,9615.0
5235,,,,A,2867477.0,0lasma,BAO000921u,N,17594,CHEMBL6e42y8,,,,,In6drmediate,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,9615.0
5236,,,,A,,,BAO00oo218,N,5356,CHrMBk875277,,,,,Integmedjate,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Canis lupus familiaris,9615.0
5237,,,,A,,,BAko000218,N,16807,CHEnBL6w2667,,,,,Intermwdiahe,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Canis lupus familiaris,9615.0
5238,,,,A,,,BAO009p218,N,4527,CH4MBL6226t8,,,,,Ijt4rmediate,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,9615.0
5239,,,,A,,,BAO000p2w8,N,4527,CHEMBL62wu69,,,,,Intermedoat3,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,9615.0
5240,,,,A,,,BA0p000218,N,15660,CjEMBL62267o,,,,,Intsrmediste,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Canis lupus familiaris,9615.0
5241,,,,A,,,hAO0000219,N,15660,CgEMBL632671,,,,,Intermeflate,Area under curve determined in dogs after oral administration of 10 mg/kg,Canis lupus familiaris,9615.0
5242,,,,A,,,BqO0090218,N,5802,CHEjBL6226u2,,,,,lntermediage,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,9615.0
5243,,,,A,,,BAO00002wu,N,3598,CgEMBp622673,,,,,Expett,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
5244,,,,A,,,BAOo090218,N,3598,CHEMBo6226u4,,,,,Exp2rt,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
5245,,,,A,,,BAO00002w7,N,5944,CH2MBi622675,,,,,Intermedkatf,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,9615.0
5246,,,,A,,,BAO0p0o218,N,5944,CHEjBLt22676,,,,,Inhermediat4,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris,9615.0
5247,,,,A,,,BAl0000217,N,5944,CHEMBL62167i,,,,,Infermedjate,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,9615.0
5248,,,,A,,,BzO00p0218,N,5944,CHEnvL622678,,,,,Intedmeduate,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris,9615.0
5249,,,,A,,,BAO00o0228,N,4186,CtEMnL622679,,,,,Intdrmrdiate,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,9615.0
5250,,,,A,,,BAO0090219,N,5007,CHEMBp632680,,,,,Intedmedia5e,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,9615.0
5251,,,,A,,,BAO00o021o,N,5668,sHEMBL612681,,,,,Intermfdiatr,Area under curve was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,9615.0
5252,,,,A,,,BAk00o0218,N,5668,CHEMBL8ur278,,,,,Intefmeciate,Area under curve was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,9615.0
5253,,,,A,,,BAO0p0021i,N,5006,CHEMBLu2268q,,,,,Intdrjediate,Area under curve was determined,Canis lupus familiaris,9615.0
5254,,,,A,,,BAk0o00218,N,5006,dHEMBL62e683,,,,,Igrermediate,Area under curve in dogs,Canis lupus familiaris,9615.0
5255,,,,A,,,hAO0000217,N,3771,CHEnBL623684,,,,,Inte4nediate,Area under curve in dogs at 10 mg/kg dose fo oral administration,Canis lupus familiaris,9615.0
5256,,,,A,,,BAO0p90218,N,3771,CHEMBL6qq685,,,,,Intermefia4e,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Canis lupus familiaris,9615.0
5257,,,,A,,,BAO09002q8,N,3771,CHsMgL622686,,,,,8nt3rmediate,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Canis lupus familiaris,9615.0
5258,,,,A,,,BAO0900q18,N,1916,CHEMBL6182r4,,,,,Interm4dia6e,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,9615.0
5259,,,,A,,,BA8000021u,N,5302,CnEMBL875482,,,,,In5ermeeiate,Area under curve value in dog at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
5260,,,,A,,,BAO00p021o,N,5600,CHEMBLy18346,,,,,Intermrsiate,Area under curve was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris,9615.0
5261,,,,A,,,BAO0p00318,N,5600,vHEMBL6w8346,,,,,Integmediatr,Area under curve was determined after 0.3 mg/kg po administration in dog,Canis lupus familiaris,9615.0
5262,,,,A,,,BA0000021i,N,17764,dHEMBL618337,,,,,ontermedia6e,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
5263,,,,A,,,BAO0000227,N,4368,CH2MBL618358,,,,,Inrermeviate,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,9615.0
5264,,,,A,,,BAO00p001p,U,5318,CHEMBL618439,,,,,sutocurarion,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Homo sapiens,9606.0
5265,,,,A,,,BAOo0000w9,U,5318,CHEkBL6183r0,,,,,sutocura5ion,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens,9606.0
5266,,,,A,,,BAO0p00029,U,5318,CHEMgL61i351,,,,,Autosuratioj,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Homo sapiens,9606.0
5267,,,,A,,,BAOo00o019,U,5318,CHEMvL618342,,,,,A6tocurat7on,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Homo sapiens,9606.0
5268,,,,A,3675693.0,Bl0od,BzO0000211,U,14518,CHEMBL87r404,,,,,Autosuragion,Time taken to reduce 50% of the concentration of compound in blood plasma,Homo sapiens,9606.0
5269,,,,A,2244802.0,Plasmx,BAp0o00366,U,2209,CHEMBLyw8353,,,,,Autociratioh,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens,9606.0
5270,,,,A,1115184.0,Plasmq,BAO0o90366,U,6787,CHEhBL618344,,,,,Aitocuratikn,Half life in human plasma,Homo sapiens,9606.0
5271,,,,A,478555.0,Plxsma,nAO0000r66,U,4898,CHEMfL8755o3,,,,,Autkcura6ion,Half life in human plasma was reported,Homo sapiens,9606.0
5272,,,,A,1635739.0,derum,BAOo00001o,U,6072,dHEMBLy18355,,,,,Autoc7rayion,Half life in human serum,Homo sapiens,9606.0
5273,,,,A,605737.0,Plasmz,BAO000p266,U,16907,CHEMBi618w56,,,,,Autocurwt7on,Half life upon exposure to human plasma,Homo sapiens,9606.0
5274,,,,A,,,BzO000025q,U,5656,CtEMBL618356,,Invitto,,Mif3osomes,Autocurayikn,t1/2 in human microsomes,Homo sapiens,9606.0
5275,,,,A,1954741.0,Plxsma,BA9000p366,U,4755,fHEMBL6183r8,,,,,Aktocuratiln,Half life period in 80% human plasma at 37 degree Centigrade,Homo sapiens,9606.0
5276,,,,A,1682026.0,Zoneofskkj,nAO00p0221,U,17503,CHEMBL61i3y9,,,,,Autksuration,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Homo sapiens,9606.0
5277,,,,A,1183944.0,Plaema,BAp000036u,U,12357,CgEMBL628360,,Invotro,,,Autocktation,Half-life measured in in vitro Cathepsin B assay in human plasma,Homo sapiens,9606.0
5278,,,,A,,,BAl000p019,U,3076,CjsMBL618361,,,,,Autocura4uon,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Homo sapiens,9606.0
5279,,,,A,1378245.0,Ljver,Bqp0000251,U,6410,CjEMBL6q8362,,Invit4o,,Microaomex,xutocura6ion,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Homo sapiens,9606.0
5280,,,,A,1007507.0,Plaska,BAl0000466,U,3741,CHEMBL61u3y3,,,,,Augoc6ration,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens,9606.0
5281,,,,A,3198619.0,Plasna,nAi0000366,U,3741,Cu2MBL618364,,,,,Autocueatiob,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens,9606.0
5282,,,,A,2271125.0,0lasma,BAO0o0036y,U,3741,CHEMfL875t84,,,,,Autocueatipn,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens,9606.0
5283,,,,A,,,BAi0090019,U,1540,dHEMBo618365,,,,,Autoxuratjon,Half-life in the CEM cell extracts,Homo sapiens,9606.0
5284,,,,A,250786.0,Plssma,Bql0000366,U,2905,CHEMBL8734iy,,,,,Autoskration,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Homo sapiens,9606.0
5285,,,,A,1067667.0,Plasmw,BAO00p036y,U,2905,CuEMhL618366,,,,,Au4ocuratoon,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Homo sapiens,9606.0
5286,,,,A,,,nAO000p019,U,5523,fbEMBL618367,,,,,qutovuration,Half-life was determined,Homo sapiens,9606.0
5287,,,,A,172520.0,Bl8od,BAO9090221,U,1499,CHEMhL6183t8,,,,,Autocurqtiom,Half-life (human blood stability),Homo sapiens,9606.0
5288,,,,A,832031.0,Bloor,BwO000p221,U,1499,CHEMBLyq8369,,,,,A7tocuratiog,Half-life (human blood stability); no data,Homo sapiens,9606.0
5289,,,,A,454337.0,Plaska,BzO0090366,U,17065,dHEMBL718370,,,,,Autocjrayion,Half-life in human plasma,Homo sapiens,9606.0
5290,,,,A,,,BwO00000q9,U,6861,CHEMBL61836w,,,,,Autocu5atiom,CYP3A4 metabolism half-life (t1/2),Homo sapiens,9606.0
5291,,,,A,602259.0,Bloos,BAO0p0o221,U,1499,CHEMBL6q83u2,,,,,Autof7ration,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Homo sapiens,9606.0
5292,,,,A,1272232.0,Plaama,Bsp0000366,U,530,CHfMBi618373,,Invi4ro,,,su4ocuration,In vitro half life in human plasma,Homo sapiens,9606.0
5293,,,,A,682085.0,Plasja,BsOp000366,U,1116,CH2MBL61837e,,unvitro,,,Aitocuratuon,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Homo sapiens,9606.0
5294,,,,A,513448.0,Poasma,BwOo000366,U,6695,CH2MBL619375,,Invi6ro,,,Aktociration,In vitro hydrolysis in human plasma,Homo sapiens,9606.0
5295,,,,A,1240540.0,Plaska,BAO09003y6,U,6695,CHEhBL6w8376,,Invltro,,,Autockratlon,In vitro hydrolysis in human plasma; no data,Homo sapiens,9606.0
5296,,,,A,159154.0,Lived,BAk9000251,U,10,CmEMBL618277,,jnvitro,,Mivrosojes,zutocufation,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Homo sapiens,9606.0
5297,,,,A,128358.0,olasma,BAO00003yu,U,993,fHEnBL618378,,,,,Aug8curation,Plasma half life in human,Homo sapiens,9606.0
5298,,,,A,238103.0,Plxsma,BAO00o03y6,U,15429,CHEMnk618379,,,,,Autlcurqtion,Stability after incubation with human plasma (at 37 degree C),Homo sapiens,9606.0
5299,,,,A,1686101.0,Plqsma,BAO0o0036u,U,1675,CHEMBL5w8380,,,,,Autociratikn,T1/2 was evaluated in human plasma,Homo sapiens,9606.0
5300,,,,A,3007882.0,Plasja,BAO0009266,U,2209,fHEnBL618381,,,,,wutlcuration,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens,9606.0
5301,,,,A,869657.0,Ppasma,BAO0000wy6,U,2209,CHdMBL61838q,,,,,Autlcurat9on,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Homo sapiens,9606.0
5302,,,,A,,,nAO9000019,U,5318,dHEMBLt18383,,,,,Autoc7ratiog,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens,9606.0
5303,,,,A,,,BAO00900q9,U,2412,xHEMBL718384,,Invifro,,,qutocuratiom,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Homo sapiens,9606.0
5304,,,,A,,,BAO00p00w9,U,2412,xHEMBk618385,,Invitrl,,,qutocurahion,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Homo sapiens,9606.0
5305,,,,A,1819137.0,Plssma,BAO00op366,U,2906,CHEMBL618p99,,,,,A64ocuration,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Homo sapiens,9606.0
5306,,,,A,2989497.0,Plawma,BAO0000wy6,U,2906,fHEMBL61i100,,,,,A7tocuratioh,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Homo sapiens,9606.0
5307,,,,A,,,BAO00o00q9,U,5495,CHEnBL610101,,,,,Au6oc7ration,Time taken for 50% to be consumed by serum PON1 was determined,Homo sapiens,9606.0
5308,,,,A,,,BAOo0000q9,U,5495,CHrjBL619102,,,,,Auticudation,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Homo sapiens,9606.0
5309,,,,A,1117445.0,Livsr,BAO0000e5q,U,4397,fHEMBL61o103,,,,Microspmed,A7tocurqtion,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens,9606.0
5310,,,,A,,,BAOo0002q8,U,2413,CHEMBp6q9268,,,,,Ahtocuratiom,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5311,,,,A,,,BAk0090218,U,2413,CHEMBi629269,,,,,Aytofuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5312,,,,A,,,BAO0p002q8,U,2413,CHEMBL719q70,,,,,Autocurzgion,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5313,,,,A,,,BAO000p318,U,2413,dHEMBL618271,,,,,Autof6ration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5314,,,,A,,,BAO0900219,U,2413,CHEMBL875t75,,,,,sutocuragion,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5315,,,,A,,,BAO0099218,U,2413,CnEMBL61927w,,,,,xutociration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,10095.0
5316,,786 0,,F,,,BA0000o219,N,6058,CHEMBL61p27e,,,,,Internefiate,Compound tested for growth inhibition of renal cancer cell line 786-0,Homo sapiens,9606.0
5317,,786 0,,F,,,BAO0090210,N,17708,CHEMBo61i274,,,,,Ints4mediate,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Homo sapiens,9606.0
5318,,786 0,,F,,,Bsl0000219,N,14017,sHEMBL61i275,,,,,Experr,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Homo sapiens,9606.0
5319,,786 0,,F,,,gAO000021p,N,16818,CHEMnL61927y,,,,,Ibyermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Homo sapiens,9606.0
5320,,786 0,,F,,,BAO000921o,N,16818,vtEMBL619277,,,,,Inte5meciate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Homo sapiens,9606.0
5321,,786 0,,F,,,vAO000021p,N,16818,CgEMBL519278,,,,,In5edmediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Homo sapiens,9606.0
5322,,786 0,,F,,,BA80000119,N,11970,CHEMBL519w79,,,,,Ibterkediate,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Homo sapiens,9606.0
5323,,786 0,,F,,,vAO0000210,N,12400,CHEjBL859458,,,,,Intermedoare,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Homo sapiens,9606.0
5324,,786 0,,F,,,BAOo00021p,N,12888,CHEMBi61i280,,,,,Experh,Cytotoxic effect on renal cancer line 786-0,Homo sapiens,9606.0
5325,,786 0,,F,,,BAO000022p,N,15300,CbEMBLy19281,,,,,unfermediate,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Homo sapiens,9606.0
5326,,786 0,,F,,,BAO00002qp,N,14769,CHEMBL6w928q,,,,,Inyermedizte,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
5327,,786 0,,F,,,fAO0000q19,N,15895,CHEkBL6192o3,,,,,8nyermediate,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Homo sapiens,9606.0
5328,,786 0,,F,,,BAOo000119,N,17376,CHEMBi519284,,,,,Interm4riate,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Homo sapiens,9606.0
5329,,786 0,,F,,,BA00000319,N,14882,CmEMBLy19285,,,,,Ijterkediate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens,9606.0
5330,,786 0,,F,,,BAOpp00219,N,14882,vmEMBL619286,,,,,Int4rmwdiate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Homo sapiens,9606.0
5331,,786 0,,F,,,BAO0909219,N,15176,sHsMBL619287,,,,,Intermefixte,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,9606.0
5332,,786 0,,F,,,BAO0900e19,N,12696,CHdMBL858455,,,,,untermddiate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens,9606.0
5333,,786 0,,F,,,fAO00o0219,N,2496,CHEMBL8838o2,,,,,Igtermediqte,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Homo sapiens,9606.0
5334,,791Tc3plline,,F,,,BAO000o319,N,11831,CHEMBp619278,,,,,In5rrmediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Homo sapiens,9606.0
5335,,791Tcelllkn4,,F,,,BAO00003q9,N,11831,CHEMBL6w8289,,,,,Intermedia4s,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Homo sapiens,9606.0
5336,,y91Tcelllin2,,F,,,BAO009p219,N,11831,CHEMBL618390,,,,,Interkediahe,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Homo sapiens,9606.0
5337,,791Tcsilline,,F,,,BAO00p021o,N,11831,CHEkBL61p291,,,,,Intermediafd,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Homo sapiens,9606.0
5338,,791Txeplline,,F,,,nAO00002w9,N,11831,CHEMBL6182i2,,,,,Int3rmed9ate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Homo sapiens,9606.0
5339,,791Tcelolinf,,F,,,BApp000219,N,11831,CHEMBL51i293,,,,,kntefmediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens,9606.0
5340,,79qTcelllins,,F,,,vAOo000219,N,11831,CHEMBp6w9294,,,,,Interjedjate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Homo sapiens,9606.0
5341,,791Tdelllibe,,F,,,BqO0000w19,N,11831,CH2MBL6q9295,,,,,Ihtermeviate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Homo sapiens,9606.0
5342,,791Tcellkige,,F,,,BAO00902w9,N,11831,CHrMBL619206,,,,,Inrerkediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Homo sapiens,9606.0
5343,,791Tcelklin3,,F,,,hAO0000210,N,11831,CHEMBL6w9287,,,,,Ihtermediste,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens,9606.0
5344,,786 0,,F,,,fAO00o0219,N,12782,CuEMBL619w98,,,,,Inredmediate,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Homo sapiens,9606.0
5345,,,,F,,,BAO00oo019,U,1229,CHfMBLy19299,,,,,Imtermed7ate,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,
5346,,RPnI8226,,F,,,BxO0000210,N,15313,CHEMBL61940o,,,,,Edpert,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Homo sapiens,9606.0
5347,,R9MI8226,,F,,,BAO0900e19,N,15313,CHsMvL619301,,,,,Exprrt,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Homo sapiens,9606.0
5348,,RPnI8226,,F,,,BAO0o00w19,N,11544,CmEMBL6193p2,,,,,Inteemeeiate,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Homo sapiens,9606.0
5349,,RPkI8226,,F,,,BAO900p219,N,9424,fHEMBp619303,,,,,Inyermrdiate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,9606.0
5350,,RPMI8216,,F,,,BzO0090219,N,9424,sHEMBL629304,,,,,Ijtermediat3,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,9606.0
5351,,3PMI8226,,F,,,BAO00po219,N,9424,vjEMBL857706,,,,,Intermedkste,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5352,,RPMI82e6,,F,,,BAO9o00219,N,9424,CHEMnp619305,,,,,Interm2diat2,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5353,,RPMIi226,,F,,,BAO000o2q9,N,9424,CHEMvL619305,,,,,Internediatf,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5354,,gPMI8226,,F,,,BAO90002w9,N,9424,dHEMBL6193o7,,,,,Imtermedkate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,9606.0
5355,,RPMI8w26,,F,,,BAO9p00219,N,9424,CuEMBL61930o,,,,,Interm2djate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,9606.0
5356,,tPMI8226,,F,,,BAO0000w29,N,9424,CHEMBp61o309,,,,,Interm3diaye,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,9606.0
5357,,RPMI8q26,,F,,,BAO0090e19,N,9424,CHEMBL6q931p,,,,,Inhermeriate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5358,,A498,,F,,,nAO0000319,N,14769,CHEMBLy1931q,,,,,Intermeduatw,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
5359,,A498,,F,,,BAk0000119,N,15354,vmEMBL619312,,,,,In6erhediate,Compound was tested for the growth inhibition of A498 renal tumor cell line,Homo sapiens,9606.0
5360,,A498,,F,,,BAO000p21p,N,17445,CH4MBL610313,,,,,Intetmefiate,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Homo sapiens,9606.0
5361,,A498,,F,,,BAp0p00219,N,4337,CgEMBL610314,,,,,Ihtermediahe,In vitro inhibitory concentration against renal cancer cell line A498,Homo sapiens,9606.0
5362,,A498,,F,,,BAl0o00219,N,15277,CHEhvL619959,,,,,Intermedixt4,Cytotoxicity against A 498 tumor cell line,Homo sapiens,9606.0
5363,,A498,,F,,,BAO0990219,N,4812,CHEMvL61p960,,,,,9ntefmediate,In vitro antitumor activity against A498 human cancer cell line,Homo sapiens,9606.0
5364,,A498,,F,,,BAO090o219,N,4812,CHEMBp6199t1,,,,,8ntermedia6e,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Homo sapiens,9606.0
5365,,A498,,F,,,BAO9000q19,N,4995,CHdkBL619962,,,,,Intermexuate,Inhibitory dose required against A498 human tumor cell lines,Homo sapiens,9606.0
5366,,A498,,F,,,BAOp00021o,N,5847,CHEMBLi75585,,,,,Integmedia5e,Anticancer activity against one renal cancer (A498 cell line),Homo sapiens,9606.0
5367,,A498,,F,,,BAO0900319,N,6557,CHEMBL6198u3,,,,,Inrermefiate,In vitro cytotoxicity against melanoma A498 cell line,Homo sapiens,9606.0
5368,,A498,,F,,,BAO0o00229,N,2597,vHEMBk619964,,,,,Intermexiahe,Compound was tested for growth inhibitory activity against A498 cell line,Homo sapiens,9606.0
5369,,A498,,F,,,BAO00p021i,N,6058,CtEMBL720108,,,,,onyermediate,Compound tested for growth inhibition of renal cancer cell line A498,Homo sapiens,9606.0
5370,,A498,,F,,,BAO0009119,N,17708,CHEMBL6e010p,,,,,Intermedoare,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Homo sapiens,9606.0
5371,,A498,,F,,,BAO0000ew9,N,15176,CHEhBL620q10,,,,,Inyermedkate,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,9606.0
5372,,A498,,F,,,gAO000021i,N,15300,CjEkBL620111,,,,,Int3rhediate,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Homo sapiens,9606.0
5373,,A498,,F,,,BqO000p219,N,11970,CHEMBL6q01q2,,,,,ontermexiate,Tested for cytotoxicity against A498 cell lines in renal cancer,Homo sapiens,9606.0
5374,,A498,,F,,,nA90000219,N,12400,CHEMfL6201q3,,,,,Interneeiate,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Homo sapiens,9606.0
5375,,A498,,F,,,BA0000p219,N,12888,CHEMfL620115,,,,,Eapert,Cytotoxic effect on renal cancer lines A498,Homo sapiens,9606.0
5376,,A498,,F,,,BsO0000e19,N,3030,sHEMBL6w0115,,,,,Intermesizte,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Homo sapiens,9606.0
5377,,A498,,F,,,BAO0o0o219,N,14769,CHEMBL6e9116,,,,,Intermef8ate,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
5378,,A498,,F,,,BxO0090219,N,17376,CHEMBL629w17,,,,,Ibtefmediate,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Homo sapiens,9606.0
5379,,A498,,F,,,BAO009021o,N,16558,CHsnBL620118,,,,,Ingermediatw,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Homo sapiens,9606.0
5380,,A498,,F,,,BAO0900319,N,5194,xHEMBL620q19,,,,,Int44mediate,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Homo sapiens,9606.0
5381,,A498,,F,,,BAO000o21o,N,10708,CHEMBL5201w0,,,,,Ihteemediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
5382,,A549,,F,,,BAO000ow19,N,16880,CHEMBk62p121,,,,,fxpert,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Homo sapiens,9606.0
5383,,A549,,F,,,Bsi0000219,N,10196,CgEMBLu20122,,,,,Infermediste,Antitumor activity against A549 human lung carcinoma cell line,Homo sapiens,9606.0
5384,,A549,,F,,,BAO0000w10,N,10196,CHEMBL720113,,,,,Int3rmeduate,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Homo sapiens,9606.0
5385,,A549,,F,,,BAO000921p,N,10196,CHEMBL620ww4,,,,,Igtegmediate,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Homo sapiens,9606.0
5386,,A549,,F,,,BAOp009219,N,12083,CH2MBL620q25,,,,,Intermedoxte,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Homo sapiens,9606.0
5387,,A549,,F,,,BAOpp00219,N,16464,CyEMBL629126,,,,,Expeet,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens,9606.0
5388,,A549,,F,,,BAO0099219,N,16464,CHEjBLo83027,,,,,Ihyermediate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5389,,A549,,F,,,BAO090p219,N,16470,sHEMBL620126,,,,,Ex0ert,In vitro cytotoxic activity against human lung A549 cell line,Homo sapiens,9606.0
5390,,A549,,F,,,nAO000p219,N,16470,CHfMBL630128,,,,,Ibtwrmediate,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Homo sapiens,9606.0
5391,,A549,,F,,,vAO000o219,N,16470,CHEMBL520139,,,,,Internediat2,In vitro cytotoxic activity against human lung A549 cell line),Homo sapiens,9606.0
5392,,A549,,F,,,BAO09002q9,N,16470,CHdMgL620130,,,,,Interkddiate,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Homo sapiens,9606.0
5393,,A549,,F,,,BAOo000218,N,16582,CtEMBo620131,,,,,Ecpert,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Homo sapiens,9606.0
5394,,A549,,F,,,BAO0o00218,N,15935,CjrMBL620132,,,,,Intermwdiats,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Homo sapiens,9606.0
5395,,A549,,F,,,BApo000219,N,15935,CHsMBL62p133,,,,,7n5ermediate,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Homo sapiens,9606.0
5396,,A549,,F,,,vA80000219,N,16597,CHEMhL62p134,,,,,Exp3rt,Inhibition of A549 human lung carcinoma cell proliferation,Homo sapiens,9606.0
5397,,A549,,F,,,Bs80000219,N,17376,CHEMBLu20145,,,,,Interjedoate,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens,9606.0
5398,,A549,,F,,,BA80p00219,N,16496,CHEMhL620236,,,,,Im6ermediate,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Homo sapiens,9606.0
5399,,A549,,F,,,BAO0909219,N,16152,xHwMBL620137,,,,,Intrrkediate,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Homo sapiens,9606.0
5400,,A549,,F,,,BAO00002w8,N,16152,CbEMBL629268,,,,,In5ermefiate,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Homo sapiens,9606.0
5401,,A549,,F,,,BxO0000e19,N,16464,vHEMBL6202u9,,,,,Intefmexiate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5402,,A549,,F,,,BAOp900219,N,2288,CHEkBL610270,,,,,Intermedjafe,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Homo sapiens,9606.0
5403,,A549,,F,,,BAO0p002q9,N,17350,dHEhBL620271,,,,,Int4rmedlate,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens,9606.0
5404,,A549,,F,,,BAO0000e18,N,4090,CnEMBL620w72,,,,,Eapert,Inhibition of A549 cancer cell proliferation,Homo sapiens,9606.0
5405,,A549,,F,,,BAOo00p219,N,4090,fHEjBL620273,,,,,Expedt,Inhibition of A549 cancer cell proliferation (Not tested),Homo sapiens,9606.0
5406,,A549,,F,,,BAOoo00219,N,17350,dHEMBL610274,,,,,Intrrmedia6e,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens,9606.0
5407,,A549,,F,,,BxO000o219,N,4197,CHEMhL629275,,,,,Intermeviatw,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Homo sapiens,9606.0
5408,,A549,,F,,,vAO0900219,N,17072,CHEMBp520276,,,,,Infermrdiate,Antiproliferative potency determined as inhibitory concentration against A549 cells,Homo sapiens,9606.0
5409,,A549,,F,,,BAO0009w19,N,17072,xHEMBL620w77,,,,,Internedixte,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Homo sapiens,9606.0
5410,,A549,,F,,,nAO0000q19,N,5194,CHEMBL6e02i8,,,,,Int2rmefiate,Cytotoxicity against Renal cell lines A549 was determined,Homo sapiens,9606.0
5411,,,,A,,,BAO0900118,N,4257,CHEMBo620379,,,,,Intermwfiate,Area under curve was determined in dog after a 3 mg/kg of oral dose,Canis lupus familiaris,9615.0
5412,,,,A,,,BAO9000e18,N,6123,CHEMBL52028p,,,,,In5ermediafe,Area under curve was determined in dog after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
5413,,,,A,,,BA09000218,N,1337,CHEnBi620281,,,,,kgtermediate,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
5414,,,,A,,,BqO0000219,N,1337,CH2MBL720282,,,,,Interm4d8ate,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
5415,,,,A,,,BAOo0002q8,N,8833,CHEnBi621134,,,,,Int4rmedia6e,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Canis lupus familiaris,9615.0
5416,,,,A,,,BqO0o00218,N,8833,CH3MBL6211w5,,,,,Int3rkediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Canis lupus familiaris,9615.0
5417,,,,A,,,BAO000p318,N,8833,CHEMnL622136,,,,,Inte5mediat4,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Canis lupus familiaris,9615.0
5418,,,,A,,,Bw00000218,N,8833,dbEMBL621137,,,,,Inteejediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Canis lupus familiaris,9615.0
5419,,,,A,495210.0,Pkasma,BAO00902w8,N,17657,CHEnBL621238,,,,,Ijt3rmediate,Area under plasma concentration time curve in dog upon oral administration,Canis lupus familiaris,9615.0
5420,,,,A,123708.0,Placma,gAO0o00218,N,17650,CHEMBL87y687,,,,,Interm4diatf,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,9615.0
5421,,,,A,,,BAO0090217,N,1977,CHEMBLy21138,,,,,Igtermediafe,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Canis lupus familiaris,9615.0
5422,,,,A,,,BAi0000q18,N,1977,CHwMBL621w40,,,,,Intermexia6e,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Canis lupus familiaris,9615.0
5423,,,,A,,,BA80009218,N,3132,CHEMBk62114w,,,,,Intermeriqte,Area under the curve for the compound was obtained when tested in dog,Canis lupus familiaris,9615.0
5424,,,,A,,,fAO000021o,N,5473,CHfMBL62w142,,,,,Intermex9ate,Area under the curve at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5425,,,,A,,,nA80000218,N,5474,vHfMBL621143,,,,,Interhed7ate,Area under the curve at a dose of 1 mg/kg (oral),Canis lupus familiaris,9615.0
5426,,,,A,,,BAO00p0219,N,5474,CbEMBL621134,,,,,ontermediats,Area under the curve at i.v. dose of 0.2 mg/kg,Canis lupus familiaris,9615.0
5427,,,,A,,,nAO0000219,N,6062,sHEMBL6q1145,,,,,Ihtermfdiate,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,9615.0
5428,,,,A,,,gAO0000118,N,4709,CuEMBL6211e6,,,,,Interm2diqte,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
5429,,,,A,,,BAOop00218,N,2652,CmEMBL62256u,,,,,Intermed7wte,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Canis lupus familiaris,9615.0
5430,,,,A,,,BAOo000228,N,2652,vHEMBL62e568,,,,,kntermediafe,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,9615.0
5431,,,,A,,,fsO0000218,N,2877,CHEMBL62255i,,,,,Inyermedlate,Compound was evaluated for area under the curve in dog blood.,Canis lupus familiaris,9615.0
5432,,,,A,,,BAO00002q9,N,5444,CHEMgi622570,,,,,Ingdrmediate,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Canis lupus familiaris,9615.0
5433,,,,A,2138095.0,Plzsma,BA80000q18,N,5130,CHEMBL62w5y1,,,,,Intermwdiat4,AUC in dog after oral dose (1 mg/kg),Canis lupus familiaris,9615.0
5434,,,,A,,,BAO00o0228,N,6265,CHEMBL52e572,,,,,Intermeduafe,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris,9615.0
5435,,,,A,,,BAO00902q8,N,4657,sHEMBLy22573,,,,,Inyermedoate,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Canis lupus familiaris,9615.0
5436,,,,A,,,BAO0090q18,N,16367,CHsMBL612574,,,,,Inrermediste,Pharmacokinetic parameter AUC after intravenous administration to dogs,Canis lupus familiaris,9615.0
5437,,,,A,,,fAO00p0218,N,16367,xHEMBL62257y,,,,,jntermfdiate,Pharmacokinetic parameter AUC after oral administration to dogs,Canis lupus familiaris,9615.0
5438,,,,A,,,BAO0000229,N,9579,CHEMBL6q257y,,,,,Intermdsiate,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Canis lupus familiaris,9615.0
5439,,,,A,,,BAO00p0118,N,9579,CjEMBL6q2577,,,,,Intermediwtr,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Canis lupus familiaris,9615.0
5440,,,,A,,,BAO0000ww8,N,5983,CHEMBL62e568,,,,,Intsrmfdiate,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris,9615.0
5441,,,,A,,,BwO00p0218,N,6241,CuEMBL62q579,,,,,Interhediatr,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
5442,,,,A,,,BqO000021u,N,5313,CHEMBL722590,,,,,Imterm2diate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Canis lupus familiaris,9615.0
5443,,,,A,,,BwO0000228,N,5313,CH2MnL622581,,,,,untermwdiate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Canis lupus familiaris,9615.0
5444,,,,A,,,BAOo0002w8,N,6642,vHEMBL622572,,,,,Interkeriate,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,9615.0
5445,,,,A,,,BAk0000318,N,6642,CHEjBL6225i3,,,,,jntermediatr,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,9615.0
5446,,,,A,,,BqO00o0218,N,6641,CHEjBL62w584,,,,,9nteemediate,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris,9615.0
5447,,,,A,,,gAO000021u,N,6642,CyEMvL622585,,,,,Int2rmediaye,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris,9615.0
5448,,,,A,,,BA0000p218,N,17791,CHEMBL6225iu,,,,,Inte4jediate,Compound was evaluated for oral bioavailability in dog; 90-100,Canis lupus familiaris,9615.0
5449,,,,A,,,BA80009218,N,17655,CHEMBLy23291,,,,,Ijte4mediate,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Canis lupus familiaris,9615.0
5450,,,,A,,,nAO0000228,N,17655,CHEMBo62e282,,,,,Intermed9aye,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Canis lupus familiaris,9615.0
5451,,,,A,,,BAO09002w8,N,6596,CHEMBL723e83,,,,,Intermediagw,PAPP (membrane permeability) in dog kidney cell monolayer assay,Canis lupus familiaris,9615.0
5452,,,,A,,,BzO00p0218,N,3880,CHEMBL6232o5,,,,,9ntermedoate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5453,,,,A,,,BAO00002qi,N,16367,CHEMBLy2328r,,,,,onterkediate,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Canis lupus familiaris,9615.0
5454,,,,A,2360505.0,0lasma,nAp0000218,N,17409,CHEMBL523473,,,,,jntermeeiate,Plasma protein binding towards dog plasma at 10 uM,Canis lupus familiaris,9615.0
5455,,,,A,1777153.0,Pkasma,BAOp000q18,N,17409,fHEMBL875i52,,,,,Infermediste,Plasma protein binding towards dog plasma at 100 uM,Canis lupus familiaris,9615.0
5456,,,,A,,,vAO00002w8,N,2959,CHEhBL62170r,,Invovo,,,Intsrmedia4e,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris,9615.0
5457,,,,A,,,BAO0000qw8,N,13501,CHEMBL611i06,,8nvivo,,,Inteemediafe,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Canis lupus familiaris,9615.0
5458,,,,A,,,BAO000p21i,N,4527,fHEMBLt21707,,Invibo,,,Intermevia5e,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,9615.0
5459,,,,A,,,vAO00o0218,N,15145,vHEMBL6217o8,,Ingivo,,,Inte5medoate,Bioavailability in dogs,Canis lupus familiaris,9615.0
5460,,,,A,,,BAO0009118,N,4219,CHEhBL6e1709,,unvivo,,,unterm2diate,Bioavailability,Canis lupus familiaris,9615.0
5461,,,,A,,,BAO0p0p218,N,17538,CmEMBL621u10,,Ingivo,,,Intwrmedizte,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
5462,,,,A,,,BAOp090218,N,17538,CHEkBo621711,,Invigo,,,Igtermediqte,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Canis lupus familiaris,9615.0
5463,,,,A,,,BsO00o0218,N,1466,CjEMnL621712,,Invido,,,Interm3diatw,Bioavailability in dog (dose 10.0 mg/kg p.o.),Canis lupus familiaris,9615.0
5464,,,,A,,,BA80o00218,N,17650,dHEMfL621713,,Invido,,,Ijtermesiate,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,9615.0
5465,,,,A,,,BsO0000219,N,3132,CyEMBL721714,,Invlvo,,,Intermrdizte,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Canis lupus familiaris,9615.0
5466,,,,A,,,BAOp000q18,U,2413,CmEhBL621715,,,,,Autocura4i0n,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5467,,,,A,548738.0,Luver,BqO000p218,U,2413,fHEMBLt23717,,,,,Aut0curati9n,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5468,,,,A,4525188.0,Ljver,BAO00op218,U,2413,CHEkBp623718,,,,,A8ticuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,10095.0
5469,,,,A,431857.0,Lider,BAO09o0218,U,2413,CbEMBi623719,,,,,Autocurqtoon,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5470,,,,A,,,BsO0000q18,U,2413,CgEMBL623730,,,,,Autoxurati0n,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5471,,,,A,,,BsO0o00218,U,2413,CgEMBp623721,,,,,A7tocuratioh,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5472,,,,A,2420218.0,juscletizsue,BAO0090219,U,2413,fHEMBL62372w,,,,,Aut9ciration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5473,,,,A,1010909.0,Muxcletiswue,BsO000021u,U,2413,CHEMBp6237e3,,,,,Aufocu4ation,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,10095.0
5474,,,,A,723586.0,huscldtissue,Bz80000218,U,2413,CHEjBo618543,,,,,Autocura6iob,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5475,,,,A,3361442.0,Spleeg,BAO00p02q8,U,2413,CHEMBp61u544,,,,,Autocu5atioh,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5476,,,,A,473032.0,Spieen,BAO00003w8,U,2413,vHEMfL875155,,,,,Auf0curation,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5477,,,,A,,,BAOp000w18,U,2413,CHEMfL618y45,,,,,Autoc8ratipn,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,10095.0
5478,,,,A,,,BAO0000qq8,U,2413,CHEMBL619y46,,,,,Auticurqtion,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,10095.0
5479,,,,A,,,BAO0000w1u,U,2413,CHEkBL623528,,,,,wutocurati0n,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5480,,,,A,,,hxO0000218,U,2413,CyEMBL623539,,,,,Autpcuratipn,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,10095.0
5481,,,,A,,,BAl0000318,U,2413,CHEMBo621774,,,,,A66ocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,10095.0
5482,,,,A,,,BAO00o0p19,U,17827,CHEjBL62176r,,,,,Autocurzt7on,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae,9527.0
5483,,,,A,3645933.0,C4rebelkum,BAO9000p19,U,17827,CHEMBL621777,,,,,Autocuratkin,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,9527.0
5484,,,,A,1378832.0,Fr8ntalcortdx,BAi0o00019,U,17827,CHEMBi521767,,,,,Autocuratj9n,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae,9527.0
5485,,,,A,,,BzO0000919,U,17827,CHEMBi721768,,,,,Autocurwtuon,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Cercopithecidae,9527.0
5486,,,,A,2084277.0,S5riatum,BA00000029,U,17827,dHEMBp621769,,,,,Autlcura5ion,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Cercopithecidae,9527.0
5487,,,,A,,,BAO0000o1p,U,17827,CmEMBL622770,,,,,Aufocurat7on,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae,9527.0
5488,,,,A,400847.0,Cedebrllum,BAO00oo019,U,17827,CHEMBL62w671,,,,,Autocurato8n,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,9527.0
5489,,,,A,3663030.0,Frobtalco5tex,BAOp000018,U,17827,dHEMBL611772,,,,,Aktoc6ration,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae,9527.0
5490,,,,A,,,vAO00000q9,U,17827,CHEjBL621763,,,,,Aurocuratioh,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Cercopithecidae,9527.0
5491,,,,A,2049718.0,Striatuk,BAO0900018,U,17827,CHEMBp631774,,,,,qutocu5ation,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,9527.0
5492,,,,A,,,BAp000021o,U,17791,dH2MBL621775,,,,,Au6ocurxtion,Compound was evaluated for oral bioavailability in rats,Cercopithecidae,9527.0
5493,,,,A,853606.0,Ppasma,BAO090021o,U,17667,CuEhBL621776,,Invigo,,,Autocugat9on,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Cercopithecidae,9527.0
5494,,,,A,,,BAOp00001i,U,17791,CHEMhL621787,,,,,Autlcuratiob,Half life period was evaluated in monkey,Cercopithecidae,9527.0
5495,,,,A,,,gAO0000e18,U,110,CHEMBi8u5162,,9nvivo,,,Autoci5ation,Half-life in rhesus monkeys by intravenous administration of dose,Cercopithecidae,9527.0
5496,,,,A,383014.0,Plaama,BA000002q8,N,5781,CH4MBk621778,,,,,In6ernediate,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Mus musculus,10090.0
5497,,,,A,1040522.0,9lasma,BzO0o00218,N,17734,CHEMBLtq1779,,,,,Intwrmeeiate,AUC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
5498,,,,A,3138878.0,Plaxma,hAO0009218,N,17718,CHEMBpu22479,,,,,Intermeeiwte,AUC value was determined after oral administration,Mus musculus,10090.0
5499,,,,A,,,BAp0000e18,N,4573,CuEjBL622480,,,,,Interm3dizte,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus,10090.0
5500,,,,A,,,BA90000q18,N,3277,fHEMBp622481,,,,,untermeriate,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,10090.0
5501,,,,A,,,BAO0p00228,N,2862,CHEMvL623482,,,,,untermediatr,Area under curve by ioral administration in mouse,Mus musculus,10090.0
5502,,,,A,,,BAO000921u,N,2862,CHEMBL522493,,,,,Ihtermedjate,Area under curve by iv administration in mouse,Mus musculus,10090.0
5503,,,,A,,,BAO900021u,N,5951,CyEMBL722484,,,,,Intermweiate,Area under curve at 0-8 hr in IRC mice after peroral administration,Mus musculus,10090.0
5504,,,,A,,,BAO90002q8,N,17729,CHwMBL62264w,,,,,Intermeduat4,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus,10090.0
5505,,,,A,,,BAi0000318,N,17728,CHEMBL622t43,,,,,unterjediate,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Mus musculus,10090.0
5506,,,,A,,,BAO0090e18,N,17728,CHEMBi62264r,,,,,Intrrmediare,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Mus musculus,10090.0
5507,,,,A,,,BAOp009218,N,17729,CydMBL622644,,,,,Interm4eiate,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus,10090.0
5508,,RPMI8227,,F,,,hAO00o0219,N,9424,CgEMBp622645,,,,,Intfrmedoate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,9606.0
5509,,RPnI8226,,F,,,BsO0009219,N,9424,CHEMBL722t46,,,,,In6ermedoate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,9606.0
5510,,RPMI8326,,F,,,BAOo00p219,N,9424,djEMBL621238,,,,,Intermeduage,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5511,,RPMI8e26,,F,,,BxO0090219,N,9424,CHEMBL6w123o,,,,,Int3rmediste,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5512,,RPMIu226,,F,,,Bq00000219,N,9424,CHsMBL621340,,,,,Ig4ermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5513,,RPMI8q26,,F,,,BA80000210,N,9424,CHEMBL62q141,,,,,7btermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,9606.0
5514,,RPMI8236,,F,,,BAOoo00219,N,9424,xyEMBL621242,,,,,unterm2diate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,9606.0
5515,,RPMI9226,,F,,,BAO000o2w9,N,9424,CHEnBo620350,,,,,In5ermedlate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5516,,RPMI8326,,F,,,BA0000021o,N,9424,CHEnBL62o351,,,,,Ihtermediat4,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,9606.0
5517,,RPMI8216,,F,,,BA00000119,N,9424,CHEhBi620352,,,,,Intefmedixte,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,9606.0
5518,,tPMI8226,,F,,,BxO00p0219,N,9424,CHEMBL620ry3,,,,,8ntermeduate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5519,,RlMI8226,,F,,,BxO9000219,N,9424,CHEMBL620365,,,,,Ijte3mediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,9606.0
5520,,5PMI8226,,F,,,BsO0o00219,N,9424,CuEMgL620355,,,,,Intermrdkate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5521,,RPM98226,,F,,,BAO900021o,N,9424,CjEMBL620e56,,,,,Intrrmedoate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,9606.0
5522,,RPjI8226,,F,,,BAO0900210,N,9424,CgEMBL6203r7,,,,,Int3gmediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,9606.0
5523,,RPM78226,,F,,,gAO0000218,N,9424,CHfMBL6q0358,,,,,lntermedixte,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,9606.0
5524,,RPMI82q6,,F,,,BAO00o0210,N,9424,CHEMhL62035p,,,,,Ezpert,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Homo sapiens,9606.0
5525,,RPM88226,,F,,,BsO0o00219,N,11544,CHEMBLt20369,,,,,7ntermediste,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Homo sapiens,9606.0
5526,,tPMI8226,,F,,,gAO000021i,N,17378,fH4MBL620361,,,,,7ntedmediate,Cytotoxicity of compound against 8226/DOX1V cells,Homo sapiens,9606.0
5527,,RPMI822u,,F,,,BxO00002w9,N,17378,dHEMBo620362,,,,,Intrrmediage,Cytotoxicity of compound against 8226/S cells,Homo sapiens,9606.0
5528,,RPMI8e26,,F,,,BAO0090218,N,17079,sgEMBL620363,,,,,Inhermediwte,Inhibitory concentration against 8226 myeloma cancer cell line,Homo sapiens,9606.0
5529,,RPMj8226,,F,,,BA90000q19,N,17079,CHEMBL6203y5,,,,,Inte4media6e,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Homo sapiens,9606.0
5530,,833K,,F,,,hAO000p219,N,13466,fHEMBL62o365,,,,,Intsrmedia6e,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Homo sapiens,9606.0
5531,,833K,,F,,,BAO09002w9,N,13466,vHEMBi620366,,,,,Imt3rmediate,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Homo sapiens,9606.0
5532,,833K,,F,,,BAO000p119,N,2392,CyEMBL62036u,,,,,Exp4rt,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Homo sapiens,9606.0
5533,,833K,,F,,,BA80o00219,N,2392,CHEnBL630368,,,,,Interm2doate,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Homo sapiens,9606.0
5534,,,,B,,,BAO00p0o19,U,6608,sHEMBL62o369,,,,,Autosurayion,Inhibitory activity against caspase-1,,
5535,,,,B,,,BzO00003r7,H,10199,sHsMBL620370,,,,,Aitocuratjon,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Enterococcus faecalis,1351.0
5536,,8i01BC,,F,,,BAO0009210,N,17749,CHEMhL620471,,,,,kntegmediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Homo sapiens,9606.0
5537,,8701Bs,,F,,,BzO0000w19,N,17749,CHEjBo620372,,,,,In5erhediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Homo sapiens,9606.0
5538,,,,F,,,BAk000001o,U,1229,CH4MBL876493,,,,,Imterhediate,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,
5539,,,,F,,,BAO000p010,U,1229,CHEMBL6203u4,,,,,7nt3rmediate,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,
5540,,,,F,,,BwO000001p,U,1229,CHEMBL62p3i4,,,,,Intermeejate,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,
5541,,,,B,,,BqO000p019,U,6390,CuEhBL620375,,,,,Autochrztion,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,
5542,,,,F,,,BAOp090019,U,16219,CHEMBL857i92,,,,,Autocu5atipn,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes,1314.0
5543,,,,F,,,vAO0000029,U,16219,CHEMfL6203y6,,,,,Autocu4atlon,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes,1314.0
5544,,,,B,,,BsO0000r57,H,17043,fHEMBL62p377,,,,,Autocurztiob,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,
5545,,KB,,F,,,BAO0o002w9,N,6929,CHEnBL62o378,,,,,7ntermrdiate,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens,9606.0
5546,,KB,,A,,,BAO0p00e19,N,6929,CtEMBL610379,,,,,untermedlate,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens,9606.0
5547,,,,F,,,BzO000021p,U,7083,CnEMBL620280,,,,,Autocirwtion,In vitro cytotoxicity of compound was tested against 9KB cells.,Homo sapiens,9606.0
5548,,9L,,F,,,vAO00002w9,N,12446,vHEMBL8840o6,,,,,Inhermedia6e,Cytotoxic concentration against 9L cells was determined on day 3,Rattus norvegicus,10116.0
5549,,9L,,F,,,BAO0090w19,N,15345,CHEMBL6q03i1,,,,,Expe3t,Tested in vitro for anticancer activity against 9L cells,Rattus norvegicus,10116.0
5550,,9L,,F,,,BAO000o119,N,15345,CHfMBL620381,,,,,Ex0ert,Tested in vitro for anticancer activity against 9L cells; Not determined,Rattus norvegicus,10116.0
5551,,A549,,F,,,BAk0000w19,N,6301,CHEjBL620483,,,,,Intefmediaye,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Homo sapiens,9606.0
5552,,A549,,F,,,BAOpp00219,N,4833,CH4MBL875493,,,,,jntermediaye,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Homo sapiens,9606.0
5553,,A549,,F,,,BA00000218,N,4833,CurMBL620384,,,,,Intermev9ate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Homo sapiens,9606.0
5554,,A549,,F,,,BAOp000218,N,4833,sH3MBL620385,,,,,Ibtegmediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Homo sapiens,9606.0
5555,,A549,,F,,,fAO0000319,N,13330,CH2MBL520386,,,,,rxpert,Cytotoxicity against human lung carcinoma A549 cell line,Homo sapiens,9606.0
5556,,A549,,F,,,gAOp000219,D,17517,vmEMBL620387,,,,,Expery,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Homo sapiens,9606.0
5557,,A549,,F,,,BAO0o90219,D,17517,CHEMBo62140e,,,,,Experf,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Homo sapiens,9606.0
5558,,A549,,F,,,BAO00002q8,N,14425,CHEMBLuq1405,,,,,Intermeria5e,"In vitro growth inhibition of A549, lung carcinoma",Homo sapiens,9606.0
5559,,A549,,F,,,BAO0099219,N,14425,CHEkBp621406,,,,,Intermediwtw,"In vitro growth inhibition of A549, lung carcinoma.",Homo sapiens,9606.0
5560,,A549,,F,,,BAO0p002q9,N,5228,CHEMBL6214py,,,,,Expe4t,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
5561,,A549,,F,,,vAO00002w9,N,5351,CHEjBL621r08,,,,,Inte3med9ate,Cytotoxic activity against human lung cancer A549 cell line was determined,Homo sapiens,9606.0
5562,,A549,,F,,,BAO000p119,N,12198,sHEhBL885345,,,,,Exoert,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Homo sapiens,9606.0
5563,,A549,,F,,,BAO00o021i,N,13891,CHEnBL621509,,,,,untermed8ate,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Homo sapiens,9606.0
5564,,A549,,F,,,BAp00002q9,N,5677,fHEMBL886034,,,,,dxpert,Cytotoxicity in A549 (human carcinoma) cell line.,Homo sapiens,9606.0
5565,,A549,,F,,,nwO0000219,N,13788,CtEMBL621420,,,,,Ijt3rmediate,Cytotoxicity on lung carcinoma (A-549) cell line,Homo sapiens,9606.0
5566,,A549,,F,,,BAi000021i,N,13384,CHEMnL621421,,,,,dxpert,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Homo sapiens,9606.0
5567,,A549,,F,,,gAO9000219,N,6726,CnEMBLy21412,,,,,Ihtermedjate,Effective dose of compound against replication of A549 cell line was evaluated,Homo sapiens,9606.0
5568,,A549,,F,,,BAOp090219,N,3455,CH2MBi621413,,,,,Edpert,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Homo sapiens,9606.0
5569,,A549,,F,,,BA900002w9,N,5726,CH3MBp621414,,,,,onyermediate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Homo sapiens,9606.0
5570,,A549,,F,,,BAO00p0q19,N,5726,CHEMhL62141y,,,,,jntermed9ate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Homo sapiens,9606.0
5571,,A549,,F,,,BA80000229,N,3936,xHsMBL621416,,,,,Interm2diste,The compound was evaluated for antiproliferative activity against A549 cell line,Homo sapiens,9606.0
5572,,A549,,F,,,BwO000o219,N,14991,CyEMBL621427,,,,,7ntdrmediate,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Homo sapiens,9606.0
5573,,A549,,F,,,BAO000p21i,N,5243,CHdMBL6214q8,,,,,Intsrmeeiate,Concentration required for growth inhibition of human lung carcinoma cell line A549,Homo sapiens,9606.0
5574,,A549,,F,,,Bzi0000219,N,12858,CtEMBLy21419,,,,,Interm4dia4e,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Homo sapiens,9606.0
5575,,A549,,F,,,BAO0000q10,N,6776,CHEMBL521r20,,,,,onterkediate,Growth inhibition against A549 cell line was evaluated,Homo sapiens,9606.0
5576,,A549,,F,,,fAO000021i,N,16558,CHEnBL8i5823,,,,,Integmediare,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Homo sapiens,9606.0
5577,,A549,,F,,,BqO0o00219,N,4583,CHEMBLu21321,,,,,Expegt,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Homo sapiens,9606.0
5578,,A549,,F,,,BwO0000218,N,13514,CHEMfL62w422,,,,,Interkeriate,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Homo sapiens,9606.0
5579,,A549,,F,,,BA9000p219,N,15166,CgEMBL884o14,,,,,Ezpert,Chemosensitivity against DT-diaphorase rich A549 cell lines,Homo sapiens,9606.0
5580,,A549,,F,,,vAO0000319,N,13873,CHrMBL621422,,,,,jntermedoate,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens,9606.0
5581,,A549,,F,,,BAO09002w9,N,6447,CHEMBL6w14e4,,,,,wxpert,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Homo sapiens,9606.0
5582,,A549,,F,,,BAO09002w9,N,2068,CbEnBL621425,,,,,Intermed8ste,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Homo sapiens,9606.0
5583,,A549,,F,,,BwO00p0219,N,1863,CHEMBp621t26,,,,,Expdrt,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Homo sapiens,9606.0
5584,,A549,,F,,,gAO0000119,N,13873,CH2MgL621427,,,,,Int2rkediate,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Homo sapiens,9606.0
5585,,A549,,F,,,nAOo000219,N,13873,CjEMBL6e1428,,,,,Intermwdiwte,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens,9606.0
5586,,A549,,F,,,BAO0000q10,N,13873,fHEMBL622429,,,,,Exp2rt,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens,9606.0
5587,,A549,,F,,,BAO00902w9,N,579,CyEMBL6q1430,,,,,Intefmediwte,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Homo sapiens,9606.0
5588,,A549,,F,,,BAO0000228,N,579,CHEhvL621431,,,,,Imtermediat2,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Homo sapiens,9606.0
5589,,A549,,F,,,BAO9000w19,N,4584,CtEMBL621e32,,,,,Intermwdlate,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Homo sapiens,9606.0
5590,,A549,,F,,,BqO0o00219,N,5421,CHEMBL62w443,,,,,Expwrt,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Homo sapiens,9606.0
5591,,A549,,F,,,vAOo000219,N,5421,CyEkBL875824,,,,,Inte4msdiate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens,9606.0
5592,,A549,,F,,,BAO0909219,N,5421,vHEMBLy21434,,,,,Infetmediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens,9606.0
5593,,A549,,F,,,nAO000p219,N,5421,CbEMBL621535,,,,,lntermedia6e,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Homo sapiens,9606.0
5594,,A549,,F,,,Bqk0000219,N,14188,xHEMBL62w436,,,,,Ijrermediate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Homo sapiens,9606.0
5595,,A549,,F,,,BsO000p219,N,14188,CHwjBL621437,,,,,Intfrmfdiate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Homo sapiens,9606.0
5596,,A549,,F,,,BAO00p9219,N,15354,CHsMBL62q438,,,,,In6efmediate,Compound was tested for the growth inhibition of A549 lung tumor cell line,Homo sapiens,9606.0
5597,,A549,,F,,,BzO0000229,N,14253,CHwjBL621439,,,,,3xpert,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Homo sapiens,9606.0
5598,,A549,,F,,,BwO000021o,N,13873,CmEMnL621440,,,,,In5ermediat2,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens,9606.0
5599,,,,A,,,BAO009021o,N,3043,CHEMBL7214r1,,Ibvivo,,,Intrrmeeiate,Oral bioavailability in dog (conscious),Canis lupus familiaris,9615.0
5600,,,,A,,,vAO000021u,N,3045,CHfkBL621442,,Imvivo,,,lntermediqte,Compound was evaluated for the oral bioavailability after oral administration in dog.,Canis lupus familiaris,9615.0
5601,,,,A,,,BAO00o0228,N,3022,CtEnBL621443,,Ibvivo,,,knfermediate,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Canis lupus familiaris,9615.0
5602,,,,A,,,BAOo090218,N,4453,CyEMBL621e44,,Inviv0,,,Intermrdiaye,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5603,,,,A,,,BwO0000228,N,1696,CHEMBL635w33,,Invivi,,,8n5ermediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5604,,,,A,,,fAO000021o,N,5045,fHEMBi625134,,Inv9vo,,,Int2rmediste,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5605,,,,A,,,BAO00002w9,N,5356,CHEMvLy25135,,Invivk,,,Interm2duate,Oral bioavailability in dog (fasted),Canis lupus familiaris,9615.0
5606,,,,A,,,BAO0000317,N,17764,sHEMBL625236,,Inv9vo,,,Intermesiats,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
5607,,,,A,,,BAO000p21o,N,6448,CHrMBL6251e7,,Invivp,,,7nterkediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5608,,,,A,,,BAO00o0228,N,1475,CjEMBL625137,,Incivo,,,Intermedjste,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5609,,,,A,,,BAO0900q18,N,3788,CgEMfL625139,,Inviv9,,,Ihtermediage,Percent bioavailability in dog,Canis lupus familiaris,9615.0
5610,,,,A,,,nAO00p0218,N,3639,CHEMBo87q264,,Infivo,,,Intwrmwdiate,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Canis lupus familiaris,9615.0
5611,,,,A,,,BAO00p0q18,N,13397,CHsMBL625q40,,Inbivo,,,Int4rmedia6e,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5612,,,,A,,,nAO0000219,N,2137,CHEMBk614436,,Inv9vo,,,Intdrmed8ate,The compound was evaluated for bioavailability in dogs; 34-44,Canis lupus familiaris,9615.0
5613,,,,A,,,BAO0p00w18,N,2959,CHEMBL614537,,Invivp,,,kntermeviate,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris,9615.0
5614,,,,A,,,BAO0o00217,N,6448,CHEkBo872261,,unvivo,,,kntermediats,Oral bioavailability in dog,Canis lupus familiaris,9615.0
5615,,,,A,,,nAO0000e18,N,6084,CH3MBk624438,,,,,Intfrm2diate,8 hour trough Blood level in dog was measured after administration of compound,Canis lupus familiaris,9615.0
5616,,,,A,1911720.0,Plazma,BAO0009118,N,3639,CHEjBL624449,,Invido,,,Intetmedixte,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Canis lupus familiaris,9615.0
5617,,,,A,,,BAO0009228,N,6316,CHEngL624440,,,,,8ntermeeiate,C24 after oral administration at 5 mg/kg,Canis lupus familiaris,9615.0
5618,,,,A,,,BAO0op0218,N,5238,CH3MBL6244e1,,,,,Intermeciafe,Clearance after oral and iv dosing in dogs,Canis lupus familiaris,9615.0
5619,,,,A,3243235.0,Plqsma,BAOp000217,N,17796,vHdMBL624442,,,,,Intermeviats,Clearance of the drug was measured in the plasma of dog,Canis lupus familiaris,9615.0
5620,,,,A,,,BAO0oo0218,N,2652,CHEMBk624t43,,,,,Igterm2diate,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Canis lupus familiaris,9615.0
5621,,,,A,,,BwO0000228,N,5654,vgEMBL624444,,Incivo,,,Intetmrdiate,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5622,,,,A,,,BxO0000228,N,6621,CyEMBLu24445,,Infivo,,,Intermedis5e,Clearance of compound was determined in dogs,Canis lupus familiaris,9615.0
5623,,,,A,,,BxO00o0218,N,6505,sHEjBL624446,,Invico,,,Intdrmedkate,Clearance on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,9615.0
5624,,,,A,,,BAO00o02w8,N,5802,CyEMBL624e47,,Incivo,,,lntermediaye,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,9615.0
5625,,,,A,,,BAO000022u,N,17267,CjEMBL62e448,,Inv7vo,,,Integmefiate,Plasma clearance in dog was determined,Canis lupus familiaris,9615.0
5626,,,,A,,,BxO00o0218,N,4521,CHEMBL634459,,Invlvo,,,7ntermewiate,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,9615.0
5627,,,,A,,,BAk0o00218,N,6535,CgEMBp624450,,Invigo,,,Imtermeeiate,Plasma clearance in dog after administration of 0.25 mg/kg iv,Canis lupus familiaris,9615.0
5628,,,,A,,,BsO0900218,N,6535,sHEMBL874942,,Invido,,,Intwrmediage,Plasma clearance in dog after administration of 1 mg/kg iv,Canis lupus familiaris,9615.0
5629,,,,A,,,BzO0000318,N,6535,CHEMBot24451,,Invivi,,,Intermewuate,Plasma clearance in dogs,Canis lupus familiaris,9615.0
5630,,,,A,,,BAk0000w18,N,5542,CHEMBLy2445q,,Infivo,,,Intetmedia6e,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,9615.0
5631,,,,A,,,BAO000o2w8,N,5199,CHsMBL624463,,Invivi,,,Igtermeeiate,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris,9615.0
5632,,,,A,,,gAO000021o,N,16907,CHrMBL62r454,,Inbivo,,,Internediat2,Plasma clearance after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
5633,,,,A,,,gA90000218,N,16907,CH2hBL624455,,Imvivo,,,Ibt3rmediate,Plasma clearance after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
5634,,,,A,,,BAO0o90218,N,16367,CuEMBk624456,,Inviv9,,,Intermed8zte,Plasma administration to dogs,Canis lupus familiaris,9615.0
5635,,,,A,,,BwO0o00218,N,5505,fHEMBL724457,,7nvivo,,,Intermedja5e,Plasma clearance was determined,Canis lupus familiaris,9615.0
5636,,,,A,,,BAOp000q18,N,6215,CHEMnL62445i,,Inviv8,,,Infermediwte,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
5637,,,,A,,,nAO0090218,N,1466,Cn2MBL624459,,Imvivo,,,Interjedjate,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
5638,,,,A,1630874.0,L9ver,BAO000o25q,S,5007,CHEMBL614r60,,Inv8tro,,M8crksomes,Int3rmwdiate,Intrinsic clearance in human liver microsomes,Homo sapiens,9606.0
5639,,,,A,390414.0,Livdr,BA00000252,S,5007,CbEMBL524461,,Invltro,,Mifrosomez,Im5ermediate,Intrinsic clearance in human liver microsomes,Homo sapiens,9606.0
5640,,,,A,,,BA00009218,N,16452,CHEMfLi75943,,Invlvo,,,Ihtermediatw,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,9615.0
5641,,,,A,,,nAO0000e18,N,16452,CHEMhL624472,,Infivo,,,Intsrmfdiate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,9615.0
5642,,,,A,,,BxO000o218,N,16452,CHEMBL6244tr,,Imvivo,,,Int4rmediatr,Clearance in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,9615.0
5643,,,,A,,,nAi0000218,N,6221,CyEMBL724464,,Ibvivo,,,Igtermexiate,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,9615.0
5644,,,,A,,,BAO0p00w18,N,5007,fHEnBL624465,,Indivo,,,ontermedizte,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,9615.0
5645,,,,A,,,BAO0o0o218,N,5668,CHEMgLu24466,,Igvivo,,,Intwrmsdiate,Plasma clearance after peroral administration at 10 mpk in dog,Canis lupus familiaris,9615.0
5646,,,,A,,,hAO00002w8,N,5668,CHEMBL63e467,,Infivo,,,Intermex9ate,Plasma clearance after peroral administration at 5 mpk in dog,Canis lupus familiaris,9615.0
5647,,,,A,,,BAO0000q1o,N,5668,CHEMBLt2446o,,Ingivo,,,Interneriate,Plasma clearance after peroral administration at 5 mg/kg in dog,Canis lupus familiaris,9615.0
5648,,,,A,,,BAk00p0218,N,15660,CH2MBi624469,,Ingivo,,,Inyernediate,Plasma clearance was measured in dog,Canis lupus familiaris,9615.0
5649,,,,A,,,BAO00o021o,N,15660,CmEMBL6q4470,,Invuvo,,,9ntrrmediate,Plasma clearance was measured in dog,Canis lupus familiaris,9615.0
5650,,,,A,,,BA80000w18,N,5983,CHEhnL624471,,Invico,,,Intermedlatd,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris,9615.0
5651,,,,A,,,BAO00o0118,N,5600,CnEMBL6244i2,,Inbivo,,,Intermexiat3,Total clearance was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris,9615.0
5652,,,,A,,,BAl0000w18,N,17764,CHEMBo62e775,,Indivo,,,Intermeriqte,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
5653,,,,A,,,BqO0p00218,N,6039,dHEMBL6227i6,,Inv8vo,,,Interjrdiate,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris,9615.0
5654,,,,A,,,BAO0p00q18,N,6039,CHEMBL6w3777,,Ijvivo,,,8ntermed9ate,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris,9615.0
5655,,,,A,,,BAOp0002w8,N,6039,CbEMBL62e778,,8nvivo,,,In4ermedia6e,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris,9615.0
5656,,,,A,,,Bzl0000218,N,4368,CHEjBL62q779,,Ibvivo,,,Interjeciate,Clearance by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,9615.0
5657,,,,A,,,BwO000021i,N,4305,CHEMBL62q7i0,,Inv9vo,,,Ibtermediat2,Clearance by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5658,,,,A,1887230.0,Plzsma,fAO00o0218,N,1918,CHEMBL63278w,,knvivo,,,7ntermedia5e,Clearance value was evaluated in dog plasma,Canis lupus familiaris,9615.0
5659,,,,A,,,BAO0900217,N,6005,CHEMBLt22792,,Invifo,,,Intwrjediate,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5660,,,,A,2102550.0,0lasma,BAO0o0o218,N,4839,CHEMBp622883,,Invuvo,,,Interjediafe,Compound was tested for plasma clearance in dog,Canis lupus familiaris,9615.0
5661,,,,A,,,BAO0p0p218,N,4239,suEMBL622784,,Inv8vo,,,Intermed9atw,Pharmacokinetic property (Plasma clearance) was measured in dog,Canis lupus familiaris,9615.0
5662,,,,A,,,BAO090021i,N,17729,CHEnBL632785,,,,,kntermed7ate,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Mus musculus,10090.0
5663,,,,A,,,BAO0000229,N,17728,CHwMnL622786,,,,,Intermedoat2,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Mus musculus,10090.0
5664,,,,A,,,vwO0000218,N,5302,dHEMBL622786,,,,,Intermedia52,Area under curve value in mouse at a dose of 10 mg/kg,Mus musculus,10090.0
5665,,,,A,,,BAO0000q19,N,5506,CbEkBL875949,,,,,Inte3mexiate,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,10090.0
5666,,,,A,,,BAO000022o,N,5506,CHEMBL522787,,,,,Inhedmediate,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,10090.0
5667,,,,F,,,BAO0000w19,N,17764,CHEMhL622y89,,,,,Intrrmed7ate,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,10090.0
5668,,,,F,,,BzO0000318,N,17764,CHEMBo6q2790,,,,,Ibterjediate,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,10090.0
5669,,,,F,,,BA90o00218,N,17764,CHEMBL62wy91,,,,,Intfrmedixte,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,10090.0
5670,,,,F,,,BqO00o0218,N,17764,CHEMBL6q3792,,,,,knterkediate,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,10090.0
5671,,,,A,,,fAO00o0218,N,17764,CHEMBL613793,,,,,untermediat3,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
5672,,,,A,,,BAO000921u,N,17753,CHEhBL722794,,,,,Ibtegmediate,Area under curve was determined for the compound at 24 mg/Kg,Mus musculus,10090.0
5673,,,,A,,,BAk00002q8,N,17753,CHsMBk622795,,,,,Intermeduahe,Area under curve was determined for the compound at 40 mg/Kg,Mus musculus,10090.0
5674,,,,A,,,BsO0000e18,N,17753,CHEMBLy2180w,,,,,kntermedia5e,Area under curve was determined for the compound at 5 mg/Kg,Mus musculus,10090.0
5675,,,,A,,,BAO0p90218,N,3132,sHEMBL62q804,,,,,Ingetmediate,Area under the curve for the compound is obtained at dose 25 mg/kg,Mus musculus,10090.0
5676,,,,A,,,BAO0900228,N,3132,CbEMBLu21805,,,,,Inferjediate,Area under the curve for the compound was obtained when tested in mouse,Mus musculus,10090.0
5677,,,,A,,,BqO000021o,N,17837,CtEMBL521806,,,,,Intwrkediate,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,10090.0
5678,,,,A,,,BAO9p00218,N,17837,CHEMBp621u07,,,,,Inteemeduate,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus,10090.0
5679,,,,A,,,BAO00op218,N,6062,vHEMBLy21808,,,,,Interjeriate,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,10090.0
5680,,,,A,,,BsO0000318,N,4066,xHEkBL621809,,,,,Intermec8ate,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,10090.0
5681,,,,A,,,BAOp009218,N,16597,sHEMBL622810,,,,,Interjediqte,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus,10090.0
5682,,,,A,,,BAO0op0218,N,14239,sHEMhL875164,,,,,unterhediate,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Mus musculus,10090.0
5683,,,,A,,,BqO0o00218,N,14239,CHEMfi621811,,,,,Intermwciate,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Mus musculus,10090.0
5684,,,,A,,,BAOp00o218,N,4890,CHEhBL6218w2,,,,,Intefmedizte,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Mus musculus,10090.0
5685,,,,A,,,gA00000218,N,429,CHEMBLy21814,,,,,ontermedixte,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Mus musculus,10090.0
5686,,,,A,,,nAO0090218,N,429,CHEMBLy2q814,,,,,lntermrdiate,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Mus musculus,10090.0
5687,,,,A,,,BAl0o00218,N,5969,CHEnBL62181t,,,,,9ntermediatf,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,10090.0
5688,,,,A,,,BAO00o02q8,N,5969,CHEkvL621816,,,,,unrermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,10090.0
5689,,,,A,,,hAO00o0218,N,5969,CHEnBLu21817,,,,,Ijtermedia5e,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,10090.0
5690,,,,A,,,BAO00092q8,N,6091,CgEMnL621818,,,,,Intwrmedixte,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Mus musculus,10090.0
5691,,,,A,,,gAp0000218,N,6091,CHEMBL631810,,,,,Ihternediate,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Mus musculus,10090.0
5692,,,,A,,,BAOp000e18,N,6091,CHEMBp611820,,,,,Igtermed7ate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Mus musculus,10090.0
5693,,,,A,,,BAO000p228,N,6091,CHEMBL631822,,,,,In4erjediate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Mus musculus,10090.0
5694,,,,A,,,BAOp009218,N,6178,CHEMBLy21i22,,,,,Inteemeciate,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Mus musculus,10090.0
5695,,,,A,,,BwO0o00218,N,6178,CtEMBL6w9474,,,,,Intermedis4e,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Mus musculus,10090.0
5696,,,,A,,,BA900p0218,N,6619,CHEMBL61p47y,,,,,Int4rmeriate,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus,10090.0
5697,,,,A,,,BA8000021u,N,6619,CHEMBL61p4i6,,,,,kntermediatr,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus,10090.0
5698,,,,A,,,BsO0009218,N,3760,CHEMBL61o577,,,,,Intsrmediqte,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Mus musculus,10090.0
5699,,,,A,,,nqO0000218,N,3760,CHEMBL61948u,,,,,Inf2rmediate,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Mus musculus,10090.0
5700,,,,A,,,BwO9000218,N,3760,Ct4MBL619479,,,,,Intdrmediage,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Mus musculus,10090.0
5701,,,,A,,,BAi0000219,N,3760,CHEMBL71948p,,,,,Imtermed9ate,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Mus musculus,10090.0
5702,,,,A,,,BAl0000e18,N,3192,CHEMBL61958w,,,,,Intermexia6e,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Mus musculus,10090.0
5703,,,,A,,,BsO0000228,N,3192,CHEMBL6qi482,,,,,kn4ermediate,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Mus musculus,10090.0
5704,,,,A,,,hAO0000q18,N,2675,CHEMBL519493,,,,,Intermrdiqte,Area under the curve was evaluated in mice after intravenous administration,Mus musculus,10090.0
5705,,,,A,,,BAO0o002w8,N,2675,CHEjBL61948e,,,,,Ibtermed8ate,Area under the curve was evaluated in mice after oral administration,Mus musculus,10090.0
5706,,,,A,1760169.0,Piasma,BzO0000217,N,16597,fHEMBp619485,,,,,Imternediate,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
5707,,,,A,1397861.0,Plazma,BAO9000228,N,16597,CHEMBkt19486,,,,,Int2rmesiate,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
5708,,,,A,,,BAO9009218,N,16597,CmEMBL610487,,,,,Interhedia4e,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus,10090.0
5709,,,,A,,,BxO0000217,N,17734,CH3MBL61948o,,,,,Integmexiate,AUMC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
5710,,,,A,1513605.0,Blopd,BAO0p00w18,N,7767,CbEjBL620106,,Inv9vo,,,Inteemeeiate,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Mus musculus,10090.0
5711,,9L,,F,,,BAO00p0q19,N,15345,CHEnBp620107,,,,,Intermsdiatw,The compound was tested in vitro for anticancer activity against 9L cells,,
5712,,,,F,,,BAO9000o19,U,2181,CHEkBk620283,,,,,Autocu4a4ion,Anti proliferation activity determined; Weak effect,Rattus norvegicus,10116.0
5713,,,,F,,,BAi00002w9,U,2181,CH3MBL875175,,,,,Autocitation,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus,10116.0
5714,,,,F,,,BAO0090w19,U,2181,CHEMhL62028r,,,,,Autovuratoon,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Rattus norvegicus,10116.0
5715,,,,F,,,Bqi0000219,U,2181,CHEMgL613515,,,,,Aktockration,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus,10116.0
5716,,,,F,,,BAO00o001i,U,10486,CHwMBL6235q6,,,,,Augocuratiln,The cytotoxic activity was in vitro tested by 9PS assay method,Mus musculus,10090.0
5717,,,,F,,,BA00000p19,U,10486,CHEMBL6wr517,,,,,Autocurahikn,The cytotoxic activity was in vitro tested by 9PS assay method.,Mus musculus,10090.0
5718,,,,A,,,BAO000p919,U,15508,CHEMgLo57878,,,,,Au6ocuratiin,Partition coefficient (logD6.5),,
5719,,Aw780,,F,,,BxO0p00219,N,5242,CHwMBL624518,,,,,Expfrt,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Homo sapiens,9606.0
5720,,A375,,F,,,BAOo00p219,N,16167,CHEMBk625195,,,,,Interjediwte,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Homo sapiens,9606.0
5721,,A431,,F,,,BAip000219,N,4782,vHEjBL624196,,,,,4xpert,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Homo sapiens,9606.0
5722,,A431,,F,,,BAOop00219,D,16093,CgEjBL624197,,,,,4xpert,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens,9606.0
5723,,A498,,F,,,BAO900021i,N,2596,CHrMBL62419o,,,,,Intermed9atr,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens,9606.0
5724,,A498,,F,,,gAO0000q19,N,2596,CHEMBLt21288,,,,,Intermeeiste,in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens,9606.0
5725,,A498,,F,,,BAk9000219,N,3239,CH4MBL6q1288,,,,,Iht2rmediate,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Homo sapiens,9606.0
5726,,A498,,F,,,BAO00o021o,N,1847,CHEMBL875497,,,,,Intermediwtw,Cytotoxic activity against A 498 renal cancer cell lines.,Homo sapiens,9606.0
5727,,A498,,F,,,BAi0p00219,N,10553,CHEkBL6212o9,,,,,In5ermeciate,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Homo sapiens,9606.0
5728,,,,F,,,hAO0o00019,U,16219,CmEMBL622290,,,,,zutocuratiom,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus,1280.0
5729,,,,F,,,BAO0o09019,U,16219,CmEMBL62129w,,,,,qutocu4ation,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus,1280.0
5730,,,,F,,,BAO000o01i,U,16219,CHEhBp621292,,,,,Autovurafion,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus,1280.0
5731,,,,F,,,BAO000901o,U,16219,xHEMBL622293,,,,,Aufocurarion,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus,1280.0
5732,,A549,,F,,,gAO0000218,N,4782,CHEhfL621294,,,,,Ijternediate,Inhibitory concentration required against A 549 lung cancer cell line,Homo sapiens,9606.0
5733,,A549,,F,,,BzO0000e19,N,11805,CHEMBL6e1195,,,,,Internediste,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Homo sapiens,9606.0
5734,,A549,,F,,,BsO0000229,N,11805,CHEMgL884907,,,,,Interjefiate,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Homo sapiens,9606.0
5735,,A549,,F,,,BAO0p00q19,N,2007,CHEkBL621q96,,,,,Interm3diste,In vitro cytotoxicity against lung cancer A 549 cell lines,Homo sapiens,9606.0
5736,,A549,,F,,,hAO000021i,N,4594,CH3MgL621297,,,,,Intf4mediate,Compound was tested for its cytotoxicity against A 549 cell line,Homo sapiens,9606.0
5737,,A549,,F,,,BA8000o219,N,6018,CHEMBL838u28,,,,,Expegt,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Homo sapiens,9606.0
5738,,A549,,F,,,BAOpp00219,N,6018,CHEkBLt20397,,,,,8ntermedia4e,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Homo sapiens,9606.0
5739,,A549,,F,,,BA000002q9,N,3599,CHEnBL620399,,,,,Ex9ert,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Homo sapiens,9606.0
5740,,A549,,F,,,BqO0p00219,N,2551,CHEMBi6203o9,,,,,Interhedlate,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens,9606.0
5741,,A549,,F,,,BqO00002w9,N,16132,CHEMBL62p4p0,,,,,Espert,In vitro inhibition of A549 (human lung cancer) cell growth.,Homo sapiens,9606.0
5742,,A549,,F,,,gAl0000219,N,16132,CHEjBL620501,,,,,onterjediate,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Homo sapiens,9606.0
5743,,A549,,F,,,BAO00o0e19,N,2551,CHEMgL62040w,,,,,Expfrt,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens,9606.0
5744,,A549,,F,,,BAO000022i,N,2551,CHwMvL620403,,,,,Expe4t,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Homo sapiens,9606.0
5745,,,,F,,,BAO00p02q8,U,11913,CHEMBo620494,,,,,zutovuration,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,
5746,,,,F,,,BAOp000q18,H,12621,xHEMBL620404,,Invico,,,Autosugation,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,
5747,,,,F,,,BAO000p21u,H,12621,xHEMBL6204p6,,Imvivo,,,Autocufatuon,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,
5748,,,,F,,,BAOo000228,H,12621,CH2MBL62p407,,Inviv0,,,Autocjrati8n,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,
5749,,,,F,,,BAO0000qw8,H,12621,xHEMBLu20408,,jnvivo,,,Autociratkon,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,
5750,,,,F,,,BAO0000e1i,H,12621,CHEhBL620t09,,Inviv8,,,Aut0curatikn,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,
5751,,A498,,F,,,vzO0000219,N,3600,CHEhBL629410,,,,,Experh,Inhibition of A-498 human Renal cell proliferation,Homo sapiens,9606.0
5752,,,,F,,,gwO0000019,U,1796,CuEMgL620411,,,,,Autocjgation,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Rattus norvegicus,10116.0
5753,,,,F,,,BxO00000q9,U,1796,CHEMBL62051w,,,,,Autocura68on,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Rattus norvegicus,10116.0
5754,,,,F,,,BAO900p019,U,1796,CHEMfLi76596,,,,,Aut8curatiob,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Rattus norvegicus,10116.0
5755,,A172,,F,,,gAO00002w9,N,16464,CHEMfL620423,,,,,Expdrt,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Homo sapiens,9606.0
5756,,A172,,F,,,BAO00o021o,N,16464,fHwMBL620414,,,,,Ijterkediate,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5757,,A172,,F,,,BAOo00p219,N,16464,CHEMBL629515,,,,,Intermedizfe,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5758,,A549,,F,,,BA80000q19,N,13617,CH2MBL6204w6,,,,,Ex9ert,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Homo sapiens,9606.0
5759,,A549,,F,,,BAO9090219,N,4584,CHEMBp62o417,,,,,Ihtermesiate,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Homo sapiens,9606.0
5760,,A549,,F,,,BAO090021i,N,13799,CHsjBL620418,,,,,Exoert,Cytotoxic activity evaluated against A549 tumor cells,Homo sapiens,9606.0
5761,,A549,,F,,,BzO9000219,N,16726,CHEMvL620t19,,,,,Intermedlatf,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Homo sapiens,9606.0
5762,,A549,,F,,,BAO00pp219,N,16109,CHEMBk6w0420,,,,,Intsrmediahe,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Homo sapiens,9606.0
5763,,A549,,F,,,nAO0000119,N,16109,CHEMBk62p421,,,,,Interm2diwte,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Homo sapiens,9606.0
5764,,A549,,F,,,fAO0000210,N,15474,sHEMBL6204q2,,,,,unrermediate,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Homo sapiens,9606.0
5765,,A549,,F,,,BAO90o0219,N,6851,dHfMBL620423,,,,,Inrernediate,Cytotoxicity of compound against A549 cell line,Homo sapiens,9606.0
5766,,A549,,F,,,BAO00o0229,N,17534,CHwMBL620414,,,,,Ex0ert,Cytotoxicity against human lung cell carcinoma A549 cell line,Homo sapiens,9606.0
5767,,A549,,F,,,hAO000p219,N,2621,CHEkBLu20425,,,,,Int2rmediatr,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Homo sapiens,9606.0
5768,,A549,,F,,,hAOp000219,N,830,CHEMBL6q0416,,,,,Inyermeeiate,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Homo sapiens,9606.0
5769,,A549,,F,,,hAO0900219,N,14255,CHEnBLy20427,,,,,Igtermedizte,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Homo sapiens,9606.0
5770,,A549,,F,,,BwO000p219,N,14255,CHEnBL62042o,,,,,Igtermediahe,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Homo sapiens,9606.0
5771,,A549,,F,,,BAO0p00w19,N,1590,CHEMBL6204qp,,,,,Ihtermediat2,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Homo sapiens,9606.0
5772,,A549,,F,,,BAO0o00229,N,6146,CHEnBL630430,,,,,Ezpert,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Homo sapiens,9606.0
5773,,A549,,F,,,BwO000p219,N,17427,vHEkBL839887,,,,,Eapert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
5774,,A549,,F,,,fAO00002w9,N,5280,sHEhBL620431,,,,,Internrdiate,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Homo sapiens,9606.0
5775,,A549,,F,,,BAO0o0o219,N,16786,CHrMBo884010,,,,,Intsrkediate,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Homo sapiens,9606.0
5776,,A549,,F,,,BAOo000w19,N,5895,CHEMBLu20638,,,,,7gtermediate,In vitro cytotoxicity against A549 (human lung cancer),Homo sapiens,9606.0
5777,,A549,,F,,,BAk000p219,N,14297,CHEMBL620r49,,,,,Expeft,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
5778,,A549,,F,,,vAO0000228,N,17824,vHEMBL62r373,,,,,Intermedkatw,In vivo antiproliferative activity against A549 cell line,Homo sapiens,9606.0
5779,,A549,,F,,,gAO0000w19,N,14368,xHEjBL623374,,,,,Intwrmed9ate,Inhibition of non-small-cell lung adenocarcinoma (A549),Homo sapiens,9606.0
5780,,A549,,F,,,BAO0pp0219,N,14368,CHEMBL5e3375,,,,,Imtermedixte,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Homo sapiens,9606.0
5781,,A549,,F,,,BAO9090219,N,14254,CHEMBLt13376,,,,,Ijtermedizte,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Homo sapiens,9606.0
5782,,A549,,F,,,BAOo0002q9,N,15897,xHEMBL62e377,,,,,8ntermddiate,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Homo sapiens,9606.0
5783,,A549,,F,,,BzOp000219,N,13866,CHEMBL6e337i,,,,,Imtermediat3,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens,9606.0
5784,,A549,,F,,,BAO090p219,N,13370,CHEMfLt23379,,,,,Internediatr,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Homo sapiens,9606.0
5785,,A549,,F,,,BAl00002q9,N,4862,dHEMBL6e3380,,,,,Interm4diare,Inhibitory activity against A549 lung cancer cell line,Homo sapiens,9606.0
5786,,A549,,F,,,BAO0o0o219,N,4862,CHEjBL6233i1,,,,,jntermwdiate,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Homo sapiens,9606.0
5787,,A549,,F,,,BAO090p219,N,4862,CHEMBL613383,,,,,Intermed7afe,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Homo sapiens,9606.0
5788,,A549,,F,,,BA99000219,N,15970,CnEMBL623r83,,,,,Ijtermediat2,Inhibitory concentration against A549 (lung cancer) cell line,Homo sapiens,9606.0
5789,,A549,,F,,,BAO009o219,N,17713,CjrMBL623384,,,,,Ezpert,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
5790,,A549,,F,,,BAO0090229,N,4833,CHsMfL623385,,,,,7nt4rmediate,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Homo sapiens,9606.0
5791,,A549,,F,,,BAO090021o,N,13736,CHEMBL6w3376,,,,,Exp2rt,Activity against A549 cancer cell line.,Homo sapiens,9606.0
5792,,A549,,F,,,BAOp000229,N,4312,CHEMBL874q05,,,,,Intermfd8ate,The compound was evaluated for cytotoxicity against A549 cell line,Homo sapiens,9606.0
5793,,A549,,F,,,BAO0p00218,N,5421,CHEMBLu24387,,,,,Ihtermed8ate,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Homo sapiens,9606.0
5794,,A549,,F,,,BAO90o0219,N,5421,CjEMBL6w1568,,,,,Interhedizte,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens,9606.0
5795,,A549,,F,,,BAO0p002q9,N,14717,CHEMBL6e156p,,,,,Intermedjatw,Growth inhibitory activity was measured for human A549 tumor cell line.,Homo sapiens,9606.0
5796,,A549,,F,,,BAO0990219,N,4634,CjEMBLt21570,,,,,ungermediate,Inhibitory activity against A549 lung cancer cell line,Homo sapiens,9606.0
5797,,A549,,F,,,BA80009219,N,1149,CHEMnL6215u1,,,,,Interkedkate,Inhibitory activity against A549 cell line; inactive,Homo sapiens,9606.0
5798,,A549,,F,,,BA8000p219,N,5421,CHEMgLt21572,,,,,Expeft,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens,9606.0
5799,,A549,,F,,,BAO0000220,N,5421,CgsMBL621573,,,,,Eapert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens,9606.0
5800,,A549,,F,,,BAO0000w1p,N,5421,CHEMBL621y7e,,,,,Intrrmedixte,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens,9606.0
5801,,A549,,F,,,BAO00002q0,N,3320,CjEMBL62w575,,,,,Interm4d8ate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Homo sapiens,9606.0
5802,,A549,,F,,,BAO0o00q19,N,3320,vHEMBL521576,,,,,Igternediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Homo sapiens,9606.0
5803,,A549,,F,,,BzO000021p,N,3320,CHEMBL6e1477,,,,,Inretmediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Homo sapiens,9606.0
5804,,A549,,F,,,Bw90000219,N,3320,dHEMBL6215i8,,,,,Inte4medizte,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Homo sapiens,9606.0
5805,,A549,,F,,,BAO0o00210,N,3320,CHEMBL62qr79,,,,,Intermedixt4,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Homo sapiens,9606.0
5806,,A549,,F,,,hAO0000210,N,5726,CHsMvL621580,,,,,Igtermediahe,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Homo sapiens,9606.0
5807,,,,A,,,fAO0000w18,N,17800,CHEMhL621y81,,Invivk,,,In6etmediate,Plasma clearance (in vivo) in mongrel dogs was determined,Canis lupus familiaris,9615.0
5808,,,,A,,,BAOo000q18,N,5985,CH4MBk621582,,Invico,,,jntermed9ate,Plasma clearance was measured in dog,Canis lupus familiaris,9615.0
5809,,,,A,,,nwO0000218,N,5530,CH3MgL621583,,Ibvivo,,,Intermddiat4,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris,9615.0
5810,,,,A,,,nsO0000218,N,5530,CHfMBLt21584,,lnvivo,,,Ihterhediate,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5811,,,,A,3157821.0,Plasha,nAO0000q18,N,4839,CHdMBL611585,,Invibo,,,Intermedia64,Tested for plasma clearance in dog,Canis lupus familiaris,9615.0
5812,,,,A,,,BqO000o218,N,3639,CHEMBi621576,,Invigo,,,Igtermedixte,The compound was tested for clearance in dog plasma.,Canis lupus familiaris,9615.0
5813,,,,A,,,BAO9000118,N,4838,fHEMBL87583y,,Invovo,,,Inte4mediaye,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Canis lupus familiaris,9615.0
5814,,,,A,,,gAO9000218,N,4137,CHEMBit21587,,Invigo,,,knfermediate,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,9615.0
5815,,,,A,1325300.0,Plaema,BAO000011i,N,5017,CHEMBLuw1588,,Igvivo,,,Inf4rmediate,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris,9615.0
5816,,,,A,3484457.0,Ljver,BAOo000228,N,17538,dHdMBL621589,,Ingitro,,Mictoeomes,Inyermediat4,In vitro clearance in dog liver microsomes,Canis lupus familiaris,9615.0
5817,,,,A,,,BAO0p09218,N,6161,CHEMhk621590,,Invuvo,,,Intethediate,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris,9615.0
5818,,,,A,,,BAi00002q8,N,6161,CbEMBL621r91,,Ihvivo,,,Intermedia5r,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris,9615.0
5819,,,,A,,,BAO0o0021o,N,1696,xHEMBL62159e,,Invibo,,,9ntermediatd,Plasma clearance in dog,Canis lupus familiaris,9615.0
5820,,,,A,,,BAp0000w18,N,6762,CHEMBi621y93,,lnvivo,,,Intermfdkate,Clearance rate in dog,Canis lupus familiaris,9615.0
5821,,,,A,3416726.0,9lasma,BAO00002wu,N,5932,CHEhBL721594,,Infivo,,,onte3mediate,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Canis lupus familiaris,9615.0
5822,,,,A,,,BAO0099218,N,6305,CuEMBL62159r,,unvivo,,,knte3mediate,Clearance in dogs,Canis lupus familiaris,9615.0
5823,,,,A,,,BAO00o0118,N,4942,CHEMBp631596,,Invido,,,Intermef9ate,Plasma clearance in dogs,Canis lupus familiaris,9615.0
5824,,,,A,,,BAO0000ew8,N,4219,CHEhhL621597,,Invuvo,,,Inhermediste,Plasma clearance was determined,Canis lupus familiaris,9615.0
5825,,,,A,,,vAO00002w8,N,17853,dHEMBL6215p8,,Ijvivo,,,7ntermed7ate,Lower clearance in dog (i.v.) at 0.5 mpk,Canis lupus familiaris,9615.0
5826,,,,A,,,BAO0009e18,N,4514,CHEMvL62w599,,Infivo,,,Intermedisge,Plasma clearance in Beagle dogs,Canis lupus familiaris,9615.0
5827,,,,A,,,BAO0o0p218,N,6448,CHEMhL87583t,,Invido,,,jntermfdiate,Plasma clearance (Clp) in dog,Canis lupus familiaris,9615.0
5828,,,,A,,,BAO0000227,N,6227,CHEMvL622600,,Invigo,,,7htermediate,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
5829,,,,A,,,BAlo000218,N,6227,CH3MBL721601,,Invido,,,Ibtermeriate,Plasma clearance (pharmacokinetic parameter) in dog was determined,Canis lupus familiaris,9615.0
5830,,,,A,,,BAO00002wi,N,6062,CuEhBL618474,,Ibvivo,,,7ngermediate,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,9615.0
5831,,,,A,,,BAO0090e18,N,6821,CHEkBL618r75,,Invigo,,,Intedmewiate,Plasma clearance of compound was determined in dog,Canis lupus familiaris,9615.0
5832,,,,A,,,BAO009p218,N,4709,xHEMBL624y24,,Inviv0,,,In5ermedixte,Plasma clearance after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
5833,,,,A,,,BAO00p021i,N,4521,vjEMBL624525,,Indivo,,,Interm3diat3,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,9615.0
5834,,,,A,,,BAi000o218,N,5374,CHEMvL624y26,,unvivo,,,In64rmediate,Plasma clearance in dog was determined,Canis lupus familiaris,9615.0
5835,,,,A,,,BsO0o00218,N,6057,CHrMBL524527,,Inbivo,,,Intermediqts,Plasma clearance was calculated in dog,Canis lupus familiaris,9615.0
5836,,,,A,,,fsO0000218,N,4727,CgEMBL6245e8,,Invifo,,,Intermefiat2,Plasma clearance at the dose of 2 mg/kg in dog,Canis lupus familiaris,9615.0
5837,,,,A,,,fAO00002w8,N,5145,sHEMBL6245q9,,Invivl,,,Intermsdiat2,Plasma clearance in dog,Canis lupus familiaris,9615.0
5838,,,,A,,,BAO0o00e18,N,17657,CHEMBp624540,,onvivo,,,Interm3dia4e,Plasma clearance in dog,Canis lupus familiaris,9615.0
5839,,,,A,,,BAi0p00218,N,17657,CHEMBL623532,,Ijvivo,,,Interm2d9ate,Plasma clearance in dog; Unable to calculate,Canis lupus familiaris,9615.0
5840,,,,A,,,BAO00o0q18,N,5145,CHEMhL62453q,,8nvivo,,,Inyermrdiate,Plasma clearance in rhesus monkey,Canis lupus familiaris,9615.0
5841,,,,A,,,BAO0099218,N,6642,sHEMBL62453r,,Invigo,,,Intermddixte,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,9615.0
5842,,,,A,,,BAOp00p218,N,6641,CHEMBL624635,,knvivo,,,7btermediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
5843,,,,A,,,BAO0op0218,N,6642,CHEkBL6e4535,,onvivo,,,lnt3rmediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
5844,,,,A,,,BAO09o0218,N,5472,CHEkBL614536,,7nvivo,,,Intermfdixte,Plasma clearance was evaluated in dog,Canis lupus familiaris,9615.0
5845,,,,A,,,hqO0000218,N,5472,CHEMBky24537,,lnvivo,,,Inteemediatr,Plasma clearance was evaluated in dog; Not tested,Canis lupus familiaris,9615.0
5846,,,,A,,,BAO900p218,N,5472,CHsMBL625538,,Invico,,,Int2rkediate,Plasma clearance was evaluated in rhesus,Canis lupus familiaris,9615.0
5847,,,,A,,,BsO000o218,N,5472,CHEMBL6e453i,,Invivi,,,Intermediztw,Plasma clearance was evaluated in rhesus; Not tested,Canis lupus familiaris,9615.0
5848,,,,A,,,gAO0000e18,N,4257,CHEMBLu245r0,,Ibvivo,,,Intdrjediate,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris,9615.0
5849,,,,A,,,BAk0000228,N,6679,CHEMBL6ee541,,lnvivo,,,kbtermediate,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,9615.0
5850,,,,A,,,BsO00p0218,N,5546,CHEMBL62e552,,Invlvo,,,kntermedizte,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,9615.0
5851,,,,A,,,vAOo000218,N,6348,CHwMBL6q4543,,Invuvo,,,knteemediate,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
5852,,,,A,,,BA90p00218,N,5474,CyEMBL62r544,,Infivo,,,Inhermsdiate,Clearance value at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris,9615.0
5853,,,,A,669214.0,Plaska,fAO0o00218,N,6316,sHEkBL624545,,Indivo,,,Ihte4mediate,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris,9615.0
5854,,,,A,,,BAO00o02w8,N,17594,CHEMBp624r46,,Ibvivo,,,Int3rmediafe,Cmax after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,9615.0
5855,,,,A,,,BAO00oo218,N,17594,xHrMBL875957,,Invifo,,,Ingermediwte,Cmax after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,9615.0
5856,,,,A,,,vqO0000218,N,5802,CHrMBL6q4547,,Invibo,,,In4etmediate,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,9615.0
5857,,,,A,,,BAO900o218,N,6535,dHEMBi624548,,Invico,,,Imt3rmediate,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris,9615.0
5858,,,,A,,,BsO000021i,N,6535,CHEnBL6w4549,,Inviv0,,,Intermedka6e,Cmax in dog after administration of 1 mg/kg iv,Canis lupus familiaris,9615.0
5859,,,,A,2303785.0,Plazma,BAO00o021i,N,1466,CgEMBL624560,,Invjvo,,,In5e5mediate,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
5860,,,,A,,,BxO000p218,N,6505,CHEMBLy22613,,Invlvo,,,Intermeduqte,Cmax on p.o. administration of 10 mg/kg was measured in dog,Canis lupus familiaris,9615.0
5861,,,,A,,,BAO00002q9,N,5668,CHEMBLy2161r,,Inv9vo,,,Inte5kediate,Cmax was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,9615.0
5862,,,,A,,,gAO0p00218,N,5668,CHEMvL623t31,,Igvivo,,,untermediatr,Cmax was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,9615.0
5863,,,,A,,,BsO0000118,N,5668,CHEMBL5w3432,,Invivk,,,In5frmediate,Cmax was determine after peroral administration at 5 mg/kg in dog,Canis lupus familiaris,9615.0
5864,,,,A,,,BqO9000218,N,5600,CmEMBL623t33,,Inv7vo,,,kntermexiate,Cmax after 0.3 mg/kg po administration in dog,Canis lupus familiaris,9615.0
5865,,,,A,,,hAO000p218,N,17764,CHEhBk623434,,Igvivo,,,In5ermed7ate,Cmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris,9615.0
5866,,,,A,,,BqO00p0218,N,6123,CHEMBL523t35,,Ijvivo,,,Intermedia63,Cmax in dog after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
5867,,,,A,,,vqO0000218,N,6123,CHsMBL613436,,Infivo,,,Intedmediat4,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Canis lupus familiaris,9615.0
5868,,,,A,,,BA80o00218,N,6757,CH4MBL8759y8,,Invivp,,,Intermwdiatr,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Canis lupus familiaris,9615.0
5869,,,,A,,,BAp0000219,N,16907,CHEMBLue3437,,Inbivo,,,Int2rkediate,Cmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
5870,,,,A,1645762.0,Bl0od,BAO0o00e18,N,7767,CHEMBL623tr8,,Invovo,,,Int2rmedoate,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5871,,,,A,1008697.0,Bloox,BxO0o00218,N,7767,CHEhvL623439,,Indivo,,,8ntermediatw,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5872,,,,A,48345.0,Bone,BAl000021u,N,7767,CH3MBp623440,,lnvivo,,,Inyegmediate,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5873,,,,A,627231.0,Bone,gAO0000e18,N,7767,CgEMBL624441,,Inv7vo,,,Inyermed7ate,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5874,,,,A,6153511.0,Bone,BAOp00021i,N,7767,fHEMBL622442,,Invigo,,,Inherjediate,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5875,,,,A,,,BAO0009w18,N,7767,CHEMBL633479,,Inbivo,,,Intermediagw,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5876,,,,A,,,BA9o000218,N,7767,xHEMBi623470,,knvivo,,,Intermediwfe,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5877,,,,A,,,BAO0p00318,N,7767,CHdMBL6234y1,,Invifo,,,Intermeviste,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5878,,,,A,936411.0,Heqrt,BAO0p00228,N,7767,CHEMBL6e3t72,,jnvivo,,,Internwdiate,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5879,,,,A,627919.0,H3art,BAlo000218,N,7767,CHwMBLy23473,,jnvivo,,,Intermeriat3,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5880,,,,A,1179060.0,Hezrt,BAO0p00q18,N,7767,CjEMBk623474,,lnvivo,,,jntermedizte,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5881,,,,A,1761925.0,Kicney,BAO900p218,N,7767,vHEMBL623575,,Inviv8,,,Inte3hediate,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5882,,,,A,2418793.0,Kidmey,BAO00p0217,N,7767,CH3MBL623576,,Ibvivo,,,Interhediqte,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5883,,,,A,89667.0,midney,BAOo009218,N,7767,CbEMBL62347y,,Imvivo,,,Intdrnediate,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5884,,,,A,1424045.0,Intestihe,vAO0000217,N,7767,CHEjBL62q896,,Igvivo,,,Im5ermediate,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5885,,,,A,2879466.0,Ibtestine,BAp0009218,N,7767,CHEMBp6w1897,,Inbivo,,,8ntrrmediate,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5886,,,,A,590843.0,Int4stine,BzO9000218,N,7767,CHsMBk621898,,Inviv9,,,Intfrm3diate,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5887,,,,A,907295.0,Livee,BAO0900228,N,7767,fHEMBL6218p9,,Incivo,,,Intermed9atw,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5888,,,,A,152216.0,Liv2r,BzO00p0218,N,7767,CHEMBLu2w900,,Inv7vo,,,Intermsdoate,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5889,,,,A,1145407.0,L9ver,hAO0p00218,N,7767,CHdMBL62190q,,Ibvivo,,,In4ermediwte,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5890,,,,A,3885614.0,Lung,BzO0000e18,N,7767,CHEMBL611i02,,lnvivo,,,kn6ermediate,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5891,,,,A,791641.0,Lung,BAO0p90218,N,7767,dHEMBLy21903,,Invivk,,,8nt2rmediate,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5892,,,,A,242415.0,Lung,nAO0000318,N,7767,CHEjBo622587,,Inbivo,,,8ntermediat4,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5893,,,,A,1328554.0,Mhscletiwsue,gA80000218,N,7767,CHEMhL6202o5,,Ibvivo,,,Ingermwdiate,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5894,,,,A,1029654.0,Muscletosske,BAO00o0217,N,7767,CHfMBL775285,,Inv8vo,,,Intermedjat3,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5895,,,,A,1360177.0,Muwcpetissue,BAO000pq18,N,7767,CHEnBk620286,,Igvivo,,,9ntermedlate,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5896,,,,A,,,BAO000ow18,N,7767,xHrMBL620287,,8nvivo,,,Inte5mewiate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5897,,,,A,,,BAO0o0p218,N,7767,CtEMBi620288,,Ihvivo,,,Int2rmediatf,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5898,,,,A,,,nAOo000218,N,7767,CHEMBLt29289,,Invjvo,,,Ihterm2diate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5899,,,,A,675613.0,In4estine,BAk00p0218,N,7767,CHEMBL62o200,,Igvivo,,,Inrerm4diate,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5900,,,,A,3197432.0,Intestije,BzOp000218,N,7767,dHEMBLu20291,,Ijvivo,,,Interhediat2,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5901,,,,A,3153158.0,Intestin3,BAO0000e1i,N,7767,CHEMBL630291,,Invivl,,,untdrmediate,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5902,,,,A,4253541.0,Slleen,BAl0000118,N,7767,CHwMBL620193,,Invigo,,,Imtermedixte,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5903,,,,A,282337.0,qpleen,BqOp000218,N,7767,CHEhBL62o294,,Invibo,,,Iht3rmediate,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5904,,,,A,3141648.0,S0leen,BzO000021u,N,7767,CH2MBi618614,,Inviv0,,,Inysrmediate,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5905,,,,A,3386146.0,Stomwch,BwO000p218,N,7767,CHEMnLt18615,,Invuvo,,,Imtermediare,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5906,,,,A,8295.0,atomach,BAO0p002w8,N,7767,CHrMnL618616,,Inviv8,,,9ntfrmediate,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
5907,,A172,,F,,,nAO0000119,N,2036,CHEMgLt18617,,,,,Expwrt,Cytotoxicity against A-172 human tumor cell lines,Homo sapiens,9606.0
5908,,A172,,F,,,nAO0000210,N,2357,CHEMgL518618,,,,,ontermediste,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Homo sapiens,9606.0
5909,,A204,,F,,,BAO0o002q9,N,1457,CHEhBL618y19,,,,,Intermeeiwte,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Homo sapiens,9606.0
5910,,A2789,,F,,,gxO0000219,N,4379,CH3kBL618620,,,,,Intermesoate,Tested for antiproliferative activity against A-2780 tumoral cell line,Homo sapiens,9606.0
5911,,A375,,F,,,BAO00p02w9,N,1093,CHEMnp618621,,,,,Intermedja6e,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Homo sapiens,9606.0
5912,,A375,,F,,,BAO0o002q9,N,12152,CHEMBky18622,,,,,Infegmediate,Tested in vitro against A-375 cell line human melanoma,Homo sapiens,9606.0
5913,,A427,,F,,,BAO0po0219,N,16464,CHdMBk618623,,,,,Ecpert,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens,9606.0
5914,,A427,,F,,,fAO0009219,N,16464,dHEMBL618524,,,,,Intfrmediatf,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5915,,A427,,F,,,BAOo090219,N,16582,fHEMBL618635,,,,,Expwrt,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Homo sapiens,9606.0
5916,,A427,,F,,,BA800002w9,N,16464,CHEMBp618u26,,,,,Int3rmedia4e,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,9606.0
5917,,A427,,F,,,BAO000p218,N,10413,CHEhBLt18627,,,,,Intermedkats,Antitumor activity on A-427 lung carcinoma cell lines,Homo sapiens,9606.0
5918,,A427,,F,,,hAO0p00219,N,6418,CHsMBi618628,,,,,Ihtermediaye,Cytotoxic activity against human A-427 lung tumor cell line,Homo sapiens,9606.0
5919,,A427,,F,,,BAO000o2q9,N,17134,CHEMBL718529,,,,,Expery,In vitro antitumor effects against human A-427 cell lines.,Homo sapiens,9606.0
5920,,A427,,F,,,BAOo000229,N,16132,CyEMvL618630,,,,,Ecpert,In vitro inhibition of A-427 (human lung cancer) cell growth.,Homo sapiens,9606.0
5921,,A427,,F,,,BAlp000219,N,16132,CHEMBL618521,,,,,Intermediqge,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Homo sapiens,9606.0
5922,,A427,,F,,,BqO0p00219,N,16780,CHfMgL618632,,,,,Internwdiate,Cytotoxic activity of compound against A-427 lung human tumor cell line,Homo sapiens,9606.0
5923,,A431,,F,,,BAO0000qq9,N,4085,CuEMBLt18633,,,,,Eapert,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Homo sapiens,9606.0
5924,,A498,,F,,,BAO000o21p,N,1276,CHEMBL61p316,,,,,Intermediahs,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Homo sapiens,9606.0
5925,,A498,,F,,,vAO0000q19,N,3498,CHrnBL619316,,,,,Ex0ert,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Homo sapiens,9606.0
5926,,A498,,F,,,BAOp000q19,N,1169,CHEMvLu19317,,,,,Intfrmfdiate,Cytotoxicity against human kidney carcinoma A-498cell lines,Homo sapiens,9606.0
5927,,A498,,F,,,BAO0oo0219,N,4450,xHEMBLy19318,,,,,knterkediate,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Homo sapiens,9606.0
5928,,A498,,F,,,BAO0p00319,N,3311,CHEMgLy19319,,,,,Int2rmediat4,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Homo sapiens,9606.0
5929,,A498,,F,,,BAO0p002w9,N,4461,CH3MBL519739,,,,,Intermed9wte,Antitumor cytotoxic activity against A-498 cell line was determined,Homo sapiens,9606.0
5930,,A498,,F,,,BAO0p09219,N,3311,CHEhBLu19740,,,,,Intrrmediaye,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Homo sapiens,9606.0
5931,,A498,,F,,,BA90000q19,N,3311,CjEMBL88w158,,,,,Intrrmediqte,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Homo sapiens,9606.0
5932,,A498,,F,,,BqO00002q9,N,1457,CHEMBL874p12,,,,,ontermediwte,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Homo sapiens,9606.0
5933,,A498,,F,,,BAOp0p0219,N,3664,CHfkBL619741,,,,,jbtermediate,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Homo sapiens,9606.0
5934,,A498,,F,,,BAO0000329,N,15895,CHEMBi6q9742,,,,,knternediate,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Homo sapiens,9606.0
5935,,A549,,F,,,BqO0090219,N,11843,CHEMBo8766q0,,,,,7ntermefiate,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Homo sapiens,9606.0
5936,,A549,,F,,,fAOp000219,N,11843,CHEMBp619u43,,,,,Infermediage,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Homo sapiens,9606.0
5937,,A549,,F,,,BAO0o00119,N,17705,vH2MBL619744,,,,,7ntermesiate,In vitro antiproliferative activity against human A-549 NSCL cell line,Homo sapiens,9606.0
5938,,A549,,F,,,BAO0o00229,N,17705,CHrMBL719745,,,,,Intermfdizte,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Homo sapiens,9606.0
5939,,A549,,F,,,BsO0000e19,N,4369,fHEMhL619746,,,,,Ihtermrdiate,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Homo sapiens,9606.0
5940,,A549,,F,,,BAO0000129,N,4369,CHEMBL619u4i,,,,,Intermedia54,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Homo sapiens,9606.0
5941,,A549,,F,,,BAO000022o,N,4369,CHEMBL610738,,,,,Internediare,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,9606.0
5942,,A549,,F,,,BAO0o0o219,N,4369,CHEMhL618749,,,,,Inyermediqte,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Homo sapiens,9606.0
5943,,A549,,F,,,BAO00p0e19,N,4369,CHEMBLy19650,,,,,Intermdxiate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,9606.0
5944,,A549,,F,,,BAO00o021i,N,4369,xHEMBL62t014,,,,,Internedoate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Homo sapiens,9606.0
5945,,A549,,F,,,BqO0p00219,N,4369,CHEnBL62r015,,,,,Interkediste,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,9606.0
5946,,A549,,F,,,BqO9000219,N,4787,CHEMBL88t34e,,,,,Exp3rt,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Homo sapiens,9606.0
5947,,A549,,F,,,gAO00o0219,N,4787,CHEMBk62r224,,,,,Imtermwdiate,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Homo sapiens,9606.0
5948,,A549,,F,,,BAOo000q19,N,6513,CHEMBk62e225,,,,,Intstmediate,Cytotoxic activity against A-549 cell line,Homo sapiens,9606.0
5949,,A549,,F,,,BA80o00219,N,6690,CHEMBL6w26p8,,,,,Interm2diatr,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Homo sapiens,9606.0
5950,,A549,,F,,,fAO00o0219,N,6690,CHEMBL62q799,,,,,Intermediarr,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Homo sapiens,9606.0
5951,,A549,,F,,,fAO0000229,N,12263,CbEMBL6227o0,,,,,Eapert,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Homo sapiens,9606.0
5952,,A549,,F,,,BAO0090w19,N,1054,xHEMBL622702,,,,,Inhfrmediate,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Homo sapiens,9606.0
5953,,A549,,F,,,BA0000o219,N,1359,CgEMBL622i02,,,,,Intermedizhe,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Homo sapiens,9606.0
5954,,A549,,F,,,BAO000o229,N,3547,CHEhBL622793,,,,,Intetmediage,Cytotoxic activity against human lung carcinoma (A-549) cell line,Homo sapiens,9606.0
5955,,A549,,F,,,BAO009o219,N,5771,CHEMvL6227o4,,,,,Ex9ert,Cytotoxic activity towards A-549 cells,Homo sapiens,9606.0
5956,,A549,,F,,,BAp00o0219,N,14425,CHEnvL622705,,,,,Igtetmediate,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens,9606.0
5957,,A549,,F,,,hAO000021o,N,14425,xHEMBL612706,,,,,Imtermed7ate,"In vitro percent inhibition of A549, lung carcinoma",Homo sapiens,9606.0
5958,,A549,,F,,,BAi0o00219,N,14425,CHEMBL63270i,,,,,Inrermfdiate,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens,9606.0
5959,,A549,,F,,,BAi0000q19,N,14425,CHEMBL611708,,,,,Intwrmediaye,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Homo sapiens,9606.0
5960,,A549,,F,,,BzOp000219,N,5280,vHEMBo622709,,,,,Intermed9are,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Homo sapiens,9606.0
5961,,A549,,F,,,BAl0009219,N,15176,CHEMBL6227qo,,,,,jngermediate,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Homo sapiens,9606.0
5962,,A549,,F,,,BAO000pe19,N,15300,CHEMBp6227w1,,,,,kntermedlate,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Homo sapiens,9606.0
5963,,A549,,F,,,BAOo000219,N,17824,CHEMBp62q712,,,,,Ibtermediahe,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,9606.0
5964,,A549,,F,,,BAO00o0228,N,17824,vHEMBo622713,,,,,Ibt2rmediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,9606.0
5965,,A549,,F,,,fAO000p218,N,17824,fHEMBi622714,,,,,Inte3medkate,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,9606.0
5966,,A549,,F,,,vAO00002q8,N,17824,CHEkBLu22715,,,,,Inhe4mediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,9606.0
5967,,A549,,F,,,BAOp00021o,N,17824,CHEMBL62eu16,,,,,untermedia4e,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,9606.0
5968,,A549,,F,,,BAl00002w9,N,17824,CtEMBL6227w7,,,,,Inyermexiate,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Homo sapiens,9606.0
5969,,A549,,F,,,fzO0000218,N,17528,CHfMBL622717,,,,,In4ermesiate,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Homo sapiens,9606.0
5970,,A549,,F,,,BAO0p0021p,N,6870,CH2MBL622819,,,,,sxpert,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens,9606.0
5971,,A549,,F,,,BAOo000229,N,6870,CbEMvL622720,,,,,Intermevizte,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens,9606.0
5972,,A549,,F,,,nAO0p00219,N,6870,CHEMBL6227q2,,,,,Intefmed9ate,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens,9606.0
5973,,A549,,F,,,gAO00p0219,N,6870,CHsMBL622i22,,,,,Int4rmediats,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens,9606.0
5974,,A549,,F,,,vAO0009219,N,16726,sHEMBL976030,,,,,Inte3mediatw,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens,9606.0
5975,,A549,,F,,,BAk00002w9,N,6170,CgsMBL620206,,,,,7ntermediat3,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Homo sapiens,9606.0
5976,,A549,,F,,,BAOp000218,N,6583,CHEMhL6202o7,,,,,Experg,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Homo sapiens,9606.0
5977,,A549,,F,,,BAOo000218,N,6583,CHEhBL620w08,,,,,Exlert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Homo sapiens,9606.0
5978,,A549,,F,,,BAO00002w0,N,6583,fHEMBL6202o9,,,,,Ex0ert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Homo sapiens,9606.0
5979,,A549,,F,,,BAO0p0o219,N,6583,CHEjBL62o210,,,,,Expsrt,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Homo sapiens,9606.0
5980,,A549,,F,,,hAO0090219,N,6583,CHEhBLy21639,,,,,Eapert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Homo sapiens,9606.0
5981,,A549,,F,,,BAO0op0219,N,17321,CHEMBL6w164o,,,,,Interhedixte,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Homo sapiens,9606.0
5982,,A549,,F,,,nAO000o219,N,17528,CHEMBL621t51,,,,,Expedt,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens,9606.0
5983,,A549,,F,,,vzO0000219,N,12888,CgEMBL621t42,,,,,Ex0ert,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Homo sapiens,9606.0
5984,,A549,,F,,,BAk00002q9,N,4312,CHEMBL62q743,,,,,Infermsdiate,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Homo sapiens,9606.0
5985,,A549,,F,,,BAO00001w9,N,4312,CHwMBL621u44,,,,,In63rmediate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Homo sapiens,9606.0
5986,,A549,,F,,,BAl000o219,N,4312,CHEMBL6ww645,,,,,lntermeviate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Homo sapiens,9606.0
5987,,A549,,F,,,BA90000119,N,17737,CH3MBL6q1646,,,,,In63rmediate,In vitro antiproliferative activity against A549 cell line,Mus musculus,10090.0
5988,,A549,,F,,,BA900o0219,N,6630,CHfMBL621648,,,,,Inte4mediage,Synergism with indomethacin in A549 cells,,
5989,,A549,,F,,,BAO00092w9,N,6630,CHEkBp621648,,,,,Intefmediahe,Synergism with tolmetin in A549 cells,,
5990,,A549,,F,,,BAOo000q19,N,6630,CHEjBL721649,,,,,Ingermediatw,Synergism with sulindac in A549 cells,,
5991,,A549,,F,,,BAl000p219,N,6630,CHEMBL6q16r0,,,,,In6ermediare,Antagonism of indomethacin in A549 cells,,
5992,,A549,,F,,,BAO090p219,N,6630,xmEMBL621651,,,,,lntermediatf,Antagonism of sulindac in A549 cells,,
5993,,A549,,F,,,fAO9000219,N,6630,xHEMhL621652,,,,,Imterm2diate,Antagonism of tolmetin in A549 cells,,
5994,,A549,,F,,,BzOp000219,N,6630,CHEMfL62w653,,,,,Intermwdlate,Synergism with indomethacin in A549 cells,,
5995,,A549,,F,,,BAO9090219,N,6630,fHEMBL62q654,,,,,Inte5medizte,Synergism with sulindac in A549 cells,,
5996,,A549,,F,,,BAO0900319,N,6630,CyEMBL621656,,,,,Int3rmedizte,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,
5997,,,,A,,,BAO0009e18,N,16907,CHEMBL6w165y,,Imvivo,,,Ih6ermediate,Cmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
5998,,,,A,,,BAO009o218,N,5944,CHEMvL621y57,,Inbivo,,,7ntetmediate,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,9615.0
5999,,,,A,,,BsO0090218,N,5944,CHEjnL621658,,Igvivo,,,Int3rmedia4e,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris,9615.0
6000,,,,A,,,BAOp00p218,N,5944,sHEMBL6216r9,,Invkvo,,,Intedmedixte,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,9615.0
6001,,,,A,,,BzO0o00218,N,5944,CHEMBLy2w660,,Inv7vo,,,Ibtermediat2,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris,9615.0
6002,,,,A,,,BAO0p0021o,N,2959,CnEMBL6216u1,,Inviv0,,,Interneduate,Cmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,9615.0
6003,,,,A,,,Bz00000218,N,6241,CHrkBL621662,,Invivl,,,Ihtfrmediate,Cmax value in dog,Canis lupus familiaris,9615.0
6004,,,,A,,,BAO0009228,N,6241,CHrkBL621663,,Ingivo,,,Intermedlzte,Cmax value in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
6005,,,,A,,,BwO0000318,N,2652,CHEjhL621664,,Incivo,,,Igtetmediate,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Canis lupus familiaris,9615.0
6006,,,,A,601666.0,9lasma,BsO000o218,N,1806,CHEnBL62q665,,knvivo,,,Interm4diahe,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,9615.0
6007,,,,A,804366.0,Plasmz,BAO0p00228,N,1806,vHEMvL621666,,Invifo,,,Infrrmediate,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,9615.0
6008,,,,A,,,fAO000021u,N,1021,fHEMBL621767,,Indivo,,,Int2rmedia4e,Concentration maxima after oral dosing in dogs,Canis lupus familiaris,9615.0
6009,,,,A,,,BA800002q8,N,1021,CHEMBL8iy738,,jnvivo,,,Intsrmedixte,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris,9615.0
6010,,,,A,,,hAO000p218,N,1021,xbEMBL621668,,Invuvo,,,Ibtermedizte,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris,9615.0
6011,,,,A,,,BAO0009318,N,5444,CyEMBL62166i,,Inv8vo,,,Ihteemediate,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Canis lupus familiaris,9615.0
6012,,,,A,,,hAO0000w18,N,5444,CHwMBk621670,,Ijvivo,,,Intermddiats,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Canis lupus familiaris,9615.0
6013,,,,A,,,gAOp000218,N,5444,CHEMBL62177w,,Ijvivo,,,Intermedlatf,In vivo maximal concentration was calculated at 1 mg/kg in dog,Canis lupus familiaris,9615.0
6014,,,,A,,,BAO000o2w8,N,5444,fHEMBL623360,,unvivo,,,Intedjediate,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Canis lupus familiaris,9615.0
6015,,,,A,,,BAO0p0p218,N,5444,CbEMBL622371,,Incivo,,,Interhediat2,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Canis lupus familiaris,9615.0
6016,,,,A,1586297.0,Ppasma,BwO0009218,N,5130,CH2MBL62q362,,Inv9vo,,,9n5ermediate,Cmax in dog plasma after oral dose (1 mg/kg),Canis lupus familiaris,9615.0
6017,,,,A,3249230.0,Plasna,BA80000w18,N,3249,CH4MBL62e363,,Imvivo,,,Int3rm3diate,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
6018,,,,A,1513455.0,Plasna,BAO00002qu,N,5473,CHEnBL622354,,Ijvivo,,,Intwrmed8ate,Maximal plasma concentration at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
6019,,,,A,905930.0,llasma,nAp0000218,N,5474,dHEMBL6w2365,,Invkvo,,,Integmedia4e,Maximal plasma concentration at a dose of 1 mg/kg (oral),Canis lupus familiaris,9615.0
6020,,,,A,3774618.0,Plzsma,BAO0090e18,N,4657,CHEMBk622y33,,Inviv9,,,lntrrmediate,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Canis lupus familiaris,9615.0
6021,,,,A,,,BA99000218,N,3031,dHEMBL62q534,,Incivo,,,Integmediwte,Maximum concentration of compound in dog was evaluated.,Canis lupus familiaris,9615.0
6022,,,,A,,,BAO000p2w8,N,4527,CHwMBL6225e5,,Igvivo,,,Inteehediate,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,9615.0
6023,,,,A,,,BAO0009w18,N,4186,dHEMBL87t739,,Invigo,,,knternediate,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,9615.0
6024,,,,A,,,BAO0990218,N,5007,sHEMBL622537,,Invjvo,,,Intermedis6e,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,9615.0
6025,,,,A,136787.0,Piasma,BAk0000e18,N,3132,CHEhBL62253u,,Inv8vo,,,Intfrmesiate,Maximum concentration obtained in dog plasma was determined,Canis lupus familiaris,9615.0
6026,,,,A,,,BxO00002w8,N,5006,CHEkgL622538,,Invifo,,,Ibtermediqte,Maximum concentration was determined,Canis lupus familiaris,9615.0
6027,,,,A,,,nAO00002w8,N,4727,CHEMBL6e8867,,Invifo,,,Intfrmediwte,Maximum concentration at the dose of 2 mg/kg in dog,Canis lupus familiaris,9615.0
6028,,,,A,,,BAOo00p218,N,1916,CHEMfL627768,,Invjvo,,,Intdrmedizte,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,9615.0
6029,,,,A,6030674.0,Plasmx,BAO0900q18,N,1918,CHEMBL62i8u9,,lnvivo,,,Intermfciate,Maximum concentration was evaluated in dog plasma,Canis lupus familiaris,9615.0
6030,,,,A,,,BAO000022o,N,3045,CHEMfL6278i0,,Inviv0,,,kntrrmediate,Maximum concentration was evaluated after 75 min after administration in dog,Canis lupus familiaris,9615.0
6031,,,,A,2984341.0,Plssma,BAio000218,N,9579,CHrMBL627771,,Invigo,,,Intwdmediate,Maximum plasma concentration determined in dog after oral administration of 17b,Canis lupus familiaris,9615.0
6032,,,,A,1875052.0,Ppasma,BAO090p218,N,9579,CHEMhL62i872,,Invuvo,,,Interkedlate,Maximum plasma concentration determined in dog after oral administration of 2b,Canis lupus familiaris,9615.0
6033,,,,A,4641787.0,olasma,hAi0000218,N,933,CHEMBk6278i3,,Incivo,,,Ibte3mediate,Maximum plasma concentration in dog,Canis lupus familiaris,9615.0
6034,,,,A,1902995.0,Plaama,nAOo000218,N,17839,CHEMBL6w7u74,,Invido,,,jnterm3diate,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris,9615.0
6035,,,,A,165461.0,Piasma,BxO000p218,N,17839,CH4MBL62y875,,Ibvivo,,,Intdrmedia4e,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris,9615.0
6036,,,,A,530628.0,Pkasma,gAOo000218,N,17839,fHEMBL727876,,Ijvivo,,,Intedm4diate,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris,9615.0
6037,,,,A,1539599.0,Plaska,BAO0o0021u,N,17839,CuEMBLu27877,,Invibo,,,Intermediwt3,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris,9615.0
6038,,,,A,3299976.0,Poasma,BAO0o00w18,N,6348,CHEMBk627868,,8nvivo,,,Interkediats,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
6039,,,,A,1748830.0,Plasmz,BAO0pp0218,N,16367,CyEMBL626879,,Inviv8,,,Intermeciage,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
6040,,,,A,357473.0,Plaska,BAO000o2w8,N,1337,CHEMBLo75255,,Inbivo,,,Inyermedlate,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
6041,,,,A,3760955.0,Placma,gAO0000w18,N,1337,CHEMvL6e7880,,Invkvo,,,lnt3rmediate,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
6042,,,,A,763647.0,Plasna,BAO000921i,N,5199,CHEnBLu27881,,Ijvivo,,,Igtermeviate,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris,9615.0
6043,,,,A,26642.0,Plaama,BAO0099218,N,17650,CHEMBL626o82,,lnvivo,,,Inte4meciate,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,9615.0
6044,,,,A,976556.0,Plaska,vAO000021o,N,6679,CHwMBL627873,,Invibo,,,Intermreiate,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
6045,,,,A,1952204.0,Plaska,vAO00002w8,N,5356,CHEMBo62i526,,Invuvo,,,Int2rmediage,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Canis lupus familiaris,9615.0
6046,,,,A,566049.0,Plasmz,BAO0000229,N,5356,vHEMBp628527,,Inv7vo,,,Intermefiste,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Canis lupus familiaris,9615.0
6047,,,,A,1076131.0,Ppasma,BA900002w8,N,6227,vHEMBL628y28,,Invico,,,In4erm2diate,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
6048,,,,A,2313253.0,Plxsma,BAp9000218,N,6227,CmEMBL628519,,7nvivo,,,Interkediatf,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Canis lupus familiaris,9615.0
6049,,,,A,195123.0,olasma,BAO0p00219,N,6227,xHEMBi628530,,Invovo,,,9ntermediare,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Canis lupus familiaris,9615.0
6050,,,,A,1286461.0,Piasma,BAO9090218,N,6227,CHEMBL525343,,Invifo,,,untermsdiate,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
6051,,,,A,5475038.0,Plasmz,BA0000021o,N,3598,CHsMBL635244,,Inv9vo,,,2xpert,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
6052,,,,A,,,BAO00902q8,N,4368,CHsMBL62t245,,Incivo,,,Intermediw5e,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,9615.0
6053,,,,A,,,BAO0p09218,N,6265,sHEMBL62r246,,Igvivo,,,9nterjediate,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris,9615.0
6054,,,,A,90472.0,Stomwch,vAOo000218,N,7767,vHEMBL626247,,Inviv9,,,Interheviate,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,10090.0
6055,,,,A,304634.0,Urije,BsO00002w8,N,7767,xHEMBL625247,,Indivo,,,Ibtermedoate,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,10090.0
6056,,,,A,163730.0,Urinr,BA90000w18,N,7767,CHwMBL6e5249,,Invido,,,Intermedjzte,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus,10090.0
6057,,,,A,425739.0,U4ine,BAOo000e18,N,7767,CHEkBL615250,,onvivo,,,Ijtermeciate,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus,10090.0
6058,,,,A,,,fAO00002w8,N,17811,CHEMBLu25q51,,,,,Igtermewiate,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Mus musculus,10090.0
6059,,,,A,,,fqO0000218,N,17811,CHEMBku75356,,,,,9ntwrmediate,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Mus musculus,10090.0
6060,,,,A,,,BAO0009217,N,17827,CHEMBk6252r2,,,,,Inte4mesiate,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Mus musculus,10090.0
6061,,,,A,3174013.0,Blooc,BA90o00218,N,17827,fHEMBp625253,,,,,jnyermediate,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus,10090.0
6062,,,,A,,,BAO0009217,N,17827,xHEhBL625254,,,,,Intermedoat2,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Mus musculus,10090.0
6063,,,,A,,,BAO00pp218,N,17827,CHEkBL625256,,,,,Inte3mesiate,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Mus musculus,10090.0
6064,,,,A,,,BAO9000219,N,17827,vHrMBL625256,,,,,Inte3mddiate,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Mus musculus,10090.0
6065,,,,A,350045.0,Bloos,vAO000o218,N,17827,CmEMBL6252r7,,,,,Interm4djate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus,10090.0
6066,,,,A,1425099.0,Blooe,hAO0000217,N,17827,CHEMBp625248,,,,,Igtermedjate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Mus musculus,10090.0
6067,,,,A,,,BzOp000218,N,17827,fHEMBLy25259,,,,,Interhrdiate,Compound was evaluated for washout rate in mice (Radiolabeled compound),Mus musculus,10090.0
6068,,,,A,,,BAO0p002w8,N,17827,xHfMBL625260,,,,,Interkediat2,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Mus musculus,10090.0
6069,,,,A,,,BqO0000318,N,17827,CHEMBp62526q,,,,,Int3rmwdiate,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,10090.0
6070,,,,A,,,BqO00o0218,N,17827,CHEhBk625262,,,,,8n6ermediate,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,10090.0
6071,,,,A,,,BAO90002q8,N,17827,CHfMBL623639,,,,,Interhsdiate,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,10090.0
6072,,,,A,,,hAO000021o,N,17257,dHEMBL6e2640,,,,,Intermedoa4e,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Mus musculus,10090.0
6073,,,,A,,,BAO009p218,N,17257,CHEMBL632822,,,,,Ibtermesiate,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Mus musculus,10090.0
6074,,,,A,,,vAO0900218,N,17257,CtEMhL622813,,,,,Intermedlwte,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Mus musculus,10090.0
6075,,,,A,,,gAO0009218,N,17257,CHsMBL622714,,,,,lntermexiate,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Mus musculus,10090.0
6076,,,,A,,,BA00000w18,N,17827,CjEMBo622815,,,,,In4ermedoate,Time at maximum activity in mice (Radiolabeled compound),Mus musculus,10090.0
6077,,,,A,,,BA0p000218,N,3760,CyEMBL635342,,,,,Infermedia4e,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Mus musculus,10090.0
6078,,,,A,,,BxO00o0218,N,3760,CHfMBL625r43,,,,,7ntermediatd,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Mus musculus,10090.0
6079,,,,A,,,BzO0900218,N,17409,CHEMBL877r9q,,,,,7ntermediatd,Binding towards mouse plasma protein at 10 uM,Mus musculus,10090.0
6080,,,,A,,,vxO0000218,N,17409,sHEnBL625344,,,,,9btermediate,Binding towards mouse plasma protein at 100 uM,Mus musculus,10090.0
6081,,,,A,,,BAO00o0w18,N,2675,CnEMBo625345,,Imvivo,,,Ibteemediate,Bioavailability was evaluated in mice after intravenous administration,Mus musculus,10090.0
6082,,,,A,,,BzO0000118,N,2675,CHdMBL625345,,Incivo,,,Int2rmefiate,Bioavailability was evaluated in mice after oral administration,Mus musculus,10090.0
6083,,,,A,,,BzOo000218,N,3132,CHEMvL615347,,Invibo,,,Integmediwte,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Mus musculus,10090.0
6084,,,,A,,,BA90p00218,N,3132,vHEMBo625348,,Inviv8,,,In4ermedjate,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Mus musculus,10090.0
6085,,,,A,,,gAO0000q18,N,16597,CHEMBp625r49,,Invjvo,,,Imt4rmediate,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
6086,,,,A,,,fAO00p0218,N,2862,CHEMBL62r35o,,Invido,,,In5ermediatd,Oral bioavailability in mouse,Mus musculus,10090.0
6087,,,,A,,,BAO0p00w18,N,17764,CHwMBL882o52,,unvivo,,,Int3rmedia4e,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
6088,,,,A,1689070.0,Brxin,BqO9000218,N,846,fHEMBL6e5351,,Ihvivo,,,jnterhediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6089,,,,A,873444.0,hrain,BAO00op218,N,846,vHEMBL625362,,Inviv8,,,Internedizte,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6090,,,,A,485320.0,Brsin,BAO0o0021i,N,846,CHEMBL8u7t92,,8nvivo,,,Intermedoatd,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6091,,,,A,2607816.0,Brxin,nAO0000217,N,846,CHEMvL625352,,unvivo,,,Integmedia5e,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6092,,,,A,2339741.0,B4ain,Bw00000218,N,846,CHEMBL626r54,,Invifo,,,Intermeeiwte,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6093,,,,A,1109132.0,Braim,BAO00002wi,N,846,CHEMBL6wy019,,Ibvivo,,,8ntermwdiate,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6094,,,,A,170636.0,Hea5t,BwO0000118,N,846,dHEMBL626p20,,lnvivo,,,Ij5ermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6095,,,,A,295090.0,Hea5t,BxO0000228,N,846,CHEMBL6w602q,,7nvivo,,,9ntermed8ate,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6096,,,,A,2970149.0,H3art,BAO0p00217,N,846,CHEhfL626022,,7nvivo,,,In6ermedixte,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6097,,,,A,1675715.0,neart,BAOp0o0218,N,846,dHEMBLu26192,,Inv9vo,,,7ngermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6098,,A549,,F,,,vzO0000219,N,1276,CnEMBL626q93,,,,,Inhe4mediate,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Homo sapiens,9606.0
6099,,A549,,F,,,BAO9000229,N,3498,CHEjBi626194,,,,,Exlert,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Homo sapiens,9606.0
6100,,A549,,F,,,nA00000219,N,1169,CuEMBL6q6195,,,,,Intermrdiwte,Cytotoxicity against human lung carcinoma A-549 cell lines,Homo sapiens,9606.0
6101,,A549,,F,,,BAO0000e29,N,4450,CHEMBL516196,,,,,In5ermexiate,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Homo sapiens,9606.0
6102,,A549,,F,,,hAO0000210,N,358,CHEMgL626q97,,,,,Ibtermwdiate,In vitro cytotoxicity against human lung carcinoma cell line A-549,Homo sapiens,9606.0
6103,,A549,,F,,,nAk0000219,N,358,Cj2MBL626198,,,,,Imternediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Homo sapiens,9606.0
6104,,A549,,F,,,BAOo0o0219,N,358,CHEMfL636199,,,,,Ing3rmediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Homo sapiens,9606.0
6105,,A549,,F,,,BAl00002w9,N,358,CHEkBL62620o,,,,,Inyermediatd,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Homo sapiens,9606.0
6106,,A549,,F,,,BqO0000218,N,358,fHEMnL626201,,,,,Intdrmddiate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Homo sapiens,9606.0
6107,,A549,,F,,,BA000002w9,N,358,CHEhBL626102,,,,,Intermfdjate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Homo sapiens,9606.0
6108,,A549,,F,,,gAl0000219,N,358,CuEMBL626e03,,,,,lnteemediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Homo sapiens,9606.0
6109,,A549,,F,,,BqO0000q19,N,15167,xHwMBL626204,,,,,Intermedozte,In vitro cytotoxicity against A-549 human lung cancer cells,Homo sapiens,9606.0
6110,,A549,,F,,,BAO000o229,N,4139,CHEMvLy24701,,,,,Ijtedmediate,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Homo sapiens,9606.0
6111,,A549,,F,,,nA00000219,N,833,CHEMBL62ey02,,,,,Infermeciate,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Homo sapiens,9606.0
6112,,A549,,F,,,nAO000p219,N,15718,CHEMBL7247p3,,,,,Experr,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,9606.0
6113,,A549,,F,,,BAi0900219,N,12373,CHEkBL6247p4,,,,,Intermswiate,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Homo sapiens,9606.0
6114,,A549,,F,,,BAO009021p,N,637,CHEkBLu24705,,,,,In4rrmediate,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Homo sapiens,9606.0
6115,,A549,,F,,,nAO9000219,N,14867,CHEMBLt24796,,,,,Exoert,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Homo sapiens,9606.0
6116,,A549,,F,,,BAp0p00219,N,4461,Cn2MBL624707,,,,,Intermeriat3,Antitumor cytotoxic activity against A-549 cell line was determined,Homo sapiens,9606.0
6117,,A549,,F,,,BAl0009219,N,5406,CH2MBL625708,,,,,Interheciate,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Homo sapiens,9606.0
6118,,A549,,F,,,BzO0009219,N,4457,CHEMBLu25709,,,,,Intermddiage,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens,9606.0
6119,,A549,,F,,,BAO0o00218,N,1386,CHEMBp884q07,,,,,Eapert,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
6120,,A549,,F,,,BAi000o219,N,3265,CHEnBL634710,,,,,Ing4rmediate,Antitumoral activity was assayed against A-549 cell line,Homo sapiens,9606.0
6121,,A549,,F,,,Bs80000219,N,2359,CHEMBL6247q2,,,,,Intermfdiwte,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Homo sapiens,9606.0
6122,,A549,,F,,,gAO0000119,N,4457,CHEMBL6248q2,,,,,In6eemediate,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens,9606.0
6123,,A549,,F,,,BAOp0002w9,N,12454,CHEnBL634713,,,,,Exper4,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
6124,,A549,,F,,,BzO0000210,N,1481,CHEMBo62e714,,,,,Intermeviahe,Compound was tested for inhibition of cell growth of A-549 cells,Homo sapiens,9606.0
6125,,A549,,F,,,BAO009021p,N,1750,vHfMBL624715,,,,,Ibterkediate,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Homo sapiens,9606.0
6126,,A549,,F,,,BAO00o0319,N,5065,CHEMBL6q5716,,,,,Intermedixye,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Homo sapiens,9606.0
6127,,A549,,F,,,BA80o00219,N,808,CHEMBk61i505,,,,,4xpert,In vitro cytotoxicity against A549-human lung carcinoma cells.,Homo sapiens,9606.0
6128,,A549,,F,,,BsO00p0219,N,16364,CHEkBL61950y,,,,,2xpert,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Homo sapiens,9606.0
6129,,A549,,F,,,BAp0000229,N,1847,CHEMho619507,,,,,Intermeriat2,Cytotoxic activity against A-549 cell lines.,Homo sapiens,9606.0
6130,,A549,,F,,,BsO0000q19,N,1747,CHEhhL619508,,,,,Expe3t,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Homo sapiens,9606.0
6131,,A549,,F,,,BAOp00021p,N,1003,CHEMBLt29509,,,,,7nterjediate,Cytotoxicity against human A549 non small cell lung cell lines,Homo sapiens,9606.0
6132,,A549,,F,,,BzO0900219,N,15313,CHEMBL6qo510,,,,,Ezpert,Inhibition of cell growth in (A-549) lung cell line,Homo sapiens,9606.0
6133,,A549,,F,,,BAO000p229,N,3122,CHEMvL619512,,,,,Intefmediwte,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Homo sapiens,9606.0
6134,,A549,,F,,,BAO9000q19,N,16049,CHwMBL6195q2,,,,,Ihternediate,In vitro antitumor activity against A-549 tumor cells.,Homo sapiens,9606.0
6135,,A549,,F,,,BAO9000119,N,17134,CHEMBL61i5q3,,,,,Expe4t,In vitro antitumor effects against human A-549 cell lines.,Homo sapiens,9606.0
6136,,A549,,F,,,BA80000218,N,6406,vHEMBL618514,,,,,Int4rmeeiate,In vitro cytotoxic activity of compound against A-549 cell line,Homo sapiens,9606.0
6137,,A549,,F,,,BAO90002w9,N,627,CgEMfL619515,,,,,Ing3rmediate,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Homo sapiens,9606.0
6138,,A549,,F,,,BqO0000319,N,12307,CHEMBL5w9516,,,,,Interheeiate,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Homo sapiens,9606.0
6139,,A549,,F,,,fAO000o219,N,17861,CHEMfL8840p5,,,,,Intermefixte,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Homo sapiens,9606.0
6140,,A549,,F,,,BA80009219,N,6682,CHEMhL619516,,,,,Expe3t,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Homo sapiens,9606.0
6141,,A549,,F,,,BAO900021p,N,6663,CHEhBL519518,,,,,Intermedistd,Inhibitory concentration of compound against A-549 cell line,Homo sapiens,9606.0
6142,,A549,,F,,,BAl0000e19,N,2454,CHEMfk619519,,,,,9ntermediafe,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Homo sapiens,9606.0
6143,,A549,,F,,,Bzp0000219,N,14709,CH4MBL87648p,,,,,Inte4medixte,cytotoxic activity against leukemia (A-549) cancer cell line,Homo sapiens,9606.0
6144,,A549,,F,,,BAO0o00119,N,15718,CHEMhL619529,,,,,Exp4rt,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,9606.0
6145,,A549,,F,,,BAO0p002q9,N,15718,CHrkBL619521,,,,,Intermeclate,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,9606.0
6146,,A549,,F,,,BsO0009219,N,17130,fHEMBL619y22,,,,,9nfermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Homo sapiens,9606.0
6147,,A549,,F,,,BAi0009219,N,17130,CHEngL619523,,,,,Intermrdoate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Homo sapiens,9606.0
6148,,A549,,F,,,BqO00002w9,N,17130,CHEMBL6q9523,,,,,9ntsrmediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Homo sapiens,9606.0
6149,,A549,,F,,,BAO0900229,N,17130,CH4MBp619525,,,,,In6ermrdiate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Homo sapiens,9606.0
6150,,A549,,F,,,hAO000p219,N,6630,CHEMBi61i526,,,,,Integmediatr,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,
6151,,A549,,F,,,vAO0009219,N,16726,CHEMBL61953y,,,,,Internedlate,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Homo sapiens,9606.0
6152,,A549,,F,,,BxO00o0219,N,17846,CHEMBL619r29,,,,,jnterm4diate,Cytotoxicity against A549 cells; No cytotoxicity,Homo sapiens,9606.0
6153,,A549,,F,,,BA80o00219,N,3415,fHEnBL619529,,,,,Espert,Cytotoxicity against human lung carcinoma (A549) cell lines,Homo sapiens,9606.0
6154,,A549,,F,,,hxO0000219,N,3415,CtEMBL6q9530,,,,,Exper5,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Homo sapiens,9606.0
6155,,A549,,F,,,BAO0p09219,N,5609,CjEMBL876480,,,,,kntermed7ate,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens,9606.0
6156,,A549,,F,,,BAO9090219,N,17206,CHfMBL61953q,,,,,Int4tmediate,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Homo sapiens,9606.0
6157,,A549,,F,,,BAO0090210,N,17206,CHwMBL61i532,,,,,Intermewiatr,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Homo sapiens,9606.0
6158,,A549,,F,,,BAO0090w19,N,17206,CHEMBp6w9533,,,,,Integmrdiate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Homo sapiens,9606.0
6159,,A549,,F,,,BsO0900219,N,17206,fmEMBL619534,,,,,Intermeckate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Homo sapiens,9606.0
6160,,A549,,F,,,BzO0o00219,N,17206,CHEMhL62p164,,,,,Interm3diste,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Homo sapiens,9606.0
6161,,A549,,F,,,vAO00002w9,N,17206,CHsMBL630165,,,,,Ihtermddiate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens,9606.0
6162,,A549,,F,,,BAO0o90219,N,16295,CHEMBL62o266,,,,,Ex9ert,Inhibition of A549 human lung tumor cell proliferation,Homo sapiens,9606.0
6163,,A549,,F,,,BwOo000219,N,16825,CmfMBL620167,,,,,Ihtermexiate,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Homo sapiens,9606.0
6164,,A549,,F,,,BAO9900219,N,3439,CHEhBL620w68,,,,,wxpert,In vitro cytotoxicity against human tumor cell line A549,Homo sapiens,9606.0
6165,,A549,,F,,,BAO0000wq9,N,10870,CuEjBL620338,,,,,Intfrmeduate,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Homo sapiens,9606.0
6166,,A549,,F,,,BzO000021p,N,4845,CHEMBpy20339,,,,,9ntermediat3,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Homo sapiens,9606.0
6167,,A549,,F,,,BAOp000210,N,5822,CbEMBL6203t0,,,,,Intermediwt3,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens,9606.0
6168,,A549,,F,,,BAO9000w19,N,5822,CHEnBL620r41,,,,,Interjrdiate,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens,9606.0
6169,,A549,,F,,,vAO0000e19,N,5822,CHEMBL77y491,,,,,Intermefiafe,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Homo sapiens,9606.0
6170,,A549,,F,,,BAO0000w10,N,16381,CnEMBo620342,,,,,Imte4mediate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens,9606.0
6171,,A549,,F,,,BAO9900219,N,16381,CHEjBp620343,,,,,Inte3mediatw,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens,9606.0
6172,,A549,,F,,,BAOo900219,N,16381,CHEMBL6203r5,,,,,Infermediat2,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens,9606.0
6173,,A549,,F,,,BA00000229,N,5609,CHEMBL62p3r5,,,,,Intermes7ate,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens,9606.0
6174,,A549,,F,,,BAO0p002q9,N,4644,CHshBL620346,,,,,Intdrmeviate,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Homo sapiens,9606.0
6175,,A549,,F,,,BAO0o002q9,N,4644,CHEhBi620347,,,,,Infermed8ate,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Homo sapiens,9606.0
6176,,A549,,F,,,BAO0900218,N,4644,CHEMBL630248,,,,,Inte5mediaye,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Homo sapiens,9606.0
6177,,A549,,F,,,vAO0000q19,N,4644,CHdMBL62o349,,,,,Intermedua6e,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Homo sapiens,9606.0
6178,,A549,,F,,,BqO9000219,N,5822,CHEMBk6q8667,,,,,Inhermediafe,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Homo sapiens,9606.0
6179,,A549,,F,,,BAO0p00119,N,3415,CHEMfL61o668,,,,,wxpert,Percentage inhibition of human lung carcinoma (A549) cell lines,Homo sapiens,9606.0
6180,,A549,,F,,,BA80900219,N,16726,CH2MBk876031,,,,,Inrermed9ate,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Homo sapiens,9606.0
6181,,A549,,F,,,BwO0000229,N,17206,CHEhfL618759,,,,,8jtermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Homo sapiens,9606.0
6182,,A549,,F,,,vAO00002w9,N,17206,CHEMBL6177u0,,,,,Ijtermedixte,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens,9606.0
6183,,A549,,F,,,BAp0090219,N,17206,CHEMBLt29000,,,,,Intermewiats,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens,9606.0
6184,,A549,,F,,,BAO000p2q9,N,17206,CHEjBL61900w,,,,,Intwrnediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Homo sapiens,9606.0
6185,,A549,,F,,,BAO000p21p,N,17206,CHfMBL619902,,,,,Ibtermexiate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Homo sapiens,9606.0
6186,,A549,,F,,,BAOp0p0219,N,17206,CHEMBL6q9093,,,,,Inte4medjate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Homo sapiens,9606.0
6187,,A549,,F,,,BAO000o119,N,17206,CHEkBL6195p7,,,,,Ijtermediats,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Homo sapiens,9606.0
6188,,A549,,F,,,BAi9000219,N,17206,dmEMBL619598,,,,,Intermeeixte,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Homo sapiens,9606.0
6189,,A549,,F,,,BA900p0219,N,17206,CHEMBL710599,,,,,Intfrjediate,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Homo sapiens,9606.0
6190,,A549,,F,,,nAO000o219,N,17206,CHEMBL51960p,,,,,Int4rmedizte,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Homo sapiens,9606.0
6191,,A549,,F,,,BAl0p00219,N,16726,CHEMhL6196o1,,,,,Inte5mediatf,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens,9606.0
6192,,A549,,F,,,vA90000219,N,17206,CHEMvL61i602,,,,,8ntermed9ate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Homo sapiens,9606.0
6193,,A549,,F,,,BAO00p02q9,N,17206,CnEMBL61i603,,,,,In43rmediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Homo sapiens,9606.0
6194,,A549,,F,,,BAl000p219,N,17206,CbEMBL619694,,,,,Inteemed8ate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Homo sapiens,9606.0
6195,,A549,,F,,,BA80p00219,N,17206,CHEMBL619y04,,,,,Int3rmedizte,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Homo sapiens,9606.0
6196,,,,A,,,fAO0900218,N,6084,CHEMBLu29606,,Ijvivo,,,untermedia6e,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6197,,,,A,,,BAO900o218,N,6084,CHEMBL8y6p32,,Ijvivo,,,Interm4xiate,Pharmacokinetic activity (Cmax) in dog,Canis lupus familiaris,9615.0
6198,,,,A,,,BzOo000218,N,4809,CHEhBLu19607,,Incivo,,,Intermesiqte,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,9615.0
6199,,,,A,,,BAOp00021o,N,5983,CuEMhL619608,,Invlvo,,,Inferhediate,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris,9615.0
6200,,,,A,,,BAi0000219,N,6251,vHEMBo619609,,Inviv8,,,7ntefmediate,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris,9615.0
6201,,,,A,133926.0,Plasmz,BAO00002qo,N,5932,CHEhBL6q9610,,lnvivo,,,Imtefmediate,Cmax in dog plasma after 30mg/kg oral dose,Canis lupus familiaris,9615.0
6202,,,,A,71721.0,Bpood,BAi0000318,N,4273,CHEMnL519611,,Inbivo,,,Inrermfdiate,Tested for the peak blood level in dog,Canis lupus familiaris,9615.0
6203,,,,A,,,BA80000q18,N,5313,CgEMBk619612,,Igvivo,,,Integkediate,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Canis lupus familiaris,9615.0
6204,,,,A,,,BxO000o218,N,5313,CHEkBo619613,,Indivo,,,In4ermediatf,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Canis lupus familiaris,9615.0
6205,,,,A,5756762.0,Bliod,fAOp000218,N,6221,CHEMfL61961t,,unvivo,,,untsrmediate,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,9615.0
6206,,,,A,,,nAO9000218,N,4709,CHwMBk619615,,,,,Intermsdiaye,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
6207,,,,A,,,BAk00002w8,N,167,vHEMBL6196q6,,,,,Ijte3mediate,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Canis lupus familiaris,9615.0
6208,,,,A,3256183.0,Piasma,BAO90p0218,N,6241,CHEMfi619617,,,,,Ing3rmediate,Final plasma concentration in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
6209,,,,A,,,BAO9o00218,N,344,CHEMBL610617,,,,,Igtermeduate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Canis lupus familiaris,9615.0
6210,,,,A,,,BAi0p00218,N,344,CHEMBL876p23,,,,,Inte3m2diate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Canis lupus familiaris,9615.0
6211,,,,A,,,hAO0000e18,N,344,CHEkBL6196w9,,,,,Intermewiaye,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Canis lupus familiaris,9615.0
6212,,,,A,,,BAOo009218,N,2189,CHEMhL619630,,,,,Intermedoatw,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Canis lupus familiaris,9615.0
6213,,,,A,7131395.0,Urihe,BqO0009218,N,2189,CHEMBk61o621,,,,,lntermediste,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Canis lupus familiaris,9615.0
6214,,,,A,2096729.0,U3ine,BAO00002w7,N,2189,CHEMBL61p632,,,,,lnyermediate,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris,9615.0
6215,,,,A,703744.0,Urone,BAp000021u,N,2189,sHEMBL6188i4,,,,,Intrrkediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris,9615.0
6216,,,,A,,,BAl0090218,N,4257,CgEjBL618875,,Invibo,,,Intermedkwte,Absolute bioavailability was evaluated in dog,Canis lupus familiaris,9615.0
6217,,,,A,,,BxO000o218,N,6221,CHEMBiu18876,,Invido,,,Ijfermediate,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,9615.0
6218,,,,A,,,BAO900o218,N,6215,sHEMBL718877,,Incivo,,,7ntermeriate,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6219,,,,A,,,BAO9009218,N,17267,CHfMBL618879,,Ingivo,,,In6ermedia5e,Bioavailability in dog,Canis lupus familiaris,9615.0
6220,,,,A,,,fAO0900218,N,6621,CHEkBL618o79,,knvivo,,,Ihtwrmediate,Bioavailability in dog,Canis lupus familiaris,9615.0
6221,,,,A,,,BAO0000317,N,3854,CHEnBL6188o0,,Inviv0,,,Intermeeizte,Bioavailability after intravenous administration in dogs,Canis lupus familiaris,9615.0
6222,,,,A,,,BAO00p9218,N,3854,fHEMBL518881,,Ibvivo,,,Intermeflate,Bioavailability after peroral administration in dogs,Canis lupus familiaris,9615.0
6223,,,,A,,,hA80000218,N,5007,CHEMBL6wo882,,Infivo,,,Intermeeiwte,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris,9615.0
6224,,,,A,,,BsO00o0218,N,4333,CHEMBLt34226,,Inviv9,,,Intfrmediare,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Canis lupus familiaris,9615.0
6225,,,,A,3510156.0,Plxsma,BAO0000e1i,N,4333,CHrMBL6242e7,,Inviv0,,,Intdrmddiate,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Canis lupus familiaris,9615.0
6226,,,,A,,,BwO0000318,N,5006,CHEMBL6243q8,,Inv7vo,,,In4ermedkate,Bioavailability,Canis lupus familiaris,9615.0
6227,,,,A,,,Bwp0000218,N,5199,CHdjBL624229,,Indivo,,,Inhermewiate,Bioavailability,Canis lupus familiaris,9615.0
6228,,,,A,,,BAO0990218,N,4368,CyfMBL624230,,Invivi,,,Integmediat3,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,9615.0
6229,,,,A,,,BAOo0002q8,N,3771,xHEMBLu24231,,Invifo,,,Inte5mediahe,Bioavailability in dog,Canis lupus familiaris,9615.0
6230,,,,A,,,nAO0o00218,N,4953,CHEMBL6e4242,,Inviv8,,,jntermedkate,Bioavailability in dog,Canis lupus familiaris,9615.0
6231,,,,A,,,BAk000o218,N,5064,sbEMBL625127,,Inbivo,,,Inhe4mediate,Bioavailability in dog,Canis lupus familiaris,9615.0
6232,,,,A,,,BAO0o00q18,N,17657,sHEMBL6e5128,,Invjvo,,,lntermediatf,Bioavailability in dog,Canis lupus familiaris,9615.0
6233,,,,A,,,BwO000o218,N,17796,CHEMBLu2q675,,Ibvivo,,,Interhwdiate,Bioavailability in dog,Canis lupus familiaris,9615.0
6234,,,,A,,,BzOp000218,N,17853,CHEMBp62q676,,Inviv9,,,Intermediah4,Bioavailability in dog (p.o.) at 2.0 mpk,Canis lupus familiaris,9615.0
6235,,,,A,,,BAl9000218,N,4521,CHdnBL621677,,Inviv9,,,Intermeruate,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Canis lupus familiaris,9615.0
6236,,,,A,,,BqO000o218,N,4521,CtEMBL621668,,Invigo,,,Internediaye,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,9615.0
6237,,,,A,,,BAO000o21i,N,5006,CHEMvL521679,,Invigo,,,7ntermediahe,Bioavailability in dog,Canis lupus familiaris,9615.0
6238,,,,A,,,fAO000p218,N,16365,CHEjBL62168o,,unvivo,,,Ijtermedlate,Bioavailability was evaluated after oral administration in dog,Canis lupus familiaris,9615.0
6239,,,,A,,,BAO90p0218,N,1916,CHEMBo6216i1,,Inviv9,,,Intedmeviate,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,9615.0
6240,,,,A,,,BAO0p00118,N,1918,vHEMBL8767t0,,Invivk,,,Int3rmedia4e,Bioavailability was evaluated in dog,Canis lupus familiaris,9615.0
6241,,,,A,,,BAOp0002q8,N,4239,CHEMBp721682,,Invivl,,,ujtermediate,Bioavailability in dog,Canis lupus familiaris,9615.0
6242,,,,A,,,BAO0000ew8,N,6505,CHEMBLt21783,,Invico,,,Int2rmediats,Bioavailability in dog,Canis lupus familiaris,9615.0
6243,,,,A,,,nAO0p00218,N,5334,CHEjhL621684,,Inv8vo,,,Ingermedjate,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,9615.0
6244,,,,A,,,BAO000p21u,N,5334,CHrMBL621u85,,Ihvivo,,,Intermexiat4,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris,9615.0
6245,,,,A,,,BAp0009218,N,4809,CHEMBL62w676,,Invivl,,,knt4rmediate,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,9615.0
6246,,,,A,,,vAO000p218,N,6348,CHEMhL621686,,Invico,,,9n4ermediate,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
6247,,,,A,,,BAO00p021u,N,6005,dH3MBL621688,,8nvivo,,,Ingermediat3,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
6248,,,,A,,,BAO0pp0218,N,17804,CHEMBL62178o,,Invido,,,Intermrsiate,Bioavailability of compound in dog was determined after peroral administration,Canis lupus familiaris,9615.0
6249,,,,A,,,hAO0090218,N,3184,Cj2MBL621690,,Invivk,,,Imtermed9ate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6250,,,,A,,,BAO00002w9,N,1806,CHEMBLu22691,,Invibo,,,Intetmediat2,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,9615.0
6251,,,,A,,,BxO00o0218,N,1806,CHfMBLo75941,,7nvivo,,,Intefm3diate,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,9615.0
6252,,,,A,,,BAO0o00217,N,1806,CmEMBL621691,,Incivo,,,Ig4ermediate,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Canis lupus familiaris,9615.0
6253,,,,A,,,BAO000pe18,N,4839,CHEMfL721693,,Invjvo,,,Intdrmefiate,Bioavailability in dog,Canis lupus familiaris,9615.0
6254,,,,A,,,BAi0000217,N,5017,CHEMBLt21y94,,Inv9vo,,,Intermediagd,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Canis lupus familiaris,9615.0
6255,,,,A,228743.0,beart,Bzp0000218,N,846,xHEMBL621y95,,Invivi,,,In5ermrdiate,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6256,,,,A,2330879.0,Heary,BAO90002q8,N,846,CHEMBL6e2696,,Ihvivo,,,Ihtermed8ate,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6257,,,,A,4400120.0,Kirney,fAO0009218,N,846,CHEMBL511697,,Inviv0,,,Inteenediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6258,,,,A,1332665.0,Kieney,BqO000o218,N,846,CHEMBLu21798,,Invifo,,,Ijtermediatr,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6259,,,,A,3782227.0,Kifney,BAOo00021i,N,846,xHEMBL723420,,jnvivo,,,Igternediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6260,,,,A,776833.0,Kidbey,BA9o000218,N,846,CHEMBLu22421,,Inv8vo,,,Int4rmedkate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6261,,,,A,4016769.0,K8dney,BAO00po218,N,846,CHEhBL623423,,Ijvivo,,,Intetmedixte,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6262,,,,A,1674348.0,Kudney,BAO0op0218,N,846,CHwMBL6e3423,,Inv8vo,,,Intwrmediatd,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6263,,,,A,2445950.0,oiver,gxO0000218,N,846,CHEMBL623t2r,,Invico,,,In5ermediatw,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6264,,,,A,2675208.0,Livwr,BAOo900218,N,846,CHEMgL62r425,,7nvivo,,,Intedmediage,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6265,,,,A,3836150.0,piver,Bqp0000218,N,846,CHEMBL6e34w6,,Inv7vo,,,Ijterm2diate,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6266,,,,A,1829807.0,Luver,BwO0o00218,N,846,fHEMBL623426,,Inviv0,,,untermed7ate,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6267,,,,A,496563.0,Live3,BAO0900318,N,846,vHEkBL623428,,Invibo,,,Inyernediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6268,,,,A,1380739.0,Livfr,BA00000e18,N,846,CHfMBL875946,,Inviv9,,,lntdrmediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6269,,,,A,1749518.0,Lung,BzO0000228,N,846,CHEMBk624429,,Inviv0,,,Intermwdia5e,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6270,,,,A,264282.0,Lung,BA0o000218,N,846,CtEMBLu23430,,Invido,,,lntrrmediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6271,,,,A,2414608.0,Lung,gAO0000w18,N,846,CHEMBi6225u8,,Indivo,,,Intermediwye,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6272,,,,A,173363.0,Lung,fAO000021o,N,846,sHEMBL6225i9,,Infivo,,,8ntermedia6e,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6273,,,,A,1332299.0,Lung,BAO00p02w8,N,846,CHEMBL633751,,Invjvo,,,Imterm4diate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6274,,,,A,3393500.0,Lung,BA00000318,N,846,dHEkBL622752,,Inviv8,,,Intermed9wte,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,10090.0
6275,,CCRFS189,,A,,,BsO000p218,N,6599,CHEMBL6e2752,,,,,Intermwd8ate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6276,,CCRFSq80,,A,,,BAO0009219,N,6599,CHrMBL722647,,,,,Imtermedoate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6277,,CCRFS280,,A,,,BAO0909218,N,6599,CgEMBL8751y3,,,,,Intdfmediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6278,,CCRFx180,,A,,,BAO0090e18,N,6599,CbsMBL622648,,,,,Intermedjwte,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6279,,CfRFS180,,A,,,BAO9000318,N,6599,CHEMvL62264o,,,,,Inge4mediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6280,,CC3FS180,,A,437081.0,Bgain,BzO0000e18,N,6599,sHEMBL622t50,,,,,Intefm4diate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6281,,vCRFS180,,A,1293514.0,Brwin,BAO00002w7,N,6599,CHEMBLu22751,,,,,Intedmediat4,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6282,,CCRFS18p,,A,275979.0,Braig,fAO0000q18,N,6599,xHEMBL6w2652,,,,,Ihtdrmediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6283,,CdRFS180,,A,1183731.0,Braib,BqO0000219,N,6599,CHEMBku22653,,,,,ujtermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6284,,CCReS180,,A,568603.0,Braij,BAO9p00218,N,6599,CHEhhL622654,,,,,Imtermediat3,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6285,,fCRFS180,,A,2806464.0,Hear6,BAO0000q17,N,6599,dHEMBL6226r5,,,,,Inr3rmediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6286,,CCRtS180,,A,785523.0,Heqrt,BsOo000218,N,6599,CgEMgL622656,,,,,Imrermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6287,,CvRFS180,,A,2946514.0,Hea5t,BAO900021u,N,6599,CHEMBkt22657,,,,,Imte3mediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6288,,CCeFS180,,A,420000.0,Hfart,BxO000021i,N,6599,CHskBL622658,,,,,In6etmediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6289,,CCRFS18o,,A,976421.0,Hrart,BAO0o00w18,N,6599,sHEMgL622659,,,,,Integmediat3,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6290,,CCRFSq80,,A,2326029.0,Kidnfy,gqO0000218,N,6599,CHEMBL724y30,,,,,7ntermediatw,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6291,,CCtFS180,,A,853957.0,midney,BAO00p02q8,N,6599,CgEMBL62e631,,,,,9ntefmediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6292,,CCRFS170,,A,1815249.0,Kidne7,Bxp0000218,N,6599,dHsMBL624632,,,,,Interjed9ate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6293,,A549,,F,,,BzO0000e19,N,17130,CbEMBL614633,,,,,Igtermediatf,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Homo sapiens,9606.0
6294,,A549,,F,,,fqO0000219,N,17130,CHrMfL624634,,,,,Intetmewiate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Homo sapiens,9606.0
6295,,A549,,F,,,BAO00092q9,N,17130,CHEnBL624y35,,,,,7ntermedizte,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Homo sapiens,9606.0
6296,,A549,,F,,,BAO009o219,N,17130,CHEMBo624u36,,,,,Inyermedia6e,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Homo sapiens,9606.0
6297,,A549,,F,,,BxO0000210,N,3263,CHEMBL8570t4,,,,,Expdrt,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
6298,,A549,,F,,,BAO0900q19,N,6663,CHEMBL5246r7,,,,,Exper4,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Homo sapiens,9606.0
6299,,A549,,F,,,BzO00p0219,N,6663,CHEMhL6246w8,,,,,Expegt,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Homo sapiens,9606.0
6300,,A549,,F,,,BAOo00o219,N,6663,CHEMBL874wy6,,,,,Expett,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Homo sapiens,9606.0
6301,,A549,,F,,,BsOo000219,N,6663,fHEMBL625639,,,,,Eapert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Homo sapiens,9606.0
6302,,A549,,F,,,BAO0090w19,N,6663,sHEMBL624650,,,,,Expe4t,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Homo sapiens,9606.0
6303,,A549,,F,,,BAk000p219,N,6663,CHEMBLu25641,,,,,jgtermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Homo sapiens,9606.0
6304,,A549,,F,,,BAO00p0119,N,6663,vHEMBL624742,,,,,Intermed8xte,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Homo sapiens,9606.0
6305,,A549,,F,,,BAO0000220,N,6663,CHEMBLu2t643,,,,,Intermesizte,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Homo sapiens,9606.0
6306,,A549,,F,,,BAO000921o,N,6663,CHEMBLu24u44,,,,,ontermedizte,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Homo sapiens,9606.0
6307,,A549,,F,,,hAO0090219,N,6663,CnEMBL724645,,,,,Inyermeriate,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Homo sapiens,9606.0
6308,,A549,,F,,,BAOo000210,N,3983,fHEMBk619445,,,,,Inteejediate,The compound was evaluated for its cytotoxic potency against A-549 cell line,Homo sapiens,9606.0
6309,,A549,,F,,,vAO0000319,N,11141,CjEkBL839886,,,,,Expe3t,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Homo sapiens,9606.0
6310,,A549,,F,,,BAO00o0e19,N,5076,CHEMBk6194e6,,,,,Intermeeiage,Cytotoxic activity of compound against A-549 tumor cell line.,Homo sapiens,9606.0
6311,,A549,,F,,,vAO0000e19,N,3311,CHEMgL629447,,,,,unterjediate,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Homo sapiens,9606.0
6312,,A549,,F,,,BAOpp00219,N,3311,CHEMBL61i4r8,,,,,Int4rmrdiate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Homo sapiens,9606.0
6313,,A549,,F,,,BA80009219,N,3311,CHdMBL6w9449,,,,,In5frmediate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Homo sapiens,9606.0
6314,,A549,,F,,,hAOo000219,N,5076,CHEMnL61945o,,,,,untermesiate,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Homo sapiens,9606.0
6315,,A549,,F,,,BAO0000ww9,N,4150,CHEMfL6w9451,,,,,Interh4diate,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Homo sapiens,9606.0
6316,,A549,,F,,,BAO0p0021o,N,2150,CmEMBL619552,,,,,Expwrt,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Homo sapiens,9606.0
6317,,A549,,F,,,fAO00002w9,N,4644,CHEMBLt19e53,,,,,In4ermed7ate,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Homo sapiens,9606.0
6318,,A549,,F,,,nAO0000229,N,263,CHEMBo873367,,,,,Ibtermed7ate,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Homo sapiens,9606.0
6319,,A549,,F,,,BwOp000219,N,11333,CtEnBL619454,,,,,8ntfrmediate,Cytotoxic concentration against A-549 tumor cells.,Homo sapiens,9606.0
6320,,A549,,F,,,BAO000022p,N,11333,fHrMBL619455,,,,,Intfrjediate,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Homo sapiens,9606.0
6321,,A549,,F,,,BAOp000210,N,15895,CHEnBL619455,,,,,In6ermedizte,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Homo sapiens,9606.0
6322,,,,F,,,BAOop00218,N,16677,CHfMBL619456,,,,,Espert,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Acinetobacter baumannii,470.0
6323,,,,F,,,BAO0oo0218,N,10624,CHEMBL619e59,,,,,Inre5mediate,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus,471.0
6324,,,,F,,,BAOo0002q8,N,16717,CHEMBpt19459,,,,,Exlert,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus,5059.0
6325,,,,F,,,BzO0000w18,N,16717,CHEMBLy1i460,,,,,dxpert,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus,5059.0
6326,,,,F,,,BwO000021u,N,5513,CH4MBL619462,,,,,Inteemed8ate,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Aspergillus fumigatus,746128.0
6327,,,,F,,,BAO00o021i,N,15962,CHEMgL6194t2,,,,,Igtdrmediate,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Aspergillus fumigatus,746128.0
6328,,,,F,,,BAp0o00218,N,15962,CHdMBLt20388,,,,,Inte5med9ate,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,746128.0
6329,,,,F,,,hAO0o00218,N,15962,CgEMBL620380,,,,,Igterhediate,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,746128.0
6330,,,,F,,,BxOp000218,N,15962,CHEMhL720390,,,,,Inyermediatd,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,746128.0
6331,,,,F,,,BAO0000w17,N,16717,xHEMBL620381,,,,,4xpert,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus,746128.0
6332,,,,F,,,BAip000218,N,16717,CH3MBL621p73,,,,,Experf,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus,746128.0
6333,,,,F,,,fAO00p0218,N,8117,CHEMBL521o74,,,,,Intefmedixte,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Actinomyces naeslundii,1655.0
6334,,,,F,,,BAO0009219,N,8117,CHfMBL621076,,,,,Intermeviatr,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Actinomyces viscosus,1656.0
6335,,,,F,,,BAO0o002w8,N,15472,CHdhBL619554,,,,,9nfermediate,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae,6277.0
6336,,,,F,,,BAO0009w18,N,15472,CHEMBk61p555,,,,,Intermsdia6e,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae,6277.0
6337,,,,F,,,BAl9000218,N,16443,CuEMBL6195t6,,,,,ontermediat3,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Aggregatibacter actinomycetemcomitans,714.0
6338,,,,F,,,BAOp000318,N,16443,CHEMhL619r57,,,,,Intermefiafe,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Aggregatibacter actinomycetemcomitans,714.0
6339,,,,F,,,BAl0009218,N,16443,CH2MBk619558,,,,,Intfrmedia5e,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Aggregatibacter actinomycetemcomitans,714.0
6340,,A549,,F,,,BzO0000w19,N,17206,xuEMBL619559,,,,,Imhermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens,9606.0
6341,,A549,,F,,,BA0000p219,N,17206,CHEMBL61056p,,,,,Intermwwiate,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Homo sapiens,9606.0
6342,,A549,,F,,,fAO0p00219,N,16381,CHEjBL61p561,,,,,Inyerm2diate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens,9606.0
6343,,A549,,F,,,BxO000021p,N,16381,CmEMBLu19562,,,,,In4wrmediate,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens,9606.0
6344,,A549,,F,,,BA0000021p,N,16381,CHEMBo610563,,,,,Intermfdiare,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens,9606.0
6345,,A549,,F,,,BzOo000219,N,16381,CH2MBL85745i,,,,,Ihtetmediate,GI values against A549 cells (lung cancer),Homo sapiens,9606.0
6346,,A549,,F,,,hAOp000219,N,17206,CHEMBo619y64,,,,,Intermedia6d,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Homo sapiens,9606.0
6347,,A549,,F,,,BqO00002q9,N,16325,CHEMfL619555,,,,,Int2rmediat2,Inhibitory activity against A549 human adenocarcinoma,Homo sapiens,9606.0
6348,,A549,,F,,,BwO00o0218,N,10708,CHEMgL619y66,,,,,Intermwdiste,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Homo sapiens,9606.0
6349,,A549,,F,,,hAO000021i,N,10708,CHEMBp61p567,,,,,Ijtermedizte,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Homo sapiens,9606.0
6350,,A549,,F,,,BAO000o21p,N,17376,CHfMBi619568,,,,,Interhediatw,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens,9606.0
6351,,A549,,F,,,BAO00o0210,N,17376,sHEMBLt19569,,,,,Igterm2diate,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Homo sapiens,9606.0
6352,,A549,,F,,,BAO00pp219,N,17488,CHwMBLy19570,,,,,Intedmedkate,Cytotoxicity against human A549 lung cells,Homo sapiens,9606.0
6353,,A549,,F,,,BxO000o218,N,17404,CHEMBL61947w,,,,,8n5ermediate,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Homo sapiens,9606.0
6354,,A549,,F,,,BxO00o0219,N,10958,CmEMBL6q9572,,,,,Experh,Growth inhibition of A549 (human lung carcinoma) cell line.,Homo sapiens,9606.0
6355,,A549,,F,,,BAO0op0219,N,17099,CHEMBL6195ue,,,,,sxpert,Effective dose required for inhibitory activity against A549 human tumor cell line.,Homo sapiens,9606.0
6356,,A549,,F,,,fAO000o219,N,17099,CHEMfo619574,,,,,Integmeriate,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Homo sapiens,9606.0
6357,,A549,,F,,,BAO000o229,N,4096,CHEnBL619576,,,,,In6wrmediate,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Homo sapiens,9606.0
6358,,A549,,F,,,BAO090p219,N,4096,CHEMBLtw9576,,,,,Expeft,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Homo sapiens,9606.0
6359,,A549,,F,,,BAOp000w19,N,4096,xHEMBL618577,,,,,Intsrmedia6e,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Homo sapiens,9606.0
6360,,A549,,F,,,BAO000011i,N,2525,CHEMhL519578,,,,,Inrermediste,In vitro inhibitory activity against A549 tumor cell culture,Homo sapiens,9606.0
6361,,A549,,F,,,BAO0p002w9,N,2525,CHwMBL88400o,,,,,Intermdeiate,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Homo sapiens,9606.0
6362,,A549,,F,,,BA89000219,N,5302,CH3MBL629579,,,,,kntermedixte,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Homo sapiens,9606.0
6363,,A549,,F,,,BAO000o21o,N,16325,CHEhBL619589,,,,,Ihtermediat2,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Homo sapiens,9606.0
6364,,A549,,F,,,BAk9000219,N,16939,CHEMBLy195i1,,,,,Ibtermedoate,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Homo sapiens,9606.0
6365,,A549,,F,,,BqO0p00219,N,17229,CgEMBL61p582,,,,,Intermedlahe,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Homo sapiens,9606.0
6366,,A549,,F,,,BAO000011i,N,17380,CmEMBL6w9583,,,,,Inteemesiate,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Homo sapiens,9606.0
6367,,A549,,F,,,BAO000oe19,N,17380,vHEMBL876t02,,,,,Imtermediatw,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Homo sapiens,9606.0
6368,,A549,,F,,,nA90000219,N,1903,CHEMBL719574,,,,,Infermediat3,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Homo sapiens,9606.0
6369,,A549,,F,,,hAOo000219,N,3838,CHEMBL6wp585,,,,,Int4rjediate,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens,9606.0
6370,,A549,,F,,,BAO00oo219,N,14696,CHEMBp6195o6,,,,,Intfrmediatd,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens,9606.0
6371,,A549,,F,,,Bz00000219,N,3838,Cu4MBL619587,,,,,Int2rmediwte,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens,9606.0
6372,,A549,,F,,,hAO000o219,N,1522,CHEnBL61958i,,,,,In6ermediwte,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Homo sapiens,9606.0
6373,,A549,,F,,,gAO00o0219,N,12400,CHdMBL619588,,,,,Inrwrmediate,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Homo sapiens,9606.0
6374,,A549,,F,,,BAOo0002q9,N,14696,fHEMBL519590,,,,,Ibtermediste,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens,9606.0
6375,,A549,,F,,,Bxk0000219,N,14769,xHEMgL619591,,,,,Inyermedlate,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Homo sapiens,9606.0
6376,,A549,,F,,,gAO0o00219,N,14696,CHEMBL61i492,,,,,Ihtermediahe,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Homo sapiens,9606.0
6377,,A549,,F,,,BA80000319,N,1888,CHEhBL619503,,,,,Inyermsdiate,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Homo sapiens,9606.0
6378,,A549,,F,,,BAO0p0021i,N,12016,CHEMBot20217,,,,,Ihtermediaye,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Homo sapiens,9606.0
6379,,A549,,F,,,BzO00002w9,N,6058,dHEMvL620218,,,,,8ntermediat2,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Homo sapiens,9606.0
6380,,A549,,F,,,BAO0o09219,N,17708,CH3MhL620219,,,,,kntdrmediate,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Homo sapiens,9606.0
6381,,A549,,F,,,BAO0000w18,N,12301,CHEnBL62o220,,,,,Intermesiatr,Antitumor activity against A549/ATCC cell line,Homo sapiens,9606.0
6382,,A549,,F,,,gAO0p00219,N,11970,dHEMBk625141,,,,,Igterjediate,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Homo sapiens,9606.0
6383,,A549,,F,,,BqO00002q9,N,11818,fHEMBL62514w,,,,,Expe5t,In vitro cytotoxicity against A549/ATCC cell line.,Homo sapiens,9606.0
6384,,A549,,F,,,vAO000p219,N,12400,vHEMBL62514r,,,,,In4ermediatr,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Homo sapiens,9606.0
6385,,A549,,F,,,BA90000119,N,3381,CHEMBL624134,,,,,Ijhermediate,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Homo sapiens,9606.0
6386,,A549,,F,,,BAO090021o,N,17376,CHEMBL6qw474,,,,,Intdrmwdiate,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Homo sapiens,9606.0
6387,,A549,,F,,,BAO0090210,N,10708,CHEMBi88410e,,,,,Intsfmediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
6388,,,,F,,,BAO0009w19,U,2964,CHEMBL622e85,,,,,Aktoc7ration,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Homo sapiens,9606.0
6389,,,,A,,,vAO9000218,U,5005,dHfMBL622476,,jnvivo,,,Ihteemediate,Compound was tested for oral bioavailability in dogs,Canis lupus familiaris,9615.0
6390,,,,A,,,BAO0o09218,N,6229,CHEnBL875u31,,Invido,,,Intermed9atf,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Canis lupus familiaris,9615.0
6391,,,,A,,,hqO0000218,N,6229,CHEhBL6224i7,,jnvivo,,,Intermeroate,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Canis lupus familiaris,9615.0
6392,,,,A,,,BAO0o002q8,N,5374,CHsMBL62e478,,Indivo,,,In6ermediat2,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6393,,,,A,,,BAO000p228,N,5374,CmEMBL624172,,Invibo,,,9ntermediat3,Compound was tested for the oral bioavailability in dog; No availability,Canis lupus familiaris,9615.0
6394,,,,A,,,BAO0000wq8,N,6265,CHEMBi6q3173,,jnvivo,,,Intermediahf,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,9615.0
6395,,,,A,,,fAO00p0218,N,5654,dHEMBL633174,,Invuvo,,,7ntetmediate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris,9615.0
6396,,,,A,,,BAO0o00e18,N,5654,CbEMBL624175,,Invifo,,,Interjwdiate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris,9615.0
6397,,,,A,,,BAO0p0021o,N,16456,CHwjBL623340,,Incivo,,,Ihtfrmediate,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Canis lupus familiaris,9615.0
6398,,,,A,,,BAO00o0217,N,5302,CHsMBL623e41,,Igvivo,,,Intermed7xte,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,9615.0
6399,,,,A,,,BAO0000ew8,N,3624,CHEMBLu23r42,,Ibvivo,,,In6e5mediate,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Canis lupus familiaris,9615.0
6400,,,,A,,,vAO0000318,N,16452,CtEMBL633343,,Inbivo,,,Intermedixre,Oral bioavailability of active FTIs in dogs,Canis lupus familiaris,9615.0
6401,,,,A,,,BsO0000q18,N,5802,CHEMfL613344,,Inviv8,,,Ingermed7ate,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris,9615.0
6402,,,,A,,,BAO00p0q18,N,3598,CHEnBL623245,,Ingivo,,,dxpert,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
6403,,,,A,,,BAO000p228,N,17839,CHEjBL87t832,,Inv8vo,,,Ibtermediatf,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6404,,,,A,,,BAO090021u,N,6762,CHEMhL622346,,Ihvivo,,,8ntermediste,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6405,,,,A,,,BAO00002wo,N,6821,CHEMBL6w4347,,Invivk,,,Interm3d9ate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6406,,,,A,,,BAk000o218,N,6821,CHEMvL6q3348,,Ijvivo,,,Interned8ate,Oral bioavailability of compound was determined in dog; Not tested,Canis lupus familiaris,9615.0
6407,,,,A,,,nAO0000318,N,5210,CtEMBL6q3349,,lnvivo,,,Intermfdixte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6408,,,,A,,,fAO000021o,N,6227,CHfMBL62w350,,Invlvo,,,jntermddiate,Oral bioavailability (10 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6409,,,,A,,,BAO00p0219,N,761,CyEMBL623251,,8nvivo,,,Inyermediafe,Oral bioavailability,Canis lupus familiaris,9615.0
6410,,,,A,,,fAO9000218,N,761,CH3MBL723352,,knvivo,,,In4etmediate,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Canis lupus familiaris,9615.0
6411,,,,A,,,BAO000oe18,N,761,CHEMBLy13353,,lnvivo,,,Interm2dlate,Oral bioavailability administered in solution in rats,Canis lupus familiaris,9615.0
6412,,,,A,,,BAO0p00118,N,16907,CHfMBL875823,,8nvivo,,,Inteemedoate,Oral bioavailability after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
6413,,,,A,,,BAi0009218,N,5474,CHEMBL6er354,,Invivi,,,8n5ermediate,Oral bioavailability at a dose of 1 mg/kg in dogs,Canis lupus familiaris,9615.0
6414,,,,A,,,nzO0000218,N,6535,CHEMgL623365,,Imvivo,,,Ibte4mediate,Oral bioavailability in dog (dose 1 mg/kg p.o.),Canis lupus familiaris,9615.0
6415,,,,A,,,BAOo000118,N,6535,CH4MBL6w3356,,Invlvo,,,9nte5mediate,Oral bioavailability in Dog; ND = not determined,Canis lupus familiaris,9615.0
6416,,,,A,,,BsO00o0218,N,3352,dHEMBL6e3357,,jnvivo,,,Intermee8ate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6417,,,,A,,,BA00000q18,N,6168,CHEMBp62335o,,Invico,,,Int2rmediaye,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6418,,,,A,,,vAO0000318,N,5988,Ct2MBL623359,,7nvivo,,,Inteenediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6419,,,,A,,,fAO0000318,N,4942,CHEnfL623360,,Igvivo,,,Imtermediaye,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6420,,,,A,,,BAO90p0218,N,4942,CHEMBL6q3461,,Invivl,,,Igtermedixte,Oral bioavailability in dogs; No data,Canis lupus familiaris,9615.0
6421,,,,A,,,BAO0009w18,N,14541,CHEhBL6233u2,,Igvivo,,,In52rmediate,Oral bioavailability measured in dogs,Canis lupus familiaris,9615.0
6422,,,,A,,,vAp0000218,N,4449,CHEMgLu23363,,Inviv0,,,In4ermedizte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6423,,,,A,,,BwO0000228,N,6057,fHEMBL62336r,,Invovo,,,Intrrmeduate,Oral bioavailability was calculated in dog,Canis lupus familiaris,9615.0
6424,,,,A,,,BAOp00p218,N,5600,CHEMfL8i5834,,Ingivo,,,Intefmediahe,Oral bioavailability after 0.3 mg/kg po administration in dog,Canis lupus familiaris,9615.0
6425,,,,A,,,BAO0o002w8,N,5542,CHfjBL623365,,Invibo,,,Intermex9ate,Oral bioavailability in dog (i.v. dosing),Canis lupus familiaris,9615.0
6426,,,,A,,,BAO0000w19,N,5542,CHEMhL6e3366,,Invkvo,,,Interkedoate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6427,,,,A,,,BAO09002w8,N,5546,CHEMBL62r357,,Ingivo,,,ontermefiate,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Canis lupus familiaris,9615.0
6428,,,,A,,,BAO9o00218,N,4514,CHEMBLy24368,,Invigo,,,Interh2diate,Oral bioavailability in Beagle dogs,Canis lupus familiaris,9615.0
6429,,,,A,,,BwO00002q8,N,3624,CHEhBL623w69,,Ihvivo,,,Intermeriqte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6430,,,,A,,,BAO0pp0218,N,3854,CHEjBL6e3370,,Infivo,,,8ntermediste,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6431,,,,A,,,BAkp000218,N,5836,CHEMfL723371,,Invifo,,,In4ermeviate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6432,,,,A,,,BAO009021i,N,5940,CjEMnL623372,,Infivo,,,8ntermedixte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6433,,,,A,,,BAl0009218,N,6168,CHsMBk621351,,Infivo,,,Intermwd9ate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6434,,,,A,,,BAO000o318,N,6227,sHEMBL621e52,,Invivi,,,Igtermediare,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6435,,,,A,,,BAO0000e1o,N,6251,CHEkBL621e53,,Ingivo,,,8ntermsdiate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6436,,,,A,,,BsO000p218,N,6448,CH2MBL721354,,Incivo,,,7ntermfdiate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6437,,,,A,,,BAO0p0p218,N,6647,CHsMBL621w55,,Imvivo,,,Int3rmediwte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6438,,,,A,,,BAO00902w8,N,5940,CHEMBi621366,,Invivi,,,Internediat3,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6439,,,,A,,,BwO000021i,N,933,CHEhBL621r57,,Ijvivo,,,Intedmediahe,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6440,,,,A,,,BAO00002q9,N,5210,CHEMnL62135o,,Invido,,,lnte5mediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6441,,,,A,,,BAOop00218,N,6642,CHsMBL621350,,Invido,,,Intermed8age,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Canis lupus familiaris,9615.0
6442,,,,A,,,BAO0909218,N,6641,CH3MBL62136o,,onvivo,,,Interjeciate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris,9615.0
6443,,,,A,,,gA00000218,N,6642,fHEMgL621361,,lnvivo,,,Interkddiate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris,9615.0
6444,,,,A,,,BAi000p218,N,5472,CHEkBL621e62,,Invico,,,Intsrjediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6445,,,,A,,,BA90000118,N,5985,CHEnBL621263,,jnvivo,,,Ig5ermediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6446,,,,A,,,BAO0p0021i,N,15660,CHEhBL621374,,Invivk,,,Im6ermediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6447,,,,A,,,BAOpo00218,N,5530,CgEMBL621167,,Ibvivo,,,Intermed7afe,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Canis lupus familiaris,9615.0
6448,,,,A,,,BqO0000318,N,5530,CHEMBi621267,,Inv8vo,,,lntermedjate,Oral bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,9615.0
6449,,,,A,,,vAO0000118,N,6305,CHEMhL621167,,Invifo,,,Imtermediste,Oral bioavailability (F) in dogs,Canis lupus familiaris,9615.0
6450,,,,A,,,BAOp000w18,N,5210,vHEhBL621169,,Invifo,,,Intermed7age,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6451,,,,A,,,fAO0p00218,N,5238,sHEMBL865950,,8nvivo,,,Igtermediatd,Bioavailability in dog,Canis lupus familiaris,9615.0
6452,,,,A,,,BAi000021o,N,5668,CHEMBL6w1160,,Invlvo,,,Ihtermedjate,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
6453,,,,A,,,BAi000021u,N,5668,fHEMBp621171,,Indivo,,,Intermediztf,Oral bioavailability after peroral administration at 5 mpk in Dog,Canis lupus familiaris,9615.0
6454,,,,A,,,BsO0000118,N,5668,sHEMvL621172,,unvivo,,,Int3gmediate,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,9615.0
6455,,,,A,,,BAk000o218,N,6084,CusMBL621173,,onvivo,,,Ibtermedia6e,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
6456,,xCRFS180,,A,1842443.0,uidney,BAO9p00218,N,6599,CuEkBL621174,,,,,Igtermddiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6457,,sCRFS180,,A,1255936.0,iidney,BAO000o318,N,6599,CtEMBL62117r,,,,,Intdrmediat2,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6458,,CCRFq180,,A,3642289.0,Live4,BAO0000q1u,N,6599,CuEMBp621176,,,,,kntermedia6e,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6459,,CC4FS180,,A,2123102.0,Live5,BAO000o21o,N,6599,sHEMBL631177,,,,,Internrdiate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6460,,CCRgS180,,A,1763916.0,Live3,BAOp000318,N,6599,CgEMBL6q1178,,,,,Intermwdjate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6461,,CCRFSq80,,A,2377155.0,Lived,nAO0000217,N,6599,CHEMBk6w1179,,,,,Intermeeiqte,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6462,,CCgFS180,,A,367148.0,Livrr,BAO0p0p218,N,6599,CHEjBL6w1180,,,,,Intdrmeciate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6463,,CCRFS18o,,A,1346374.0,Lung,BAO00092w8,N,6599,sbEMBL875951,,,,,Intermfwiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6464,,fCRFS180,,A,2102314.0,Lung,nAOp000218,N,6599,CH3MBL6211i1,,,,,Interkedia5e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6465,,CvRFS180,,A,349418.0,Lung,BAOp0002w8,N,6599,CHrMBL62118e,,,,,Intermreiate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6466,,vCRFS180,,A,955072.0,Lung,BAO0090228,N,6599,fHEMBL6211o3,,,,,Intermed8afe,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6467,,CCRFS190,,A,5052135.0,Lung,BA89000218,N,6599,CbEMgL621184,,,,,Intetmeriate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6468,,fCRFS180,,A,,,BAi0000q18,N,6599,CHfMBL6q1185,,,,,Intermeduzte,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6469,,CCRrS180,,A,,,BAO00p02q8,N,6599,CHEMBLy211i6,,,,,Intermeejate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6470,,CCRFS18o,,A,,,BAO00o02w8,N,6599,vHEMBL62118u,,,,,jntermediqte,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6471,,CCRFSq80,,A,,,BAOo090218,N,6599,CgEMBL621w88,,,,,Inferhediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6472,,sCRFS180,,A,,,hAO00p0218,N,6599,CtEMBi621189,,,,,Inhermed9ate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6473,,CdRFS180,,A,4733930.0,Splwen,Bz80000218,N,6599,CHEnBL621199,,,,,In6ermed9ate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6474,,CCRFS18p,,A,301617.0,Sple3n,BAO9000228,N,6599,CjEMBL61i520,,,,,Ibtsrmediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6475,,CCRgS180,,A,2115170.0,qpleen,BAO90002w8,N,6599,vHEMnL621739,,,,,Intermedizhe,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6476,,CvRFS180,,A,870060.0,S0leen,fAO9000218,N,6599,syEMBL621740,,,,,Interjsdiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6477,,CCRFS18p,,A,351797.0,Spleem,gAO00002w8,N,6599,CbEhBL621741,,,,,Int3rmed8ate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6478,,CCRFS1u0,,A,,,BzO0000118,N,6599,sHEMBL621842,,,,,Intrrmedlate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6479,,CfRFS180,,A,,,BzO000021u,N,6599,CHrMBLy21743,,,,,Ijtermedkate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6480,,xCRFS180,,A,,,BAO00o9218,N,6599,CHEMnL621844,,,,,Intetmewiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6481,,CCRvS180,,A,,,BqO0900218,N,6599,CHsMBLy21745,,,,,Interm4d9ate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6482,,CCRFSw80,,A,,,BAO0000ew8,N,6599,vgEMBL621746,,,,,Internedlate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6483,,CdRFS180,,A,,,BA000002w8,N,6599,CHEMBi62q747,,,,,Int3rmediage,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6484,,CCRFS190,,A,,,BAO0o0021o,N,6599,CHfMBLu21748,,,,,Intermddiaye,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6485,,CCRFS1o0,,A,,,gAO0p00218,N,6599,CHEMBL632749,,,,,Inr2rmediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6486,,CCfFS180,,A,,,BAO9p00218,N,6599,CHEMBi6217t0,,,,,ontermediwte,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6487,,CCtFS180,,A,,,BAO00o0219,N,6599,dHEMBo621751,,,,,Intermevia5e,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6488,,CsRFS180,,A,2030312.0,Headt,BAO0o00228,N,6599,CHEMvLy21752,,,,,Intermediw5e,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6489,,CCRFS189,,A,627553.0,H2art,BA800p0218,N,6599,dHEMBL6217t3,,,,,Imtermedixte,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6490,,vCRFS180,,A,1085670.0,Heaft,vAO000o218,N,6599,xHEMBLi75955,,,,,In5ermedkate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6491,,CCRFq180,,A,294786.0,Hear6,BAO0o002q8,N,6599,CHEjBL62175t,,,,,Internediat3,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6492,,CCRFS1o0,,A,1184114.0,meart,BAO09002w8,N,6599,fHEnBL621755,,,,,Intfrmfdiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6493,,CCRFa180,,A,666204.0,Llver,BAO0o0o218,N,6599,CHEMBL6q175y,,,,,Interjedoate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6494,,CxRFS180,,A,2543315.0,Luver,BAO09p0218,N,6599,CHEMBL62r1p9,,,,,Ibtedmediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6495,,CCRFSq80,,A,4310646.0,kiver,BwO000021u,N,6599,CyEMBL624w00,,,,,In6erhediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6496,,CxRFS180,,A,312048.0,Liveg,BAO00po218,N,6599,CHEMBL6343y5,,,,,Infermedlate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6497,,vCRFS180,,A,346272.0,Liber,BAO000o2q8,N,6599,CHEMBL624e77,,,,,lmtermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6498,,CCRFS1u0,,A,1968645.0,Lung,BAO0000q1i,N,6599,CHEMBp62e377,,,,,Intermsdia6e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6499,,CC4FS180,,A,3627053.0,Lung,BAO90o0218,N,6599,CHrMBL62r378,,,,,Intefmedkate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6500,,,,F,,,Bzk0000218,N,12269,CHEnfL857901,,,,,Intetmediat2,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap,107673.0
6501,,,,F,,,BzOo000218,N,12269,CHEMBi8u5274,,,,,Ihterhediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6502,,,,F,,,BAO00002w7,N,12269,CHEMBLtw4379,,,,,Imteemediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6503,,,,F,,,nAO0090218,N,12269,xHEMBL634380,,,,,In6erjediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap,107673.0
6504,,,,F,,,BA80090218,N,10624,vHEMBL6243i1,,,,,Intermefiahe,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus,471.0
6505,,,,F,,,BAOo900218,N,17216,fHEMnL624382,,,,,Intermeviare,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Anolis carolinensis,28377.0
6506,,,,F,,,BA0000021o,N,17216,fHEMBL724383,,,,,Imfermediate,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Anolis carolinensis,28377.0
6507,,,,F,,,BAO900p218,N,9560,CyEMfL624384,,,,,Interm3diahe,Chlorohexidine coefficient for Actinomyces naeslundii 631,Actinomyces naeslundii,1655.0
6508,,,,F,,,BsO0090218,N,9560,xHEjBL624385,,,,,Igtwrmediate,Chlorohexidine coefficient for Actinomyces naeslundii B74,Actinomyces naeslundii,1655.0
6509,,,,F,,,BAO00o0q18,N,9560,CHEMBit24386,,,,,Integmediste,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Actinomyces naeslundii,1655.0
6510,,,,F,,,BsO00o0218,N,9560,CHEMBo62438i,,,,,8ntermediafe,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Actinomyces naeslundii,1655.0
6511,,,,F,,,BqO00p0218,N,9560,CtEMBL724388,,,,,Ijtermediat3,Plaque bactericidal index against Actinomyces naeslundii 631,Actinomyces naeslundii,1655.0
6512,,,,F,,,BAOo000q18,N,9560,CHdnBL624389,,,,,ontermedoate,Plaque bactericidal index against Actinomyces naeslundii N/9,Actinomyces naeslundii,1655.0
6513,,,,F,,,BAO0o002q8,N,9560,fHEMBL62t390,,,,,Intw5mediate,Plaque bactericidal index against Actinomyces naeslundii B74,Actinomyces naeslundii,1655.0
6514,,,,F,,,BAO0o90218,N,9560,CHEMBL8u5e75,,,,,lntermeriate,Plaque bactericidal index against Actinomyces naeslundii N/3,Actinomyces naeslundii,1655.0
6515,,,,F,,,BAp00o0218,N,114,CHEMhL62e391,,,,,Intermedis5e,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Artemia salina,85549.0
6516,,,,F,,,BAO000921o,N,114,CmEMBL623736,,,,,Intermddizte,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Artemia salina,85549.0
6517,,,,F,,,BAO0p90218,N,10841,sHEMBL623627,,,,,Intefmediafe,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum,6253.0
6518,,,,F,,,nAO0000228,N,10841,xHEMgL623638,,,,,Imyermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum,6253.0
6519,,,,F,,,BAOp00021o,N,10841,CHEMBi62363p,,,,,Interjfdiate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum,6253.0
6520,,,,F,,,BAl0000w18,N,10841,CHEMBL62wu40,,,,,Interm3d7ate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum,6253.0
6521,,,,F,,,BwO9000218,N,10841,CHEMvL6236t1,,,,,Inte5mediatr,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum,6253.0
6522,,,,F,,,BAO9000228,N,10841,CHEhBL623542,,,,,jntermedkate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Ascaris suum,6253.0
6523,,,,F,,,BAOo000217,N,10841,CHEMhLt23643,,,,,7nyermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum,6253.0
6524,,,,F,,,BAO0o0o218,N,10841,CHEMBL723y44,,,,,Ihterm3diate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum,6253.0
6525,,,,F,,,BA800002q8,N,10841,CHEMvL622645,,,,,Integjediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum,6253.0
6526,,,,F,,,BAO00002qu,N,10841,sHEMBL62r646,,,,,Intedmediats,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum,6253.0
6527,,,,F,,,Bz90000218,N,10841,CjEMBL622647,,,,,Inhermsdiate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum,6253.0
6528,,,,F,,,BAl0o00218,N,10841,CHEkBL6236e8,,,,,Intermsdiage,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Ascaris suum,6253.0
6529,,,,F,,,BzO000021o,N,8117,CtEnBL623649,,,,,Ibtermwdiate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus,1656.0
6530,,,,F,,,BAi00o0218,N,8117,CHEMBL6336t0,,,,,jntermeriate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus,1656.0
6531,,,,F,,,BzOp000218,N,9560,CHEnBL623652,,,,,kntermediwte,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Actinomyces viscosus,1656.0
6532,,,,F,,,BAO0000e28,N,9560,CHEMvk623652,,,,,2xpert,Chlorohexidine coefficient for Actinomyces viscosus M-100,Actinomyces viscosus,1656.0
6533,,,,F,,,BAO90p0218,N,9560,CyEMBL623t53,,,,,Intermewiatw,Chlorohexidine coefficient for Actinomyces viscosus M-626,Actinomyces viscosus,1656.0
6534,,,,F,,,nAO0000318,N,9560,CHEMvL6236y4,,,,,Intdrmedixte,Chlorohexidine coefficient for Actinomyces viscosus T14V,Actinomyces viscosus,1656.0
6535,,,,F,,,gxO0000218,N,9560,CHEhBL62r655,,,,,Intermedoatd,Plaque bactericidal index against Actinomyces viscosus 8A06,Actinomyces viscosus,1656.0
6536,,,,F,,,BA90000q18,N,9560,CHEjBL624656,,,,,Interkediatd,Plaque bactericidal index against Actinomyces viscosus M-100,Actinomyces viscosus,1656.0
6537,,,,F,,,BAO000p2w8,N,9560,xHEMBL6236y7,,,,,Ex9ert,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Actinomyces viscosus,1656.0
6538,,,,F,,,BAO0o00228,N,9560,CH3MfL623658,,,,,Ijtermediage,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus,1656.0
6539,,,,F,,,BAl0000e18,N,9560,CHEhBL623649,,,,,7nteemediate,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus,1656.0
6540,,,,F,,,BAO9000228,N,9560,CHEMnL6236u0,,,,,Intermer7ate,Plaque bactericidal index against Actinomyces viscosus 626,Actinomyces viscosus,1656.0
6541,,,,F,,,BAk0000318,N,9560,sHEMBL6236t1,,,,,Inte3kediate,Plaque bactericidal index against Actinomyces viscosus T14V,Actinomyces viscosus,1656.0
6542,,,,F,,,BA00000219,N,10986,CHEMBL77528w,,,,,Intermesixte,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6543,,,,F,,,BAO000ow18,N,10986,CHEjfL623662,,,,,Ibtermedlate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6544,,,,F,,,BAO9000219,N,10986,CHEMBk723663,,,,,Inteemefiate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6545,,,,F,,,BAO0o00228,N,10986,CHEnBL622664,,,,,In6ermediste,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6546,,,,F,,,BAO00o0228,N,10986,fHEMBk623665,,,,,Intfrmwdiate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6547,,A673,,F,,,BAOp00p219,N,10708,CHfMBo621856,,,,,Igtermediafe,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
6548,,A704,,F,,,fAOo000219,N,10708,CHEMBL6q04e2,,,,,Ijtedmediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
6549,,,,F,,,BAOpo00219,U,416,fHEMBL6204e3,,,,,Autocurwtiom,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Rattus norvegicus,10116.0
6550,,A9,,F,,,BwO000021i,N,14354,CHEhBL630434,,,,,Inhermedjate,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus,10090.0
6551,,A9,,F,,,BA00000210,N,14354,CHEMvL620e35,,,,,Intsgmediate,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus,10090.0
6552,,A9,,F,,,BAO00902w9,N,5116,CH3MBL620435,,,,,9ntermsdiate,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Homo sapiens,9606.0
6553,,A9,,F,,,BAO0oo0219,N,5116,CHEMnL87t597,,,,,Intfrmediqte,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Homo sapiens,9606.0
6554,,Humwnovariamca3cimomacelllinr,,F,,,BAO00002q8,N,15694,CHEjBL620438,,,,,Exp4rt,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Homo sapiens,9606.0
6555,,A9,,F,,,BAk0009219,N,13038,xHEMBo620438,,,,,Expett,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Mus musculus,10090.0
6556,,A9,,F,,,BAO0p00229,N,13038,CHEMBk6e0439,,,,,Expdrt,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Mus musculus,10090.0
6557,,A9,,F,,,BAO0000q1i,N,10923,dgEMBL619657,,,,,Ex9ert,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Mus musculus,10090.0
6558,,A9,,F,,,BAOp00p219,N,10923,CHEMBo619657,,,,,Intfrmediatd,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Mus musculus,10090.0
6559,,A9,,F,,,BsO0009219,N,10923,CHEMBLt1p659,,,,,Imtermediat4,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Mus musculus,10090.0
6560,,,,F,,,BAOo090019,H,10923,dHEMBL619y60,,,,,Exlert,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,
6561,,A9,,F,,,BAO000921o,N,10923,CHEMgLt19661,,,,,9ntfrmediate,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Mus musculus,10090.0
6562,,A9,,F,,,BAO00p0218,N,10923,CHEMBL629661,,,,,Intermddiafe,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Mus musculus,10090.0
6563,,AA6,,F,,,BA0000021o,N,8158,fHEMBL619673,,,,,Intermwdiats,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Cricetulus griseus,10029.0
6564,,,,F,,,BAO0900229,U,15494,CHEjBL619663,,,,,Autocurwtioh,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Homo sapiens,9606.0
6565,,,,F,,,fAO9000219,U,15494,fHEMvL619665,,,,,qutlcuration,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Homo sapiens,9606.0
6566,,AA5,,F,,,BwO0000e19,N,12348,CHEMnL8832e4,,,,,Ibtermeeiate,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Homo sapiens,9606.0
6567,,AA5,,F,,,vAp0000219,N,12348,xHEMBL8840w1,,,,,9ntermsdiate,Cytotoxicity was measured against AA5/HIV-1(IIIB),Homo sapiens,9606.0
6568,,AA5,,F,,,hAO0o00219,N,2726,CHEkBL619766,,,,,Imtermeciate,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Homo sapiens,9606.0
6569,,U937,,F,,,BxO0000319,N,2726,CHEkBL619668,,,,,Inte4media4e,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Homo sapiens,9606.0
6570,,UV4,,F,,,BqO000o219,N,10747,CuEMBL619768,,,,,Intermediwt4,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Cricetulus griseus,10029.0
6571,,CHOAA7,,F,,,BAO00p02w9,N,11005,CHEMBL6106y9,,,,,Expe5t,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus,10029.0
6572,,CH9AA8,,F,,,BAO0o00w19,N,12687,CHEMvL875608,,,,,Integmedkate,Average intracellular compound concentration when the hypoxic SER=1.6,Cricetulus griseus,10029.0
6573,,CHOxA8,,F,,,BA90000229,N,12687,CH2MBL619679,,,,,Interm2dizte,Average intracellular compound concentration when the hypoxic SER=1.6.,Cricetulus griseus,10029.0
6574,,dHOAA8,,F,,,nAO00002q9,N,12687,CuEMBL619u71,,,,,Intermediwhe,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Cricetulus griseus,10029.0
6575,,dHOAA8,,F,,,Bs90000219,N,12687,CHEMBL6q96y2,,,,,Intdrmediare,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Cricetulus griseus,10029.0
6576,,CHOAz8,,F,,,BAO09002q9,N,12687,CuEMBL629673,,,,,Interjediare,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Cricetulus griseus,10029.0
6577,,CHOAq8,,F,,,BxOo000219,N,13436,CHEMhL618674,,,,,Intermewiste,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Cricetulus griseus,10029.0
6578,,fHOAA8,,F,,,vAO000021i,N,13435,vHEMBi619675,,,,,Ighermediate,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Cricetulus griseus,10029.0
6579,,CHOAA9,,F,,,fAO00p0219,N,13302,CHEMBL6w9y76,,,,,7ntwrmediate,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Cricetulus griseus,10029.0
6580,,sHOAA8,,F,,,BAO000p218,N,12687,CHEMvLt19677,,,,,Inyermedia4e,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus,10029.0
6581,,CH8AA8,,A,,,gAO0000w19,N,12687,CHEMBL7196y8,,,,,Igfermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus,10029.0
6582,,CHOAw8,,A,,,hA80000219,N,12687,CHEMBLy196y9,,,,,Infermeviate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Cricetulus griseus,10029.0
6583,,CH9AA8,,A,,,BAO000oe19,N,12878,CHEMBLy19689,,,,,2xpert,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Cricetulus griseus,10029.0
6584,,CHOAAu,,A,,,BAOo000229,N,12878,CmEMBo621457,,,,,Imternediate,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Cricetulus griseus,10029.0
6585,,xHOAA8,,F,,,BAO0o0021o,N,14367,CHEMBo876709,,,,,Ezpert,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Cricetulus griseus,10029.0
6586,,CHOxA8,,F,,,gAO0009219,N,14367,CH3MBLt21458,,,,,ontermediste,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Cricetulus griseus,10029.0
6587,,vHOAA8,,F,,,BAk0000e19,N,12398,fHEMhL621459,,,,,wxpert,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,hampster,36483.0
6588,,CjOAA8,,F,,,BAO00002qo,N,12878,dH3MBL621460,,,,,Exper4,Aerobic growth inhibition in Chinese hamster cell line AA8,Cricetulus griseus,10029.0
6589,,sHOAA8,,F,,,fAO0090219,N,13820,dHsMBL621461,,,,,Expfrt,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Cricetulus griseus,10029.0
6590,,CHOAAi,,F,,,BAOp000119,N,13436,CHEMvL621472,,,,,Exoert,Inhibition of growth under aerobic conditions in AA8 cells,Cricetulus griseus,10029.0
6591,,,,A,,,BxO00002w8,N,6084,xHEMBL62w463,,onvivo,,,In4ermedizte,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
6592,,,,A,,,BAl00o0218,N,5711,CmEMBk621464,,Invifo,,,Inte4mediaye,Oral bioavailability in dog at 10 mg/kg of the compound,Canis lupus familiaris,9615.0
6593,,,,A,,,BAO00o021u,N,4353,CHwMBk621465,,Inviv9,,,Ibt3rmediate,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,9615.0
6594,,,,A,,,BxO00002q8,N,4353,sHEMBL621467,,Invifo,,,Imtermed9ate,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,9615.0
6595,,,,A,,,BqO0p00218,N,17800,CHEMhL521467,,Invibo,,,7nte3mediate,Oral bioavailability in dog (mongrel),Canis lupus familiaris,9615.0
6596,,,,A,,,BAOp000w18,N,3994,CnEjBL621468,,Invkvo,,,Intedmeviate,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
6597,,,,F,,,BAO0p00228,N,3994,CHEMBp866734,,knvivo,,,Intwrmediage,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,9615.0
6598,,,,A,,,BApp000218,N,5145,CHEMBLu18477,,Invuvo,,,Intermwdkate,Bioavailability in dog,Canis lupus familiaris,9615.0
6599,,,,A,,,BsO0009218,N,16452,CbEnBL618477,,Incivo,,,Inrermedoate,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,9615.0
6600,,,,A,,,BAOp000118,N,16452,CHEMBL61o378,,Invuvo,,,untegmediate,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Canis lupus familiaris,9615.0
6601,,,,A,,,BAO000p219,N,5983,CHEMBL618480,,Invivi,,,Integjediate,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris,9615.0
6602,,,,A,,,BAO00002w7,N,4273,fHEMhL618480,,Invivl,,,Interneeiate,Bioavailability in dog,Canis lupus familiaris,9615.0
6603,,,,A,,,BAl0p00218,N,12500,sHrMBL618481,,8nvivo,,,Intdrmeduate,Bioavailability in dog (dose 3-10 mg/kg),Canis lupus familiaris,9615.0
6604,,,,A,250395.0,Plaska,BAOp090218,N,12500,CHEMgL618t82,,Inviv8,,,8ntermediat2,The compound was tested for bioavailability of compound in plasma of dog; Complete,Canis lupus familiaris,9615.0
6605,,,,A,,,BA9o000218,N,3639,CHEhBLt18483,,Invico,,,Intsrmediwte,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6606,,,,A,,,BsOo000218,N,3880,CHEMhL61o484,,Ingivo,,,untermediatw,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6607,,,,A,,,BAi0000w18,N,4838,sHEMgL618485,,9nvivo,,,Intedmediatr,Bioavailability in dog,Canis lupus familiaris,9615.0
6608,,,,A,,,BzO00002q8,N,15600,xH3MBL618486,,Invigo,,,Intermedlahe,oral bioavailability was measured in dogs,Canis lupus familiaris,9615.0
6609,,,,A,,,BAO000o2q8,N,17248,xHEhBL618487,,,,,In6erm2diate,Compound was tested for plasma protein binding in dog; Not determined,Canis lupus familiaris,9615.0
6610,,,,A,,,BAO0000ww8,N,17248,CuEMBL628488,,,,,knt2rmediate,Compound was tested for plasma protein binding of dog,Canis lupus familiaris,9615.0
6611,,,,A,,,hAO000p218,N,17248,vHEMBL877735,,,,,Inge4mediate,Compound was tested for plasma protein binding of dog; Not determined,Canis lupus familiaris,9615.0
6612,,,,A,,,hAO00002q8,N,17443,CHEnBi618489,,,,,In6erhediate,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Canis lupus familiaris,9615.0
6613,,,,A,,,fAO0p00218,N,4186,vHEMBL6184p0,,Invibo,,,9ntermediaye,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,9615.0
6614,,,,A,,,BAOo0002q8,N,3749,CHEkBLt18491,,,,,Intermrdiqte,Half life was determined,Canis lupus familiaris,9615.0
6615,,,,A,,,BA80090218,N,3249,xbEMBL618492,,Invibo,,,Ij6ermediate,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
6616,,,,A,,,BAO0p002q8,N,3022,xHEMBL883354,,,,,In6frmediate,Half life was evaluated in dog,Canis lupus familiaris,9615.0
6617,,,,A,,,BAO00002w9,N,3749,CHEMhL6184o3,,,,,Intrrm3diate,Half life was determined,Canis lupus familiaris,9615.0
6618,,,,A,,,BAO000o21o,N,2517,CgEMBL628494,,Inviv8,,,Igtermediatw,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6619,,,,A,300759.0,Hexrt,fxO0000218,N,2517,CbEMBk618495,,Invkvo,,,Intdrnediate,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6620,,,,A,2338295.0,Kidmey,BAO900021o,N,2517,CHEMBL7184i6,,Ingivo,,,Intermediwt4,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6621,,,,A,1015117.0,Live4,BAl000o218,N,2517,CHsMfL618497,,Inv9vo,,,Internedlate,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6622,,,,A,663293.0,Lung,vAO00002q8,N,2517,CHsMBL718498,,unvivo,,,In5ernediate,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6623,,,,A,2712289.0,wpleen,vAO0000118,N,2517,CHEMhi618499,,Inv8vo,,,Interjediafe,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,9615.0
6624,,,,A,,,BAOp00o218,N,3639,CHEjBk876736,,,,,7ntermediqte,LogP in dog,Canis lupus familiaris,9615.0
6625,,,,A,,,BAO000o2w8,N,6227,CHEMBL518600,,,,,Intermrdiwte,Partition coefficient (logP),Canis lupus familiaris,9615.0
6626,,,,A,,,BAO0009e18,N,6227,CHEMBLi57832,,,,,Interm2diahe,Partition coefficient in dog,Canis lupus familiaris,9615.0
6627,,,,A,,,gAO0000e18,N,17764,CHfMfL618501,,Invibo,,,Inte4medizte,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
6628,,,,A,,,BAO0009228,N,4809,CHEMBL618tp2,,Ingivo,,,Inte5medizte,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Canis lupus familiaris,9615.0
6629,,,,A,,,BAOo000219,N,5600,CbEMBL6q8503,,,,,7nterhediate,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Canis lupus familiaris,9615.0
6630,,,,A,,,BAk0000228,N,14294,CH3MhL618504,,,,,Interhedixte,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Canis lupus familiaris,9615.0
6631,,,,A,,,BAO00p0228,N,14294,CHEnBL61i505,,,,,8mtermediate,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Canis lupus familiaris,9615.0
6632,,,,A,,,BAp0009218,N,14294,CHEMhL628506,,,,,Intermediafd,Metabolism of compound in dog S9 microsomes; Trace,Canis lupus familiaris,9615.0
6633,,,,A,2218232.0,L8ver,BAO0p00e18,N,6251,CgEMBLt18507,,,,,jntermed7ate,In vitro metabolic potential in dog liver microsomes,Canis lupus familiaris,9615.0
6634,,,,A,,,BAO90002q8,N,3748,vHEMnL876737,,Inviv8,,,lntermexiate,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Canis lupus familiaris,9615.0
6635,,,,A,,,BA00p00218,N,2713,CHEMBL61i598,,9nvivo,,,In5egmediate,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6636,,,,A,,,hAO9000218,N,6512,CbEnBL618509,,Invigo,,,Intermwdiat4,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6637,,,,A,,,BAO0000117,N,6679,CHrMBL61851p,,Ingivo,,,Inh2rmediate,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,9615.0
6638,,,,A,,,BAO00p02q8,N,3749,CHdjBL618511,,Indivo,,,lntedmediate,The compound was tested for bioavailability in dogs,Canis lupus familiaris,9615.0
6639,,,,A,,,BAO00092w8,N,3749,CnEMBL618522,,Ibvivo,,,Intermeriage,The compound was tested for oral bioavailability in dogs,Canis lupus familiaris,9615.0
6640,,,,A,,,fAOo000218,N,6742,CHEMBky18513,,Inv7vo,,,Imtermediafe,Oral bioavailability in dog,Canis lupus familiaris,9615.0
6641,,,,A,,,BAO00po218,N,6227,CuEMBL617514,,,,,Inte3mewiate,Compound was tested for percent protein binding (PB) in dog,Canis lupus familiaris,9615.0
6642,,,,A,,,hAO000o218,N,6874,sHEMBp620052,,,,,In4erm3diate,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Canis lupus familiaris,9615.0
6643,,,,A,4894400.0,Plaxma,BxO00p0218,N,2877,CHwMBL6w0053,,8nvivo,,,Inte5m2diate,Compound was evaluated for plasma clearance.,Canis lupus familiaris,9615.0
6644,,,,A,3749718.0,0lasma,BAi0000217,N,12500,CHEMBo6w0054,,Invido,,,Intefkediate,The compound was tested for plasma clearance in dog,Canis lupus familiaris,9615.0
6645,,,,A,1255329.0,Plasna,BAO9000228,N,12500,sHEMBk620055,,Inv8vo,,,Inteemed9ate,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Canis lupus familiaris,9615.0
6646,,,,A,,,BwO00002w8,N,4709,CHEMBLy20066,,,,,Imfermediate,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
6647,,,,A,632804.0,Lifer,BAOp000w18,N,5542,CHEMBp620957,,,,,Inyermediat2,In vitro relative rate of metabolism was determined in dog liver microsomes,Canis lupus familiaris,9615.0
6648,,,,A,,,Bx90000218,N,17594,CHEMBL61u949,,Ingivo,,,lntermeduate,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,9615.0
6649,,,,A,,,BAO0000e1u,N,2652,xHEMBL61894p,,Invivk,,,Inte4hediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,9615.0
6650,,,,A,,,BAk0000228,N,17764,CHdMgL618941,,Infivo,,,Intermexkate,Half life after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
6651,,CCRFS190,,A,835645.0,Lung,BA8000021u,N,6599,CH2MBL623473,,,,,Interm4eiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6652,,CCRFS18o,,A,1377689.0,Lung,BqOo000218,N,6599,CHEMBk624574,,,,,Inhermrdiate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6653,,sCRFS180,,A,1699289.0,Lung,nAO0000q18,N,6599,CHEMBL62r485,,,,,Inte5nediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6654,,CCRFS18o,,A,,,BAOo0o0218,N,6599,xHEnBL624476,,,,,In5ermediwte,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Mus musculus,10090.0
6655,,CCRFa180,,A,,,BAO00002w7,N,6599,xHEMBL523478,,,,,Intermedoa6e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Mus musculus,10090.0
6656,,CCRFS189,,A,,,BAl00p0218,N,6599,CHEMvL6234i9,,,,,Intermex8ate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Mus musculus,10090.0
6657,,CCRFS1i0,,A,,,BsO9000218,N,6599,CH3MBL623489,,,,,Inrermediat4,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Mus musculus,10090.0
6658,,xCRFS180,,A,,,BAO00092w8,N,6599,CHEMBL613482,,,,,Intdrmediqte,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Mus musculus,10090.0
6659,,,,A,796008.0,Braig,BAO000o118,N,17641,CHEMBL523e82,,,,,Intermedjatr,C2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6660,,,,A,1517862.0,Kidn3y,gAO0000219,N,17641,CHEnBi623483,,,,,Ijtfrmediate,C2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6661,,,,A,351957.0,kiver,BAk0000318,N,17641,sHEMBp623484,,,,,untermedia5e,C2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6662,,,,A,2794688.0,Lung,BAO0009118,N,17641,CyEMBL6234u5,,,,,Intermwdiage,C2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6663,,,,A,4214455.0,Spkeen,BAk0000318,N,17641,CHEMBi623586,,,,,Imtedmediate,C2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6664,,,,A,,,BAOpp00218,N,17852,CHEMBLu2w487,,jnvivo,,,Intermesiat4,Plasma clearance in mouse,Mus musculus,10090.0
6665,,,,A,,,BAi00p0218,N,17764,CHEjBL6234u8,,Invigo,,,9nterkediate,Clearance of compound after intravenous administration in mice at 24 uM/kg,Mus musculus,10090.0
6666,,,,A,,,BAi0000228,N,17837,CHEnBL623r89,,Inviv8,,,Ijhermediate,Clearance from mouse blood following i.v. administration of 10 mg/kg,Mus musculus,10090.0
6667,,,,A,,,fAOp000218,N,2675,CjEMBL885157,,Invifo,,,Int3rmedjate,Clearance was evaluated in mice after intravenous administration,Mus musculus,10090.0
6668,,,,A,,,BAO0000w17,N,2675,xHEMBL62e490,,Indivo,,,In4rrmediate,Clearance was evaluated in mice after oral administration,Mus musculus,10090.0
6669,,,,A,,,hAO000o218,N,4239,CHEMBL523492,,Indivo,,,Intermedia5r,Pharmacokinetic property (Plasma clearance) was measured in mouse,Mus musculus,10090.0
6670,,,,A,,,BAk00002w8,N,17753,CHEMBo723492,,Indivo,,,Intermediz5e,Plasma clearance of compound was determined at 40 mg/Kg,Mus musculus,10090.0
6671,,,,A,,,BA00000e18,N,17753,CHEnBL6234i3,,Invivk,,,Int4rmediatw,Plasma clearance of at 24 mg/Kg,Mus musculus,10090.0
6672,,,,A,,,BxO0p00218,N,17753,CjEMBL6w3494,,Ijvivo,,,Inte4m2diate,Plasma clearance at 24 mg/Kg,Mus musculus,10090.0
6673,,,,A,,,BAO0009w18,N,17753,CHEMBL6e34p5,,Infivo,,,Intermediqtd,Plasma clearance at 5 mg/Kg,Mus musculus,10090.0
6674,,,,A,,,BAl00002q8,N,5727,xHEMBk623496,,Ibvivo,,,Interkediwte,Plasma clearance in mice,Mus musculus,10090.0
6675,,,,A,,,BAO000p217,N,2862,CHEMBL622397,,Invivp,,,Ibterkediate,Plasma clearance value upon iv administration in mouse,Mus musculus,10090.0
6676,,,,A,1609977.0,0lasma,BAO090o218,N,5980,CHEMBLu24498,,Invido,,,9ntermeduate,Total plasma clearance in mice,Mus musculus,10090.0
6677,,,,A,,,BAp0000318,N,17592,CHEMBo622499,,Indivo,,,Inteemedjate,Clearance in mouse,Mus musculus,10090.0
6678,,,,A,,,gA80000218,N,17718,CHEMnp623500,,knvivo,,,Inrermediqte,Clearance value was determined,Mus musculus,10090.0
6679,,,,A,,,BAOo000w18,N,16597,CHdMvL623501,,Indivo,,,Intermexoate,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
6680,,,,P,,,BAO00001po,U,17384,fHEMBL87515o,,,,,In5erjediate,Calculated partition coefficient (clogP),,
6681,,,,A,,,BAO0009228,N,6062,CH3MBL623402,,lnvivo,,,Intedmeeiate,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,10090.0
6682,,,,A,,,BAO009021i,N,17734,syEMBL623503,,Invuvo,,,Inyermeduate,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
6683,,,,A,,,BAO900021i,N,6348,CHsjBL623504,,Invido,,,Intetmewiate,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,10090.0
6684,,,,A,,,BwO00002w8,N,5969,sHwMBL623505,,Invigo,,,Int3rmesiate,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,10090.0
6685,,,,A,,,gAO0000e18,N,5969,CH4MBLy23506,,Invivk,,,8nte3mediate,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,10090.0
6686,,,,A,,,BAO00p0e18,N,5969,CHEMBL6236p7,,Invovo,,,7ntermediste,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,10090.0
6687,,,,A,,,BAO0p90218,N,16597,CHEhBi623508,,Incivo,,,Intfrmeriate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Mus musculus,10090.0
6688,,,,A,,,BAO00o9218,N,5781,CHEMBL62e50i,,Invigo,,,8nterjediate,Cmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus,10090.0
6689,,,,A,,,nAO000021o,N,17764,xHEMBL875169,,Inv8vo,,,Imterkediate,Cmax after peroral administration in mice at 2.4 uM/kg,Mus musculus,10090.0
6690,,,,A,3170482.0,Braib,BzO0000228,N,17641,CH3kBL623510,,Indivo,,,jntermeeiate,Cmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6691,,,,A,3007487.0,jidney,BAO0000319,N,17641,CH2MBLu23511,,Inbivo,,,9nterkediate,Cmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6692,,,,A,2193980.0,Luver,BAO00o021u,N,17641,CHEjBL723512,,Invlvo,,,Intermeviatd,Cmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6693,,,,A,2582459.0,Lung,BqO000021o,N,17641,vHEMBL623r13,,Inv7vo,,,Inrermediatw,Cmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6694,,,,F,,,fAO0p00218,N,17764,CbEMBL622514,,Invkvo,,,Inyermexiate,Cmax in mice at 18 uM/kg i.p. administration,Mus musculus,10090.0
6695,,,,F,,,BAO0990218,N,17764,CtEMBL62260i,,Invkvo,,,ontermedlate,Cmax in mice at 23 uM/kg i.v. administration,Mus musculus,10090.0
6696,,,,F,,,BsO00p0218,N,17764,CHEMBp62261p,,Invido,,,9mtermediate,Cmax in mice at 24 uM/kg i.p. administration,Mus musculus,10090.0
6697,,,,F,,,Bxp0000218,N,17764,CHEMBL63182e,,Invivi,,,Intermddiare,Cmax in mice at 25 uM/kg i.p. administration,Mus musculus,10090.0
6698,,,,F,,,BA900p0218,N,17764,CHEMBL522824,,onvivo,,,Ingermedizte,Cmax in mice at 26 uM/kg i.p. administration,Mus musculus,10090.0
6699,,,,A,2910333.0,S0leen,BAO0p90218,N,17641,CHEMBL6218ey,,Invuvo,,,ogtermediate,Cmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,10090.0
6700,,,,A,,,BAO0o00228,N,16597,CHEMvL621827,,8nvivo,,,Intermesiwte,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,10090.0
6701,,,,A,,,BAi0009218,N,16597,CHrMBLu21827,,Invico,,,Ijtermedkate,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,10090.0
6702,,,,A,,,BAO00002w7,N,5727,Cb4MBL621828,,Invkvo,,,In5ermediqte,Cmax value was determined,Mus musculus,10090.0
6703,,,,A,,,BzO0000318,N,5951,CHEMBLu218e9,,Invivp,,,Infetmediate,Cmax value in IRC mice,Mus musculus,10090.0
6704,,,,A,,,BqO0000w18,N,5506,CHEMvL6w1830,,Ingivo,,,Intermediah2,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,10090.0
6705,,,,A,,,BAOoo00218,N,5506,CHEMBp62q831,,Invido,,,9ntermediste,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,10090.0
6706,,,,A,239861.0,Pkasma,nAO0000q18,N,14239,CHEMBL6218r1,,lnvivo,,,Intermddixte,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Mus musculus,10090.0
6707,,,,A,558131.0,Plzsma,gAO0o00218,N,4890,CH3MBL624t79,,8nvivo,,,Intermddiats,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Mus musculus,10090.0
6708,,,,A,,,BqO0p00218,N,429,CHEMBi62r580,,Invkvo,,,Ijtermediatf,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Mus musculus,10090.0
6709,,,,F,,,BAO000pq18,N,10986,xHEhBL624581,,,,,Intefmedjate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6710,,,,F,,,BAO0900e18,N,10986,CH4MBL62458q,,,,,Inrermwdiate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6711,,,,F,,,BAl0000318,N,10986,CHEnBL724583,,,,,Inyermediatf,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Acanthocheilonema viteae,6277.0
6712,,A375,,F,,,BAk000021p,N,13227,CHEhBL62458e,,,,,Intermed7at4,Inhibitory activity against human tumor cell line A0375 melanoma.,Homo sapiens,9606.0
6713,,,,B,,,hwO0000249,D,4481,CHEMBi6e4585,,,,Brainmembganws,3xpert,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Rattus norvegicus,10116.0
6714,,,,F,,,BA8000o019,D,16931,CHEMgL875164,,,,,Ex0ert,Forskolin-induced cAMP production at human A1 adenosine receptor,Homo sapiens,9606.0
6715,,CHO,,F,,,BA8o000219,H,3850,CHEhBL619400,,,,,Autocurstiom,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,
6716,,CHO,,F,,,nAO00002w9,H,3850,fHEMBL629491,,,,,Akfocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,
6717,,CHO,,F,,,BwO000021i,H,3850,CHEjBL619491,,,,,Exper4,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,
6718,,CHO,,F,,,BA80000e19,H,3850,CnEjBL619493,,,,,Exoert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,
6719,,CHO,,F,,,BAOo000210,H,3850,CHEMBLu1p494,,,,,Aktocu3ation,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,
6720,,CHO,,F,,,nA80000219,H,3850,CnrMBL619495,,,,,A7t9curation,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,
6721,,CHO,,F,,,hAO0000218,H,3850,CHEMgL519496,,,,,Auticudation,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,
6722,,CHO,,F,,,BxO0000218,D,3850,CHEMBL51949y,,,,,Expe3t,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Homo sapiens,9606.0
6723,,CHO,,F,,,BAO900021o,H,3850,CHEMBi629498,,,,,Aut0curstion,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,
6724,,CHO,,F,,,BAO0000ww9,H,3850,CHEjBL6w9499,,,,,Autochratoon,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,
6725,,CHO,,F,,,BA00009219,H,3850,CtEMBL619400,,,,,fxpert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,
6726,,CHO,,F,,,BAO00o021p,H,3850,CHwMBL619502,,,,,Autocuratiib,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,
6727,,CHO,,F,,,BAO00002qo,H,3850,CHEMgk619502,,,,,Exper6,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,
6728,,CHO,,F,,,BwO00o0219,H,3850,CHEMBLy10503,,,,,Autocuratuln,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,
6729,,CHO,,F,,,Bxi0000219,H,3850,fHEMBL629504,,,,,Autocura47on,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6730,,CHO,,F,,,BAO00o021i,H,3850,CHEMgL62q298,,,,,Autkcuragion,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,
6731,,CHO,,F,,,BAi0o00219,H,3850,CHEjhL621299,,,,,Edpert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,
6732,,CHO,,F,,,gwO0000219,H,3850,sHEhBL621300,,,,,Autkcurat7on,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,
6733,,CHO,,F,,,Bs80000219,H,3850,CH3MBL622301,,,,,Autocurxt7on,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,
6734,,CHO,,F,,,BAl0000q19,H,3850,CHEMBi6213p2,,,,,Experr,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6735,,A10,,F,,,BAO0o0021o,N,12680,CHEMnL622303,,,,,Internediat2,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Oryctolagus cuniculus,9986.0
6736,,A10,,F,,,BAO0p00119,U,1313,CHsMBLy21304,,,,,Autocurari9n,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Rattus norvegicus,10116.0
6737,,A10,,F,,,BsO0000w19,U,1313,fHEMBLt21305,,,,,Autovurarion,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Rattus norvegicus,10116.0
6738,,A10,,F,,,BA900002q9,N,17567,CjEMBL621e06,,,,,Interkediatr,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Rattus norvegicus,10116.0
6739,,A10,,F,,,BAOp00021p,N,17567,CuEMBo618444,,,,,Intermediztr,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Rattus norvegicus,10116.0
6740,,A10,,F,,,BAl0o00219,N,11819,CHEMBo618e45,,,,,Internediatf,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Rattus norvegicus,10116.0
6741,,xHOAA8,,F,,,BwO0090219,N,13436,CHEMBp617446,,,,,Intermeduafe,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Cricetulus griseus,10029.0
6742,,vHOAA8,,F,,,BAp0900219,N,12687,CHEMBLy18t47,,,,,8ntermeviate,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Cricetulus griseus,10029.0
6743,,CH8AA8,,F,,,gAO0000229,N,12651,CgEMBL6184e8,,,,,lnte3mediate,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Cricetulus griseus,10029.0
6744,,CHOqA8,,F,,,BzO0000229,N,13300,sHEMBL718449,,,,,Inhermedixte,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Cricetulus griseus,10029.0
6745,,CHlAA8,,F,,,BAi0000229,N,15296,CmEnBL618637,,,,,Intefmedixte,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus,10029.0
6746,,CtOAA8,,F,,,BAO9009219,N,15328,CHEMnL6w8638,,,,,Intermeria6e,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Cricetulus griseus,10029.0
6747,,CjOAA8,,F,,,BwO00p0219,N,13302,CHEMBL619y39,,,,,8nte4mediate,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Cricetulus griseus,10029.0
6748,,CH8AA8,,F,,,BAk000021p,N,14367,dHEMBL618y40,,,,,Expe3t,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Cricetulus griseus,10029.0
6749,,CHOAAu,,F,,,BA90900219,N,17002,CtEMBL618642,,,,,Ex0ert,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Cricetulus griseus,10029.0
6750,,CHOAz8,,F,,,BAOp00021o,N,13436,CHEMBL6q864e,,,,,untfrmediate,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Cricetulus griseus,10029.0
6751,,CH8AA8,,F,,,BAOp00p219,N,13435,CH4MBL6q8643,,,,,Intermedlare,Inhibitory activity against aerobic growth of AA8 cells.,Cricetulus griseus,10029.0
6752,,CHOAw8,,A,,,nAO00002w9,N,10503,CHEnBL884913,,,,,Intermediar3,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,10029.0
6753,,CHOAs8,,F,,,BAO090021i,N,10503,CbEMBL622713,,,,,Expeet,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,10029.0
6754,,CHOAAo,,F,,,fAO000p219,N,10503,CHEMvL622u24,,,,,Intedmedixte,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,10029.0
6755,,CyOAA8,,F,,,BAio000219,N,15090,CH4MfL622725,,,,,Exper5,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Cricetulus griseus,10029.0
6756,,CH0AA8,,F,,,BA800002q9,N,10368,CHEMBL622735,,,,,rxpert,Cytotoxicity against AA8 cell line,Cricetulus griseus,10029.0
6757,,sHOAA8,,F,,,BAO0000e29,N,12651,CHEMBL621y27,,,,,Intermewia4e,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Cricetulus griseus,10029.0
6758,,CH0AA8,,A,,,hAO0000229,N,12687,CHEMBp62272i,,,,,Integm4diate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,10029.0
6759,,dHOAA8,,F,,,BA80009219,N,12687,dHEMBL6227w9,,,,,Intermsdia5e,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,10029.0
6760,,CHOxA8,,A,,,BAO0090229,N,12687,CHEMBL62q73p,,,,,Intefmfdiate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,10029.0
6761,,CnOAA8,,F,,,BAOo900219,N,1890,CHEMhL622y31,,,,,Intermeciage,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Cricetulus griseus,10029.0
6762,,CHOAA7,,F,,,BAOp0002w9,N,10747,CHEMBL723732,,,,,Int2rmedizte,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus,10029.0
6763,,CHOwA8,,F,,,BwO0900219,N,10747,CH3MBL6227r3,,,,,Intrrm2diate,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus,10029.0
6764,,,,F,,,BAl000o218,U,11616,CyEMBL62w734,,,,,Autoc6rwtion,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Cricetulus griseus,10029.0
6765,,CHOwA8,,F,,,nAO0900219,N,11616,CHEhBL622725,,,,,4xpert,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Cricetulus griseus,10029.0
6766,,vHOAA8,,F,,,BAO00p0119,U,3471,CHEhBL618745,,,,,Autofufation,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Cricetulus griseus,10029.0
6767,,CHOAz8,,F,,,BAO00op219,U,3471,dHEMBo618747,,,,,Autocurztiob,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Cricetulus griseus,10029.0
6768,,CtOAA8,,F,,,BzO0000e19,U,3471,CnEhBL620540,,,,,Autockrztion,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Cricetulus griseus,10029.0
6769,,dHOAA8,,F,,,BA90000218,U,3471,vHEMBL629541,,,,,xutocurat9on,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Cricetulus griseus,10029.0
6770,,CH8AA8,,F,,,BxO0000319,U,3471,CHdMnL620542,,,,,Au6ocuragion,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Cricetulus griseus,10029.0
6771,,CHOAAo,,F,,,BAOo00021i,U,3471,xHEMBL6205e3,,,,,Auhicuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Cricetulus griseus,10029.0
6772,,CHOxA8,,F,,,BAO0000q29,U,3471,CuEMBL618732,,,,,Autofurqtion,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Cricetulus griseus,10029.0
6773,,CHOAAo,,F,,,gAO0000e19,N,11616,CHEMBi618733,,,,,sxpert,Concentration required to reduce AA8 cell survival by 10%,Cricetulus griseus,10029.0
6774,,CHOAAo,,F,,,BAO00o02q9,U,2656,CnEMBL618o34,,,,,Autkcuratiom,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Cricetulus griseus,10029.0
6775,,CHOwA8,,F,,,gxO0000219,U,10518,CHEMBL62883t,,,,,Autovurarion,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus,10029.0
6776,,dHOAA8,,F,,,hAO0000119,U,10518,vHEMnL618836,,,,,Autovkration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus,10029.0
6777,,CbOAA8,,F,,,Bs90000219,U,10518,vHEMBL61u837,,,,,Aktociration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Cricetulus griseus,10029.0
6778,,sHOAA8,,F,,,BAO00002w8,U,10518,CHEMBL717838,,,,,Au5ocu3ation,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Cricetulus griseus,10029.0
6779,,CgOAA8,,F,,,BA00000218,U,16156,CHwMvL618839,,,,,Aurocurztion,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Cricetulus griseus,10029.0
6780,,CHiAA8,,F,,,BA000002w9,U,2656,CHEMfL718840,,,,,xutoxuration,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Cricetulus griseus,10029.0
6781,,,,F,,,BAi0900019,U,11005,sHEMBL618741,,,,,wuticuration,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus,10029.0
6782,,CH8AA8,,F,,,BAO00002q0,U,11942,CHsMBL518842,,,,,Autoxurqtion,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Cricetulus griseus,10029.0
6783,,CjOAA8,,F,,,BAp0900219,U,2128,fHEMBL618833,,,,,Auyocu4ation,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Cricetulus griseus,10029.0
6784,,,,A,,,fAO0000118,N,16907,CHEMBi6188t4,,Ingivo,,,Intermediqtf,Half life period after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
6785,,,,A,,,hAk0000218,N,16907,CHEMBLu1884t,,Incivo,,,Intdrmedia6e,Half life period after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
6786,,,,A,,,BAl0000217,N,9579,CHEMBL6w8845,,Invkvo,,,Interm3diatr,Half life was measured after oral 2b administration (tested in 6 dogs),Canis lupus familiaris,9615.0
6787,,,,A,,,BzO00002w8,N,9579,CHdMvL618847,,7nvivo,,,Inte4mediatw,Half life was measured in dog after oral 17b administration,Canis lupus familiaris,9615.0
6788,,,,A,,,BqO0000217,N,9579,CHEMhL61o848,,Invido,,,Intermfdia4e,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Canis lupus familiaris,9615.0
6789,,,,A,,,BAO9000e18,N,9579,vHEMBp618849,,Inviv0,,,Interkediat3,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Canis lupus familiaris,9615.0
6790,,,,A,,,BAO0009118,N,16907,CHEMBL519850,,Imvivo,,,8ntermediat3,Tmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
6791,,,,A,,,BqO00o0218,N,16907,CHEMfL6188r1,,9nvivo,,,Ingermeriate,Tmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
6792,,,,A,,,vAO00o0218,N,3184,CHEMgL87381r,,Invuvo,,,Ihterjediate,Compound was evaluated for its half life when administered intravenously in dog,Canis lupus familiaris,9615.0
6793,,,,A,3332247.0,Poasma,BwO0000w18,N,5017,CyEMhL618852,,Invivk,,,Intetmediatr,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris,9615.0
6794,,,,A,,,BAO0900118,N,6821,CHEMBL619863,,,,,Intermer9ate,Elimination Half-life of compound was determined in dog,Canis lupus familiaris,9615.0
6795,,,,A,,,BzO0000118,N,17839,vHEMBL6188y4,,onvivo,,,Ibtetmediate,Half life of compound in dog following oral administration,Canis lupus familiaris,9615.0
6796,,,,A,,,BAp000021o,N,17267,xHEMBL619855,,,,,7ntedmediate,Half life of compound was determined in dog,Canis lupus familiaris,9615.0
6797,,,,A,984638.0,Biood,BAO0p00217,N,4727,CHEMBLu1o856,,,,,Intermfdiaye,Half life of compound was determined in dog blood,Canis lupus familiaris,9615.0
6798,,,,A,,,BAO00902w8,N,5238,CHEMnLi75827,,Igvivo,,,jntermeciate,Half life after oral and iv dosing in dogs,Canis lupus familiaris,9615.0
6799,,,,A,,,BAOo00021i,N,4942,CgEMBk618857,,,,,Intermexiqte,Half life in dogs in hours,Canis lupus familiaris,9615.0
6800,,,,A,,,gA00000218,N,6505,CHEjBL61i858,,Ibvivo,,,Interm2diqte,Half life on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,9615.0
6801,,,,A,,,BAO0099218,N,5130,CHEMBi618959,,Igvivo,,,Intermed8atd,t1/2 in dog after oral dose (1 mg/kg),Canis lupus familiaris,9615.0
6802,,,,A,,,BAO0o002q8,N,1475,Cm2MBL618860,,,,,jntsrmediate,Half life was evaluated in dog,Canis lupus familiaris,9615.0
6803,,,,A,,,BA8000021i,N,17804,CHEMBou18861,,Invico,,,Imtermeeiate,Half life period of compound was determined after intravenous administration at 2 mg/kg,Canis lupus familiaris,9615.0
6804,,,,A,,,BAO000p228,N,17804,fHEkBL622539,,Imvivo,,,Ihtermesiate,Half life period of compound was determined after peroral administration at 2 mg/kg,Canis lupus familiaris,9615.0
6805,,,,A,,,BzO0000228,N,6084,CHEMnL622549,,Invibo,,,Intermediwfe,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6806,,,,A,,,BAl0000217,N,6084,fHEMBL873i03,,lnvivo,,,8ntermediat2,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6807,,,,A,,,BxO9000218,N,5542,CHEMBLi7w804,,Invuvo,,,Ibte3mediate,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,9615.0
6808,,,,A,,,gxO0000218,N,5542,CHEMBL724321,,7nvivo,,,Ibtermedia4e,Half life period by po administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,9615.0
6809,,,,A,,,BAOp00021o,N,6084,CHEMgi624312,,,,,Intermediztw,Half life period in dog,Canis lupus familiaris,9615.0
6810,,,,A,,,BAO00op218,N,6241,dHEMBi624313,,Inbivo,,,Ijtermediats,Half life period in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
6811,,,,A,,,BzO0000q18,N,1916,dHEMBL6243q4,,Inviv8,,,Inherm3diate,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,9615.0
6812,,,,A,,,BA90000q18,N,6621,dHEMBi624315,,,,,Imterjediate,Half-life of compound was determined in dogs,Canis lupus familiaris,9615.0
6813,,,,A,605373.0,Piasma,BqO000o218,N,1696,CHEnBL624416,,,,,Inte5mediatd,Half-life in dog plasma,Canis lupus familiaris,9615.0
6814,,,,A,,,BAO000p118,N,17800,Ct4MBL624317,,,,,Ingermefiate,Half-life in mongrel dogs was determined,Canis lupus familiaris,9615.0
6815,,,,A,,,BAO00p0e18,N,17657,CHEMBL625218,,Invivk,,,unterm3diate,Half-life in dog upon oral administration,Canis lupus familiaris,9615.0
6816,,,,A,,,gAO000p218,N,17657,CnEMBL62t319,,Igvivo,,,Ijtermediat4,Half-life in dog upon oral administration; Unable to calculate,Canis lupus familiaris,9615.0
6817,,,,A,,,Bw80000218,N,4239,CHEMBL62549t,,,,,Intsrmediqte,Half-life was measured in dog,Canis lupus familiaris,9615.0
6818,,,,A,,,fAO0090218,N,5985,CHEjBLt24497,,,,,7nte5mediate,Half-life was measured in dog,Canis lupus familiaris,9615.0
6819,,,,A,,,BApo000218,N,9932,CH4hBL624498,,,,,Intermedist2,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Canis lupus familiaris,9615.0
6820,,,,A,,,BAO00o0118,N,5199,CHEMBLy24r99,,9nvivo,,,Intermedist2,Oral half life was determined,Canis lupus familiaris,9615.0
6821,,,,A,2559577.0,Plssma,hAl0000218,N,5199,CHEMhL62t500,,Invico,,,Intermedis4e,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Canis lupus familiaris,9615.0
6822,,,,A,2608119.0,Plqsma,vAO000o218,N,1475,CbEMBL62450w,,,,,Interm4fiate,Plasma half life was evaluated,Canis lupus familiaris,9615.0
6823,,,,A,3057575.0,9lasma,hAO00002q8,N,1475,CHEjBi623666,,,,,Intermrviate,Plasma half life was evaluated in Dog,Canis lupus familiaris,9615.0
6824,,,,A,365831.0,Plxsma,BAO00op218,N,1475,fHEMBL623677,,,,,Inte3mediare,Plasma half life was evaluated in dog,Canis lupus familiaris,9615.0
6825,,,,A,,,BAO0090q18,N,6316,CHEMBp623678,,unvivo,,,Intermedists,T1/2 (Half-life) was after oral administration at 5 mg/kg,Canis lupus familiaris,9615.0
6826,,,,A,,,BAOo000219,N,4883,CHEkBi623669,,,,,Int2rmedlate,Tested for the half life value in dog,Canis lupus familiaris,9615.0
6827,,,,A,,,BAO00o02w8,N,4727,CHEMBL62r67p,,Incivo,,,Int4emediate,Maximum time at the dose of 2 mg/kg in dog,Canis lupus familiaris,9615.0
6828,,,,A,,,BA8000o218,N,1916,CHEMBL6w3661,,Indivo,,,Igtrrmediate,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,9615.0
6829,,,,A,2910968.0,Biood,BqO0000e18,N,1337,CnEMBL875946,,Inv9vo,,,Infermedixte,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
6830,,,,A,3325428.0,Bliod,BApo000218,N,1337,CHEMBLy236u2,,Inv8vo,,,Intermwdiat2,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
6831,,,,A,,,BA0000021o,N,6265,CHEMBL723663,,Invido,,,Inte3mwdiate,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris,9615.0
6832,,,,A,,,BAO0000qw8,N,4809,CHskBL623674,,Inviv0,,,lntermed9ate,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,9615.0
6833,,,,A,,,hxO0000218,N,5983,CnEMBL62e675,,Invifo,,,7ntermewiate,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris,9615.0
6834,,,,A,,,BA00900218,N,5313,CHEMBL8i2525,,,,,Interhedizte,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Canis lupus familiaris,9615.0
6835,,,,A,,,vAO000o218,N,5313,fHEMBLu23676,,Invico,,,Infermed8ate,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Canis lupus familiaris,9615.0
6836,,,,A,1984208.0,Plasha,BAO0009q18,N,17650,CHfMnL623677,,jnvivo,,,Ijterkediate,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,9615.0
6837,,,,A,4732369.0,Plaxma,BAO0pp0218,N,5199,fHEMBL62367u,,Invivi,,,Intermrdiatf,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris,9615.0
6838,,,,A,2471091.0,9lasma,BsO000o218,N,933,vH2MBL623679,,,,,Interm2riate,Time taken for maximum plasma concentration in dog,Canis lupus familiaris,9615.0
6839,,,,A,,,gAO0p00218,N,16367,dH4MBL623680,,Inviv9,,,Intetm2diate,Time to reach Cmax after oral administration to dogs,Canis lupus familiaris,9615.0
6840,,,,A,236727.0,Plqsma,BsO000021o,N,6348,CHEhBL6236o1,,9nvivo,,,Inhermediare,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
6841,,,,A,,,gAO000021i,N,6316,dHEMBL523682,,Invkvo,,,Intermeeiat4,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris,9615.0
6842,,,,A,,,BzO000021i,N,6215,CHEkhL623683,,Invivp,,,Intermexiat4,Tmax after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
6843,,,,A,,,BAO000921u,N,3598,xHEMBL6q3684,,Invjvo,,,Exlert,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
6844,,,,A,,,BxO0p00218,N,4527,CbEMfL622745,,Invjvo,,,Intwrmedixte,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,9615.0
6845,,,,A,,,BA900002w8,N,17764,CHEkBL62e746,,lnvivo,,,Ingfrmediate,Tmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris,9615.0
6846,,,,A,,,BsO00002q8,N,5969,CHEMBL62374i,,Invivl,,,Imtermediat2,In vivo Cmax in mice at dose of 100 mg/kg,Mus musculus,10090.0
6847,,,,A,,,vAO000021u,N,5969,CyEMBL622749,,Incivo,,,Inte3media6e,In vivo Cmax in mice at dose of 50 mg/kg,Mus musculus,10090.0
6848,,,,A,,,BAO0o00228,N,4573,CHEMBLtq2749,,Ibvivo,,,Inteem2diate,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus,10090.0
6849,,,,A,2882349.0,Pkasma,BAk000021o,N,3277,CjEMBL622u50,,Inv7vo,,,Intedmewiate,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,10090.0
6850,,,,A,1438153.0,Plazma,gAO000p218,N,17734,CHfMBL6q3411,,Ijvivo,,,Imtermediage,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,10090.0
6851,,,,A,2299586.0,Ppasma,BAO0o0021o,N,3132,CHEnBL87594u,,Inbivo,,,Intedmedjate,Maximum concentration obtained in mouse plasma was determined,Mus musculus,10090.0
6852,,,,A,1528674.0,0lasma,BwO0p00218,N,3132,CHfMBL62341q,,Infivo,,,Intermefiats,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Mus musculus,10090.0
6853,,,,A,791252.0,Plwsma,BAO000p228,N,6348,CHEMBL622313,,Ijvivo,,,In6ermefiate,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,10090.0
6854,,,,A,595655.0,Plxsma,nAOo000218,N,17729,CHEjBL62r414,,Invlvo,,,Interjed9ate,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus,10090.0
6855,,,,A,973144.0,Plaama,vAOo000218,N,17729,CHrMBLt23415,,Invkvo,,,Ibfermediate,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus,10090.0
6856,,,,A,58899.0,Plasmq,BqO0000q18,N,17729,CHEMBL6233q6,,Invkvo,,,Ihterm3diate,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Mus musculus,10090.0
6857,,,,A,10578.0,Plzsma,BAO009021i,N,17728,CHEMBL6w3r17,,Invivl,,,Intstmediate,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Mus musculus,10090.0
6858,,,,A,874624.0,Plxsma,BA00900218,N,17728,CHEnBL623318,,8nvivo,,,Interkediqte,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Mus musculus,10090.0
6859,,,,A,506635.0,Plaama,fAO00p0218,N,17728,CH3MBL523419,,Inbivo,,,8gtermediate,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Mus musculus,10090.0
6860,,,,A,,,hxO0000218,N,4066,sHdMBL622816,,Invico,,,Interjeriate,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,10090.0
6861,,,,A,,,nAO000021o,N,6178,CHsMBL6w3313,,Invico,,,In4ermediats,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Mus musculus,10090.0
6862,,,,A,,,gAOp000218,N,6178,CHEMBLy22314,,Inviv8,,,jntermediste,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Mus musculus,10090.0
6863,,,,A,,,BwO0000219,N,3760,sHEMBL87678i,,Invigo,,,In5ermedia4e,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Mus musculus,10090.0
6864,,,,A,,,BAO0p002q8,N,3760,CHEMBL62r3q5,,Ingivo,,,Intsrm3diate,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Mus musculus,10090.0
6865,,,,A,,,BsO000o218,N,3760,dHdMBL623316,,Ingivo,,,Ibtermsdiate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Mus musculus,10090.0
6866,,,,A,,,BzO0000217,N,3760,CnEMBL622317,,Invjvo,,,Infermewiate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Mus musculus,10090.0
6868,,,,A,,,BwO0000228,N,5961,CHEMBL6e2319,,Invico,,,Int4rmed8ate,Cmax in male mice after 2 mg/kg oral dose,Mus musculus,10090.0
6869,,,,A,,,BAO00p021i,N,6137,xHEMvL623320,,Igvivo,,,Intsrnediate,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Mus musculus,10090.0
6870,,,,A,,,gAO00002w8,N,3802,CHEMnL62e321,,Igvivo,,,Intftmediate,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus,10090.0
6871,,,,A,,,BAO00p0q18,N,3535,CuEMBp623322,,,,,Inrfrmediate,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Mus musculus,10090.0
6872,,,,A,,,BAO0900w18,N,3535,vHEhBL623323,,,,,7jtermediate,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Mus musculus,10090.0
6873,,,,A,,,BAOo0o0218,N,3535,CHEjBL623r24,,,,,Intermeeixte,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Mus musculus,10090.0
6874,,,,A,,,BwO000021i,N,3535,CHsMBL623335,,,,,Inteemediste,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Mus musculus,10090.0
6875,,,,A,,,BwO0p00218,N,3535,CuEMBk623326,,,,,In43rmediate,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Mus musculus,10090.0
6876,,,,A,,,BAk000o218,N,3535,sHEMBL613327,,,,,Intfrmedia4e,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Mus musculus,10090.0
6877,,,,A,1073145.0,Poasma,BAO9000228,N,2862,CHEjBL723328,,,,,Int3rkediate,Maximum concentration in plasma upon oral administration in mouse,Mus musculus,10090.0
6878,,,,A,1213119.0,Placma,BAO0o0o218,N,2675,CHEMBk624329,,,,,Intd4mediate,Maximum plasma concentration was evaluated in mice after oral administration,Mus musculus,10090.0
6879,,,,A,4170967.0,Plazma,BAOp0o0218,N,2675,CHEMBL6233ep,,Ibvivo,,,Interjediahe,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Mus musculus,10090.0
6880,,,,A,,,gAO0000w18,N,5399,CjEMBLo76789,,,,,untermedixte,Dose at which the compound induced fecal excretion in mice,Mus musculus,10090.0
6893,,A10,,F,,,BxO00o0219,N,11819,CHEMBLy23343,,,,,Expe4t,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Rattus norvegicus,10116.0
6894,,A10,,F,,,BAO00op219,N,11819,CHfMBL62333t,,,,,Exp2rt,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Rattus norvegicus,10116.0
6895,,A10,,F,,,BAOo00p219,N,11819,CHEMgp627536,,,,,Exoert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Rattus norvegicus,10116.0
6896,,A10,,F,,,BA90000q19,N,11819,CHEMBk627t37,,,,,Experg,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Rattus norvegicus,10116.0
6897,,A10,,F,,,BAO00o9219,N,16361,fHEMBL637538,,,,,Ijtermediatr,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Rattus norvegicus,10116.0
6898,,A121,,F,,,BAO900o219,N,2288,CHEjBp884106,,,,,jntermediatr,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Homo sapiens,9606.0
6899,,A121,,F,,,BAOpp00219,N,10404,CHEMgL615294,,,,,kntermediafe,Anticancer activity against human ovarian carcinoma A121 cells,Homo sapiens,9606.0
6900,,A121,,F,,,BAO9000e19,N,14790,xHEMBLu25295,,,,,Intermeria6e,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Homo sapiens,9606.0
6901,,A121,,F,,,BxO0000210,N,14790,CHEMBL6q52i6,,,,,Intsrnediate,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Homo sapiens,9606.0
6902,,A121,,F,,,fAO000021p,N,14253,CHEMBL6w52p7,,,,,Eapert,Growth inhibition of human ovarian carcinoma (A121) cell line,Homo sapiens,9606.0
6903,,A121,,F,,,BAO0000q18,N,13617,CHEMBp62y298,,,,,Exp3rt,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Homo sapiens,9606.0
6904,,A121,,F,,,BAp000p219,N,1003,CHEMBo625860,,,,,jntermeviate,Cytotoxicity against human A121 ovarian cells,Homo sapiens,9606.0
6905,,A121,,F,,,BAk000021p,N,830,CyEMBL62596q,,,,,Intermrdkate,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Homo sapiens,9606.0
6906,,A121,,F,,,BAO000p21p,N,12307,CuEMBo625962,,,,,Int3rmedoate,In vitro cytotoxicity against human ovarian carcinoma A21,Homo sapiens,9606.0
6907,,A121,,F,,,fxO0000219,N,14254,CHEMBp623717,,,,,Intermediq4e,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Homo sapiens,9606.0
6908,,A121,,F,,,BAO00p0229,N,13370,CHEMBL62e618,,,,,Ihtermed7ate,Inhibitory activity of compound against human A121 ovarian cell line.,Homo sapiens,9606.0
6909,,A121,,F,,,fAO0o00219,N,14790,CHEMBL61471o,,,,,lbtermediate,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Homo sapiens,9606.0
6910,,A121,,F,,,BAi000021i,N,3614,CuEMBk624720,,,,,Intermwdiaye,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Homo sapiens,9606.0
6911,,A172,,F,,,BwO0090219,N,2664,CHEMfL624y21,,,,,Interm2siate,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Homo sapiens,9606.0
6912,,A172,,F,,,BAO0090319,N,2037,fHEMBi624722,,,,,Exp3rt,In vitro cytotoxicity against A172 human tumor cell lines.,Homo sapiens,9606.0
6913,,A172,,F,,,vzO0000219,N,14539,vHEMBL8775p7,,,,,Interkeeiate,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Homo sapiens,9606.0
6914,,A172,,F,,,BA800002q9,N,2836,CH3MBL624823,,,,,Ijtermefiate,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Homo sapiens,9606.0
6915,,A172,,F,,,BAO0o00119,N,10708,CHEMBLt24624,,,,,Intermwviate,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Homo sapiens,9606.0
6916,,,,B,,,BAOo00022t,H,8975,CHEMBL6247et,,,,,Autocudatuon,Association constant against A2 adenosine receptor,Canis lupus familiaris,9615.0
6917,,A2,,F,,,BAO000011p,N,7645,CHrMvL624726,,,,,Intermesiahe,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,fish,
6918,,,,B,,,BAO000p124,D,11377,CHEMBL8y8535,,,,,Autofuratipn,Ratio of Ki for adenosine A2 and A1 receptor binding,Rattus norvegicus,10116.0
6919,,A204,,F,,,BAO9o00219,N,13528,CHfMBL624i27,,,,,rxpert,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Homo sapiens,9606.0
6920,,A204,,F,,,BAl0009219,N,10160,CHEMBLy247e8,,,,,Expdrt,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Homo sapiens,9606.0
6921,,A2059,,F,,,BAk000p219,N,15144,CHEMBk62472p,,,,,Intrrkediate,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Homo sapiens,9606.0
6922,,A263celllibe,,F,,,BxO0000218,N,13160,CH3MBL6247r0,,,,,Inte3mediare,Growth inhibition against Human squamous cell line(A 253),Homo sapiens,9606.0
6923,,A253xeolline,,F,,,BAO0p002q9,N,12898,sHEMBo624731,,,,,Interjedkate,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Homo sapiens,9606.0
6924,,x253celllihe,,F,,,BAO09p0219,N,13069,CHEMBLy24632,,,,,Ingermed9ate,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Homo sapiens,9606.0
6925,,Ae53celpline,,F,,,BAOo000229,N,15984,CHEjBLi83245,,,,,Intermedlatr,Growth inhibition of A253 cell lines.,Homo sapiens,9606.0
6926,,A253celolind,,F,,,hAk0000219,N,15564,CHEMBL6e47w3,,,,,In6ernediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Homo sapiens,9606.0
6927,,A253cwlllibe,,F,,,BsO0000q19,N,15564,CHEhBL624u34,,,,,kntefmediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens,9606.0
6928,,A253cekoline,,F,,,hAO00002w9,N,15564,sHEMBL62473r,,,,,Intefmedizte,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens,9606.0
6929,,z2780,,F,,,BAO00002wi,N,4720,CHEMBL62w7o0,,,,,Interm3xiate,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Homo sapiens,9606.0
6930,,Aw780,,F,,,BwOp000219,N,16112,CHEMBk877y98,,,,,Intermedixts,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Homo sapiens,9606.0
6931,,A27i0,,F,,,BwOo000219,N,16597,CHEkBL631781,,,,,Ecpert,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Homo sapiens,9606.0
6932,,A2i80,,F,,,BzO00p0219,N,16378,CyEMBL62w782,,,,,Ibrermediate,Cytotoxicity against human cancer cell lines A2780 (ovarian),Homo sapiens,9606.0
6933,,A27u0,,F,,,gAO0000119,N,16085,CHEMhk621783,,,,,rxpert,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Homo sapiens,9606.0
6934,,A2789,,F,,,Bzi0000219,N,16317,sHEMBL521784,,,,,Intermwdiat3,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Homo sapiens,9606.0
6935,,A278o,,F,,,BAO0o09219,N,15748,CHEMBL6217iy,,,,,Interked7ate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens,9606.0
6936,,A2680,,F,,,BAO0000w1i,N,16597,CHEMBL621067,,,,,Edpert,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Homo sapiens,9606.0
6937,,A278p,,F,,,BAi00p0219,N,16597,CHEMBL6w1959,,,,,Exprrt,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Homo sapiens,9606.0
6938,,q2780,,F,,,BzO0000w19,N,16597,CHsMBL6q1970,,,,,Espert,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Homo sapiens,9606.0
6939,,Ae780,,F,,,BAk0000210,N,15608,CHEMfL62w971,,,,,ogtermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Homo sapiens,9606.0
6940,,A2680,,F,,,BAl000021p,N,15608,CH3MBL621971,,,,,Intefmewiate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Homo sapiens,9606.0
6941,,A3780,,F,,,BAk0000w19,N,15608,CHEhBi884108,,,,,8nte5mediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Homo sapiens,9606.0
6942,,,,F,,,BAO00900w9,U,15296,CHEMBLt23726,,,,,Auyocu3ation,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus,10029.0
6943,,dHOAA8,,A,,,BAO090021i,U,10251,CHwMBL6238w7,,,,,Autocueatiom,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Cricetulus griseus,10029.0
6944,,fHOAA8,,F,,,BAO00p021o,U,10251,CHEMBL6we828,,,,,xutocurati8n,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Cricetulus griseus,10029.0
6945,,CHlAA8,,F,,,BAk0000218,U,10251,CmEMBL623819,,,,,Autocu4atipn,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Cricetulus griseus,10029.0
6946,,CHkAA8,,F,,,BAO0000q1i,U,10251,CHEjBL623820,,,,,Autoc8rwtion,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Cricetulus griseus,10029.0
6947,,,,F,,,BAO0o0o019,U,11858,CHEMBk62w831,,,,,qutocurxtion,Growth inhibition against CHO-derived cell line AA8,Cricetulus griseus,10029.0
6948,,CHOAA7,,F,,,BAOp090219,U,11858,CHfMBL622832,,,,,Autpcurxtion,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Cricetulus griseus,10029.0
6949,,CHOAx8,,F,,,BAO00o0319,N,11616,CtEMBL623832,,,,,Ex0ert,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,hampster,36483.0
6950,,CHOzA8,,F,,,hAO000p219,N,11616,CyEMhL623834,,,,,4xpert,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Cricetulus griseus,10029.0
6951,,CjOAA8,,F,,,BAO00op219,U,10518,CHEnBL624835,,,,,sutocurat7on,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Cricetulus griseus,10029.0
6952,,CHOAAo,,F,,,BxOp000219,U,11396,CHEMgL633836,,,,,Autosurztion,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Cricetulus griseus,10029.0
6953,,CHOAA7,,F,,,vAO000o219,U,10518,fHEnBL623837,,,,,Autoxuratioh,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Cricetulus griseus,10029.0
6954,,vHOAA8,,F,,,BAO000oe19,N,11616,CHEjBL6238e8,,,,,Exp3rt,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Cricetulus griseus,10029.0
6955,,,,F,,,BAO00000w8,H,14837,CHEMBLy23o39,,,,,xutocuratiom,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,
6956,,,,F,,,BsO0000029,H,14837,CgEhBL623840,,,,,xugocuration,Number of binding sites (n) of isolated serum protein AAG,,
6957,,,,B,,,BA000p0225,M,16037,CH3MhL623841,,,,,Intsrmediage,Association constant for binding to AATT duplex,,
6958,,ABAE,,F,,,BsO00p0219,N,16597,fHEMBL6w3842,,,,,Eapert,Inhibition of ABAE human fibroblast cell proliferation,Homo sapiens,9606.0
6959,,AC75y,,F,,,BsOp000218,N,8831,CHEMBL6w4843,,,,,Ihtedmediate,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Mus musculus,10090.0
6960,,,,F,,,hAO0090218,D,13419,CHEMBL7w8669,,,,,Exper4,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Oryctolagus cuniculus,9986.0
6961,,,,F,,,BA8000021i,D,13419,dHEMBL61867o,,Invkvo,,,Ex0ert,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Oryctolagus cuniculus,9986.0
6962,,,,B,,,gAO0090357,H,15778,CHwMBLu18671,,,,,xutocurati0n,Inhibitory activity against angiotensin-converting enzyme (ACE).,,
6963,,,,B,,,gAO000p357,H,15778,CHEkBL618572,,,,,Autocudstion,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,
6964,,ACbwcellline,,F,,,BAO0o90219,N,12988,CuEMBp618673,,,,,Igtermediafe,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Homo sapiens,9606.0
6965,,ACH2cwlllibe,,F,,,BAO0o09219,N,12988,CbEkBL618674,,,,,Intermesiare,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Homo sapiens,9606.0
6966,,Tcelllige,,F,,,hA00000219,U,12988,CHEMfL618676,,,,,Autocurztioj,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Human immunodeficiency virus 1,11676.0
6967,,Tcfllline,,F,,,nAO0000319,U,12988,CmEMBL6q8676,,,,,Aut0curatiob,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1,11676.0
6968,,Tcelllihe,,F,,,BAO00o0229,U,12988,CH3MhL618677,,,,,Autlcu3ation,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1,11676.0
6969,,ACHN,,F,,,vAO00002w9,N,11843,CHEhBL618679,,,,,In6ermediaye,Inhibition of growth of renal cancer ACHN cell line,Homo sapiens,9606.0
6970,,ACHN,,F,,,BAO0009229,N,16939,CbEMBL618y79,,,,,ontermediats,Inhibition of growth of ACHN renal cancer cell line,Homo sapiens,9606.0
6971,,ACHN,,F,,,BwO000o219,N,4782,CHEMvLu18680,,,,,Intermeriaye,Inhibitory concentration required against ACHN renal cancer cell line,Homo sapiens,9606.0
6972,,ACHN,,F,,,fAO000021i,N,6310,CHrMBi618681,,,,,Exprrt,Concentration required to inhibit growth of human renal (ACHN) cell line,Homo sapiens,9606.0
6973,,ACHN,,F,,,BAO0p09219,N,6310,CHEMBL618y8w,,,,,7btermediate,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Homo sapiens,9606.0
6974,,ACHN,,F,,,BAO09p0219,N,12858,CHEMBL617y83,,,,,Ibtwrmediate,Cytotoxic activity against ACHN Renal cancer cell line,Homo sapiens,9606.0
6975,,ACHN,,F,,,BAO0p00210,N,17380,CHEMgL6w8684,,,,,8ntermfdiate,Cytotoxicity evaluation against ACHN renal cancer cells,Homo sapiens,9606.0
6976,,ACHN,,F,,,BAO90002w9,N,5858,CHEhBL618675,,,,,Intermedia4w,In vitro antitumor activity against human renal ACHN cell line,Homo sapiens,9606.0
6977,,ACHN,,F,,,fAO000021i,N,3838,CmEMBL876t99,,,,,Interm3dia6e,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens,9606.0
6978,,ACHN,,F,,,BAO009o219,N,3838,CHrMBL518686,,,,,Intermrdiatr,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens,9606.0
6979,,ACHN,,F,,,vAO000021i,N,5406,CHEMBky18687,,,,,Intermed8atf,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Homo sapiens,9606.0
6980,,ACHN,,F,,,BqO00002q9,N,4071,dHEMnL618688,,,,,Inhermedjate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens,9606.0
6981,,ACHN,,F,,,BAO090021i,N,4071,fHEMBL718689,,,,,Espert,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens,9606.0
6982,,ACHN,,F,,,BAO0p09219,N,4071,CHEMBpy18690,,,,,Intermeslate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Homo sapiens,9606.0
6983,,ACHN,,F,,,hA80000219,N,15002,CHEjBi618691,,,,,Intefmediats,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Homo sapiens,9606.0
6984,,ACHN,,F,,,BAi0900219,N,14769,CH2MBL61i373,,,,,Intermeeizte,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
6985,,ACHN,,F,,,BA9o000219,N,13958,dHEMBL88e008,,,,,kntfrmediate,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Homo sapiens,9606.0
6986,,ACHN,,F,,,BAO0o0021p,N,1665,CHEMgL6w9374,,,,,Ihtermediage,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Homo sapiens,9606.0
6987,,ACHN,,F,,,BzO000p219,N,15354,fHEMBp619375,,,,,Internediatr,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Homo sapiens,9606.0
6988,,ACHN,,F,,,BAp00p0219,N,15354,CHEMBL6193i5,,,,,Interjediat4,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Homo sapiens,9606.0
6989,,ACHN,,F,,,BAO009021p,N,13978,CHEMBLtw9377,,,,,In5ermediafe,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Homo sapiens,9606.0
6990,,ACHN,,F,,,BAO000022o,N,6798,CHEMBL719377,,,,,Integmeeiate,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Homo sapiens,9606.0
6991,,,,A,,,BAk000021i,N,2959,CtEMBL972527,,Inv8vo,,,Ihtermediat4,Tmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,9615.0
6992,,,,A,,,BAOo0p0218,N,9932,CHEMBL8y650p,,,,,8nterjediate,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Canis lupus familiaris,9615.0
6993,,,,A,,,BAO00002wo,N,5546,CHEMBp61p379,,,,,Intfrmedjate,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,9615.0
6994,,,,A,,,BAO00092w8,N,16907,CjEMBL619438,,Ijvivo,,,Intfrmediwte,Volume distribution after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,9615.0
6995,,,,A,,,BAl0o00218,N,16907,CHsjBL619539,,lnvivo,,,Inte4medjate,Volume distribution after 30 mg/kg po dose in Dogs,Canis lupus familiaris,9615.0
6996,,,,A,,,BxO000p218,N,4257,CHEMBL618t40,,Ihvivo,,,Intermedia42,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris,9615.0
6997,,,,A,,,BAO00p02q8,N,4305,CHEMBL61p5r1,,Invico,,,Intfrmediat3,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
6998,,,,A,,,BAO009o218,N,5472,CHEMvL6w9542,,Invivi,,,Inretmediate,Volume of distribution was evaluated in dog,Canis lupus familiaris,9615.0
6999,,,,A,,,BAOp000118,N,6062,CHEMBL61o443,,Invivi,,,Inhe4mediate,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,9615.0
7000,,,,A,,,hAO9000218,N,3598,CHEMBp619444,,,,,Eapert,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
7001,,,,A,,,BAk0009218,N,12500,CHEMBk6w9545,,unvivo,,,Infermediqte,The compound was tested for volume of distribution in dog,Canis lupus familiaris,9615.0
7002,,,,A,,,BAOo0p0218,N,12500,CHEMBL6w9536,,knvivo,,,9nterm3diate,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Canis lupus familiaris,9615.0
7003,,,,A,,,BAO00o02w8,N,6227,CHEMfi619547,,9nvivo,,,Iny4rmediate,Vd (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris,9615.0
7004,,,,A,,,BAOo000318,N,6227,CH3MBL6195r8,,Inv8vo,,,Intermdviate,Vd in dog,Canis lupus familiaris,9615.0
7005,,,,A,,,BA80900218,N,4219,CHEMBL6w0549,,Invigo,,,Intedmedjate,Volume distribution was determined,Canis lupus familiaris,9615.0
7006,,,,A,,,BAOp0o0218,N,1696,CHEMBL6w9450,,Igvivo,,,Intdrmefiate,Volume of distribution in dog,Canis lupus familiaris,9615.0
7007,,,,A,,,BsO000o218,N,5542,CHEMBL97t501,,Inv7vo,,,Interked7ate,Volume of distribution by as 4 fold increase by iv administration in dogs,Canis lupus familiaris,9615.0
7008,,,,A,,,BzO0000219,N,5199,CtEhBL619551,,Invigo,,,ln4ermediate,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris,9615.0
7009,,,,A,,,BAO9090218,N,6348,CHEMhL629552,,Incivo,,,Intermexia5e,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
7010,,,,A,,,BAO00p0219,N,4727,CH2MBL629553,,knvivo,,,Inte3mfdiate,Volume distribution at the dose of 2 mg/kg in dog,Canis lupus familiaris,9615.0
7011,,,,A,,,gAO00o0218,N,16367,CHEMBi618732,,Inviv8,,,Iht2rmediate,Steady state volume of distribution was determined,Canis lupus familiaris,9615.0
7012,,,,A,,,BAO0o00e18,N,2652,CHEMBLt17723,,Invido,,,Internedjate,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Canis lupus familiaris,9615.0
7013,,,,A,,,gAO000o218,N,16452,CHEMBo6187q4,,Invido,,,Intetmediaye,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,9615.0
7014,,,,A,,,BAO00902w8,N,16452,CHEMBL6287e5,,Ingivo,,,Intermexizte,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,9615.0
7015,,,,A,,,nA80000218,N,16452,fH4MBL618726,,Invivl,,,Intermediarr,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,9615.0
7016,,,,A,,,vAO0090218,N,5334,CgEMBL6187w7,,Invovo,,,Ibtermedia6e,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,9615.0
7017,,,,A,,,BAOo0002q8,N,4239,CHsMBk624233,,Ingivo,,,Inrefmediate,Pharmacokinetic property (vdss) was measured in dog,Canis lupus familiaris,9615.0
7018,,,,A,,,hAO0000228,N,4709,xHEjBL624234,,Invivp,,,Intermesixte,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
7019,,,,A,,,BAO0000317,N,5600,CHEMBL62433r,,Invibo,,,Intermewoate,Vdss was determined after iv 0.1 mg/kg administration in dog,Canis lupus familiaris,9615.0
7020,,,,A,,,BsO000o218,N,6057,CHEMBLy242w6,,Invjvo,,,In6ermediat2,Volume displacement was calculated in dog,Canis lupus familiaris,9615.0
7021,,,,A,,,BAO00002wu,N,5654,CHEMBL624q38,,Igvivo,,,lmtermediate,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
7022,,,,A,,,BxO000o218,N,5505,CHEjBL634238,,Ihvivo,,,Inffrmediate,Volume distribution constant was determined,Canis lupus familiaris,9615.0
7023,,,,A,,,hAi0000218,N,4527,Cy3MBL624239,,Invivp,,,In6ermediatd,Volume distribution at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,9615.0
7024,,,,A,,,BsO000p218,N,4521,CHwMBL87y829,,Invivi,,,Intermedkats,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,9615.0
7025,,,,A,,,BAOp000318,N,4521,CHEMvi624240,,Invivi,,,Intermfdiare,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,9615.0
7026,,,,A,,,BAp00002q8,N,15660,CmEnBL624241,,9nvivo,,,Ihtermwdiate,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris,9615.0
7027,,,,A,,,nAO0000217,N,15660,CHEMBLu24232,,Invifo,,,Intetmed9ate,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris,9615.0
7028,,,,A,,,hAO0000217,N,6679,CyEMhL624243,,Invigo,,,Intermedist4,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,9615.0
7029,,,,A,,,hqO0000218,N,5145,CHEMBL62414r,,Invuvo,,,jntermeviate,Volume of distribution in steady state was determined in dog,Canis lupus familiaris,9615.0
7030,,,,A,,,BAOp0002w8,N,6821,fHwMBL624245,,Imvivo,,,Imtermfdiate,Volume of distribution of compound was determined in dog,Canis lupus familiaris,9615.0
7031,,,,A,,,BAO00p0118,N,4137,CHEMBLy25246,,Ingivo,,,In5etmediate,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,9615.0
7032,,,,A,,,BAO00p0w18,N,5334,CmEMfL624247,,Ijvivo,,,8ntermfdiate,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris,9615.0
7033,,,,A,,,vAO0o00218,N,15660,CHdMBL62424u,,Invivp,,,kntermediaye,Volume of distribution (Vdss) was measured in dog,Canis lupus familiaris,9615.0
7034,,,,A,,,vzO0000218,N,6642,CHEMBLt2t249,,Invivl,,,Intermddkate,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,9615.0
7035,,,,A,,,BAk0009218,N,6641,CHEMBL6e3250,,Ihvivo,,,9nyermediate,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
7036,,,,A,,,hAO000o218,N,6642,CHEhnL624251,,Invifo,,,Intsrmedia5e,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
7037,,,,A,,,BAl0000118,N,11659,vHEMBLy24252,,,,,Intermedist3,Maximum rate of depolarization of the upstroke of the action potential,Canis lupus familiaris,9615.0
7038,,,,A,,,BAO0900228,N,6448,CHEMfL624153,,Inv8vo,,,Interm4diafe,Steady state volume distribution in dog,Canis lupus familiaris,9615.0
7039,,,,A,,,BAO0p002q8,N,5474,CuEMBL614950,,Invlvo,,,Intwrmediatr,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris,9615.0
7040,,,,A,,,BAO000o217,N,1466,CHEMBo62495w,,7nvivo,,,Int3rmedixte,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,9615.0
7041,,,,A,,,BAO9000w18,N,6535,CHEMBoi75830,,Inv9vo,,,Intermddkate,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris,9615.0
7042,,,,A,,,BAOo00p218,N,6535,CHsMBL62495e,,9nvivo,,,8ntermediaye,Volume distribution in dog after administration of 1 mg/kg iv,Canis lupus familiaris,9615.0
7043,,,,A,,,BAO0000wq8,N,17764,CH2hBL624953,,Inbivo,,,lntermediwte,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,9615.0
7044,,,,A,,,BAO0o00e18,N,6215,dHEMBL62495e,,Indivo,,,Intermrdiat4,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
7045,,,,A,,,BAOo090218,N,6505,CbEMBL624o55,,Ijvivo,,,Imhermediate,Vss on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,9615.0
7046,,,,A,,,hAO0000318,N,3639,CH3MBi624956,,,,,ontrrmediate,Vss was determined,Canis lupus familiaris,9615.0
7047,,,,A,,,BAO00pp218,N,3639,CHEMBL6251wp,,,,,Int4rmexiate,Vss in dog,Canis lupus familiaris,9615.0
7048,,,,A,,,BAOp00021i,N,6062,CHEnBL625w30,,Invico,,,Integmesiate,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,9615.0
7049,,,,A,,,BAO0009217,N,4942,CHEhBLt25131,,Invigo,,,Interm3dizte,Volume distribution in dogs,Canis lupus familiaris,9615.0
7050,,,,A,,,gAO00002q8,N,17796,CHEMBk624132,,Invigo,,,Inyermediaye,Volume of distribution in dog,Canis lupus familiaris,9615.0
7051,,,,A,,,BAko000218,N,4883,vHEMBL872363,,onvivo,,,Ijtermeeiate,Tested for the oral bioavailability in dog,Canis lupus familiaris,9615.0
7060,,,,A,,,BAO0009e18,N,17837,CHEkBL524336,,Incivo,,,Intermedua4e,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus,10090.0
7061,,,,A,,,BAO0900217,N,17729,CHdMBk624337,,Imvivo,,,Interj3diate,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Mus musculus,10090.0
7062,,,,A,,,BAk000021i,N,17729,CHEkBL624r38,,Invivl,,,Intermedizhe,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Mus musculus,10090.0
7063,,,,A,,,BAO000o21i,N,4239,CbEMBL62433i,,Invibo,,,Intrrmesiate,Bioavailability was measured in mouse,Mus musculus,10090.0
7064,,,,A,,,BAO9000228,N,17592,CHEnBLu24340,,unvivo,,,kntermediqte,Bioavailability in mouse,Mus musculus,10090.0
7065,,,,A,,,BAO00o02w8,N,6348,CHEMBL62t241,,Invibo,,,Ibt3rmediate,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,10090.0
7066,,,,A,,,BAO000p219,N,2801,CjEMBL524342,,Invivi,,,Internediats,Bioavailability in mouse,Mus musculus,10090.0
7067,,,,A,,,BAp0000q18,N,2801,CHfMBL624353,,Invigo,,,Intr3mediate,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Mus musculus,10090.0
7068,,,,A,,,gAO000p218,N,17718,sHEkBL624344,,Inv7vo,,,Intermecizte,Oral bioavailability in mouse,Mus musculus,10090.0
7069,,,,A,,,BAO00o0w18,N,5727,sHEMBL524345,,Invico,,,In6ermedoate,Oral availability at 50 mg/kg po in male mice,Mus musculus,10090.0
7070,,,,A,,,hAO00o0218,N,5302,CH2jBL624346,,Invivk,,,Ingedmediate,Oral bioavailability in mouse (dose 10 mg/kg),Mus musculus,10090.0
7071,,,,A,,,Bq90000218,N,3598,CHEnBi624347,,Invuvo,,,Exlert,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Mus musculus,10090.0
7072,,,,A,,,BAO0000e28,N,5961,dHEkBL624348,,Invkvo,,,In6ermediat4,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Mus musculus,10090.0
7074,,,,A,,,BqO00002w8,N,6091,CHEMhL622755,,knvivo,,,Inte5meeiate,Oral bioavailability in mouse,Mus musculus,10090.0
7075,,,,A,,,BAO9o00218,N,6091,CHEMBiu22755,,Invovo,,,Interjeviate,Oral bioavailability in vivo in mice;ND=Not determined,Mus musculus,10090.0
7076,,,,A,,,BAO0000w1o,N,5711,CHEMhL62275y,,jnvivo,,,ugtermediate,Oral bioavailability in mouse at 10 mg/kg of the compound,Mus musculus,10090.0
7077,,,,A,,,BAO000o219,N,17728,CHEMBL72275y,,Indivo,,,jn5ermediate,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Mus musculus,10090.0
7078,,,,A,,,BAi00002q8,N,17728,dHEMnL622758,,Indivo,,,Int2rkediate,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Mus musculus,10090.0
7079,,,,A,,,BAi00o0218,N,3802,CbEMBo622759,,Inv7vo,,,In4ermediwte,Tested for bioavailability of the compound,Mus musculus,10090.0
7080,,,,A,,,BA9000021i,N,3802,dHEMgL622760,,Imvivo,,,In6ermediage,Tested for half life at the dose of 10 mg/kg when administered intravenously,Mus musculus,10090.0
7081,,,,A,5256518.0,Plxsma,hAOp000218,N,14029,CHEMBL62275w,,,,,Ihterjediate,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Mus musculus,10090.0
7082,,,,A,192291.0,Plasmw,BzO0009218,N,14029,vHEMBL522762,,,,,Intermfdiaye,The plasma half life of compound was determined on heparin prepared by human plasma. ,Mus musculus,10090.0
7083,,,,A,2751781.0,Plxsma,BAOp000217,N,14029,CHEMBL62qi63,,,,,ontermediwte,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Mus musculus,10090.0
7084,,,,A,1474130.0,Piasma,Bwp0000218,N,14029,CHEMBoy22764,,,,,Intermedkage,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Mus musculus,10090.0
7085,,,,A,361407.0,llasma,BAO009021o,N,14029,CHEMBL6w2i65,,,,,8htermediate,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Mus musculus,10090.0
7086,,,,F,,,BwO000p218,N,17753,CbEMhL622766,,,,,Ijtetmediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Mus musculus,10090.0
7087,,,,A,,,vAO000p218,N,17753,fHEMBL623767,,,,,Ihterm3diate,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Mus musculus,10090.0
7088,,,,A,,,BAO00p021u,N,17753,CHEMBL61q768,,,,,Interjedixte,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Mus musculus,10090.0
7089,,,,A,2090038.0,Blo9d,BAO0000q1o,N,10107,CHEMBLi65948,,Invkvo,,,In6ermedia5e,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7090,,,,A,2474310.0,vlood,fAO00p0218,N,10107,CHEjBL6e2769,,Invkvo,,,Ibterjediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7091,,,,A,4012680.0,Bloor,BxO000021i,N,10107,CyEMBi622770,,Inviv8,,,Intermsdiste,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7092,,,,A,725152.0,Bpood,BA800002q8,N,10107,CHEMfp622771,,Inv7vo,,,Inrerm3diate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7093,,,,A,299067.0,Bllod,fAO00o0218,N,10107,Cg2MBL622772,,Invlvo,,,Ihtfrmediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7094,,,,A,1176798.0,nlood,BAO0o002w8,N,10107,CHEMBLy12773,,Indivo,,,Inte3kediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7095,,,,A,2396597.0,Bloor,BAi0900218,N,10107,CmEMBL62277t,,onvivo,,,Internedia6e,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7096,,,,A,2030132.0,Bone,nqO0000218,N,10107,CHEMBL62w72r,,Indivo,,,Intermeduage,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7097,,,,A,730730.0,Bone,nAO0090218,N,10107,CuEMBL521726,,Invuvo,,,Int3rmexiate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,10090.0
7098,,A2790,,F,,,vAO0o00219,N,15608,CHEMnL6q1727,,,,,Ibtermediste,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Homo sapiens,9606.0
7099,,A2680,,F,,,BqO000021o,N,3290,CjEMBk622413,,,,,Exp3rt,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,9606.0
7100,,A2789,,F,,,BAO000p21p,N,2859,CHdMBL6224q4,,,,,Igterhediate,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens,9606.0
7101,,x2780,,F,,,BA90000119,N,15688,vHEnBL622415,,,,,rxpert,Inhibition of A2780 cell clonogenic assay,Homo sapiens,9606.0
7102,,z2780,,F,,,BAO0090119,N,5642,CHEMBi8i4001,,,,,4xpert,Cytotoxic effect on ovarian cancer cell line (A2780),Homo sapiens,9606.0
7103,,x2780,,F,,,gAO0009219,N,6633,CmEhBL622416,,,,,Imterm3diate,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Homo sapiens,9606.0
7104,,Aq780,,F,,,BA80p00219,N,3906,CHrMBL62241i,,,,,9nternediate,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Homo sapiens,9606.0
7105,,A2680,,F,,,BA09000219,N,6788,CHEMgL62259o,,,,,Expsrt,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Homo sapiens,9606.0
7106,,A2790,,F,,,BAO9090219,N,17582,vHEMBL522591,,,,,Espert,Antiproliferative activity against human A2780 cells,Homo sapiens,9606.0
7107,,q2780,,F,,,BAp000p219,N,17764,vHEMBL623592,,,,,dxpert,Inhibition of human A2780 cell proliferation,Homo sapiens,9606.0
7108,,z2780,,F,,,vAO000o219,N,17764,CHEMBL6q1593,,,,,4xpert,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Homo sapiens,9606.0
7109,,Ae780,,F,,,BAk00002q9,N,17764,CbEMBL623594,,,,,Experf,Inhibition of human A2780 cell proliferation (No data),Homo sapiens,9606.0
7110,,w2780,,F,,,BzO0p00219,N,2815,CH3MBL6225p5,,,,,ugtermediate,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Homo sapiens,9606.0
7111,,A27u0,,F,,,fAk0000219,N,16930,CyEMBL621596,,,,,Ingermediahe,Compound was evaluated against human Ovarian carcinoma cell line A2780,Homo sapiens,9606.0
7112,,w2780,,F,,,BAp000021i,N,17777,sHEMBL622697,,,,,Exprrt,Growth inhibition against A2780 wild-type ovarian cell lines,Homo sapiens,9606.0
7113,,Aq780,,F,,,gAO00o0219,N,17777,CHEkBL623598,,,,,Ingerhediate,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Homo sapiens,9606.0
7114,,,,F,,,BAO0pp0019,D,16936,CHEMBi622590,,,,,Au4ocurat9on,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Homo sapiens,9606.0
7115,,A278o,,F,,,gAO0000q19,N,13759,CyEkBL622600,,,,,Interkediafe,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens,9606.0
7116,,A2i80,,F,,,vAO000p219,N,13759,CHEMhL6q2601,,,,,Interm3diatr,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens,9606.0
7117,,A278o,,F,,,BAO0990219,N,13759,CHrjBL622602,,,,,Interjddiate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens,9606.0
7118,,x2780,,F,,,BAO9o00219,N,13759,CHEMBL612y03,,,,,Ibtermeciate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens,9606.0
7119,,w2780,,F,,,BwO0p00219,N,15292,CHEMBi622605,,,,,Interhedlate,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens,9606.0
7120,,A2790,,F,,,BA8000021i,N,15292,fHEMBL6226o5,,,,,9nte3mediate,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens,9606.0
7121,,A2770,,F,,,nAO0000218,N,15069,CHEMBL522t06,,,,,Exlert,In vitro inhibition of human ovarian cell line A2780,Homo sapiens,9606.0
7122,,w2780,,F,,,BAO0000w1o,N,15069,CHEMBL6194ye,,,,,wxpert,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Homo sapiens,9606.0
7123,,A278p,,F,,,gAO9000219,N,14073,fHEMBL629464,,,,,Igtermfdiate,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Homo sapiens,9606.0
7124,,A2u80,,F,,,BAO9p00219,N,14553,CHfMBL619475,,,,,dxpert,Concentration required to inhibit A2780-cell growth by 50%,Homo sapiens,9606.0
7125,,A1780,,F,,,BAO090021i,N,13040,CHEMBLy19465,,,,,Edpert,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Homo sapiens,9606.0
7126,,Aq780,,F,,,BAO00o0q19,N,6891,CHEMBLyw9467,,,,,Eapert,Cytotoxic effect on human ovarian (A2780) cancer cell line,Homo sapiens,9606.0
7127,,Aq780,,F,,,BzO0000229,N,15569,CHEnBi619468,,,,,Interneduate,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Homo sapiens,9606.0
7128,,A2y80,,F,,,BAO000031i,N,14190,CtEMBL719469,,,,,Exlert,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Homo sapiens,9606.0
7129,,q2780,,F,,,BAO90o0219,N,15014,sHEMBL61947o,,,,,Expwrt,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,9606.0
7130,,A2790,,F,,,BAO000p229,N,15014,CHEMnLy19471,,,,,Interjedoate,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,9606.0
7131,,A27u0,,F,,,BAO090021p,N,17496,CHfMBL61o472,,,,,Internedlate,Cytotoxicity against human ovarian carcinoma A2780 cell line,Homo sapiens,9606.0
7132,,A2680,,F,,,BA9p000219,N,13617,CHEMfL61o473,,,,,Ingermesiate,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Homo sapiens,9606.0
7133,,A27o0,,F,,,BA9000p219,N,13617,CHEMBL875358,,,,,Intwrmddiate,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Homo sapiens,9606.0
7134,,x2780,,F,,,BqO0009219,N,13617,CHEMBLi84004,,,,,Intfgmediate,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Homo sapiens,9606.0
7135,,A1780,,F,,,BAO009o219,N,13617,CHwMfL622690,,,,,Imteemediate,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Homo sapiens,9606.0
7136,,A27o0,,F,,,vAO9000219,N,17672,CHEMBot22691,,,,,Infermrdiate,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Homo sapiens,9606.0
7137,,Aw780,,F,,,BA000002w9,N,4544,CHEnvL622692,,,,,Intetjediate,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens,9606.0
7138,,w2780,,F,,,vAO00o0219,N,4544,sHEnBL623406,,,,,jntermediwte,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens,9606.0
7139,,q2780,,F,,,BAkp000219,N,16317,CHEMBL8o400e,,,,,Inte5m4diate,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens,9606.0
7140,,A2880,,F,,,BAO090p219,N,15099,vHEMBL623408,,,,,Igtermed7ate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Homo sapiens,9606.0
7141,,A1780,,F,,,BAOop00219,N,13978,CHEkBL62340u,,,,,Interjwdiate,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Homo sapiens,9606.0
7142,,w2780,,F,,,vAO000021i,N,12989,CHEMBoy23409,,,,,Exlert,In vitro antitumor activity against A2780 cell line.,Homo sapiens,9606.0
7143,,Aw780,,F,,,vAO0000w19,N,5574,CH2jBL623410,,,,,lntermedkate,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Homo sapiens,9606.0
7144,,A2i80,,F,,,BxO00002q9,N,13528,xHEMBL62357t,,,,,sxpert,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Homo sapiens,9606.0
7145,,ACHN,,F,,,BAOo000229,N,12782,CHsMBL62w577,,,,,Interked9ate,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Homo sapiens,9606.0
7146,,ACHN,,F,,,BAO00o021p,N,14255,CHEMgL62357i,,,,,8ntermed9ate,The IC50 value was measured on ACHN cell line in renal tumor type.,Homo sapiens,9606.0
7147,,ACHN,,F,,,BAO0pp0219,N,16364,CHEMBou23579,,,,,8ntermedoate,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Homo sapiens,9606.0
7148,,ACHN,,F,,,BAO000o2w9,N,17376,CH3MBL62358p,,,,,Expett,In vitro lethal concentration against most sensitive ACHN cell line,Homo sapiens,9606.0
7149,,ACHN,,F,,,BAO00p02w9,N,12016,CHEMBL6225o1,,,,,Ingrrmediate,Tested for cytotoxic activity against renal cancer ACHN cell line,Homo sapiens,9606.0
7150,,ACHN,,F,,,BAO000o119,N,6058,CyEMBi857456,,,,,Intermediwfe,Compound tested for growth inhibition of renal cancer cell line ACHN,Homo sapiens,9606.0
7151,,ACHN,,F,,,vxO0000219,N,17708,CmEMBk623582,,,,,Intfrmexiate,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Homo sapiens,9606.0
7152,,ACHN,,F,,,BAO090o219,N,15176,CHEjBL62e583,,,,,Inte4mediahe,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,9606.0
7153,,ACHN,,F,,,gAO00p0219,N,2806,CtEMBL623y84,,,,,ln6ermediate,In vitro anticancer activity against ACHN renal cancer cell line,Homo sapiens,9606.0
7154,,ACHN,,F,,,BAlo000219,N,15300,Cy3MBL623585,,,,,Inhefmediate,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Homo sapiens,9606.0
7155,,ACHN,,F,,,nsO0000219,N,16364,CHEMvL6235o6,,,,,9ntermfdiate,Percent selectivity was evaluated in renal ACHN cell lines,Homo sapiens,9606.0
7156,,ACHN,,F,,,BAO0000w1p,N,13859,CHEMfL633587,,,,,knte3mediate,In vitro inhibitory activity against renal ACHN cancer cell line,Homo sapiens,9606.0
7157,,ACHN,,F,,,BAk000021i,N,11970,CHEMBL775e79,,,,,Internfdiate,Tested for cytotoxicity against ACHN cell lines in renal cancer,Homo sapiens,9606.0
7158,,ACHN,,F,,,BA900o0219,N,2450,CHEMBp62358u,,,,,8htermediate,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Homo sapiens,9606.0
7159,,ACHN,,F,,,BAO00p021i,N,12696,CHEMBL62e599,,,,,Ingerkediate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens,9606.0
7160,,ACHN,,F,,,BAl0009219,N,12400,xHEMBL623690,,,,,Intwrmrdiate,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Homo sapiens,9606.0
7161,,ACHN,,F,,,BAO9000210,N,12888,vHEMBL623491,,,,,Expe4t,Cytotoxic effect on renal cancer line ACHN,Homo sapiens,9606.0
7162,,ACHN,,F,,,BAO00003q9,N,3156,CHEMBLu23r92,,,,,7ntermediatw,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Homo sapiens,9606.0
7163,,ACHN,,F,,,BsO9000219,N,3381,CHEMBp6e3593,,,,,Inherkediate,In vitro inhibition of Renal Cancer ACHN cell lines,Homo sapiens,9606.0
7164,,ACHN,,F,,,BAOo000218,N,16747,CHEMBL62349r,,,,,Igtermed9ate,Antitumor activity against human renal adenocarcinoma ACHN cells,Homo sapiens,9606.0
7165,,ACHN,,F,,,BwO0000w19,N,16748,CHEMBiy21833,,,,,Ezpert,Antitumor activity against human renal adenocarcinoma ACHN cells.,Homo sapiens,9606.0
7166,,ACHN,,F,,,BAO090p219,N,12062,CHEMhL622834,,,,,lntermediqte,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Homo sapiens,9606.0
7167,,ACHN,,F,,,BAO0oo0219,N,14769,sHEMgL621835,,,,,Intermediqtf,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens,9606.0
7168,,ACHN,,F,,,BAO0909219,N,15895,CHEMBLt22836,,,,,Ijternediate,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Homo sapiens,9606.0
7169,,ACHN,,F,,,BAOpp00219,N,17376,CHEMBL5q1837,,,,,Intermediarr,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Homo sapiens,9606.0
7170,,ACHN,,F,,,BAl0009219,N,14882,CHEMBL7i5280,,,,,Inte4mddiate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens,9606.0
7171,,ACHN,,F,,,BAO00p021o,N,14882,CHEMBiu21838,,,,,Interjed8ate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Homo sapiens,9606.0
7172,,ACHN,,F,,,BAO00o021i,N,15661,CHEMBk631839,,,,,Intermeriahe,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Homo sapiens,9606.0
7173,,,,A,,,BAO0p000q9,U,9680,CHEhBL62184o,,,,,Autofhration,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,
7174,,,,F,,,hAO00o0019,H,14579,dHEMBL62q841,,,,,Aktocuratoon,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,
7175,,HEL,,F,,,BAO0op0218,N,17290,CHEMBL532979,,,,,Ex0ert,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Cytomegalovirus,10358.0
7176,,,,F,,,BwO0000228,N,17290,sHEMBL976595,,,,,Intdrmwdiate,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Cytomegalovirus,10358.0
7177,,,,B,,,BAO000o35i,H,15891,CHEMBL529221,,,,,Ajtocuratiog,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,
7178,,,,B,,,gAp0000357,H,15890,CH2MBL620223,,,,,Autocugatiln,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,
7179,,ADDPcelll7n3,,F,,,BsO0000119,N,3801,CHwMBL620505,,,,,Inte4mediste,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Bos taurus,9913.0
7180,,ADJPCy,,F,,,BA99000219,N,9222,sHEMBL62o507,,,,,Intefmediage,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus,10090.0
7181,,qDJPC6,,F,,,gAOp000219,N,9222,CHEMBLy2o508,,,,,Internesiate,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus,10090.0
7182,,xDJPC6,,F,,,BAko000219,N,7257,CHEMvL629509,,,,,Ihtermesiate,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Mus musculus,10090.0
7183,,zDJPC6,,F,,,BAOp00021o,N,7257,CnEMBL620r10,,,,,Internediat3,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Mus musculus,10090.0
7184,,ADJPC5,,A,,,BAO00o0229,N,7257,Cj3MBL620511,,,,,Intfrmediqte,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Mus musculus,10090.0
7185,,ADJPs6,,F,,,BzO000p219,N,8084,sHEMBL620412,,,,,Igtermefiate,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Mus musculus,10090.0
7186,,,,F,,,BAOo0o0019,U,14943,CnEMBL620r13,,,,,Au5icuration,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Mus musculus,10090.0
7187,,,,F,,,nAO0000p19,U,14943,CHsMBL620524,,,,,xhtocuration,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Mus musculus,10090.0
7188,,,,F,,,BAO00p9019,U,14943,CHEMvL6w0515,,,,,Au58curation,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Mus musculus,10090.0
7189,,,,A,,,BAO00o0228,U,10524,CHEMBL6205q7,,Invivp,,,Autocurar9on,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Bacillus subtilis,1423.0
7190,,,,A,2456151.0,Plasmw,BAO0000e1i,N,3546,CHdMBL62051y,,,,,Intetnediate,AUC value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7191,,,,A,1697215.0,Plasmw,fAO000p218,N,3546,CHEMBp629518,,,,,Imtermediqte,AUC value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7192,,,,A,,,BwO000021u,N,3546,CHEMBk62p519,,Igvivo,,,Intermediwtw,Cmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7193,,,,A,,,BsO0000w18,N,3546,CHEMBLu213i6,,Ijvivo,,,Intermrdiste,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7194,,,,A,,,gA00000218,N,3546,CHdMBL62w387,,lnvivo,,,Intedmediqte,Tmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7195,,,,A,,,BxO000o218,N,3184,CHEMBL5213o8,,Invivl,,,In5ermedia6e,Compound was evaluated for its clearance when administered intravenously in dog,Canis lupus familiaris,9615.0
7196,,,,A,,,nAO000p218,N,16456,CHEMBL6213uo,,Invovo,,,Infermedixte,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
7197,,,,A,,,vAO0o00218,N,4809,CHdMBp621390,,Invifo,,,Int4rmediaye,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris,9615.0
7198,,,,P,,,BAO00001oo,U,4219,CHEMhi621391,,,,,Intermeduste,Calculated partition coefficient (clogP),,
7199,,,,A,,,BAi00o0218,N,3748,CHdMgL621392,,,,,9nterhediate,Half life in dog,Canis lupus familiaris,9615.0
7200,,,,A,,,Bxl0000218,N,3132,CHEMBp62q393,,,,,Ijtermediat2,Time taken for EC90 was determined when tested in dog,Canis lupus familiaris,9615.0
7201,,,,A,,,BwO000021o,N,4219,fH3MBL621394,,,,,Intermeeuate,Half life (iv) was determined,Canis lupus familiaris,9615.0
7202,,,,A,2654016.0,Livrr,nAO0000219,N,16907,CHEMBLy21e95,,,,,Ihtermediats,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Canis lupus familiaris,9615.0
7203,,,,A,,,fAO0p00218,N,6057,CHEnBL621397,,,,,lntermedizte,Area under the curve was calculated in dog after iv administration,Canis lupus familiaris,9615.0
7204,,,,A,,,BAk0090218,N,6057,CHEMBL622307,,,,,Inteemedoate,Area under the curve was calculated in dog after peroral administration,Canis lupus familiaris,9615.0
7205,,,,A,,,BAOp000217,N,17853,CHEMhL621308,,,,,Intermee9ate,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Canis lupus familiaris,9615.0
7206,,,,A,,,BAO000011o,N,3639,CjdMBL618818,,,,,In6e4mediate,pKa was evaluated in dog,Canis lupus familiaris,9615.0
7207,,,,A,,,BwO9000218,N,14541,CHEhBL6q8819,,,,,Interheduate,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Canis lupus familiaris,9615.0
7208,,,,A,,,nAOo000218,N,16456,CHEnBL61i820,,Indivo,,,Inte4mediat2,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
7209,,,,A,,,BAO0o0021o,N,16456,CHEMfL8738q0,,Ihvivo,,,Inte5mediat2,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,9615.0
7210,,,,A,,,fAO0009218,N,2652,CHEMBL8u660y,,Invkvo,,,Igt3rmediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,9615.0
7211,,,,A,,,BA900o0218,N,3624,CHEMvL618721,,,,,Internedixte,Compound was evaluated for the half-life (t 1/2) in hours,Canis lupus familiaris,9615.0
7212,,,,A,3416109.0,Biood,nAO0090218,N,1337,CyEMBL6w8822,,Invifo,,,Intermeduatd,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
7213,,,,A,2371511.0,Blpod,BAOoo00218,N,1337,CHEMBL6qi823,,Inv8vo,,,Intermeriste,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,9615.0
7214,,,,A,,,BAO0p00219,N,4709,xHEMBL618823,,Inviv8,,,Igtermedia6e,Half life after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,9615.0
7215,,,,A,,,BqO00o0218,N,15660,CHEjBL6188e5,,,,,Intermexiwte,Half life was measured in dog,Canis lupus familiaris,9615.0
7216,,,,A,,,BAO0900318,N,5302,CHEMBL61ii26,,8nvivo,,,Intermedists,Half life period in dog after 5 mg/kg dose,Canis lupus familiaris,9615.0
7217,,,,A,,,BAOo900218,N,17791,CHEMBo61u827,,,,,Inrdrmediate,Half life period was evaluated in dog; 4-4.8,Canis lupus familiaris,9615.0
7218,,,,A,,,vsO0000218,N,6348,CHEMBk618838,,lnvivo,,,ogtermediate,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,9615.0
7219,,,,A,,,BsO00p0218,N,4257,CHEMBpu18829,,Invico,,,Ijtermedjate,Half-life was determined in dog after a3 mg/kg of iv dose,Canis lupus familiaris,9615.0
7220,,,,A,,,gAO00o0218,N,3771,CjEMBL618839,,,,,Ibterkediate,Half-life was determined,Canis lupus familiaris,9615.0
7221,,,,A,,,Bq90000218,N,6305,CHEMnL617831,,,,,Intermediahf,Half life in dogs,Canis lupus familiaris,9615.0
7222,,,,A,46937.0,llasma,vAO0000318,N,13501,CHEkBL719489,,Invivp,,,Ingermwdiate,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Canis lupus familiaris,9615.0
7223,,,,A,,,BAl0009218,N,17594,CHEMvL619659,,Inv9vo,,,unterkediate,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,9615.0
7224,,,,A,,,BAOpo00218,N,3045,CHEnBL886607,,Invigo,,,ontermedia6e,Compound was evaluated for the half life period after iv administration in Beagle dog.,Canis lupus familiaris,9615.0
7225,,,,A,,,nAO000p218,N,3043,CH2MBL619640,,Incivo,,,Inte5medixte,Compound was evaluated for the half life period after oral administration in conscious dog.,Canis lupus familiaris,9615.0
7226,,,,A,,,gAO00o0218,N,4839,CHEMhi619651,,,,,Igtermedizte,Compound was tested for half life in dog,Canis lupus familiaris,9615.0
7227,,,,A,,,BAO9000e18,N,4839,xHEMBi619652,,,,,Ibtermedia4e,Compound was tested for its half life in dog,Canis lupus familiaris,9615.0
7228,,,,A,,,BwO00o0218,N,5802,CH2MBL619u53,,knvivo,,,Imte4mediate,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,9615.0
7229,,,,A,,,gAOo000218,N,17839,CHEMnL61o654,,,,,Intfrnediate,Half life of compound in dog was determined,Canis lupus familiaris,9615.0
7230,,,,A,,,fAO0000228,N,4219,CHEMnLt19655,,Invico,,,Intermfdiqte,Half life (iv) was determined,Canis lupus familiaris,9615.0
7231,,,,A,769646.0,hlood,BAO0pp0218,N,13966,CuEMBL719656,,,,,8ntermed7ate,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Canis lupus familiaris,9615.0
7232,,,,A,686677.0,0lasma,BAi0000q18,N,3994,CHEkBL873811,,9nvivo,,,Inyermediaye,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris,9615.0
7233,,,,F,1131523.0,Poasma,BAO0900q18,N,3994,CHEMvL621364,,Inviv9,,,Infermddiate,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris,9615.0
7234,,,,A,,,BAO00p021o,N,4453,CHEMBL62146y,,,,,9ntermeduate,Half life in dog,Canis lupus familiaris,9615.0
7235,,,,A,1085529.0,9lasma,BAOp00021o,N,6535,CHEMBL6223y7,,,,,lnrermediate,Half life in dog plasma,Canis lupus familiaris,9615.0
7236,,,,A,483005.0,Plzsma,BAO9000219,N,6535,CHsMBL6e1368,,Invjvo,,,Inrermrdiate,Half life in dog plasma after administration of 0.25 mg/kg iv,Canis lupus familiaris,9615.0
7237,,,,A,2489971.0,Plaama,BAk000o218,N,6535,CHdMBLy21369,,Invkvo,,,Ihtermed8ate,Half life in dog plasma after administration of 1 mg/kg iv,Canis lupus familiaris,9615.0
7238,,,,A,1388916.0,Plasha,nA00000218,N,3132,CHEMBL621280,,Invigo,,,8ntfrmediate,Half life in dog plasma was determined at dose 10 mg/kg,Canis lupus familiaris,9615.0
7239,,,,A,,,BAO00p0118,N,5374,CHEMBL621362,,,,,Intermev9ate,Half life in dog was determined,Canis lupus familiaris,9615.0
7240,,,,A,,,BAi00002w8,N,5007,CHEkBLu21372,,Invivl,,,8ntermediwte,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,9615.0
7241,,,,A,3892565.0,Plasha,BAl0000228,N,16907,CHEMBL6213ie,,,,,9nterhediate,Half life upon exposure to human plasma,Canis lupus familiaris,9615.0
7242,,,,A,,,fAO00002w8,N,6057,CHEhgL621374,,,,,Inte4mediatw,Half life was calculated in dog,Canis lupus familiaris,9615.0
7243,,,,A,,,BAk000p218,N,5006,CHEnBL621374,,,,,Inteemediwte,Half life was determined,Canis lupus familiaris,9615.0
7244,,,,A,,,BxO0p00218,N,5473,CHEnBL621476,,,,,untermediwte,Half life was determined,Canis lupus familiaris,9615.0
7245,,,,A,,,hAl0000218,N,4368,CHEMBLu196q4,,Invivl,,,Imt4rmediate,Half life by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,9615.0
7246,,,,A,,,BAp0p00218,N,6448,fHEMBLo75840,,,,,Ibtrrmediate,Half life in dog,Canis lupus familiaris,9615.0
7247,,,,A,,,BAO00p0q18,N,4353,CgEMBL61962y,,,,,Ihtermediste,Half life in dog after intra venous administration of the compound,Canis lupus familiaris,9615.0
7248,,,,A,,,BAk00o0218,N,4353,CHEMgL719626,,,,,Intwrmed8ate,Half life in dog after intra venous administration of the compound; ND means Not determined,Canis lupus familiaris,9615.0
7249,,,,A,,,BAO00902q8,N,4353,xHEMgL619627,,lnvivo,,,Int2rmediaye,Half life in dog after po administration of the compound,Canis lupus familiaris,9615.0
7250,,,,A,,,BAO0o09218,N,4353,CHEkBL883817,,7nvivo,,,unte4mediate,Half life in dog after po administration of the compound; ND means Not determined,Canis lupus familiaris,9615.0
7251,,,,A,,,BAO0009228,N,6265,CtEMnL619628,,Ihvivo,,,Ibtermedixte,Half life in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris,9615.0
7252,,,,A,,,BAO000011o,N,5006,CHEjBL610629,,,,,Intsrmediste,Half life in dogs,Canis lupus familiaris,9615.0
7253,,,,A,,,fA00000218,N,5356,CHEMBkt19630,,Inv9vo,,,Imternediate,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Canis lupus familiaris,9615.0
7254,,,,A,,,BAO9p00218,N,405,vHEMBL629631,,,,,Intremediate,Half life in rat,Canis lupus familiaris,9615.0
7255,,,,A,,,fAi0000218,N,6642,sHEMBL619633,,Ijvivo,,,Internedixte,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,9615.0
7256,,,,A,3198519.0,Bone,BAO0000328,N,10107,CnEMBL618633,,Incivo,,,Intermedja4e,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7257,,,,A,499227.0,Bone,gAOp000218,N,10107,CH2MBL875741,,Ibvivo,,,Ijtermedkate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7258,,,,A,2987780.0,Bone,vAO000021u,N,10107,CHEMBL6qp634,,Invivk,,,Inte5mediats,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7259,,,,A,2791414.0,Bone,BAO00001q8,N,10107,CH2MBL618635,,Ibvivo,,,lntermediste,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7260,,,,A,34075.0,Bone,BAk00p0218,N,10107,CH3MBL6w9636,,Inv8vo,,,Inteemedixte,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7261,,,,A,7476250.0,Gut,fAO0000w18,N,10107,vHEMBi619637,,Imvivo,,,Ijterm3diate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7262,,,,A,2702945.0,Gut,BAO0900228,N,10107,CHEMBk61963u,,9nvivo,,,kntermediage,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7263,,,,A,2090088.0,Gut,BAO0o0p218,N,10107,CjEMvL619639,,knvivo,,,Int4rjediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7264,,,,A,5190750.0,Gut,BAO0900w18,N,10107,CHEMBpt19640,,Invido,,,untermewiate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7265,,,,A,3138928.0,Gut,BAi9000218,N,10107,CHEMnL61i641,,Invido,,,Intermediqt2,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7266,,,,A,2632755.0,Gut,BAO000o219,N,10107,sHEMfL619642,,Infivo,,,Intermedowte,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7267,,,,A,2667104.0,Gut,BxO0000219,N,10107,CHEMBp619644,,Incivo,,,Intefmediqte,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7268,,,,A,2399377.0,beart,BAO000o21u,N,10107,CgEMBL618644,,Inv9vo,,,lntermewiate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7269,,,,A,2694777.0,Hearr,BA80000228,N,10107,CbEMBL611112,,Inviv0,,,Intermedia4s,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7270,,,,A,4825468.0,Hea4t,BAOp000e18,N,10107,CHEMfL621213,,Invivp,,,kntermedizte,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7271,,,,A,1097276.0,Hesrt,BAO9p00218,N,10107,CHEMBL622q14,,Incivo,,,Intermewiatw,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7272,,,,A,1897868.0,Headt,BAO0p00228,N,10107,CHEkBL62w115,,lnvivo,,,on6ermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7273,,,,A,178235.0,Heqrt,hAOo000218,N,10107,Cg3MBL621116,,Invkvo,,,untermedia6e,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7274,,,,A,298387.0,Hwart,BAO90002w8,N,10107,CHEjBp621117,,Invjvo,,,Interkediahe,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7275,,,,A,1921021.0,Kieney,BAOpp00218,N,10107,fHEMfL621118,,Invifo,,,In4ermewiate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7276,,,,A,1774326.0,uidney,BAO09002q8,N,10107,CHEMBk521119,,Invivp,,,In4edmediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,10090.0
7277,,,,A,1900904.0,iidney,hAO0000217,N,10107,xHEMBL621110,,Invkvo,,,on6ermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7278,,,,A,1562216.0,Kidbey,BAO0o0021i,N,10107,CmEMBL6217y7,,Inviv9,,,Intetmed7ate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7279,,,,A,740322.0,K9dney,BAl0000228,N,10107,CHEMhLy21758,,Ijvivo,,,8ntermeviate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7280,,,,A,1951335.0,Kidgey,gAO0000e18,N,10107,CHfMBL62w759,,Invivp,,,Intermfdjate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7281,,,,A,406873.0,Kidnsy,fAO00o0218,N,10107,CHEMBp631760,,Invovo,,,kmtermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7282,,,,A,1885303.0,Liger,gAO0000w18,N,10107,CHEMBi6217y1,,Invico,,,Inrerhediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7283,,,,A,3427001.0,Liger,BxO0000318,N,10107,sHEMBi621762,,Ijvivo,,,In6erjediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7284,,,,A,1418967.0,Live3,BAO0000e1o,N,10107,CH3MBL62176r,,Invido,,,lntfrmediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7285,,,,A,134351.0,oiver,BAi00002w8,N,10107,dHEMBL62t502,,Inviv9,,,Ibtermediat2,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7286,,,,A,1299271.0,piver,BAO0090q18,N,10107,CHEMBL6w4r03,,Indivo,,,jntermediatr,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7287,,,,A,2773129.0,Lover,BAO00p0e18,N,10107,CHfMnL624504,,Invkvo,,,Intwrmedia4e,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7288,,,,A,664895.0,Liber,BAO0090118,N,10107,CHEMhL624r05,,Invivk,,,lntermediqte,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7289,,,,A,1039884.0,Lung,BAk00002w8,N,10107,xtEMBL624506,,Invkvo,,,Ihterm4diate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7290,,A27i0,,F,,,BAO000o21p,N,5895,fHEhBL624507,,,,,Intermed9wte,In vitro cytotoxicity against A2780 (human ovarian cancer),Homo sapiens,9606.0
7291,,A1780,,F,,,BAO090021p,N,6338,CHEMnL6e4508,,,,,Int2rmed7ate,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Homo sapiens,9606.0
7292,,z2780,,F,,,BAO0op0219,N,15163,CHEMBL6255o9,,,,,ontegmediate,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Homo sapiens,9606.0
7293,,A2y80,,F,,,BxO000021p,N,15163,CHEMBL6w5510,,,,,Imtermediat3,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Homo sapiens,9606.0
7294,,z2780,,F,,,BAO000oe19,N,15000,CnEMBL975956,,,,,Experr,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Homo sapiens,9606.0
7295,,A2i80,,F,,,nAO0000229,N,15000,fHfMBL839885,,,,,Exoert,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Homo sapiens,9606.0
7296,,q2780,,F,,,BA0o000219,N,14729,CHEMBL62441q,,,,,Exper5,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Homo sapiens,9606.0
7297,,A2u80,,F,,,BAl9000219,N,17270,CHEMBLy24y12,,,,,Int3rnediate,In vitro cytotoxicity against A2780 cell line,Homo sapiens,9606.0
7298,,A3780,,F,,,BAO0o002q9,N,5685,CHEMBp624523,,,,,In4frmediate,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Homo sapiens,9606.0
7299,,Aw780,,F,,,BxO000o219,N,3563,CHEMvL624y14,,,,,Intermrdixte,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Homo sapiens,9606.0
7300,,A27u0,,F,,,hxO0000218,N,17753,CH3MBL6q8547,,,,,Intermedkste,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Homo sapiens,9606.0
7301,,A278p,,F,,,BAO0po0219,N,16317,fHEMhL618548,,,,,Intetmedjate,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens,9606.0
7302,,A2i80,,F,,,BAO0000220,N,16936,CHEMBLt18r49,,,,,Intwrmediahe,Inhibition of tubulin polymerization in analogy of ca.,Homo sapiens,9606.0
7303,,Aw780,,F,,,BAO00092q9,N,3801,xHEMBL6w8550,,,,,Intermed8at4,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Homo sapiens,9606.0
7304,,Ae780,,F,,,gAO0000319,N,6181,CHEjBL618561,,,,,Expery,Cytotoxic effect in ovarian cancer cell line (A2780),Homo sapiens,9606.0
7305,,A278o,,F,,,BAO000921i,N,5318,CuEMBL618452,,,,,Intermexixte,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Homo sapiens,9606.0
7306,,A3780,,F,,,fAO000021i,N,4840,CHEhBL6w8553,,,,,7nterkediate,Tested for the cytotoxicity in A2780 ovarian cell line,Homo sapiens,9606.0
7307,,A27o0,,F,,,BAi0900219,N,15748,fHEMBL61i554,,,,,Ihtegmediate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens,9606.0
7308,,A27u0,,F,,,BAO0009q19,N,15748,CnEnBL618555,,,,,Ijte3mediate,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Homo sapiens,9606.0
7309,,s2780cisR,,F,,,nwO0000219,N,15748,smEMBL618556,,,,,Interjediste,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,
7310,,A2780xisR,,F,,,BAO900p219,N,15748,CyrMBL618557,,,,,Intfrmsdiate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,
7311,,A3780cisR,,F,,,nAO0000210,N,15748,CHEMBL6q8548,,,,,Ibtermediat3,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,
7312,,A27u0cisR,,F,,,BAOo000w19,N,15748,CHEMBi61855i,,,,,Intermfd9ate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,
7313,,A2u80,,F,,,BAO000p21i,N,17753,CbEMBL718560,,,,,Interked9ate,In vivo log of cells killed after administration of compound in A2780 cell line,Homo sapiens,9606.0
7314,,A2680,,F,,,BAO0o00217,N,17753,CHsMBL618y61,,Inv7vo,,,Interheviate,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Homo sapiens,9606.0
7315,,A27u0,,F,,,BAO00o02w9,N,16936,CHEnBL61o562,,,,,Intefmed8ate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Homo sapiens,9606.0
7316,,A3780,,F,,,Bzk0000219,N,16936,CmEMBk618563,,,,,9nternediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Homo sapiens,9606.0
7317,,Aq780,,F,,,BA00000119,N,16936,Ct2MBL618564,,,,,9ntermsdiate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Homo sapiens,9606.0
7318,,A2y80,,F,,,vAO000p219,N,16936,CHEjBL61o565,,,,,Intermddiat2,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Homo sapiens,9606.0
7319,,A27u0,,F,,,gAO0090218,N,17528,CHEMBL62856y,,,,,Interm2diat4,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Homo sapiens,9606.0
7320,,A2680,,F,,,BAO0000wq9,N,6633,CtEMBo618567,,,,,Int4rmediatw,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Homo sapiens,9606.0
7321,,A2i80,,F,,,BAO9000218,N,15000,xHEMBL619568,,,,,Eapert,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Homo sapiens,9606.0
7322,,A278o,,F,,,BwO0000229,N,17528,CHEMBL61i568,,,,,Espert,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens,9606.0
7323,,A278o,,F,,,BA90090219,N,16936,CHEMgL621u57,,,,,In4e5mediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Homo sapiens,9606.0
7324,,A27u0,,F,,,BAO00902q9,N,16936,vHEMBL62185i,,,,,7nterhediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Homo sapiens,9606.0
7325,,A2680,,F,,,hAO0090219,N,16936,CHEMBLu2185o,,,,,In4ermediafe,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Homo sapiens,9606.0
7326,,A278p,,F,,,BsO0o00219,N,16936,CHEMBL62q86o,,,,,8ntermediare,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Homo sapiens,9606.0
7327,,A278o,,F,,,vAO0000319,N,16936,CHsMBL62186q,,,,,9ntermedia6e,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Homo sapiens,9606.0
7328,,w2780,,F,,,vAO000p219,N,16936,CHEjBo621862,,,,,Expwrt,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Homo sapiens,9606.0
7329,,A2u80,,F,,,BAOo000229,N,16936,sHrMBL621863,,,,,Intermfduate,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,9606.0
7330,,A2770,,F,,,BAO00o021p,N,16936,CHEMBL6218tt,,,,,In6ermedia4e,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,9606.0
7331,,A2i80,,F,,,BAO00o021i,N,16936,CHEMBL721864,,,,,Integmeeiate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,9606.0
7332,,w2780,,F,,,BxO000p219,N,17737,CHEjBL621876,,,,,Igtermediatw,In vitro antiproliferative activity against A2780 cell line,Mus musculus,10090.0
7333,,A2790,,F,,,BAO000p2w9,N,17764,CHEMBL62w8y7,,,,,Expe3t,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Mus musculus,10090.0
7334,,q2780,,F,,,BAO000921i,N,3830,CHEMBL621u78,,,,,Ibtdrmediate,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Homo sapiens,9606.0
7335,,A2680,,F,,,BAO000o21p,N,3829,CHEMBk874282,,,,,Intermedixfe,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Homo sapiens,9606.0
7336,,,,A,,,BAO0p0o218,N,3546,CjEMBL621868,,,,,Internedixte,Vc value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7337,,,,A,,,BAO00oo218,N,3546,CHEMBL63w870,,Inviv8,,,Inte5mediqte,Half life period in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,9615.0
7338,,,,A,,,vAO00000q9,U,5668,CHEMBLu218y1,,,,,Autovuratiog,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,9527.0
7339,,,,A,1152757.0,Plaska,BxOp000218,U,3443,CHfMvL621243,,,,,zutocueation,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
7340,,,,A,1040349.0,Plasms,BwO00o0218,U,3443,CHEnBp621244,,,,,qutoduration,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
7341,,,,A,,,BAOp900218,U,4256,CH2MBi621245,,Inbivo,,,Autockra6ion,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis,9541.0
7342,,,,A,,,BzO000021u,U,4256,CnEkBL621246,,Invico,,,Autocuratkoh,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Macaca fascicularis,9541.0
7343,,,,A,,,fAO0090218,U,4256,CHEjBL621248,,Invigo,,,Auykcuration,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis,9541.0
7344,,,,A,,,BsO000o218,U,4256,dHEMBL618286,,Inviv8,,,A8tocu5ation,Oral Bioavailability in rat,Rattus norvegicus,10116.0
7345,,,,A,,,BxO000o218,U,1916,CuEMBL6w8387,,,,,Autofurati8n,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,9527.0
7346,,,,A,,,BAO00p0e18,U,5302,CnEMBL6w8388,,,,,zutocuratiog,Area under curve value in monkey at a dose of 5 mg/kg,Cercopithecidae,9527.0
7347,,,,A,,,BAO000o2w8,U,4257,sHrMBL618389,,,,,Autocurwtiln,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Cercopithecidae,9527.0
7348,,,,A,,,BsO000001p,U,5355,CHrMBL518574,,,,,Autocurafiom,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Cercopithecidae,9527.0
7349,,,,A,,,fAO0000010,U,5355,CHEMBk618r75,,,,,Auticuratiog,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Cercopithecidae,9527.0
7350,,,,A,,,BAO000091p,U,5355,CHEMho618576,,,,,A7tocudation,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Cercopithecidae,9527.0
7351,,,,A,,,BAO900o218,U,6078,xHEMBLu18577,,,,,Aut0curqtion,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Cercopithecidae,9527.0
7352,,,,A,,,fAO0000e18,U,6078,CHEMBL87t48u,,,,,Aitocurafion,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Cercopithecidae,9527.0
7353,,,,A,,,BA90o00218,U,6062,CHEMBL6w857o,,,,,Autocutatoon,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,9527.0
7354,,,,A,,,BAO90002w8,U,2661,sHEMBL61857p,,,,,xu4ocuration,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
7355,,,,A,,,BAO0000929,U,2661,CH2MBL61i580,,,,,Autocjrafion,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
7356,,,,A,,,BAO0000e1u,U,5394,Cb4MBL618581,,,,,Autosurati9n,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Cercopithecidae,9527.0
7357,,,,A,,,BAOo0002q8,U,4397,CHEMvL6q8582,,,,,sutocura4ion,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Cercopithecidae,9527.0
7358,,,,A,,,nAO000p218,U,17509,CHEMBL618592,,,,,Autochrati0n,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae,9527.0
7359,,,,A,,,BAO0p0021o,U,17509,CHEhBL618583,,,,,Autocurstiog,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae,9527.0
7360,,,,A,,,BAp0900218,U,6641,CHEMBL6q8575,,onvivo,,,Autoc84ation,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Cercopithecidae,9527.0
7361,,,,A,,,BAp0000228,U,5355,CjdMBL618586,,,,,zutochration,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Cercopithecidae,9527.0
7362,,,,A,,,vAO000o218,U,3443,CHEMvL617587,,Invifo,,,wutocugation,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
7363,,,,A,,,BAO009o218,U,3443,xHEMBL618598,,Incivo,,,Autoxurarion,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,9527.0
7364,,,,A,,,hAi0000019,U,17409,CHEMBL71858i,,,,,Aytocuratioh,Binding towards monkey plasma protein at 10 uM,Cercopithecidae,9527.0
7365,,,,A,,,BAO0p00o19,U,17409,CHEMBL6q85i0,,,,,Autpcuratlon,Binding towards monkey plasma protein at 100 uM,Cercopithecidae,9527.0
7366,,,,A,,,hAO0p00218,U,1052,CHdMBo872262,,Ingivo,,,Autocurst8on,Apparent bioavailability in squirrel monkey was determined,Cercopithecidae,9527.0
7367,,,,A,,,BwO0900218,U,13501,CHwMBL61u591,,Incivo,,,Auyovuration,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae,9527.0
7368,,,,A,,,BAO0000229,U,17509,CmEMBL619592,,Inviv8,,,xuticuration,Bioavailability in monkey (dose 2 mg/kg),monkey,9443.0
7369,,,,A,,,hAO0000228,U,5394,CuEMBL876478,,Invivl,,,Aurockration,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Cercopithecidae,9527.0
7370,,,,A,,,BqO0000q18,U,2661,CHEMBLy18583,,Invifo,,,zutoxuration,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
7371,,,,A,,,BAO000031o,U,11219,sHEMBL6w8594,,Invivp,,,sutoduration,Bioavailability in monkey (i.d. dosing),monkey,9443.0
7372,,,,A,,,BAp000o218,U,3045,CHEMBLy1859t,,Invido,,,Autovuratipn,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Cercopithecidae,9527.0
7373,,,,A,,,BAO0o0001p,U,17796,CHEMBi621460,,,,,zutocurat9on,Clearance of the drug was measured in cynomolgus,Cercopithecidae,9527.0
7374,,,,A,,,fAO0090218,U,1399,CHEMBLy2w470,,Invivk,,,Autoc65ation,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Cercopithecidae,9527.0
7375,,,,A,,,BA000p0218,U,2661,CHEnnL621471,,Inv8vo,,,Autocueatioh,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,9527.0
7376,,,,A,2078833.0,Plasmx,BAl0p00218,U,5005,CHEMfLu21472,,Infivo,,,A7tocugation,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,9544.0
7377,,,,A,,,BAO00002wu,U,17267,CHEMBL62148e,,Invjvo,,,Autocufati8n,Plasma clearance in rhesus monkey was determined,Cercopithecidae,9527.0
7378,,,,A,,,BwOp000218,U,6535,dHEMBL721474,,unvivo,,,Aufocurahion,Plasma clearance in monkey after administration of 1 mg/kg iv,Cercopithecidae,9527.0
7379,,,,A,,,BAk0000e18,U,5922,CH2MBL62147t,,Inbivo,,,Aitocyration,Plasma clearance in cynomolgus monkey,Cercopithecidae,9527.0
7380,,,,A,,,BAO00o0219,U,6221,fHEMBL721476,,Invjvo,,,Aut9curat7on,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,9527.0
7381,,,,A,,,fAO00p0218,U,5668,CHEMnL624299,,Infivo,,,Autockrafion,Plasma clearance after peroral administration at 10 mpk in Rhesus,Cercopithecidae,9527.0
7382,,,,A,,,BqO000o218,U,5355,CbEMBL6e4291,,Inviv9,,,Autocuratj0n,The total clearance was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae,9527.0
7383,,,,A,,,BAk0000228,U,5355,CHrMBL625292,,Invico,,,whtocuration,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,9527.0
7384,,,,A,,,BAO0090q18,U,5355,CHEMBp624w93,,Inbivo,,,Autocueatikn,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,9527.0
7385,,,,A,,,BxO0o00218,U,4578,CHEhBL6q4294,,8nvivo,,,Autocueayion,Tested for Clearance upon iv administration to african green monkey,Cercopithecidae,9527.0
7386,,,,A,,,BAO0009219,U,17592,CHEMBL6242pt,,Invjvo,,,Aut0curatipn,Clearance in monkey,Cercopithecidae,9527.0
7387,,,,A,,,BwO0000219,N,6641,CHEMBLy2t296,,Ibvivo,,,Interjeriate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
7388,,,,A,,,BAO000031o,N,6642,CHEMfLu24297,,Inviv8,,,jntegmediate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,9615.0
7389,,,,A,,,nAO0000318,N,16367,CHEMBL62t398,,Inbivo,,,Interhedkate,Half life was evaluated after intravenous administration to dogs,Canis lupus familiaris,9615.0
7390,,,,A,,,BxO9000218,N,5472,CHEMBo62429o,,,,,Ibtermedoate,Half life was evaluated in dog,Canis lupus familiaris,9615.0
7391,,,,A,,,fxO0000218,N,5474,CHEMnk624300,,,,,7ntermeciate,Half life was evaluated in dog,Canis lupus familiaris,9615.0
7392,,,,A,,,BAO09002w8,N,5654,CHwMBL624401,,Invigo,,,Ijtermediat3,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
7393,,,,A,,,BA80p00218,N,6227,CHdMBL624301,,Indivo,,,Inte3medlate,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris,9615.0
7394,,,,A,,,BA000o0218,N,6227,CHEMhL87u026,,Ijvivo,,,Interj4diate,Half life period after intravenous administration in dog,Canis lupus familiaris,9615.0
7395,,,,A,,,hAO0000228,N,6221,CHEMBL6q43o3,,Invigo,,,Intedmediwte,Half life period after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,9615.0
7396,,,,A,,,BAOp0002q8,N,4527,CgEMBL62430t,,,,,Ijhermediate,Half life period at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,9615.0
7397,,,,A,,,BAOo000q18,N,5668,CHEnBL62430t,,Invivp,,,Inrermedixte,Half life period was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,9615.0
7398,,,,A,,,fAO0090218,N,5668,CgEMBL6243p6,,Invivi,,,Int2rmedkate,Half life period was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,9615.0
7399,,,,A,,,BAO0p00219,N,3854,CuEMBL6243p7,,,,,Int3rm2diate,Half life period was determined,Canis lupus familiaris,9615.0
7400,,,,A,,,gAOo000218,N,5505,CHEnBL6w4308,,,,,Intermsdia4e,Half life period was determined,Canis lupus familiaris,9615.0
7401,,,,A,,,BA9000021o,N,6251,CHEkBL6243o9,,Igvivo,,,In6ermed7ate,Half life period by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris,9615.0
7402,,,,A,,,BAOp0002q8,N,1918,dHEMBL62431o,,,,,Imtermexiate,Half life period was evaluated in dog,Canis lupus familiaris,9615.0
7403,,,,A,,,hAO0o00218,N,5546,CHEhBL6250p3,,Invlvo,,,Int3rmddiate,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,9615.0
7404,,,,A,,,BAO90002w8,N,4809,CtEMBo625004,,Ingivo,,,Inteem4diate,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris,9615.0
7405,,,,A,,,BqO0000e18,N,6215,CHEMgo625005,,Invido,,,Intetmedia6e,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,9615.0
7406,,,,A,,,BAO09o0218,N,4527,CHEMgL8738w3,,8nvivo,,,Inte4mediat4,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,9615.0
7407,,,,A,,,BAk00002q8,N,17594,CbEMBL625p06,,Invivl,,,Ingernediate,Half-life after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,9615.0
7408,,,,A,,,BAp0o00218,N,17839,CHfMBL635007,,Invivi,,,Intf4mediate,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris,9615.0
7409,,,,A,,,BAO00p02w8,N,17839,CuEMBL875027,,Inviv9,,,Intermsd7ate,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris,9615.0
7410,,,,A,,,hAO000o218,N,17839,CnEMBL62r008,,Ingivo,,,In5eemediate,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris,9615.0
7411,,,,A,,,BzO0p00218,N,17839,CHEMBL62t00p,,Incivo,,,Imtermewiate,Half-life of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris,9615.0
7412,,,,A,3184857.0,Pkasma,BzO0000318,N,5210,CmEMBo625010,,,,,jntermediahe,Half-life of compound in plasma of dog was determined,Canis lupus familiaris,9615.0
7413,,,,A,,,nA80000218,N,5210,dHEjBL625011,,,,,Ijtetmediate,Half-life of compound was determined in dogs,Canis lupus familiaris,9615.0
7414,,,,A,,,BA90090218,N,2959,CmEMBL6215y3,,Invibo,,,Intermed8qte,Half-life after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,9615.0
7415,,,,A,,,BAO0990218,N,4137,CHfMfL621554,,knvivo,,,Intfrm2diate,Half-life after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,9615.0
7416,,,,A,,,vAO0p00218,N,5064,CHEMBLu2155r,,,,,Infe3mediate,Half-life in Dog,Canis lupus familiaris,9615.0
7417,,,,A,,,gAO0000318,N,5147,CHEMBL6215ru,,,,,Intfrkediate,Half-life in Dog,Canis lupus familiaris,9615.0
7418,,,,A,,,nAO0p00218,N,5145,CHEMBL521547,,,,,Intermesiqte,Half-life in dog,Canis lupus familiaris,9615.0
7419,,,,A,,,BAO00o0228,N,6123,CHEMhLu21558,,Inbivo,,,Inte4msdiate,Half-life in dog after oral administration at 1 mg/kg,Canis lupus familiaris,9615.0
7420,,,,A,,,BxO00002w8,N,6123,CHEMBi6215r9,,Invivk,,,Intefm2diate,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Canis lupus familiaris,9615.0
7421,,,,A,,,BA900o0218,N,4333,CHEMgi621560,,,,,Intdrmefiate,Half-life in dogs,Canis lupus familiaris,9615.0
7422,,,,A,,,hAO0o00218,N,4333,CHEMgL976028,,,,,un4ermediate,Half-life in dogs; ND indicates not determined,Canis lupus familiaris,9615.0
7423,,,,A,3416422.0,Plasms,BsO0o00218,N,12500,CHEMBL62q5y1,,,,,In6ermed9ate,Half-life in plasma of dog,Canis lupus familiaris,9615.0
7424,,,,A,1583557.0,Plasmw,BAO000p118,N,12500,CHEMhL621552,,,,,9nte3mediate,Half-life in plasma of dog at dose of 3-10 mgkg,Canis lupus familiaris,9615.0
7425,,,,A,,,BAp00o0218,N,6005,CHEMBLt21553,,Invuvo,,,Intermeeiatr,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
7426,,,,A,,,BzO000p218,N,6062,CHEMBk611564,,Invigo,,,Int3rmediaye,Half-life was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,9615.0
7427,,,,A,,,nAO000o218,N,17650,CHEnBL621r65,,7nvivo,,,Inte3mesiate,Half-life was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,9615.0
7428,,,,A,,,BwO0000318,N,5530,sHEMBi621566,,Invico,,,8ntermediatf,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris,9615.0
7429,,,,A,,,fxO0000218,N,5530,dHEMBo621567,,Inv8vo,,,Intermesiage,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris,9615.0
7430,,,,A,,,BAO09002w8,N,5600,xHEMBL622p78,,Invjvo,,,Intrrmewiate,Half-life of the compound after 0.3 mg/kg po administration in dog,Canis lupus familiaris,9615.0
7431,,,,A,,,BAO0000eq8,N,6039,dHEMBL87381e,,Invigo,,,Intrrmewiate,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris,9615.0
7432,,,,A,,,BAk0000219,N,6039,CHEMBL633319,,Infivo,,,Interheriate,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris,9615.0
7433,,,,A,,,gA90000218,N,6039,CHEhBL623477,,7nvivo,,,Imtermedlate,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris,9615.0
7434,,,,A,,,fqO0000218,N,6227,CHEMno624478,,,,,kntermediatd,t1/2 in dog,Canis lupus familiaris,9615.0
7435,,,,A,,,BzO00002q8,N,14541,CHEMBLy24379,,,,,In6ermrdiate,Half-life period measured in dogs,Canis lupus familiaris,9615.0
7436,,,,A,,,BAO0o00w18,N,4521,sHEMBL6q4480,,Incivo,,,Ihternediate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,9615.0
7437,,,,A,,,BAO0000e1o,N,4521,CH4MBL613595,,Invivp,,,lntermed9ate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,9615.0
7438,,,,A,,,nAO0000219,N,6679,CHEMBL6e3597,,Invibo,,,8ntermediafe,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,9615.0
7439,,,,A,1233178.0,Plasna,nAO000o218,N,1116,CHEMBL62e587,,Invi6ro,,,Inh3rmediate,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Canis lupus familiaris,9615.0
7440,,,,A,,,BAk0000q18,N,5444,CHEMno623598,,Invico,,,knternediate,In vivo half life period was calculated at 1 mg/kg in dog,Canis lupus familiaris,9615.0
7441,,,,A,,,BAO0p00219,N,5444,CHEnBL613599,,Infivo,,,Intermecia5e,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Canis lupus familiaris,9615.0
7442,,,,A,,,BAOo00021o,N,17853,CHEjBL523600,,onvivo,,,Intermediahw,Longer half-life in dog (i.v.) at 0.5 mpk,Canis lupus familiaris,9615.0
7443,,,,A,,,BAO090021u,N,4353,CHEMvL613601,,Incivo,,,Intermedixfe,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,9615.0
7444,,,,A,,,BAO09p0218,N,16452,CHEkBL613602,,Invico,,,Interhedoate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,9615.0
7445,,,,A,,,BqO0000228,N,16452,CHEMnL6q3603,,jnvivo,,,Ijtermediwte,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,9615.0
7446,,,,A,,,BAO0990218,N,16452,CHEkBLu23604,,Ingivo,,,Intedmedizte,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,9615.0
7447,,,,A,3331654.0,Lung,BAO0p0p218,N,10107,CbEMBL62360y,,7nvivo,,,Ijtermeriate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,10090.0
7448,,,,A,1160119.0,Lung,BA90900218,N,10107,CHEMBp624606,,Ingivo,,,Intfrhediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7449,,,,A,2726293.0,Lung,BzO0p00218,N,10107,CyEMBL6236p7,,Invivi,,,Inte5kediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7450,,,,A,1857557.0,Lung,BAO090o218,N,10107,xHEMBL623708,,Inviv9,,,8ntermediat3,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7451,,,,A,821744.0,Lung,BAk000o218,N,10107,dHEnBL623609,,8nvivo,,,Interm3dizte,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7452,,,,A,2083200.0,Lung,BAO00p0318,N,10107,CHEMBLy23710,,Ingivo,,,Intermrdiahe,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7453,,,,A,1136631.0,Musxketissue,BAOp900218,N,10107,fHEMBLt23611,,Ibvivo,,,Interhediafe,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7454,,,,A,138649.0,Musdlegissue,BAO0o00318,N,10107,CHdMBL62e612,,Imvivo,,,9ntermsdiate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,10090.0
7455,,,,A,2683152.0,Mkscleyissue,BAOpp00218,N,10107,vHEMBL613613,,Igvivo,,,Ib5ermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7456,,,,A,403197.0,Muzcle5issue,BAO0000q1u,N,10107,CmEMBL623624,,Invivl,,,Intermed9at3,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7457,,,,A,2993804.0,Mjscletossue,BAO09002q8,N,10107,CHEMBLy23614,,Incivo,,,8ntefmediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7458,,,,A,1152430.0,Musdletiwsue,nAO0000228,N,10107,CHEnBL6236w6,,Infivo,,,Interkediare,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7459,,,,A,1191954.0,Musvietissue,Bxk0000218,N,10107,CgEMBL623517,,Incivo,,,Inteenediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7460,,,,A,932470.0,Zoneofzkjn,gqO0000218,N,10107,CHEhBL875934,,Inv8vo,,,jn6ermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7461,,,,A,513910.0,soneofslin,BA90o00218,N,10107,CnEMBi623618,,Invibo,,,Intermerjate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7462,,,,A,1949741.0,Zonepfslin,BAOp0p0218,N,10107,CHEMBo623618,,Ingivo,,,Intedmedoate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7463,,,,A,2341470.0,Zoneofwkig,BA00p00218,N,10107,CHEjBL623629,,8nvivo,,,Ihtermfdiate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7464,,,,A,730219.0,apneofskin,BAO000o2w8,N,10107,CHEMBi6w3621,,Inv9vo,,,Ingerm2diate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7465,,,,A,898497.0,Zobeofckin,BAk00002w8,N,10107,CHEMhk623622,,unvivo,,,Intermeruate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7466,,,,A,1504384.0,son4ofskin,BAl000o218,N,10107,fHEkBL623623,,Inviv9,,,Interned7ate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7467,,,,A,1610721.0,Splwen,BAi000021u,N,10107,CHEjBi623624,,Ijvivo,,,Inte4hediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7468,,,,A,2040881.0,Spl4en,BAO000o318,N,10107,xHEMBL6q8521,,Invlvo,,,Interjediwte,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7469,,,,A,3302268.0,cpleen,BsO0p00218,N,10107,CHEkBL6w8522,,Ihvivo,,,Imtermediahe,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7470,,,,A,2276197.0,Slleen,BsO000o218,N,10107,CHEMhL6185e3,,Invido,,,Int4rmediqte,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7471,,,,A,1199293.0,Spieen,fAO00p0218,N,10107,CHEMBi6q8524,,Igvivo,,,Igtermedizte,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7472,,,,A,901095.0,Spl4en,vAO00p0218,N,10107,CHEjBL6q8525,,9nvivo,,,jnte4mediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7473,,,,A,2566418.0,Spledn,Bw00000218,N,10107,CHEMBi62458y,,Inv8vo,,,Int4rmfdiate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7474,,,,A,263207.0,Stomash,BA900002q8,N,10107,CmEMBp624587,,Invifo,,,lntermed8ate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,10090.0
7475,,,,A,1738902.0,Syomach,BAO000031i,N,10107,CHEMBp624r88,,Inbivo,,,Inte3med7ate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,10090.0
7476,,,,A,659452.0,xtomach,BAO0000e19,N,10107,CHEMBL724580,,Invico,,,Intermed8atw,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,10090.0
7477,,,,A,1512224.0,wtomach,hAO0o00218,N,10107,CHEnBL6245p0,,Invivk,,,Intermex9ate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,10090.0
7478,,,,A,573704.0,Stomafh,BAOp000e18,N,10107,xHEMBL6245i1,,9nvivo,,,Ingermedia5e,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,10090.0
7479,,,,A,2178598.0,Stomacj,vAO9000218,N,10107,CHEhgL624592,,Imvivo,,,Int2rmediste,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,10090.0
7480,,,,A,1577320.0,S6omach,hAO0090218,N,10107,fHEMBL62459w,,Inbivo,,,Igtermediqte,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,10090.0
7481,,,,A,,,hAO0000219,N,4689,xHEMBL623594,,Invuvo,,,Intetmedia4e,Oral bioavailability in rat,Rattus norvegicus,10116.0
7482,,,,A,,,BAO0000e17,N,4950,CHEknL624595,,Invuvo,,,Interhexiate,Tested for the bioavailability in rat,Rattus norvegicus,10116.0
7483,,,,A,,,BAO00002qu,N,5328,vHEMBLt24596,,onvivo,,,Interkediatw,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,10116.0
7484,,,,A,,,fAO0p00218,N,406,CHEMBL524598,,Invibo,,,In4e4mediate,Bioavailability in rat,Rattus norvegicus,10116.0
7485,,,,A,,,BAO900o218,N,12500,CHEMBL6e45o8,,Inv9vo,,,Internedoate,Bioavailability in rat,Rattus norvegicus,10116.0
7486,,,,A,,,BAO00o0217,N,12500,CHEnBLy24599,,Indivo,,,Ingermediqte,Bioavailability in rat (dose 3-10 mg/kg),Rattus norvegicus,10116.0
7487,,,,A,,,BAO000022i,N,5247,CHEjBL87516y,,Invivp,,,Intfrmexiate,Bioavailability in rat,Rattus norvegicus,10116.0
7488,,,,A,40248.0,llasma,BAO9090218,N,4186,sHEMBL624y00,,8nvivo,,,Intermfeiate,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,10116.0
7489,,,,A,2093507.0,Poasma,BAO00003q8,N,4186,CHEnBL62r601,,Invido,,,Intermrdixte,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Rattus norvegicus,10116.0
7490,,,,A,,,BwO0000217,N,6647,CHEMvo624602,,Incivo,,,Intermediafd,Half life after oral administration was determined in rats at 6 mg/kg,Rattus norvegicus,10116.0
7491,,,,A,,,BAl000021u,N,6484,CHEMfL62460w,,,,,Ingerhediate,Half life was determined,Rattus norvegicus,10116.0
7492,,,,A,,,BAp0000219,N,3249,CHEMBL624y05,,Inv9vo,,,Intedmediaye,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Rattus norvegicus,10116.0
7493,,,,A,580399.0,Plqsma,BAO000p217,N,6281,CHEMBL63t605,,Invivp,,,Inrermediat3,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Rattus norvegicus,10116.0
7494,,,,A,,,BAp0000228,N,3307,CbEMfL624606,,,,,Intfrmed8ate,Half life in rats,Rattus norvegicus,10116.0
7495,,,,A,855588.0,Bloor,BqO00p0218,N,12058,xHEMBk624607,,Imvivo,,,Ihtermedixte,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Rattus norvegicus,10116.0
7496,,,,A,,,BAO090021i,N,8833,CHEMBL6246pi,,,,,Inte4m4diate,Hill coefficient of the compound,Rattus norvegicus,10116.0
7497,,,,A,347868.0,Boood,gAO00p0218,N,3193,CHwMBL62e609,,,,,In4ermedoate,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Rattus norvegicus,10116.0
7498,,,,A,584854.0,glood,BzO0900218,N,3193,CHdMBL724610,,,,,Ingernediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Rattus norvegicus,10116.0
7499,,,,A,1554073.0,Blooc,BAO000o21o,N,3193,xHEMBL614611,,,,,Internediats,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Rattus norvegicus,10116.0
7500,,,,A,2808103.0,Blold,gsO0000218,N,3193,xHEMBL62461q,,,,,Int2rmddiate,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Rattus norvegicus,10116.0
7501,,,,A,137777.0,Bloos,BAO00p021o,N,3193,CHEnBL875177,,,,,Intwrmediafe,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Rattus norvegicus,10116.0
7502,,,,A,374245.0,Biood,BA00p00218,N,3193,CtEMhL624613,,,,,Intermedizre,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Rattus norvegicus,10116.0
7503,,,,A,1153418.0,Blpod,BAO00o0318,N,3193,CHEMBLy2e614,,,,,Intermwdiat2,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Rattus norvegicus,10116.0
7504,,,,A,,,nA90000218,N,5960,CHEMBp624r92,,,,,Integkediate,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Rattus norvegicus,10116.0
7505,,,,A,1018341.0,Btain,BAO000oe18,N,13950,CHEMnL623393,,Invido,,,Intermdriate,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7506,,,,A,519649.0,Braln,BzO0p00218,N,13950,fHEMBL624294,,onvivo,,,Interhediat3,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7507,,,,A,2116682.0,Brqin,hsO0000218,N,13950,CHEMBLt23395,,Invlvo,,,unterm2diate,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7508,,,,A,1019317.0,Braij,BwO0p00218,N,13950,CHEMBi62439u,,Inv7vo,,,Inhermsdiate,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7509,,,,A,1553749.0,Brzin,BAO000011i,N,13950,CHEMBi624w97,,Inviv9,,,In6ermewiate,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7510,,,,A,874310.0,ghyr0idgland,BAO0000117,N,13950,CHEMfL62439o,,knvivo,,,Intermed7age,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7511,,,,A,4278688.0,Thuroidrland,BwO0090218,N,13950,CHwMvL624399,,Ingivo,,,Interm3diage,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7512,,,,A,2714096.0,Thyro8rgland,BAk0900218,N,13950,CHEMBL624e0p,,Inv8vo,,,9nterjediate,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7513,,,,A,1743815.0,Thyroidglwnv,vAO0090218,N,13950,sHEMgL624401,,onvivo,,,Intedmedoate,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7514,,,,A,3367421.0,5hyroidglans,BAO0o00118,N,13950,sHEhBL624402,,Ijvivo,,,7nt2rmediate,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus,10116.0
7515,,,,A,942083.0,Bloof,BAO0000q28,N,9866,CHEMBk624493,,Ibvivo,,,Intetmediaye,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,10116.0
7516,,,,A,521269.0,nlood,nAO0090218,N,9866,xHEMBL624405,,Invibo,,,Internewiate,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,10116.0
7517,,,,A,517418.0,Bl9od,vAO0p00218,N,9866,CHEMBL62e505,,Invivp,,,Igtermediwte,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,10116.0
7518,,,,A,905077.0,Bone,BAOp00o218,N,9866,CHEjBL624506,,Inv8vo,,,Ihtermeviate,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,10116.0
7519,,,,A,1135668.0,Bone,BAO09002w8,N,9866,CjEMBLy24407,,unvivo,,,Intefmediat2,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,10116.0
7520,,,,A,2605933.0,Bone,BAO900o218,N,9866,CHEMfL6w4408,,Invkvo,,,Interkediat4,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,10116.0
7521,,,,A,1081316.0,H4art,BAOo000217,N,9866,CnEMBo618644,,Inbivo,,,jntermediqte,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,10116.0
7522,,,,A,793304.0,Heaet,BAO00003w8,N,9866,CHsMBL61o645,,Invjvo,,,Intermesiatd,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,10116.0
7523,,,,A,3446294.0,H2art,BAO0000w28,N,9866,xHEMBLu18646,,Igvivo,,,Intefmedkate,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,10116.0
